metformin has been researched along with Polycystic Ovarian Syndrome in 1343 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Short-term combined treatment with beinaglutide and metformin appears superior to metformin monotherapy in lowering body weight, BMI, WC,WHtR and improving insulin sensitivity and androgen excess in women with PCOS and obesity, with tolerable adverse events." | 9.69 | Short-term effect of beinaglutide combined with metformin versus metformin alone on weight loss and metabolic profiles in obese patients with polycystic ovary syndrome: a pilot randomized trial. ( Chen, Q; Chen, Y; Fang, S; Liang, Y; Tian, Y; Wen, Q; Yuan, J, 2023) |
| "s-PROK1 was analysed using ELISA at gestational week 19 and related to pregnancy complications, fasting insulin levels, homoeostatic model assessment for insulin resistance (HOMA-IR), testosterone, or androstenedione levels, metformin use, PCOS phenotype and hyperandrogenism." | 9.69 | Maternal serum levels of prokineticin-1 related to pregnancy complications and metformin use in women with polycystic ovary syndrome: a post hoc analysis of two prospective, randomised, placebo-controlled trials. ( Hirschberg, AL; Trouva, A; Ujvari, D; Vanky, E, 2023) |
| "To compare the effects of insulin sensitizers metformin (MET) and myo-inositol (MI) on adiponectin levels and metabolic characteristics in women with polycystic ovary syndrome (PCOS) with respect to their body mass index (BMI)." | 9.51 | The effect of metformin and myoinositol on metabolic outcomes in women with polycystic ovary syndrome: role of body mass and adiponectin in a randomized controlled trial. ( Bjekić-Macut, J; Livadas, S; Macut, D; Malešević, G; Mastorakos, G; Micić, D; Ognjanović, S; Popović-Pejičić, S; Prtina, A; Soldat-Stanković, V; Stanković, S, 2022) |
| "To determine the safety and efficacy of canagliflozin in comparison to metformin in polycystic ovary syndrome (PCOS) patients with insulin resistance (IR)." | 9.51 | Efficacy of canagliflozin versus metformin in women with polycystic ovary syndrome: A randomized, open-label, noninferiority trial. ( Cai, M; Dilimulati, D; Gao, X; Qu, S; Shao, X; Xing, F; Zeng, Q; Zhang, M; Zhang, Y, 2022) |
| " The TSH level was not affected by metformin, whereas fT4 was significantly higher in the metformin group with less decrease throughout pregnancy compared to placebo, p<0." | 9.51 | Thyroid Status During Pregnancy in Women With Polycystic Ovary Syndrome and the Effect of Metformin. ( Alvarsson, M; Åsvold, BO; Calissendorff, J; Hirschberg, AL; Trouva, A; Vanky, E, 2022) |
| "In this long-term follow-up study, 160 overweight or obese infertility Chinese PCOS were randomized to exenatide or metformin treatment for 12 weeks." | 9.51 | Effect of metformin and exenatide on pregnancy rate and pregnancy outcomes in overweight or obese infertility PCOS women: long-term follow-up of an RCT. ( Li, R; Mai, T; Zhang, Y; Zheng, S, 2022) |
| "To investigate the adjuvant efficacy of metformin treatment to achieve pathological complete response (CR) in patients with endometrial complex hyperplasia (CH) and complex atypical hyperplasia (CAH), and secondarily, to evaluate their pregnancy outcomes after following assisted reproductive technology (ART)." | 9.51 | A Prospective Cohort Study of Metformin as an Adjuvant Therapy for Infertile Women With Endometrial Complex Hyperplasia/Complex Atypical Hyperplasia and Their Subsequent Assisted Reproductive Technology Outcomes. ( Kong, WY; Liu, ZA; Wu, X; Yan, L; Zhang, N; Zhao, XB, 2022) |
| "To observe the effect of metformin (MET) monotherapy versus MET plus liraglutide (LIRA) on gonadal and metabolic profiles in overweight patients with polycystic ovary syndrome (PCOS)." | 9.51 | Effect of metformin versus metformin plus liraglutide on gonadal and metabolic profiles in overweight patients with polycystic ovary syndrome. ( He, B; Xing, C; Zhang, J; Zhao, H, 2022) |
| " This randomized controlled trial compared the efficacy and safety of CANA and metformin (MET) combination therapy and MET monotherapy in endocrine and metabolic profiles of overweight and obese women with polycystic ovary syndrome (PCOS)." | 9.51 | Canagliflozin combined with metformin versus metformin monotherapy for endocrine and metabolic profiles in overweight and obese women with polycystic ovary syndrome: A single-center, open-labeled prospective randomized controlled trial. ( Cheng, X; He, B; Xing, C; Zhang, J, 2022) |
| " Metformin, which ameliorate hormonal disturbances in non-pregnant women with PCOS is increasingly used in pregnancy." | 9.41 | Maternal PCOS status and metformin in pregnancy: Steroid hormones in 5-10 years old children from the PregMet randomized controlled study. ( Carlsen, SM; Hanem, LGE; Juliusson, PB; Madsen, A; Mellgren, G; Sagen, JV; Salvesen, Ø; Vanky, E; Ødegård, R, 2021) |
| "Fifty overweight/obese women with PCOS diagnosed via the Rotterdam criteria were randomized to one of two treatment groups: MET (500 mg three times a day [TID]) or combination treatment (COM) (MET 500 mg TID, exenatide 2 mg QW) for 12 weeks." | 9.41 | Short-term combined treatment with exenatide and metformin for overweight/obese women with polycystic ovary syndrome. ( Deng, Y; Ding, XS; Ma, RL; Sun, AJ; Wang, YF; Zhu, SY, 2021) |
| "Metformin is the gold standard insulin sensitizer, which is widely used to treat insulin resistance in polycystic ovary syndrome (PCOS)." | 9.41 | Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. ( Ács, N; Greff, D; Hegyi, P; Horváth, EM; Juhász, AE; Nyirády, P; Park, S; Sipos, Z; Szinte, J; Váncsa, S; Váradi, A; Várbíró, S, 2023) |
| "Metformin is considered as first-line treatment for type 2 diabetes and an effective treatment for polycystic ovary syndrome (PCOS)." | 9.41 | Major malformations risk following early pregnancy exposure to metformin: a systematic review and meta-analysis. ( Abolhassani, N; Del Giovane, C; Jaques, C; Kaplan, YC; Minder Wyssmann, B; Panchaud, A; Winterfeld, U, 2023) |
| "To summarize the effects of metformin treatment on markers of hyperandrogenism in patients diagnosed with polycystic ovary syndrome (PCOS)." | 9.41 | Influence of metformin on hyperandrogenism in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized clinical trials. ( Cândido, AL; Fontes, AFS; Gomes, KB; Reis, FM; Tosatti, JAG, 2023) |
| "To compare OCs(oral contraceptives) + metformin and OCs alone for metabolic effects in nonobese polycystic ovary syndrome (PCOS) patients." | 9.41 | Oral contraceptives (OCs) in combination with metformin versus OCs alone on metabolism in nonobese polycystic ovary syndrome: A meta-analysis and systematic review of randomized controlled trials. ( Hua, Y; Huang, X; Li, Z; Lin, K; Liu, Y; Song, L; Wang, X; Wei, T; Wu, L, 2023) |
| "To analyze whether metformin treatment in patients with polycystic ovary syndrome (PCOS) results in a decrease of anti-Müllerian hormone (AMH) levels, we reviewed and analyzed PCOS studies which evaluated serum AMH levels before and after metformin treatment." | 9.41 | The effects of metformin on anti-Müllerian hormone levels in patients with polycystic ovary syndrome: a systematic review and meta-analysis. ( Chen, H; Chen, Q; Chu, L; Liu, Y; Ou, X; Yang, J; Zhou, Z; Zou, Q, 2023) |
| "This document purpose is to create an evidence-based position statement on the role of metformin therapy in pregnancy complicated by obesity, gestational diabetes (GDM), type 2 diabetes mellitus (T2DM), polycystic ovary syndrome (PCOS) and in women undergoing assisted reproductive technology (ART)." | 9.41 | Position paper of the Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), and the Italian Study Group of Diabetes in pregnancy: Metformin use in pregnancy. ( Bianchi, C; Burlina, S; Formoso, G; Manicardi, E; Resi, V; Sciacca, L; Sculli, MA, 2023) |
| "Available evidence has shown that metformin improves insulin sensitivity and weight management in polycystic ovary syndrome (PCOS)." | 9.41 | The impact of metformin with or without lifestyle modification versus placebo on polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. ( Alesi, S; Forslund, M; Melin, J; Mousa, A; Pena, A; Piltonen, T; Romualdi, D; Spritzer, PM; Tay, CT; Teede, H; Witchel, SF, 2023) |
| "To evaluate clinical efficacy of exenatide (EX), metformin (MET), or combination (COM) for prediabetes in PCOS." | 9.41 | Exenatide, Metformin, or Both for Prediabetes in PCOS: A Randomized, Open-label, Parallel-group Controlled Study. ( Cai, J; Fan, W; Fu, JR; Gao, YN; Liu, W; Ma, JY; Sun, Y; Tao, T; Wang, YY; Xu, Y; Zhang, Y; Zhu, YC, 2021) |
| "Assessing the impact of adding combined oral contraceptives (COCs) or metformin to laser hair removal on the quality of life of polycystic ovarian syndrome (PCOS) patients with hirsutism." | 9.41 | Adding Combined Oral Contraceptives or Metformin to Laser Treatment in Polycystic Ovarian Syndrome Hirsute Patients. ( Dorgham, D; Dorgham, N; El-Kalioby, M; Haggag, H; Sharobim, A, 2021) |
| "Polycystic ovary syndrome (PCOS) is the most common cause of anovulatory infertility, for which the insulin sensitizer metformin has been used therapeutically." | 9.41 | Therapeutic Effect of Curcumin in Women with Polycystic Ovary Syndrome Receiving Metformin: A Randomized Controlled Trial. ( Atkin, SL; Azarpazhooh, MR; Heydari, B; Karimi-Zarchi, M; Sahebkar, A; Simental-Mendía, LE; Sohrevardi, SM; Teymourzadeh, M, 2021) |
| "This study aims to assess the therapeutic effects of a well-known component (puerarin) obtained from a Chinese herb root in patients with polycystic ovary syndrome (PCOS)." | 9.41 | Therapeutic effects of puerarin on polycystic ovary syndrome: A randomized trial in Chinese women. ( Hu, H; Li, F; Li, W; Liu, J; Ma, Z; Zou, G, 2021) |
| "To compare the effects of metformin, rosiglitazone, and their combination in obese polycystic ovary syndrome (PCOS) patients with insulin resistance." | 9.34 | Comparing the individual effects of metformin and rosiglitazone and their combination in obese women with polycystic ovary syndrome: a randomized controlled trial. ( Duan, C; Hu, Y; Huang, W; Li, Y; Tan, J; Wang, Q, 2020) |
| "This study aimed at investigating the therapeutic effect and mechanism of pioglitazone metformin complex preparation (PM) in polycystic ovary syndrome (PCOS) comorbid psychological distress." | 9.34 | Pioglitazone Metformin Complex Improves Polycystic Ovary Syndrome Comorbid Psychological Distress via Inhibiting NLRP3 Inflammasome Activation: A Prospective Clinical Study. ( Guo, QJ; Hu, YY; Huang, Q; Huo, CL; Shan, J; Song, JY; Wang, CQ; Xu, YF; Yu, CQ; Zhou, H, 2020) |
| " While metformin has a mild androgen-lowering effect in non-pregnant women with PCOS, its effects on maternal androgen levels in pregnancy are less well understood." | 9.34 | Sustained Maternal Hyperandrogenism During PCOS Pregnancy Reduced by Metformin in Non-obese Women Carrying a Male Fetus. ( Abbott, D; Andræ, F; Odsæter, IH; Salvesen, Ø; Schmedes, AV; Stridsklev, S; Vanky, E, 2020) |
| "To investigate the factors that are associated with the effect of metformin on endothelial dysfunction in polycystic ovary syndrome (PCOS)." | 9.30 | Effect of Metformin on Microvascular Endothelial Function in Polycystic Ovary Syndrome. ( Chang, AY; Heidari, B; Lalia, AZ; Lerman, A; Lerman, LO, 2019) |
| "To evaluate the impact of metformin on in vitro fertilization (IVF) outcomes in overweight and obese women with polycystic ovary syndrome (PCOS)." | 9.30 | Impact of Metformin on IVF Outcomes in Overweight and Obese Women With Polycystic Ovary Syndrome: A Randomized Double-Blind Controlled Trial. ( Abbas, AM; Abdalmageed, OS; Abdelaleem, AA; Abdelmagied, AE; Ali, MK; Farghaly, TA, 2019) |
| "OCP resulted in a higher reduction in serum luteinizing hormone (LH) and androgens whereas metformin resulted in significant reduction in BMI, waist circumference, and insulin resistance." | 9.30 | Doppler analysis of ovarian stromal blood flow changes after treatment with metformin versus ethinyl estradiol-cyproterone acetate in women with polycystic ovarian syndrome: A randomized controlled trial. ( Mohanty, J; Nagy, A; Sahu, A; Tripathy, P, 2019) |
| "This investigation was conducted to evaluate comparison of myo-inositol and metformin on glycemic control, lipid profiles, and gene expression related to insulin and lipid metabolism in women with polycystic ovary syndrome (PCOS)." | 9.30 | Comparison of myo-inositol and metformin on glycemic control, lipid profiles, and gene expression related to insulin and lipid metabolism in women with polycystic ovary syndrome: a randomized controlled clinical trial. ( Afshar Ebrahimi, F; Aghadavod, E; Asemi, Z; Foroozanfard, F; Ghaderi, A; Shokrpour, M; Vahedpoor, Z, 2019) |
| " Therefore, we here aim to investigate if acupuncture treatment or metformin together with lifestyle or lifestyle management alone improves insulin sensitivity and related symptoms in overweight/obese women with PCOS." | 9.30 | Acupuncture or metformin to improve insulin resistance in women with polycystic ovary syndrome: study protocol of a combined multinational cross sectional case-control study and a randomised controlled trial. ( Chang, C; Friden, C; Huo, Z; Ji, X; Li, D; Li, R; Li, S; Linden-Hirschberg, A; Qiao, J; Stener-Victorin, E; Wang, H; Wang, W; Zhang, H, 2019) |
| " To study the combined efficacy of exercise and metformin on above parameters in women with polycystic ovary syndrome." | 9.30 | Randomised controlled trial to study the efficacy of exercise with and without metformin on women with polycystic ovary syndrome. ( Jain, S; Pasrija, S; Tiwari, N, 2019) |
| " Epi-analysis of two previous randomised controlled trials that compared metformin with placebo during pregnancy in women with PCOS showed a significant reduction in late miscarriages and preterm births in the metformin group." | 9.30 | Use of metformin to treat pregnant women with polycystic ovary syndrome (PregMet2): a randomised, double-blind, placebo-controlled trial. ( Andræ, F; Berg, AH; Bixo, M; Carlsen, SM; Gómez-Real, F; Hestvold, KV; Hirschberg, AL; Hjelle, S; Lønnebotn, M; Løvvik, TS; Mohlin, J; Poromaa, IS; Salvesen, Ø; Steffensen, B; Thorarinsdottir, S; Trouva, A; Underdal, M; Vanky, E; Zabielska, R, 2019) |
| "The purpose is a comparison of effectiveness of myo-inositol and metformin in infertile women with polycystic ovary syndrome (PCOS) treated with letrozole." | 9.30 | The effectiveness of inositol and metformin on infertile polycystic ovary syndrome women with resistant to letrozole. ( Bazarganipour, F; Kutenaee, MA; Pourghasem, S; Taghavi, SA, 2019) |
| " PCOS is associated with obesity, dyslipidaemia and insulin resistance, and metformin treatment may improve such metabolic features." | 9.27 | The Pharmacogenetics of Metformin in Women with Polycystic Ovary Syndrome: A Randomized Trial. ( Andersen, M; Christensen, MMH; Glintborg, D; Pedersen, AJT; Stage, TB, 2018) |
| "Data on comparison of myo-inositol and metformin on mental health parameters and biomarkers of oxidative stress in subjects with polycystic ovary syndrome (PCOS) are scarce." | 9.27 | Comparison of myo-inositol and metformin on mental health parameters and biomarkers of oxidative stress in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. ( Afshar Ebrahimi, F; Asemi, Z; Bahmani, F; Foroozanfard, F; Jamilian, H; Jamilian, M, 2018) |
| "A total of 202 patients with clomiphene citrate (CC) -resistant polycystic ovary syndrome (PCOS) were randomly allocated into two arms of induction of ovulation; the first group (n = 102) received CC 100 mg and metformin 500 mg while the second group (n = 100) received letrozole 2." | 9.27 | Clomiphene citrate combined with metformin versus letrozole for induction of ovulation in clomiphene-resistant polycystic ovary syndrome: a randomized clinical trial. ( Rezk, M; Saif El-Nasr, I; Shaheen, AE, 2018) |
| "The long-term effects of metformin in women with polycystic ovarian syndrome (PCOS) are inadequately studied." | 9.27 | The Efficacy of 24-Month Metformin for Improving Menses, Hormones, and Metabolic Profiles in Polycystic Ovary Syndrome. ( Chen, CH; Chen, MJ; Chen, SU; Ho, HN; Hsu, CY; Lai, MY; Li, ZR; Yang, PK, 2018) |
| "Metformin-exposed children had higher BMI and increased prevalence of overweight/obesity at 4 years of age." | 9.27 | Metformin Use in PCOS Pregnancies Increases the Risk of Offspring Overweight at 4 Years of Age: Follow-Up of Two RCTs. ( Carlsen, SM; Hanem, LGE; Júlíusson, PB; Roelants, M; Salvesen, Ø; Stridsklev, S; Vanky, E; Ødegård, R, 2018) |
| "To evaluate the effect of Diane-35, alone or in combination with orlistat or metformin, on androgen and body fat percentage parameters in Chinese overweight and obese polycystic ovary syndrome (PCOS) patients with insulin resistance." | 9.27 | Effect of Diane-35, alone or in combination with orlistat or metformin in Chinese polycystic ovary syndrome patients. ( Gu, M; Mueck, AO; Ruan, X; Song, J; Wang, H; Wang, L, 2018) |
| "Health-related quality of life (HRQoL) is impaired in polycystic ovary syndrome (PCOS), but the effect of treatment with metformin (M) and/or oral contraceptives (OCP) is undetermined." | 9.27 | Effect of 12-month treatment with metformin and/or oral contraceptives on health-related quality of life in polycystic ovary syndrome. ( Altinok, ML; Andersen, M; Glintborg, D; Ravn, P, 2018) |
| "Worldwide, metformin is prescribed to improve pregnancy outcome in polycystic ovary syndrome (PCOS)." | 9.27 | Does Metformin Treatment During Pregnancy Modify the Future Metabolic Profile in Women With PCOS? ( Andersen, MS; Høgetveit, K; Oppen, IH; Stridsklev, S; Underdal, MO; Vanky, E, 2018) |
| " The potential impact of short-term preconception intervention with liraglutide on fertility potential in polycystic ovary syndrome (PCOS) has not been evaluated yet." | 9.27 | Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study. ( Janez, A; Jensterle, M; Salamun, V; Vrtacnik Bokal, E, 2018) |
| "The aim of the current work was to investigate the value of the long term effects of combined use of simvastatin and metformin treatment for a year versus the effects of their individual treatment on the clinical, biochemical abnormalities, and ovulation dysfunction in young single women with polycystic ovary syndrome (PCOS)." | 9.27 | Long-term effects of combined simvastatin and metformin treatment on the clinical abnormalities and ovulation dysfunction in single young women with polycystic ovary syndrome. ( Hefzy, E; Seyam, E, 2018) |
| " The aim of the study was to evaluate whether dipeptidyl peptidase-4 (DPP-4) inhibitor alogliptin (ALO) alone or in combination with pioglitazone (PIO) improves β-cell function along with insulin resistance (IR) in metformin (MET) treated obese women with PCOS with persistent IR." | 9.24 | Add on DPP-4 inhibitor alogliptin alone or in combination with pioglitazone improved β-cell function and insulin sensitivity in metformin treated PCOS. ( Goricar, K; Janez, A; Jensterle, M, 2017) |
| "To our knowledge, data on comparison of myo-inositol and metformin on clinical, metabolic and genetic parameters in subjects with polycystic ovary syndrome (PCOS) are limited." | 9.24 | Comparison of myo-inositol and metformin on clinical, metabolic and genetic parameters in polycystic ovary syndrome: A randomized controlled clinical trial. ( Afshar Ebrahimi, F; Aghadavod, E; Asemi, Z; Badehnoosh, B; Bahmani, F; Farhat, P; Foroozanfard, F; Jamilian, H; Jamilian, M, 2017) |
| "We aimed to compare a combined oral contraceptive (COC) plus the antiandrogen spironolactone with the insulin sensitizer metformin in women with polycystic ovary syndrome (PCOS)." | 9.24 | Combined oral contraceptives plus spironolactone compared with metformin in women with polycystic ovary syndrome: a one-year randomized clinical trial. ( Alpañés, M; Álvarez-Blasco, F; Escobar-Morreale, HF; Fernández-Durán, E; Luque-Ramírez, M, 2017) |
| "The present study was designed to evaluate the effects of metformin on metabolic and endocrine parameters in patients with polycystic ovary syndrome (PCOS)." | 9.24 | Effects of Metformin on Endocrine and Metabolic Parameters in Patients with Polycystic Ovary Syndrome. ( Ali, A; Rahim, R; Shah, M; Zahra, M, 2017) |
| "The aim of this randomized clinical trial (RCT) was to evaluate the effect of vitamin D supplementation in obese, insulin-resistant (IR) and vitamin D-deficient polycystic ovary syndrome (PCOS) women on metabolic abnormalities in comparison to the effect of metformin or combined metformin plus vitamin D therapy." | 9.24 | The effect of alfacalcidiol and metformin on metabolic disturbances in women with polycystic ovary syndrome. ( Dravecká, I; Figurová, J; Javorský, M; Lazúrová, I; Petríková, J, 2017) |
| "To evaluate efficacy with the dipeptidyl peptidase-4 inhibitor saxagliptin (SAXA), metformin extended release (MET), and combination (SAXA-MET) in patients with polycystic ovary syndrome (PCOS) and impaired glucose regulation." | 9.24 | Short-term therapy with combination dipeptidyl peptidase-4 inhibitor saxagliptin/metformin extended release (XR) is superior to saxagliptin or metformin XR monotherapy in prediabetic women with polycystic ovary syndrome: a single-blind, randomized, pilot ( Elkind-Hirsch, KE; Gutowski, HC; Paterson, MS; Seidemann, EL, 2017) |
| "Although several clinical trials have compared the clinical efficacy of clomiphene citrate (CC) combined with metformin (MET) in the treatment of women with polycystic ovary syndrome (PCOS), the results are controversial." | 9.22 | Therapeutic efficacy of clomiphene citrate combined with metformin in patients with polycystic ovary syndrome. ( Chen, X; Diao, W; Feng, J; Lin, W; Ma, P; Zhou, H, 2022) |
| "The aim of this study was to perform a meta-analysis of randomized controlled trials (RCTs) to evaluate the role of metformin in improving the reproduction outcomes for non-obese, infertile women with polycystic ovary syndrome." | 9.22 | Does metformin improve reproduction outcomes for non-obese, infertile women with polycystic ovary syndrome? Meta-analysis and systematic review. ( Kheirelseid, EAH; Lewis, S; Magzoub, R; Perks, C, 2022) |
| "Using the terms "metformin" and "polycystic ovary syndrome," we conducted a search the PubMed, EMBASE, and Google Scholar databases." | 9.22 | The use of metformin in women with polycystic ovary syndrome: an updated review. ( Neto, FTL; Notaro, ALG, 2022) |
| "Metformin is the most commonly used treatment to increase insulin sensitivity in insulin-resistant (IR) conditions such as diabetes, prediabetes, polycystic ovary syndrome, and obesity." | 9.22 | Metformin and Insulin Resistance: A Review of the Underlying Mechanisms behind Changes in GLUT4-Mediated Glucose Transport. ( Dolžan, V; Herman, R; Janež, A; Jensterle, M; Kravos, NA, 2022) |
| "This meta-analysis aims to perform an updated meta-analysis to evaluate myo-inositol (myo-ins) and the classical insulin sensitizer metformin in terms of efficacy and safety for treating women with polycystic ovary syndrome (PCOS)." | 9.22 | Short period-administration of myo-inositol and metformin on hormonal and glycolipid profiles in patients with polycystic ovary syndrome: a systematic review and updated meta-analysis of randomized controlled trials. ( He, B; Xing, C; Zhang, JQ, 2022) |
| "This meta-analysis was conducted to evaluate the effect of statins combined or not combined with metformin on polycystic ovary syndrome (PCOS)." | 9.22 | Effect of statins combined or not combined with metformin on polycystic ovary syndrome: A systematic review and meta-analysis. ( Miao, K; Zhou, H, 2022) |
| "To evaluate the efficacy and safety of using metformin in pregnant women with polycystic ovarian syndrome (PCOS) and to explore the most effective and safe protocol by using a meta-analysis method." | 9.22 | Efficacy and safety of metformin in pregnant women with polycystic ovary syndrome: a systematic review with meta-analysis of randomized and non-randomized controlled trials. ( He, J; Zhao, Q, 2022) |
| "Based on the results of this study, compared with metformin alone, acupuncture combined with metformin has a positive effect on pregnancy rate, ovulation rate, and insulin resistance in PCOS." | 9.22 | Acupuncture combined with metformin versus metformin alone to improve pregnancy rate in polycystic ovary syndrome: A systematic review and meta-analysis. ( Chen, X; Lan, Y; Li, H; Li, Z; Liu, Y; Long, C; Wang, M; Wu, J; Xie, Q; Yang, L; Zhao, Y; Zhu, X, 2022) |
| "The purpose of this study is to evaluate the effectiveness and safety of liraglutide/liraglutide + metformin in overweight/obese women with polycystic ovary syndrome (PCOS)." | 9.22 | The effectiveness and safety of liraglutide in treating overweight/obese patients with polycystic ovary syndrome: a meta-analysis. ( Ge, JJ; Ge, WH; Shen, SM; Song, W; Wang, DJ, 2022) |
| "The aim of this study was to evaluate and compare the effects of spironolactone and spironolactone plus metformin treatments on body mass index (BMI), hirsutism score, hormone levels, and insulin resistance in women with polycystic ovary syndrome (PCOS)." | 9.22 | Comparison of spironolactone and spironolactone plus metformin in the treatment of polycystic ovary syndrome. ( Acmaz, B; Diri, H; Karaburgu, S; Karaca, Z; Kelestimur, F; Tanriverdi, F; Unluhizarci, K, 2016) |
| "To determine serum vascular endothelial growth factor B (VEGF-B) levels in polycystic ovary syndrome, their association with insulin resistance and β-cell dysfunction, and the effect of metformin on serum VEGF-B levels." | 9.22 | Serum vascular endothelial growth factor B is elevated in women with polycystic ovary syndrome and can be decreased with metformin treatment. ( Chen, C; Cheng, F; Huang, T; Jia, F; Liu, D; Wu, J; Wu, Y; Yang, G; Zhang, Z; Zhao, L, 2016) |
| "To examine the efficacy of clomifene citrate, metformin, and pioglitazone versus letrozole, metformin, and pioglitazone among women with polycystic ovary syndrome (PCOS) resistant to clomifene citrate." | 9.22 | A randomized controlled trial of clomifene citrate, metformin, and pioglitazone versus letrozole, metformin, and pioglitazone for clomifene-citrate-resistant polycystic ovary syndrome. ( Abdel Moety, G; Al Mohammady, M; El-khayat, W; Hamed, D, 2016) |
| "To compare N-acetyl cysteine (NAC) and metformin on polycystic ovary syndrome (PCOS)." | 9.22 | A comparison between the effects of metformin and N-acetyl cysteine (NAC) on some metabolic and endocrine characteristics of women with polycystic ovary syndrome. ( Javanmanesh, F; Kashanian, M; Rahimi, M; Sheikhansari, N, 2016) |
| "Metformin in pregnancy did not affect cervical length in women with PCOS." | 9.22 | Cervical Length and Androgens in Pregnant Women With Polycystic Ovary Syndrome: Has Metformin Any Effect? ( Carlsen, SM; Salvesen, Ø; Shetelig Løvvik, T; Stridsklev, S; Vanky, E, 2016) |
| "Aim of this study was to evaluate the effect of vitamin D supplementation in obese, insulin resistant and vitamin D deficient PCOS women on biochemical and clinical hyperandrogenism and menstrual irregularity in comparison to effect of metformin or combined metformin plus vitamin D therapy." | 9.22 | The effect of alfacalcidiol and metformin on phenotype manifestations in women with polycystic ovary syndrome - a preliminary study. ( Dravecká, I; Figurová, J; Javorský, M; Lazúrová, I; Petríková, J; Vaľková, M, 2016) |
| "To compare the therapeutic effects of metformin (Met) and laparoscopic ovarian drilling (LOD) in clomiphene and insulin-resistant patients with polycystic ovary syndrome (CIRPCOS)." | 9.20 | Therapeutic effects of metformin and laparoscopic ovarian drilling in treatment of clomiphene and insulin-resistant polycystic ovary syndrome. ( Huang, LP; Wang, JQ; Wang, XH; Xu, Y, 2015) |
| "Conclusions on the effect of metformin on circulating anti-Müllerian hormone (AMH) levels in women with polycystic ovary syndrome (PCOS) are ambiguous." | 9.20 | Impact of metformin on anti-Müllerian hormone in women with polycystic ovary syndrome: a secondary analysis of a randomized controlled trial. ( Ingerslev, HJ; Lauszus, FF; Madsen, HN; Trolle, B; Tørring, N, 2015) |
| "Short-term monotherapy with liraglutide or roflumilast was associated with significant weight loss in obese PCOS." | 9.20 | Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study. ( Janez, A; Jensterle, M; Kocjan, T; Salamun, V; Vrtacnik Bokal, E, 2015) |
| "We aim to assess the effect of metformin treatment on metabolic parameters, endothelial function and inflammatory markers in polycystic ovary syndrome (PCOS) subjects." | 9.20 | Metformin modulates human leukocyte/endothelial cell interactions and proinflammatory cytokines in polycystic ovary syndrome patients. ( Alvarez, A; Bañuls, C; Diaz-Morales, N; Escribano-López, I; Gomez, M; Hernandez-Mijares, A; Lopez-Domenech, S; Rios-Navarro, C; Rocha, M; Rovira-Llopis, S; Victor, VM, 2015) |
| "Polycystic ovary syndrome (PCOS) is associated with risk factors for cardiovascular disease (CVD) which may be modified by the use of metformin and oral contraceptives (OC)." | 9.20 | Increased thrombin generation in women with polycystic ovary syndrome: A pilot study on the effect of metformin and oral contraceptives. ( Altinok, ML; Andersen, M; Glintborg, D; Mumm, H; Sidelmann, JJ, 2015) |
| "To assess the adjuvant effect of metformin and N-acetylcysteine (NAC) to clomiphene citrate (CC) in induction of ovulation in Polycystic Ovary Syndrome (PCOS) patients." | 9.20 | The adjuvant effect of metformin and N-acetylcysteine to clomiphene citrate in induction of ovulation in patients with Polycystic Ovary Syndrome. ( Abdelhafez, A; Bakry, A; Elsawah, H; Maged, AM; Mostafa, WA, 2015) |
| " It also indicates that the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism as compared to metformin alone." | 9.19 | In PCOS patients the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism than metformin alone. ( Belfiore, A; D'Orrico, B; Fava, A; Fruci, B; Guzzi, P; Malaguarnera, R; Mazza, A; Veltri, P, 2014) |
| "Berberine and metformin treatments prior to IVF improved the pregnancy outcome by normalizing the clinical, endocrine and metabolic parameters in PCOS women." | 9.19 | The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. ( An, Y; Guan, Y; Liu, B; Lu, M; Sun, Z; Zhang, Y, 2014) |
| "Metformin is used to reduce pregnancy complications in women with polycystic ovary syndrome (PCOS), although it is not approved for this indication and solid evidence is lacking." | 9.19 | Midpregnancy Doppler ultrasound of the uterine artery in metformin- versus placebo-treated PCOS women: a randomized trial. ( Carlsen, SM; Clemens, I; Salvesen, Ø; Stridsklev, S; Vanky, E, 2014) |
| "Metformin is suggested to reduce pregnancy complications in women with polycystic ovary syndrome (PCOS)." | 9.19 | Maternal and fetal insulin levels at birth in women with polycystic ovary syndrome: data from a randomized controlled study on metformin. ( Carlsen, SM; Helseth, R; Stridsklev, S; Vanky, E; Vogt, C, 2014) |
| "Although metformin is widely used to improve insulin resistance in women with polycystic ovary syndrome (PCOS), its mechanism of action is complex, with inconsistent effects on insulin sensitivity and variability in treatment response." | 9.19 | Metformin improves glucose effectiveness, not insulin sensitivity: predicting treatment response in women with polycystic ovary syndrome in an open-label, interventional study. ( Duran, J; Keefe, C; Pau, CT; Welt, CK, 2014) |
| "Training during pregnancy was not associated with altered levels of cffDNA cfmDNA or cftDNA, but metformin treatment may reduce cfmDNA and cftDNA in pregnant PCOS women." | 9.19 | The effect of exercise and metformin treatment on circulating free DNA in pregnancy. ( Carlsen, SM; Christiansen, SC; Klungland, H; Mørkved, S; Salvesen, KÅ; Stafne, SN; Sæther, M; Vanky, E, 2014) |
| "The aim of this study was to compare the effect of low-dose metformin and rosiglitazone on clinical, biochemical, ultrasound features and endothelial function in patients with polycystic ovary syndrome (PCOS)." | 9.17 | Effects of low-dose metformin and rosiglitazone on biochemical, clinical, metabolic and biophysical outcomes in polycystic ovary syndrome. ( Alexandraki, KI; Apostolopoulos, NV; Berry, R; Jude, EB; Mohiyiddeen, L; Watson, AJ, 2013) |
| "The aim of this study was to evaluate the effectiveness of Metformin on ovulation and eventual clinical pregnancy in different phenotypes of polycystic ovary syndrome (PCOS)." | 9.17 | Metformin treatment in different phenotypes of polycystic ovary syndrome. ( Alleyassin, A; Fanisalek, M; Hosseini, MA; Kokab, A; Safdarian, L; Sarvi, F, 2013) |
| "To evaluate the long-term effects of drospirenone (DRSP)/ethinylestradiol (EE) alone, metformin alone, and DRSP/EE-metformin on CD4(+)CD28(null) T lymphocytes frequency, a cardiovascular risk marker, in patients with hyperinsulinemic polycystic ovary syndrome (PCOS)." | 9.17 | Effects of drospirenone-ethinylestradiol and/or metformin on CD4(+)CD28(null) T lymphocytes frequency in women with hyperinsulinemia having polycystic ovary syndrome: a randomized clinical trial. ( Apa, R; Ciardulli, A; Cosentino, N; Crea, F; Familiari, A; Lanzone, A; Liuzzo, G; Martinez, D; Morciano, A; Moro, F; Niccoli, G; Palla, C; Sagnella, F; Scarinci, E; Tritarelli, A; Tropea, A, 2013) |
| "To improve the treatment outcomes in women with polycystic ovary syndrome (PCOS), various drugs like glitazones, oral contraceptive pills, or antiandrogens have been combined with metformin." | 9.17 | Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study. ( Ganie, MA; Gupta, N; Khurana, ML; Kulshrestha, B; Mir, FA; Mudasir, S; Nisar, S; Shah, PA; Shah, ZA; Taing, S; Wani, TA; Zargar, MA, 2013) |
| "To compare the ovulation and conception rates after the treatment with Clomiphene Citrate (CC) alone and in combination with metformin in infertile patients presented with polycystic ovarian syndrome (PCOS)." | 9.17 | Efficacy of combined metformin-clomiphene citrate in comparison with clomiphene citrate alone in infertile women with polycystic ovarian syndrome (PCOS). ( Alwan, Y; Ayaz, A; Farooq, MU, 2013) |
| " We conducted the present study to compare the antidepressant efficacy of pioglitazone with another insulin-sensitizer, metformin, in obese patients with concomitant polycystic ovarian syndrome (PCOS) and major depressive disorder (MDD)." | 9.17 | Does pioglitazone improve depression through insulin-sensitization? Results of a randomized double-blind metformin-controlled trial in patients with polycystic ovarian syndrome and comorbid depression. ( Akhondzadeh, S; Ashrafi, M; Farazmand, B; Kashani, L; Modabbernia, A; Omidvar, T; Ramzanzadeh, F; Tabrizi, M; Tehraninejad, ES, 2013) |
| "Metformin treatment, compared with placebo, statistically significantly decreased 8-OHdG levels in women with polycystic ovary syndrome." | 9.17 | Metformin decreases serum 8-hydroxy-2'-deoxyguanosine levels in polycystic ovary syndrome. ( Karihtala, P; Morin-Papunen, L; Puistola, U; Sova, H, 2013) |
| "Prospectively assess whether metformin/diet pre-conception and throughout pregnancy would safely reduce first trimester miscarriage and improve pregnancy outcomes in women with polycystic ovary syndrome (PCOS)." | 9.17 | Effects of metformin-diet intervention before and throughout pregnancy on obstetric and neonatal outcomes in patients with polycystic ovary syndrome. ( Glueck, CJ; Goldenberg, N; Khan, Z; Padda, J; Pranikoff, J; Wang, P, 2013) |
| "The aim of the present study was to investigate the efficacy of Metformin compared with a hypocaloric diet on C-reactive protein (CRP) level and markers of insulin resistance in obese and overweight women with polycystic ovary syndrome (PCOS)." | 9.17 | Effect of metformin compared with hypocaloric diet on serum C-reactive protein level and insulin resistance in obese and overweight women with polycystic ovary syndrome. ( Esfahanian, F; Heshmat, R; Moini nia, F; Zamani, MM, 2013) |
| "To compare the hormonal-metabolic profiles and reproductive outcomes between women receiving metformin plus letrozole and women undergoing bilateral ovarian drilling in clomiphene citrate (CC)-resistant women with polycystic ovary syndrome (PCOS)." | 9.17 | Efficacy of combined metformin-letrozole in comparison with bilateral ovarian drilling in clomiphene-resistant infertile women with polycystic ovarian syndrome. ( Abd Elgafor, I, 2013) |
| "Hyperandrogenaemia in polycystic ovary syndrome (PCOS) represents a composite of raised serum concentrations of testosterone, androstenedione, dehydroepiandrosterone (DHEA) and DHEA sulphate (DHEAS)." | 9.16 | Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study. ( Atkin, SL; Coady, AM; Kilpatrick, ES; Sathyapalan, T; Smith, KA, 2012) |
| "To compare the efficacy of metformin with that of lifestyle changes in patients with polycystic ovary syndrome (PCOS)." | 9.16 | Metformin versus lifestyle changes in treating women with polycystic ovary syndrome. ( Almeida, JA; Bagnoli, VR; Baracat, EC; Curi, DD; Fonseca, AM; Marcondes, JA; Soares, JM, 2012) |
| "The aim of this study was to evaluate the effects of diet alone, and in association with metformin in monotherapy or in cotreatment with myoinositol (MYO) on menstrual irregularities, hirsutism, body weight and composition in overweight/obese women with polycystic ovary syndrome (PCOS)." | 9.16 | [Diet, metformin and inositol in overweight and obese women with polycystic ovary syndrome: effects on body composition]. ( Alibrandi, A; Giarrusso, R; Le Donne, M; Lo Monaco, I; Muraca, U, 2012) |
| "The role of metformin in the treatment of infertility in women with polycystic ovary syndrome (PCOS) is still controversial." | 9.16 | Metformin improves pregnancy and live-birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double-blind, placebo-controlled randomized trial. ( Bloigu, R; Hippeläinen, M; Morin-Papunen, L; Perheentupa, A; Puukka, K; Rantala, AS; Ruokonen, A; Tapanainen, JS; Tiitinen, A; Tinkanen, H; Unkila-Kallio, L, 2012) |
| "these results suggest pioglitazone is as effective as metformin in improving insulin sensitivity and some cardiovascular risk biomarkers but it has no significant effect on reducing BMI and body weight." | 9.16 | Effect of metformin and pioglitazone treatment on cardiovascular risk profile in polycystic ovary syndrome. ( Abedini, A; Ghorbani, A; Hashemipour, S; Karimzadeh, T; Oveisi, S; Ziaee, A, 2012) |
| "To study the significance of breast size increment in pregnancy, and the impact of metformin during pregnancy on breastfeeding in women with polycystic ovary syndrome (PCOS)." | 9.16 | Breast size increment during pregnancy and breastfeeding in mothers with polycystic ovary syndrome: a follow-up study of a randomised controlled trial on metformin versus placebo. ( Carlsen, SM; Hjorth-Hansen, AK; Leithe, H; Martinussen, M; Nordskar, JJ; Vanky, E, 2012) |
| "Twelve weeks of atorvastatin led to a significant reduction in oxidative stress as determined by MDA concentrations among patients with polycystic ovary syndrome that was independently predicted by changes in testosterone, 25OHD, and high-sensitivity C-reactive protein." | 9.16 | Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome. ( Atkin, SL; Coady, AM; Kilpatrick, ES; Sathyapalan, T; Shepherd, J, 2012) |
| "The impact of metformin medication in pregnant women with polycystic ovary syndrome on weight gain during pregnancy and after delivery and the impact on growth of the offspring are essentially unexplored." | 9.16 | Metformin's effect on first-year weight gain: a follow-up study. ( Carlsen, SM; Martinussen, MP; Vanky, E, 2012) |
| "In young women with PCOS, treatment with metformin or pioglitazone for 6 months induces a similar beneficial effect on endothelial function; this may be partially attributed to an improvement in insulin resistance." | 9.15 | Effect of the insulin sensitizers metformin and pioglitazone on endothelial function in young women with polycystic ovary syndrome: a prospective randomized study. ( Bechlioulis, A; Calis, KA; Chrousos, GP; Kalantaridou, SN; Katsouras, CS; Kazakos, N; Kravariti, M; Makrigiannakis, A; Michalis, LK; Naka, KK; Tsatsoulis, A, 2011) |
| "To assess the impact of metformin and of two different oral contraceptives (OCs) containing cyproterone acetate and drospirenone, on serum anti-Müllerian hormone (AMH) levels, in a cohort of women with polycystic ovary syndrome (PCOS) with hyperandrogenism." | 9.15 | The impact of oral contraceptives and metformin on anti-Müllerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia. ( Decavalas, G; Diamanti-Kandarakis, E; Georgopoulos, NA; Katsikis, I; Panidis, D; Piouka, A; Saltamavros, AD, 2011) |
| " ADMA, homocysteine, high sensitive C-reactive protein (hs-CRP) and homeostasis model assessment estimate of insulin resistance (HOMA-IR) were investigated." | 9.15 | Inflammatory-metabolic parameters in obese and nonobese normoandrogenemic polycystic ovary syndrome during metformin and oral contraceptive treatment. ( Aydin, M; Batioglu, S; Erdogan, G; Kilic, S; Yilmaz, N; Zulfikaroglu, E, 2011) |
| "To compare the effect of combined metformin and clomiphene citrate (CC) with laparoscopic ovarian diathermy (LOD) meant for ovulation induction in CC-resistant women with polycystic ovary syndrome (PCOS)." | 9.15 | Combined metformin and clomiphene citrate versus laparoscopic ovarian diathermy for ovulation induction in clomiphene-resistant women with polycystic ovary syndrome: a randomized controlled trial. ( Abu Hashim, H; El Lakany, N; Sherief, L, 2011) |
| "To determine if the combination of lifestyle (caloric restriction and exercise) and metformin (MET) would be superior to lifestyle and placebo (PBO) in improving the polycystic ovary syndrome (PCOS) phenotype." | 9.15 | The effects of metformin with lifestyle therapy in polycystic ovary syndrome: a randomized double-blind study. ( Archibong, AE; Coney, P; Demers, LM; Dodson, WC; Kunselman, AR; Ladson, G; Legro, RS; Sweet, SD; Williams, NI, 2011) |
| "There is no benefit from increased doses of metformin in PCOS but reduction of insulin resistance is more significant in those patients with a lower insulin sensitivity at baseline." | 9.15 | Effect of dose escalation of metformin on clinical features, insulin sensitivity and androgen profile in polycystic ovary syndrome. ( Balen, AH; Barth, J; Glanville, J; Yasmin, E, 2011) |
| "Comparing the effects of metformin or orlistat on hormone, lipid profile and ovulation status in obese women with polycystic ovary syndrome." | 9.15 | The effects of metformin or orlistat on obese women with polycystic ovary syndrome: a prospective randomized open-label study. ( Aflatoonian, A; Ghandi, S; Moghaddam, MH; Tabibnejad, N, 2011) |
| "To compare the efficacy of 1000 mg and 1700 mg of metformin on ovulation induction in polycystic ovary syndrome (PCOS) women." | 9.15 | Randomized controlled trial of different doses of metformin for ovulation induction in infertile women with polycystic ovary syndrome. ( Jultanmas, R; Leelaphiwat, S; Lertvikool, S; Satirapot, C; Sophonsritsuk, A; Weerakiet, S, 2011) |
| "Metformin can improve insulin resistance and imbalance of endocrine hormones." | 9.15 | Metformin versus metformin plus rosiglitazone in women with polycystic ovary syndrome. ( Dong, JJ; Liao, L; Tian, YJ; Xin, Y; Xing, HY; Zhao, JJ, 2011) |
| "Thirty-three patients with PCOS were specifically selected for being either treated with levothyroxine for a previous diagnosis of hypothyroidism (n = 7), untreated subclinically hypothyroid (n = 2) or euthyroid without levothyroxine treatment (n = 24) before the starting of metformin." | 9.15 | Thyroidal effect of metformin treatment in patients with polycystic ovary syndrome. ( Botta, R; Cappelli, C; Castellano, M; Chiovato, L; De Cata, P; Dionisio, R; Iacobello, C; Magri, F; Nappi, RE; Rotondi, M, 2011) |
| "To prospectively evaluate the safety of metformin administration during pregnancy in a group of PCOS patients by assessing its effect on the prevalence of gestational complications and neonatal outcome." | 9.15 | The administration of metformin during pregnancy reduces polycystic ovary syndrome related gestational complications. ( De Leo, V; Di Sabatino, A; Morgante, G; Musacchio, MC; Piomboni, P, 2011) |
| "To study the effect of metformin before and during assisted reproductive technology (ART) on the clinical pregnancy rate (CPR) in non-obese women with polycystic ovary syndrome (PCOS)." | 9.15 | Use of metformin before and during assisted reproductive technology in non-obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double-blind, multi-centre study. ( Carlsen, SM; Haapaniemikouru, K; Holst-Larsen, T; Humaidan, P; Kjøtrød, SB; Mellembakken, J; Morin-Papunen, L; Rasmussen, PE; Sunde, A; Thurin-Kjellberg, A; von Düring, V, 2011) |
| "In LBW-PP girls, early metformin therapy was found to prevent or delay the development of hirsutism, androgen excess, oligomenorrhea, and PCOS more effectively than late metformin." | 9.15 | Early metformin therapy (age 8-12 years) in girls with precocious pubarche to reduce hirsutism, androgen excess, and oligomenorrhea in adolescence. ( de Zegher, F; Díaz, M; Ibáñez, L; López-Bermejo, A; Marcos, MV, 2011) |
| "In this randomized, double-blind, placebo-controlled study, 19 overweight women with polycystic ovary syndrome were randomized to a 3-month course of either metformin plus combined hormonal oral contraceptive (OC) (n = 9) or OC plus matched placebo (n = 10)." | 9.15 | Effect of combined metformin and oral contraceptive therapy on metabolic factors and endothelial function in overweight and obese women with polycystic ovary syndrome. ( Adawadkar, SS; Arrowood, JA; Cheang, KI; Essah, PA; Nestler, JE; Stovall, DW, 2011) |
| " The metformin therapy improved insulin sensitivity as evidenced by an increase in ISI by 41." | 9.15 | [Effects of metformin therapy on markers of coagulation disorders in hyperinsulinemic women with polycystic ovary syndrome]. ( Banaszewska, B; Pawelczyk, L; Serdyńska-Szuster, M; Spaczyński, R, 2011) |
| "To evaluate the clinical, endocrine and metabolic effects of metformin and N-acetyl-cysteine (NAC) in patients with polycystic ovary syndrome (PCOS)." | 9.15 | Clinical, endocrine and metabolic effects of metformin vs N-acetyl-cysteine in women with polycystic ovary syndrome. ( Muderris, II; Oner, G, 2011) |
| " Both simvastatin and metformin improved menstrual cyclicity and decreased hirsutism, acne, ovarian volume, body mass index, C-reactive protein, and soluble vascular cell adhesion molecule-1." | 9.15 | Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. ( Banaszewska, B; Duleba, AJ; Pawelczyk, L; Spaczynski, RZ, 2011) |
| "To evaluate the effects of metformin on the ovarian response to gonadotropins given for in vitro fertilization (IVF) programs in patients with polycystic ovary syndrome (PCOS) and reduced ovarian reserve." | 9.15 | Does metformin affect the ovarian response to gonadotropins for in vitro fertilization treatment in patients with polycystic ovary syndrome and reduced ovarian reserve? A randomized controlled trial. ( Cappiello, F; Di Cello, A; Falbo, A; Palomba, S; Tolino, A; Zullo, F, 2011) |
| " We conducted this study to evaluate the levels of AMH in women with polycystic ovarian syndrome (PCOS) before and after metformin therapy." | 9.15 | Anti-Müllerian hormone in women with polycystic ovary syndrome before and after therapy with metformin. ( Deepinder, F; Kirilov, G; Kumanov, P; Mechandjiev, Z; Robeva, R; Tomova, A, 2011) |
| "To test whether metformin administration reduces the incidence of ovarian hyperstimulation syndrome (OHSS) in infertile high-risk patients with polycystic ovary syndrome (PCOS) who have been treated with gonadotropins for IVF." | 9.15 | Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial. ( Capasso, S; Cappiello, F; Carrillo, L; Cittadini, E; Colao, A; Di Cello, A; Falbo, A; La Sala, GB; Mastrantonio, P; Orio, F; Palomba, S; Russo, T; Tolino, A; Villani, MT; Zullo, F, 2011) |
| "Only orlistat reduced both IR and its variability significantly, though all three drugs were effective in reducing hyperandrogenism within the 12-week period of the study." | 9.14 | Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome. ( Atkin, SL; Cho, LW; Coady, AM; Keevil, BG; Kilpatrick, ES, 2009) |
| "To compare the effects of metformin versus an antiandrogenic contraceptive pill on ambulatory blood pressure monitoring (ABPM) and carotid intima media thickness (CIMT) in women with polycystic ovary syndrome (PCOS)." | 9.14 | Effects of metformin versus ethinyl-estradiol plus cyproterone acetate on ambulatory blood pressure monitoring and carotid intima media thickness in women with the polycystic ovary syndrome. ( Alvarez-Blasco, F; Escobar-Morreale, HF; Luque-Ramírez, M; Mendieta-Azcona, C, 2009) |
| " Hirsutism was significantly better controlled in the metformin group (p = 0." | 9.14 | Increased insulin sensitivity by metformin enhances intense-pulsed-light-assisted hair removal in patients with polycystic ovary syndrome. ( Adibi, N; Asilian, A; Kachuei, A; Rezvanian, H; Shojaee-Moradie, F; Siavash, M, 2009) |
| "Rimonabant has been shown to reduce weight, free androgen index (FAI) and insulin resistance in obese patients with polycystic ovary syndrome (PCOS) compared to metformin." | 9.14 | Metformin maintains the weight loss and metabolic benefits following rimonabant treatment in obese women with polycystic ovary syndrome (PCOS). ( Atkin, SL; Cho, LW; Coady, AM; Kilpatrick, ES; Sathyapalan, T, 2009) |
| " Obesity increased circulating fibrinogen levels, prothrombin activity and platelet counts, and reduced prothrombin and activated partial thromboplastin times." | 9.14 | Effects of an antiandrogenic oral contraceptive pill compared with metformin on blood coagulation tests and endothelial function in women with the polycystic ovary syndrome: influence of obesity and smoking. ( del Rey Sánchez, JM; Escobar-Morreale, HF; Luque-Ramírez, M; Matíes, M; Mendieta-Azcona, C, 2009) |
| "There were no adverse effects of short-term cyclic MPA plus metformin treatment on metabolic parameters or insulin resistance in patients with PCOS over a 3-month treatment period." | 9.14 | Metabolic and endocrine effects of metformin and metformin plus cyclic medroxyprogesterone acetate in women with polycystic ovary syndrome. ( Bagis, T; Haydardedeoglu, B; Kilicdag, EB; Simsek, E, 2009) |
| "Circulating levels of interleukin-6 (IL-6) and C-reactive protein (CRP) were determined in 59 women with polycystic ovary syndrome, of whom 37 were retested after receiving metformin for 6 weeks and 6 months, to ascertain the response of these inflammatory markers to weight loss and insulin sensitization." | 9.14 | Determinants of interleukin-6 and C-reactive protein vary in polycystic ovary syndrome, as do effects of short- and long-term metformin therapy. ( Conway, GS; Mohamed-Ali, V; Tsilchorozidou, T, 2009) |
| " Total renin, aldosterone, androgen levels and insulin sensitivity indices were significantly improved after 6 months on metformin treatment." | 9.14 | Hyperreninemia characterizing women with polycystic ovary syndrome improves after metformin therapy. ( Diamanti-Kandarakis, E; Economou, FN; Livadas, S; Panidis, D; Papavassiliou, AG; Piperi, C; Tantalaki, E, 2009) |
| "To investigate metformin effects on the endocrine-metabolic parameters and ovarian morphology in normoinsulinemic women with polycystic ovary syndrome (PCOS)." | 9.14 | Metformin effects on ovarian ultrasound appearance and steroidogenic function in normal-weight normoinsulinemic women with polycystic ovary syndrome: a randomized double-blind placebo-controlled clinical trial. ( Cristello, F; Fulghesu, AM; Giuliani, M; Guido, M; Lanzone, A; Romualdi, D; Selvaggi, L, 2010) |
| "To compare the effect of clomiphene citrate, metformin, and lifestyle modification on treatment of patients with polycystic ovary syndrome (PCOS)." | 9.14 | An assessment of lifestyle modification versus medical treatment with clomiphene citrate, metformin, and clomiphene citrate-metformin in patients with polycystic ovary syndrome. ( Javedani, M; Karimzadeh, MA, 2010) |
| "Our prospective study aim is to compare the effectiveness of clomifene citrate plus metformin and clomifene citrate plus placebo in women with newly diagnosed polycystic ovary syndrome." | 9.14 | Metformin effects on clomifene-induced ovulation in the polycystic ovary syndrome. ( Ben Arab, H; Ben Ayed, B; Chahtour, H; Dammak dit Mlik, S; Dhuib, M; Guermazi, M; Kassis, M; Mathlouthi, N; Saiidane, D; Trabelssi, H; Trabelssi, K, 2009) |
| " To elucidate the dynamics of FSH, LH, prolactin (PRL), TSH and insulin secretion in women with polycystic ovarian syndrome (PCOS) treated with metformin (MET)." | 9.14 | Metformin administration was associated with a modification of LH, prolactin and insulin secretion dynamics in women with polycystic ovarian syndrome. ( Adamopoulos, DA; Antsaklis, A; Billa, E; Kapolla, N; Koukkou, E; Milingos, S; Nicopoulou, SC; Venaki, E, 2009) |
| "To evaluate the effect of a short-course pretreatment with metformin on hyperandrogenism, insulin resistance, cervical scores, and pregnancy rates in women with clomiphene citrate (CC)-resistant polycystic ovary syndrome (PCOS)." | 9.14 | Short-term metformin treatment for clomiphene citrate-resistant women with polycystic ovary syndrome. ( Ghaffarpasand, F; Kazerooni, M; Kazerooni, T; Kazerooni, Y; Setoodeh, S, 2009) |
| "The aim of this study was to evaluate the effects of calcium-vitamin D and metformin on the menstrual cycle and ovulation in patients with polycystic ovary syndrome (PCOS)." | 9.14 | The effects of calcium-vitamin D and metformin on polycystic ovary syndrome: a pilot study. ( Haghollahi, F; Rashidi, B; Shariat, M; Zayerii, F, 2009) |
| "To determine whether metformin, when given to women with polycystic ovary syndrome (PCOS), promotes folliculogenesis by prompting a drop in free sex steroids resulting in a compensatory follicle stimulating hormone (FSH) rise, we conducted a randomized, double-blind, placebo-controlled crossover clinical trial." | 9.14 | Metformin does not improve the reproductive or metabolic profile in women with polycystic ovary syndrome (PCOS). ( Adel, G; Aubuchon, M; Cohen, HW; Isaac, B; Lieman, H; Polotsky, AJ; Santoro, N; Stein, D; Tetrokalashvili, M; Weitzman, V, 2009) |
| "To compare hormone levels and clinical outcomes in patients with polycystic ovary syndrome (PCOS) after metformin therapy or laparoscopic ovarian diathermy (LOD) at 6 months follow-up." | 9.14 | Comparison of metformin treatment and laparoscopic ovarian diathermy in patients with polycystic ovary syndrome. ( Asgari, Z; Ashrafinia, M; Eslami, B; Hosseini, R; Moini, A, 2009) |
| "This study was conducted to determine the efficacy of metformin vs placebo in women with polycystic ovary syndrome (PCOS) undergoing IVF treatment." | 9.14 | Metformin in the treatment of clomiphene citrate-resistant women with polycystic ovary syndrome undergoing in vitro fertilisation treatment: a randomised controlled trial. ( Abu-Salem, AN; Al-Ahmad, N; Al-Ibrahim, N; Al-Khaderei, S; Al-Khateeb, M; Al-Zpoon, A; Megdadi, M; Qublan, HS, 2009) |
| "We studied the effect of metformin or placebo in a lifestyle modification program combined with oral contraceptives (OC) on quality-of-life parameters measured by the polycystic ovary syndrome (PCOS) questionnaire in obese adolescent women with validated PCOS." | 9.14 | Improvement in quality-of-life questionnaire measures in obese adolescent females with polycystic ovary syndrome treated with lifestyle changes and oral contraceptives, with or without metformin. ( Davidson, K; Guzick, D; Harris-Glocker, M; Hoeger, K; Kochman, L, 2010) |
| "To compare the hormonal-metabolic profiles and reproductive outcomes in clomiphene-resistant patients with polycystic ovary syndrome and insulin resistance between women receiving metformin and those undergoing laparoscopic ovarian drilling." | 9.14 | Metformin versus laparoscopic ovarian drilling in clomiphene- and insulin-resistant women with polycystic ovary syndrome. ( Ahmed, MA; Ahmed, OG; Hamed, HO; Hasan, AF, 2010) |
| "To evaluate the effects of a pill with drospirenone (3 mg) plus ethinyl E(2) (20 μg) (DRP/20EE) alone or associated with metformin or cyproterone acetate (CPA) on some metabolic cardiovascular risk factors in women with polycystic ovary syndrome (PCOS)." | 9.14 | Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome. ( Fruzzetti, F; Gambacciani, M; Genazzani, AR; Lazzarini, V; Parrini, D; Perini, D, 2010) |
| "In 20 adolescents age < or = 17 (16 +/- 1 yr) with polycystic ovary syndrome (PCOS), we assessed efficacy and safety of metformin-diet for 1 year in treatment of endocrinopathy and coronary heart disease (CHD) risk factors." | 9.14 | Metformin-diet ameliorates coronary heart disease risk factors and facilitates resumption of regular menses in adolescents with polycystic ovary syndrome. ( Glueck, CJ; Goldenberg, N; Wang, P, 2009) |
| " The aim of this study was to determine leptin concentrations in PCOS patients before and after metformin treatment depending on BMI, insulin resistance calculated on the basis of the Homeostasis Model Assessment (HOMA) index, as well as concentrations of androgens: testosterone and androstendion." | 9.14 | Leptin concentrations in patients with polycystic ovary syndrome before and after met-formin treatment depending on insulin resistance, body mass index and androgen con-centrations--introductory report. ( Brodowska, A; Marciniak, A; Nawrocka-Rutkowska, J; Sienkiewicz, R; Starczewski, A; Szydłowska, I, 2009) |
| " Metformin improves insulin sensitivity and circulating markers of cardiovascular risk in patients with PCOS, but it is unclear whether this translates into improvements in vascular function." | 9.14 | Metformin reduces arterial stiffness and improves endothelial function in young women with polycystic ovary syndrome: a randomized, placebo-controlled, crossover trial. ( Agarwal, N; Bolusani, H; Dunseath, G; Ludgate, M; Luzio, SD; Rees, DA; Rice, SP, 2010) |
| "The aim of this study was to evaluate long-term changes in endocrine and metabolic parameters and body mass index in women with polycystic ovary syndrome (PCOS) who were treated with metformin over 2 years without caloric restriction." | 9.14 | The effect of metformin treatment for 2 years without caloric restriction on endocrine and metabolic parameters in women with polycystic ovary syndrome. ( Beckmann, MW; Cupisti, S; Dittrich, R; Jentsch, K; Kronawitter, D; Mueller, A; Oppelt, PG; Reissmann, C, 2010) |
| " 'Cases' were women with PCOS who conceived while taking Metformin and it whom it was continued throughout pregnancy." | 9.14 | Continuation of metformin reduces early pregnancy loss in obese Pakistani women with polycystic ovarian syndrome. ( Nawaz, FH; Rizvi, J, 2010) |
| "This report has demonstrated that the combination of metformin and simvastatin could lead to a better reduction of T and LH levels and thus reversing the LH:FSH ratio, lipid profile, and insulin resistance in patients with PCOS and may be an appropriate management option for patients with PCOS." | 9.14 | Effects of metformin plus simvastatin on polycystic ovary syndrome: a prospective, randomized, double-blind, placebo-controlled study. ( Asadi, N; Dehbashi, S; Ghaffarpasand, F; Kazerooni, T; Kazerooni, Y; Shojaei-Baghini, A, 2010) |
| "The purpose of this study was to compare the effectiveness of laparoscopic ovarian diathermy (LOD) vs clomiphene citrate (CC) plus metformin in infertile patients with CC-resistant polycystic ovary syndrome (PCOS)." | 9.14 | Laparoscopic ovarian diathermy vs clomiphene citrate plus metformin as second-line strategy for infertile anovulatory patients with polycystic ovary syndrome: a randomized controlled trial. ( Battista, L; Falbo, A; Orio, F; Palomba, S; Russo, T; Tolino, A; Venturella, R; Zullo, F, 2010) |
| "The aim of this study was to evaluate the effects of metformin in addition to diet and exercise on endocrine and metabolic disturbances in women with polycystic ovary syndrome (PCOS) in a prospective, double-blind, randomized, placebo (PBO) control trial." | 9.14 | Clinical, metabolic, and endocrine parameters in response to metformin and lifestyle intervention in women with polycystic ovary syndrome: a randomized, double-blind, and placebo control trial. ( Fux Otta, C; Gaido, MI; Iraci, GS; Kaplan, R; Torres, D; Wior, M; Wyse, EP, 2010) |
| " Metformin had no effect on adiponectin in spite of significant decreases in weight, fasting glucose, and insulin resistance." | 9.14 | Adiponectin levels in women with polycystic ovary syndrome: impact of metformin treatment in a randomized controlled study. ( Flyvbjerg, A; Frystyk, J; Lauszus, FF; Trolle, B, 2010) |
| "For women with BMI > 32 kg/m(2), clinical pregnancy and live birth rates were 22% (7/32) and 16% (5/32) with metformin, 15% (5/33) and 6% (2/33) with placebo." | 9.14 | PCOSMIC: a multi-centre randomized trial in women with PolyCystic Ovary Syndrome evaluating Metformin for Infertility with Clomiphene. ( Buckingham, KL; Falkiner, J; Farquhar, CM; Johnson, NP; Milsom, S; Okonkwo, QL; Singh, VP; Stewart, AW, 2010) |
| "This study was performed with the aim of evaluating the effect of metformin in reducing miscarriage when continued until the end of the first trimester of pregnancy in patients with polycystic ovary syndrome (PCOS) and infertility." | 9.14 | Effect of metformin on miscarriage in pregnant patients with polycystic ovary syndrome. ( Bagheri, B; Haghollahi, F; Shariat, M; Sohrabvand, F, 2009) |
| "To compare the efficacy of metformin and clomiphene citrate (CC) therapies for ovulation induction in anovulatory infertile women with polycystic ovary syndrome (PCOS)." | 9.14 | Comparison of metformin and clomiphene citrate therapy for induction of ovulation in the polycystic ovary syndrome. ( Api, M; Baran, S; Cetin, A; Goksedef, BP, 2010) |
| "In overweight patients with PCOS with hyperinsulinism, allopregnanolone secretion is impaired and metformin administration restored normal allopregnanolone concentrations modulating both steroid syntheses from the ovaries and from adrenal gland." | 9.14 | Metformin administration restores allopregnanolone response to adrenocorticotropic hormone (ACTH) stimulation in overweight hyperinsulinemic patients with PCOS. ( Casarosa, E; Chierchia, E; Genazzani, AD; Genazzani, AR; Luisi, M; Rattighieri, E; Santagni, S, 2010) |
| "The objective of this study was to investigate the effect of metformin versus acarbose in terms of ovulation rate, their impact on hormonal and metabolic status and tolerability of both drugs in patients with polycystic ovary syndrome (PCOS)." | 9.14 | Metformin versus acarbose therapy in patients with polycystic ovary syndrome (PCOS): a prospective randomised double-blind study. ( Denschlag, D; Gabriel, B; Hanjalic-Beck, A; Keck, C; Schaefer, W; Schories, M; Tempfer, C; Zahradnik, HP, 2010) |
| "The determinants of the variability in the clinical response to metformin in women with the polycystic ovary syndrome (PCOS) are enigmatic." | 9.14 | Organic cation transporter 1 polymorphisms predict the metabolic response to metformin in women with the polycystic ovary syndrome. ( Altieri, P; Di Rocco, A; Fulghesu, AM; Gambineri, A; Gasparini, DI; Mantovani, V; Pagotto, U; Pasquali, R; Sanna, S; Tomassoni, F, 2010) |
| " We aimed to study if the changes observed in the insulin sensitivity of PCOS patients during treatment with oral contraceptives or metformin associate changes in the serum inflammatory markers interleukin-6 (IL-6) and interleukin-18 (IL-18)." | 9.14 | Treatment of polycystic ovary syndrome (PCOS) with metformin ameliorates insulin resistance in parallel with the decrease of serum interleukin-6 concentrations. ( Escobar-Morreale, HF; Luque-Ramírez, M, 2010) |
| "Metformin is widely prescribed to pregnant women with polycystic ovary syndrome (PCOS) in an attempt to reduce pregnancy complications." | 9.14 | Metformin versus placebo from first trimester to delivery in polycystic ovary syndrome: a randomized, controlled multicenter study. ( Almås, I; Berg, AH; Berg, KF; Bjerke, C; Bunford, G; Carlsen, SM; Danielson, A; Eikeland, T; Flo, K; Heimstad, R; Hjelle, S; Kleggetveit, O; Lahmami, G; Lund, A; Romundstad, P; Skogøy, K; Stridsklev, S; Vanky, E; von Brandis, P, 2010) |
| "To measure the vascularization and ovarian volume with three-dimensional sonography in patients diagnosed of polycystic ovary syndrome with stimulated ovulation treatment, and to analyse the differences between the patients treated with clomiphen citrate versus clomiphen citrate and metformin." | 9.14 | [Sonographic ovarian vascularization and volume in women with polycystic ovary syndrome treated with clomiphene citrate and metformin]. ( Alvarez-Alvarez, P; Bajo-Arenas, JM; de la Fuente-Valero, J; Engels-Calvo, V; Orensanz-Fernández, I; Zapardiel-Gutiérrez, I, 2010) |
| "To compare the effects of combined N-acetyl cysteine (NAC) and clomiphene citrate (CC) and of combined metformin and CC on ovulation induction in anovulatory CC-resistant women with polycystic ovary syndrome (PCOS)." | 9.14 | N-acetyl cysteine plus clomiphene citrate versus metformin and clomiphene citrate in treatment of clomiphene-resistant polycystic ovary syndrome: a randomized controlled trial. ( Abu Hashim, H; Anwar, K; El-Fatah, RA, 2010) |
| " This study was designed to show the effect of metformin, one of the most important drugs used to reduce insulin resistance in patients with polycystic ovary syndrome (PCOS), on these adipokines." | 9.14 | Impact of treatment with metformin on adipokines in patients with polycystic ovary syndrome. ( Cantürk, Z; Cetinarslan, B; Dikmen, E; Tarkun, I, 2010) |
| "To determine the effects of metformin treatment on serum androgen levels ahead of and during the IVF cycle in infertile polycystic ovary syndrome (PCOS) women." | 9.14 | Possible metformin effect on adrenal androgens during pretreatment and IVF cycle in women with polycystic ovary syndrome. ( Carlsen, SM; Kjøtrød, SB; Sunde, A; von Düring, V, 2009) |
| "To evaluate ovulation and pregnancy predictors in infertile polycystic ovary syndrome (PCOS) patients who received clomiphene citrate (CC) and metformin as first-line ovulation inductors." | 9.14 | Efficacy predictors for metformin and clomiphene citrate treatment in anovulatory infertile patients with polycystic ovary syndrome. ( Falbo, A; Orio, F; Palomba, S; Tolino, A; Zullo, F, 2009) |
| "Our first specific aim in an observational study of 431 nondiabetic women with polycystic ovary syndrome (PCOS), aged >or=20 years and with >or=11 months follow-up on metformin diet, was to prospectively assess relationships between pretreatment glucose and insulin resistance (IR) and the development of type 2 diabetes mellitus (T2DM) or gestational diabetes (GD)." | 9.13 | An observational study of reduction of insulin resistance and prevention of development of type 2 diabetes mellitus in women with polycystic ovary syndrome treated with metformin and diet. ( Glueck, CJ; Goldenberg, N; Sieve, L; Wang, P, 2008) |
| "To decide if metformin augments clomiphene response for ovulation induction in non-obese women with polycystic ovary syndrome, a prospective randomised placebo-controlled trial was undertaken among 27 patients, who were found eligible for this study following clinical assessment and basic investigations." | 9.13 | Does metformin augment the ovulation inducing effects of clomiphene in non-obese women with polycystic ovary syndrome? ( Chaudhury, K; Chaudhury, S; Chowdhury, S, 2008) |
| "One hundred forty-two nondiabetic women with polycystic ovary syndrome (PCOS) who had at least one live-birth (LB) pregnancy on metformin diet (172 pregnancies, 180 LBs)." | 9.13 | Prevention of gestational diabetes by metformin plus diet in patients with polycystic ovary syndrome. ( Aregawi, D; Glueck, CJ; Pranikoff, J; Wang, P, 2008) |
| "To determine the effect of metformin pretreatment on in vitro maturation (IVM) in the patients with clomiphene citrate-resistant polycystic ovary syndrome." | 9.13 | Effect of metformin pretreatment on pregnancy outcome of in vitro matured oocytes retrieved from women with polycystic ovary syndrome. ( Cao, Y; Cong, L; Li, J; Wei, Z; Zhang, Z; Zhou, P, 2008) |
| "Serum uric acid levels were measured in 40 polycystic ovary syndrome (PCOS) patients and 40 non-hyperandrogenic women matched for BMI and grade of obesity, and were followed-up in 34 PCOS patients who were randomized to an oral contraceptive containing 35 mg ethinyl-estradiol plus 2 mg cyproterone acetate (Diane(35) Diario) or metformin (850 mg twice daily) for 24 weeks." | 9.13 | Serum uric acid concentration as non-classic cardiovascular risk factor in women with polycystic ovary syndrome: effect of treatment with ethinyl-estradiol plus cyproterone acetate versus metformin. ( Alvarez-Blasco, F; Escobar-Morreale, HF; Luque-Ramírez, M; Uriol Rivera, MG, 2008) |
| "To compare the effects of insulin sensitization with metformin to weight reduction by rimonabant on biochemical hyperandrogenaemia and insulin resistance in patients with PCOS." | 9.13 | A comparison between rimonabant and metformin in reducing biochemical hyperandrogenaemia and insulin resistance in patients with polycystic ovary syndrome (PCOS): a randomized open-label parallel study. ( Atkin, SL; Cho, LW; Coady, AM; Kilpatrick, ES; Sathyapalan, T, 2008) |
| "The beneficial effects of metformin in patients with type 2 diabetes mellitus (T2DM) and polycystic ovarian syndrome (PCOS) are thought to be in part due to weight reduction." | 9.13 | Metformin increases fasting plasma peptide tyrosine tyrosine (PYY) in women with polycystic ovarian syndrome (PCOS). ( Batterham, RL; Conway, GS; Tsilchorozidou, T, 2008) |
| "We evaluated exenatide (EX) and metformin (MET), alone and in combination (COM), on menstrual cyclicity, hormonal parameters, metabolic profiles, and inflammatory markers in overweight, insulin-resistant women with PCOS." | 9.13 | Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. ( Bhushan, M; Bhushan, R; Elkind-Hirsch, K; Marrioneaux, O; Vernor, D, 2008) |
| "An RCT among newly diagnosed, therapy naive women with polycystic ovary syndrome (PCOS) showed no significant differences in ovulation rate, ongoing pregnancy rate or spontaneous abortion rate in favour of clomifene citrate plus metformin compared with clomifene citrate." | 9.13 | Does adding metformin to clomifene citrate lead to higher pregnancy rates in a subset of women with polycystic ovary syndrome? ( Bossuyt, PM; Korevaar, JC; Moll, E; van der Veen, F, 2008) |
| "To evaluate metformin's effects on pregnancy outcomes in women with polycystic ovary syndrome." | 9.12 | Gestational metformin administration in women with polycystic ovary syndrome: A systematic review and meta-analysis of randomized control studies. ( Cao, Q; Fu, J; Hu, Y; Huang, W; Huang, X; Wu, L; Zhang, J, 2021) |
| "Our aim was to conduct a systematic review and meta-analysis to evaluate the efficacy of metformin for treatment of PCOS-related acne." | 9.12 | Metformin Therapy for Acne in Patients with Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis. ( Chang, YT; Huang, YC; Yee, FJ; Yen, H, 2021) |
| "The present study aimed to investigate the effects of metformin on body weight in polycystic ovary syndrome (PCOS) patients by model-based meta-analysis (MBMA)." | 9.12 | Effects of metformin on body weight in polycystic ovary syndrome patients: model-based meta-analysis. ( Chen, X; He, S; Wang, D, 2021) |
| "The efficacy of simvastatin plus metformin to treat polycystic ovary syndrome (PCOS) remained controversial." | 9.12 | Efficacy of simvastatin plus metformin for polycystic ovary syndrome: A meta-analysis of randomized controlled trials. ( Meng, J; Zhu, Y, 2021) |
| "To assess the impact of bariatric surgery on pregnancy outcomes in women with PCOS compared to metformin therapy in a systematic review and meta-analysis." | 9.12 | The Impact of Bariatric Surgery Compared to Metformin Therapy on Pregnancy Outcomes in Patients with Polycystic Ovarian Syndrome: a Systematic Review and Meta-analysis. ( Chang, C; Chang, S; Poles, J; Popov, V, 2021) |
| "This review covers the current evidence regarding the use of metformin as a therapeutic intervention for optimizing pregnancy outcomes in women with polycystic ovary syndrome (PCOS)." | 9.12 | Effects of metformin treatment on pregnancy outcomes in patients with polycystic ovary syndrome. ( Chronopoulou, E; Homburg, R; Raperport, C, 2021) |
| "Metformin is widely used as an insulin sensitizer in polycystic ovary syndrome (PCOS) patients." | 9.12 | The effect of metformin on homocysteine levels in patients with polycystic ovary syndrome: A systematic review and meta-analysis. ( Bai, Y; Fang, Z; Li, X; Pan, H; Wang, F; Yang, X; Zhang, C, 2021) |
| "Recent studies have revealed that myo-inositol could be more influential in patients with polycystic ovary syndrome (PCOS)." | 9.12 | The effects of myo-inositol vs. metformin on the ovarian function in the polycystic ovary syndrome: a systematic review and meta-analysis. ( Azizi Kutenaei, M; Eini, F; Ghaemmaghami, P; Hosseini Teshnizi, S; Roozbeh, N, 2021) |
| "To improve insulin action, most clinicians prescribe Metformin in patients with insulin resistance (IR)." | 9.12 | Metformin does not improve insulin sensitivity over hypocaloric diets in women with polycystic ovary syndrome: a systematic review of 12 studies. ( Garcia-Hernandez, SC; Gonzalez-Mejia, ME; López-Bayghen, E; Pacheco-Soto, BT; Porchia, LM, 2021) |
| "Several previous randomized controlled trials (RCTs) evaluated the efficacy of metformin combined with simvastatin in the treatment of polycystic ovary syndrome (PCOS), yet the results of the researches are not consistent." | 9.12 | The efficacy and safety of metformin combined with simvastatin in the treatment of polycystic ovary syndrome: A meta-analysis and systematic review. ( Chen, L; Liu, Y; Shao, Y; Xie, J; Zhu, G, 2021) |
| "It has been reported that women with polycystic ovary syndrome (PCOS) benefit from metformin therapy." | 9.12 | Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study. ( Balen, AH; Barth, JH; Glanville, J; Hayden, CJ; Tang, T; White, D, 2006) |
| "Metformin has been shown to improve fertility in anovulatory patients with polycystic ovary syndrome (PCOS), inducing not only a high ovulation and pregnancy rate but also reducing the incidence of miscarriages." | 9.12 | Uterine effects of metformin administration in anovulatory women with polycystic ovary syndrome. ( Carmina, E; Cascella, T; Colao, A; Falbo, A; Manguso, F; Orio, F; Palomba, S; Russo, T; Tolino, A; Zullo, F, 2006) |
| "Metformin is successfully used in the treatment of cycle disorders and anovulation in women with polycystic ovary syndrome (PCOS)." | 9.12 | Early effects of metformin in women with polycystic ovary syndrome: a prospective randomized, double-blind, placebo-controlled trial. ( Eisenhardt, S; Germeyer, A; Hamann, A; Henschel, V; Schwarzmann, N; Strowitzki, T; von Wolff, M, 2006) |
| " Much better decrease in the level of testosterone and free androgen index was established in group treated with metformin, while the indices of insulin resistance were better influenced in the group treated with rosiglitazone." | 9.12 | Metformin versus rosiglitazone in the treatment of polycystic ovary syndrome. ( Mitkov, M; Pehlivanov, B; Terzieva, D, 2006) |
| "In women with polycystic ovary syndrome, C-reactive protein levels and D-dimer, antithrombin III, activated protein C resistance, and activated partial thromboplastin time were unaffected by metformin treatment throughout pregnancy." | 9.12 | Beneficial effect of metformin on pregnancy outcome in women with polycystic ovary syndrome is not associated with major changes in C-reactive protein levels or indices of coagulation. ( Bjerve, K; Carlsen, SM; Hjorth-Hansen, H; Salvesen, KA; Vanky, E, 2006) |
| "Metformin significantly lowered total testosterone concentrations, increased the likelihood of menses, and improved high-density lipoprotein cholesterol levels without affecting measures of insulin sensitivity or body weight." | 9.12 | Randomized placebo-controlled trial of metformin for adolescents with polycystic ovary syndrome. ( Baltzer, F; Bridger, T; MacDonald, S; Rodd, C, 2006) |
| "To determine if short courses of metformin (MET) administration in patients with polycystic ovary syndrome (PCOS) would reduce fasting insulin and improve the efficacy of clomiphene citrate (CC) to induce ovulation." | 9.12 | Two weeks of metformin improves clomiphene citrate-induced ovulation and metabolic profiles in women with polycystic ovary syndrome. ( Bonpane, CM; Helliwell, JP; Jaramillo, L; Katz, S; Khorram, O, 2006) |
| "To compare the efficacy of rosiglitazone and clomiphene citrate (CC) with metformin and CC in women with CC-resistant polycystic ovary syndrome (PCOS)." | 9.12 | A randomized controlled trial of the efficacy of rosiglitazone and clomiphene citrate versus metformin and clomiphene citrate in women with clomiphene citrate-resistant polycystic ovary syndrome. ( Ardawi, MS; Rouzi, AA, 2006) |
| "Current data supporting the effectiveness of metformin as a fertility treatment for women with polycystic ovary syndrome have been misinterpreted." | 9.12 | No more surrogate end-points in randomised trials: the PCOSMIC trial protocol for women with polycystic ovary syndrome using metformin for infertility with clomiphene. ( Johnson, NP, 2006) |
| "The purpose of this retrospective study was to compare the frequency of menstrual cyclicity between two groups of patients with polycystic ovary syndrome: women who were followed while on metformin for 3-6 months and those who were followed for >6 months." | 9.12 | Effects of short-term and long-term metformin treatment on menstrual cyclicity in women with polycystic ovary syndrome. ( Apridonidze, T; Essah, PA; Iuorno, MJ; Nestler, JE, 2006) |
| "To evaluate the effects of metformin on insulin resistance, androgen concentration, ovulation rates and pregnancy rates in infertile women with polycystic ovary syndrome (PCOS)." | 9.12 | Effects of metformin on insulin resistance, androgen concentration, ovulation and pregnancy rates in women with polycystic ovary syndrome following laparoscopic ovarian drilling. ( Kocak, I; Ustün, C, 2006) |
| "To compare the effectiveness of clomifene citrate plus metformin and clomifene citrate plus placebo in women with newly diagnosed polycystic ovary syndrome." | 9.12 | Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. ( Bossuyt, PM; Korevaar, JC; Lambalk, CB; Moll, E; van der Veen, F, 2006) |
| "To establish whether metformin has a significant action in reducing visceral fat and improving other metabolic parameters in women with polycystic ovary syndrome (PCOS)." | 9.12 | The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome--a randomised, double-blind, placebo-controlled trial. ( Acharya, U; Fox, B; Lord, J; Thomas, R; Wilkin, T, 2006) |
| "To evaluate the therapeutic effect of metformin on the clinical features, hormonal and metabolic profile in obese women with a hyperinsulinemic polycystic ovary syndrome (PCOS)." | 9.12 | Metformin improves menstrual patterns, endocrine and metabolic profile in obese hyperinsulinemic women with a polycystic ovary syndrome. ( Ahmeti, I; Dimitrovski, Ch; Dimova, Z; Krstevska, B; Misevska, S; Pemovska, G; Simeonova, S, 2006) |
| "The few controlled trials performed so far indicate that the addition of metformin and/or flutamide to a hypocaloric diet in obese women with polycystic ovary syndrome (PCOS) effectively influences different phenotypic aspects of the syndrome." | 9.12 | Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study. ( Cacciari, M; Cavazza, C; Gambineri, A; Morselli-Labate, AM; Pagotto, U; Pasquali, R; Patton, L; Vaccina, A, 2006) |
| "8 kg/m2, we assessed effeicacy of metformin-diet for 1 year for reduction of weight, insulin, HOMA insulin resistance (IR), cholesterol, triglycerides, and resumption of regular menses." | 9.12 | Metformin-diet ameliorates coronary heart disease risk factors and facilitates resumption of regular menses in adolescents with polycystic ovary syndrome. ( Agloria, M; Aregawi, D; Glueck, CJ; Luo, G; Sieve, L; Wang, P; Winiarska, M, 2006) |
| "To evaluate the effects of metformin and of clomiphene citrate (CC) on the ovarian blood perfusion and on perifollicular and peri-corpus luteum (CL) vascularity in anovulatory women with polycystic ovary syndrome (PCOS)." | 9.12 | Effects of metformin and clomiphene citrate on ovarian vascularity in patients with polycystic ovary syndrome. ( Falbo, A; Orio, F; Palomba, S; Russo, T; Tolino, A; Zullo, F, 2006) |
| "Metformin is better for ovulation induction than CC alone and equivalent for pregnancy achievement." | 9.12 | Comparison of clomiphene citrate, metformin, or the combination of both for first-line ovulation induction and achievement of pregnancy in 154 women with polycystic ovary syndrome. ( Granger, L; Lavoie, HB; Neveu, N; St-Michel, P, 2007) |
| "The authors hypothesized that a metformin (MET)-diet would improve symptoms of idiopathic intracranial hypertension (IIH) in women who also had polycystic ovary syndrome (PCOS) or hyperinsulinemia without PCOS." | 9.12 | Changes in weight, papilledema, headache, visual field, and life status in response to diet and metformin in women with idiopathic intracranial hypertension with and without concurrent polycystic ovary syndrome or hyperinsulinemia. ( Aregawi, D; Glueck, CJ; Goldenberg, N; Golnik, KC; Sieve, L; Wang, P, 2006) |
| "A prospective cohort study was set up to determine the beneficial effects of metformin on PCOS patients during pregnancy." | 9.12 | Metformin reduces abortion in pregnant women with polycystic ovary syndrome. ( Al-Inany, H; Foutouh, IA; Khattab, S; Moaz, M; Mohsen, IA; Ramadan, A, 2006) |
| "to compare the clinical, hormonal and biochemical changes after the application of the two ways of influence upon insulin resistance in women with PCOS - reduction of weight and application of metformin." | 9.12 | [Clinical, hormonal and biochemical changes after treatment with metformin and weight reduction in women with polycystic ovary syndrome]. ( Kavŭrdzhikova, S; Mitkov, M; Pekhlivanov, B, 2006) |
| "Metformin appears to be an effective medicine to induce ovulation in women with polycystic ovary syndrome and insulin resistance." | 9.12 | Increase of multiple pregnancies caused by ovulation induction with gonadotropin in combination with metformin in infertile women with polycystic ovary syndrome. ( Hirano, Y; Kikuchi, K; Shibahara, H; Suzuki, M; Suzuki, T; Takamizawa, S, 2007) |
| "We randomly assigned 626 infertile women with the polycystic ovary syndrome to receive clomiphene citrate plus placebo, extended-release metformin plus placebo, or a combination of metformin and clomiphene for up to 6 months." | 9.12 | Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. ( Barnhart, HX; Carr, BR; Carson, SA; Cataldo, NA; Coutifaris, C; Diamond, MP; Giudice, LC; Gosman, GG; Legro, RS; Leppert, PC; McGovern, PG; Myers, ER; Nestler, JE; Schlaff, WD; Steinkampf, MP, 2007) |
| "Forty pregnant women with polycystic ovary syndrome (PCOS) were enrolled in a randomized, double-blind, placebo-controlled trial of metformin (1700 mg/day) during pregnancy." | 9.12 | Metformin treatment in pregnant women with polycystic ovary syndrome--is reduced complication rate mediated by changes in the uteroplacental circulation? ( Carlsen, SM; Salvesen, KA; Vanky, E, 2007) |
| "To compare the effect of N-acetyl cysteine and metformin on hormonal profile (insulin and T) and ovulation rate in women with clomiphene citrate-resistant polycystic ovary syndrome." | 9.12 | N-acetyl cysteine vs. metformin in treatment of clomiphene citrate-resistant polycystic ovary syndrome: a prospective randomized controlled study. ( Elnashar, A; Fahmy, M; Ibrahim, K; Mansour, A, 2007) |
| "One hundred and two women with insulin-resistant polycystic ovary syndrome were randomized to treatment with a vitamin B preparation, metformin, or both, in conjunction with standard infertility treatment." | 9.12 | Prospective, randomized trial of metformin and vitamins for the reduction of plasma homocysteine in insulin-resistant polycystic ovary syndrome. ( Friedler, S; Raziel, A; Ron-El, R; Rotem, C; Schachter, M; Strassburger, D, 2007) |
| "Serum homocysteine levels were unaffected by metformin treatment both in nonpregnant and pregnant women with polycystic ovary syndrome." | 9.12 | Homocysteine levels are unaffected by metformin treatment in both nonpregnant and pregnant women with polycystic ovary syndrome. ( Carlsen, SM; Kjøtrød, S; Romundstad, P; Vanky, E, 2007) |
| "Randomized open-label study of metformin and rosiglitazone in 16 women with polycystic ovary syndrome (PCOS) performed at a single academic health center." | 9.12 | The effects of metformin and rosiglitazone, alone and in combination, on the ovary and endometrium in polycystic ovary syndrome. ( Demers, LM; Dodson, WC; Gnatuk, CL; Kunselman, AR; Legro, RS; Williams, NI; Zaino, RJ, 2007) |
| "The objective of the study was to evaluate the effects of metformin suspension on insulin sensitivity in PCOS patients." | 9.12 | Insulin sensitivity after metformin suspension in normal-weight women with polycystic ovary syndrome. ( De Feo, P; Falbo, A; Manguso, F; Orio, F; Palomba, S; Russo, T; Tolino, A; Zullo, F, 2007) |
| "65 kg/m(2)) hirsute women with polycystic ovary syndrome and normal insulin sensitivity were treated with 850 mg metformin orally, three times daily, for 4 months." | 9.12 | Metformin in normal-weight hirsute women with polycystic ovary syndrome with normal insulin sensitivity. ( Baracat, EC; Halpern, A; Maciel, GA; Marcondes, JA; Yamashita, SA, 2007) |
| "The aim of the study was to compare in a clinical setting the efficacy of CC and metformin as first-line approaches for treating anovulation in infertile PCOS patients." | 9.12 | Clomiphene citrate versus metformin as first-line approach for the treatment of anovulation in infertile patients with polycystic ovary syndrome. ( Falbo, A; Orio, F; Palomba, S; Russo, T; Tolino, A; Zullo, F, 2007) |
| "To compare the efficacy of weight loss, metformin and rosiglitazone in women with polycystic ovary syndrome (PCOS)." | 9.12 | [Effect of lifestyle adjustment, metformin and rosiglitazone in polycystic ovary syndrome]. ( Jin, LN; Ma, LK; Xu, L; Yu, Q, 2007) |
| "Our aim was to assess the effects of metformin on menstrual frequency, fasting plasma glucose (FPG), insulin resistance assessed as HOMA-index, weight, waist/hip ratio, blood pressure (BP), serum lipids, and testosterone levels in women with polycystic ovary syndrome (PCOS) METHODS: In a randomized, controlled, double-blinded setup, 56 women aged 18-45 with PCOS were treated with either metformin 850 mg or placebo twice daily for 6 months." | 9.12 | Efficacy of metformin in obese and non-obese women with polycystic ovary syndrome: a randomized, double-blinded, placebo-controlled cross-over trial. ( Flyvbjerg, A; Kesmodel, U; Lauszus, FF; Trolle, B, 2007) |
| "To compare the clinical results and reproductive outcome in obese women with polycystic ovary syndrome (PCOS) following dietary intervention or treatment with metformin." | 9.12 | Dietary intervention versus metformin to improve the reproductive outcome in women with polycystic ovary syndrome. A prospective comparative study. ( Al-Qudah, MA; El-Uri, FI; Qublan, HS; Yannakoula, EK, 2007) |
| "To determine the clinical, hormonal, and biochemical effects of metformin therapy in obese and nonobese patients with polycystic ovary syndrome (PCOS)." | 9.11 | Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin. ( Abi Haidar, M; Alves da Motta, EL; Baracat, EC; de Lima, GR; Maciel, GA; Soares Júnior, JM, 2004) |
| "Women with polycystic ovary syndrome treated with metformin and lifestyle advice were studied." | 9.11 | Dexamethasone reduces androgen levels in metformin-treated patients with polycystic ovary syndrome. ( Bjerve, KS; Carlsen, SM; Kjøtrød, SB; Maesel, A; Vanky, E, 2004) |
| "In a prospective observational study of 42 pregnancies in 39 Caucasian women (age 30 +/- 4 years) with polycystic ovary syndrome (PCOS), we examined effects of metformin on maternal insulin, insulin resistance (IR), insulin secretion (IS), weight gain, development of gestational diabetes (GD), testosterone and plasminogen activator inhibitor activity." | 9.11 | Metformin during pregnancy reduces insulin, insulin resistance, insulin secretion, weight, testosterone and development of gestational diabetes: prospective longitudinal assessment of women with polycystic ovary syndrome from preconception throughout preg ( Glueck, CJ; Goldenberg, N; Loftspring, M; Sherman, A; Wang, P, 2004) |
| "To evaluate the effects of metformin on insulin resistance, ovarian androgen production, and clomiphene-induced ovulation and pregnancy rates in infertile women with polycystic ovary syndrome (PCOS)." | 9.11 | The effects of metformin on insulin resistance, clomiphene-induced ovulation and pregnancy rates in women with polycystic ovary syndrome. ( Aygen, E; Keleştimur, F; Sahin, Y; Yirmibeş, U, 2004) |
| "We prospectively assessed growth and motor-social development during the first 18 months of life in 126 live births (122 pregnancies) to 109 women with polycystic ovary syndrome (PCOS) who conceived on and continued metformin (1." | 9.11 | Height, weight, and motor-social development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on and continued metformin through pregnancy. ( Glueck, CJ; Goldenberg, N; Loftspring, M; Pranikoff, J; Sieve, L; Wang, P, 2004) |
| "Our aim was to investigate the effect of pre-treatment with metformin in women with polycystic ovary syndrome (PCOS) scheduled for IVF stimulation." | 9.11 | Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study. ( Carlsen, SM; Kjøtrød, SB; von Düring, V, 2004) |
| "103 PCOS women (age 18-40) were treated, according to their body weight, with either 1000 mg or 1700 mg metformin per day after assessment of insulin resistance." | 9.11 | [Metformin, an efficacious drug in the treatment of polycystic ovary syndrome]. ( Elsenbruch, S; Finke, R; Gärtner, R; Hahn, S; Janssen, OE; Mann, K; Quadbeck, B, 2004) |
| "Investigation of a possible effect of metformin on androgen levels in pregnant women with polycystic ovary syndrome (PCOS)." | 9.11 | Metformin reduces pregnancy complications without affecting androgen levels in pregnant polycystic ovary syndrome women: results of a randomized study. ( Carlsen, SM; Fougner, KJ; Heimstad, R; Romundstad, P; Salvesen, KA; Vanky, E, 2004) |
| "We compared the efficacy of spironolactone (50 mg/d) with metformin (1000 mg/d) after random allocation in 82 adolescent and young women with polycystic ovary syndrome (PCOS) on body mass index (BMI), waist-to-hip ratio, blood pressure, menstrual cyclicity, hirsutism, hormonal levels, glycemia, and insulin sensitivity at baseline and at the 3rd and 6th months of treatment." | 9.11 | Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open-labeled study. ( Ammini, AC; Dwivedi, SN; Eunice, M; Ganie, MA; Gulati, M; Gupta, N; Khurana, ML, 2004) |
| "To assess the effects of 6 months of metformin therapy on clinical and biochemical parameters in polycystic ovary syndrome (PCOS) and to evaluate those parameters in responders and nonresponders to identify the subjects who respond to an insulin sensitizer in PCOS." | 9.11 | Effects of metformin on clinical and biochemical parameters in polycystic ovary syndrome. ( Agarwal, N; Kriplani, A, 2004) |
| "Low-dose flutamide-metformin has been developed as a background therapy for non-obese adolescents and young women with hyperinsulinaemic hyperandrogenism, a variant of polycystic ovary syndrome (PCOS)." | 9.11 | Flutamide-metformin plus an oral contraceptive (OC) for young women with polycystic ovary syndrome: switch from third- to fourth-generation OC reduces body adiposity. ( De Zegher, F; Ibáñez, L, 2004) |
| " Modest weight reduction was found in all treatment groups, with the most significant reduction occurring with the combination of metformin and lifestyle intervention." | 9.11 | A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. ( Craig, K; Guzick, DS; Hoeger, KM; Kochman, L; Miller, RK; Wixom, N, 2004) |
| "A low-dose combination of flutamide-metformin and ethinylestradiol-drospirenone was recently found to reduce the excess of total and abdominal fat, to diminish the deficit in lean mass, and to attenuate the dysadipocytokinemia of young women with ovarian hyperandrogenism, a variant of polycystic ovary syndrome." | 9.11 | Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of early, low-dose flutamide. ( Cabré, S; De Zegher, F; Ibáñez, L; Valls, C, 2004) |
| "At present, it is unclear what the role is of laparoscopic ovarian diathermy (LOD) and of metformin administration as second-line treatments for ovulation induction in women with polycystic ovary syndrome (PCOS) after failure of clomiphene citrate (CC) treatment." | 9.11 | Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate-resistant women with polycystic ovary syndrome: a prospective parallel randomized double-blind placebo-controlled trial. ( Colao, A; Corea, D; Doldo, P; Falbo, A; Lombardi, G; Nardo, LG; Orio, F; Palomba, S; Russo, T; Tolino, A; Zullo, F, 2004) |
| "Flutamide (Flu)-metformin (Met) with ethinylestradiol-drospirenone is a combination therapy that reduces the total and abdominal fat excess, diminishes the lean mass deficit, and attenuates the dysadipocytokinemia of young and nonobese women with ovarian hyperandrogenism, a variant of polycystic ovary syndrome." | 9.11 | Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of metformin at the start and after more than one year of therapy. ( de Zegher, F; Ibáñez, L, 2005) |
| "The aim of this study was to evaluate the effects of metformin and acarbose on insulin resistance, hormone profiles and ovulation rates in patients with clomiphene citrate-resistant polycystic ovary syndrome (PCOS)." | 9.11 | Comparison of the effects of acarbose and metformin use on ovulation rates in clomiphene citrate-resistant polycystic ovary syndrome. ( Akgün, A; Koç, S; Ozcan, J; Savan, K; Sönmez, AS; Sut, N; Toklar, A; Yasar, L; Yazicioğu, F, 2005) |
| " metformin on the hormonal and biochemical features of patients with polycystic ovarian syndrome (PCOS)." | 9.11 | Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome. ( Atkin, SL; Holding, S; Jayagopal, V; Jennings, PE; Kilpatrick, ES, 2005) |
| "To determine the clinical, biochemical, hormonal, and ultrasonographic effects of 6 months of metformin therapy in women with polycystic ovary syndrome (PCOS) and compare with pretherapy parameters." | 9.11 | Metformin therapy in women with polycystic ovary syndrome. ( Aruna, J; Dadhwal, V; Kumar, S; Misra, R; Mittal, S; Vimala, N, 2004) |
| "Adding metformin slightly modified the treatment effect of COC, causing a more significant decrease in the free androgen index but having no additional positive impact on lipids, insulin sensitivity, SHBG or testosterone." | 9.11 | The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients. ( Cibula, D; Dvorakova, K; Fanta, M; Hill, M; Skrenkova, J; Skrha, J; Stanicka, S; Vrbikova, J; Zivny, J, 2005) |
| " The purpose of this study was to evaluate whether pioglitazone decreases insulin resistance (IR) and hyperandrogenism to the same extent as metformin in obese women with PCOS who have not received any previous treatment." | 9.11 | Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. ( Aguayo, P; Arteaga-Troncoso, G; Crespo, G; Hernández, L; Luna, S; Ortega-González, C; Parra, A, 2005) |
| " Although long-term treatment with metformin can increase Hcy levels in patients with type II diabetes mellitus or coronary heart disease, it is becoming an increasingly accepted and widespread medication in polycystic ovary syndrome (PCOS)." | 9.11 | Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: a randomized study. ( Aslan, E; Bagis, T; Erkanli, S; Haydardedeoglu, B; Kilicdag, EB; Tarim, E; Zeyneloglu, HB, 2005) |
| "Assessment of ovarian responses to metformin treatment in obese women with polycystic ovary syndrome (PCOS)." | 9.11 | Metformin reduces serum mullerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment. ( Fleming, R; Harborne, L; Ling, D; MacLaughlin, DT; Norman, J; Sattar, N; Seifer, DB, 2005) |
| "Much better and faster decrease in the level of testosterone and free androgen index in group with combined use of metformin and Diane35 was established, without deterioration of the anthropometric and biochemical indices and insulin sensitivity." | 9.11 | Combined use of metformin and ethinyl estradiol-cyproterone acetate in polycystic ovary syndrome. ( Mitkov, M; Pehlivanov, B; Terzieva, D, 2005) |
| "We aimed to investigate whether metformin would reverse the endocrinopathy of polycystic ovary syndrome (PCOS), allowing resumption of cyclic ovulation and regular menses, and whether metformin causes any change in the serum concentration of insulin-like growth factor-I (IGF-I) in patients with PCOS." | 9.11 | Increased insulin-like growth factor-I levels in women with polycystic ovary syndrome, and beneficial effects of metformin therapy. ( Berker, B; Corapcioglu, D; Demirel, C; Emral, R; Kose, K; Unlu, C, 2004) |
| "The aim of the current study was to assess the effects of B-group vitamins and folic acid administration on serum levels of homocysteine (Hcy) in patients with polycystic ovarian syndrome (PCOS) on short-term metformin treatment." | 9.11 | Administration of B-group vitamins reduces circulating homocysteine in polycystic ovarian syndrome patients treated with metformin: a randomized trial. ( Aslan, E; Bagis, T; Erkanli, S; Haydardedeoglu, B; Kilicdag, EB; Kuscu, E; Simsek, E; Tarim, E, 2005) |
| "Although metformin has been shown to be effective in the treatment of anovulation in women with polycystic ovary syndrome (PCOS), clomiphene citrate (CC) is still considered to be the first-line drug to induce ovulation in these patients." | 9.11 | Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. ( Carmina, E; Cascella, T; Colao, A; Falbo, A; Manguso, F; Orio, F; Palomba, S; Russo, T; Tolino, A; Zullo, F, 2005) |
| "The aim of this study was to investigate the endothelial status in young women with polycystic ovary syndrome (PCOS), using a simple and easily reproducible hemodynamic method combined with a biological marker and to evaluate the effect of metformin treatment on these parameters." | 9.11 | Metformin administration improves endothelial function in women with polycystic ovary syndrome. ( Aessopos, A; Alexandraki, K; Diamanti-Kandarakis, E; Lekakis, J; Mavrikakis, M; Papamichael, C; Piperi, C; Protogerou, A, 2005) |
| "Weight loss is a feature of protracted metformin therapy in obese women with PCOS, with greater weight reduction potentially achievable with higher doses." | 9.11 | Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses. ( Fleming, R; Harborne, LR; Norman, JE; Sattar, N, 2005) |
| "To evaluate the effect of ultra-short (12 days) metformin pretreatment in clomiphene-citrate (CC) resistant polycystic ovary syndrome (PCOS)." | 9.11 | Ultra-short metformin pretreatment for clomiphene citrate-resistant polycystic ovary syndrome. ( Huang, WY; Hwu, YM; Lee, RK; Lin, MH; Lin, SY, 2005) |
| "In order to explore the effects of metformin combined with cyproterone acetate (CPA) on the clinical features, endocrine and metabolism of the patients with polycystic ovarian syndrome (PCOS), 50 cases of non-obese PCOS were randomly subjected to CPA (CPA treatment group, n = 25) and CPA+ metformin (n = 25) treatment for 6 months." | 9.11 | Effects of metformin combined with cyproterone acetate on clinical features, endocrine and metabolism of non-obese women with polycystic ovarian syndrome. ( Liu, Y; Lv, L; Sun, Y; Tan, K, 2005) |
| " The aim of this study was to assess the effects of rosiglitazone and metformin on cardiovascular disease risk factors such as insulin resistance, oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome (PCOS)." | 9.11 | The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome. ( Arslan, M; Ayvaz, G; Bukan, N; Cakir, N; Karakoç, A; Törüner, F; Yilmaz, M, 2005) |
| "In the present study, we investigated the impact of metformin therapy on in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) outcomes in patients with polycystic ovary syndrome (PCOS)." | 9.11 | Metformin treatment in patients with polycystic ovary syndrome undergoing in vitro fertilization: a prospective randomized trial. ( Bagis, T; Ceyhan, T; Cincik, M; Goktolga, U; Onalan, G; Pabuçcu, R, 2005) |
| "Adolescents with PCOS treated with metformin or OCP experienced similar beneficial outcomes including reduction in androgen levels, weight loss, and increased insulin sensitivity." | 9.11 | Randomized controlled trial evaluating response to metformin versus standard therapy in the treatment of adolescents with polycystic ovary syndrome. ( Allen, HF; Heptulla, RA; Koenigs, L; Mazzoni, C; Miller, N; Murray, MA; Reiter, EO, 2005) |
| "To determine the effect of metformin therapy in achieving menstrual regularity, pregnancy, reducing obesity and hyperinsulinemia in patients with polycystic ovarian syndrome (PCOS)." | 9.11 | Impact of metformin therapy in patients with polycystic ovarian syndrome. ( Hasan, JA; Memon, GU, 2005) |
| "The aim of the present study was to assess the effects of metformin and rosiglitazone on menstrual cyclicity and hirsutism in patients with polycystic ovary syndrome (PCOS)." | 9.11 | The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome. ( Arslan, M; Ayvaz, G; Cakir, N; Karakoç, A; Tiras, B; Törüner, FB; Yilmaz, M, 2005) |
| "To compare the efficacy of clomiphene citrate (CC) administration for ovulation induction in CC-resistant oligo-ovulatory women with polycystic ovary syndrome (PCOS) after metformin treatment or laparoscopic ovarian drilling (LOD)." | 9.11 | Metformin administration and laparoscopic ovarian drilling improve ovarian response to clomiphene citrate (CC) in oligo-anovulatory CC-resistant women with polycystic ovary syndrome. ( Caterina, G; Colao, A; Falbo, A; Manguso, F; Orio, F; Palomba, S; Russo, T; Tolino, A; Zullo, F, 2005) |
| " There was a significant improvement in hirsutism at the end of the metformin phase compared with placebo: F-G score 15." | 9.10 | The effect of metformin on hirsutism in polycystic ovary syndrome. ( Gordon, D; Kelly, CJ, 2002) |
| "Most patients with polycystic ovary syndrome (PCOS) have hyperinsulinemia; thus it has been postulated that insulin-lowering drugs, such as metformin, might be a useful long-term choice." | 9.10 | Clinical and endocrinological effects of 6 months of metformin treatment in young hyperinsulinemic patients affected by polycystic ovary syndrome. ( De Pergola, G; Lorusso, F; Loverro, G; Mei, L; Nicolardi, V; Selvaggi, L, 2002) |
| "Metformin, an insulin-sensitizing drug, has been shown to improve ovarian function and glucose metabolism in obese women with polycystic ovary syndrome (PCOS), but its effects and possible benefits in nonobese PCOS subjects are not well known." | 9.10 | Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. ( Koivunen, R; Martikainen, H; Morin-Papunen, L; Ruokonen, A; Tapanainen, JS; Vauhkonen, I, 2003) |
| "The endocrine-metabolic status of non-obese, young women with polycystic ovary syndrome (PCOS) is normalized more effectively by combined treatment with flutamide and metformin than by either of these drugs in monotherapy." | 9.10 | Low-dose combination of flutamide, metformin and an oral contraceptive for non-obese, young women with polycystic ovary syndrome. ( de Zegher, F; Ibáñez, L, 2003) |
| "There is still some controversy concerning the effects of metformin in the treatment of Polycystic Ovary Syndrome (PCOS)." | 9.10 | Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double-blind and placebo-controlled trial. ( Capp, E; Chou, KH; Spritzer, PM; von Eye Corleta, H, 2003) |
| "Metformin effectively restores insulin sensitivity in insulin-resistant women with polycystic ovary syndrome (PCOS)." | 9.10 | The effect of metformin on ovarian stimulation and in vitro fertilization in insulin-resistant women with polycystic ovary syndrome: an open-label randomized cross-over trial. ( Abyholm, T; Dale, PO; Fedorcsák, P; Storeng, R; Tanbo, T, 2003) |
| "To study the endocrinologic and metabolic effects of metformin in combination with compound cyproterone acetate (CPA) on patients with polycystic ovarian syndrome (PCOS)." | 9.10 | [Endocrine and metabolic effects of metformin in combination with compound cyproterone acetate in women with polycystic ovarian syndrome]. ( Lin, JJ; Lin, WQ; Yang, HY; Ye, BL; Zhao, JZ, 2003) |
| "To evaluate the effect of metformin therapy on hyperandrogenism, insulin resistance, cervical scores, ovulation, and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome (PCOS)." | 9.10 | Metformin therapy improves ovulatory rates, cervical scores, and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome. ( Caliskan, E; Haberal, A; Kocak, M; Simsir, C, 2002) |
| "This study aims to evaluate the impact of metformin on ovarian response when co-administered during recombinant (r)FSH using the low-dose step-up protocol in clomiphene citrate-resistant polycystic ovarian syndrome (PCOS) patients with normal glucose tolerance." | 9.10 | Co-administration of metformin during rFSH treatment in patients with clomiphene citrate-resistant polycystic ovarian syndrome: a prospective randomized trial. ( Bükülmez, O; Demirol, A; Koray, Z; Yarali, H; Yiğit, N; Yildiz, BO; Zeyneloğlu, HB, 2002) |
| "To determine whether metformin pretreatment has beneficial effects in clomiphene resistant infertile women with polycystic ovary syndrome (PCOS) in an infertility clinic." | 9.10 | Metformin does not enhance ovulation induction in clomiphene resistant polycystic ovary syndrome in clinical practice. ( Fay, TN; Lannon, B; Sturrock, ND, 2002) |
| "To study the effect of metformin in combination with clomiphene citrate, as compared with placebo plus clomiphene citrate, on the ovulation and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome." | 9.10 | The effect of metformin plus clomiphene citrate on ovulation and pregnancy rates in clomiphene-resistant women with polycystic ovary syndrome. ( Malkawi, HY; Qublan, HS, 2002) |
| " After treatment, women in the OC + metformin group had significant decreases in BMI and WHR, and a significant increase in insulin sensitivity, in contrast to those in the OC group, who had insignificant changes in these parameters." | 9.10 | Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. ( Durmusoglu, F; Elter, K; Imir, G, 2002) |
| "In 43 amenorrheic women with polycystic ovary syndrome (PCOS), 31 (74%) with fasting hyperinsulinemia (> or =20 microU/mL), our aim was to determine whether Metformin (Bristol-Myers Squibb, Princeton, NJ), which reduces hyperinsulinemia, would reverse the endocrinopathy of PCOS, allowing resumption of regular normal menses." | 9.09 | Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome. ( Fontaine, R; Glueck, CJ; Sieve-Smith, L; Tracy, T; Wang, P, 1999) |
| "To evaluate whether pretreatment with metformin improves FSH-induced ovulation in women with clomiphene-resistant polycystic ovary syndrome (PCOS)." | 9.09 | Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome. ( Cianci, A; De Leo, V; Ditto, A; la Marca, A; Morgante, G, 1999) |
| "To determine whether the administration of metformin, an insulin-sensitizing agent, is followed by changes in adrenal steroidogenesis in women with polycystic ovary syndrome (PCOS)." | 9.09 | Effects of metformin on adrenal steroidogenesis in women with polycystic ovary syndrome. ( Cianci, A; Ciotta, L; De Leo, V; la Marca, A; Morgante, G; Paglia, T, 1999) |
| "To evaluate the effects of 12 weeks of metformin therapy on hormonal and clinical indices in polycystic ovary syndrome (PCOS)." | 9.09 | Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. ( Duleba, AJ; Kolodziejczyk, B; Pawelczyk, L; Spaczynski, RZ, 2000) |
| "Metformin, a biguanide antihyperglycemic drug, has been shown to improve ovarian function and glucose metabolism in women with polycystic ovary syndrome (PCOS), but results concerning its effects on insulin sensitivity are controversial." | 9.09 | Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. ( Koivunen, RM; Martikainen, HK; Morin-Papunen, LC; Ruokonen, A; Tapanainen, JS; Vauhkonen, I, 2000) |
| "To determine whether metformin would safely reduce the rate of first-trimester spontaneous abortion without teratogenicity in 19 women with the polycystic ovary syndrome (PCOS)." | 9.09 | Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. ( Cameron, D; Glueck, CJ; Phillips, H; Sieve-Smith, L; Wang, P, 2001) |
| "To determine whether metformin treatment increases the ovulation and pregnancy rates in response to clomiphene citrate (CC) in women who are resistant to CC alone." | 9.09 | Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. ( Evans, WS; Kauma, SW; Nestler, JE; Ratts, VS; Stovall, DW; Vandermolen, DT, 2001) |
| "To determine the clinical, hormonal and biochemical effect of 4-5 months of insulin-sensitizing therapy (hypocaloric diet+metformin) in obese patients with polycystic ovary syndrome (PCOS)." | 9.09 | Insulin, leptin, IGF-I and insulin-dependent protein concentrations after insulin-sensitizing therapy in obese women with polycystic ovary syndrome. ( Kinalska, I; Kinalski, M; Kowalska, I; Straczkowski, M; Wolczyski, S, 2001) |
| "To describe our clinical experience in using Metformin combined with a high protein-low carbohydrate diet to restore normal menstrual cycles in teenaged females with polycystic ovary syndrome (PCOS)." | 9.09 | Metformin to restore normal menses in oligo-amenorrheic teenage girls with polycystic ovary syndrome (PCOS). ( Fontaine, R; Glueck, CJ; Sieve-Smith, L; Tracy, T; Wang, P, 2001) |
| "To determine the clinical, hormonal, and biochemical effects of 4-6 months of metformin therapy in obese patients with polycystic ovary syndrome (PCOS)." | 9.08 | Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. ( Koivunen, RM; Martikainen, HK; Morin-Papunen, LC; Ruokonen, A, 1998) |
| "We performed oral glucose-tolerance tests before and after the administration of 500 mg of metformin or placebo three times daily for 35 days in 61 obese women with the polycystic ovary syndrome." | 9.08 | Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. ( Evans, WS; Jakubowicz, DJ; Nestler, JE; Pasquali, R, 1998) |
| "Previous studies have suggested that metformin is clinically useful in the treatment of polycystic ovary syndrome (PCOS)." | 9.08 | Decreased serum leptin concentrations during metformin therapy in obese women with polycystic ovary syndrome. ( Koivunen, RM; Martikainen, HK; Morin-Papunen, LC; Ruokonen, A; Tomás, C, 1998) |
| " Metformin is taken by many patients before pregnancy due to both previously diagnosed type 2 diabetes and in the treatment of prediabetes, obesity and polycystic ovary syndrome (PCOS) as part of therapy for insulin resistance." | 9.05 | Metformin therapy in pregnancy [Zastosowanie metforminy w ciąży]. ( Cichocka, E; Gumprecht, J; Kędzierski, L; Krupej-Kędzierska, J; Okopień, B, 2020) |
| " Liraglutide is a glucagon-like peptide-1 receptor agonist that promotes sustained weight loss, as well as abdominal fat reduction, in individuals with obesity, prediabetes, and type 2 diabetes mellitus." | 9.05 | Liraglutide: New Perspectives for the Treatment of Polycystic Ovary Syndrome. ( Constantinidou, KG; Filippou, PK; Papaetis, GS; Stylianou, CS, 2020) |
| "Metformin is widely used among women with polycystic ovary syndrome (PCOS)." | 9.05 | Association of Metformin With Pregnancy Outcomes in Women With Polycystic Ovarian Syndrome Undergoing In Vitro Fertilization: A Systematic Review and Meta-analysis. ( Huang, Y; Liu, Y; Tu, M; Wu, Y; Zhang, D, 2020) |
| "A systematic review and meta-analysis of clinical trials or observational studies of metformin intervention in preventing symptoms of GDM during pregnancy were performed." | 9.05 | The Effect of Metformin Therapy for Preventing Gestational Diabetes Mellitus in Women with Polycystic Ovary Syndrome: A Meta-Analysis. ( Liu, X; Zhang, W; Zhao, J, 2020) |
| "Metformin (MET), the most commonly used insulin sensitizer, is the reference off-label drug for the treatment of polycystic ovary syndrome (PCOS), worldwide." | 9.01 | Short-term effects of metformin and myo-inositol in women with polycystic ovarian syndrome (PCOS): a meta-analysis of randomized clinical trials. ( Facchinetti, F; Grandi, G; Orrù, B; Unfer, V, 2019) |
| "For overweight polycystic ovary syndrome patients, our evidence revealed that EE/CA and EE/SRSP combined with metformin or lifestyle changes can reduce the adverse effects on glucose and lipid metabolism of the use of oral contraceptive agents alone." | 9.01 | The effectiveness of metformin, oral contraceptives, and lifestyle modification in improving the metabolism of overweight women with polycystic ovary syndrome: a network meta-analysis. ( Li, Q; Liu, M; Mo, T; Shen, C; Wang, A, 2019) |
| "Metformin use in pregnancy is increasing worldwide as randomised controlled trial (RCT) evidence is emerging demonstrating its safety and efficacy." | 8.98 | Metformin in Pregnancy: Mechanisms and Clinical Applications. ( Balani, J; Hyer, S; Shehata, H, 2018) |
| "The impact of the recommended first-line treatment with metformin on C-reactive protein (CRP) levels in patients with polycystic ovary syndrome (PCOS) is still controversial." | 8.95 | Impact of metformin on C-reactive protein levels in women with polycystic ovary syndrome: a meta-analysis. ( Chen, L; Chen, Y; Deng, H; Li, M; Li, N; Wang, Q; Wang, S; Xu, D, 2017) |
| "Metformin alone compared with placebo increases the ovulation rate in women with polycystic ovary syndrome (PCOS) but should not be used as first-line therapy for anovulation because oral ovulation induction agents such as clomiphene citrate or letrozole alone are much more effective in increasing ovulation, pregnancy, and live-birth rates in women with PCOS." | 8.95 | Role of metformin for ovulation induction in infertile patients with polycystic ovary syndrome (PCOS): a guideline. ( , 2017) |
| "Metformin is effective for the treatment of polycystic ovary syndrome (PCOS), but conflicting results regarding its impact on serum levels of C-reactive protein (CRP) and interleukin-6 (IL-6) in women with PCOS have been reported." | 8.95 | Effects of metformin treatment on serum levels of C-reactive protein and interleukin-6 in women with polycystic ovary syndrome: a meta-analysis: A PRISMA-compliant article. ( Hu, K; Liu, J; Tang, Y; Wang, J; Xu, J; Zeng, X; Zhu, L, 2017) |
| " Insulin-sensitising agents such as metformin may be effective in treating PCOS-related anovulation." | 8.95 | Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. ( Balen, AH; Morley, LC; Norman, RJ; Tang, T; Yasmin, E, 2017) |
| "To systematically review the impact of Yasmin (drospirenone pill) compares with other standard treatments for symptoms of Polycystic Ovary Syndrome (PCOS)." | 8.95 | A comparative systematic review of Yasmin (drospirenone pill) versus standard treatment options for symptoms of polycystic ovary syndrome. ( Li, J; Ren, J; Sun, W, 2017) |
| "Metformin has been used as a treatment option for polycystic ovary syndrome (PCOS) since 1994; however, more than a hundred randomized clinical trials have reported controversial results regarding the efficacy of metformin in PCOS." | 8.95 | Effect of metformin on clinical, metabolic and endocrine outcomes in women with polycystic ovary syndrome: a meta-analysis of randomized controlled trials. ( Patel, R; Shah, G, 2017) |
| " Metformin may increase the effectiveness of ovulation induction with gonadotrophins and may promote safety by preventing multiple pregnancy." | 8.95 | Metformin during ovulation induction with gonadotrophins followed by timed intercourse or intrauterine insemination for subfertility associated with polycystic ovary syndrome. ( Bordewijk, EM; Costello, MF; Mol, BW; Nahuis, M; Tso, LO; Van der Veen, F; van Wely, M, 2017) |
| "For several years there is an evidence for a relationship between the polycystic ovary syndrome (PCOS) and of insulin resistance; therefore metformin, an insulin sensitizer, is used for the treatment for more than 10 years." | 8.93 | [Metformin for the treatment of polycystic ovary syndrome]. ( Bekes, I; Gundelach, T; Hancke, K; Janni, W; Rodewald, M, 2016) |
| "The aim of the study is to evaluate the effects of metformin on pregnancy outcomes in women with polycystic ovary syndrome (PCOS)." | 8.93 | Effects of metformin on pregnancy outcomes in women with polycystic ovary syndrome: A meta-analysis. ( An, RF; Tian, Q; Xue, Y; Zeng, XL; Zhang, YF, 2016) |
| "Our results showed that continued use during of metformin, during pregnancy in women with PCOS, had no effect on incidence of fetal abnormalities or fetal birth weight." | 8.93 | Effect of metformin treatment during pregnancy on women with PCOS: a systematic review and meta-analysis. ( Chang, Y; Fang, C; Li, S; Liu, H; Tan, X; Wang, Y; Zhang, X, 2016) |
| "Combined statin and metformin therapy can improve lipid and inflammation parameters, but cannot effectively improve insulin sensitivity and reduce hyperandrogenism in women with PCOS." | 8.91 | An investigation into the therapeutic effects of statins with metformin on polycystic ovary syndrome: a meta-analysis of randomised controlled trials. ( Cai, R; Huang, R; Sun, H; Sun, J; Wang, P; Wang, S; Xia, W; Yuan, Y; Zhou, Y, 2015) |
| "PubMed, SCOPUS and CENTRAL databases were searched until April 2014 with the key words: PCOS, polycystic ovary syndrome, metformin, clomiphene citrate, ovulation induction and pregnancy." | 8.91 | Combined metformin-clomiphene in clomiphene-resistant polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. ( Abu Hashim, H; Foda, O; Ghayaty, E, 2015) |
| "In women with polycystic ovary syndrome, metformin treatment before or during assisted reproductive technology cycles increases clinical pregnancy rates and decreases the risk of ovarian hyperstimulation syndrome." | 8.91 | Metformin treatment before and during in vitro fertilization or intracytoplasmic sperm injection in women with polycystic ovary syndrome: summary of a Cochrane review. ( Albuquerque, LE; Andriolo, RB; Costello, MF; Macedo, CR; Marjoribanks, J; Tso, LO, 2015) |
| "Metformin is used among patients with polycystic ovary syndrome (PCOS), but findings for its effects on outcomes of assisted reproductive technology (ART) have been conflicting." | 8.91 | A systematic review and meta-analysis of metformin among patients with polycystic ovary syndrome undergoing assisted reproductive technology procedures. ( Huang, X; Li, Y; Lv, F; Tal, R; Wang, P; Zhang, X, 2015) |
| "To evaluate the efficacy of metformin administration throughout pregnancy on pregnancy-related complications in women with polycystic ovary syndrome (PCOS)." | 8.91 | Efficacy of metformin on pregnancy complications in women with polycystic ovary syndrome: a meta-analysis. ( Du, YK; Feng, L; Hu, D; Lin, XF; Wan, ZH, 2015) |
| "Metformin is effective for the treatment of polycystic ovary syndrome, but conflicting results regarding its effect on adipocytokine levels (adiponectin, resistin, visfatin, and leptin) in patients with polycystic ovary syndrome receiving metformin treatment have been reported." | 8.91 | Impact of Treatment with Metformin on Adipocytokines in Patients with Polycystic Ovary Syndrome: A Meta-Analysis. ( Chen, L; Kong, W; Lu, M; Niu, X; Zeng, T, 2015) |
| "The current systematic review with meta-analysis of randomized controlled trials (RCTs) was aimed to evaluate the effects of metformin on reproductive outcomes in patients with polycystic ovary syndrome (PCOS) who receive gonadotropins for ovulation induction." | 8.90 | Metformin and gonadotropins for ovulation induction in patients with polycystic ovary syndrome: a systematic review with meta-analysis of randomized controlled trials. ( Falbo, A; La Sala, GB; Palomba, S, 2014) |
| "Metformin, an insulin-sensitizing drug commonly used to treat Type 2 Diabetes Mellitus (T2DM), has been increasingly used off-label for the treatment of polycystic ovary syndrome (PCOS), which affects at least 5-10% of reproductive- age women." | 8.90 | The utility of metformin therapy in reproductive-aged women with polycystic ovary syndrome (PCOS). ( Nathan, N; Sullivan, SD, 2014) |
| "Although a number of in vitro studies have demonstrated the antiproliferative, anti-invasive, and antimetastatic effects of metformin in multiple cancer cell types, its cellular and molecular mechanisms of anti-cancer action in the endometrium of women with polycystic ovary syndrome (PCOS) have not yet been fully elucidated." | 8.90 | Direct effects of metformin in the endometrium: a hypothetical mechanism for the treatment of women with PCOS and endometrial carcinoma. ( Billig, H; Feng, Y; Li, X; Lin, JF; Shao, R, 2014) |
| "The use of insulin-sensitising agents, such as metformin, in women with polycystic ovary syndrome (PCOS) who are undergoing ovulation induction or in vitro fertilisation (IVF) cycles has been widely studied." | 8.90 | Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. ( Albuquerque, LE; Andriolo, RB; Costello, MF; Macedo, CR; Tso, LO, 2014) |
| "A review of the existing literature on weight loss through lifestyle modification and/or metformin treatment in overweight women with PCOS." | 8.89 | Overweight in polycystic ovary syndrome. An update on evidence based advice on diet, exercise and metformin use for weight loss. ( Glintborg, D; Haugen, AG; Ravn, P, 2013) |
| "The role of metformin in the treatment of pregnant women with polycystic ovary syndrome (PCOS) is controversial." | 8.89 | The efficacy of metformin in pregnant women with polycystic ovary syndrome: a meta-analysis of clinical trials. ( Gu, W; Shan, PF; Zheng, J, 2013) |
| "Metformin is an effective oral anti-hyperglycemic agent that is widely used to manage diabetes mellitus type 2 in the general population and more recently, in pregnancy." | 8.89 | Efficacy and safety of metformin during pregnancy in women with gestational diabetes mellitus or polycystic ovary syndrome: a systematic review. ( Goulis, DG; Lautatzis, ME; Vrontakis, M, 2013) |
| "Metformin is widely used for treating women with polycystic ovary syndrome (PCOS), and many patients with PCOS who are infertile receive gonadotrophins while being treated with metformin." | 8.89 | Effects of metformin in women with polycystic ovary syndrome treated with gonadotrophins for in vitro fertilisation and intracytoplasmic sperm injection cycles: a systematic review and meta-analysis of randomised controlled trials. ( Falbo, A; La Sala, GB; Palomba, S, 2013) |
| "This article is a review of the literature assessing pregnancy outcomes and the effect of metformin treatment among women with polycystic ovary syndrome (PCOS)." | 8.88 | Pregnancy outcomes and the effect of metformin treatment in women with polycystic ovary syndrome: an overview. ( Awwad, JT; Ghazeeri, GS; Nassar, AH; Younes, Z, 2012) |
| "Evidence indicates that metformin and pioglitazone both improve insulin resistance and hirsutism among patient with polycystic ovarian syndrome (PCOS)." | 8.88 | A systematic review and meta-analysis of randomized controlled trials comparing pioglitazone versus metformin in the treatment of polycystic ovary syndrome. ( Du, Q; Han, P; Wang, YJ; Wu, B; Yang, S; Zhao, YY, 2012) |
| "Metformin, an oral anti-diabetic drug, is being considered increasingly for treatment and prevention of cancer, obesity as well as for the extension of healthy lifespan." | 8.88 | Metformin in obesity, cancer and aging: addressing controversies. ( Berstein, LM, 2012) |
| "In agreement with the previous review, metformin was associated with improved clinical pregnancy but there was no evidence that metformin improves live birth rates whether it is used alone or in combination with clomiphene, or when compared with clomiphene." | 8.88 | Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. ( Balen, AH; Lord, JM; Norman, RJ; Tang, T; Yasmin, E, 2012) |
| "Compared to metformin, TZDs had the same effectiveness in treating insulin sensitivity and lowering androgen in PCOS patients, but the effect on weight loss was not as good as metformin." | 8.88 | Comparative efficacy of thiazolidinediones and metformin for polycystic ovary syndrome. ( Du, Q; Wang, YJ, 2012) |
| "Our aim was to re-evaluate whether metformin may reduce late miscarriage/preterm delivery, pre-eclampsia and gestational diabetes in women with polycystic ovary syndrome (PCOS)." | 8.88 | On the potential of metformin to prevent preterm delivery in women with polycystic ovary syndrome - an epi-analysis. ( Carlsen, SM; DE Zegher, F; Díaz, M; Ibáñez, L; Vanky, E, 2012) |
| "To evaluate the efficacy of metformin (MTF) in treatment of clomiphene (CC)-resistant patients with polycystic ovary syndrome (PCOS)." | 8.88 | [Therapeutic effect of metformin for clomiphene-resistant infertility patients with polycystic ovary syndrome: a systematic analysis]. ( Cheng, QF; Fan, XD; Ren, W; Wang, LL, 2012) |
| "There are differences in opinion as to whether metformin should play a role in the primary treatment of anovulatory infertility for women with polycystic ovary syndrome (PCOS)." | 8.87 | Metformin is a reasonable first-line treatment option for non-obese women with infertility related to anovulatory polycystic ovary syndrome--a meta-analysis of randomised trials. ( Johnson, N, 2011) |
| "In agreement with the previous review, metformin is still of benefit in improving clinical pregnancy and ovulation rates." | 8.86 | Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. ( Balen, AH; Lord, JM; Norman, RJ; Tang, T; Yasmin, E, 2010) |
| " metformin, or the combination of both drugs as first-line therapy in anovulatory polycystic ovary syndrome (PCOS) patients seeking pregnancy." | 8.85 | Clomiphene citrate, metformin or both as first-step approach in treating anovulatory infertility in patients with polycystic ovary syndrome (PCOS): a systematic review of head-to-head randomized controlled studies and meta-analysis. ( Nestler, JE; Orio, F; Palomba, S; Pasquali, R, 2009) |
| "To evaluate the effect of pregestational metformin administration on abortion risk in polycystic ovary syndrome (PCOS) patients." | 8.85 | Effect of preconceptional metformin on abortion risk in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. ( Falbo, A; Orio, F; Palomba, S; Zullo, F, 2009) |
| "The use of insulin-sensitising agents, such as metformin, in women with polycystic ovary syndrome (PCOS) who are undergoing ovulation induction or in vitro fertilisation (IVF) cycles has been widely studied." | 8.85 | Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. ( Albuquerque, LE; Andriolo, RB; Costello, MF; Freitas, V; Tso, LO, 2009) |
| " The biguanide, N, N' dimethyl-biguanide: Metformin is an antidiabetic drug that increases glucose utilization in insulin-sensitive tissues and is useful in the reduction of both insulin resistance and circulating androgens as well as restoring ovulation." | 8.84 | Metformin in the treatment of polycystic ovary syndrome. ( Motta, DA, 2008) |
| "To systematically evaluate the efficacy and safety of Diane-35 for treating polycystic ovary syndrome (PCOS) and compare it with metformin, either in combination or alone." | 8.84 | The effects of Diane-35 and metformin in treatment of polycystic ovary syndrome: an updated systematic review. ( Jing, Z; Liang-Zhi, X; Tai-Xiang, W; Ying, T; Yu-Jian, J, 2008) |
| " Limited data demonstrated no evidence of a difference in effect between metformin and the OCP on hirsutism, acne or development of type 2 diabetes mellitus." | 8.84 | Metformin versus oral contraceptive pill in polycystic ovary syndrome: a Cochrane review. ( Costello, MF; Eden, J; Johnson, NP; Shrestha, B; Sjoblom, P, 2007) |
| "Metformin improves the endocrinopathy of polycystic ovary syndrome (PCOS), facilitates conception, appears to reduce first trimester miscarriage and gestational diabetes and does not appear to be teratogenic." | 8.84 | Metformin before and during pregnancy and lactation in polycystic ovary syndrome. ( Glueck, CJ; Wang, P, 2007) |
| "To report a case of triplet pregnancy after metformin treatment only, in a woman with polycystic ovary syndrome (PCOS) and a family history of twin pregnancies." | 8.84 | Triplet pregnancy after metformin in a woman with polycystic ovary syndrome. ( Clapauch, R; Mattos, TM, 2008) |
| " Reduction of hyperinsulinism and improvement of insulin sensitivity with metformin has been reported to ameliorate these abnormalities in many, but not all studies, with few adverse effects." | 8.84 | Metformin and polycystic ovary syndrome. ( Lebinger, TG, 2007) |
| "Metformin, an insulin sensitizer widely used for the treatment of patients with type-2 diabetes mellitus (DM), was recently introduced in the clinical practice to treat women with polycystic ovary syndrome (PCOS)." | 8.84 | Role of metformin in patients with polycystic ovary syndrome: the state of the art. ( Falbo, A; Orio, F; Palomba, S; Russo, T; Tollino, A; Zullo, F, 2008) |
| "Metformin is an insulin sensitizer currently used for treating type-2 diabetes mellitus and recently administered for inducing ovulatory menstrual cycles in oligo-amenorrhoeic patients with polycystic ovary syndrome (PCOS)." | 8.84 | Outlook: metformin use in infertile patients with polycystic ovary syndrome: an evidence-based overview. ( Oppedisano, R; Orio, F; Palomba, S; Tolino, A; Zullo, F, 2008) |
| "To update the state of evidence on the efficacy of metformin, used either alone or in combination with clomiphene citrate in women with polycystic ovary syndrome, by examining three outcomes: ovulation, pregnancy, and live birth." | 8.84 | Use of metformin in polycystic ovary syndrome: a meta-analysis. ( Bradley, HM; Creanga, AA; McCormick, C; Witkop, CT, 2008) |
| "To describe the first reported cases of two women with polycystic ovary syndrome (PCOS) desirous of pregnancy who conceived trichorionic pregnancies following ovulation induction with metformin alone and metformin plus clomiphene." | 8.83 | Higher-order multiple pregnancy associated with metformin in women with polycystic ovary syndrome: two cases and review of the literature. ( Boothroyd, C; Yazdani, A, 2006) |
| "A systematic review of randomized controlled trials (RCTs) comparing whether metformin co-administration with gonadotrophins for ovulation induction (OI) with timed intercourse or IVF improves outcome in women with polycystic ovary syndrome (PCOS)." | 8.83 | A systematic review and meta-analysis of randomized controlled trials on metformin co-administration during gonadotrophin ovulation induction or IVF in women with polycystic ovary syndrome. ( Chapman, M; Conway, U; Costello, MF, 2006) |
| "To conduct a systematic review and meta-analysis of pregnancy outcome after metformin use for polycystic ovary syndrome (PCOS), because the efficacy of metformin has been demonstrated in the treatment of infertility caused by PCOS, whereas the fetal safety of metformin has received very little attention, and the few studies addressing this issue are limited by small sample sizes." | 8.83 | Pregnancy outcome after first-trimester exposure to metformin: a meta-analysis. ( Gilbert, C; Koren, G; Valois, M, 2006) |
| "The aim of this literature search is to establish if metformin is efficacious when given to clomiphene citrate (CC)-resistant polycystic ovary syndrome (PCOS) patients." | 8.83 | Is the addition of metformin efficacious in the treatment of clomiphene citrate-resistant patients with polycystic ovary syndrome? A structured literature review. ( Kruger, TF; Nosarka, S; Siebert, TI; Steyn, DW, 2006) |
| "To review the effectiveness of metformin in restoring regular menstrual cycles and ovulation and achieving pregnancy in women with polycystic ovary syndrome (PCOS)." | 8.82 | A systematic review of the reproductive system effects of metformin in patients with polycystic ovary syndrome. ( Costello, MF; Eden, JA, 2003) |
| "Metformin has been used as a treatment in many studies of the infertility associated with polycystic ovary syndrome (PCOS)." | 8.82 | Effects of metformin on body mass index, menstrual cyclicity, and ovulation induction in women with polycystic ovary syndrome. ( Attia, GR; Carr, BR; Haas, DA, 2003) |
| "To familiarize obstetrician-gynecologists with the use of metformin for the treatment of polycystic ovary syndrome (PCOS)." | 8.82 | Metformin for the treatment of polycystic ovary syndrome. ( Barbieri, RL, 2003) |
| "Use of metformin in polycystic ovary syndrome (PCOS) is becoming increasingly accepted and widespread, but clinical practice is ahead of the evidence." | 8.82 | Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome. ( Fleming, R; Harborne, L; Lyall, H; Norman, J; Sattar, N, 2003) |
| "Metformin is an effective treatment for anovulation in women with PCOS." | 8.82 | Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. ( Flight, IH; Lord, JM; Norman, RJ, 2003) |
| "To assess the effectiveness of metformin in improving clinical and biochemical features of polycystic ovary syndrome." | 8.82 | Metformin in polycystic ovary syndrome: systematic review and meta-analysis. ( Flight, IH; Lord, JM; Norman, RJ, 2003) |
| "No adverse pregnancy outcomes with metformin use have been reported, except in one unmatched study." | 8.82 | Metformin therapy and diabetes in pregnancy. ( McIntyre, HD; Rowan, JA; Simmons, D; Walters, BN, 2004) |
| "Metformin has become an established treatment for women with polycystic ovary syndrome, although controversy remains as to how effective it is and in which populations it should be used." | 8.82 | Metformin in polycystic ovary syndrome. ( Lord, J; Wilkin, T, 2004) |
| " The most extensively studied insulin-lowering agent in the treatment of PCOS is metformin: an oral antihyperglycaemic agent used initially in the treatment of type 2 diabetes mellitus." | 8.81 | Should patients with polycystic ovarian syndrome be treated with metformin? ( Duleba, AJ; Seli, E, 2002) |
| "The debate on metformin use in polycystic ovary syndrome (PCOS) has mainly focused on its treatment for infertility in ovulation induction and menstrual cyclicity." | 8.81 | Should patients with polycystic ovary syndrome be treated with metformin? Benefits of insulin sensitizing drugs in polycystic ovary syndrome--beyond ovulation induction. ( Oehninger, S; Stadtmauer, LA; Wong, BC, 2002) |
| "To review the use of the insulin-sensitizing agent metformin in women with polycystic ovary syndrome (PCOS)." | 8.81 | Use of metformin in polycystic ovary syndrome. ( De Sloover Koch, Y; Ernst, ME, 2001) |
| "To study the involvement of microribonucleic acids (miRNAs) in the pathogenesis of chronic anovulation and mechanism of metformin treatment in polycystic ovary syndrome (PCOS)." | 8.31 | The role of circulating miRNAs in mechanism of action and prediction of therapeutic responses of metformin in polycystic ovarian syndrome. ( Chen, MJ; Chen, SU; Huang, CC; Huang, YS; Yang, PK; Yang, YS, 2023) |
| "To study the effectiveness of metformin treatment in patients with acne but who do not have PCOS and to understand the mechanisms of action of metformin in acne not related to PCOS." | 8.31 | Effects of metformin on clinical, hormonal and relevant gene expression parameters in patients with acne: an observational study. ( De, D; Dutta, P; Handa, S; Kamboj, P; Kaushik, A; Pal, A; Saikia, UN, 2023) |
| " We compared the clinical pregnancy rate (primary outcome) and controlled ovarian stimulation (COS)-related parameters (secondary outcomes) between patients with and without metformin pre-treatment for all PCOS patients not grouped by HOMA-IR, PCOS patients with HOMA-IR < 2." | 8.31 | The homeostasis model assessment of insulin resistance is a judgment criterion for metformin pre-treatment before IVF/ICSI and embryo transfer cycles in patients with polycystic ovarian syndrome. ( Gao, R; Li, Z; Min, W; Qin, L, 2023) |
| "Metformin counteracts excessive weight gain and leptin resistance in pregnant women with polycystic ovary syndrome." | 8.12 | Gestational weight gain, appetite regulating hormones, and metformin treatment in polycystic ovary syndrome: A longitudinal, placebo-controlled study. ( Bixo, M; Dehlin, E; Løvvik, TS; Molin, J; Vanky, E, 2022) |
| "The mean steady-state serum concentration of metformin during pregnancy was 9." | 8.12 | Metformin serum concentrations during pregnancy and post partum - A clinical study in patients with polycystic ovary syndrome. ( Espnes, KA; Gundersen, POM; Hønnås, A; Løvvik, TS; Naavik, A; Skogvoll, E; Spigset, O; Vanky, E; Westin, AA, 2022) |
| " Metformin appears to reduce these risks in mothers with polycystic ovary syndrome and their children; but may increase the risk of childhood-obesity in children form women without PCOS." | 8.12 | Pregnancy, perinatal and childhood outcomes in women with and without polycystic ovary syndrome and metformin during pregnancy: a nationwide population-based study. ( Brusselaers, N; Crisosto, N; Cruz, G; Engstrand, L; Fornes, R; Nguyen, MH; Simin, J; van der Schaaf, M, 2022) |
| "Metformin (MET) can effectively treat endometrial hyperplasia (EH), and the expression of glucose transporter type 4 insulin‑responsive (GLUT4) is closely associated with the development of EH." | 8.12 | Role of metformin in functional endometrial hyperplasia and polycystic ovary syndrome involves the regulation of MEG3/miR‑223/GLUT4 and SNHG20/miR‑4486/GLUT4 signaling. ( Chen, L; Li, R; Liu, J; Ning, Y; Zhao, Y; Zhu, X, 2022) |
| "The study aimed to investigate the effect of metformin treatment on leukocyte telomere length (LTL) and the relationship of LTL with C-reactive protein (CRP), homocysteine, albumin, complete blood count, and HOMA-IR values in patients with polycystic ovary syndrome (PCOS)." | 8.12 | The effect of metformin treatment on leukocyte telomere length in patients with polycystic ovary syndrome: a prospective case-control study. ( Kayacık Günday, Ö; Özdemir Erdoğan, M; Pehlivan, A; Yılmazer, M, 2022) |
| "This observational, retrospective study utilized EHR data from 52 hospitals for COVID-19 patients with PCOS or prediabetes treated with metformin or levothyroxine/ondansetron (controls)." | 8.12 | Metformin is associated with reduced COVID-19 severity in patients with prediabetes. ( Antony, B; Blau, H; Bramante, C; Casiraghi, E; Chan, LE; Coleman, B; Gargano, M; Haendel, M; Harris, NL; Laraway, B; Reese, J; Robinson, PN; Sahner, D; Valentini, G; Wilkins, K; Zaman, A, 2022) |
| "This study provides evidence for the efficacy and safety of the clinical application of acupuncture combined with metformin in the treatment of polycystic ovary syndrome." | 8.12 | Acupuncture combined with metformin for polycystic ovary syndrome: A protocol for systematic review and meta-analysis. ( Ding, Q; Liu, X; Sun, Y; Yang, H; Yin, S, 2022) |
| " After metformin and exenatide supplementation, body weight, chow intake and ovarian morphology were observed." | 8.02 | Metformin and exenatide upregulate hepatocyte nuclear factor-4α, sex hormone binding globulin levels and improve hepatic triglyceride deposition in polycystic ovary syndrome with insulin resistance rats. ( He, B; Li, X; Lv, B; Wang, D; Xing, C; Zhao, H, 2021) |
| "The beneficial effects of metformin, especially its capacity to ameliorate insulin resistance (IR) in polycystic ovary syndrome (PCOS), explains why it is widely prescribed." | 8.02 | Effects of Metformin on Reproductive, Endocrine, and Metabolic Characteristics of Female Offspring in a Rat Model of Letrozole-Induced Polycystic Ovarian Syndrome With Insulin Resistance. ( Li, S; Xiao, L; Xie, Y, 2021) |
| "The possible relationship between dehydroepiandrosterone (DHEA)-induced polycystic ovary syndrome (PCOS) and epigenetic changes (ECs) leading to the impaired oocyte quality, has not been investigated yet." | 8.02 | Metformin improves epigenetic modification involved in oocyte growth and embryo development in polycystic ovary syndrome mice model. ( Amani Abkenari, S; Amidi, F; Aryanpour, R; Hosseini, A; Safdarian, L; Salahi, E; Sobhani, A, 2021) |
| " Metformin increases insulin sensitivity, but it is associated with unsatisfied benefits of weight loss." | 8.02 | The therapeutic effects of glucagon-like peptide-1 receptor agonists and metformin on polycystic ovary syndrome: A protocol for systematic review and meta-analysis. ( Deng, Y; Ding, X; Ma, R; Sun, A; Wang, Y, 2021) |
| " We aimed to confirm the correlation between SFRP5, metabolic inflammation and PCOS, investigate the predictive value of SFRP5 for PCOS and the involvement of SFRP5 in metformin treated PCOS." | 8.02 | Decreased SFRP5 correlated with excessive metabolic inflammation in polycystic ovary syndrome could be reversed by metformin: implication of its role in dysregulated metabolism. ( Chen, Y; Geng, L; Hu, J; Huang, H; Kong, L; Qi, H; Ran, Y; Zhang, H; Zhang, Y, 2021) |
| "The present study was conducted to investigate the therapeutic effects of a potent polyphenol, fisetin, on the letrozole-induced rat model of polycystic ovary syndrome (PCOS)." | 8.02 | Ameliorative effects of fisetin in letrozole-induced rat model of polycystic ovary syndrome. ( Khadem-Ansari, MH; Mihanfar, A; Nouri, M; Roshangar, L, 2021) |
| "After six months, the fasting insulin, glucose/insulin ratio, and homeostatic model assessment estimates for insulin resistance were significantly improved in metformin group." | 7.96 | Metformin metabolic and vascular effects in normal weight hyperinsulinemic polycystic ovary syndrome patients treated with contraceptive vaginal ring. A pilot study. ( Artini, PG; Battaglia, B; Battaglia, C; Casadio, P; Rizzo, R, 2020) |
| "Metformin has long been used in the treatment of polycystic ovarian syndrome (PCOS)." | 7.96 | Sitagliptin/Metformin: A New Medical Treatment in Polycystic Ovary Syndrome. ( Daneshjou, D; Shariatzadeh, MA; Soleimani Mehranjani, M; Zadeh Modarres, S, 2020) |
| "This study aimed to investigate the molecular mechanisms underlying the roles of metformin (MET) and Sorafenib (SOR) in the treatment of endometrial hyperplasia (EH) in polycystic ovary syndrome (PCOS)." | 7.96 | Treatment with metformin and sorafenib alleviates endometrial hyperplasia in polycystic ovary syndrome by promoting apoptosis via synergically regulating autophagy. ( Gao, ZH; Guo, XC; Ji, M; Li, L; Wang, QQ, 2020) |
| "Scarce data exist on the body composition of lean women with polycystic ovary syndrome (PCOS) on treatment with metformin and oral contraceptives (OCs)." | 7.91 | Lean Women on Metformin and Oral Contraceptives for Polycystic Ovary Syndrome Demonstrate a Dehydrated Osteosarcopenic Phenotype: A Pilot Study. ( Bacopoulou, F; Boschiero, D; Diamandi-Kandarakis, E; Kandaraki, E; Stefanaki, C, 2019) |
| "To investigate the effect of metformin on endometrial receptivity in women with polycystic ovary syndrome (PCOS)." | 7.91 | The Effect of Metformin on the Endometrium of Women with Polycystic Ovary Syndrome. ( Anifandis, G; Antonakis, PT; Dafopoulos, K; Daponte, A; Dragamestianos, C; Garas, A; Georgoulias, P; Kostopoulou, E; Makrigiannakis, A; Messini, CI; Messinis, IE; Zacharouli, K, 2019) |
| " Metformin is commonly used to treat insulin resistance-glucose intolerance, and flutamide, an androgen receptor (AR) antagonist, is used to target hyperandrogenemia and dyslipidemia." | 7.91 | Effect of metformin and flutamide on insulin, lipogenic and androgen-estrogen signaling, and cardiometabolic risk in a PCOS-prone metabolic syndrome rodent model. ( Diane, A; Ghosh, M; Kupreeva, M; Lehner, R; Proctor, S; Vine, D; Watts, R, 2019) |
| "We examine the effects of metformin on insulin resistance (IR) and mood including in adolescent and adult women with polycystic ovary syndrome (PCOS)." | 7.91 | A pilot trial of metformin for insulin resistance and mood disturbances in adolescent and adult women with polycystic ovary syndrome. ( Aghamohammadzadeh, N; Erensoy, H; Ghafarzadeh, S; Nader, ND; Niafar, M, 2019) |
| "The aim of this study was to evaluate the effect of orlistat or metformin combined with Diane-35 on anthropometric, hormonal and metabolic parameters in overweight and obese polycystic ovary syndrome (PCOS) patients with insulin resistance (fasting insulin > 10 mIU/L)." | 7.88 | Effect of orlistat or metformin in overweight and obese polycystic ovary syndrome patients with insulin resistance. ( Gu, M; Mueck, AO; Ruan, X; Song, J; Wang, H; Wang, L, 2018) |
| "The aim of this study was to evaluate the risk of major birth defects and spontaneous abortion after metformin use during the first trimester of pregnancy." | 7.88 | Pregnancy outcome after first-trimester exposure to metformin: A prospective cohort study. ( Beck, E; Grupe, K; Schaefer, C; Scherneck, S; Schlinke, N; Weber-Schoendorfer, C, 2018) |
| "Metformin toxicity is well known to cause lactic acidosis." | 7.88 | Recurrent hypoglycemia secondary to metformin toxicity in the absence of co-ingestions: a case report. ( Aldobeaban, S; Alshehri, AA; Mzahim, B, 2018) |
| "The objective of this study was to evaluate the levels of total microparticles (MPs) and microparticles-expressing tissue factor (TFMPs) in women with polycystic ovarian syndrome (PCOS) who use metformin comparing to those who do not take metformin." | 7.85 | Metformin reduces total microparticles and microparticles-expressing tissue factor in women with polycystic ovary syndrome. ( Candido, AL; Carvalho, LML; Ferreira, CN; Gomes, KB; Nunes, FFC; Reis, FM; Sales, MF; Silva, IFO; Sóter, MO, 2017) |
| "To evaluate the norepinephrine (NE) and placental NE transporter (NET) in women with polycystic ovary syndrome (PCOS) non-treated and treated with metformin during pregnancy." | 7.85 | Metformin increases norepinephrine transporter expression in placenta of patients with polycystic ovary syndrome. ( Crisosto, N; Echiburú, B; Lara, HE; Maliqueo, M; Medina, G; Sir-Petermann, T, 2017) |
| "BMI in overweight patients were significantly improved with metformin treatment duration (p < 0." | 7.85 | Effect of metformin by employing 2-hour postload insulin for measuring insulin resistance in Taiwanese women with polycystic ovary syndrome. ( Chen, PC; Ou, HT; Wu, MH, 2017) |
| " Clinical pregnancy rates and implantation rates were similar in all groups, although the numbers of oocytes, mature oocytes, fertilized oocytes, and transferred embryos were lower in the treatment groups received metformin compared to the OC group and control group." | 7.85 | Effect of metformin and oral contraceptives on polycystic ovary syndrome and IVF cycles. ( Gurgan, T; Kalem, MN; Kalem, Z, 2017) |
| "In this study, we assessed the efficacy and safe usage of the oral contraceptive, Diane-35, in the treatment of polycystic ovary syndrome (PCOS) when combined with the drug metformin." | 7.83 | Management of polycystic ovarian syndrome with Diane-35 or Diane-35 plus metformin. ( Feng, W; Jia, YY; Shi, HR; Zhang, DY, 2016) |
| "To investigate whether there is any therapeutic effect of colchicine on a rat model of polycystic ovary syndrome (PCOS)." | 7.83 | Effect of colchicine on polycystic ovary syndrome: an experimental study. ( Aksoy, AN; Dokuyucu, R; Gozukara, IO; Kucur, SK; Kurt, RK; Ozcan, O; Ozgur, T; Pınar, N, 2016) |
| "Polycystic ovary syndrome (PCOS) is common in obese women with insulin resistant type 2 diabetes for which metformin treatment is getting established in addition to clomiphene." | 7.83 | A case of lean polycystic ovary syndrome with early stage of type 1 diabetes successfully treated with metformin. ( Hirose, T; Kitamura, M; Kumashiro, N; Rikitake, T; Saegusa, M; Shigiyama, F; Uchino, H; Usui, S, 2016) |
| "Metformin hydrochloride (MTF-HCl) is extensively recommended by physicians for the treatment of polycystic ovary syndrome (PCOS)." | 7.83 | Intravaginal administration of metformin hydrochloride loaded cationic niosomes amalgamated with thermosensitive gel for the treatment of polycystic ovary syndrome: In vitro and in vivo studies. ( Bajaj, L; Jain, UK; Katare, OP; Madan, J; Pandey, RS; Saini, N; Sodhi, RK, 2016) |
| "Metformin might improve health-related quality of life of polycystic ovary syndrome women by ameliorating psychological disturbances due to acne, hair loss and infertility problems, especially for overweight and hyperandrogenic patients." | 7.83 | Metformin improved health-related quality of life in ethnic Chinese women with polycystic ovary syndrome. ( Chen, PC; Lin, CY; Ou, HT; Wu, MH, 2016) |
| "To evaluate effects of metformin on endocrine, metabolic parameters and endometrial androgen receptor (AR) expression in polycystic ovary syndrome (PCOS)." | 7.81 | Effects of metformin on endocrine, metabolic milieus and endometrial expression of androgen receptor in patients with polycystic ovary syndrome. ( Fujimori, K; Hashimoto, S; Ito-Yamaguchi, A; Kumagami, A; Suganuma, R; Yoshida-Komiya, H, 2015) |
| "The aim of this proof-of-concept study was to determine the effects of three-month Metformin therapy on the expression of tumor-regulatory genes (p53, cyclin D2 and BCL-2) in the endometrium of women with polycystic ovary syndrome (PCOS)." | 7.81 | The effect of Metformin on endometrial tumor-regulatory genes and systemic metabolic parameters in polycystic ovarian syndrome--a proof-of-concept study. ( Atiomo, W; Chapman, C; Ghani, NA; Hatta, AZ; Malik, DA; Mokhtar, NM; Omar, MH; Seedhouse, C; Shafiee, MN; Yunos, RI, 2015) |
| " Metformin has been introduced in the treatment of PCOS to manage insulin resistance and hyperglycemia." | 7.81 | Metformin regulates ovarian angiogenesis and follicular development in a female polycystic ovary syndrome rat model. ( Abramovich, D; Bas, D; Bianchi, MS; Di Pietro, M; Irusta, G; Parborell, F; Pascuali, N; Tesone, M, 2015) |
| "To assess the effect of metformin in controlling Gestational Diabetes Mellitus (GDM) in women with Polycystic Ovarian Syndrome (PCOS)." | 7.81 | Metformin for preventing gestational diabetes in women with polycystic ovarian syndrome. ( Aftab, S; Ainuddin, JA; Kamran, A; Kazi, S, 2015) |
| "To evaluate the role of anti-Mullerian hormone (AMH) and inhibin B in the evaluation of the effectiveness of short- (3 months) and long-term (6 months or more) metformin therapy in Iraqi women with polycystic ovarian syndrome (PCOS)." | 7.81 | The role of anti-Mullerian hormone and inhibin B in the assessment of metformin therapy in women with polycystic ovarian syndrome. ( Ameen, NS; Ibraheem, WF; Saleh, BO, 2015) |
| "To evaluate the effectiveness of metformin therapy in reducing early pregnancy loss in pregnant women with polycystic ovary syndrome (PCOS)." | 7.81 | Effect of metformin on early pregnancy loss in women with polycystic ovary syndrome. ( Al-Biate, MA, 2015) |
| "The aim of this study was to determine the relevance of apelin and insulin resistance (IR) with polycystic ovary syndrome (PCOS) and to assess the possible therapeutic effect of the combined therapy of drospirenone-ethinylestradiol (DRSP-EE) combined with metformin." | 7.81 | Evaluation of Apelin and Insulin Resistance in Patients with PCOS and Therapeutic Effect of Drospirenone-Ethinylestradiol Plus Metformin. ( Sun, X; Wu, X; Yu, X; Zhang, W; Zhou, Y, 2015) |
| "To investigate the expression of silent information regulator 1 (SIRT1) in rats with polycystic ovary syndrome (PCOS) and its alteration after exenatide treatment." | 7.81 | Expression of SIRT1 in the ovaries of rats with polycystic ovary syndrome before and after therapeutic intervention with exenatide. ( Ge, SQ; Tao, X; Zhang, B; Zhang, EH; Zhang, X, 2015) |
| "Metformin decreases polycystic ovary syndrome (PCOS) symptoms, induces ovulation, and may improve developmental competence of in vitro oocyte maturation." | 7.81 | Does metformin improve in vitro maturation and ultrastructure of oocytes retrieved from estradiol valerate polycystic ovary syndrome-induced rats. ( Mesbah, F; Mirkhani, H; Moslem, M; Vojdani, Z, 2015) |
| "The aim of our study was to assess the value of blood pressure and heart rate using the 24-hour blood pressure monitoring (ABPM) before and after treatment with metformin to patients with polycystic ovary syndrome (PCOS) and normal lean." | 7.81 | [Metformin and changes in blood pressure and heart rate in lean patients with polycystic ovary syndrome (PCOS)--preliminary study]. ( Kiałka, M; Klocek, M; Kowalczuk, A; Migacz, K; Milewicz, T; Ociepka, A; Tomczyk, R, 2015) |
| "To authenticate the effect of metformin treatment on ovarian stromal blood flow in women with polycystic ovary syndrome (PCOS) using 3-dimensional (3D) power Doppler." | 7.80 | Assessment of ovarian stromal blood flow after metformin treatment in women with polycystic ovary syndrome. ( El Sherbiny, M; Elkabarity, R; Makled, AK, 2014) |
| " The aim of this study was to assess the effects of metformin on insulin resistance, oxidant-antioxidant status, endothelial dysfunction, lipid metabolism and their contribution to the risks of cardiovascular disease in women with PCOS." | 7.80 | The effects of metformin on endothelial dysfunction, lipid metabolism and oxidative stress in women with polycystic ovary syndrome. ( Bayram, F; Diri, H; Kocer, D, 2014) |
| "Insulin-sensitizer treatment with metformin is common in polycystic ovary syndrome (PCOS)." | 7.80 | Metformin resistance alleles in polycystic ovary syndrome: pattern and association with glucose metabolism. ( Lerchbaum, E; Obermayer-Pietsch, B; Pieber, T; Schweighofer, N; Schwetz, V; Trummer, O, 2014) |
| "Metformin administration resulted in significant decrease in the body weight, body mass index, hirsutism score, fasting and postprandial blood glucose, fasting serum insulin, HOMA index, sleep disturbances scale, and Epworth sleepiness scale compared to the untreated PCOS group." | 7.80 | Effect of metformin on sleep disorders in adolescent girls with polycystic ovarian syndrome. ( Abdelmotaleb, GS; Aly, MK; El-Sharkawy, AA; Kabel, AM, 2014) |
| "To investigate the therapeutical effects of visfatin and metformin on insulin resistance and reproductive endocrine disorder in rats with polycystic ovary syndrome (PCOS)." | 7.80 | [Effects of visfatin and metformin on insulin resistance and reproductive endocrine in rats with polycystic ovary syndrome]. ( Gu, J; Li, T; Su, S; Wan, J; Zhang, T; Zou, X, 2014) |
| "To analyze the level of serum leptin and its relations with insulin resistance in patients with polycystic ovary syndrome (PCOS) so as to investigate the clinical effect of aciesis in PCOS under treatment of metformin." | 7.80 | [Association between levels of serum leptin and insulin resistance in patients with polycystic ovary syndrome]. ( Cheng, X; Guo, J; Xie, J, 2014) |
| "Women with anovulatory polycystic ovary syndrome (PCOS) are generally insulin-resistant and as a consequence are often treated with the biguanide metformin." | 7.79 | Metformin inhibits follicle-stimulating hormone (FSH) action in human granulosa cells: relevance to polycystic ovary syndrome. ( Elia, A; Jawad, Z; Mason, HD; Pellatt, L; Rice, S, 2013) |
| "Metformin treatment enhances both adiponectin activity and insulin sensitivity, resulting in a less hyperandrogenic state in patients with PCOS." | 7.79 | Role of adiponectin and its receptor in prediction of reproductive outcome of metformin treatment in patients with polycystic ovarian syndrome. ( Hamed, HO, 2013) |
| " The secondary objective was to evaluate changes in body mass index (BMI), waist-to-hip ratio (WHR), and insulin sensitivity after 3 months of metformin therapy." | 7.79 | Insulin resistance assessment in patients with polycystic ovary syndrome using different diagnostic criteria--impact of metformin treatment. ( Brodowska, A; Ciećwież, S; Kotlega, D; Marciniak, A; Nawrocka-Rutkowska, J; Starczewski, A; Wiśniewska, B, 2013) |
| "The latest list of reimbursed medicines includes, as a new addition, metformin for the treatment of polycystic ovary syndrome (PCOS), which is extremely important for practicing physicians." | 7.79 | Metformin for polycystic ovary syndrome. ( Milewicz, A, 2013) |
| "We examined the effects of therapy with metformin alone (n = 14) vs metformin with EP (n = 13) on HbA1C and lipid parameters over 10-14 months in 27 overweight girls, drawn from a clinic population of adolescents with PCOS." | 7.79 | Impact of metformin monotherapy versus metformin with oestrogen-progesterone on lipids in adolescent girls with polycystic ovarian syndrome. ( Bredella, MA; McManus, S; Misra, M, 2013) |
| "Metformin has been shown to be an effective treatment for anovulatory polycystic ovary syndrome (PCOS) patients in terms of menstrual cyclicity, ovulation, and pregnancy, as well as reduction of early miscarriage rate." | 7.79 | Effect of metformin treatment on endometrial vascular indices in anovulatory obese/overweight women with polycystic ovarian syndrome using three-dimensional power doppler ultrasonography. ( Elkattan, E; Khattab, S; Mohsen, IA; Nabil, H, 2013) |
| "The study aim was to evaluate our personal experience regarding the use and the reproductive effect of metformin administration in a large population of infertile patients with polycystic ovary syndrome (PCOS) undergoing gonadotropins ovarian stimulation for in vitro fertilization (IVF)." | 7.78 | Metformin administration in patients with polycystic ovary syndrome who receive gonadotropins for in vitro fertilization cycles: 10-year experience in a large infertile population. ( Cappiello, F; Di Cello, A; Falbo, A; Morelli, M; Orio, F; Palomba, S; Russo, T; Tolino, A; Zullo, F, 2012) |
| "We studied patient persistence with oral contraceptive pills (OCPs) compared to metformin for treatment of polycystic ovary syndrome (PCOS) in an urban university clinic population." | 7.78 | Persistence with oral contraceptive pills versus metformin in women with polycystic ovary syndrome. ( Cheang, KI; Karjane, NW; Mandolesi, GA; Stovall, DW, 2012) |
| "Serum hsCRP improved with lifestyle modification and metformin therapy for 3 months in overweight subjects from India with PCOS, along with serum total cholesterol, triglycerides, and HDL-C." | 7.78 | Effect of lifestyle modification and metformin therapy on emerging cardiovascular risk factors in overweight Indian women with polycystic ovary syndrome. ( Bitla, A; P V L N Rao, S; Rajagopal, G; Reddy, AP; Sachan, A; Suresh, V; Venkata Harinarayan, C, 2012) |
| "Metformin (an insulin sensitizer) and spironolactone (an antiandrogen) are both used for treatment of polycystic ovary syndrome." | 7.78 | Effect of metformin and spironolactone therapy on OGTT in patients with polycystic ovarian syndrome - a retrospective analysis. ( Ammini, AC; Ganie, MA; Gupta, N; Kulshreshtha, B, 2012) |
| "We aimed to compare the effects of metformin and metformin-rosuvastatin combination therapies on hyperandrogenism in patients with polycystic ovary syndrome (PCOS)." | 7.78 | Effects of metformin plus rosuvastatin on hyperandrogenism in polycystic ovary syndrome patients with hyperlipidemia and impaired glucose tolerance. ( Acbay, O; Celik, O, 2012) |
| "The objective was to explore the effects of metformin on the expression of endometrial glucose transporter 4 (GLUT4) and analyze the related factors of GLUT4 in patients with polycystic ovary syndrome (PCOS)." | 7.78 | Effects of metformin on the expression of GLUT4 in endometrium of obese women with polycystic ovary syndrome. ( Jiang, QH; Liu, CX; Sun, YP; Tian, ZR; Zhai, J, 2012) |
| "Metformin is a promising medication for the prevention or reduction of the incidence of GDM and pre-eclampsia in PCOS women." | 7.77 | Can metformin reduce the incidence of gestational diabetes mellitus in pregnant women with polycystic ovary syndrome? Prospective cohort study. ( Aboul Foutouh, I; Ashmawi, HS; Khattab, S; Mohsen, IA; Mohsen, MN; van der Veen, F; van Wely, M; Youssef, MA, 2011) |
| "To assess the effect of metformin administration on thyroid function in overweight women with polycystic ovarian syndrome (PCOS)." | 7.77 | Metformin decreases thyrotropin in overweight women with polycystic ovarian syndrome and hypothyroidism. ( Fatemi, S; Morteza Taghavi, S; Rokni, H, 2011) |
| " The aim of the study was to assess serum vaspin levels in PCOS and the effects on vaspin levels of metformin or of weight loss." | 7.77 | The effect of weight loss and treatment with metformin on serum vaspin levels in women with polycystic ovary syndrome. ( Delkos, D; Dinas, K; Kalaitzakis, E; Kandaraki, EA; Katsikis, I; Koiou, E; Panidis, D; Tziomalos, K, 2011) |
| "Treatment with metformin three times 500 mg daily had been advised since 2002, to patients suffering from the polycystic ovary syndrome diagnosed by the Rotterdam criteria and who did not want to take contraceptive pills." | 7.77 | [Metformin treatment with or without life style changes in patients with polycystic ovary syndrome]. ( Petrányi, G; Zaoura-Petrányi, M, 2011) |
| "To search for predictors of metformin response in women with polycystic ovary syndrome (PCOS) through a detailed analysis of clinical and laboratory parameters." | 7.77 | Influence of LH and high-density lipoprotein cholesterol (HDL-C) on metformin response in women with polycystic ovary syndrome. ( Baracat, EC; da Costa, LC; da Fonseca, AM; Hayashida, SA; Maciel, GA; Marcondes, JA; Soares, JM, 2011) |
| "The use of metformin throughout gestation by pregnant women with polycystic ovary syndrome (PCOS) significantly reduces the number of first trimester spontaneous abortions and the rate of occurrence of gestational diabetes." | 7.77 | Metformin pharmacokinetics in nondiabetic pregnant women with polycystic ovary syndrome. ( Cavalli, RC; Dantas Moisés, EC; Dantes Moisés, EC; de Jesus Antunes, N; de Jesus Ponte Carvalho, TM; de Oliveira Baraldi, C; Duarte, G; Lanchote, VL, 2011) |
| "The objective of this study is to determine the ability of metformin treatment in reducing the prevalence of metabolic syndrome (MS) and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome (PCOS)." | 7.77 | Long-term metformin treatment is able to reduce the prevalence of metabolic syndrome and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome. ( Apa, R; Cefalo, C; Ciardulli, A; Gangale, MF; Grieco, A; Lanzone, A; Martinez, D; Miele, L; Morciano, A; Moro, F; Palla, C; Pompili, M; Sagnella, F; Tropea, A, 2011) |
| "To evaluate serum visfatin levels and to determine the effects of metformin treatment on visfatin levels in patients with polycystic ovary syndrome (PCOS)." | 7.76 | Effect of metformin on serum visfatin levels in patients with polycystic ovary syndrome. ( Cakal, E; Engin-Ustun, Y; Ozkaya, M; Ustun, Y, 2010) |
| "To evaluate whether the administration of metformin exerts any effects on serum homocysteine (Hcy) levels in patients with polycystic ovary syndrome (PCOS) and whether supplementation with folate enhances the positive effects of metformin on the structure and function of the vascular endothelium." | 7.76 | Effects of metformin with or without supplementation with folate on homocysteine levels and vascular endothelium of women with polycystic ovary syndrome. ( Colao, A; Falbo, A; Giallauria, F; Orio, F; Palomba, S; Russo, T; Tolino, A; Zullo, F, 2010) |
| "Several data have demonstrated the efficacy of metformin in inducing ovulation in patients with polycystic ovary syndrome (PCOS), however, the exact mechanism by which this drug acts remains unknown." | 7.76 | Systemic and local effects of metformin administration in patients with polycystic ovary syndrome (PCOS): relationship to the ovulatory response. ( Falbo, A; Orio, F; Palomba, S; Russo, T; Tolino, A; Zullo, F, 2010) |
| "Abstract Objective: To evaluate the effects of oral contraceptives and metformin on the outcome of in vitro maturation (IVM) in infertile women with polycystic ovary syndrome (PCOS)." | 7.76 | Effects of oral contraceptives and metformin on the outcome of in vitro maturation in infertile women with polycystic ovary syndrome. ( Huang, XF; Huang, YP; Lin, JJ; Yang, HY; Zhang, W; Zhao, JZ, 2010) |
| " Women who had elective cryopreservation due to ovarian hyperstimulation syndrome risk were found to have significantly higher LBRs if metformin was taken in the fresh IVF/ICSI cycle (A = 44." | 7.76 | Effect of metformin taken in the 'fresh' in vitro fertilization/intracytoplasmic sperm injection cycle upon subsequent frozen embryo replacement in women with polycystic ovary syndrome. ( Acharya, S; Balen, A; Brewer, C; Tang, T; Thake, F, 2010) |
| "To evaluate the effects of metformin on the ovarian stromal blood perfusion in the patients with polycystic ovary syndrome (PCOS)." | 7.75 | The effect of metformin treatment on ovarian stromal blood flow in women with polycystic ovary syndrome. ( Ciftci, FC; Ozcimen, EE; Uckuyu, A; Zeyneloglu, HB, 2009) |
| "The aim of the present study was to assess whether continuation of metformin therapy throughout pregnancy can reduce the development of gestational diabetes in women with polycystic ovarian syndrome (PCOS)." | 7.75 | Prevention of gestational diabetes mellitus by continuing metformin therapy throughout pregnancy in women with polycystic ovary syndrome. ( Begum, A; Begum, MR; Begum, MS; Ferdous, J; Khan, F; Khanam, NN; Quadir, E, 2009) |
| "This study aimed to assess the perinatal outcome, especially foetal growth, following the continuation of metformin during the first trimester of pregnancy." | 7.75 | Continuation of metformin in the first trimester of women with polycystic ovarian syndrome is not associated with increased perinatal morbidity. ( Bolton, S; Cleary, B; Dempsey, E; Turner, MJ; Walsh, J, 2009) |
| "Most research confirms that metformin therapy has a positive influence on cardiovascular risk factors (CVRF) such as dyslipidemia, insulin resistance and hyperandrogenism in polycystic ovary syndrome (PCOS)." | 7.74 | Plasma cytokines in obese women with polycystic ovary syndrome, before and after metformin treatment. ( Bednarek-Tupikowska, G; Bohdanowicz-Pawlak, A; Demissie, M; Jakubowska, J; Milewicz, A; Szymczak, J, 2008) |
| " We present a case of psychosis associated with the menstrual cycle in a patient with polycystic ovary syndrome, a disorder typically characterized by anovulatory cycles, in whom the restoration of normal menstruation with use of metformine led to significant improvement of psychotic symptoms." | 7.74 | Metformine for psychosis associated with the menstrual cycle in a patient with polycystic ovary syndrome. ( Andreou, C; Karavatos, A; Syngelakis, M, 2008) |
| "In women with PCOS, continuous use of metformin during pregnancy significantly reduced the rate of miscarriage, gestational diabetes requiring insulin treatment and fetal growth restriction." | 7.74 | Does continuous use of metformin throughout pregnancy improve pregnancy outcomes in women with polycystic ovarian syndrome? ( Khalid, R; Naru, T; Nawaz, FH; Rizvi, J, 2008) |
| "Metformin therapy in polycystic ovary syndrome (PCOS) improves metabolic and hormonal profiles." | 7.74 | Effect of metformin administration on plasma advanced glycation end product levels in women with polycystic ovary syndrome. ( Aessopos, A; Alexandraki, K; Diamanti-Kandarakis, E; Katsikis, I; Panidis, D; Paterakis, T; Piperi, C, 2007) |
| "To evaluate the acute effects of metformin therapy on biochemical markers and polycystic ovarian morphology among insulin-resistant (IR) and noninsulin-resistant (NIR) patients with polycystic ovary syndrome (PCOS)." | 7.74 | Acute effects of metformin therapy include improvement of insulin resistance and ovarian morphology. ( Bayrak, A; Mor, E; Paulson, RJ; Stanczyk, FZ; Terbell, H; Urwitz-Lane, R, 2007) |
| "There are conflicting data regarding the effects of metformin in lean women with polycystic ovary syndrome (PCOS)." | 7.74 | The effects of metformin on metabolic and cardiovascular risk factors in nonobese women with polycystic ovary syndrome. ( Aygen, E; Kelestimur, F; Sahin, Y; Unluhizarci, K; Yikilmaz, A; Yilmazsoy, A, 2007) |
| "The effect of 6 months of metformin treatment was prospectively assessed in 188 PCOS patients, divided into three groups according to body mass index (BMI; lean: BMI<25 kg/m2, overweight: BMI 25-29 kg/m2, and obese: BMI30 kg/m2)." | 7.74 | Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance. ( Benson, S; Dietz, T; Elsenbruch, S; Hahn, S; Janssen, OE; Kimmig, R; Lahner, H; Mann, K; Moeller, LC; Schmidt, M; Tan, S, 2007) |
| " We sought to characterize patients with biochemical hyperandrogenism in respect of tumor versus non-tumor etiologies, explore possible links between non-tumor hyperandrogenism and metabolic syndrome, and ascertain whether metformin therapy can elicit diagnostic reductions in serum testosterone (T)." | 7.74 | The investigation and management of severe hyperandrogenism pre- and postmenopause: non-tumor disease is strongly associated with metabolic syndrome and typically responds to insulin-sensitization with metformin. ( Advani, A; Al-Ozairi, E; Ball, SG; James, RA; Lim, E; Quinton, R; Vaikkakara, S, 2008) |
| " In this study, therefore, we aimed (1) to determine the circulating ADMA concentrations in 44 women with PCOS and 22 age- and BMI-matched healthy controls, (2) to evaluate its correlations with insulin resistance, gonadotrophins, and androgen secretion, and (3) to compare effects of metformin and ethinyl estradiol-cyproterone acetate (EE/CPA) treatments on circulating ADMA concentrations." | 7.74 | Metformin and oral contraceptive treatments reduced circulating asymmetric dimethylarginine (ADMA) levels in patients with polycystic ovary syndrome (PCOS). ( Baser, I; Dede, M; Erbil, MK; Kenar, L; Oktenli, C; Ozgurtas, T; Sanisoglu, SY; Tapan, S; Yenen, MC; Yesilova, Z, 2008) |
| "This study evaluated the use of metformin as first line treatment for patients with polycystic ovary syndrome." | 7.74 | The use of metformin as first line treatment in polycystic ovary syndrome. ( Abbas, M; Gannon, M, 2008) |
| " It has been suggested that metformin in combination with clomiphene can restore ovulation to some clomiphene-resistant anovulators with polycystic ovary syndrome (PCOS)." | 7.74 | Extended-release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome. ( Barnhart, HX; Carr, BR; Carson, SA; Cataldo, NA; Coutifaris, C; Diamond, MP; Giudice, LC; Gosman, G; Legro, RS; McGovern, PG; Myers, ER; Nestler, JE; Schlaff, WD; Steinkampf, MP, 2008) |
| "We prospectively assessed whether metabolic and menstrual benefits of metformin-diet were equally realized in women with polycystic ovary syndrome (PCOS), categorized by pretreatment top (n = 32) and bottom (n = 35) quintile homeostasis model assessment insulin resistance (IR)." | 7.73 | Metformin-diet benefits in women with polycystic ovary syndrome in the bottom and top quintiles for insulin resistance. ( Glueck, CJ; Goldenberg, N; Loftspring, M; Sherman, A; Wang, P, 2005) |
| "Metformin had differential effects on fasting insulin levels, insulin resistance as demonstrated by homeostasis model assessment (HOMA), LH, total testosterone, dehydroepiandrosterone sulphate and free testosterone index on the basis of IRS genotype." | 7.73 | The importance of IRS-1 Gly972Arg polymorphism in evaluating the response to metformin treatment in polycystic ovary syndrome. ( Aktas, A; Dilek, S; Erdal, EM; Ertunc, D; Tok, EC, 2005) |
| "This study was carried out to compare ovulation and pregnancy rates in response to metformin therapy in lean and obese women with polycystic ovary syndrome (PCOS)." | 7.73 | Metformin monotherapy in lean women with polycystic ovary syndrome. ( Abdel-Wareth, LO; Al Haija, SA; Alvares, M; Haq, A; Jayasundaram, R; Kumari, AS, 2005) |
| "Based on the favourable international experience with metformin in the most common female endocrine disease, the polycystic ovary syndrome, which has insulin resistance in the background, the author's treatment advice has been this in such cases since early 2002: for sexually active women who do not want to become pregnant for the time being, anti-androgenic contraceptive pill; for those who do not want to take contraceptives, contraceptives are contraindicated, or who do want to conceive, metformin." | 7.73 | [Treatment experience with metformin in polycystic ovary syndrome]. ( Petrányi, G, 2005) |
| "Recent data indicate that women affected by the polycystic ovary syndrome (PCOS) are at greater risk for cardiovascular disease and that metformin may improve the metabolic alterations in these patients." | 7.73 | Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: results of a 6-month study. ( Azziz, R; Cascella, T; Colao, A; De Simone, B; Lombardi, G; Manguso, F; Orio, F; Palomba, S; Russo, T; Savastano, S; Tolino, A; Zullo, F, 2005) |
| "In women with polycystic ovary syndrome, metformin administration, not laparoscopic ovarian drilling, reduces plasminogen activator inhibitor 1 (PAI-1) activity." | 7.73 | Plasminogen activator inhibitor 1 and miscarriage after metformin treatment and laparoscopic ovarian drilling in patients with polycystic ovary syndrome. ( Falbo, A; Orio, F; Palomba, S; Russo, T; Tolino, A; Zullo, F, 2005) |
| "Our data showed that both metformin and rosiglitazone increased insulin sensitivity in obese patients with PCOS as expected, and in lean patients as well." | 7.73 | The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome. ( Arslan, M; Ayvaz, G; Bingöl, B; Biri, A; Cakir, N; Karakoç, A; Tiras, B; Törüner, F; Yilmaz, M, 2005) |
| "Plasma androgen levels were decreased significantly by metformin treatment, as were plasma LH and allopregnanolone levels and insulin resistance." | 7.73 | Metformin administration modulates neurosteroids secretion in non-obese amenorrhoic patients with polycystic ovary syndrome. ( Baraldi, E; Casarosa, E; Genazzani, AD; Genazzani, AR; Lanzoni, C; Luisi, M; Mehmeti, H; Ricchieri, F; Strucchi, C, 2006) |
| "A pregnant patient with polycystic ovary syndrome asked me whether continuing metformin, which she was taking to treat infertility before her pregnancy, is safe for her fetus." | 7.73 | Metformin use during the first trimester of pregnancy. Is it safe? ( Gilbert, C; Koren, G; Valois, M, 2006) |
| "To analyze pregnancy complications and outcome in patients with polycystic ovary syndrome (PCOS) treated with metformin." | 7.73 | Pregnancy outcome in infertile patients with polycystic ovary syndrome who were treated with metformin. ( Jackson, EM; Thatcher, SS, 2006) |
| "To report the effect of metformin treatment on a patient with recurrent miscarriage (RM) and polycystic ovary syndrome (PCOS)." | 7.73 | Metformin hydrochloride and recurrent miscarriage in a woman with polycystic ovary syndrome. ( Falbo, A; Orio, F; Palomba, S; Russo, T; Tolino, A; Zullo, F, 2006) |
| "The present study supports the notion that metformin may be considered as a prophylactic therapy lowering cardiovascular risk factors in hyperinsulinemic women with polycystic ovary syndrome." | 7.73 | Lipids in polycystic ovary syndrome: role of hyperinsulinemia and effects of metformin. ( Banaszewska, B; Duleba, AJ; Pawelczyk, L; Spaczynski, RZ, 2006) |
| "55 g metformin per day throughout pregnancy and lactation." | 7.73 | Growth, motor, and social development in breast- and formula-fed infants of metformin-treated women with polycystic ovary syndrome. ( Glueck, CJ; Salehi, M; Sieve, L; Wang, P, 2006) |
| " Metformin therapy reduces whole-body insulin resistance (IR) in patients with type-2 diabetes mellitus (DM)." | 7.73 | Metformin therapy improves coronary microvascular function in patients with polycystic ovary syndrome and insulin resistance. ( Caliskan, M; Erdogan, D; Gullu, H; Muderrisoglu, H; Ozcimen, EE; Tok, D; Topcu, S; Uckuyu, A; Zeyneloglu, H, 2006) |
| "To determine whether women with polycystic ovary syndrome (PCOS) and abnormal insulin levels treated with metformin had different rates of ovulation and pregnancy from women with PCOS and normal insulin levels." | 7.73 | Use of metformin for ovulation induction in women who have polycystic ovary syndrome with or without evidence of insulin resistance. ( Liu, KE; Sagle, M; Tataryn, IV, 2006) |
| "The mean birth weight percentile of neonates exposed to metformin in utero during the first trimester was significantly lower than that of neonates delivered to normal healthy matched controls." | 7.73 | Neonatal outcome in polycystic ovarian syndrome patients treated with metformin during pregnancy. ( Glezerman, M; Gur, D; Kovo, M; Levran, D; Rotmensch, S; Weissman, A, 2006) |
| "In 74 women with polycystic ovary syndrome, treated for 4 years with metformin (MET) and diet, we prospectively assessed whether, and to what degree, weight loss, reduction of insulin resistance, and amelioration of coronary heart disease risk factors could be sustained." | 7.73 | Sustainability of 8% weight loss, reduction of insulin resistance, and amelioration of atherogenic-metabolic risk factors over 4 years by metformin-diet in women with polycystic ovary syndrome. ( Agloria, M; Aregawi, D; Glueck, CJ; Sieve, L; Wang, P; Winiarska, M, 2006) |
| "In an observational study of 13 women with polycystic ovary syndrome (PCOS) not optimally responsive to metformin diet, we assessed the efficacy and safety of addition of pioglitazone." | 7.72 | Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin. ( Glueck, CJ; Goldenberg, N; Moreira, A; Sieve, L; Wang, P, 2003) |
| "The purpose of this review is to provide a critical summary of recent studies on the clinical effects of metformin in polycystic ovary syndrome." | 7.72 | The role of metformin in the management of polycystic ovary syndrome. ( Prelevic, GM; Tsilchorozidou, T, 2003) |
| "To evaluate the effects of metformin on gonadotropin-induced ovulation in patients with polycystic ovary syndrome (PCOS)." | 7.72 | [Effects of metformin on gonadotropin-induced ovulation in patients with polycystic ovary syndrome]. ( Chi, HH; Lin, JJ; Lin, WQ; Ye, BL; Zhao, JZ, 2003) |
| "Women with polycystic ovary syndrome (PCOS) are increasingly being treated with metformin as an insulin sensitizing agent to reduce symptoms of hyperandrogenism and promote fertility." | 7.72 | Women with polycystic ovary syndrome (PCOS) often undergo protracted treatment with metformin and are disinclined to stop: indications for a change in licensing arrangements? ( Fleming, R; Muth, S; Norman, J; Sattar, N, 2004) |
| "The aim of this study was to assess the efficacy of metformin on induction of ovulation in Asian women with clomiphene citrate (CC)-resistant polycystic ovary syndrome (PCOS)." | 7.72 | Efficacy of metformin on ovulation induction in Asian women with polycystic ovary syndrome. ( Choktanasiri, W; Rojanasakul, A; Sophonsritsuk, A; Tingthanatikul, Y; Wansumrith, S; Weerakiet, S, 2004) |
| "We sought to determine whether metformin, which had facilitated conception in 72 oligoamenorrhoeic women with polycystic ovary syndrome (PCOS), would safely reduce the rate of first trimester spontaneous abortion (SAB) and increase the number of live births without teratogenicity." | 7.71 | Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. ( Glueck, CJ; Goldenberg, N; Sieve-Smith, L; Wang, P, 2002) |
| "To determine if metformin therapy improves in vitro fertilization (IVF) outcomes in patients with clomiphene-resistant polycystic ovarian syndrome (PCOS)." | 7.71 | Metformin treatment of patients with polycystic ovary syndrome undergoing in vitro fertilization improves outcomes and is associated with modulation of the insulin-like growth factors. ( Riehl, RM; Stadtmauer, LA; Talbert, LM; Toma, SK, 2001) |
| "Long-term metformin treatment reduced various steroid enzymatic activities both in the ovary and the adrenal glands, without apparent changes in basal steroid levels and in insulin sensitivity." | 7.71 | The effects of long-term metformin treatment on adrenal and ovarian steroidogenesis in women with polycystic ovary syndrome. ( Bendlová, B; Cibula, D; Hill, M; Snajderová, M; Stárka, L; Sulcová, J; Vondra, K; Vrbíková, J, 2001) |
| " Metformin, an oral hypoglycaemic agent that increases insulin sensitivity, has been shown to reduce serum concentrations of insulin and androgens, to reduce hirsutism, and to improve ovulation rates." | 7.71 | Metformin and intervention in polycystic ovary syndrome. Endocrine Society of Australia, the Australian Diabetes Society and the Australian Paediatric Endocrine Group. ( Cuneo, RC; Kidson, WJ; Norman, RJ; Zacharin, MR, 2001) |
| "We evaluated the fertility promoting effect of metformin in infertile patients with polycystic ovary syndrome." | 7.71 | Metformin improves ovulation and pregnancy rates in patients with polycystic ovary syndrome. ( Batukan, C; Baysal, B, 2001) |
| "The aim of the present study was to investigate the steroidogenic response pattern to HCG in obese women with polycystic ovary syndrome (PCOS) and the possible effects of metformin treatment on it." | 7.71 | Ovarian steroidogenic response to human chorionic gonadotrophin in obese women with polycystic ovary syndrome: effect of metformin. ( Koivunen, RM; Martikainen, HK; Morin-Papunen, LC; Ruokonen, A; Tapanainen, JS, 2001) |
| "Basing on the key role of the hyperinsulinemia in the etiopathogenesis of the Polycystic ovary syndrome, the authors treat the affected women with Metformin." | 7.71 | [Our experience in the treatment of polycystic ovary syndrome with Metformin]. ( Mitkov, M; Pekhlivanov, B; Simeonov, S; Velchev, G, 2001) |
| "Long-term therapy with metformin led to the improvement in menstrual cyclicity, without significant change in basal steroid levels or parameters of insulin resistance." | 7.71 | [Effect of long-term treatment with metformin on steroid levels and parameters of insulin resistance in women with polycystic ovary syndrome]. ( Bendlová, B; Cibula, D; Hill, M; Snajderová, M; Stárka, L; Sulcová, J; Vondra, K; Vrbíková, J, 2001) |
| "To evaluate the long-term effects of metformin on biochemical variables and body weight in polycystic ovary syndrome (PCOS)." | 7.71 | Biochemical and body weight changes with metformin in polycystic ovary syndrome. ( Batukan, C; Batukan, M; Baysal, B, 2001) |
| "Before metformin therapy, after covariance adjustment for age, the two cohorts did not differ in height, weight, basal metabolic index, insulin, insulin resistance, or insulin secretion." | 7.71 | Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. ( Glueck, CJ; Kobayashi, S; Phillips, H; Sieve-Smith, L; Wang, P, 2002) |
| " In the present study we tested the hypothesis that metformin therapy in obese adolescents with PCOS will attenuate the adrenal steroidogenic response to ACTH, with reduction of insulin resistance/insulinemia." | 7.71 | Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. ( Arslanian, SA; Danadian, K; Lewy, V; Saad, R, 2002) |
| "To assess pregnancy outcome in anovulatory infertility patients diagnosed with polycystic ovary syndrome (PCOS) who were treated with metformin." | 7.71 | Pregnancies following use of metformin for ovulation induction in patients with polycystic ovary syndrome. ( Buster, JE; Carson, SA; Heard, MJ; Pierce, A, 2002) |
| "To assess the therapeutic effects of metformin in patients with polycystic ovary syndrome (PCOS) and clomiphene (CC) resistant cases." | 7.71 | [Effects of metformin on the plasminogen activator system, endocrine, metabolic profiles in patients with polycystic ovary syndrome and clomiphene resistant cases]. ( Huang, Z; Li, J; Shen, H; Song, J; Zhang, Y, 2002) |
| "The objective of the study was to find predictors of a successful therapy with metformin in polycystic ovary syndrome." | 7.71 | Prediction of the effect of metformin treatment in patients with polycystic ovary syndrome. ( Hill, M; Stárka, L; Vondra, K; Vrbíková, J, 2002) |
| " Metformin therapy improved menstrual disturbances in 25% of the women with PCOS and also resulted in some improvement in insulin sensitivity and reduced basal and post glucose load insulin levels." | 7.70 | The effects of metformin on insulin resistance and ovarian steroidogenesis in women with polycystic ovary syndrome. ( Bayram, F; Keleştimur, F; Sahin, Y; Tutuş, A; Unlühizarci, K, 1999) |
| "The objective of the present study was to investigate whether metformin affected plasma concentrations of insulin-like growth factor (IGF) I and IGF-binding protein I (IGFBP-I) in polycystic ovary syndrome (PCOS) patients." | 7.70 | Effect of metformin on insulin-like growth factor (IGF) I and IGF-binding protein I in polycystic ovary syndrome. ( De Leo, V; La Marca, A; Morgante, G; Orvieto, R, 2000) |
| " Metformin, a medication that improves insulin sensitivity and decreases serum insulin levels, restores menstrual cyclicity and ovulatory function and may improve fertility rates in women with PCOS." | 7.70 | Association of metformin and pregnancy in the polycystic ovary syndrome. A report of three cases. ( Neal, GS; Robinson, RD; Seale, FG, 2000) |
| "Using polycystic ovary syndrome (PCOS) as a model of insulin resistance and hyperandrogenism, our specific aim was to assess the effect of Metformin on lipoproteins, sex hormones, gonadotropins, and blood pressure in 26 women with PCOS who were studied at baseline, received Metformin 1." | 7.69 | Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. ( Glueck, CJ; Hamer, T; Mendoza, S; Sosa, F; Velazquez, EM, 1994) |
| "Insulin sensitivity, the mean fasting serum levels of glucose, insulin, total cholesterol, triglyceride, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, total T, free T, androstenedione, DHEAS, and LH:FSH ratio, and the areas under the curve for plasma glucose and insulin during OGTT were not changed by either placebo or metformin treatment." | 7.69 | Can metformin reduce insulin resistance in polycystic ovary syndrome? ( Açbay, O; Gündoğdu, S, 1996) |
| "Sixteen nondiabetic women with polycystic ovary syndrome (PCOS) aged 18 to 33 years were studied before and after 8 weeks on metformin (1." | 7.69 | Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome. ( Glueck, CJ; Mendoza, SG; Velazquez, EM; Wang, P, 1997) |
| "Treatment with metformin is associated with a time-dependent decrease in mtDNA-CN in patients with PCOS who are treated over the course of one year." | 6.94 | Changes in peripheral mitochondrial DNA copy number in metformin-treated women with polycystic ovary syndrome: a longitudinal study. ( Chang, CH; Chen, MJ; Chen, SU; Chou, CH; Ho, HN; Yang, PK, 2020) |
| "Metformin is one of the treatments used for PCOS pathology decreasing body weight, plasma androgen, FSH and glucose levels." | 6.90 | Metformin induces lipid changes on sphingolipid species and oxidized lipids in polycystic ovary syndrome women. ( Bañuls, C; Hernandez-Mijares, A; Jové, M; Naudí, A; Pamplona, R; Pradas, I; Rocha, M; Rovira-Llopis, S; Victor, VM, 2019) |
| "Empagliflozin is a sodium-glucose-cotransporter-2 inhibitor that improves cardiovascular risk and promotes weight loss in patients with type-2 diabetes." | 6.90 | Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: A randomized controlled study. ( Abbas, J; Atkin, SL; Deshmukh, H; Javed, Z; Khan, AY; Kilpatrick, ES; Papageorgiou, M; Qamar, U; Rigby, AS; Sathyapalan, T, 2019) |
| "Treatment with metformin and NAC significantly increased ovulation and pregnancy rates in CC-resistant PCOS patients." | 6.84 | Comparison of metformin and N-acetyl cysteine, as an adjuvant to clomiphene citrate, in clomiphene-resistant women with polycystic ovary syndrome. ( Heidari, B; Nemati, M; Nemati, S; Taheri, AM, 2017) |
| "Metformin treatment was also associated with a significant decrease in LH and oestradiol levels, androgens and anti-müllerian hormone levels." | 6.84 | Metformin vs myoinositol: which is better in obese polycystic ovary syndrome patients? A randomized controlled crossover study. ( De Cicco, S; Di Florio, C; Guido, M; Immediata, V; Lanzone, A; Romualdi, D; Tagliaferri, V, 2017) |
| " This study aimed to compare the different effects of drospirenone (DRP)-containing COCs with cyproterone acetate (CPA)-containing COCs, combined with metformin and lifestyle modifications in women with PCOS and metabolic disorders." | 6.82 | Comparison of Drospirenone- with Cyproterone Acetate-Containing Oral Contraceptives, Combined with Metformin and Lifestyle Modifications in Women with Polycystic Ovary Syndrome and Metabolic Disorders: A Prospective Randomized Control Trial. ( Feng, GM; Huang, W; Song, Y; Wang, QS; Wang, QY; Xiao, L, 2016) |
| "Both metformin and statin have been used as methods to ameliorate symptoms and improve prognosis." | 6.80 | Inadequacy of initiating rosuvastatin then metformin on biochemical profile of polycystic ovarian syndrome patients. ( Abbas, HA; Awwad, J; Ghazeeri, G; Harajly, S; Skaff, B, 2015) |
| "The objective of the study was to evaluate whether treatment with metformin (M) or M combined with oral contraceptive pills (OCPs) resulted in a more advantageous body composition than treatment with OCP alone." | 6.79 | Body composition is improved during 12 months' treatment with metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. ( Altinok, ML; Andersen, M; Glintborg, D; Hermann, AP; Mumm, H; Ravn, P, 2014) |
| "Chronic low-grade inflammation is a common feature of insulin resistant states, including obesity and type 2 diabetes." | 6.78 | Inflammatory cytokines and chemokines, skeletal muscle and polycystic ovary syndrome: effects of pioglitazone and metformin treatment. ( Aroda, V; Ciaraldi, TP; Henry, RR; Mudaliar, SR, 2013) |
| "Berberine (BBR) is an isoquinoline derivative alkaloid extracted from Chinese medicinal herbs that has been used as an insulin sensitizer." | 6.77 | A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. ( Deng, H; Guan, Y; Liang, K; Ma, Y; Sui, M; Wang, A; Wei, W; Zhang, H; Zhang, Y; Zhao, H, 2012) |
| "The objective of this study was to assess the efficacy and safety of metformin at the dosage of 2,500 mg/day in the treatment of obese women with PCOS and also to evaluate its effect on weight, hormones, and lipid profile." | 6.75 | Metformin 2,500 mg/day in the treatment of obese women with polycystic ovary syndrome and its effect on weight, hormones, and lipid profile. ( Aghahosseini, M; Aleyaseen, A; Kashani, L; Moddaress-Hashemi, S; Mofid, B; Safdarian, L, 2010) |
| " No adverse maternal-fetal side effects were reported on enoxaparin alone or enoxaparin-metformin." | 6.74 | Enoxaparin-metformin and enoxaparin alone may safely reduce pregnancy loss. ( Glueck, CJ; Goldenberg, N; Khan, N; Ramidi, G; Wang, P, 2009) |
| "Simvastatin treatment was superior to metformin alone, whereas a combination of simvastatin and metformin was not significantly superior to simvastatin alone." | 6.74 | Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. ( Banaszewska, B; Duleba, AJ; Pawelczyk, L; Spaczynski, RZ, 2009) |
| "Metformin therapy has many useful effects in these patients." | 6.73 | Metformin therapy in girls with polycystic ovary syndrome: a self-controlled clinical trial. ( Bayat, R; Hamedi, M; Nazari, T, 2007) |
| "Metformin treatment induced a significant decrease in insulin levels (P < 0." | 6.73 | Alteration of ghrelin-neuropeptide Y network in obese patients with polycystic ovary syndrome: role of hyperinsulinism. ( Campagna, G; De Marinis, L; Guido, M; Lanzone, A; Proto, C; Romualdi, D, 2008) |
| "Metformin was then given at a dose of 500 mg three times a day for 8 weeks, after which time the pretreatment study was repeated." | 6.71 | Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome. ( Dehghan-Kooshkghazi, M; Kazerooni, T, 2003) |
| "Flutamide-metformin treatment (n = 30) was followed within 3 months by marked decreases in hirsutism score and serum androgens, by a more than 50% increase in insulin sensitivity and by a less atherogenic lipid profile (all P < 0." | 6.71 | Low-dose flutamide-metformin therapy reverses insulin resistance and reduces fat mass in nonobese adolescents with ovarian hyperandrogenism. ( Amin, R; de Zegher, F; Dunger, D; Ferrer, A; Ibáñez, L; Ong, K, 2003) |
| "Hirsutism is a common and distressing symptom frequently encountered in women with polycystic ovary syndrome (PCOS), who also show relative insulin resistance." | 6.71 | Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. ( Fleming, R; Harborne, L; Lyall, H; Norman, J; Sattar, N, 2003) |
| "The results suggest that hyperinsulinemia/insulin resistance may be responsible for low progesterone levels during the luteal phase in PCOS." | 6.71 | Effects of metformin treatment on luteal phase progesterone concentration in polycystic ovary syndrome. ( Agarwal, S; Krishna, A; Meenakumari, KJ; Pandey, LK, 2004) |
| "In conclusion, metformin treatment improved insulin sensitivity and decreased androgen levels, and flutamide decreased androgen levels but failed to improve insulin sensitivity in the non-obese women with PCOS." | 6.71 | Metformin versus flutamide in the treatment of metabolic consequences of non-obese young women with polycystic ovary syndrome: a randomized prospective study. ( Aral, Y; Culha, C; Demirbas, B; Karakurt, F; Kosar, F; Sahin, I; Serter, R; Taskapan, C, 2004) |
| "Metformin was well tolerated except for one case of flatulence." | 6.69 | Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. ( Bergiele, A; Diamanti-Kandarakis, E; Kouli, C; Tsianateli, T, 1998) |
| "When metformin was compared with CC, data for live birth were inconclusive, and the findings were limited by lack of evidence." | 6.61 | Metformin for ovulation induction (excluding gonadotrophins) in women with polycystic ovary syndrome. ( Balen, AH; Morley, LC; Norman, RJ; Sharpe, A; Tang, T, 2019) |
| "Metformin was associated with generally mild gastrointestinal adverse events." | 6.61 | Effect of the combined oral contraceptive pill and/or metformin in the management of polycystic ovary syndrome: A systematic review with meta-analyses. ( Costello, M; Joham, A; Malhotra, J; McAllister, V; Misso, ML; Mol, BW; Peña, A; Piltonen, T; Romualdi, D; Tassone, EC; Teede, H; Thondan, M; Witchel, SF, 2019) |
| "Metformin and OCPs were similar in terms of impact on hirsutism." | 6.53 | Metformin or Oral Contraceptives for Adolescents With Polycystic Ovarian Syndrome: A Meta-analysis. ( Al Khalifah, RA; Bassilious, E; Dennis, B; Florez, ID; Thabane, L, 2016) |
| "Metformin is an insulin sensitising agent which is safe, widely available and currently licensed for type-2 diabetes." | 6.50 | Preventing endometrial cancer risk in polycystic ovarian syndrome (PCOS) women: could metformin help? ( Abu, J; Ariffin, R; Atiomo, W; Barrett, DA; Chapman, C; Deen, S; Khan, G; Nunns, D; Seedhouse, C; Shafiee, MN, 2014) |
| " Currently, there is no evidence that cardiovascular morbidity is decreased by long-term use of insulin sensitizers in PCOS women." | 6.50 | Metformin and other insulin sensitizers in polycystic ovary syndrome. ( Bhagavath, B; Hoeger, K; Queenan, J; Vitek, W, 2014) |
| "Metformin is an effective insulin sensitizer treating type 2 diabetes mellitus." | 6.50 | Effect of metformin intervention during pregnancy on the gestational diabetes mellitus in women with polycystic ovary syndrome: a systematic review and meta-analysis. ( Wang, A; Yu, H; Zhuo, Z, 2014) |
| "Metformin is an oral insulin-sensitizing anti-diabetic drug." | 6.50 | [Metformin in pregnancy]. ( Bijok, J; Bińkowska, M; Jakiel, G, 2014) |
| "Metformin has been introduced as a therapeutic option in PCOS, targeting of cardiometabolic and reproductive abnormalities on the basis of its action on the reduction of glucose levels and the attenuation of insulin resistance." | 6.46 | Metformin in polycystic ovary syndrome. ( Christakou, C; Diamanti-Kandarakis, E; Economou, F; Palimeri, S, 2010) |
| "Metformin is an insulin sensitizer widely used for the treatment of patients affected by type 2 diabetes mellitus." | 6.45 | Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. ( Falbo, A; Orio, F; Palomba, S; Zullo, F, 2009) |
| "Polycystic ovary syndrome is characterized among other things by oligo-amenorrhea and may account for more than 75% of cases with anoluvatory infertility." | 6.43 | Is metformin therapy for polycystic ovary syndrome safe during pregnancy? ( Brock, B; Ovesen, P; Rungby, J; Schmitz, O; Smidt, K, 2005) |
| "Insulin resistance is an important pathophysiological feature of the polycystic ovary syndrome (PCOS)." | 6.43 | Is metformin a primary ovulatory agent in patients with polycystic ovary syndrome? ( Cheang, KI; Nestler, JE; Sharma, ST, 2006) |
| "Polycystic ovary syndrome is a frequent endocrine disorder often associated with insulin resistance and hyperinsulinaemia which may play a role in hyperandrogenism and anovulation." | 6.42 | [Should infertile women with polycystic ovarian syndrome be treated with metformine?]. ( Basille, C; Bry-Gauillard, H; Cédrin-Durnerin, I; Galey, J; Hugues, JN; Massin, N; Théron-Gérard, L, 2003) |
| "Insulin resistance is a prominent feature of polycystic ovarian syndrome (PCOS), and women with the disorder are at increased risk for the development of other diseases that have been linked to insulin resistance-namely, type 2 diabetes and cardiovascular disease." | 6.41 | Should patients with polycystic ovarian syndrome be treated with metformin?: an enthusiastic endorsement. ( Nestler, JE, 2002) |
| " They also suggest that long term administration of metformin might be helpful in treating insulin resistance, thus reducing risks of type 2 (non-insulin-dependent) diabetes and cardiovascular disease in these patients." | 6.40 | Insulin resistance, polycystic ovary syndrome and metformin. ( Ducluzeau, PH; Pugeat, M, 1999) |
| "Metformin was used as a positive control." | 5.91 | Pioglitazone can improve liver sex hormone-binding globulin levels and lipid metabolism in polycystic ovary syndrome by regulating hepatocyte nuclear factor-4α. ( He, B; Lv, B; Wang, D; Wang, X; Xing, C; Zhao, H, 2023) |
| "Metformin is a commonly used drug of PCOS but few studies on whether metformin can improve the follicle development and ovarian function in PCOS." | 5.91 | Metformin improves polycystic ovary syndrome in mice by inhibiting ovarian ferroptosis. ( Chang, Q; Chen, X; He, R; Hei, C; Li, G; Liang, X; Liu, H; Liu, X; Ouyang, J; Peng, Q; Ren, S; Sun, M; Sun, Y; Wang, C; Wang, Q; Wu, X; Xie, H, 2023) |
| " This study aimed to investigate the effect of letrozole and metformin combined with targeted nursing on ovarian function, LH, and FSH in infertile patients with PCOS." | 5.72 | The Effects of Letrozole and Metformin Combined with Targeted Nursing Care on Ovarian Function, LH, and FSH in Infertile Patients with Polycystic Ovary Syndrome. ( Jiang, S; Li, R; Sheng, Y; Tang, T; Xu, H, 2022) |
| "Metformin (MTF) treatment improves insulin signaling in endometrial tissues, but its mechanism is not fully understood." | 5.72 | Metformin Treatment Regulates the Expression of Molecules Involved in Adiponectin and Insulin Signaling Pathways in Endometria from Women with Obesity-Associated Insulin Resistance and PCOS. ( Astorga, I; Carvajal, R; García, V; Oróstica, ML; Plaza-Parrochia, F; Poblete, C; Romero, C; Vega, M, 2022) |
| "Letrozole (1 mg/kg/day) was administered to female Sprague-Dawley (SD) rats for 21 days to induce PCOS." | 5.72 | Kelulut Honey Improves Folliculogenesis, Steroidogenic, and Aromatase Enzyme Profiles and Ovarian Histomorphology in Letrozole-Induced Polycystic Ovary Syndrome Rats. ( Ibrahim, SF; Kamal, DAM; Mokhtar, MH; Ugusman, A; Zaid, SSM, 2022) |
| "Short-term combined treatment with beinaglutide and metformin appears superior to metformin monotherapy in lowering body weight, BMI, WC,WHtR and improving insulin sensitivity and androgen excess in women with PCOS and obesity, with tolerable adverse events." | 5.69 | Short-term effect of beinaglutide combined with metformin versus metformin alone on weight loss and metabolic profiles in obese patients with polycystic ovary syndrome: a pilot randomized trial. ( Chen, Q; Chen, Y; Fang, S; Liang, Y; Tian, Y; Wen, Q; Yuan, J, 2023) |
| "s-PROK1 was analysed using ELISA at gestational week 19 and related to pregnancy complications, fasting insulin levels, homoeostatic model assessment for insulin resistance (HOMA-IR), testosterone, or androstenedione levels, metformin use, PCOS phenotype and hyperandrogenism." | 5.69 | Maternal serum levels of prokineticin-1 related to pregnancy complications and metformin use in women with polycystic ovary syndrome: a post hoc analysis of two prospective, randomised, placebo-controlled trials. ( Hirschberg, AL; Trouva, A; Ujvari, D; Vanky, E, 2023) |
| "A rat model of PCOS-IR was established using a high-fat diet (49 d) combined with letrozole (1 mg/kg·d, for 28 d)." | 5.62 | Effects of total flavonoids from Eucommia ulmoides Oliv. leaves on polycystic ovary syndrome with insulin resistance model rats induced by letrozole combined with a high-fat diet. ( Li, CX; Li, M; Miao, MS; Peng, MF; Ren, Z; Song, YG; Tian, S, 2021) |
| "Berberine is a monomer from Chinese herbs such as Coptis chinensis, whose effect on improving ovulation and endometrial receptivity of PCOS is uncertain." | 5.62 | Berberine improves ovulation and endometrial receptivity in polycystic ovary syndrome. ( Dong, H; Nie, K; Su, H; Tang, Y; Wang, H; Wang, Z; Xu, X, 2021) |
| "Treatment with dapsone and metformin reversed the effects of testosterone in the DAP and MET groups." | 5.62 | The effect of dapsone in testosterone enanthate-induced polycystic ovary syndrome in rat. ( Dehpour, AR; Khaledi, E; Khazaei, M; Noori, T; Sadeghi, F; Shirooie, S; Sobarzo-Sánchez, E, 2021) |
| "Metformin treatment elevates serum MANF levels and alleviates insulin resistance and hyperandrogenism in PCOS women." | 5.56 | Decreased Circulating MANF in Women with PCOS is Elevated by Metformin Therapy and is Inversely Correlated with Insulin Resistance and Hyperandrogenism. ( Deng, W; Jia, Y; Li, Y; Liu, D; Long, M; Wang, C; Wei, J; Yang, G, 2020) |
| "Letrozole (1 mg/kg) was administered orally for a period of 28 days to induce PCOS." | 5.56 | The effects of thylakoid-rich spinach extract and aqueous extract of caraway (Carum carvi L.) in letrozole-induced polycystic ovarian syndrome rats. ( Ekramzadeh, M; Golmakani, MT; Koohpeyma, F; Sherafatmanesh, S; Tanideh, N, 2020) |
| "To compare the effects of insulin sensitizers metformin (MET) and myo-inositol (MI) on adiponectin levels and metabolic characteristics in women with polycystic ovary syndrome (PCOS) with respect to their body mass index (BMI)." | 5.51 | The effect of metformin and myoinositol on metabolic outcomes in women with polycystic ovary syndrome: role of body mass and adiponectin in a randomized controlled trial. ( Bjekić-Macut, J; Livadas, S; Macut, D; Malešević, G; Mastorakos, G; Micić, D; Ognjanović, S; Popović-Pejičić, S; Prtina, A; Soldat-Stanković, V; Stanković, S, 2022) |
| "To determine the safety and efficacy of canagliflozin in comparison to metformin in polycystic ovary syndrome (PCOS) patients with insulin resistance (IR)." | 5.51 | Efficacy of canagliflozin versus metformin in women with polycystic ovary syndrome: A randomized, open-label, noninferiority trial. ( Cai, M; Dilimulati, D; Gao, X; Qu, S; Shao, X; Xing, F; Zeng, Q; Zhang, M; Zhang, Y, 2022) |
| "Metformin is prescribed to women with polycystic ovary syndrome (PCOS) to prevent pregnancy complications." | 5.51 | Metformin exposure, maternal PCOS status and fetal venous liver circulation: A randomized, placebo-controlled study. ( Ebbing, C; Grindheim, S; Karlsen, HO; Kessler, J; Lønnebotn, M; Løvvik, T; Real, FG; Skulstad, SM; Vanky, E, 2022) |
| " The TSH level was not affected by metformin, whereas fT4 was significantly higher in the metformin group with less decrease throughout pregnancy compared to placebo, p<0." | 5.51 | Thyroid Status During Pregnancy in Women With Polycystic Ovary Syndrome and the Effect of Metformin. ( Alvarsson, M; Åsvold, BO; Calissendorff, J; Hirschberg, AL; Trouva, A; Vanky, E, 2022) |
| "In this long-term follow-up study, 160 overweight or obese infertility Chinese PCOS were randomized to exenatide or metformin treatment for 12 weeks." | 5.51 | Effect of metformin and exenatide on pregnancy rate and pregnancy outcomes in overweight or obese infertility PCOS women: long-term follow-up of an RCT. ( Li, R; Mai, T; Zhang, Y; Zheng, S, 2022) |
| "To investigate the adjuvant efficacy of metformin treatment to achieve pathological complete response (CR) in patients with endometrial complex hyperplasia (CH) and complex atypical hyperplasia (CAH), and secondarily, to evaluate their pregnancy outcomes after following assisted reproductive technology (ART)." | 5.51 | A Prospective Cohort Study of Metformin as an Adjuvant Therapy for Infertile Women With Endometrial Complex Hyperplasia/Complex Atypical Hyperplasia and Their Subsequent Assisted Reproductive Technology Outcomes. ( Kong, WY; Liu, ZA; Wu, X; Yan, L; Zhang, N; Zhao, XB, 2022) |
| "To observe the effect of metformin (MET) monotherapy versus MET plus liraglutide (LIRA) on gonadal and metabolic profiles in overweight patients with polycystic ovary syndrome (PCOS)." | 5.51 | Effect of metformin versus metformin plus liraglutide on gonadal and metabolic profiles in overweight patients with polycystic ovary syndrome. ( He, B; Xing, C; Zhang, J; Zhao, H, 2022) |
| " This randomized controlled trial compared the efficacy and safety of CANA and metformin (MET) combination therapy and MET monotherapy in endocrine and metabolic profiles of overweight and obese women with polycystic ovary syndrome (PCOS)." | 5.51 | Canagliflozin combined with metformin versus metformin monotherapy for endocrine and metabolic profiles in overweight and obese women with polycystic ovary syndrome: A single-center, open-labeled prospective randomized controlled trial. ( Cheng, X; He, B; Xing, C; Zhang, J, 2022) |
| "Polycystic ovary syndrome is one of the most common causes of female infertility, affecting 5-10% of the population." | 5.51 | Ocimum kilimandscharicum L. restores ovarian functions in letrozole - induced Polycystic Ovary Syndrome (PCOS) in rats: Comparison with metformin. ( AbdelMaksoud, S; El-Bahy, AA; Handoussa, H; Khaled, N; Radwan, R, 2019) |
| "Letrozole-treated patients required a significantly lower amount of gonadotropins units (p < 0." | 5.48 | Mild ovarian stimulation with letrozole plus fixed dose human menopausal gonadotropin prior to IVF/ICSI for infertile non-obese women with polycystic ovarian syndrome being pre-treated with metformin: a pilot study. ( Cantatore, C; Caringella, AM; Caroppo, E; D'Amato, G; Palini, S; Stanziano, A, 2018) |
| "Metformin was originally shown to lower testosterone levels in women with PCOS in the 1990s, an effect presumably related to its insulin sensitising actions." | 5.46 | Metformin therapy for the reproductive and metabolic consequences of polycystic ovary syndrome. ( Ehrmann, DA; Sam, S, 2017) |
| "Metformin was also given as a standard control to one of the rat groups." | 5.43 | Ameliorative effects of rutin against metabolic, biochemical and hormonal disturbances in polycystic ovary syndrome in rats. ( Afsar, T; Ain, QU; Almajwal, A; Jahan, S; Mehboob, A; Munir, F; Razak, S; Shaheen, G; Ullah, H, 2016) |
| " Metformin, which ameliorate hormonal disturbances in non-pregnant women with PCOS is increasingly used in pregnancy." | 5.41 | Maternal PCOS status and metformin in pregnancy: Steroid hormones in 5-10 years old children from the PregMet randomized controlled study. ( Carlsen, SM; Hanem, LGE; Juliusson, PB; Madsen, A; Mellgren, G; Sagen, JV; Salvesen, Ø; Vanky, E; Ødegård, R, 2021) |
| "Fifty overweight/obese women with PCOS diagnosed via the Rotterdam criteria were randomized to one of two treatment groups: MET (500 mg three times a day [TID]) or combination treatment (COM) (MET 500 mg TID, exenatide 2 mg QW) for 12 weeks." | 5.41 | Short-term combined treatment with exenatide and metformin for overweight/obese women with polycystic ovary syndrome. ( Deng, Y; Ding, XS; Ma, RL; Sun, AJ; Wang, YF; Zhu, SY, 2021) |
| "Metformin is the gold standard insulin sensitizer, which is widely used to treat insulin resistance in polycystic ovary syndrome (PCOS)." | 5.41 | Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. ( Ács, N; Greff, D; Hegyi, P; Horváth, EM; Juhász, AE; Nyirády, P; Park, S; Sipos, Z; Szinte, J; Váncsa, S; Váradi, A; Várbíró, S, 2023) |
| "Metformin is considered as first-line treatment for type 2 diabetes and an effective treatment for polycystic ovary syndrome (PCOS)." | 5.41 | Major malformations risk following early pregnancy exposure to metformin: a systematic review and meta-analysis. ( Abolhassani, N; Del Giovane, C; Jaques, C; Kaplan, YC; Minder Wyssmann, B; Panchaud, A; Winterfeld, U, 2023) |
| "To summarize the effects of metformin treatment on markers of hyperandrogenism in patients diagnosed with polycystic ovary syndrome (PCOS)." | 5.41 | Influence of metformin on hyperandrogenism in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized clinical trials. ( Cândido, AL; Fontes, AFS; Gomes, KB; Reis, FM; Tosatti, JAG, 2023) |
| "To compare OCs(oral contraceptives) + metformin and OCs alone for metabolic effects in nonobese polycystic ovary syndrome (PCOS) patients." | 5.41 | Oral contraceptives (OCs) in combination with metformin versus OCs alone on metabolism in nonobese polycystic ovary syndrome: A meta-analysis and systematic review of randomized controlled trials. ( Hua, Y; Huang, X; Li, Z; Lin, K; Liu, Y; Song, L; Wang, X; Wei, T; Wu, L, 2023) |
| "A total of 27 RCTs with 12 interventions were included, and all therapies tended to increase clinical pregnancy, especially pioglitazone (PIO) (log OR 3." | 5.41 | The effects of first-line pharmacological treatments for reproductive outcomes in infertile women with PCOS: a systematic review and network meta-analysis. ( Li, J; Liu, Y; Ma, J; Peng, G; Tong, N; Wang, Y; Yan, Z, 2023) |
| "To analyze whether metformin treatment in patients with polycystic ovary syndrome (PCOS) results in a decrease of anti-Müllerian hormone (AMH) levels, we reviewed and analyzed PCOS studies which evaluated serum AMH levels before and after metformin treatment." | 5.41 | The effects of metformin on anti-Müllerian hormone levels in patients with polycystic ovary syndrome: a systematic review and meta-analysis. ( Chen, H; Chen, Q; Chu, L; Liu, Y; Ou, X; Yang, J; Zhou, Z; Zou, Q, 2023) |
| "This document purpose is to create an evidence-based position statement on the role of metformin therapy in pregnancy complicated by obesity, gestational diabetes (GDM), type 2 diabetes mellitus (T2DM), polycystic ovary syndrome (PCOS) and in women undergoing assisted reproductive technology (ART)." | 5.41 | Position paper of the Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), and the Italian Study Group of Diabetes in pregnancy: Metformin use in pregnancy. ( Bianchi, C; Burlina, S; Formoso, G; Manicardi, E; Resi, V; Sciacca, L; Sculli, MA, 2023) |
| "Available evidence has shown that metformin improves insulin sensitivity and weight management in polycystic ovary syndrome (PCOS)." | 5.41 | The impact of metformin with or without lifestyle modification versus placebo on polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. ( Alesi, S; Forslund, M; Melin, J; Mousa, A; Pena, A; Piltonen, T; Romualdi, D; Spritzer, PM; Tay, CT; Teede, H; Witchel, SF, 2023) |
| "Metformin is a widely used and effective medication in type 2 diabetes (T2DM) as well as in polycystic ovary syndrome (PCOS)." | 5.41 | Identification of Novel Intronic SNPs in Transporter Genes Associated with Metformin Side Effects. ( Obermayer, A; Obermayer-Pietsch, B; Schweighofer, N; Sourij, C; Sourij, H; Strasser, M; Trummer, O, 2023) |
| "To evaluate the benefits of myoinositol plus metformin versus myoinositol alone in infertile polycystic ovarian syndrome (PCOS) women undergoing ovulation induction cycles." | 5.41 | Impact of myoinositol with metformin and myoinositol alone in infertile PCOS women undergoing ovulation induction cycles - randomized controlled trial. ( Bhatla, N; Gupta, M; Kachhawa, G; Khadgawat, R; Kumari, R; Mahey, R; Prabhakar, P; Sharma, JB; Vanamail, P, 2021) |
| "To evaluate clinical efficacy of exenatide (EX), metformin (MET), or combination (COM) for prediabetes in PCOS." | 5.41 | Exenatide, Metformin, or Both for Prediabetes in PCOS: A Randomized, Open-label, Parallel-group Controlled Study. ( Cai, J; Fan, W; Fu, JR; Gao, YN; Liu, W; Ma, JY; Sun, Y; Tao, T; Wang, YY; Xu, Y; Zhang, Y; Zhu, YC, 2021) |
| "Assessing the impact of adding combined oral contraceptives (COCs) or metformin to laser hair removal on the quality of life of polycystic ovarian syndrome (PCOS) patients with hirsutism." | 5.41 | Adding Combined Oral Contraceptives or Metformin to Laser Treatment in Polycystic Ovarian Syndrome Hirsute Patients. ( Dorgham, D; Dorgham, N; El-Kalioby, M; Haggag, H; Sharobim, A, 2021) |
| "Polycystic ovary syndrome (PCOS) is the most common cause of anovulatory infertility, for which the insulin sensitizer metformin has been used therapeutically." | 5.41 | Therapeutic Effect of Curcumin in Women with Polycystic Ovary Syndrome Receiving Metformin: A Randomized Controlled Trial. ( Atkin, SL; Azarpazhooh, MR; Heydari, B; Karimi-Zarchi, M; Sahebkar, A; Simental-Mendía, LE; Sohrevardi, SM; Teymourzadeh, M, 2021) |
| "This study aims to assess the therapeutic effects of a well-known component (puerarin) obtained from a Chinese herb root in patients with polycystic ovary syndrome (PCOS)." | 5.41 | Therapeutic effects of puerarin on polycystic ovary syndrome: A randomized trial in Chinese women. ( Hu, H; Li, F; Li, W; Liu, J; Ma, Z; Zou, G, 2021) |
| "We conclude that addition of ALC therapy is superior to metformin plus pioglitazone in ameliorating insulin resistance, polycystic ovaries, menstrual irregularities, and hypoadiponectinemia in women with PCOS." | 5.41 | Acetyl-L-Carnitine Ameliorates Metabolic and Endocrine Alterations in Women with PCOS: A Double-Blind Randomized Clinical Trial. ( Badshah, H; Ehtesham, E; Habib, SH; Israr, M; Malik, MO; Rauf, B; Raza, MA; Shah, FA; Shah, I; Shah, M; Tauqir, S; Usman, M, 2021) |
| "Metformin treatment after 6 and 12 months significantly reduced weight, BMI, waist circumference, insulin and HOMA-IR (p=0." | 5.39 | Evaluation of endocrine changes in women with the polycystic ovary syndrome during metformin treatment. ( Velija-Ašimi, Z, 2013) |
| "Metformin treatment increases serum cartonectin levels in these women and in omental AT explants." | 5.39 | Metformin increases the novel adipokine cartonectin/CTRP3 in women with polycystic ovary syndrome. ( Adya, R; Amar, O; Chen, J; Hu, J; Lehnert, H; Mattu, HS; Patel, V; Ramanjaneya, M; Randeva, HS; Tan, BK, 2013) |
| "Metformin treatment, lead to a significant decrease in serum insulin (p = 0." | 5.39 | Effects of metformin on serum insulin and anti-Mullerian hormone levels and on hyperandrogenism in patients with polycystic ovary syndrome. ( Ferriani, RA; Japur de Sá Rosa-e-Silva, AC; Nascimento, AD; Reis, RM; Silva Lara, LA, 2013) |
| "Metformin has beneficial effects on insulin resistance and endothelial functions." | 5.38 | The effects of treatment with drospirenone/ethinyl oestradiol alone or in combination with metformin on elastic properties of aorta in women with polycystic ovary syndrome. ( Akpek, M; Calapkorur, B; Celik, A; Karaca, Z; Kaya, MG; Kelestimur, F; Unluhizarci, K; Yildirim, S, 2012) |
| "Metformin treatment decreases serum ASAA in these women." | 5.37 | The anti-atherogenic aspect of metformin treatment in insulin resistant women with the polycystic ovary syndrome: role of the newly established pro-inflammatory adipokine Acute-phase Serum Amyloid A; evidence of an adipose tissue-monocyte axis. ( Adya, R; Aghilla, M; Keay, SD; Lehnert, H; Randeva, HS; Shan, X; Tan, BK, 2011) |
| "Metformin is widely used in women with Type 2 diabetes of child-bearing age, many of whom become pregnant." | 5.36 | Metformin treatment for Type 2 diabetes in pregnancy? ( Simmons, D, 2010) |
| "The preferred treatment for polycystic ovary syndrome, which affects women of fertile age, is diet and lifestyle interventions - especially in association with overweight." | 5.35 | [Use of metformin in polycystic ovary syndrome]. ( Carlsen, SM, 2009) |
| "Insulin resistance is a central feature of the PCOS and may increase cardiovascular risk." | 5.35 | Long-term effect of metformin on metabolic parameters in the polycystic ovary syndrome. ( Best, AM; Cheang, KI; Essah, PA; Huszar, JM; Nestler, JE; Sharma, S, 2009) |
| "Metformin treatment led to improvement of hormonal and metabolic parameters and decreased ADMA levels possibly independent of BMI and metabolic changes." | 5.35 | Asymmetrical dimethylarginine, inflammatory and metabolic parameters in women with polycystic ovary syndrome before and after metformin treatment. ( Heutling, D; Kaltwasser, P; Kleinstein, J; Krzyzanowska, K; Lehnert, H; Mittermayer, F; Nickel, I; Randeva, H; Schernthaner, G; Schulz, H; Westphal, S; Wolzt, M, 2008) |
| "An 8-year clinical follow-up study including self-reported asthma diagnoses and spirometry of women with PCOS randomized to metformin or placebo during pregnancy in the original studies (the Pilot and the PregMet-study), compared with matched controls from a population-based cohort study (The HUNT Study)." | 5.34 | Impaired Respiratory Function in Women With PCOS Compared With Matched Controls From a Population-Based Study. ( Andersen, M; Henriksen, AH; Salvesen, Ø; Underdal, MO; Vanky, E, 2020) |
| "The aim of this study was to compare the efficacy and safety of adding metformin or spironolactone to rosiglitazone in women with polycystic ovary syndrome (PCOS)." | 5.34 | Coadministration of metformin or spironolactone enhances efficacy of rosiglitazone in management of PCOS. ( Bhat, D; Butt, TP; Choh, N; Ganie, MA; Gupta, N; Masoodi, SR; Nisar, S; Rashid, A; Sofi, NY; Sood, M; Wani, IA, 2020) |
| "To compare the effects of metformin, rosiglitazone, and their combination in obese polycystic ovary syndrome (PCOS) patients with insulin resistance." | 5.34 | Comparing the individual effects of metformin and rosiglitazone and their combination in obese women with polycystic ovary syndrome: a randomized controlled trial. ( Duan, C; Hu, Y; Huang, W; Li, Y; Tan, J; Wang, Q, 2020) |
| "Metformin is widely used in pregnancy to treat gestational diabetes mellitus and polycystic ovary syndrome (PCOS)." | 5.34 | Cognitive function in metformin exposed children, born to mothers with PCOS - follow-up of an RCT. ( Greger, HK; Hanem, LGE; Vanky, E; Østgård, HF, 2020) |
| "This study aimed at investigating the therapeutic effect and mechanism of pioglitazone metformin complex preparation (PM) in polycystic ovary syndrome (PCOS) comorbid psychological distress." | 5.34 | Pioglitazone Metformin Complex Improves Polycystic Ovary Syndrome Comorbid Psychological Distress via Inhibiting NLRP3 Inflammasome Activation: A Prospective Clinical Study. ( Guo, QJ; Hu, YY; Huang, Q; Huo, CL; Shan, J; Song, JY; Wang, CQ; Xu, YF; Yu, CQ; Zhou, H, 2020) |
| " While metformin has a mild androgen-lowering effect in non-pregnant women with PCOS, its effects on maternal androgen levels in pregnancy are less well understood." | 5.34 | Sustained Maternal Hyperandrogenism During PCOS Pregnancy Reduced by Metformin in Non-obese Women Carrying a Male Fetus. ( Abbott, D; Andræ, F; Odsæter, IH; Salvesen, Ø; Schmedes, AV; Stridsklev, S; Vanky, E, 2020) |
| "Metformin is a logical treatment in these circumstances but there has always been concern about its safety for the fetus, particularly as it crosses the placenta and it may increase the risk of teratogenesis." | 5.33 | Metformin use and diabetic pregnancy-has its time come? ( Hawthorne, G, 2006) |
| "Metformin treatment also significantly decreased testosterone (by 37%, P = 0." | 5.32 | Metformin therapy increases insulin-like growth factor binding protein-1 in hyperinsulinemic women with polycystic ovary syndrome. ( Banaszewska, B; Duleba, AJ; Pawelczyk, L; Spaczynski, RZ, 2004) |
| "Polycystic ovary syndrome is considered the most frequent endocrine abnormality during the fertile age." | 5.31 | [Effects of metformin on insulin resistance and on ovarian steroidogenesis in women with polycystic ovary syndrome]. ( De Conciliis, B; Passannanti, G; Romano, L; Santarpia, R, 2001) |
| "Polycystic ovary syndrome is the most common form of female infertility in the United States." | 5.31 | Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. ( Iuorno, MJ; Jakubowicz, DJ; Jakubowicz, S; Nestler, JE; Roberts, KA, 2002) |
| "Treatment with metformin in women with PCOS can lead to the increase in homocysteine levels--a risk factor for atherosclerosis." | 5.31 | Homocysteine and steroids levels in metformin treated women with polycystic ovary syndrome. ( Bicíková, M; Hill, M; Stárka, L; Tallová, J; Vrbíková, J, 2002) |
| "To investigate the factors that are associated with the effect of metformin on endothelial dysfunction in polycystic ovary syndrome (PCOS)." | 5.30 | Effect of Metformin on Microvascular Endothelial Function in Polycystic Ovary Syndrome. ( Chang, AY; Heidari, B; Lalia, AZ; Lerman, A; Lerman, LO, 2019) |
| "To evaluate the impact of metformin on in vitro fertilization (IVF) outcomes in overweight and obese women with polycystic ovary syndrome (PCOS)." | 5.30 | Impact of Metformin on IVF Outcomes in Overweight and Obese Women With Polycystic Ovary Syndrome: A Randomized Double-Blind Controlled Trial. ( Abbas, AM; Abdalmageed, OS; Abdelaleem, AA; Abdelmagied, AE; Ali, MK; Farghaly, TA, 2019) |
| "OCP resulted in a higher reduction in serum luteinizing hormone (LH) and androgens whereas metformin resulted in significant reduction in BMI, waist circumference, and insulin resistance." | 5.30 | Doppler analysis of ovarian stromal blood flow changes after treatment with metformin versus ethinyl estradiol-cyproterone acetate in women with polycystic ovarian syndrome: A randomized controlled trial. ( Mohanty, J; Nagy, A; Sahu, A; Tripathy, P, 2019) |
| "This investigation was conducted to evaluate comparison of myo-inositol and metformin on glycemic control, lipid profiles, and gene expression related to insulin and lipid metabolism in women with polycystic ovary syndrome (PCOS)." | 5.30 | Comparison of myo-inositol and metformin on glycemic control, lipid profiles, and gene expression related to insulin and lipid metabolism in women with polycystic ovary syndrome: a randomized controlled clinical trial. ( Afshar Ebrahimi, F; Aghadavod, E; Asemi, Z; Foroozanfard, F; Ghaderi, A; Shokrpour, M; Vahedpoor, Z, 2019) |
| " Therefore, we here aim to investigate if acupuncture treatment or metformin together with lifestyle or lifestyle management alone improves insulin sensitivity and related symptoms in overweight/obese women with PCOS." | 5.30 | Acupuncture or metformin to improve insulin resistance in women with polycystic ovary syndrome: study protocol of a combined multinational cross sectional case-control study and a randomised controlled trial. ( Chang, C; Friden, C; Huo, Z; Ji, X; Li, D; Li, R; Li, S; Linden-Hirschberg, A; Qiao, J; Stener-Victorin, E; Wang, H; Wang, W; Zhang, H, 2019) |
| "The present study was planned to evaluate the benefit of synergetic effect of Metformin plus Myo-inositol versus Metformin alone in infertile polycystic ovarian syndrome (PCOS) women undergoing ovulation induction." | 5.30 | Comparison of metformin plus myoinositol vs metformin alone in PCOS women undergoing ovulation induction cycles: randomized controlled trial. ( Agrawal, A; Kachhawa, G; Khadgawat, R; Kriplani, A; Mahey, R; Vanamail, P, 2019) |
| " To study the combined efficacy of exercise and metformin on above parameters in women with polycystic ovary syndrome." | 5.30 | Randomised controlled trial to study the efficacy of exercise with and without metformin on women with polycystic ovary syndrome. ( Jain, S; Pasrija, S; Tiwari, N, 2019) |
| "Metformin is increasingly used to treat gestational diabetes and type 2 diabetes in pregnancy, and in attempts to improve pregnancy outcomes in polycystic ovary syndrome and obesity." | 5.30 | Intrauterine metformin exposure and offspring cardiometabolic risk factors (PedMet study): a 5-10 year follow-up of the PregMet randomised controlled trial. ( Carlsen, SM; Hanem, LGE; Juliusson, PB; Nossum, MCF; Salvesen, Ø; Vaage, MØ; Vanky, E; Ødegård, R, 2019) |
| " Epi-analysis of two previous randomised controlled trials that compared metformin with placebo during pregnancy in women with PCOS showed a significant reduction in late miscarriages and preterm births in the metformin group." | 5.30 | Use of metformin to treat pregnant women with polycystic ovary syndrome (PregMet2): a randomised, double-blind, placebo-controlled trial. ( Andræ, F; Berg, AH; Bixo, M; Carlsen, SM; Gómez-Real, F; Hestvold, KV; Hirschberg, AL; Hjelle, S; Lønnebotn, M; Løvvik, TS; Mohlin, J; Poromaa, IS; Salvesen, Ø; Steffensen, B; Thorarinsdottir, S; Trouva, A; Underdal, M; Vanky, E; Zabielska, R, 2019) |
| "To evaluate the reproductive and metabolic effects of L-carnitine plus metformin in clomiphene citrate (CC) resistant obese polycystic ovary syndrome (PCOS) women." | 5.30 | l-Carnitine plus metformin in clomiphene-resistant obese PCOS women, reproductive and metabolic effects: a randomized clinical trial. ( El Sharkwy, I; Sharaf El-Din, M, 2019) |
| "The purpose is a comparison of effectiveness of myo-inositol and metformin in infertile women with polycystic ovary syndrome (PCOS) treated with letrozole." | 5.30 | The effectiveness of inositol and metformin on infertile polycystic ovary syndrome women with resistant to letrozole. ( Bazarganipour, F; Kutenaee, MA; Pourghasem, S; Taghavi, SA, 2019) |
| " PCOS is associated with obesity, dyslipidaemia and insulin resistance, and metformin treatment may improve such metabolic features." | 5.27 | The Pharmacogenetics of Metformin in Women with Polycystic Ovary Syndrome: A Randomized Trial. ( Andersen, M; Christensen, MMH; Glintborg, D; Pedersen, AJT; Stage, TB, 2018) |
| "Data on comparison of myo-inositol and metformin on mental health parameters and biomarkers of oxidative stress in subjects with polycystic ovary syndrome (PCOS) are scarce." | 5.27 | Comparison of myo-inositol and metformin on mental health parameters and biomarkers of oxidative stress in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. ( Afshar Ebrahimi, F; Asemi, Z; Bahmani, F; Foroozanfard, F; Jamilian, H; Jamilian, M, 2018) |
| "A total of 202 patients with clomiphene citrate (CC) -resistant polycystic ovary syndrome (PCOS) were randomly allocated into two arms of induction of ovulation; the first group (n = 102) received CC 100 mg and metformin 500 mg while the second group (n = 100) received letrozole 2." | 5.27 | Clomiphene citrate combined with metformin versus letrozole for induction of ovulation in clomiphene-resistant polycystic ovary syndrome: a randomized clinical trial. ( Rezk, M; Saif El-Nasr, I; Shaheen, AE, 2018) |
| "Metformin is used in an attempt to reduce pregnancy complications associated with polycystic ovary syndrome (PCOS)." | 5.27 | Fetal Growth and Birth Anthropometrics in Metformin-Exposed Offspring Born to Mothers With PCOS. ( Eggebø, T; Engen Hanem, LG; Hjorth-Hansen, A; Salvesen, KÅ; Salvesen, Ø; Vanky, E; Ødegård, R, 2018) |
| "The long-term effects of metformin in women with polycystic ovarian syndrome (PCOS) are inadequately studied." | 5.27 | The Efficacy of 24-Month Metformin for Improving Menses, Hormones, and Metabolic Profiles in Polycystic Ovary Syndrome. ( Chen, CH; Chen, MJ; Chen, SU; Ho, HN; Hsu, CY; Lai, MY; Li, ZR; Yang, PK, 2018) |
| "Saxagliptin and metformin were comparably effective in regulating weight loss, glycemic control, and β-cell function, improving lipid profiles, and reducing inflammation in newly diagnosed type 2 diabetes mellitus patients with polycystic ovary syndrome." | 5.27 | Comparison of glycemic control and β-cell function in new onset T2DM patients with PCOS of metformin and saxagliptin monotherapy or combination treatment. ( Liu, W; Tao, T; Wang, Y; Wu, P, 2018) |
| "Metformin-exposed children had higher BMI and increased prevalence of overweight/obesity at 4 years of age." | 5.27 | Metformin Use in PCOS Pregnancies Increases the Risk of Offspring Overweight at 4 Years of Age: Follow-Up of Two RCTs. ( Carlsen, SM; Hanem, LGE; Júlíusson, PB; Roelants, M; Salvesen, Ø; Stridsklev, S; Vanky, E; Ødegård, R, 2018) |
| "To evaluate the effect of Diane-35, alone or in combination with orlistat or metformin, on androgen and body fat percentage parameters in Chinese overweight and obese polycystic ovary syndrome (PCOS) patients with insulin resistance." | 5.27 | Effect of Diane-35, alone or in combination with orlistat or metformin in Chinese polycystic ovary syndrome patients. ( Gu, M; Mueck, AO; Ruan, X; Song, J; Wang, H; Wang, L, 2018) |
| "Health-related quality of life (HRQoL) is impaired in polycystic ovary syndrome (PCOS), but the effect of treatment with metformin (M) and/or oral contraceptives (OCP) is undetermined." | 5.27 | Effect of 12-month treatment with metformin and/or oral contraceptives on health-related quality of life in polycystic ovary syndrome. ( Altinok, ML; Andersen, M; Glintborg, D; Ravn, P, 2018) |
| "Worldwide, metformin is prescribed to improve pregnancy outcome in polycystic ovary syndrome (PCOS)." | 5.27 | Does Metformin Treatment During Pregnancy Modify the Future Metabolic Profile in Women With PCOS? ( Andersen, MS; Høgetveit, K; Oppen, IH; Stridsklev, S; Underdal, MO; Vanky, E, 2018) |
| " The potential impact of short-term preconception intervention with liraglutide on fertility potential in polycystic ovary syndrome (PCOS) has not been evaluated yet." | 5.27 | Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study. ( Janez, A; Jensterle, M; Salamun, V; Vrtacnik Bokal, E, 2018) |
| "In this randomized, prospective, controlled study, 87 non-obese (18-30 BMI) women of reproductive age (18-39) with polycystic ovary syndrome (PCOS) were assigned to control (n = 17), OC (n = 21), combination (n = 20) and metformin (n = 29) therapy groups." | 5.27 | The effects of different therapeutic modalities on cardiovascular risk factors in women with polycystıc ovary syndrome: A randomızed controlled study. ( Bodur, S; Dundar, O; Kanat-Pektas, M; Kinci, MF; Tutuncu, L, 2018) |
| "The aim of the current work was to investigate the value of the long term effects of combined use of simvastatin and metformin treatment for a year versus the effects of their individual treatment on the clinical, biochemical abnormalities, and ovulation dysfunction in young single women with polycystic ovary syndrome (PCOS)." | 5.27 | Long-term effects of combined simvastatin and metformin treatment on the clinical abnormalities and ovulation dysfunction in single young women with polycystic ovary syndrome. ( Hefzy, E; Seyam, E, 2018) |
| " The aim of the study was to evaluate whether dipeptidyl peptidase-4 (DPP-4) inhibitor alogliptin (ALO) alone or in combination with pioglitazone (PIO) improves β-cell function along with insulin resistance (IR) in metformin (MET) treated obese women with PCOS with persistent IR." | 5.24 | Add on DPP-4 inhibitor alogliptin alone or in combination with pioglitazone improved β-cell function and insulin sensitivity in metformin treated PCOS. ( Goricar, K; Janez, A; Jensterle, M, 2017) |
| "To our knowledge, data on comparison of myo-inositol and metformin on clinical, metabolic and genetic parameters in subjects with polycystic ovary syndrome (PCOS) are limited." | 5.24 | Comparison of myo-inositol and metformin on clinical, metabolic and genetic parameters in polycystic ovary syndrome: A randomized controlled clinical trial. ( Afshar Ebrahimi, F; Aghadavod, E; Asemi, Z; Badehnoosh, B; Bahmani, F; Farhat, P; Foroozanfard, F; Jamilian, H; Jamilian, M, 2017) |
| "We aimed to compare a combined oral contraceptive (COC) plus the antiandrogen spironolactone with the insulin sensitizer metformin in women with polycystic ovary syndrome (PCOS)." | 5.24 | Combined oral contraceptives plus spironolactone compared with metformin in women with polycystic ovary syndrome: a one-year randomized clinical trial. ( Alpañés, M; Álvarez-Blasco, F; Escobar-Morreale, HF; Fernández-Durán, E; Luque-Ramírez, M, 2017) |
| "The present study was designed to evaluate the effects of metformin on metabolic and endocrine parameters in patients with polycystic ovary syndrome (PCOS)." | 5.24 | Effects of Metformin on Endocrine and Metabolic Parameters in Patients with Polycystic Ovary Syndrome. ( Ali, A; Rahim, R; Shah, M; Zahra, M, 2017) |
| "Liraglutide 3 mg was recently approved as an anti-obesity drug." | 5.24 | Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial. ( Goričar, K; Janez, A; Jensterle, M; Kravos, NA, 2017) |
| "The aim of this randomized clinical trial (RCT) was to evaluate the effect of vitamin D supplementation in obese, insulin-resistant (IR) and vitamin D-deficient polycystic ovary syndrome (PCOS) women on metabolic abnormalities in comparison to the effect of metformin or combined metformin plus vitamin D therapy." | 5.24 | The effect of alfacalcidiol and metformin on metabolic disturbances in women with polycystic ovary syndrome. ( Dravecká, I; Figurová, J; Javorský, M; Lazúrová, I; Petríková, J, 2017) |
| "To evaluate efficacy with the dipeptidyl peptidase-4 inhibitor saxagliptin (SAXA), metformin extended release (MET), and combination (SAXA-MET) in patients with polycystic ovary syndrome (PCOS) and impaired glucose regulation." | 5.24 | Short-term therapy with combination dipeptidyl peptidase-4 inhibitor saxagliptin/metformin extended release (XR) is superior to saxagliptin or metformin XR monotherapy in prediabetic women with polycystic ovary syndrome: a single-blind, randomized, pilot ( Elkind-Hirsch, KE; Gutowski, HC; Paterson, MS; Seidemann, EL, 2017) |
| "This study will investigate the effects of acupuncture on the insulin sensitivity of PCOS and IR women compared with metformin and sham acupuncture." | 5.24 | Acupuncture treatment for insulin sensitivity of women with polycystic ovary syndrome and insulin resistance: a study protocol for a randomized controlled trial. ( Hu, Z; Lai, M; Li, J; Li, M; Liu, J; Ma, H; Ng, EH; Shao, X; Stener-Victorin, E; Su, N; Wang, H; Wu, T; Xie, C; Yu, C, 2017) |
| " A significant reduction in homoeostatic model assessment of insulin resistance (HOMA-IR) was seen with exenatide versus metformin (MD: -0." | 5.22 | Impact of pharmacological interventions on insulin resistance in women with polycystic ovary syndrome: A systematic review and meta-analysis of randomized controlled trials. ( Abdalla, MA; Al-Rifai, RH; Atkin, SL; Deshmukh, H; Östlundh, L; Sahebkar, A; Sathyapalan, T; Shah, N, 2022) |
| "Although several clinical trials have compared the clinical efficacy of clomiphene citrate (CC) combined with metformin (MET) in the treatment of women with polycystic ovary syndrome (PCOS), the results are controversial." | 5.22 | Therapeutic efficacy of clomiphene citrate combined with metformin in patients with polycystic ovary syndrome. ( Chen, X; Diao, W; Feng, J; Lin, W; Ma, P; Zhou, H, 2022) |
| " Indeed, metformin has been involved in repair mitochondrial dysfunction, decrease of oxidative stress, reduction of androgens levels and the enhancing of insulin sensitivity." | 5.22 | Polycystic ovarian syndrome: signs and feedback effects of hyperandrogenism and insulin resistance. ( Barrera, D; Echeverría, O; Escobar, L; Espinoza-Simón, E; González, J; Hernández-Jiménez, JL; Ortíz-Hernández, R; Torres-Ramírez, N, 2022) |
| "The aim of this study was to perform a meta-analysis of randomized controlled trials (RCTs) to evaluate the role of metformin in improving the reproduction outcomes for non-obese, infertile women with polycystic ovary syndrome." | 5.22 | Does metformin improve reproduction outcomes for non-obese, infertile women with polycystic ovary syndrome? Meta-analysis and systematic review. ( Kheirelseid, EAH; Lewis, S; Magzoub, R; Perks, C, 2022) |
| "Using the terms "metformin" and "polycystic ovary syndrome," we conducted a search the PubMed, EMBASE, and Google Scholar databases." | 5.22 | The use of metformin in women with polycystic ovary syndrome: an updated review. ( Neto, FTL; Notaro, ALG, 2022) |
| "Metformin is the most commonly used treatment to increase insulin sensitivity in insulin-resistant (IR) conditions such as diabetes, prediabetes, polycystic ovary syndrome, and obesity." | 5.22 | Metformin and Insulin Resistance: A Review of the Underlying Mechanisms behind Changes in GLUT4-Mediated Glucose Transport. ( Dolžan, V; Herman, R; Janež, A; Jensterle, M; Kravos, NA, 2022) |
| " Additionally, novel cosmetic techniques like electrolysis, laser and use of topically applied eflornithine to tackle the most distressing feature of facial hirsutism associated with PCOS, non-pharmacological therapy like acupuncture and the role of herbal medicine in PCOS management have also been discussed." | 5.22 | Polycystic ovarian syndrome-current pharmacotherapy and clinical implications. ( Ali, T; Amin, F; Ara, R; Bader, GN; Kareem, O; Malik, A; Mir, SA; Rashid, R, 2022) |
| "This meta-analysis aims to perform an updated meta-analysis to evaluate myo-inositol (myo-ins) and the classical insulin sensitizer metformin in terms of efficacy and safety for treating women with polycystic ovary syndrome (PCOS)." | 5.22 | Short period-administration of myo-inositol and metformin on hormonal and glycolipid profiles in patients with polycystic ovary syndrome: a systematic review and updated meta-analysis of randomized controlled trials. ( He, B; Xing, C; Zhang, JQ, 2022) |
| " Many studies have reported improvement in insulin resistance and thereby intracellular glucose uptake after myo-inositol treatment in PCOS patients, but these studies have a small sample size, varying methodology, and outcome analysis." | 5.22 | Efficacy of Myo-inositol on Anthropometric, Metabolic, and Endocrine Outcomes in PCOS Patients: a Meta-analysis of Randomized Controlled Trial. ( Deshpande, S; Gajjar, N; Jethaliya, H; Patel, R; Patel, V, 2022) |
| "This meta-analysis was conducted to evaluate the effect of statins combined or not combined with metformin on polycystic ovary syndrome (PCOS)." | 5.22 | Effect of statins combined or not combined with metformin on polycystic ovary syndrome: A systematic review and meta-analysis. ( Miao, K; Zhou, H, 2022) |
| "To evaluate the efficacy and safety of using metformin in pregnant women with polycystic ovarian syndrome (PCOS) and to explore the most effective and safe protocol by using a meta-analysis method." | 5.22 | Efficacy and safety of metformin in pregnant women with polycystic ovary syndrome: a systematic review with meta-analysis of randomized and non-randomized controlled trials. ( He, J; Zhao, Q, 2022) |
| "Based on the results of this study, compared with metformin alone, acupuncture combined with metformin has a positive effect on pregnancy rate, ovulation rate, and insulin resistance in PCOS." | 5.22 | Acupuncture combined with metformin versus metformin alone to improve pregnancy rate in polycystic ovary syndrome: A systematic review and meta-analysis. ( Chen, X; Lan, Y; Li, H; Li, Z; Liu, Y; Long, C; Wang, M; Wu, J; Xie, Q; Yang, L; Zhao, Y; Zhu, X, 2022) |
| "The purpose of this study is to evaluate the effectiveness and safety of liraglutide/liraglutide + metformin in overweight/obese women with polycystic ovary syndrome (PCOS)." | 5.22 | The effectiveness and safety of liraglutide in treating overweight/obese patients with polycystic ovary syndrome: a meta-analysis. ( Ge, JJ; Ge, WH; Shen, SM; Song, W; Wang, DJ, 2022) |
| "The aim of this study was to evaluate and compare the effects of spironolactone and spironolactone plus metformin treatments on body mass index (BMI), hirsutism score, hormone levels, and insulin resistance in women with polycystic ovary syndrome (PCOS)." | 5.22 | Comparison of spironolactone and spironolactone plus metformin in the treatment of polycystic ovary syndrome. ( Acmaz, B; Diri, H; Karaburgu, S; Karaca, Z; Kelestimur, F; Tanriverdi, F; Unluhizarci, K, 2016) |
| "To determine serum vascular endothelial growth factor B (VEGF-B) levels in polycystic ovary syndrome, their association with insulin resistance and β-cell dysfunction, and the effect of metformin on serum VEGF-B levels." | 5.22 | Serum vascular endothelial growth factor B is elevated in women with polycystic ovary syndrome and can be decreased with metformin treatment. ( Chen, C; Cheng, F; Huang, T; Jia, F; Liu, D; Wu, J; Wu, Y; Yang, G; Zhang, Z; Zhao, L, 2016) |
| "To examine the efficacy of clomifene citrate, metformin, and pioglitazone versus letrozole, metformin, and pioglitazone among women with polycystic ovary syndrome (PCOS) resistant to clomifene citrate." | 5.22 | A randomized controlled trial of clomifene citrate, metformin, and pioglitazone versus letrozole, metformin, and pioglitazone for clomifene-citrate-resistant polycystic ovary syndrome. ( Abdel Moety, G; Al Mohammady, M; El-khayat, W; Hamed, D, 2016) |
| "To compare N-acetyl cysteine (NAC) and metformin on polycystic ovary syndrome (PCOS)." | 5.22 | A comparison between the effects of metformin and N-acetyl cysteine (NAC) on some metabolic and endocrine characteristics of women with polycystic ovary syndrome. ( Javanmanesh, F; Kashanian, M; Rahimi, M; Sheikhansari, N, 2016) |
| "Metformin in pregnancy did not affect cervical length in women with PCOS." | 5.22 | Cervical Length and Androgens in Pregnant Women With Polycystic Ovary Syndrome: Has Metformin Any Effect? ( Carlsen, SM; Salvesen, Ø; Shetelig Løvvik, T; Stridsklev, S; Vanky, E, 2016) |
| "Aim of this study was to evaluate the effect of vitamin D supplementation in obese, insulin resistant and vitamin D deficient PCOS women on biochemical and clinical hyperandrogenism and menstrual irregularity in comparison to effect of metformin or combined metformin plus vitamin D therapy." | 5.22 | The effect of alfacalcidiol and metformin on phenotype manifestations in women with polycystic ovary syndrome - a preliminary study. ( Dravecká, I; Figurová, J; Javorský, M; Lazúrová, I; Petríková, J; Vaľková, M, 2016) |
| "To compare the therapeutic effects of metformin (Met) and laparoscopic ovarian drilling (LOD) in clomiphene and insulin-resistant patients with polycystic ovary syndrome (CIRPCOS)." | 5.20 | Therapeutic effects of metformin and laparoscopic ovarian drilling in treatment of clomiphene and insulin-resistant polycystic ovary syndrome. ( Huang, LP; Wang, JQ; Wang, XH; Xu, Y, 2015) |
| "Conclusions on the effect of metformin on circulating anti-Müllerian hormone (AMH) levels in women with polycystic ovary syndrome (PCOS) are ambiguous." | 5.20 | Impact of metformin on anti-Müllerian hormone in women with polycystic ovary syndrome: a secondary analysis of a randomized controlled trial. ( Ingerslev, HJ; Lauszus, FF; Madsen, HN; Trolle, B; Tørring, N, 2015) |
| "Short-term monotherapy with liraglutide or roflumilast was associated with significant weight loss in obese PCOS." | 5.20 | Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study. ( Janez, A; Jensterle, M; Kocjan, T; Salamun, V; Vrtacnik Bokal, E, 2015) |
| "We aim to assess the effect of metformin treatment on metabolic parameters, endothelial function and inflammatory markers in polycystic ovary syndrome (PCOS) subjects." | 5.20 | Metformin modulates human leukocyte/endothelial cell interactions and proinflammatory cytokines in polycystic ovary syndrome patients. ( Alvarez, A; Bañuls, C; Diaz-Morales, N; Escribano-López, I; Gomez, M; Hernandez-Mijares, A; Lopez-Domenech, S; Rios-Navarro, C; Rocha, M; Rovira-Llopis, S; Victor, VM, 2015) |
| "Polycystic ovary syndrome (PCOS) is associated with risk factors for cardiovascular disease (CVD) which may be modified by the use of metformin and oral contraceptives (OC)." | 5.20 | Increased thrombin generation in women with polycystic ovary syndrome: A pilot study on the effect of metformin and oral contraceptives. ( Altinok, ML; Andersen, M; Glintborg, D; Mumm, H; Sidelmann, JJ, 2015) |
| "To assess the adjuvant effect of metformin and N-acetylcysteine (NAC) to clomiphene citrate (CC) in induction of ovulation in Polycystic Ovary Syndrome (PCOS) patients." | 5.20 | The adjuvant effect of metformin and N-acetylcysteine to clomiphene citrate in induction of ovulation in patients with Polycystic Ovary Syndrome. ( Abdelhafez, A; Bakry, A; Elsawah, H; Maged, AM; Mostafa, WA, 2015) |
| " It also indicates that the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism as compared to metformin alone." | 5.19 | In PCOS patients the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism than metformin alone. ( Belfiore, A; D'Orrico, B; Fava, A; Fruci, B; Guzzi, P; Malaguarnera, R; Mazza, A; Veltri, P, 2014) |
| "Berberine and metformin treatments prior to IVF improved the pregnancy outcome by normalizing the clinical, endocrine and metabolic parameters in PCOS women." | 5.19 | The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. ( An, Y; Guan, Y; Liu, B; Lu, M; Sun, Z; Zhang, Y, 2014) |
| "Metformin is used to reduce pregnancy complications in women with polycystic ovary syndrome (PCOS), although it is not approved for this indication and solid evidence is lacking." | 5.19 | Midpregnancy Doppler ultrasound of the uterine artery in metformin- versus placebo-treated PCOS women: a randomized trial. ( Carlsen, SM; Clemens, I; Salvesen, Ø; Stridsklev, S; Vanky, E, 2014) |
| "Metformin is suggested to reduce pregnancy complications in women with polycystic ovary syndrome (PCOS)." | 5.19 | Maternal and fetal insulin levels at birth in women with polycystic ovary syndrome: data from a randomized controlled study on metformin. ( Carlsen, SM; Helseth, R; Stridsklev, S; Vanky, E; Vogt, C, 2014) |
| "Although metformin is widely used to improve insulin resistance in women with polycystic ovary syndrome (PCOS), its mechanism of action is complex, with inconsistent effects on insulin sensitivity and variability in treatment response." | 5.19 | Metformin improves glucose effectiveness, not insulin sensitivity: predicting treatment response in women with polycystic ovary syndrome in an open-label, interventional study. ( Duran, J; Keefe, C; Pau, CT; Welt, CK, 2014) |
| "Roflumilast added to metformin reduced body weight in obese women with PCOS, primarily due to a loss of fat mass." | 5.19 | Phosphodiesterase 4 inhibition as a potential new therapeutic target in obese women with polycystic ovary syndrome. ( Janez, A; Jensterle, M; Kocjan, T, 2014) |
| "Training during pregnancy was not associated with altered levels of cffDNA cfmDNA or cftDNA, but metformin treatment may reduce cfmDNA and cftDNA in pregnant PCOS women." | 5.19 | The effect of exercise and metformin treatment on circulating free DNA in pregnancy. ( Carlsen, SM; Christiansen, SC; Klungland, H; Mørkved, S; Salvesen, KÅ; Stafne, SN; Sæther, M; Vanky, E, 2014) |
| "The aim of this study was to compare the effect of low-dose metformin and rosiglitazone on clinical, biochemical, ultrasound features and endothelial function in patients with polycystic ovary syndrome (PCOS)." | 5.17 | Effects of low-dose metformin and rosiglitazone on biochemical, clinical, metabolic and biophysical outcomes in polycystic ovary syndrome. ( Alexandraki, KI; Apostolopoulos, NV; Berry, R; Jude, EB; Mohiyiddeen, L; Watson, AJ, 2013) |
| "The aim of this study was to evaluate the effectiveness of Metformin on ovulation and eventual clinical pregnancy in different phenotypes of polycystic ovary syndrome (PCOS)." | 5.17 | Metformin treatment in different phenotypes of polycystic ovary syndrome. ( Alleyassin, A; Fanisalek, M; Hosseini, MA; Kokab, A; Safdarian, L; Sarvi, F, 2013) |
| "Abdominal acupuncture and metformin improved the endocrine and metabolic function of patients with obesity-type PCOS." | 5.17 | Effectiveness of abdominal acupuncture for patients with obesity-type polycystic ovary syndrome: a randomized controlled trial. ( Lai, MH; Liu, H; Ma, HX; Wang, XH; Yao, H; Zheng, YH, 2013) |
| "To evaluate the long-term effects of drospirenone (DRSP)/ethinylestradiol (EE) alone, metformin alone, and DRSP/EE-metformin on CD4(+)CD28(null) T lymphocytes frequency, a cardiovascular risk marker, in patients with hyperinsulinemic polycystic ovary syndrome (PCOS)." | 5.17 | Effects of drospirenone-ethinylestradiol and/or metformin on CD4(+)CD28(null) T lymphocytes frequency in women with hyperinsulinemia having polycystic ovary syndrome: a randomized clinical trial. ( Apa, R; Ciardulli, A; Cosentino, N; Crea, F; Familiari, A; Lanzone, A; Liuzzo, G; Martinez, D; Morciano, A; Moro, F; Niccoli, G; Palla, C; Sagnella, F; Scarinci, E; Tritarelli, A; Tropea, A, 2013) |
| "To improve the treatment outcomes in women with polycystic ovary syndrome (PCOS), various drugs like glitazones, oral contraceptive pills, or antiandrogens have been combined with metformin." | 5.17 | Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study. ( Ganie, MA; Gupta, N; Khurana, ML; Kulshrestha, B; Mir, FA; Mudasir, S; Nisar, S; Shah, PA; Shah, ZA; Taing, S; Wani, TA; Zargar, MA, 2013) |
| "To compare the ovulation and conception rates after the treatment with Clomiphene Citrate (CC) alone and in combination with metformin in infertile patients presented with polycystic ovarian syndrome (PCOS)." | 5.17 | Efficacy of combined metformin-clomiphene citrate in comparison with clomiphene citrate alone in infertile women with polycystic ovarian syndrome (PCOS). ( Alwan, Y; Ayaz, A; Farooq, MU, 2013) |
| " We conducted the present study to compare the antidepressant efficacy of pioglitazone with another insulin-sensitizer, metformin, in obese patients with concomitant polycystic ovarian syndrome (PCOS) and major depressive disorder (MDD)." | 5.17 | Does pioglitazone improve depression through insulin-sensitization? Results of a randomized double-blind metformin-controlled trial in patients with polycystic ovarian syndrome and comorbid depression. ( Akhondzadeh, S; Ashrafi, M; Farazmand, B; Kashani, L; Modabbernia, A; Omidvar, T; Ramzanzadeh, F; Tabrizi, M; Tehraninejad, ES, 2013) |
| "Metformin treatment, compared with placebo, statistically significantly decreased 8-OHdG levels in women with polycystic ovary syndrome." | 5.17 | Metformin decreases serum 8-hydroxy-2'-deoxyguanosine levels in polycystic ovary syndrome. ( Karihtala, P; Morin-Papunen, L; Puistola, U; Sova, H, 2013) |
| "Prospectively assess whether metformin/diet pre-conception and throughout pregnancy would safely reduce first trimester miscarriage and improve pregnancy outcomes in women with polycystic ovary syndrome (PCOS)." | 5.17 | Effects of metformin-diet intervention before and throughout pregnancy on obstetric and neonatal outcomes in patients with polycystic ovary syndrome. ( Glueck, CJ; Goldenberg, N; Khan, Z; Padda, J; Pranikoff, J; Wang, P, 2013) |
| "The aim of the present study was to investigate the efficacy of Metformin compared with a hypocaloric diet on C-reactive protein (CRP) level and markers of insulin resistance in obese and overweight women with polycystic ovary syndrome (PCOS)." | 5.17 | Effect of metformin compared with hypocaloric diet on serum C-reactive protein level and insulin resistance in obese and overweight women with polycystic ovary syndrome. ( Esfahanian, F; Heshmat, R; Moini nia, F; Zamani, MM, 2013) |
| "To compare the hormonal-metabolic profiles and reproductive outcomes between women receiving metformin plus letrozole and women undergoing bilateral ovarian drilling in clomiphene citrate (CC)-resistant women with polycystic ovary syndrome (PCOS)." | 5.17 | Efficacy of combined metformin-letrozole in comparison with bilateral ovarian drilling in clomiphene-resistant infertile women with polycystic ovarian syndrome. ( Abd Elgafor, I, 2013) |
| " We assessed serum lipocalin-2 levels in polycystic ovary syndrome (PCOS) and the effects of weight loss or metformin on these levels." | 5.16 | Weight loss significantly reduces serum lipocalin-2 levels in overweight and obese women with polycystic ovary syndrome. ( Delkos, D; Kalaitzakis, E; Kandaraki, EA; Katsikis, I; Koiou, E; Panidis, D; Tziomalos, K; Vosnakis, C, 2012) |
| "Hyperandrogenaemia in polycystic ovary syndrome (PCOS) represents a composite of raised serum concentrations of testosterone, androstenedione, dehydroepiandrosterone (DHEA) and DHEA sulphate (DHEAS)." | 5.16 | Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study. ( Atkin, SL; Coady, AM; Kilpatrick, ES; Sathyapalan, T; Smith, KA, 2012) |
| "To compare the efficacy of metformin with that of lifestyle changes in patients with polycystic ovary syndrome (PCOS)." | 5.16 | Metformin versus lifestyle changes in treating women with polycystic ovary syndrome. ( Almeida, JA; Bagnoli, VR; Baracat, EC; Curi, DD; Fonseca, AM; Marcondes, JA; Soares, JM, 2012) |
| "The aim of this study was to evaluate the effects of diet alone, and in association with metformin in monotherapy or in cotreatment with myoinositol (MYO) on menstrual irregularities, hirsutism, body weight and composition in overweight/obese women with polycystic ovary syndrome (PCOS)." | 5.16 | [Diet, metformin and inositol in overweight and obese women with polycystic ovary syndrome: effects on body composition]. ( Alibrandi, A; Giarrusso, R; Le Donne, M; Lo Monaco, I; Muraca, U, 2012) |
| "The role of metformin in the treatment of infertility in women with polycystic ovary syndrome (PCOS) is still controversial." | 5.16 | Metformin improves pregnancy and live-birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double-blind, placebo-controlled randomized trial. ( Bloigu, R; Hippeläinen, M; Morin-Papunen, L; Perheentupa, A; Puukka, K; Rantala, AS; Ruokonen, A; Tapanainen, JS; Tiitinen, A; Tinkanen, H; Unkila-Kallio, L, 2012) |
| "these results suggest pioglitazone is as effective as metformin in improving insulin sensitivity and some cardiovascular risk biomarkers but it has no significant effect on reducing BMI and body weight." | 5.16 | Effect of metformin and pioglitazone treatment on cardiovascular risk profile in polycystic ovary syndrome. ( Abedini, A; Ghorbani, A; Hashemipour, S; Karimzadeh, T; Oveisi, S; Ziaee, A, 2012) |
| "To estimate whether progestin-induced endometrial shedding, before ovulation induction with clomiphene citrate, metformin, or a combination of both, affects ovulation, conception, and live birth rates in women with polycystic ovary syndrome (PCOS)." | 5.16 | Endometrial shedding effect on conception and live birth in women with polycystic ovary syndrome. ( Brzyski, R; Carr, BR; Carson, S; Casson, P; Cataldo, NA; Christman, G; Coutifaris, C; Diamond, MP; Eisenberg, E; Gosman, GG; Kruger, M; Legro, RS; McGovern, PG; Myers, EE; Nestler, JE; Santoro, N; Schlaff, W; Steinkampf, MP; Zhang, H, 2012) |
| " They were treated with clomiphene citrate, metformin, or both (combination) for up to six cycles, and hirsutism evaluators were blinded to group assignment." | 5.16 | Altering hirsutism through ovulation induction in women with polycystic ovary syndrome. ( Carr, BR; Carson, SA; Cataldo, NA; Coutifaris, C; Diamond, MP; Gosman, GG; Huang, H; Legro, RS; McGovern, PG; Myers, ER; Nestler, JE; Roth, LW; Schlaff, WD; Steinkampf, MP; Zhang, H, 2012) |
| "To study the significance of breast size increment in pregnancy, and the impact of metformin during pregnancy on breastfeeding in women with polycystic ovary syndrome (PCOS)." | 5.16 | Breast size increment during pregnancy and breastfeeding in mothers with polycystic ovary syndrome: a follow-up study of a randomised controlled trial on metformin versus placebo. ( Carlsen, SM; Hjorth-Hansen, AK; Leithe, H; Martinussen, M; Nordskar, JJ; Vanky, E, 2012) |
| "Twelve weeks of atorvastatin led to a significant reduction in oxidative stress as determined by MDA concentrations among patients with polycystic ovary syndrome that was independently predicted by changes in testosterone, 25OHD, and high-sensitivity C-reactive protein." | 5.16 | Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome. ( Atkin, SL; Coady, AM; Kilpatrick, ES; Sathyapalan, T; Shepherd, J, 2012) |
| "The use of metformin throughout gestation by women with polycystic ovary syndrome (PCOS) and type 2 diabetes mellitus (T2DM) significantly reduces the number of first-trimester spontaneous abortions and the rate of occurrence of gestational diabetes and hypertensive syndromes." | 5.16 | Effect of type 2 diabetes mellitus on the pharmacokinetics of metformin in obese pregnant women. ( Cavalli, RC; de Jesus Antunes, N; de Jesus Ponte Carvalho, TM; de Oliveira Baraldi, C; Duarte, G; Lanchote, VL; Moisés, EC, 2012) |
| "The impact of metformin medication in pregnant women with polycystic ovary syndrome on weight gain during pregnancy and after delivery and the impact on growth of the offspring are essentially unexplored." | 5.16 | Metformin's effect on first-year weight gain: a follow-up study. ( Carlsen, SM; Martinussen, MP; Vanky, E, 2012) |
| "To evaluate sCD40L levels in women with polycystic ovary syndrome (PCOS) who use combination therapy with metformin and oral contraceptives." | 5.15 | Metformin plus oral contraceptive may decrease plasma sCD40 ligand in women with PCOS patients. ( Bilgir, O; Bozkaya, G; Kebapcilar, AG; Kebapcilar, L; Sari, I; Taner, CE; Yildiz, Y, 2011) |
| "To compare the effect of combined metformin-clomiphene citrate (CC) with highly purified urinary FSH (HP-uFSH) for ovulation induction in CC-resistant women with polycystic ovary syndrome (PCOS)." | 5.15 | Combined metformin and clomiphene citrate versus highly purified FSH for ovulation induction in clomiphene-resistant PCOS women: a randomised controlled trial. ( Abu Hashim, H; El Rakhawy, M; Wafa, A, 2011) |
| "In young women with PCOS, treatment with metformin or pioglitazone for 6 months induces a similar beneficial effect on endothelial function; this may be partially attributed to an improvement in insulin resistance." | 5.15 | Effect of the insulin sensitizers metformin and pioglitazone on endothelial function in young women with polycystic ovary syndrome: a prospective randomized study. ( Bechlioulis, A; Calis, KA; Chrousos, GP; Kalantaridou, SN; Katsouras, CS; Kazakos, N; Kravariti, M; Makrigiannakis, A; Michalis, LK; Naka, KK; Tsatsoulis, A, 2011) |
| "To assess the impact of metformin and of two different oral contraceptives (OCs) containing cyproterone acetate and drospirenone, on serum anti-Müllerian hormone (AMH) levels, in a cohort of women with polycystic ovary syndrome (PCOS) with hyperandrogenism." | 5.15 | The impact of oral contraceptives and metformin on anti-Müllerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia. ( Decavalas, G; Diamanti-Kandarakis, E; Georgopoulos, NA; Katsikis, I; Panidis, D; Piouka, A; Saltamavros, AD, 2011) |
| "To study the effects of early metformin treatment on menarche, height, and polycystic ovary syndrome (PCOS) markers." | 5.15 | Early metformin therapy to delay menarche and augment height in girls with precocious pubarche. ( de Zegher, F; Diaz, M; Ibáñez, L; Lopez-Bermejo, A; Marcos, MV, 2011) |
| " ADMA, homocysteine, high sensitive C-reactive protein (hs-CRP) and homeostasis model assessment estimate of insulin resistance (HOMA-IR) were investigated." | 5.15 | Inflammatory-metabolic parameters in obese and nonobese normoandrogenemic polycystic ovary syndrome during metformin and oral contraceptive treatment. ( Aydin, M; Batioglu, S; Erdogan, G; Kilic, S; Yilmaz, N; Zulfikaroglu, E, 2011) |
| "To compare the effect of combined metformin and clomiphene citrate (CC) with laparoscopic ovarian diathermy (LOD) meant for ovulation induction in CC-resistant women with polycystic ovary syndrome (PCOS)." | 5.15 | Combined metformin and clomiphene citrate versus laparoscopic ovarian diathermy for ovulation induction in clomiphene-resistant women with polycystic ovary syndrome: a randomized controlled trial. ( Abu Hashim, H; El Lakany, N; Sherief, L, 2011) |
| "To determine if the combination of lifestyle (caloric restriction and exercise) and metformin (MET) would be superior to lifestyle and placebo (PBO) in improving the polycystic ovary syndrome (PCOS) phenotype." | 5.15 | The effects of metformin with lifestyle therapy in polycystic ovary syndrome: a randomized double-blind study. ( Archibong, AE; Coney, P; Demers, LM; Dodson, WC; Kunselman, AR; Ladson, G; Legro, RS; Sweet, SD; Williams, NI, 2011) |
| "There is no benefit from increased doses of metformin in PCOS but reduction of insulin resistance is more significant in those patients with a lower insulin sensitivity at baseline." | 5.15 | Effect of dose escalation of metformin on clinical features, insulin sensitivity and androgen profile in polycystic ovary syndrome. ( Balen, AH; Barth, J; Glanville, J; Yasmin, E, 2011) |
| "Comparing the effects of metformin or orlistat on hormone, lipid profile and ovulation status in obese women with polycystic ovary syndrome." | 5.15 | The effects of metformin or orlistat on obese women with polycystic ovary syndrome: a prospective randomized open-label study. ( Aflatoonian, A; Ghandi, S; Moghaddam, MH; Tabibnejad, N, 2011) |
| "To compare the efficacy of 1000 mg and 1700 mg of metformin on ovulation induction in polycystic ovary syndrome (PCOS) women." | 5.15 | Randomized controlled trial of different doses of metformin for ovulation induction in infertile women with polycystic ovary syndrome. ( Jultanmas, R; Leelaphiwat, S; Lertvikool, S; Satirapot, C; Sophonsritsuk, A; Weerakiet, S, 2011) |
| "Metformin can improve insulin resistance and imbalance of endocrine hormones." | 5.15 | Metformin versus metformin plus rosiglitazone in women with polycystic ovary syndrome. ( Dong, JJ; Liao, L; Tian, YJ; Xin, Y; Xing, HY; Zhao, JJ, 2011) |
| "Thirty-three patients with PCOS were specifically selected for being either treated with levothyroxine for a previous diagnosis of hypothyroidism (n = 7), untreated subclinically hypothyroid (n = 2) or euthyroid without levothyroxine treatment (n = 24) before the starting of metformin." | 5.15 | Thyroidal effect of metformin treatment in patients with polycystic ovary syndrome. ( Botta, R; Cappelli, C; Castellano, M; Chiovato, L; De Cata, P; Dionisio, R; Iacobello, C; Magri, F; Nappi, RE; Rotondi, M, 2011) |
| "To prospectively evaluate the safety of metformin administration during pregnancy in a group of PCOS patients by assessing its effect on the prevalence of gestational complications and neonatal outcome." | 5.15 | The administration of metformin during pregnancy reduces polycystic ovary syndrome related gestational complications. ( De Leo, V; Di Sabatino, A; Morgante, G; Musacchio, MC; Piomboni, P, 2011) |
| " In women with PCOS, metformin co-treatment during IVF has been shown to increase pregnancy rates and reduce the risk of ovarian hyperstimulation syndrome (OHSS)." | 5.15 | Do women with ovaries of polycystic morphology without any other features of PCOS benefit from short-term metformin co-treatment during IVF? A double-blind, placebo-controlled, randomized trial. ( Child, T; Granne, I; Jayaprakasan, K; Lavery, S; Lighten, A; McVeigh, E; Raine-Fenning, N; Swanton, A; Talmor, A; Trew, G, 2011) |
| "To study the effect of metformin before and during assisted reproductive technology (ART) on the clinical pregnancy rate (CPR) in non-obese women with polycystic ovary syndrome (PCOS)." | 5.15 | Use of metformin before and during assisted reproductive technology in non-obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double-blind, multi-centre study. ( Carlsen, SM; Haapaniemikouru, K; Holst-Larsen, T; Humaidan, P; Kjøtrød, SB; Mellembakken, J; Morin-Papunen, L; Rasmussen, PE; Sunde, A; Thurin-Kjellberg, A; von Düring, V, 2011) |
| "Reduction of serum total testosterone (TT) is associated with pregnancy rate in polycystic ovary syndrome (PCOS) women receiving metformin, but most of the studies focus on the changes of basal levels of TT." | 5.15 | Prognostic value of total testosterone for pregnancy during treatment in patients with clomiphene-citrate-resistant polycystic ovary syndrome: a pilot study. ( Cheng, J; Huang, Z; Li, C; Lv, J; Wang, J; Xue, Y; Zhang, S, 2011) |
| "In LBW-PP girls, early metformin therapy was found to prevent or delay the development of hirsutism, androgen excess, oligomenorrhea, and PCOS more effectively than late metformin." | 5.15 | Early metformin therapy (age 8-12 years) in girls with precocious pubarche to reduce hirsutism, androgen excess, and oligomenorrhea in adolescence. ( de Zegher, F; Díaz, M; Ibáñez, L; López-Bermejo, A; Marcos, MV, 2011) |
| "In this randomized, double-blind, placebo-controlled study, 19 overweight women with polycystic ovary syndrome were randomized to a 3-month course of either metformin plus combined hormonal oral contraceptive (OC) (n = 9) or OC plus matched placebo (n = 10)." | 5.15 | Effect of combined metformin and oral contraceptive therapy on metabolic factors and endothelial function in overweight and obese women with polycystic ovary syndrome. ( Adawadkar, SS; Arrowood, JA; Cheang, KI; Essah, PA; Nestler, JE; Stovall, DW, 2011) |
| " The metformin therapy improved insulin sensitivity as evidenced by an increase in ISI by 41." | 5.15 | [Effects of metformin therapy on markers of coagulation disorders in hyperinsulinemic women with polycystic ovary syndrome]. ( Banaszewska, B; Pawelczyk, L; Serdyńska-Szuster, M; Spaczyński, R, 2011) |
| "To evaluate the clinical, endocrine and metabolic effects of metformin and N-acetyl-cysteine (NAC) in patients with polycystic ovary syndrome (PCOS)." | 5.15 | Clinical, endocrine and metabolic effects of metformin vs N-acetyl-cysteine in women with polycystic ovary syndrome. ( Muderris, II; Oner, G, 2011) |
| " Both simvastatin and metformin improved menstrual cyclicity and decreased hirsutism, acne, ovarian volume, body mass index, C-reactive protein, and soluble vascular cell adhesion molecule-1." | 5.15 | Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. ( Banaszewska, B; Duleba, AJ; Pawelczyk, L; Spaczynski, RZ, 2011) |
| "To evaluate the effects of metformin on the ovarian response to gonadotropins given for in vitro fertilization (IVF) programs in patients with polycystic ovary syndrome (PCOS) and reduced ovarian reserve." | 5.15 | Does metformin affect the ovarian response to gonadotropins for in vitro fertilization treatment in patients with polycystic ovary syndrome and reduced ovarian reserve? A randomized controlled trial. ( Cappiello, F; Di Cello, A; Falbo, A; Palomba, S; Tolino, A; Zullo, F, 2011) |
| " We conducted this study to evaluate the levels of AMH in women with polycystic ovarian syndrome (PCOS) before and after metformin therapy." | 5.15 | Anti-Müllerian hormone in women with polycystic ovary syndrome before and after therapy with metformin. ( Deepinder, F; Kirilov, G; Kumanov, P; Mechandjiev, Z; Robeva, R; Tomova, A, 2011) |
| "To test whether metformin administration reduces the incidence of ovarian hyperstimulation syndrome (OHSS) in infertile high-risk patients with polycystic ovary syndrome (PCOS) who have been treated with gonadotropins for IVF." | 5.15 | Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial. ( Capasso, S; Cappiello, F; Carrillo, L; Cittadini, E; Colao, A; Di Cello, A; Falbo, A; La Sala, GB; Mastrantonio, P; Orio, F; Palomba, S; Russo, T; Tolino, A; Villani, MT; Zullo, F, 2011) |
| "Various classes of medication are currently being used in Polycystic Ovary Syndrome (PCOS) patients including the biguanides and the statins." | 5.15 | Therapeutic effects of biguanide vs. statin in polycystic ovary syndrome: a randomized clinical trial. ( Fouladi, RF; Navali, N; Nikpour, MA; Pourabolghasem, S, 2011) |
| "Only orlistat reduced both IR and its variability significantly, though all three drugs were effective in reducing hyperandrogenism within the 12-week period of the study." | 5.14 | Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome. ( Atkin, SL; Cho, LW; Coady, AM; Keevil, BG; Kilpatrick, ES, 2009) |
| "To compare the effects of metformin versus an antiandrogenic contraceptive pill on ambulatory blood pressure monitoring (ABPM) and carotid intima media thickness (CIMT) in women with polycystic ovary syndrome (PCOS)." | 5.14 | Effects of metformin versus ethinyl-estradiol plus cyproterone acetate on ambulatory blood pressure monitoring and carotid intima media thickness in women with the polycystic ovary syndrome. ( Alvarez-Blasco, F; Escobar-Morreale, HF; Luque-Ramírez, M; Mendieta-Azcona, C, 2009) |
| "In polycystic ovary syndrome, metformin improves insulin resistance, inflammatory markers, and endothelial function." | 5.14 | Endothelial function and insulin resistance in polycystic ovary syndrome: the effects of medical therapy. ( Hutchison, SK; McGrath, BP; Meyer, C; Moran, LJ; Teede, HJ; Zoungas, S, 2010) |
| " Hirsutism was significantly better controlled in the metformin group (p = 0." | 5.14 | Increased insulin sensitivity by metformin enhances intense-pulsed-light-assisted hair removal in patients with polycystic ovary syndrome. ( Adibi, N; Asilian, A; Kachuei, A; Rezvanian, H; Shojaee-Moradie, F; Siavash, M, 2009) |
| "Rimonabant has been shown to reduce weight, free androgen index (FAI) and insulin resistance in obese patients with polycystic ovary syndrome (PCOS) compared to metformin." | 5.14 | Metformin maintains the weight loss and metabolic benefits following rimonabant treatment in obese women with polycystic ovary syndrome (PCOS). ( Atkin, SL; Cho, LW; Coady, AM; Kilpatrick, ES; Sathyapalan, T, 2009) |
| " Obesity increased circulating fibrinogen levels, prothrombin activity and platelet counts, and reduced prothrombin and activated partial thromboplastin times." | 5.14 | Effects of an antiandrogenic oral contraceptive pill compared with metformin on blood coagulation tests and endothelial function in women with the polycystic ovary syndrome: influence of obesity and smoking. ( del Rey Sánchez, JM; Escobar-Morreale, HF; Luque-Ramírez, M; Matíes, M; Mendieta-Azcona, C, 2009) |
| "There were no adverse effects of short-term cyclic MPA plus metformin treatment on metabolic parameters or insulin resistance in patients with PCOS over a 3-month treatment period." | 5.14 | Metabolic and endocrine effects of metformin and metformin plus cyclic medroxyprogesterone acetate in women with polycystic ovary syndrome. ( Bagis, T; Haydardedeoglu, B; Kilicdag, EB; Simsek, E, 2009) |
| "Circulating levels of interleukin-6 (IL-6) and C-reactive protein (CRP) were determined in 59 women with polycystic ovary syndrome, of whom 37 were retested after receiving metformin for 6 weeks and 6 months, to ascertain the response of these inflammatory markers to weight loss and insulin sensitization." | 5.14 | Determinants of interleukin-6 and C-reactive protein vary in polycystic ovary syndrome, as do effects of short- and long-term metformin therapy. ( Conway, GS; Mohamed-Ali, V; Tsilchorozidou, T, 2009) |
| " Total renin, aldosterone, androgen levels and insulin sensitivity indices were significantly improved after 6 months on metformin treatment." | 5.14 | Hyperreninemia characterizing women with polycystic ovary syndrome improves after metformin therapy. ( Diamanti-Kandarakis, E; Economou, FN; Livadas, S; Panidis, D; Papavassiliou, AG; Piperi, C; Tantalaki, E, 2009) |
| "To investigate metformin effects on the endocrine-metabolic parameters and ovarian morphology in normoinsulinemic women with polycystic ovary syndrome (PCOS)." | 5.14 | Metformin effects on ovarian ultrasound appearance and steroidogenic function in normal-weight normoinsulinemic women with polycystic ovary syndrome: a randomized double-blind placebo-controlled clinical trial. ( Cristello, F; Fulghesu, AM; Giuliani, M; Guido, M; Lanzone, A; Romualdi, D; Selvaggi, L, 2010) |
| " Among the treatment groups, EE/CA-metformin may be a more effective therapeutic option than the other protocols and this may be due to the beneficial effect of EE/CA-metformin on insulin resistance." | 5.14 | Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome. ( Alacacioglu, A; Kebapcilar, AG; Kebapcilar, L; Sari, I; Taner, CE, 2010) |
| "To compare the effect of clomiphene citrate, metformin, and lifestyle modification on treatment of patients with polycystic ovary syndrome (PCOS)." | 5.14 | An assessment of lifestyle modification versus medical treatment with clomiphene citrate, metformin, and clomiphene citrate-metformin in patients with polycystic ovary syndrome. ( Javedani, M; Karimzadeh, MA, 2010) |
| "Our prospective study aim is to compare the effectiveness of clomifene citrate plus metformin and clomifene citrate plus placebo in women with newly diagnosed polycystic ovary syndrome." | 5.14 | Metformin effects on clomifene-induced ovulation in the polycystic ovary syndrome. ( Ben Arab, H; Ben Ayed, B; Chahtour, H; Dammak dit Mlik, S; Dhuib, M; Guermazi, M; Kassis, M; Mathlouthi, N; Saiidane, D; Trabelssi, H; Trabelssi, K, 2009) |
| " To elucidate the dynamics of FSH, LH, prolactin (PRL), TSH and insulin secretion in women with polycystic ovarian syndrome (PCOS) treated with metformin (MET)." | 5.14 | Metformin administration was associated with a modification of LH, prolactin and insulin secretion dynamics in women with polycystic ovarian syndrome. ( Adamopoulos, DA; Antsaklis, A; Billa, E; Kapolla, N; Koukkou, E; Milingos, S; Nicopoulou, SC; Venaki, E, 2009) |
| "To evaluate the effect of a short-course pretreatment with metformin on hyperandrogenism, insulin resistance, cervical scores, and pregnancy rates in women with clomiphene citrate (CC)-resistant polycystic ovary syndrome (PCOS)." | 5.14 | Short-term metformin treatment for clomiphene citrate-resistant women with polycystic ovary syndrome. ( Ghaffarpasand, F; Kazerooni, M; Kazerooni, T; Kazerooni, Y; Setoodeh, S, 2009) |
| "The aim of this study was to evaluate the effects of calcium-vitamin D and metformin on the menstrual cycle and ovulation in patients with polycystic ovary syndrome (PCOS)." | 5.14 | The effects of calcium-vitamin D and metformin on polycystic ovary syndrome: a pilot study. ( Haghollahi, F; Rashidi, B; Shariat, M; Zayerii, F, 2009) |
| "To determine whether metformin, when given to women with polycystic ovary syndrome (PCOS), promotes folliculogenesis by prompting a drop in free sex steroids resulting in a compensatory follicle stimulating hormone (FSH) rise, we conducted a randomized, double-blind, placebo-controlled crossover clinical trial." | 5.14 | Metformin does not improve the reproductive or metabolic profile in women with polycystic ovary syndrome (PCOS). ( Adel, G; Aubuchon, M; Cohen, HW; Isaac, B; Lieman, H; Polotsky, AJ; Santoro, N; Stein, D; Tetrokalashvili, M; Weitzman, V, 2009) |
| "To compare hormone levels and clinical outcomes in patients with polycystic ovary syndrome (PCOS) after metformin therapy or laparoscopic ovarian diathermy (LOD) at 6 months follow-up." | 5.14 | Comparison of metformin treatment and laparoscopic ovarian diathermy in patients with polycystic ovary syndrome. ( Asgari, Z; Ashrafinia, M; Eslami, B; Hosseini, R; Moini, A, 2009) |
| "This study was conducted to determine the efficacy of metformin vs placebo in women with polycystic ovary syndrome (PCOS) undergoing IVF treatment." | 5.14 | Metformin in the treatment of clomiphene citrate-resistant women with polycystic ovary syndrome undergoing in vitro fertilisation treatment: a randomised controlled trial. ( Abu-Salem, AN; Al-Ahmad, N; Al-Ibrahim, N; Al-Khaderei, S; Al-Khateeb, M; Al-Zpoon, A; Megdadi, M; Qublan, HS, 2009) |
| "To investigate the association between family history and clinical symptoms of polycystic ovary syndrome (PCOS) that were thought to be inherited, by treating women with PCOS with contraceptive pills and metformin, and assessing outcomes." | 5.14 | The role of family history in clinical symptoms and therapeutic outcomes of women with polycystic ovary syndrome. ( Chen, X; Chi, H; Hu, Z; Li, M; Qiao, J; Wang, Y, 2010) |
| "We studied the effect of metformin or placebo in a lifestyle modification program combined with oral contraceptives (OC) on quality-of-life parameters measured by the polycystic ovary syndrome (PCOS) questionnaire in obese adolescent women with validated PCOS." | 5.14 | Improvement in quality-of-life questionnaire measures in obese adolescent females with polycystic ovary syndrome treated with lifestyle changes and oral contraceptives, with or without metformin. ( Davidson, K; Guzick, D; Harris-Glocker, M; Hoeger, K; Kochman, L, 2010) |
| "The aim of this study was to assess novel inflammatory markers [adipokines leptin, adiponectin, and leptinadiponectin ratio (L/A)] in overweight women with and without PCOS and to examine alterations in these markers [aldosterone, leptin, adiponectin, and L/A] with pharmacological interventions modulating insulin resistance (IR) in PCOS." | 5.14 | Novel inflammatory markers in overweight women with and without polycystic ovary syndrome and following pharmacological intervention. ( Hutchison, SK; Meyer, C; Moran, LJ; Teede, HJ; Zoungas, S, 2010) |
| "To compare the hormonal-metabolic profiles and reproductive outcomes in clomiphene-resistant patients with polycystic ovary syndrome and insulin resistance between women receiving metformin and those undergoing laparoscopic ovarian drilling." | 5.14 | Metformin versus laparoscopic ovarian drilling in clomiphene- and insulin-resistant women with polycystic ovary syndrome. ( Ahmed, MA; Ahmed, OG; Hamed, HO; Hasan, AF, 2010) |
| "To evaluate the effects of a pill with drospirenone (3 mg) plus ethinyl E(2) (20 μg) (DRP/20EE) alone or associated with metformin or cyproterone acetate (CPA) on some metabolic cardiovascular risk factors in women with polycystic ovary syndrome (PCOS)." | 5.14 | Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome. ( Fruzzetti, F; Gambacciani, M; Genazzani, AR; Lazzarini, V; Parrini, D; Perini, D, 2010) |
| "In 20 adolescents age < or = 17 (16 +/- 1 yr) with polycystic ovary syndrome (PCOS), we assessed efficacy and safety of metformin-diet for 1 year in treatment of endocrinopathy and coronary heart disease (CHD) risk factors." | 5.14 | Metformin-diet ameliorates coronary heart disease risk factors and facilitates resumption of regular menses in adolescents with polycystic ovary syndrome. ( Glueck, CJ; Goldenberg, N; Wang, P, 2009) |
| " The aim of this study was to determine leptin concentrations in PCOS patients before and after metformin treatment depending on BMI, insulin resistance calculated on the basis of the Homeostasis Model Assessment (HOMA) index, as well as concentrations of androgens: testosterone and androstendion." | 5.14 | Leptin concentrations in patients with polycystic ovary syndrome before and after met-formin treatment depending on insulin resistance, body mass index and androgen con-centrations--introductory report. ( Brodowska, A; Marciniak, A; Nawrocka-Rutkowska, J; Sienkiewicz, R; Starczewski, A; Szydłowska, I, 2009) |
| " Metformin improves insulin sensitivity and circulating markers of cardiovascular risk in patients with PCOS, but it is unclear whether this translates into improvements in vascular function." | 5.14 | Metformin reduces arterial stiffness and improves endothelial function in young women with polycystic ovary syndrome: a randomized, placebo-controlled, crossover trial. ( Agarwal, N; Bolusani, H; Dunseath, G; Ludgate, M; Luzio, SD; Rees, DA; Rice, SP, 2010) |
| "The aim of this study was to evaluate long-term changes in endocrine and metabolic parameters and body mass index in women with polycystic ovary syndrome (PCOS) who were treated with metformin over 2 years without caloric restriction." | 5.14 | The effect of metformin treatment for 2 years without caloric restriction on endocrine and metabolic parameters in women with polycystic ovary syndrome. ( Beckmann, MW; Cupisti, S; Dittrich, R; Jentsch, K; Kronawitter, D; Mueller, A; Oppelt, PG; Reissmann, C, 2010) |
| " 'Cases' were women with PCOS who conceived while taking Metformin and it whom it was continued throughout pregnancy." | 5.14 | Continuation of metformin reduces early pregnancy loss in obese Pakistani women with polycystic ovarian syndrome. ( Nawaz, FH; Rizvi, J, 2010) |
| "This report has demonstrated that the combination of metformin and simvastatin could lead to a better reduction of T and LH levels and thus reversing the LH:FSH ratio, lipid profile, and insulin resistance in patients with PCOS and may be an appropriate management option for patients with PCOS." | 5.14 | Effects of metformin plus simvastatin on polycystic ovary syndrome: a prospective, randomized, double-blind, placebo-controlled study. ( Asadi, N; Dehbashi, S; Ghaffarpasand, F; Kazerooni, T; Kazerooni, Y; Shojaei-Baghini, A, 2010) |
| "The purpose of this study was to compare the effectiveness of laparoscopic ovarian diathermy (LOD) vs clomiphene citrate (CC) plus metformin in infertile patients with CC-resistant polycystic ovary syndrome (PCOS)." | 5.14 | Laparoscopic ovarian diathermy vs clomiphene citrate plus metformin as second-line strategy for infertile anovulatory patients with polycystic ovary syndrome: a randomized controlled trial. ( Battista, L; Falbo, A; Orio, F; Palomba, S; Russo, T; Tolino, A; Venturella, R; Zullo, F, 2010) |
| "The aim of this study was to evaluate the effects of metformin in addition to diet and exercise on endocrine and metabolic disturbances in women with polycystic ovary syndrome (PCOS) in a prospective, double-blind, randomized, placebo (PBO) control trial." | 5.14 | Clinical, metabolic, and endocrine parameters in response to metformin and lifestyle intervention in women with polycystic ovary syndrome: a randomized, double-blind, and placebo control trial. ( Fux Otta, C; Gaido, MI; Iraci, GS; Kaplan, R; Torres, D; Wior, M; Wyse, EP, 2010) |
| " Metformin had no effect on adiponectin in spite of significant decreases in weight, fasting glucose, and insulin resistance." | 5.14 | Adiponectin levels in women with polycystic ovary syndrome: impact of metformin treatment in a randomized controlled study. ( Flyvbjerg, A; Frystyk, J; Lauszus, FF; Trolle, B, 2010) |
| "The aim of this study was to compare the effectiveness of myo-inositol (MYO) and metformin, in monotherapy or in association with recombinant follicle stimulating hormone (r-FSH), in the treatment of menstrual irregularities, chronic anovulation, and female infertility in patients with polycystic ovary syndrome (PCOS)." | 5.14 | Insulin sensitiser agents alone and in co-treatment with r-FSH for ovulation induction in PCOS women. ( Benedetto, V; Raffone, E; Rizzo, P, 2010) |
| "For women with BMI > 32 kg/m(2), clinical pregnancy and live birth rates were 22% (7/32) and 16% (5/32) with metformin, 15% (5/33) and 6% (2/33) with placebo." | 5.14 | PCOSMIC: a multi-centre randomized trial in women with PolyCystic Ovary Syndrome evaluating Metformin for Infertility with Clomiphene. ( Buckingham, KL; Falkiner, J; Farquhar, CM; Johnson, NP; Milsom, S; Okonkwo, QL; Singh, VP; Stewart, AW, 2010) |
| "This study was performed with the aim of evaluating the effect of metformin in reducing miscarriage when continued until the end of the first trimester of pregnancy in patients with polycystic ovary syndrome (PCOS) and infertility." | 5.14 | Effect of metformin on miscarriage in pregnant patients with polycystic ovary syndrome. ( Bagheri, B; Haghollahi, F; Shariat, M; Sohrabvand, F, 2009) |
| "To compare the efficacy of metformin and clomiphene citrate (CC) therapies for ovulation induction in anovulatory infertile women with polycystic ovary syndrome (PCOS)." | 5.14 | Comparison of metformin and clomiphene citrate therapy for induction of ovulation in the polycystic ovary syndrome. ( Api, M; Baran, S; Cetin, A; Goksedef, BP, 2010) |
| "In overweight patients with PCOS with hyperinsulinism, allopregnanolone secretion is impaired and metformin administration restored normal allopregnanolone concentrations modulating both steroid syntheses from the ovaries and from adrenal gland." | 5.14 | Metformin administration restores allopregnanolone response to adrenocorticotropic hormone (ACTH) stimulation in overweight hyperinsulinemic patients with PCOS. ( Casarosa, E; Chierchia, E; Genazzani, AD; Genazzani, AR; Luisi, M; Rattighieri, E; Santagni, S, 2010) |
| "The objective of this study was to investigate the effect of metformin versus acarbose in terms of ovulation rate, their impact on hormonal and metabolic status and tolerability of both drugs in patients with polycystic ovary syndrome (PCOS)." | 5.14 | Metformin versus acarbose therapy in patients with polycystic ovary syndrome (PCOS): a prospective randomised double-blind study. ( Denschlag, D; Gabriel, B; Hanjalic-Beck, A; Keck, C; Schaefer, W; Schories, M; Tempfer, C; Zahradnik, HP, 2010) |
| "The determinants of the variability in the clinical response to metformin in women with the polycystic ovary syndrome (PCOS) are enigmatic." | 5.14 | Organic cation transporter 1 polymorphisms predict the metabolic response to metformin in women with the polycystic ovary syndrome. ( Altieri, P; Di Rocco, A; Fulghesu, AM; Gambineri, A; Gasparini, DI; Mantovani, V; Pagotto, U; Pasquali, R; Sanna, S; Tomassoni, F, 2010) |
| "We studied the effects of the SHBG (TAAAA)(n) and androgen receptor gene [AR] (CAG)(n) allele length on endocrine-metabolic features and body composition (by dual-energy X-ray absorptiometry) before and after 1 year on metformin (850 mg/d) in 70 girls with polycystic ovary syndrome after precocious pubarche; allele lengths were assessed by polymerase chain reaction in both patients and in population control subjects (n = 107)." | 5.14 | Efficacy of metformin therapy in adolescent girls with androgen excess: relation to sex hormone-binding globulin and androgen receptor polymorphisms. ( de Zegher, F; Díaz, M; Ibáñez, L; López-Bermejo, A; Petry, CJ, 2010) |
| " We aimed to study if the changes observed in the insulin sensitivity of PCOS patients during treatment with oral contraceptives or metformin associate changes in the serum inflammatory markers interleukin-6 (IL-6) and interleukin-18 (IL-18)." | 5.14 | Treatment of polycystic ovary syndrome (PCOS) with metformin ameliorates insulin resistance in parallel with the decrease of serum interleukin-6 concentrations. ( Escobar-Morreale, HF; Luque-Ramírez, M, 2010) |
| "Metformin is widely prescribed to pregnant women with polycystic ovary syndrome (PCOS) in an attempt to reduce pregnancy complications." | 5.14 | Metformin versus placebo from first trimester to delivery in polycystic ovary syndrome: a randomized, controlled multicenter study. ( Almås, I; Berg, AH; Berg, KF; Bjerke, C; Bunford, G; Carlsen, SM; Danielson, A; Eikeland, T; Flo, K; Heimstad, R; Hjelle, S; Kleggetveit, O; Lahmami, G; Lund, A; Romundstad, P; Skogøy, K; Stridsklev, S; Vanky, E; von Brandis, P, 2010) |
| "To measure the vascularization and ovarian volume with three-dimensional sonography in patients diagnosed of polycystic ovary syndrome with stimulated ovulation treatment, and to analyse the differences between the patients treated with clomiphen citrate versus clomiphen citrate and metformin." | 5.14 | [Sonographic ovarian vascularization and volume in women with polycystic ovary syndrome treated with clomiphene citrate and metformin]. ( Alvarez-Alvarez, P; Bajo-Arenas, JM; de la Fuente-Valero, J; Engels-Calvo, V; Orensanz-Fernández, I; Zapardiel-Gutiérrez, I, 2010) |
| "To compare the effects of combined N-acetyl cysteine (NAC) and clomiphene citrate (CC) and of combined metformin and CC on ovulation induction in anovulatory CC-resistant women with polycystic ovary syndrome (PCOS)." | 5.14 | N-acetyl cysteine plus clomiphene citrate versus metformin and clomiphene citrate in treatment of clomiphene-resistant polycystic ovary syndrome: a randomized controlled trial. ( Abu Hashim, H; Anwar, K; El-Fatah, RA, 2010) |
| " This study was designed to show the effect of metformin, one of the most important drugs used to reduce insulin resistance in patients with polycystic ovary syndrome (PCOS), on these adipokines." | 5.14 | Impact of treatment with metformin on adipokines in patients with polycystic ovary syndrome. ( Cantürk, Z; Cetinarslan, B; Dikmen, E; Tarkun, I, 2010) |
| "To determine the effects of metformin treatment on serum androgen levels ahead of and during the IVF cycle in infertile polycystic ovary syndrome (PCOS) women." | 5.14 | Possible metformin effect on adrenal androgens during pretreatment and IVF cycle in women with polycystic ovary syndrome. ( Carlsen, SM; Kjøtrød, SB; Sunde, A; von Düring, V, 2009) |
| "To evaluate ovulation and pregnancy predictors in infertile polycystic ovary syndrome (PCOS) patients who received clomiphene citrate (CC) and metformin as first-line ovulation inductors." | 5.14 | Efficacy predictors for metformin and clomiphene citrate treatment in anovulatory infertile patients with polycystic ovary syndrome. ( Falbo, A; Orio, F; Palomba, S; Tolino, A; Zullo, F, 2009) |
| "Our first specific aim in an observational study of 431 nondiabetic women with polycystic ovary syndrome (PCOS), aged >or=20 years and with >or=11 months follow-up on metformin diet, was to prospectively assess relationships between pretreatment glucose and insulin resistance (IR) and the development of type 2 diabetes mellitus (T2DM) or gestational diabetes (GD)." | 5.13 | An observational study of reduction of insulin resistance and prevention of development of type 2 diabetes mellitus in women with polycystic ovary syndrome treated with metformin and diet. ( Glueck, CJ; Goldenberg, N; Sieve, L; Wang, P, 2008) |
| "Metformin was reported to improve the alterations of endothelial reactivity in normal-weight subjects with polycystic ovary syndrome (PCOS)." | 5.13 | Metformin improves endothelial function in normoinsulinemic PCOS patients: a new prospective. ( Bompiani, A; Costantini, B; Cristello, F; Giuliani, M; Guido, M; Lanzone, A; Macrì, F; Romualdi, D; Selvaggi, L, 2008) |
| "Previous non-randomized and uncontrolled studies indicate major metformin effects on glucose homeostasis in pregnant women with polycystic ovary syndrome (PCOS)." | 5.13 | Metformin has no major effects on glucose homeostasis in pregnant women with PCOS: results of a randomized double-blind study. ( Carlsen, SM; Fougner, KJ; Vanky, E, 2008) |
| "To decide if metformin augments clomiphene response for ovulation induction in non-obese women with polycystic ovary syndrome, a prospective randomised placebo-controlled trial was undertaken among 27 patients, who were found eligible for this study following clinical assessment and basic investigations." | 5.13 | Does metformin augment the ovulation inducing effects of clomiphene in non-obese women with polycystic ovary syndrome? ( Chaudhury, K; Chaudhury, S; Chowdhury, S, 2008) |
| "One hundred forty-two nondiabetic women with polycystic ovary syndrome (PCOS) who had at least one live-birth (LB) pregnancy on metformin diet (172 pregnancies, 180 LBs)." | 5.13 | Prevention of gestational diabetes by metformin plus diet in patients with polycystic ovary syndrome. ( Aregawi, D; Glueck, CJ; Pranikoff, J; Wang, P, 2008) |
| "Clomiphene and insulin sensitizers such as metformin are used to induce ovulation in polycystic ovary syndrome (PCOS), but the ovulatory response is variable, and the causes of this variation are poorly understood." | 5.13 | Ovulatory response to treatment of polycystic ovary syndrome is associated with a polymorphism in the STK11 gene. ( Barnhart, HX; Carr, BR; Carson, SA; Cataldo, NA; Coutifaris, C; Diamond, MP; Ewens, KG; Giudice, LC; Gosman, GG; Legro, RS; Leppert, PC; McGovern, PG; Myers, ER; Nestler, JE; Schlaff, WD; Spielman, RS; Steinkampf, MP, 2008) |
| "To determine the effect of metformin pretreatment on in vitro maturation (IVM) in the patients with clomiphene citrate-resistant polycystic ovary syndrome." | 5.13 | Effect of metformin pretreatment on pregnancy outcome of in vitro matured oocytes retrieved from women with polycystic ovary syndrome. ( Cao, Y; Cong, L; Li, J; Wei, Z; Zhang, Z; Zhou, P, 2008) |
| "We investigated whether poor adherence with metformin tablets may have contributed to the poor success rates seen in the metformin-containing arms of the Pregnancy in Polycystic Ovary Syndrome (PPCOS) Trial." | 5.13 | Medication adherence and treatment success in the National Institute of Child Health and Human Development-Reproductive Medicine Network's Pregnancy in Polycystic Ovary Syndrome Trial. ( Barnhart, HX; Carr, BR; Carson, SA; Cataldo, NA; Coutifaris, C; Diamond, MP; Giudice, LC; Gosman, G; Legro, RS; Leppert, PC; McGovern, PG; Myers, ER; Nestler, JE; Schlaff, WD; Steinkampf, MP, 2008) |
| "Serum uric acid levels were measured in 40 polycystic ovary syndrome (PCOS) patients and 40 non-hyperandrogenic women matched for BMI and grade of obesity, and were followed-up in 34 PCOS patients who were randomized to an oral contraceptive containing 35 mg ethinyl-estradiol plus 2 mg cyproterone acetate (Diane(35) Diario) or metformin (850 mg twice daily) for 24 weeks." | 5.13 | Serum uric acid concentration as non-classic cardiovascular risk factor in women with polycystic ovary syndrome: effect of treatment with ethinyl-estradiol plus cyproterone acetate versus metformin. ( Alvarez-Blasco, F; Escobar-Morreale, HF; Luque-Ramírez, M; Uriol Rivera, MG, 2008) |
| "To compare the effects of insulin sensitization with metformin to weight reduction by rimonabant on biochemical hyperandrogenaemia and insulin resistance in patients with PCOS." | 5.13 | A comparison between rimonabant and metformin in reducing biochemical hyperandrogenaemia and insulin resistance in patients with polycystic ovary syndrome (PCOS): a randomized open-label parallel study. ( Atkin, SL; Cho, LW; Coady, AM; Kilpatrick, ES; Sathyapalan, T, 2008) |
| "The beneficial effects of metformin in patients with type 2 diabetes mellitus (T2DM) and polycystic ovarian syndrome (PCOS) are thought to be in part due to weight reduction." | 5.13 | Metformin increases fasting plasma peptide tyrosine tyrosine (PYY) in women with polycystic ovarian syndrome (PCOS). ( Batterham, RL; Conway, GS; Tsilchorozidou, T, 2008) |
| "We evaluated exenatide (EX) and metformin (MET), alone and in combination (COM), on menstrual cyclicity, hormonal parameters, metabolic profiles, and inflammatory markers in overweight, insulin-resistant women with PCOS." | 5.13 | Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. ( Bhushan, M; Bhushan, R; Elkind-Hirsch, K; Marrioneaux, O; Vernor, D, 2008) |
| "An RCT among newly diagnosed, therapy naive women with polycystic ovary syndrome (PCOS) showed no significant differences in ovulation rate, ongoing pregnancy rate or spontaneous abortion rate in favour of clomifene citrate plus metformin compared with clomifene citrate." | 5.13 | Does adding metformin to clomifene citrate lead to higher pregnancy rates in a subset of women with polycystic ovary syndrome? ( Bossuyt, PM; Korevaar, JC; Moll, E; van der Veen, F, 2008) |
| "To evaluate metformin's effects on pregnancy outcomes in women with polycystic ovary syndrome." | 5.12 | Gestational metformin administration in women with polycystic ovary syndrome: A systematic review and meta-analysis of randomized control studies. ( Cao, Q; Fu, J; Hu, Y; Huang, W; Huang, X; Wu, L; Zhang, J, 2021) |
| "Conflicting results have been reported regarding the effect of metformin on adiponectin levels in women with polycystic ovary syndrome (PCOS)." | 5.12 | Effect of metformin on adiponectin in PCOS: A meta-analysis and a systematic review. ( Duan, X; Li, W; Zhou, G; Zhou, M; Zhu, Q, 2021) |
| "Our aim was to conduct a systematic review and meta-analysis to evaluate the efficacy of metformin for treatment of PCOS-related acne." | 5.12 | Metformin Therapy for Acne in Patients with Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis. ( Chang, YT; Huang, YC; Yee, FJ; Yen, H, 2021) |
| "The present study aimed to investigate the effects of metformin on body weight in polycystic ovary syndrome (PCOS) patients by model-based meta-analysis (MBMA)." | 5.12 | Effects of metformin on body weight in polycystic ovary syndrome patients: model-based meta-analysis. ( Chen, X; He, S; Wang, D, 2021) |
| "The efficacy of simvastatin plus metformin to treat polycystic ovary syndrome (PCOS) remained controversial." | 5.12 | Efficacy of simvastatin plus metformin for polycystic ovary syndrome: A meta-analysis of randomized controlled trials. ( Meng, J; Zhu, Y, 2021) |
| "To assess the impact of bariatric surgery on pregnancy outcomes in women with PCOS compared to metformin therapy in a systematic review and meta-analysis." | 5.12 | The Impact of Bariatric Surgery Compared to Metformin Therapy on Pregnancy Outcomes in Patients with Polycystic Ovarian Syndrome: a Systematic Review and Meta-analysis. ( Chang, C; Chang, S; Poles, J; Popov, V, 2021) |
| "This review covers the current evidence regarding the use of metformin as a therapeutic intervention for optimizing pregnancy outcomes in women with polycystic ovary syndrome (PCOS)." | 5.12 | Effects of metformin treatment on pregnancy outcomes in patients with polycystic ovary syndrome. ( Chronopoulou, E; Homburg, R; Raperport, C, 2021) |
| "Metformin is widely used as an insulin sensitizer in polycystic ovary syndrome (PCOS) patients." | 5.12 | The effect of metformin on homocysteine levels in patients with polycystic ovary syndrome: A systematic review and meta-analysis. ( Bai, Y; Fang, Z; Li, X; Pan, H; Wang, F; Yang, X; Zhang, C, 2021) |
| "Recent studies have revealed that myo-inositol could be more influential in patients with polycystic ovary syndrome (PCOS)." | 5.12 | The effects of myo-inositol vs. metformin on the ovarian function in the polycystic ovary syndrome: a systematic review and meta-analysis. ( Azizi Kutenaei, M; Eini, F; Ghaemmaghami, P; Hosseini Teshnizi, S; Roozbeh, N, 2021) |
| "To improve insulin action, most clinicians prescribe Metformin in patients with insulin resistance (IR)." | 5.12 | Metformin does not improve insulin sensitivity over hypocaloric diets in women with polycystic ovary syndrome: a systematic review of 12 studies. ( Garcia-Hernandez, SC; Gonzalez-Mejia, ME; López-Bayghen, E; Pacheco-Soto, BT; Porchia, LM, 2021) |
| "Several previous randomized controlled trials (RCTs) evaluated the efficacy of metformin combined with simvastatin in the treatment of polycystic ovary syndrome (PCOS), yet the results of the researches are not consistent." | 5.12 | The efficacy and safety of metformin combined with simvastatin in the treatment of polycystic ovary syndrome: A meta-analysis and systematic review. ( Chen, L; Liu, Y; Shao, Y; Xie, J; Zhu, G, 2021) |
| "Ours is the first study to report that for women with PCOS, myo-inositol combined with D-chiro-inositol and metformin combined with thiazolidinediones appear superior to metformin alone in improving insulin resistance and decreasing total testosterone." | 5.12 | Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis. ( He, B; Xing, C; Zhang, J; Zhao, H, 2021) |
| "It has been reported that women with polycystic ovary syndrome (PCOS) benefit from metformin therapy." | 5.12 | Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study. ( Balen, AH; Barth, JH; Glanville, J; Hayden, CJ; Tang, T; White, D, 2006) |
| "Metformin has been shown to improve fertility in anovulatory patients with polycystic ovary syndrome (PCOS), inducing not only a high ovulation and pregnancy rate but also reducing the incidence of miscarriages." | 5.12 | Uterine effects of metformin administration in anovulatory women with polycystic ovary syndrome. ( Carmina, E; Cascella, T; Colao, A; Falbo, A; Manguso, F; Orio, F; Palomba, S; Russo, T; Tolino, A; Zullo, F, 2006) |
| "Metformin is successfully used in the treatment of cycle disorders and anovulation in women with polycystic ovary syndrome (PCOS)." | 5.12 | Early effects of metformin in women with polycystic ovary syndrome: a prospective randomized, double-blind, placebo-controlled trial. ( Eisenhardt, S; Germeyer, A; Hamann, A; Henschel, V; Schwarzmann, N; Strowitzki, T; von Wolff, M, 2006) |
| " Much better decrease in the level of testosterone and free androgen index was established in group treated with metformin, while the indices of insulin resistance were better influenced in the group treated with rosiglitazone." | 5.12 | Metformin versus rosiglitazone in the treatment of polycystic ovary syndrome. ( Mitkov, M; Pehlivanov, B; Terzieva, D, 2006) |
| "Adding metformin to clomiphene citrate in clomiphene-resistant polycystic ovary syndrome (PCOS) patients increases ovulatory response." | 5.12 | Efficacy of combined metformin-letrozole in comparison with metformin-clomiphene citrate in clomiphene-resistant infertile women with polycystic ovarian disease. ( Ansari, Sh; Bagheri, M; Sohrabvand, F, 2006) |
| "In women with polycystic ovary syndrome, C-reactive protein levels and D-dimer, antithrombin III, activated protein C resistance, and activated partial thromboplastin time were unaffected by metformin treatment throughout pregnancy." | 5.12 | Beneficial effect of metformin on pregnancy outcome in women with polycystic ovary syndrome is not associated with major changes in C-reactive protein levels or indices of coagulation. ( Bjerve, K; Carlsen, SM; Hjorth-Hansen, H; Salvesen, KA; Vanky, E, 2006) |
| "Metformin appears to improve reproductive function in some women with polycystic ovary syndrome (PCOS)." | 5.12 | The use of metformin for women with PCOS undergoing IVF treatment. ( Balen, AH; Barth, JH; Glanville, J; Orsi, N; Tang, T, 2006) |
| "Metformin significantly lowered total testosterone concentrations, increased the likelihood of menses, and improved high-density lipoprotein cholesterol levels without affecting measures of insulin sensitivity or body weight." | 5.12 | Randomized placebo-controlled trial of metformin for adolescents with polycystic ovary syndrome. ( Baltzer, F; Bridger, T; MacDonald, S; Rodd, C, 2006) |
| "To determine if short courses of metformin (MET) administration in patients with polycystic ovary syndrome (PCOS) would reduce fasting insulin and improve the efficacy of clomiphene citrate (CC) to induce ovulation." | 5.12 | Two weeks of metformin improves clomiphene citrate-induced ovulation and metabolic profiles in women with polycystic ovary syndrome. ( Bonpane, CM; Helliwell, JP; Jaramillo, L; Katz, S; Khorram, O, 2006) |
| "To compare the efficacy of rosiglitazone and clomiphene citrate (CC) with metformin and CC in women with CC-resistant polycystic ovary syndrome (PCOS)." | 5.12 | A randomized controlled trial of the efficacy of rosiglitazone and clomiphene citrate versus metformin and clomiphene citrate in women with clomiphene citrate-resistant polycystic ovary syndrome. ( Ardawi, MS; Rouzi, AA, 2006) |
| "Current data supporting the effectiveness of metformin as a fertility treatment for women with polycystic ovary syndrome have been misinterpreted." | 5.12 | No more surrogate end-points in randomised trials: the PCOSMIC trial protocol for women with polycystic ovary syndrome using metformin for infertility with clomiphene. ( Johnson, NP, 2006) |
| "The purpose of this retrospective study was to compare the frequency of menstrual cyclicity between two groups of patients with polycystic ovary syndrome: women who were followed while on metformin for 3-6 months and those who were followed for >6 months." | 5.12 | Effects of short-term and long-term metformin treatment on menstrual cyclicity in women with polycystic ovary syndrome. ( Apridonidze, T; Essah, PA; Iuorno, MJ; Nestler, JE, 2006) |
| "To evaluate the effects of metformin on insulin resistance, androgen concentration, ovulation rates and pregnancy rates in infertile women with polycystic ovary syndrome (PCOS)." | 5.12 | Effects of metformin on insulin resistance, androgen concentration, ovulation and pregnancy rates in women with polycystic ovary syndrome following laparoscopic ovarian drilling. ( Kocak, I; Ustün, C, 2006) |
| "To compare the effectiveness of clomifene citrate plus metformin and clomifene citrate plus placebo in women with newly diagnosed polycystic ovary syndrome." | 5.12 | Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. ( Bossuyt, PM; Korevaar, JC; Lambalk, CB; Moll, E; van der Veen, F, 2006) |
| "To establish whether metformin has a significant action in reducing visceral fat and improving other metabolic parameters in women with polycystic ovary syndrome (PCOS)." | 5.12 | The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome--a randomised, double-blind, placebo-controlled trial. ( Acharya, U; Fox, B; Lord, J; Thomas, R; Wilkin, T, 2006) |
| "To evaluate the therapeutic effect of metformin on the clinical features, hormonal and metabolic profile in obese women with a hyperinsulinemic polycystic ovary syndrome (PCOS)." | 5.12 | Metformin improves menstrual patterns, endocrine and metabolic profile in obese hyperinsulinemic women with a polycystic ovary syndrome. ( Ahmeti, I; Dimitrovski, Ch; Dimova, Z; Krstevska, B; Misevska, S; Pemovska, G; Simeonova, S, 2006) |
| "The few controlled trials performed so far indicate that the addition of metformin and/or flutamide to a hypocaloric diet in obese women with polycystic ovary syndrome (PCOS) effectively influences different phenotypic aspects of the syndrome." | 5.12 | Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study. ( Cacciari, M; Cavazza, C; Gambineri, A; Morselli-Labate, AM; Pagotto, U; Pasquali, R; Patton, L; Vaccina, A, 2006) |
| "8 kg/m2, we assessed effeicacy of metformin-diet for 1 year for reduction of weight, insulin, HOMA insulin resistance (IR), cholesterol, triglycerides, and resumption of regular menses." | 5.12 | Metformin-diet ameliorates coronary heart disease risk factors and facilitates resumption of regular menses in adolescents with polycystic ovary syndrome. ( Agloria, M; Aregawi, D; Glueck, CJ; Luo, G; Sieve, L; Wang, P; Winiarska, M, 2006) |
| "To evaluate the effects of metformin and of clomiphene citrate (CC) on the ovarian blood perfusion and on perifollicular and peri-corpus luteum (CL) vascularity in anovulatory women with polycystic ovary syndrome (PCOS)." | 5.12 | Effects of metformin and clomiphene citrate on ovarian vascularity in patients with polycystic ovary syndrome. ( Falbo, A; Orio, F; Palomba, S; Russo, T; Tolino, A; Zullo, F, 2006) |
| "Metformin is better for ovulation induction than CC alone and equivalent for pregnancy achievement." | 5.12 | Comparison of clomiphene citrate, metformin, or the combination of both for first-line ovulation induction and achievement of pregnancy in 154 women with polycystic ovary syndrome. ( Granger, L; Lavoie, HB; Neveu, N; St-Michel, P, 2007) |
| "The authors hypothesized that a metformin (MET)-diet would improve symptoms of idiopathic intracranial hypertension (IIH) in women who also had polycystic ovary syndrome (PCOS) or hyperinsulinemia without PCOS." | 5.12 | Changes in weight, papilledema, headache, visual field, and life status in response to diet and metformin in women with idiopathic intracranial hypertension with and without concurrent polycystic ovary syndrome or hyperinsulinemia. ( Aregawi, D; Glueck, CJ; Goldenberg, N; Golnik, KC; Sieve, L; Wang, P, 2006) |
| "A prospective cohort study was set up to determine the beneficial effects of metformin on PCOS patients during pregnancy." | 5.12 | Metformin reduces abortion in pregnant women with polycystic ovary syndrome. ( Al-Inany, H; Foutouh, IA; Khattab, S; Moaz, M; Mohsen, IA; Ramadan, A, 2006) |
| "to compare the clinical, hormonal and biochemical changes after the application of the two ways of influence upon insulin resistance in women with PCOS - reduction of weight and application of metformin." | 5.12 | [Clinical, hormonal and biochemical changes after treatment with metformin and weight reduction in women with polycystic ovary syndrome]. ( Kavŭrdzhikova, S; Mitkov, M; Pekhlivanov, B, 2006) |
| "Metformin appears to be an effective medicine to induce ovulation in women with polycystic ovary syndrome and insulin resistance." | 5.12 | Increase of multiple pregnancies caused by ovulation induction with gonadotropin in combination with metformin in infertile women with polycystic ovary syndrome. ( Hirano, Y; Kikuchi, K; Shibahara, H; Suzuki, M; Suzuki, T; Takamizawa, S, 2007) |
| "We randomly assigned 626 infertile women with the polycystic ovary syndrome to receive clomiphene citrate plus placebo, extended-release metformin plus placebo, or a combination of metformin and clomiphene for up to 6 months." | 5.12 | Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. ( Barnhart, HX; Carr, BR; Carson, SA; Cataldo, NA; Coutifaris, C; Diamond, MP; Giudice, LC; Gosman, GG; Legro, RS; Leppert, PC; McGovern, PG; Myers, ER; Nestler, JE; Schlaff, WD; Steinkampf, MP, 2007) |
| "In overweight women with PCOS, metformin and low- and high-dose OCP preparations have similar efficacy but differential effects on insulin resistance and arterial function." | 5.12 | Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome. ( McGrath, BP; Meyer, C; Teede, HJ, 2007) |
| "Forty pregnant women with polycystic ovary syndrome (PCOS) were enrolled in a randomized, double-blind, placebo-controlled trial of metformin (1700 mg/day) during pregnancy." | 5.12 | Metformin treatment in pregnant women with polycystic ovary syndrome--is reduced complication rate mediated by changes in the uteroplacental circulation? ( Carlsen, SM; Salvesen, KA; Vanky, E, 2007) |
| "To compare the effect of N-acetyl cysteine and metformin on hormonal profile (insulin and T) and ovulation rate in women with clomiphene citrate-resistant polycystic ovary syndrome." | 5.12 | N-acetyl cysteine vs. metformin in treatment of clomiphene citrate-resistant polycystic ovary syndrome: a prospective randomized controlled study. ( Elnashar, A; Fahmy, M; Ibrahim, K; Mansour, A, 2007) |
| "One hundred and two women with insulin-resistant polycystic ovary syndrome were randomized to treatment with a vitamin B preparation, metformin, or both, in conjunction with standard infertility treatment." | 5.12 | Prospective, randomized trial of metformin and vitamins for the reduction of plasma homocysteine in insulin-resistant polycystic ovary syndrome. ( Friedler, S; Raziel, A; Ron-El, R; Rotem, C; Schachter, M; Strassburger, D, 2007) |
| "Serum homocysteine levels were unaffected by metformin treatment both in nonpregnant and pregnant women with polycystic ovary syndrome." | 5.12 | Homocysteine levels are unaffected by metformin treatment in both nonpregnant and pregnant women with polycystic ovary syndrome. ( Carlsen, SM; Kjøtrød, S; Romundstad, P; Vanky, E, 2007) |
| "Randomized open-label study of metformin and rosiglitazone in 16 women with polycystic ovary syndrome (PCOS) performed at a single academic health center." | 5.12 | The effects of metformin and rosiglitazone, alone and in combination, on the ovary and endometrium in polycystic ovary syndrome. ( Demers, LM; Dodson, WC; Gnatuk, CL; Kunselman, AR; Legro, RS; Williams, NI; Zaino, RJ, 2007) |
| "The objective of the study was to evaluate the effects of metformin suspension on insulin sensitivity in PCOS patients." | 5.12 | Insulin sensitivity after metformin suspension in normal-weight women with polycystic ovary syndrome. ( De Feo, P; Falbo, A; Manguso, F; Orio, F; Palomba, S; Russo, T; Tolino, A; Zullo, F, 2007) |
| "Despite the fact that treatment with Diane(35) Diario restored regular menstrual cycles in all the patients, whereas metformin only did so in 50% of them, serum ferritin levels decreased at 12 and 24 weeks of treatment only with metformin, in association with a marked increase in insulin sensitivity." | 5.12 | Increased body iron stores of obese women with polycystic ovary syndrome are a consequence of insulin resistance and hyperinsulinism and are not a result of reduced menstrual losses. ( Alvarez-Blasco, F; Botella-Carretero, JI; Escobar-Morreale, HF; Luque-Ramírez, M; San Millán, JL; Sanchón, R, 2007) |
| "65 kg/m(2)) hirsute women with polycystic ovary syndrome and normal insulin sensitivity were treated with 850 mg metformin orally, three times daily, for 4 months." | 5.12 | Metformin in normal-weight hirsute women with polycystic ovary syndrome with normal insulin sensitivity. ( Baracat, EC; Halpern, A; Maciel, GA; Marcondes, JA; Yamashita, SA, 2007) |
| "The aim of the study was to compare in a clinical setting the efficacy of CC and metformin as first-line approaches for treating anovulation in infertile PCOS patients." | 5.12 | Clomiphene citrate versus metformin as first-line approach for the treatment of anovulation in infertile patients with polycystic ovary syndrome. ( Falbo, A; Orio, F; Palomba, S; Russo, T; Tolino, A; Zullo, F, 2007) |
| "To compare the efficacy of weight loss, metformin and rosiglitazone in women with polycystic ovary syndrome (PCOS)." | 5.12 | [Effect of lifestyle adjustment, metformin and rosiglitazone in polycystic ovary syndrome]. ( Jin, LN; Ma, LK; Xu, L; Yu, Q, 2007) |
| "Our aim was to assess the effects of metformin on menstrual frequency, fasting plasma glucose (FPG), insulin resistance assessed as HOMA-index, weight, waist/hip ratio, blood pressure (BP), serum lipids, and testosterone levels in women with polycystic ovary syndrome (PCOS) METHODS: In a randomized, controlled, double-blinded setup, 56 women aged 18-45 with PCOS were treated with either metformin 850 mg or placebo twice daily for 6 months." | 5.12 | Efficacy of metformin in obese and non-obese women with polycystic ovary syndrome: a randomized, double-blinded, placebo-controlled cross-over trial. ( Flyvbjerg, A; Kesmodel, U; Lauszus, FF; Trolle, B, 2007) |
| "To verify the medical effects of metformin in polycystic ovary syndrome patients." | 5.12 | [Clinical effects of metformin in patients with polcystic ovarian syndrome]. ( Ayala, AR; Galindo, CG; Hernández, I, 2007) |
| "To compare the clinical results and reproductive outcome in obese women with polycystic ovary syndrome (PCOS) following dietary intervention or treatment with metformin." | 5.12 | Dietary intervention versus metformin to improve the reproductive outcome in women with polycystic ovary syndrome. A prospective comparative study. ( Al-Qudah, MA; El-Uri, FI; Qublan, HS; Yannakoula, EK, 2007) |
| "Metformin therapy has led to a higher pregnancy outcome, as well as to a decrease in hyperstimulation risk, cycle cancellations, and multiple pregnancy rates with a lower gonadotropin dosage." | 5.11 | The effect of metformin treatment to ovarian response in cases with PCOS. ( Basaran, T; Ficicioglu, C; Gurbuz, B; Tasdemir, S; Yalti, S; Yildirim, G, 2004) |
| "To determine the clinical, hormonal, and biochemical effects of metformin therapy in obese and nonobese patients with polycystic ovary syndrome (PCOS)." | 5.11 | Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin. ( Abi Haidar, M; Alves da Motta, EL; Baracat, EC; de Lima, GR; Maciel, GA; Soares Júnior, JM, 2004) |
| "Women with polycystic ovary syndrome treated with metformin and lifestyle advice were studied." | 5.11 | Dexamethasone reduces androgen levels in metformin-treated patients with polycystic ovary syndrome. ( Bjerve, KS; Carlsen, SM; Kjøtrød, SB; Maesel, A; Vanky, E, 2004) |
| "In a prospective observational study of 42 pregnancies in 39 Caucasian women (age 30 +/- 4 years) with polycystic ovary syndrome (PCOS), we examined effects of metformin on maternal insulin, insulin resistance (IR), insulin secretion (IS), weight gain, development of gestational diabetes (GD), testosterone and plasminogen activator inhibitor activity." | 5.11 | Metformin during pregnancy reduces insulin, insulin resistance, insulin secretion, weight, testosterone and development of gestational diabetes: prospective longitudinal assessment of women with polycystic ovary syndrome from preconception throughout preg ( Glueck, CJ; Goldenberg, N; Loftspring, M; Sherman, A; Wang, P, 2004) |
| "The purpose of this study was to investigate the effect of low-dose dexamethasone on androgen levels in women with polycystic ovary syndrome (PCOS) treated with diet and lifestyle counselling, and metformin." | 5.11 | Six-month treatment with low-dose dexamethasone further reduces androgen levels in PCOS women treated with diet and lifestyle advice, and metformin. ( Carlsen, SM; Salvesen, KA; Vanky, E, 2004) |
| "To evaluate the effects of metformin on insulin resistance, ovarian androgen production, and clomiphene-induced ovulation and pregnancy rates in infertile women with polycystic ovary syndrome (PCOS)." | 5.11 | The effects of metformin on insulin resistance, clomiphene-induced ovulation and pregnancy rates in women with polycystic ovary syndrome. ( Aygen, E; Keleştimur, F; Sahin, Y; Yirmibeş, U, 2004) |
| "We prospectively assessed growth and motor-social development during the first 18 months of life in 126 live births (122 pregnancies) to 109 women with polycystic ovary syndrome (PCOS) who conceived on and continued metformin (1." | 5.11 | Height, weight, and motor-social development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on and continued metformin through pregnancy. ( Glueck, CJ; Goldenberg, N; Loftspring, M; Pranikoff, J; Sieve, L; Wang, P, 2004) |
| "Our aim was to investigate the effect of pre-treatment with metformin in women with polycystic ovary syndrome (PCOS) scheduled for IVF stimulation." | 5.11 | Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study. ( Carlsen, SM; Kjøtrød, SB; von Düring, V, 2004) |
| "103 PCOS women (age 18-40) were treated, according to their body weight, with either 1000 mg or 1700 mg metformin per day after assessment of insulin resistance." | 5.11 | [Metformin, an efficacious drug in the treatment of polycystic ovary syndrome]. ( Elsenbruch, S; Finke, R; Gärtner, R; Hahn, S; Janssen, OE; Mann, K; Quadbeck, B, 2004) |
| "Investigation of a possible effect of metformin on androgen levels in pregnant women with polycystic ovary syndrome (PCOS)." | 5.11 | Metformin reduces pregnancy complications without affecting androgen levels in pregnant polycystic ovary syndrome women: results of a randomized study. ( Carlsen, SM; Fougner, KJ; Heimstad, R; Romundstad, P; Salvesen, KA; Vanky, E, 2004) |
| "We compared the efficacy of spironolactone (50 mg/d) with metformin (1000 mg/d) after random allocation in 82 adolescent and young women with polycystic ovary syndrome (PCOS) on body mass index (BMI), waist-to-hip ratio, blood pressure, menstrual cyclicity, hirsutism, hormonal levels, glycemia, and insulin sensitivity at baseline and at the 3rd and 6th months of treatment." | 5.11 | Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open-labeled study. ( Ammini, AC; Dwivedi, SN; Eunice, M; Ganie, MA; Gulati, M; Gupta, N; Khurana, ML, 2004) |
| "To assess the effects of 6 months of metformin therapy on clinical and biochemical parameters in polycystic ovary syndrome (PCOS) and to evaluate those parameters in responders and nonresponders to identify the subjects who respond to an insulin sensitizer in PCOS." | 5.11 | Effects of metformin on clinical and biochemical parameters in polycystic ovary syndrome. ( Agarwal, N; Kriplani, A, 2004) |
| "Low-dose flutamide-metformin has been developed as a background therapy for non-obese adolescents and young women with hyperinsulinaemic hyperandrogenism, a variant of polycystic ovary syndrome (PCOS)." | 5.11 | Flutamide-metformin plus an oral contraceptive (OC) for young women with polycystic ovary syndrome: switch from third- to fourth-generation OC reduces body adiposity. ( De Zegher, F; Ibáñez, L, 2004) |
| " Modest weight reduction was found in all treatment groups, with the most significant reduction occurring with the combination of metformin and lifestyle intervention." | 5.11 | A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. ( Craig, K; Guzick, DS; Hoeger, KM; Kochman, L; Miller, RK; Wixom, N, 2004) |
| "A low-dose combination of flutamide-metformin and ethinylestradiol-drospirenone was recently found to reduce the excess of total and abdominal fat, to diminish the deficit in lean mass, and to attenuate the dysadipocytokinemia of young women with ovarian hyperandrogenism, a variant of polycystic ovary syndrome." | 5.11 | Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of early, low-dose flutamide. ( Cabré, S; De Zegher, F; Ibáñez, L; Valls, C, 2004) |
| "At present, it is unclear what the role is of laparoscopic ovarian diathermy (LOD) and of metformin administration as second-line treatments for ovulation induction in women with polycystic ovary syndrome (PCOS) after failure of clomiphene citrate (CC) treatment." | 5.11 | Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate-resistant women with polycystic ovary syndrome: a prospective parallel randomized double-blind placebo-controlled trial. ( Colao, A; Corea, D; Doldo, P; Falbo, A; Lombardi, G; Nardo, LG; Orio, F; Palomba, S; Russo, T; Tolino, A; Zullo, F, 2004) |
| "Flutamide (Flu)-metformin (Met) with ethinylestradiol-drospirenone is a combination therapy that reduces the total and abdominal fat excess, diminishes the lean mass deficit, and attenuates the dysadipocytokinemia of young and nonobese women with ovarian hyperandrogenism, a variant of polycystic ovary syndrome." | 5.11 | Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of metformin at the start and after more than one year of therapy. ( de Zegher, F; Ibáñez, L, 2005) |
| "To investigate the effects of metformin and clomiphene on infertility caused by polycystic ovary syndrome (PCOS) with insulin-resistance (IR) and to observe the effects of metformin on PCOS with pseudoacanthosis nigricans (AN) and IR." | 5.11 | [Clinical study on treating insulin resistance and promoting ovulation in polycystic ovary syndrome]. ( Cai, Q; Chen, H; Chen, LX; Cui, QH; Ge, J; Liu, ZA; Xue, YM; Yuan, T; Zhang, J, 2004) |
| "The aim of this study was to evaluate the effects of metformin and acarbose on insulin resistance, hormone profiles and ovulation rates in patients with clomiphene citrate-resistant polycystic ovary syndrome (PCOS)." | 5.11 | Comparison of the effects of acarbose and metformin use on ovulation rates in clomiphene citrate-resistant polycystic ovary syndrome. ( Akgün, A; Koç, S; Ozcan, J; Savan, K; Sönmez, AS; Sut, N; Toklar, A; Yasar, L; Yazicioğu, F, 2005) |
| "Aim of this study was to compare the effects of metformin and a body weight reduction regimen using sibutramine on insulinemia, insulin sensitivity, and ovarian function in women with anovulatory cycles or infertility." | 5.11 | Metformin versus sibutramine in the treatment of hyperinsulinemia in chronically anovulating women. ( Dravecka, I; Kraus, V; Lazurova, I; Petrovicova, J, 2004) |
| " metformin on the hormonal and biochemical features of patients with polycystic ovarian syndrome (PCOS)." | 5.11 | Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome. ( Atkin, SL; Holding, S; Jayagopal, V; Jennings, PE; Kilpatrick, ES, 2005) |
| "This study was undertaken to evaluate the efficacy of metformin in women with anovulation who do not have evidence for hyperandrogenism and classic polycystic ovary syndrome." | 5.11 | Does metformin induce ovulation in normoandrogenic anovulatory women? ( Carmina, E; Lobo, RA, 2004) |
| "To determine the clinical, biochemical, hormonal, and ultrasonographic effects of 6 months of metformin therapy in women with polycystic ovary syndrome (PCOS) and compare with pretherapy parameters." | 5.11 | Metformin therapy in women with polycystic ovary syndrome. ( Aruna, J; Dadhwal, V; Kumar, S; Misra, R; Mittal, S; Vimala, N, 2004) |
| "Adding metformin slightly modified the treatment effect of COC, causing a more significant decrease in the free androgen index but having no additional positive impact on lipids, insulin sensitivity, SHBG or testosterone." | 5.11 | The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients. ( Cibula, D; Dvorakova, K; Fanta, M; Hill, M; Skrenkova, J; Skrha, J; Stanicka, S; Vrbikova, J; Zivny, J, 2005) |
| " The purpose of this study was to evaluate whether pioglitazone decreases insulin resistance (IR) and hyperandrogenism to the same extent as metformin in obese women with PCOS who have not received any previous treatment." | 5.11 | Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. ( Aguayo, P; Arteaga-Troncoso, G; Crespo, G; Hernández, L; Luna, S; Ortega-González, C; Parra, A, 2005) |
| " Although long-term treatment with metformin can increase Hcy levels in patients with type II diabetes mellitus or coronary heart disease, it is becoming an increasingly accepted and widespread medication in polycystic ovary syndrome (PCOS)." | 5.11 | Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: a randomized study. ( Aslan, E; Bagis, T; Erkanli, S; Haydardedeoglu, B; Kilicdag, EB; Tarim, E; Zeyneloglu, HB, 2005) |
| "To investigate whether the long-term administration of metformin or pioglitazone to women with polycystic ovary syndrome (PCOS) could induce changes in their hypothalamic dopaminergic (DA) tone and to analyze whether these changes correlated with modifications in insulin resistance, we originally studied 57 obese hyperinsulinemic, non-diabetic, insulin resistant women with PCOS, but only 34 completed the study." | 5.11 | Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome. ( Arteaga-Troncoso, G; Cardoza, L; Coutiño, B; Hidalgo, R; Ortega-González, C; Parra, A, 2005) |
| "Assessment of ovarian responses to metformin treatment in obese women with polycystic ovary syndrome (PCOS)." | 5.11 | Metformin reduces serum mullerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment. ( Fleming, R; Harborne, L; Ling, D; MacLaughlin, DT; Norman, J; Sattar, N; Seifer, DB, 2005) |
| "Much better and faster decrease in the level of testosterone and free androgen index in group with combined use of metformin and Diane35 was established, without deterioration of the anthropometric and biochemical indices and insulin sensitivity." | 5.11 | Combined use of metformin and ethinyl estradiol-cyproterone acetate in polycystic ovary syndrome. ( Mitkov, M; Pehlivanov, B; Terzieva, D, 2005) |
| "We aimed to investigate whether metformin would reverse the endocrinopathy of polycystic ovary syndrome (PCOS), allowing resumption of cyclic ovulation and regular menses, and whether metformin causes any change in the serum concentration of insulin-like growth factor-I (IGF-I) in patients with PCOS." | 5.11 | Increased insulin-like growth factor-I levels in women with polycystic ovary syndrome, and beneficial effects of metformin therapy. ( Berker, B; Corapcioglu, D; Demirel, C; Emral, R; Kose, K; Unlu, C, 2004) |
| "The aim of the current study was to assess the effects of B-group vitamins and folic acid administration on serum levels of homocysteine (Hcy) in patients with polycystic ovarian syndrome (PCOS) on short-term metformin treatment." | 5.11 | Administration of B-group vitamins reduces circulating homocysteine in polycystic ovarian syndrome patients treated with metformin: a randomized trial. ( Aslan, E; Bagis, T; Erkanli, S; Haydardedeoglu, B; Kilicdag, EB; Kuscu, E; Simsek, E; Tarim, E, 2005) |
| "Although metformin has been shown to be effective in the treatment of anovulation in women with polycystic ovary syndrome (PCOS), clomiphene citrate (CC) is still considered to be the first-line drug to induce ovulation in these patients." | 5.11 | Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome. ( Carmina, E; Cascella, T; Colao, A; Falbo, A; Manguso, F; Orio, F; Palomba, S; Russo, T; Tolino, A; Zullo, F, 2005) |
| "The aim of this study was to investigate the endothelial status in young women with polycystic ovary syndrome (PCOS), using a simple and easily reproducible hemodynamic method combined with a biological marker and to evaluate the effect of metformin treatment on these parameters." | 5.11 | Metformin administration improves endothelial function in women with polycystic ovary syndrome. ( Aessopos, A; Alexandraki, K; Diamanti-Kandarakis, E; Lekakis, J; Mavrikakis, M; Papamichael, C; Piperi, C; Protogerou, A, 2005) |
| "Weight loss is a feature of protracted metformin therapy in obese women with PCOS, with greater weight reduction potentially achievable with higher doses." | 5.11 | Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses. ( Fleming, R; Harborne, LR; Norman, JE; Sattar, N, 2005) |
| " Clomiphene citrate has been standard therapy for ovulation induction in patients seeking pregnancy, but recent evidence suggests that insulin sensitizing agents such as metformin may also be effective." | 5.11 | Estimating live birth rates after ovulation induction in polycystic ovary syndrome: sample size calculations for the pregnancy in polycystic ovary syndrome trial. ( Hafley, G; Kunselman, AR; Legro, RS; Myers, ER; Nestler, JE; Silva, SG, 2005) |
| "To evaluate the effect of ultra-short (12 days) metformin pretreatment in clomiphene-citrate (CC) resistant polycystic ovary syndrome (PCOS)." | 5.11 | Ultra-short metformin pretreatment for clomiphene citrate-resistant polycystic ovary syndrome. ( Huang, WY; Hwu, YM; Lee, RK; Lin, MH; Lin, SY, 2005) |
| "In order to explore the effects of metformin combined with cyproterone acetate (CPA) on the clinical features, endocrine and metabolism of the patients with polycystic ovarian syndrome (PCOS), 50 cases of non-obese PCOS were randomly subjected to CPA (CPA treatment group, n = 25) and CPA+ metformin (n = 25) treatment for 6 months." | 5.11 | Effects of metformin combined with cyproterone acetate on clinical features, endocrine and metabolism of non-obese women with polycystic ovarian syndrome. ( Liu, Y; Lv, L; Sun, Y; Tan, K, 2005) |
| " The aim of this study was to assess the effects of rosiglitazone and metformin on cardiovascular disease risk factors such as insulin resistance, oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome (PCOS)." | 5.11 | The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome. ( Arslan, M; Ayvaz, G; Bukan, N; Cakir, N; Karakoç, A; Törüner, F; Yilmaz, M, 2005) |
| "In the present study, we investigated the impact of metformin therapy on in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) outcomes in patients with polycystic ovary syndrome (PCOS)." | 5.11 | Metformin treatment in patients with polycystic ovary syndrome undergoing in vitro fertilization: a prospective randomized trial. ( Bagis, T; Ceyhan, T; Cincik, M; Goktolga, U; Onalan, G; Pabuçcu, R, 2005) |
| "Adolescents with PCOS treated with metformin or OCP experienced similar beneficial outcomes including reduction in androgen levels, weight loss, and increased insulin sensitivity." | 5.11 | Randomized controlled trial evaluating response to metformin versus standard therapy in the treatment of adolescents with polycystic ovary syndrome. ( Allen, HF; Heptulla, RA; Koenigs, L; Mazzoni, C; Miller, N; Murray, MA; Reiter, EO, 2005) |
| "To determine the effect of metformin therapy in achieving menstrual regularity, pregnancy, reducing obesity and hyperinsulinemia in patients with polycystic ovarian syndrome (PCOS)." | 5.11 | Impact of metformin therapy in patients with polycystic ovarian syndrome. ( Hasan, JA; Memon, GU, 2005) |
| "The aim of the present study was to assess the effects of metformin and rosiglitazone on menstrual cyclicity and hirsutism in patients with polycystic ovary syndrome (PCOS)." | 5.11 | The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome. ( Arslan, M; Ayvaz, G; Cakir, N; Karakoç, A; Tiras, B; Törüner, FB; Yilmaz, M, 2005) |
| "To compare the efficacy of clomiphene citrate (CC) administration for ovulation induction in CC-resistant oligo-ovulatory women with polycystic ovary syndrome (PCOS) after metformin treatment or laparoscopic ovarian drilling (LOD)." | 5.11 | Metformin administration and laparoscopic ovarian drilling improve ovarian response to clomiphene citrate (CC) in oligo-anovulatory CC-resistant women with polycystic ovary syndrome. ( Caterina, G; Colao, A; Falbo, A; Manguso, F; Orio, F; Palomba, S; Russo, T; Tolino, A; Zullo, F, 2005) |
| " There was a significant improvement in hirsutism at the end of the metformin phase compared with placebo: F-G score 15." | 5.10 | The effect of metformin on hirsutism in polycystic ovary syndrome. ( Gordon, D; Kelly, CJ, 2002) |
| "Most patients with polycystic ovary syndrome (PCOS) have hyperinsulinemia; thus it has been postulated that insulin-lowering drugs, such as metformin, might be a useful long-term choice." | 5.10 | Clinical and endocrinological effects of 6 months of metformin treatment in young hyperinsulinemic patients affected by polycystic ovary syndrome. ( De Pergola, G; Lorusso, F; Loverro, G; Mei, L; Nicolardi, V; Selvaggi, L, 2002) |
| "Metformin, an insulin-sensitizing drug, has been shown to improve ovarian function and glucose metabolism in obese women with polycystic ovary syndrome (PCOS), but its effects and possible benefits in nonobese PCOS subjects are not well known." | 5.10 | Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. ( Koivunen, R; Martikainen, H; Morin-Papunen, L; Ruokonen, A; Tapanainen, JS; Vauhkonen, I, 2003) |
| "The endocrine-metabolic status of non-obese, young women with polycystic ovary syndrome (PCOS) is normalized more effectively by combined treatment with flutamide and metformin than by either of these drugs in monotherapy." | 5.10 | Low-dose combination of flutamide, metformin and an oral contraceptive for non-obese, young women with polycystic ovary syndrome. ( de Zegher, F; Ibáñez, L, 2003) |
| "There is still some controversy concerning the effects of metformin in the treatment of Polycystic Ovary Syndrome (PCOS)." | 5.10 | Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double-blind and placebo-controlled trial. ( Capp, E; Chou, KH; Spritzer, PM; von Eye Corleta, H, 2003) |
| "In this study, our aim was to compare the effects of metformin and gonadotropin releasing hormone (GnRH) analogues in clinical and hormonal parameters in women with polycystic ovary syndrome (PCOS)." | 5.10 | The comparison of clinical and hormonal parameters in PCOS patients treated with metformin and GnRH analogue. ( Akyürek, C; Bala, A; Celik, C; Ciçek, MN, 2003) |
| "This study was conducted to evaluate the efficacy of metformin compared with ovarian drilling in the treatment of clomiphene citrate (CC) resistant women with polycystic ovary syndrome." | 5.10 | Medical vs. surgical treatment for clomiphene citrate-resistant women with polycystic ovary syndrome. ( Hamaideh, AH; Malkawi, HY; Qublan, HS, 2003) |
| "Metformin effectively restores insulin sensitivity in insulin-resistant women with polycystic ovary syndrome (PCOS)." | 5.10 | The effect of metformin on ovarian stimulation and in vitro fertilization in insulin-resistant women with polycystic ovary syndrome: an open-label randomized cross-over trial. ( Abyholm, T; Dale, PO; Fedorcsák, P; Storeng, R; Tanbo, T, 2003) |
| " Further we tried to identify the preventive influence of metformin on development of ovarian hyperstimulation syndrome." | 5.10 | [Importance of sensitization of insulin receptors in the prevention of ovarian hyperstimulation syndrome]. ( Crha, I; Ventruba, P; Visnová, H; Záková, J, 2003) |
| "To study the endocrinologic and metabolic effects of metformin in combination with compound cyproterone acetate (CPA) on patients with polycystic ovarian syndrome (PCOS)." | 5.10 | [Endocrine and metabolic effects of metformin in combination with compound cyproterone acetate in women with polycystic ovarian syndrome]. ( Lin, JJ; Lin, WQ; Yang, HY; Ye, BL; Zhao, JZ, 2003) |
| "To evaluate the effect of metformin therapy on hyperandrogenism, insulin resistance, cervical scores, ovulation, and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome (PCOS)." | 5.10 | Metformin therapy improves ovulatory rates, cervical scores, and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome. ( Caliskan, E; Haberal, A; Kocak, M; Simsir, C, 2002) |
| "This study aims to evaluate the impact of metformin on ovarian response when co-administered during recombinant (r)FSH using the low-dose step-up protocol in clomiphene citrate-resistant polycystic ovarian syndrome (PCOS) patients with normal glucose tolerance." | 5.10 | Co-administration of metformin during rFSH treatment in patients with clomiphene citrate-resistant polycystic ovarian syndrome: a prospective randomized trial. ( Bükülmez, O; Demirol, A; Koray, Z; Yarali, H; Yiğit, N; Yildiz, BO; Zeyneloğlu, HB, 2002) |
| "To determine whether metformin pretreatment has beneficial effects in clomiphene resistant infertile women with polycystic ovary syndrome (PCOS) in an infertility clinic." | 5.10 | Metformin does not enhance ovulation induction in clomiphene resistant polycystic ovary syndrome in clinical practice. ( Fay, TN; Lannon, B; Sturrock, ND, 2002) |
| "To study the effect of metformin in combination with clomiphene citrate, as compared with placebo plus clomiphene citrate, on the ovulation and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome." | 5.10 | The effect of metformin plus clomiphene citrate on ovulation and pregnancy rates in clomiphene-resistant women with polycystic ovary syndrome. ( Malkawi, HY; Qublan, HS, 2002) |
| " After treatment, women in the OC + metformin group had significant decreases in BMI and WHR, and a significant increase in insulin sensitivity, in contrast to those in the OC group, who had insignificant changes in these parameters." | 5.10 | Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. ( Durmusoglu, F; Elter, K; Imir, G, 2002) |
| "In 43 amenorrheic women with polycystic ovary syndrome (PCOS), 31 (74%) with fasting hyperinsulinemia (> or =20 microU/mL), our aim was to determine whether Metformin (Bristol-Myers Squibb, Princeton, NJ), which reduces hyperinsulinemia, would reverse the endocrinopathy of PCOS, allowing resumption of regular normal menses." | 5.09 | Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome. ( Fontaine, R; Glueck, CJ; Sieve-Smith, L; Tracy, T; Wang, P, 1999) |
| "To evaluate whether pretreatment with metformin improves FSH-induced ovulation in women with clomiphene-resistant polycystic ovary syndrome (PCOS)." | 5.09 | Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome. ( Cianci, A; De Leo, V; Ditto, A; la Marca, A; Morgante, G, 1999) |
| "To determine whether the administration of metformin, an insulin-sensitizing agent, is followed by changes in adrenal steroidogenesis in women with polycystic ovary syndrome (PCOS)." | 5.09 | Effects of metformin on adrenal steroidogenesis in women with polycystic ovary syndrome. ( Cianci, A; Ciotta, L; De Leo, V; la Marca, A; Morgante, G; Paglia, T, 1999) |
| "To evaluate the effects of 12 weeks of metformin therapy on hormonal and clinical indices in polycystic ovary syndrome (PCOS)." | 5.09 | Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. ( Duleba, AJ; Kolodziejczyk, B; Pawelczyk, L; Spaczynski, RZ, 2000) |
| "Metformin, a biguanide antihyperglycemic drug, has been shown to improve ovarian function and glucose metabolism in women with polycystic ovary syndrome (PCOS), but results concerning its effects on insulin sensitivity are controversial." | 5.09 | Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. ( Koivunen, RM; Martikainen, HK; Morin-Papunen, LC; Ruokonen, A; Tapanainen, JS; Vauhkonen, I, 2000) |
| "To determine whether metformin would safely reduce the rate of first-trimester spontaneous abortion without teratogenicity in 19 women with the polycystic ovary syndrome (PCOS)." | 5.09 | Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. ( Cameron, D; Glueck, CJ; Phillips, H; Sieve-Smith, L; Wang, P, 2001) |
| "To determine whether metformin treatment increases the ovulation and pregnancy rates in response to clomiphene citrate (CC) in women who are resistant to CC alone." | 5.09 | Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. ( Evans, WS; Kauma, SW; Nestler, JE; Ratts, VS; Stovall, DW; Vandermolen, DT, 2001) |
| "To determine the clinical, hormonal and biochemical effect of 4-5 months of insulin-sensitizing therapy (hypocaloric diet+metformin) in obese patients with polycystic ovary syndrome (PCOS)." | 5.09 | Insulin, leptin, IGF-I and insulin-dependent protein concentrations after insulin-sensitizing therapy in obese women with polycystic ovary syndrome. ( Kinalska, I; Kinalski, M; Kowalska, I; Straczkowski, M; Wolczyski, S, 2001) |
| "Metformin, an insulin-sensitizing agent, has been used successfully as the first-line drug to induce ovulation in women with polycystic ovary syndrome." | 5.09 | Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene-resistant polycystic ovaries: a randomized, double-blinded placebo-controlled trial. ( Ho, PC; Ng, EH; Wat, NM, 2001) |
| "To describe our clinical experience in using Metformin combined with a high protein-low carbohydrate diet to restore normal menstrual cycles in teenaged females with polycystic ovary syndrome (PCOS)." | 5.09 | Metformin to restore normal menses in oligo-amenorrheic teenage girls with polycystic ovary syndrome (PCOS). ( Fontaine, R; Glueck, CJ; Sieve-Smith, L; Tracy, T; Wang, P, 2001) |
| "We measured fasting serum steroid concentrations and the response of serum 17 alpha-hydroxyprogesterone to leuprolide, a gonadotrophin-releasing hormone agonist, and performed oral glucose-tolerance tests before and after oral administration of either metformin (500 mg three times daily) or placebo for four to eight weeks in 24 obese women with the polycystic ovary syndrome." | 5.08 | Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. ( Jakubowicz, DJ; Nestler, JE, 1996) |
| "To determine the clinical, hormonal, and biochemical effects of 4-6 months of metformin therapy in obese patients with polycystic ovary syndrome (PCOS)." | 5.08 | Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. ( Koivunen, RM; Martikainen, HK; Morin-Papunen, LC; Ruokonen, A, 1998) |
| "We performed oral glucose-tolerance tests before and after the administration of 500 mg of metformin or placebo three times daily for 35 days in 61 obese women with the polycystic ovary syndrome." | 5.08 | Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. ( Evans, WS; Jakubowicz, DJ; Nestler, JE; Pasquali, R, 1998) |
| "Previous studies have suggested that metformin is clinically useful in the treatment of polycystic ovary syndrome (PCOS)." | 5.08 | Decreased serum leptin concentrations during metformin therapy in obese women with polycystic ovary syndrome. ( Koivunen, RM; Martikainen, HK; Morin-Papunen, LC; Ruokonen, A; Tomás, C, 1998) |
| "To investigate the role of insulin in the polycystic ovary syndrome (PCOS) pathogenesis and application of Metformin in the treatment of PCOS." | 5.08 | [Role of hyperinsulinemia in pathogenesis of polycystic ovary syndrome and treatment by reduction of insulin secretion]. ( Li, M; Lu, C; Wang, A, 1998) |
| "Our aim is to evaluate the clinical effectiveness and safety by comparing N-acetyl-cysteine (NAC) with metformin administrated by polycystic ovary syndrome (PCOS) patients." | 5.05 | Comparison of the efficacy between NAC and metformin in treating PCOS patients: a meta-analysis. ( Huang, H; Song, Y; Wang, H; Zhu, Z, 2020) |
| " Metformin is taken by many patients before pregnancy due to both previously diagnosed type 2 diabetes and in the treatment of prediabetes, obesity and polycystic ovary syndrome (PCOS) as part of therapy for insulin resistance." | 5.05 | Metformin therapy in pregnancy [Zastosowanie metforminy w ciąży]. ( Cichocka, E; Gumprecht, J; Kędzierski, L; Krupej-Kędzierska, J; Okopień, B, 2020) |
| "For overweight women with PCOS, both metformin combined with GLP-1 receptor agonists and metformin combined with TZDs appear superior to monotherapy in improving hyperandrogenemia." | 5.05 | Insulin Sensitizers for Improving the Endocrine and Metabolic Profile in Overweight Women With PCOS. ( He, B; Li, C; Xing, C, 2020) |
| " Liraglutide is a glucagon-like peptide-1 receptor agonist that promotes sustained weight loss, as well as abdominal fat reduction, in individuals with obesity, prediabetes, and type 2 diabetes mellitus." | 5.05 | Liraglutide: New Perspectives for the Treatment of Polycystic Ovary Syndrome. ( Constantinidou, KG; Filippou, PK; Papaetis, GS; Stylianou, CS, 2020) |
| "Metformin is widely used among women with polycystic ovary syndrome (PCOS)." | 5.05 | Association of Metformin With Pregnancy Outcomes in Women With Polycystic Ovarian Syndrome Undergoing In Vitro Fertilization: A Systematic Review and Meta-analysis. ( Huang, Y; Liu, Y; Tu, M; Wu, Y; Zhang, D, 2020) |
| "A systematic review and meta-analysis of clinical trials or observational studies of metformin intervention in preventing symptoms of GDM during pregnancy were performed." | 5.05 | The Effect of Metformin Therapy for Preventing Gestational Diabetes Mellitus in Women with Polycystic Ovary Syndrome: A Meta-Analysis. ( Liu, X; Zhang, W; Zhao, J, 2020) |
| "In women with PCOS, letrozole improves live birth and clinical pregnancy rates and reduces time-to-pregnancy compared to CC and therefore can be recommended as the preferred first-line treatment for women with PCOS and infertility." | 5.01 | First-line ovulation induction for polycystic ovary syndrome: an individual participant data meta-analysis. ( Amer, SA; Bhattacharya, S; Bordewijk, EM; Falbo, A; Federica, G; Gao, J; Homburg, R; Huang, W; Johnson, NP; Kar, S; König, TE; Legro, RS; Li, W; Lord, J; Mol, BW; Moll, E; Morin-Papunen, L; Nazik, H; Norman, RJ; Özmen, Ü; Palomba, S; Sahin, Y; van Wely, M; Vegetti, W; Wang, R; Williams, CD; Wu, X; Zhang, H, 2019) |
| "Metformin (MET), the most commonly used insulin sensitizer, is the reference off-label drug for the treatment of polycystic ovary syndrome (PCOS), worldwide." | 5.01 | Short-term effects of metformin and myo-inositol in women with polycystic ovarian syndrome (PCOS): a meta-analysis of randomized clinical trials. ( Facchinetti, F; Grandi, G; Orrù, B; Unfer, V, 2019) |
| "For overweight polycystic ovary syndrome patients, our evidence revealed that EE/CA and EE/SRSP combined with metformin or lifestyle changes can reduce the adverse effects on glucose and lipid metabolism of the use of oral contraceptive agents alone." | 5.01 | The effectiveness of metformin, oral contraceptives, and lifestyle modification in improving the metabolism of overweight women with polycystic ovary syndrome: a network meta-analysis. ( Li, Q; Liu, M; Mo, T; Shen, C; Wang, A, 2019) |
| "Oral antidiabetic medication of metformin is increasingly used in pregnant women with gestational diabetes mellitus (GDM), polycystic ovary syndrome (PCOS) and obesity." | 5.01 | Long-term effects of prenatal exposure to metformin on the health of children based on follow-up studies of randomized controlled trials: a systematic review and meta-analysis. ( Xie, Q; Xu, Q, 2019) |
| "This meta-analysis aimed to evaluate the efficacy and safety of glucagon-like peptide 1 (GLP-1) receptor agonists for women with polycystic ovary syndrome (PCOS) by comparing their effect with that of metformin." | 5.01 | GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis. ( Han, Y; He, B; Li, Y, 2019) |
| "There is reliable evidence regarding the use of metformin for anthropometric outcomes and COCPs for hyperandrogenism in women with PCOS but not for other interventions." | 4.98 | Pharmacological and surgical treatment of nonreproductive outcomes in polycystic ovary syndrome: An overview of systematic reviews. ( Gadalla, MA; Hiam, DS; Joham, AE; Moran, LJ; Pundir, J; Tay, CT; Teede, HJ; Thangaratinam, S, 2018) |
| "Metformin use in pregnancy is increasing worldwide as randomised controlled trial (RCT) evidence is emerging demonstrating its safety and efficacy." | 4.98 | Metformin in Pregnancy: Mechanisms and Clinical Applications. ( Balani, J; Hyer, S; Shehata, H, 2018) |
| "The impact of the recommended first-line treatment with metformin on C-reactive protein (CRP) levels in patients with polycystic ovary syndrome (PCOS) is still controversial." | 4.95 | Impact of metformin on C-reactive protein levels in women with polycystic ovary syndrome: a meta-analysis. ( Chen, L; Chen, Y; Deng, H; Li, M; Li, N; Wang, Q; Wang, S; Xu, D, 2017) |
| " The vast majority of published data on insulin sensitizing PCOS treatments are reported in adult women; these have included weight loss, metformin, thiazolidinediones, and the inositols." | 4.95 | Insulin sensitizers in adolescents with polycystic ovary syndrome. ( LE, TN; Nestler, JE; Wickham, EP, 2017) |
| " Metformin is the primary insulin-sensitising drug to be used as an adjuvant therapy to lifestyle modification in patients with insulin resistance and impaired glucose tolerance, as well as in those referred to infertility treatment." | 4.95 | Insulin and the polycystic ovary syndrome. ( Bjekić-Macut, J; Doknić, M; Macut, D; Rahelić, D, 2017) |
| "Metformin alone compared with placebo increases the ovulation rate in women with polycystic ovary syndrome (PCOS) but should not be used as first-line therapy for anovulation because oral ovulation induction agents such as clomiphene citrate or letrozole alone are much more effective in increasing ovulation, pregnancy, and live-birth rates in women with PCOS." | 4.95 | Role of metformin for ovulation induction in infertile patients with polycystic ovary syndrome (PCOS): a guideline. ( , 2017) |
| "Metformin is effective for the treatment of polycystic ovary syndrome (PCOS), but conflicting results regarding its impact on serum levels of C-reactive protein (CRP) and interleukin-6 (IL-6) in women with PCOS have been reported." | 4.95 | Effects of metformin treatment on serum levels of C-reactive protein and interleukin-6 in women with polycystic ovary syndrome: a meta-analysis: A PRISMA-compliant article. ( Hu, K; Liu, J; Tang, Y; Wang, J; Xu, J; Zeng, X; Zhu, L, 2017) |
| " Insulin-sensitising agents such as metformin may be effective in treating PCOS-related anovulation." | 4.95 | Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. ( Balen, AH; Morley, LC; Norman, RJ; Tang, T; Yasmin, E, 2017) |
| "To systematically review the impact of Yasmin (drospirenone pill) compares with other standard treatments for symptoms of Polycystic Ovary Syndrome (PCOS)." | 4.95 | A comparative systematic review of Yasmin (drospirenone pill) versus standard treatment options for symptoms of polycystic ovary syndrome. ( Li, J; Ren, J; Sun, W, 2017) |
| "Metformin has been used as a treatment option for polycystic ovary syndrome (PCOS) since 1994; however, more than a hundred randomized clinical trials have reported controversial results regarding the efficacy of metformin in PCOS." | 4.95 | Effect of metformin on clinical, metabolic and endocrine outcomes in women with polycystic ovary syndrome: a meta-analysis of randomized controlled trials. ( Patel, R; Shah, G, 2017) |
| " Metformin may increase the effectiveness of ovulation induction with gonadotrophins and may promote safety by preventing multiple pregnancy." | 4.95 | Metformin during ovulation induction with gonadotrophins followed by timed intercourse or intrauterine insemination for subfertility associated with polycystic ovary syndrome. ( Bordewijk, EM; Costello, MF; Mol, BW; Nahuis, M; Tso, LO; Van der Veen, F; van Wely, M, 2017) |
| "The potential reproductive benefits of metformin, a drug endowed with the capacity to ameliorate insulin resistance in polycystic ovary syndrome (PCOS), has garnered much interest over the past 2 decades." | 4.93 | Twenty years of ovulation induction with metformin for PCOS; what is the best available evidence? ( Abu Hashim, H, 2016) |
| "For several years there is an evidence for a relationship between the polycystic ovary syndrome (PCOS) and of insulin resistance; therefore metformin, an insulin sensitizer, is used for the treatment for more than 10 years." | 4.93 | [Metformin for the treatment of polycystic ovary syndrome]. ( Bekes, I; Gundelach, T; Hancke, K; Janni, W; Rodewald, M, 2016) |
| ", pioglitazone and metformin) used for the treatment of insulin resistance in PCOS, on androgen production." | 4.93 | Cellular and Animal Studies: Insights into Pathophysiology and Therapy of PCOS. ( Indran, IR; Lee, BH; Yong, EL, 2016) |
| "The aim of this study was to assess the effects of orlistat on weight loss-related clinical variables in overweight/obese women with polycystic ovary syndrome (PCOS) and to compare treatment with orlistat vs." | 4.93 | Effects of orlistat vs. metformin on weight loss-related clinical variables in women with PCOS: systematic review and meta-analysis. ( Graff, SK; Mario, FM; Spritzer, PM; Ziegelmann, P, 2016) |
| "The aim of the study is to evaluate the effects of metformin on pregnancy outcomes in women with polycystic ovary syndrome (PCOS)." | 4.93 | Effects of metformin on pregnancy outcomes in women with polycystic ovary syndrome: A meta-analysis. ( An, RF; Tian, Q; Xue, Y; Zeng, XL; Zhang, YF, 2016) |
| "Our results showed that continued use during of metformin, during pregnancy in women with PCOS, had no effect on incidence of fetal abnormalities or fetal birth weight." | 4.93 | Effect of metformin treatment during pregnancy on women with PCOS: a systematic review and meta-analysis. ( Chang, Y; Fang, C; Li, S; Liu, H; Tan, X; Wang, Y; Zhang, X, 2016) |
| "Metformin has a potential role for insulin resistance in polycystic ovary syndrome(PCOS) and has demonstrated efficacy in diabetes." | 4.91 | Metformin in women with PCOS, cons. ( Misso, ML; Teede, HJ, 2015) |
| "Combined statin and metformin therapy can improve lipid and inflammation parameters, but cannot effectively improve insulin sensitivity and reduce hyperandrogenism in women with PCOS." | 4.91 | An investigation into the therapeutic effects of statins with metformin on polycystic ovary syndrome: a meta-analysis of randomised controlled trials. ( Cai, R; Huang, R; Sun, H; Sun, J; Wang, P; Wang, S; Xia, W; Yuan, Y; Zhou, Y, 2015) |
| "PubMed, SCOPUS and CENTRAL databases were searched until April 2014 with the key words: PCOS, polycystic ovary syndrome, metformin, clomiphene citrate, ovulation induction and pregnancy." | 4.91 | Combined metformin-clomiphene in clomiphene-resistant polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. ( Abu Hashim, H; Foda, O; Ghayaty, E, 2015) |
| "In women with polycystic ovary syndrome, metformin treatment before or during assisted reproductive technology cycles increases clinical pregnancy rates and decreases the risk of ovarian hyperstimulation syndrome." | 4.91 | Metformin treatment before and during in vitro fertilization or intracytoplasmic sperm injection in women with polycystic ovary syndrome: summary of a Cochrane review. ( Albuquerque, LE; Andriolo, RB; Costello, MF; Macedo, CR; Marjoribanks, J; Tso, LO, 2015) |
| "Metformin is used among patients with polycystic ovary syndrome (PCOS), but findings for its effects on outcomes of assisted reproductive technology (ART) have been conflicting." | 4.91 | A systematic review and meta-analysis of metformin among patients with polycystic ovary syndrome undergoing assisted reproductive technology procedures. ( Huang, X; Li, Y; Lv, F; Tal, R; Wang, P; Zhang, X, 2015) |
| "To evaluate the efficacy of metformin administration throughout pregnancy on pregnancy-related complications in women with polycystic ovary syndrome (PCOS)." | 4.91 | Efficacy of metformin on pregnancy complications in women with polycystic ovary syndrome: a meta-analysis. ( Du, YK; Feng, L; Hu, D; Lin, XF; Wan, ZH, 2015) |
| "Metformin is effective for the treatment of polycystic ovary syndrome, but conflicting results regarding its effect on adipocytokine levels (adiponectin, resistin, visfatin, and leptin) in patients with polycystic ovary syndrome receiving metformin treatment have been reported." | 4.91 | Impact of Treatment with Metformin on Adipocytokines in Patients with Polycystic Ovary Syndrome: A Meta-Analysis. ( Chen, L; Kong, W; Lu, M; Niu, X; Zeng, T, 2015) |
| " Metformin is widely used in fertility treatment of women with PCOS, due to a suggested positive effect of continued metformin treatment beyond the first trimester on pregnancy complications." | 4.91 | [Metformin and the obstetric patient]. ( Aaboe, K; Bülow, NS; Galsgaard, J; Lauenborg, J; Mathiesen, ER; Odgaard, HS; Pedersen, KD, 2015) |
| "The current systematic review with meta-analysis of randomized controlled trials (RCTs) was aimed to evaluate the effects of metformin on reproductive outcomes in patients with polycystic ovary syndrome (PCOS) who receive gonadotropins for ovulation induction." | 4.90 | Metformin and gonadotropins for ovulation induction in patients with polycystic ovary syndrome: a systematic review with meta-analysis of randomized controlled trials. ( Falbo, A; La Sala, GB; Palomba, S, 2014) |
| "Metformin, an insulin-sensitizing drug commonly used to treat Type 2 Diabetes Mellitus (T2DM), has been increasingly used off-label for the treatment of polycystic ovary syndrome (PCOS), which affects at least 5-10% of reproductive- age women." | 4.90 | The utility of metformin therapy in reproductive-aged women with polycystic ovary syndrome (PCOS). ( Nathan, N; Sullivan, SD, 2014) |
| " Treatment with metformin has been shown to improve insulin sensitivity, lowering blood glucose and androgen levels." | 4.90 | Polycystic ovary syndrome: reviewing diagnosis and management of metabolic disturbances. ( Spritzer, PM, 2014) |
| "Although a number of in vitro studies have demonstrated the antiproliferative, anti-invasive, and antimetastatic effects of metformin in multiple cancer cell types, its cellular and molecular mechanisms of anti-cancer action in the endometrium of women with polycystic ovary syndrome (PCOS) have not yet been fully elucidated." | 4.90 | Direct effects of metformin in the endometrium: a hypothetical mechanism for the treatment of women with PCOS and endometrial carcinoma. ( Billig, H; Feng, Y; Li, X; Lin, JF; Shao, R, 2014) |
| "PubMed, Medline, Embase, and the Cochrane central registry of controlled trials were searched to identify randomized controlled trials and observational studies exploring the association between metformin and vitamin B12 concentration in patients with type 2 diabetes mellitus or polycystic ovary syndrome." | 4.90 | Vitamin B12 status in metformin treated patients: systematic review. ( Li, J; Li, S; Liu, Q; Quan, H, 2014) |
| "The use of insulin-sensitising agents, such as metformin, in women with polycystic ovary syndrome (PCOS) who are undergoing ovulation induction or in vitro fertilisation (IVF) cycles has been widely studied." | 4.90 | Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. ( Albuquerque, LE; Andriolo, RB; Costello, MF; Macedo, CR; Tso, LO, 2014) |
| "A review of the existing literature on weight loss through lifestyle modification and/or metformin treatment in overweight women with PCOS." | 4.89 | Overweight in polycystic ovary syndrome. An update on evidence based advice on diet, exercise and metformin use for weight loss. ( Glintborg, D; Haugen, AG; Ravn, P, 2013) |
| "The role of metformin in the treatment of pregnant women with polycystic ovary syndrome (PCOS) is controversial." | 4.89 | The efficacy of metformin in pregnant women with polycystic ovary syndrome: a meta-analysis of clinical trials. ( Gu, W; Shan, PF; Zheng, J, 2013) |
| "Metformin is an effective oral anti-hyperglycemic agent that is widely used to manage diabetes mellitus type 2 in the general population and more recently, in pregnancy." | 4.89 | Efficacy and safety of metformin during pregnancy in women with gestational diabetes mellitus or polycystic ovary syndrome: a systematic review. ( Goulis, DG; Lautatzis, ME; Vrontakis, M, 2013) |
| " Indirect evidence from populations without PCOS demonstrated no increased risk of lactic acidosis with metformin, only case reports of liver toxicity with flutamide (no comparative evidence), and increased relative risk difference of venous thromboembolism with oral contraceptive pills but very low absolute risk." | 4.89 | Adverse effects of the common treatments for polycystic ovary syndrome: a systematic review and meta-analysis. ( Domecq, JP; Ehrmann, D; Erwin, PJ; Montori, VM; Mullan, RJ; Murad, MH; Prutsky, G; Sundaresh, V; Wang, AT; Welt, C, 2013) |
| "Metformin is widely used for treating women with polycystic ovary syndrome (PCOS), and many patients with PCOS who are infertile receive gonadotrophins while being treated with metformin." | 4.89 | Effects of metformin in women with polycystic ovary syndrome treated with gonadotrophins for in vitro fertilisation and intracytoplasmic sperm injection cycles: a systematic review and meta-analysis of randomised controlled trials. ( Falbo, A; La Sala, GB; Palomba, S, 2013) |
| "This article is a review of the literature assessing pregnancy outcomes and the effect of metformin treatment among women with polycystic ovary syndrome (PCOS)." | 4.88 | Pregnancy outcomes and the effect of metformin treatment in women with polycystic ovary syndrome: an overview. ( Awwad, JT; Ghazeeri, GS; Nassar, AH; Younes, Z, 2012) |
| "Metformin is a widely used and extensively studied insulin sensitising drug for the treatment of women with polycystic ovary syndrome (PCOS), with various actions in tissues responding to insulin that include the liver, skeletal muscle, adipose tissue, the endothelium of blood vessels, and the ovaries." | 4.88 | Neuroendocrine and endocrine dysfunction in the hyperinsulinemic PCOS patient: the role of metformin. ( Hodges, P; Randeva, HS; Tan, BK; Weickert, MO, 2012) |
| "Evidence indicates that metformin and pioglitazone both improve insulin resistance and hirsutism among patient with polycystic ovarian syndrome (PCOS)." | 4.88 | A systematic review and meta-analysis of randomized controlled trials comparing pioglitazone versus metformin in the treatment of polycystic ovary syndrome. ( Du, Q; Han, P; Wang, YJ; Wu, B; Yang, S; Zhao, YY, 2012) |
| "Metformin, an oral anti-diabetic drug, is being considered increasingly for treatment and prevention of cancer, obesity as well as for the extension of healthy lifespan." | 4.88 | Metformin in obesity, cancer and aging: addressing controversies. ( Berstein, LM, 2012) |
| "In agreement with the previous review, metformin was associated with improved clinical pregnancy but there was no evidence that metformin improves live birth rates whether it is used alone or in combination with clomiphene, or when compared with clomiphene." | 4.88 | Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. ( Balen, AH; Lord, JM; Norman, RJ; Tang, T; Yasmin, E, 2012) |
| "To evaluate of metformin effectiveness of ovulation induction treatment in polycystic ovary syndrome (PCOS) women." | 4.88 | The effectiveness of metformin ovulation induction treatment in patients with PCOS: a systematic review and meta-analysis. ( Chang, S; Chen, S; Xiao, J; Zhang, C, 2012) |
| " Obese women suffering from polycystic ovary syndrome may be first offered metformin for 3-4 months before the addition of clomiphene." | 4.88 | [Treatment of infertility]. ( Koivunen, R; Morin-Papunen, L, 2012) |
| "Though widely used, there is uncertainty about the effectiveness and adverse effects of metformin and clomiphene citrate (CC) for infertility in polycystic ovary syndrome (PCOS)." | 4.88 | Status of clomiphene citrate and metformin for infertility in PCOS. ( Costello, MF; Hart, R; Melder, AM; Misso, ML; Norman, RJ; Rombauts, L; Teede, HJ; Wong, J, 2012) |
| "Compared to metformin, TZDs had the same effectiveness in treating insulin sensitivity and lowering androgen in PCOS patients, but the effect on weight loss was not as good as metformin." | 4.88 | Comparative efficacy of thiazolidinediones and metformin for polycystic ovary syndrome. ( Du, Q; Wang, YJ, 2012) |
| "Our aim was to re-evaluate whether metformin may reduce late miscarriage/preterm delivery, pre-eclampsia and gestational diabetes in women with polycystic ovary syndrome (PCOS)." | 4.88 | On the potential of metformin to prevent preterm delivery in women with polycystic ovary syndrome - an epi-analysis. ( Carlsen, SM; DE Zegher, F; Díaz, M; Ibáñez, L; Vanky, E, 2012) |
| " The Pregnancy in PCOS trial II will determine the safety and efficacy of clomiphene citrate compared to letrozole, in achieving live birth in infertile women with PCOS." | 4.88 | Reproductive impact of polycystic ovary syndrome. ( Legro, RS; Usadi, RS, 2012) |
| "To evaluate the efficacy of metformin (MTF) in treatment of clomiphene (CC)-resistant patients with polycystic ovary syndrome (PCOS)." | 4.88 | [Therapeutic effect of metformin for clomiphene-resistant infertility patients with polycystic ovary syndrome: a systematic analysis]. ( Cheng, QF; Fan, XD; Ren, W; Wang, LL, 2012) |
| "There are differences in opinion as to whether metformin should play a role in the primary treatment of anovulatory infertility for women with polycystic ovary syndrome (PCOS)." | 4.87 | Metformin is a reasonable first-line treatment option for non-obese women with infertility related to anovulatory polycystic ovary syndrome--a meta-analysis of randomised trials. ( Johnson, N, 2011) |
| "In agreement with the previous review, metformin is still of benefit in improving clinical pregnancy and ovulation rates." | 4.86 | Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. ( Balen, AH; Lord, JM; Norman, RJ; Tang, T; Yasmin, E, 2010) |
| " Results showed that (i) polycystic ovary syndrome is a risk factor forT2DM but the magnitude of risk is uncertain, (ii) fasting plasma glucose is an inadequate screening test forT2DM in this population and the oral glucose tolerance test is superior, (iii) the identification of women with PCOS for diabetes screening is constrained by current diagnostic criteria for PCOS; however, women with oligomenorrhoea and those with diagnosed PCOS and obesity or a family history of T2DM are at highest risk, (iv) risk factors for T2DM are improved by weight loss interventions and by metformin." | 4.86 | Type 2 diabetes and cardiovascular disease in polycystic ovary syndrome: what are the risks and can they be reduced? ( Millward, A; Pinkney, J; Stenhouse, E; Tomlinson, J, 2010) |
| " metformin, or the combination of both drugs as first-line therapy in anovulatory polycystic ovary syndrome (PCOS) patients seeking pregnancy." | 4.85 | Clomiphene citrate, metformin or both as first-step approach in treating anovulatory infertility in patients with polycystic ovary syndrome (PCOS): a systematic review of head-to-head randomized controlled studies and meta-analysis. ( Nestler, JE; Orio, F; Palomba, S; Pasquali, R, 2009) |
| "To evaluate the effect of pregestational metformin administration on abortion risk in polycystic ovary syndrome (PCOS) patients." | 4.85 | Effect of preconceptional metformin on abortion risk in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. ( Falbo, A; Orio, F; Palomba, S; Zullo, F, 2009) |
| "The use of insulin-sensitising agents, such as metformin, in women with polycystic ovary syndrome (PCOS) who are undergoing ovulation induction or in vitro fertilisation (IVF) cycles has been widely studied." | 4.85 | Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. ( Albuquerque, LE; Andriolo, RB; Costello, MF; Freitas, V; Tso, LO, 2009) |
| "In this systematic review we present information relating to the effectiveness and safety of the following interventions: finasteride, flutamide, metformin, spironolactone, cyproterone acetate-ethinylestradiol (co-cyprindiol), interventions to achieve weight loss, ketoconazole, and mechanical hair removal." | 4.85 | PCOS. ( Cahill, D, 2009) |
| " Metformin is currently the preferred insulin-sensitizing drug for chronic treatment of PCOS and has been shown to improve the metabolic profile, menstrual cyclicity and fertility in women with PCOS, and is associated with weight loss." | 4.85 | Polycystic ovary syndrome and metabolic comorbidities: therapeutic options. ( De Leo, V; Di Sabatino, A; Morgante, G; Musacchio, MC; Palermo, V; Petraglia, F, 2009) |
| " The biguanide, N, N' dimethyl-biguanide: Metformin is an antidiabetic drug that increases glucose utilization in insulin-sensitive tissues and is useful in the reduction of both insulin resistance and circulating androgens as well as restoring ovulation." | 4.84 | Metformin in the treatment of polycystic ovary syndrome. ( Motta, DA, 2008) |
| "To systematically evaluate the efficacy and safety of Diane-35 for treating polycystic ovary syndrome (PCOS) and compare it with metformin, either in combination or alone." | 4.84 | The effects of Diane-35 and metformin in treatment of polycystic ovary syndrome: an updated systematic review. ( Jing, Z; Liang-Zhi, X; Tai-Xiang, W; Ying, T; Yu-Jian, J, 2008) |
| " Limited data demonstrated no evidence of a difference in effect between metformin and the OCP on hirsutism, acne or development of type 2 diabetes mellitus." | 4.84 | Metformin versus oral contraceptive pill in polycystic ovary syndrome: a Cochrane review. ( Costello, MF; Eden, J; Johnson, NP; Shrestha, B; Sjoblom, P, 2007) |
| "Metformin improves the endocrinopathy of polycystic ovary syndrome (PCOS), facilitates conception, appears to reduce first trimester miscarriage and gestational diabetes and does not appear to be teratogenic." | 4.84 | Metformin before and during pregnancy and lactation in polycystic ovary syndrome. ( Glueck, CJ; Wang, P, 2007) |
| "To report a case of triplet pregnancy after metformin treatment only, in a woman with polycystic ovary syndrome (PCOS) and a family history of twin pregnancies." | 4.84 | Triplet pregnancy after metformin in a woman with polycystic ovary syndrome. ( Clapauch, R; Mattos, TM, 2008) |
| " Reduction of hyperinsulinism and improvement of insulin sensitivity with metformin has been reported to ameliorate these abnormalities in many, but not all studies, with few adverse effects." | 4.84 | Metformin and polycystic ovary syndrome. ( Lebinger, TG, 2007) |
| " Combined aspirin and heparin for antiphospholipid syndrome, and screening and treatment of bacterial vaginosis between ten and 22 weeks of pregnancy with clindamycin, are the only interventions proven to be useful in randomised controlled trials (RCTs)." | 4.84 | Non-surgical interventions for threatened and recurrent miscarriages. ( Tan, TY; Tien, JC, 2007) |
| "Metformin, an insulin sensitizer widely used for the treatment of patients with type-2 diabetes mellitus (DM), was recently introduced in the clinical practice to treat women with polycystic ovary syndrome (PCOS)." | 4.84 | Role of metformin in patients with polycystic ovary syndrome: the state of the art. ( Falbo, A; Orio, F; Palomba, S; Russo, T; Tollino, A; Zullo, F, 2008) |
| "Metformin is an insulin sensitizer currently used for treating type-2 diabetes mellitus and recently administered for inducing ovulatory menstrual cycles in oligo-amenorrhoeic patients with polycystic ovary syndrome (PCOS)." | 4.84 | Outlook: metformin use in infertile patients with polycystic ovary syndrome: an evidence-based overview. ( Oppedisano, R; Orio, F; Palomba, S; Tolino, A; Zullo, F, 2008) |
| "To update the state of evidence on the efficacy of metformin, used either alone or in combination with clomiphene citrate in women with polycystic ovary syndrome, by examining three outcomes: ovulation, pregnancy, and live birth." | 4.84 | Use of metformin in polycystic ovary syndrome: a meta-analysis. ( Bradley, HM; Creanga, AA; McCormick, C; Witkop, CT, 2008) |
| "To describe the first reported cases of two women with polycystic ovary syndrome (PCOS) desirous of pregnancy who conceived trichorionic pregnancies following ovulation induction with metformin alone and metformin plus clomiphene." | 4.83 | Higher-order multiple pregnancy associated with metformin in women with polycystic ovary syndrome: two cases and review of the literature. ( Boothroyd, C; Yazdani, A, 2006) |
| "A systematic review of randomized controlled trials (RCTs) comparing whether metformin co-administration with gonadotrophins for ovulation induction (OI) with timed intercourse or IVF improves outcome in women with polycystic ovary syndrome (PCOS)." | 4.83 | A systematic review and meta-analysis of randomized controlled trials on metformin co-administration during gonadotrophin ovulation induction or IVF in women with polycystic ovary syndrome. ( Chapman, M; Conway, U; Costello, MF, 2006) |
| "To conduct a systematic review and meta-analysis of pregnancy outcome after metformin use for polycystic ovary syndrome (PCOS), because the efficacy of metformin has been demonstrated in the treatment of infertility caused by PCOS, whereas the fetal safety of metformin has received very little attention, and the few studies addressing this issue are limited by small sample sizes." | 4.83 | Pregnancy outcome after first-trimester exposure to metformin: a meta-analysis. ( Gilbert, C; Koren, G; Valois, M, 2006) |
| "The aim of this literature search is to establish if metformin is efficacious when given to clomiphene citrate (CC)-resistant polycystic ovary syndrome (PCOS) patients." | 4.83 | Is the addition of metformin efficacious in the treatment of clomiphene citrate-resistant patients with polycystic ovary syndrome? A structured literature review. ( Kruger, TF; Nosarka, S; Siebert, TI; Steyn, DW, 2006) |
| "To review the effectiveness of metformin in restoring regular menstrual cycles and ovulation and achieving pregnancy in women with polycystic ovary syndrome (PCOS)." | 4.82 | A systematic review of the reproductive system effects of metformin in patients with polycystic ovary syndrome. ( Costello, MF; Eden, JA, 2003) |
| "Metformin has been used as a treatment in many studies of the infertility associated with polycystic ovary syndrome (PCOS)." | 4.82 | Effects of metformin on body mass index, menstrual cyclicity, and ovulation induction in women with polycystic ovary syndrome. ( Attia, GR; Carr, BR; Haas, DA, 2003) |
| "To familiarize obstetrician-gynecologists with the use of metformin for the treatment of polycystic ovary syndrome (PCOS)." | 4.82 | Metformin for the treatment of polycystic ovary syndrome. ( Barbieri, RL, 2003) |
| "Use of metformin in polycystic ovary syndrome (PCOS) is becoming increasingly accepted and widespread, but clinical practice is ahead of the evidence." | 4.82 | Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome. ( Fleming, R; Harborne, L; Lyall, H; Norman, J; Sattar, N, 2003) |
| "To evaluate the role of laparoscopic ovarian drilling and treatment with metformin in the management of the polycystic ovary syndrome (PCOS)." | 4.82 | Laparoscopic treatment of polycystic ovaries: is it time to relinquish the procedure? ( Pirwany, I; Tulandi, T, 2003) |
| "Metformin is an effective treatment for anovulation in women with PCOS." | 4.82 | Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. ( Flight, IH; Lord, JM; Norman, RJ, 2003) |
| "To assess the effectiveness of metformin in improving clinical and biochemical features of polycystic ovary syndrome." | 4.82 | Metformin in polycystic ovary syndrome: systematic review and meta-analysis. ( Flight, IH; Lord, JM; Norman, RJ, 2003) |
| "Metformin is a common treatment for women who have insulin resistance manifesting as type 2 diabetes or polycystic ovarian syndrome (PCOS)." | 4.82 | Metformin in obstetric and gynecologic practice: a review. ( Boyle, J; McCarthy, EA; McLachlan, K; Permezel, M; Walker, SP, 2004) |
| "No adverse pregnancy outcomes with metformin use have been reported, except in one unmatched study." | 4.82 | Metformin therapy and diabetes in pregnancy. ( McIntyre, HD; Rowan, JA; Simmons, D; Walters, BN, 2004) |
| "The use of insulin sensitizing drugs such as metformin in polycystic ovary syndrome has been increasingly popular and validated by systematic reviews." | 4.82 | Should we continue or stop insulin sensitizing drugs during pregnancy? ( Hague, W; Norman, RJ; Wang, JX, 2004) |
| "The purpose of this review is to provide a critical discussion on the place of laparoscopic ovarian drilling and medical treatment with metformin for polycystic ovary syndrome." | 4.82 | Laparoscopic treatment of polycystic ovaries: is its place diminishing? ( Al-Fadhli, R; Tulandi, T, 2004) |
| "This paper is a systematic review of metformin versus clomiphene citrate (CC) in women with polycystic ovary syndrome (PCOS)." | 4.82 | Insulin-sensitizing agents as primary therapy for patients with polycystic ovarian syndrome. ( Kashyap, S; Rosenwaks, Z; Wells, GA, 2004) |
| "Metformin has become an established treatment for women with polycystic ovary syndrome, although controversy remains as to how effective it is and in which populations it should be used." | 4.82 | Metformin in polycystic ovary syndrome. ( Lord, J; Wilkin, T, 2004) |
| " Key terms used were thiazolidinediones, troglitazone, rosiglitazone, pioglitazone, polycystic ovary syndrome, and PCOS." | 4.82 | Thiazolidinediones for treatment of polycystic ovary syndrome. ( Fugate, SE; Stout, DL, 2005) |
| " The most extensively studied insulin-lowering agent in the treatment of PCOS is metformin: an oral antihyperglycaemic agent used initially in the treatment of type 2 diabetes mellitus." | 4.81 | Should patients with polycystic ovarian syndrome be treated with metformin? ( Duleba, AJ; Seli, E, 2002) |
| "The debate on metformin use in polycystic ovary syndrome (PCOS) has mainly focused on its treatment for infertility in ovulation induction and menstrual cyclicity." | 4.81 | Should patients with polycystic ovary syndrome be treated with metformin? Benefits of insulin sensitizing drugs in polycystic ovary syndrome--beyond ovulation induction. ( Oehninger, S; Stadtmauer, LA; Wong, BC, 2002) |
| "To review the use of the insulin-sensitizing agent metformin in women with polycystic ovary syndrome (PCOS)." | 4.81 | Use of metformin in polycystic ovary syndrome. ( De Sloover Koch, Y; Ernst, ME, 2001) |
| " Although no clinical trials over 6 months in duration have assessed the long-term efficacy of metformin use in adolescents, short-term trials have shown promising effects in lowering insulin secretion, improving insulin sensitivity, restoring normal menstrual cycles, and correcting lipid abnormalities." | 4.81 | Polycystic ovary syndrome in adolescents. ( Kent, SC; Legro, RS, 2002) |
| "To study the involvement of microribonucleic acids (miRNAs) in the pathogenesis of chronic anovulation and mechanism of metformin treatment in polycystic ovary syndrome (PCOS)." | 4.31 | The role of circulating miRNAs in mechanism of action and prediction of therapeutic responses of metformin in polycystic ovarian syndrome. ( Chen, MJ; Chen, SU; Huang, CC; Huang, YS; Yang, PK; Yang, YS, 2023) |
| "To study the effectiveness of metformin treatment in patients with acne but who do not have PCOS and to understand the mechanisms of action of metformin in acne not related to PCOS." | 4.31 | Effects of metformin on clinical, hormonal and relevant gene expression parameters in patients with acne: an observational study. ( De, D; Dutta, P; Handa, S; Kamboj, P; Kaushik, A; Pal, A; Saikia, UN, 2023) |
| "The keywords of PCOS research focused on PCOS, insulin resistance (IR), obesity and metformin." | 4.31 | Past and present: a bibliometric study on polycystic ovary syndrome. ( Cai, M; Ni, Z; Yao, R; Yu, C; Yu, J; Yuan, Z; Zhang, D; Zhou, L, 2023) |
| " We compared the clinical pregnancy rate (primary outcome) and controlled ovarian stimulation (COS)-related parameters (secondary outcomes) between patients with and without metformin pre-treatment for all PCOS patients not grouped by HOMA-IR, PCOS patients with HOMA-IR < 2." | 4.31 | The homeostasis model assessment of insulin resistance is a judgment criterion for metformin pre-treatment before IVF/ICSI and embryo transfer cycles in patients with polycystic ovarian syndrome. ( Gao, R; Li, Z; Min, W; Qin, L, 2023) |
| " Metformin treatment reduces the risk of late miscarriage and preterm birth in pregnant women with PCOS." | 4.31 | Immunomodulatory Effects of Metformin Treatment in Pregnant Women With PCOS. ( Giskeødegård, GF; Iversen, AC; Jarmund, AH; Løvvik, TS; Madssen, TS; Ryssdal, M; Steinkjer, B; Stokkeland, LMT; Vanky, E, 2023) |
| " To explore the potential effects of swertiamarin, on abrupted insulin and steroidogenic signaling in human luteinized granulosa cells from PCOS patients with or without insulin resistance." | 4.31 | Investigating the potential role of swertiamarin on insulin resistant and non-insulin resistant granulosa cells of poly cystic ovarian syndrome patients. ( Banker, M; Belani, MA; Gupta, SS; Shah, P, 2023) |
| "The study aims to assess the levels of Neuregulin 1 (NRG1) in patients with Polycystic Ovary Syndrome (PCOS) and to determine the impact of metformin treatment on their serum NRG1 levels." | 4.31 | METFORMIN EFFECTS ON NEUREGULIN-1 IN POLYCYSTIC OVARIAN WOMEN. ( Sarhat, E; Tawfeq, M, 2023) |
| " Metformin treatment resulted in significant elevation of the studied miRNA, significant downregulation of PI3K/AKT target genes, and significant amelioration of the gonadotrophic hormonal imbalance and insulin resistance markers: fasting blood glucose, HBA1C, fasting insulin, and GLUT4 gene expression." | 4.31 | Non-coding RNA genes modulate PI3K/AKT signaling pathway in polycystic ovary syndrome. ( Faruk, EM; Fouad, H; Ibrahim, OA; Omar, HS; Safwat, M; Sayed, MG, 2023) |
| "To identify the effects of metformin and kisspeptin structural polymorphism on the risk of polycystic ovary syndrome (PCOS) in Iraqi women." | 4.31 | Effects of ( Gholizadeh, A; Kadhem, AH; Khalaj-Kondori, M, 2023) |
| " We explored the beneficial effect of combined sodium glucose co transporter-2 inhibitor (SGLT-2i); (empagliflozin) and metformin on hormonal and metabolic parameters in an animal model of PCOS and insulin resistance (IR)." | 4.31 | SGLT-2 inhibitors enhance the effect of metformin to ameliorate hormonal changes and inflammatory markers in a rat PCOS model. ( Hussien, RES; Kamar, SS; Kamel, O; Mahmoud, MM; Rashed, LA; Sayed, SM; Soliman, SA, 2023) |
| "Metformin counteracts excessive weight gain and leptin resistance in pregnant women with polycystic ovary syndrome." | 4.12 | Gestational weight gain, appetite regulating hormones, and metformin treatment in polycystic ovary syndrome: A longitudinal, placebo-controlled study. ( Bixo, M; Dehlin, E; Løvvik, TS; Molin, J; Vanky, E, 2022) |
| "The mean steady-state serum concentration of metformin during pregnancy was 9." | 4.12 | Metformin serum concentrations during pregnancy and post partum - A clinical study in patients with polycystic ovary syndrome. ( Espnes, KA; Gundersen, POM; Hønnås, A; Løvvik, TS; Naavik, A; Skogvoll, E; Spigset, O; Vanky, E; Westin, AA, 2022) |
| " Metformin appears to reduce these risks in mothers with polycystic ovary syndrome and their children; but may increase the risk of childhood-obesity in children form women without PCOS." | 4.12 | Pregnancy, perinatal and childhood outcomes in women with and without polycystic ovary syndrome and metformin during pregnancy: a nationwide population-based study. ( Brusselaers, N; Crisosto, N; Cruz, G; Engstrand, L; Fornes, R; Nguyen, MH; Simin, J; van der Schaaf, M, 2022) |
| "Metformin (MET) can effectively treat endometrial hyperplasia (EH), and the expression of glucose transporter type 4 insulin‑responsive (GLUT4) is closely associated with the development of EH." | 4.12 | Role of metformin in functional endometrial hyperplasia and polycystic ovary syndrome involves the regulation of MEG3/miR‑223/GLUT4 and SNHG20/miR‑4486/GLUT4 signaling. ( Chen, L; Li, R; Liu, J; Ning, Y; Zhao, Y; Zhu, X, 2022) |
| "Fifty NMRI mice (7-8 weeks old) were randomly divided into five groups, including non-PCOS, PCOS and PCOS groups treated with clomiphene citrate (18 mg/kg body weight for 2 days), metformin (50 mg/100 g body weight for 30 days) and flutamide (10 mg/kg body weight injection for 15 days)." | 4.12 | Metformin, clomiphene citrate and flutamide effects on oocyte ultrastructure status and quality in PCOS mouse model. ( Esmaeilnezhad, S; Ghasemian, F, 2022) |
| "The study aimed to investigate the effect of metformin treatment on leukocyte telomere length (LTL) and the relationship of LTL with C-reactive protein (CRP), homocysteine, albumin, complete blood count, and HOMA-IR values in patients with polycystic ovary syndrome (PCOS)." | 4.12 | The effect of metformin treatment on leukocyte telomere length in patients with polycystic ovary syndrome: a prospective case-control study. ( Kayacık Günday, Ö; Özdemir Erdoğan, M; Pehlivan, A; Yılmazer, M, 2022) |
| "This observational, retrospective study utilized EHR data from 52 hospitals for COVID-19 patients with PCOS or prediabetes treated with metformin or levothyroxine/ondansetron (controls)." | 4.12 | Metformin is associated with reduced COVID-19 severity in patients with prediabetes. ( Antony, B; Blau, H; Bramante, C; Casiraghi, E; Chan, LE; Coleman, B; Gargano, M; Haendel, M; Harris, NL; Laraway, B; Reese, J; Robinson, PN; Sahner, D; Valentini, G; Wilkins, K; Zaman, A, 2022) |
| "This study provides evidence for the efficacy and safety of the clinical application of acupuncture combined with metformin in the treatment of polycystic ovary syndrome." | 4.12 | Acupuncture combined with metformin for polycystic ovary syndrome: A protocol for systematic review and meta-analysis. ( Ding, Q; Liu, X; Sun, Y; Yang, H; Yin, S, 2022) |
| " After metformin and exenatide supplementation, body weight, chow intake and ovarian morphology were observed." | 4.02 | Metformin and exenatide upregulate hepatocyte nuclear factor-4α, sex hormone binding globulin levels and improve hepatic triglyceride deposition in polycystic ovary syndrome with insulin resistance rats. ( He, B; Li, X; Lv, B; Wang, D; Xing, C; Zhao, H, 2021) |
| "The beneficial effects of metformin, especially its capacity to ameliorate insulin resistance (IR) in polycystic ovary syndrome (PCOS), explains why it is widely prescribed." | 4.02 | Effects of Metformin on Reproductive, Endocrine, and Metabolic Characteristics of Female Offspring in a Rat Model of Letrozole-Induced Polycystic Ovarian Syndrome With Insulin Resistance. ( Li, S; Xiao, L; Xie, Y, 2021) |
| "The possible relationship between dehydroepiandrosterone (DHEA)-induced polycystic ovary syndrome (PCOS) and epigenetic changes (ECs) leading to the impaired oocyte quality, has not been investigated yet." | 4.02 | Metformin improves epigenetic modification involved in oocyte growth and embryo development in polycystic ovary syndrome mice model. ( Amani Abkenari, S; Amidi, F; Aryanpour, R; Hosseini, A; Safdarian, L; Salahi, E; Sobhani, A, 2021) |
| "To investigate whether patients with polycystic ovary syndrome (PCOS) are at increased risk for incident schizophrenia and whether PCOS treatment (clomiphene, cyproterone, or metformin) affects the incidence of schizophrenia." | 4.02 | Risk of schizophrenia in patients with polycystic ovary syndrome: a nationwide population-based cohort study from Taiwan. ( Chen, SF; Hsu, CY; Shen, YC; Yang, YC, 2021) |
| "This study estimated the cost-effectiveness of metformin to reduce the risk of gestational diabetes mellitus (GDM) in pregnant women with polycystic ovary syndrome (PCOS) from the US health-care payer perspective." | 4.02 | Cost-effectiveness analysis of polycystic ovary syndrome management and the risk of gestational diabetes in pregnant women: a decision-tree model. ( Alenzi, EO, 2021) |
| " Metformin increases insulin sensitivity, but it is associated with unsatisfied benefits of weight loss." | 4.02 | The therapeutic effects of glucagon-like peptide-1 receptor agonists and metformin on polycystic ovary syndrome: A protocol for systematic review and meta-analysis. ( Deng, Y; Ding, X; Ma, R; Sun, A; Wang, Y, 2021) |
| " We aimed to confirm the correlation between SFRP5, metabolic inflammation and PCOS, investigate the predictive value of SFRP5 for PCOS and the involvement of SFRP5 in metformin treated PCOS." | 4.02 | Decreased SFRP5 correlated with excessive metabolic inflammation in polycystic ovary syndrome could be reversed by metformin: implication of its role in dysregulated metabolism. ( Chen, Y; Geng, L; Hu, J; Huang, H; Kong, L; Qi, H; Ran, Y; Zhang, H; Zhang, Y, 2021) |
| "The present study was conducted to investigate the therapeutic effects of a potent polyphenol, fisetin, on the letrozole-induced rat model of polycystic ovary syndrome (PCOS)." | 4.02 | Ameliorative effects of fisetin in letrozole-induced rat model of polycystic ovary syndrome. ( Khadem-Ansari, MH; Mihanfar, A; Nouri, M; Roshangar, L, 2021) |
| "The study investigated the risk of newly developed bipolar disorder (BD) in patients with polycystic ovary syndrome (PCOS) and examined the relationship between PCOS treatment (hormone therapy (clomiphene or cyproterone) or metformin) and risk of BD development." | 3.96 | Risk of bipolar disorder in patients with polycystic ovary syndrome: A nationwide population-based cohort study. ( Chen, SF; Hsu, CY; Shen, YC; Yang, YC, 2020) |
| " Weight loss, lifestyle modification and combined hormonal pill and metformin are considered first-line treatment." | 3.96 | Hyperandrogenism, insulin resistance and acanthosis nigricans (HAIR-AN syndrome): an extreme subphenotype of polycystic ovary syndrome. ( Dahiya, R; Kimble, R; O'Brien, B, 2020) |
| "Metformin is the most commonly prescribed drug in the management of metabolic disorders such as polycystic ovarian syndrome (PCOS) and gestational diabetes in women of reproductive age." | 3.96 | Antidiabetic drug metformin affects the developmental competence of cleavage-stage embryos. ( Adiga, SK; Agarwal, P; Kalthur, G; Kalthur, SG; Kumari, S; Mutalik, S; Nayak, G; Rao, A; Salian, SR; Shreya, AB; Suresh Poojary, P, 2020) |
| "After six months, the fasting insulin, glucose/insulin ratio, and homeostatic model assessment estimates for insulin resistance were significantly improved in metformin group." | 3.96 | Metformin metabolic and vascular effects in normal weight hyperinsulinemic polycystic ovary syndrome patients treated with contraceptive vaginal ring. A pilot study. ( Artini, PG; Battaglia, B; Battaglia, C; Casadio, P; Rizzo, R, 2020) |
| "Metformin has long been used in the treatment of polycystic ovarian syndrome (PCOS)." | 3.96 | Sitagliptin/Metformin: A New Medical Treatment in Polycystic Ovary Syndrome. ( Daneshjou, D; Shariatzadeh, MA; Soleimani Mehranjani, M; Zadeh Modarres, S, 2020) |
| "This study aimed to investigate the molecular mechanisms underlying the roles of metformin (MET) and Sorafenib (SOR) in the treatment of endometrial hyperplasia (EH) in polycystic ovary syndrome (PCOS)." | 3.96 | Treatment with metformin and sorafenib alleviates endometrial hyperplasia in polycystic ovary syndrome by promoting apoptosis via synergically regulating autophagy. ( Gao, ZH; Guo, XC; Ji, M; Li, L; Wang, QQ, 2020) |
| "Scarce data exist on the body composition of lean women with polycystic ovary syndrome (PCOS) on treatment with metformin and oral contraceptives (OCs)." | 3.91 | Lean Women on Metformin and Oral Contraceptives for Polycystic Ovary Syndrome Demonstrate a Dehydrated Osteosarcopenic Phenotype: A Pilot Study. ( Bacopoulou, F; Boschiero, D; Diamandi-Kandarakis, E; Kandaraki, E; Stefanaki, C, 2019) |
| "To investigate the effect of metformin on endometrial receptivity in women with polycystic ovary syndrome (PCOS)." | 3.91 | The Effect of Metformin on the Endometrium of Women with Polycystic Ovary Syndrome. ( Anifandis, G; Antonakis, PT; Dafopoulos, K; Daponte, A; Dragamestianos, C; Garas, A; Georgoulias, P; Kostopoulou, E; Makrigiannakis, A; Messini, CI; Messinis, IE; Zacharouli, K, 2019) |
| " Metformin is commonly used to treat insulin resistance-glucose intolerance, and flutamide, an androgen receptor (AR) antagonist, is used to target hyperandrogenemia and dyslipidemia." | 3.91 | Effect of metformin and flutamide on insulin, lipogenic and androgen-estrogen signaling, and cardiometabolic risk in a PCOS-prone metabolic syndrome rodent model. ( Diane, A; Ghosh, M; Kupreeva, M; Lehner, R; Proctor, S; Vine, D; Watts, R, 2019) |
| "We examine the effects of metformin on insulin resistance (IR) and mood including in adolescent and adult women with polycystic ovary syndrome (PCOS)." | 3.91 | A pilot trial of metformin for insulin resistance and mood disturbances in adolescent and adult women with polycystic ovary syndrome. ( Aghamohammadzadeh, N; Erensoy, H; Ghafarzadeh, S; Nader, ND; Niafar, M, 2019) |
| "To some extent, the use of metformin may improve endometrial receptivity and pregnancy outcomes of women with polycystic ovarian syndrome (PCOS) undergoing in vitro fertilization/intracytoplasmic sperm injection." | 3.91 | Metformin Regulates Key MicroRNAs to Improve Endometrial Receptivity Through Increasing Implantation Marker Gene Expression in Patients with PCOS Undergoing IVF/ICSI. ( Chang, ZY; Sun, YP; Wang, JY; Wu, L; Yang, QL; Yao, GD; Zhai, J, 2019) |
| "The underlying mechanisms of polycystic ovarian syndrome (PCOS)-induced endometrial dysfunction are not fully understood, and although accumulating evidence shows that the use of metformin has beneficial effects in PCOS patients, the precise regulatory mechanisms of metformin on endometrial function under PCOS conditions have only been partially explored." | 3.91 | Differential Expression Patterns of Glycolytic Enzymes and Mitochondria-Dependent Apoptosis in PCOS Patients with Endometrial Hyperplasia, an Early Hallmark of Endometrial Cancer, ( Billig, H; Brännström, M; Cui, P; Hu, M; Li, J; Li, X; Shao, LR; Vestin, E; Wang, T; Zhang, J; Zhang, Y, 2019) |
| "The aim of this study was to evaluate the effect of orlistat or metformin combined with Diane-35 on anthropometric, hormonal and metabolic parameters in overweight and obese polycystic ovary syndrome (PCOS) patients with insulin resistance (fasting insulin > 10 mIU/L)." | 3.88 | Effect of orlistat or metformin in overweight and obese polycystic ovary syndrome patients with insulin resistance. ( Gu, M; Mueck, AO; Ruan, X; Song, J; Wang, H; Wang, L, 2018) |
| "The aim of this study was to evaluate the risk of major birth defects and spontaneous abortion after metformin use during the first trimester of pregnancy." | 3.88 | Pregnancy outcome after first-trimester exposure to metformin: A prospective cohort study. ( Beck, E; Grupe, K; Schaefer, C; Scherneck, S; Schlinke, N; Weber-Schoendorfer, C, 2018) |
| "To evaluate the effect of metformin and pioglitazone on leutinizing hormone and follicle stimulating hormone receptor mRNA expression, hyperandrogenism and insulin resistance in high fat diet induced and letrozole induced PCOS in rats." | 3.88 | Insulin Sensitizers Modulate GnRH Receptor Expression in PCOS Rats. ( Patel, R; Shah, G, 2018) |
| "Metformin toxicity is well known to cause lactic acidosis." | 3.88 | Recurrent hypoglycemia secondary to metformin toxicity in the absence of co-ingestions: a case report. ( Aldobeaban, S; Alshehri, AA; Mzahim, B, 2018) |
| " Using metformin during pregnancy and nursing to improve the metabolic status of obese mothers could prevent the sequence of events that lead to an increase in postnatal serum estradiol levels in female offspring and, hence, reproductive dysfunction." | 3.88 | Prenatal metformin treatment improves ovarian function in offspring of obese rats. ( Álvarez, D; Ceballo, K; Cruz, G; Fernandois, D; Maliqueo, M; Martinez-Pinto, J; Olguín, S; Sotomayor-Zárate, R, 2018) |
| "The objective of this study was to evaluate the levels of total microparticles (MPs) and microparticles-expressing tissue factor (TFMPs) in women with polycystic ovarian syndrome (PCOS) who use metformin comparing to those who do not take metformin." | 3.85 | Metformin reduces total microparticles and microparticles-expressing tissue factor in women with polycystic ovary syndrome. ( Candido, AL; Carvalho, LML; Ferreira, CN; Gomes, KB; Nunes, FFC; Reis, FM; Sales, MF; Silva, IFO; Sóter, MO, 2017) |
| "To evaluate the norepinephrine (NE) and placental NE transporter (NET) in women with polycystic ovary syndrome (PCOS) non-treated and treated with metformin during pregnancy." | 3.85 | Metformin increases norepinephrine transporter expression in placenta of patients with polycystic ovary syndrome. ( Crisosto, N; Echiburú, B; Lara, HE; Maliqueo, M; Medina, G; Sir-Petermann, T, 2017) |
| "We aim to assess the effects of metformin treatment on metabolic and endocrine parameters and genes expression related to the insulin-responsive pathway in polycystic ovary syndrome (PCOS)." | 3.85 | IGF-1R and Leptin Expression Profile and the Effects of Metformin Treatment on Metabolic and Endocrine Parameters in PCOS Mice. ( Abi Haidar, M; Berguio Vidotti, D; de Almeida, BC; de Jesus Simões, M; Prado Correia, LE; Silva, I, 2017) |
| "BMI in overweight patients were significantly improved with metformin treatment duration (p < 0." | 3.85 | Effect of metformin by employing 2-hour postload insulin for measuring insulin resistance in Taiwanese women with polycystic ovary syndrome. ( Chen, PC; Ou, HT; Wu, MH, 2017) |
| " We investigated endometrial mRNA expression of 23 autophagy-related (ATG) genes and transcription factors in healthy controls (n = 12) and anovulatory polycystic ovary syndrome (PCOS) patients (n = 24), as well as in their subgroup (n = 12) before and after metformin treatment." | 3.85 | Downregulation of autophagy gene expression in endometria from women with polycystic ovary syndrome. ( Apostolovic, M; Dukanac-Stamenkovic, J; Janjetovic, K; Jeremic, D; Ljubic, A; Micic, D; Micic, J; Popadic, D; Stevanovic, D; Sumarac-Dumanovic, M; Trajkovic, V; Tubic, A, 2017) |
| " Clinical pregnancy rates and implantation rates were similar in all groups, although the numbers of oocytes, mature oocytes, fertilized oocytes, and transferred embryos were lower in the treatment groups received metformin compared to the OC group and control group." | 3.85 | Effect of metformin and oral contraceptives on polycystic ovary syndrome and IVF cycles. ( Gurgan, T; Kalem, MN; Kalem, Z, 2017) |
| "In this study, we assessed the efficacy and safe usage of the oral contraceptive, Diane-35, in the treatment of polycystic ovary syndrome (PCOS) when combined with the drug metformin." | 3.83 | Management of polycystic ovarian syndrome with Diane-35 or Diane-35 plus metformin. ( Feng, W; Jia, YY; Shi, HR; Zhang, DY, 2016) |
| "To investigate whether there is any therapeutic effect of colchicine on a rat model of polycystic ovary syndrome (PCOS)." | 3.83 | Effect of colchicine on polycystic ovary syndrome: an experimental study. ( Aksoy, AN; Dokuyucu, R; Gozukara, IO; Kucur, SK; Kurt, RK; Ozcan, O; Ozgur, T; Pınar, N, 2016) |
| " Twenty-nine patients without insulin resistance were treated with OC (group 1), and 20 patients with insulin resistance were treated with metformin and OC (group 2)." | 3.83 | Assessment of Anti-Müllerian Hormone Level in Management of Adolescents with Polycystic Ovary Syndrome. ( Dursun, F; Güven, A; Yıldız, M, 2016) |
| "Polycystic ovary syndrome (PCOS) is common in obese women with insulin resistant type 2 diabetes for which metformin treatment is getting established in addition to clomiphene." | 3.83 | A case of lean polycystic ovary syndrome with early stage of type 1 diabetes successfully treated with metformin. ( Hirose, T; Kitamura, M; Kumashiro, N; Rikitake, T; Saegusa, M; Shigiyama, F; Uchino, H; Usui, S, 2016) |
| "Metformin hydrochloride (MTF-HCl) is extensively recommended by physicians for the treatment of polycystic ovary syndrome (PCOS)." | 3.83 | Intravaginal administration of metformin hydrochloride loaded cationic niosomes amalgamated with thermosensitive gel for the treatment of polycystic ovary syndrome: In vitro and in vivo studies. ( Bajaj, L; Jain, UK; Katare, OP; Madan, J; Pandey, RS; Saini, N; Sodhi, RK, 2016) |
| "Metformin might improve health-related quality of life of polycystic ovary syndrome women by ameliorating psychological disturbances due to acne, hair loss and infertility problems, especially for overweight and hyperandrogenic patients." | 3.83 | Metformin improved health-related quality of life in ethnic Chinese women with polycystic ovary syndrome. ( Chen, PC; Lin, CY; Ou, HT; Wu, MH, 2016) |
| "Metformin is an old insulin sensitizer that has been widely used in women with polycystic ovary syndrome (PCOS) to treat metabolic comorbidities and may also improve ovarian dysfunction in women with PCOS." | 3.81 | Metformin in women with PCOS, pros. ( Pasquali, R; Renato, P, 2015) |
| "To evaluate effects of metformin on endocrine, metabolic parameters and endometrial androgen receptor (AR) expression in polycystic ovary syndrome (PCOS)." | 3.81 | Effects of metformin on endocrine, metabolic milieus and endometrial expression of androgen receptor in patients with polycystic ovary syndrome. ( Fujimori, K; Hashimoto, S; Ito-Yamaguchi, A; Kumagami, A; Suganuma, R; Yoshida-Komiya, H, 2015) |
| "The aim of this proof-of-concept study was to determine the effects of three-month Metformin therapy on the expression of tumor-regulatory genes (p53, cyclin D2 and BCL-2) in the endometrium of women with polycystic ovary syndrome (PCOS)." | 3.81 | The effect of Metformin on endometrial tumor-regulatory genes and systemic metabolic parameters in polycystic ovarian syndrome--a proof-of-concept study. ( Atiomo, W; Chapman, C; Ghani, NA; Hatta, AZ; Malik, DA; Mokhtar, NM; Omar, MH; Seedhouse, C; Shafiee, MN; Yunos, RI, 2015) |
| " Metformin has been introduced in the treatment of PCOS to manage insulin resistance and hyperglycemia." | 3.81 | Metformin regulates ovarian angiogenesis and follicular development in a female polycystic ovary syndrome rat model. ( Abramovich, D; Bas, D; Bianchi, MS; Di Pietro, M; Irusta, G; Parborell, F; Pascuali, N; Tesone, M, 2015) |
| "To assess the effect of metformin in controlling Gestational Diabetes Mellitus (GDM) in women with Polycystic Ovarian Syndrome (PCOS)." | 3.81 | Metformin for preventing gestational diabetes in women with polycystic ovarian syndrome. ( Aftab, S; Ainuddin, JA; Kamran, A; Kazi, S, 2015) |
| "To evaluate the role of anti-Mullerian hormone (AMH) and inhibin B in the evaluation of the effectiveness of short- (3 months) and long-term (6 months or more) metformin therapy in Iraqi women with polycystic ovarian syndrome (PCOS)." | 3.81 | The role of anti-Mullerian hormone and inhibin B in the assessment of metformin therapy in women with polycystic ovarian syndrome. ( Ameen, NS; Ibraheem, WF; Saleh, BO, 2015) |
| "To evaluate the sex steroid profile and histomorphometry of the adrenal cortical zones of androgenized rats (wistar) with polycystic ovary syndrome treated with metformin." | 3.81 | Effects of metformin on the adrenal cortex of androgenized rats. ( Baracat, EC; Carbonel, AA; do Amaral, VC; Fuchs, LF; Macedo, LA; Maria Soares, J; Simões, MJ; Simões, RS; Simoncini, T, 2015) |
| "To evaluate the effectiveness of metformin therapy in reducing early pregnancy loss in pregnant women with polycystic ovary syndrome (PCOS)." | 3.81 | Effect of metformin on early pregnancy loss in women with polycystic ovary syndrome. ( Al-Biate, MA, 2015) |
| "The aim of this study was to determine the relevance of apelin and insulin resistance (IR) with polycystic ovary syndrome (PCOS) and to assess the possible therapeutic effect of the combined therapy of drospirenone-ethinylestradiol (DRSP-EE) combined with metformin." | 3.81 | Evaluation of Apelin and Insulin Resistance in Patients with PCOS and Therapeutic Effect of Drospirenone-Ethinylestradiol Plus Metformin. ( Sun, X; Wu, X; Yu, X; Zhang, W; Zhou, Y, 2015) |
| "To investigate the expression of silent information regulator 1 (SIRT1) in rats with polycystic ovary syndrome (PCOS) and its alteration after exenatide treatment." | 3.81 | Expression of SIRT1 in the ovaries of rats with polycystic ovary syndrome before and after therapeutic intervention with exenatide. ( Ge, SQ; Tao, X; Zhang, B; Zhang, EH; Zhang, X, 2015) |
| "Metformin decreases polycystic ovary syndrome (PCOS) symptoms, induces ovulation, and may improve developmental competence of in vitro oocyte maturation." | 3.81 | Does metformin improve in vitro maturation and ultrastructure of oocytes retrieved from estradiol valerate polycystic ovary syndrome-induced rats. ( Mesbah, F; Mirkhani, H; Moslem, M; Vojdani, Z, 2015) |
| "The aim of our study was to assess the value of blood pressure and heart rate using the 24-hour blood pressure monitoring (ABPM) before and after treatment with metformin to patients with polycystic ovary syndrome (PCOS) and normal lean." | 3.81 | [Metformin and changes in blood pressure and heart rate in lean patients with polycystic ovary syndrome (PCOS)--preliminary study]. ( Kiałka, M; Klocek, M; Kowalczuk, A; Migacz, K; Milewicz, T; Ociepka, A; Tomczyk, R, 2015) |
| "To authenticate the effect of metformin treatment on ovarian stromal blood flow in women with polycystic ovary syndrome (PCOS) using 3-dimensional (3D) power Doppler." | 3.80 | Assessment of ovarian stromal blood flow after metformin treatment in women with polycystic ovary syndrome. ( El Sherbiny, M; Elkabarity, R; Makled, AK, 2014) |
| " The aim of this study was to assess the effects of metformin on insulin resistance, oxidant-antioxidant status, endothelial dysfunction, lipid metabolism and their contribution to the risks of cardiovascular disease in women with PCOS." | 3.80 | The effects of metformin on endothelial dysfunction, lipid metabolism and oxidative stress in women with polycystic ovary syndrome. ( Bayram, F; Diri, H; Kocer, D, 2014) |
| "Insulin-sensitizer treatment with metformin is common in polycystic ovary syndrome (PCOS)." | 3.80 | Metformin resistance alleles in polycystic ovary syndrome: pattern and association with glucose metabolism. ( Lerchbaum, E; Obermayer-Pietsch, B; Pieber, T; Schweighofer, N; Schwetz, V; Trummer, O, 2014) |
| "Metformin treatment (850 mg twice daily for 6 months) substantially increased serum adipolin concentrations (P < 0·05) in women with polycystic ovary syndrome (PCOS), a pro-inflammatory state associated with obesity, diabetes, dyslipidaemia and atherosclerosis." | 3.80 | Circulatory changes of the novel adipokine adipolin/CTRP12 in response to metformin treatment and an oral glucose challenge in humans. ( Amar, O; Chen, J; Hu, J; Lehnert, H; Mattu, HS; Patel, V; Ramanjaneya, M; Randeva, HS; Tan, BK, 2014) |
| "The combination of dimethylbiguanide and pioglitazone was more effective for the treatment of PCOS complicated with IR than simple pioglitazone; chronic inflammation occurrence was possibly one of reasons for insulin sensitivity reduction of patients with PCOS." | 3.80 | Treatment of polycystic ovarian syndrome with insulin resistance by insulin-sensitizer. ( Hu, L; Hu, MH; Shen, H; Tian, L; Wu, QF, 2014) |
| "Metformin administration resulted in significant decrease in the body weight, body mass index, hirsutism score, fasting and postprandial blood glucose, fasting serum insulin, HOMA index, sleep disturbances scale, and Epworth sleepiness scale compared to the untreated PCOS group." | 3.80 | Effect of metformin on sleep disorders in adolescent girls with polycystic ovarian syndrome. ( Abdelmotaleb, GS; Aly, MK; El-Sharkawy, AA; Kabel, AM, 2014) |
| "To investigate the therapeutical effects of visfatin and metformin on insulin resistance and reproductive endocrine disorder in rats with polycystic ovary syndrome (PCOS)." | 3.80 | [Effects of visfatin and metformin on insulin resistance and reproductive endocrine in rats with polycystic ovary syndrome]. ( Gu, J; Li, T; Su, S; Wan, J; Zhang, T; Zou, X, 2014) |
| "To analyze the level of serum leptin and its relations with insulin resistance in patients with polycystic ovary syndrome (PCOS) so as to investigate the clinical effect of aciesis in PCOS under treatment of metformin." | 3.80 | [Association between levels of serum leptin and insulin resistance in patients with polycystic ovary syndrome]. ( Cheng, X; Guo, J; Xie, J, 2014) |
| "Women with anovulatory polycystic ovary syndrome (PCOS) are generally insulin-resistant and as a consequence are often treated with the biguanide metformin." | 3.79 | Metformin inhibits follicle-stimulating hormone (FSH) action in human granulosa cells: relevance to polycystic ovary syndrome. ( Elia, A; Jawad, Z; Mason, HD; Pellatt, L; Rice, S, 2013) |
| "Metformin treatment enhances both adiponectin activity and insulin sensitivity, resulting in a less hyperandrogenic state in patients with PCOS." | 3.79 | Role of adiponectin and its receptor in prediction of reproductive outcome of metformin treatment in patients with polycystic ovarian syndrome. ( Hamed, HO, 2013) |
| " The secondary objective was to evaluate changes in body mass index (BMI), waist-to-hip ratio (WHR), and insulin sensitivity after 3 months of metformin therapy." | 3.79 | Insulin resistance assessment in patients with polycystic ovary syndrome using different diagnostic criteria--impact of metformin treatment. ( Brodowska, A; Ciećwież, S; Kotlega, D; Marciniak, A; Nawrocka-Rutkowska, J; Starczewski, A; Wiśniewska, B, 2013) |
| "The latest list of reimbursed medicines includes, as a new addition, metformin for the treatment of polycystic ovary syndrome (PCOS), which is extremely important for practicing physicians." | 3.79 | Metformin for polycystic ovary syndrome. ( Milewicz, A, 2013) |
| "We examined the effects of therapy with metformin alone (n = 14) vs metformin with EP (n = 13) on HbA1C and lipid parameters over 10-14 months in 27 overweight girls, drawn from a clinic population of adolescents with PCOS." | 3.79 | Impact of metformin monotherapy versus metformin with oestrogen-progesterone on lipids in adolescent girls with polycystic ovarian syndrome. ( Bredella, MA; McManus, S; Misra, M, 2013) |
| "Metformin has been shown to be an effective treatment for anovulatory polycystic ovary syndrome (PCOS) patients in terms of menstrual cyclicity, ovulation, and pregnancy, as well as reduction of early miscarriage rate." | 3.79 | Effect of metformin treatment on endometrial vascular indices in anovulatory obese/overweight women with polycystic ovarian syndrome using three-dimensional power doppler ultrasonography. ( Elkattan, E; Khattab, S; Mohsen, IA; Nabil, H, 2013) |
| "The October 2010 ESHRE/ASRM polycystic ovary syndrome (PCOS) workshop concluded: (1) all combined oral contraceptives (COC) appear to have equal efficacy for PCOS, (2) addition of antiandrogens (spironolactone) to COCs has little treatment benefit and (3) metformin does not improve the live-birth rate and should only be used with impaired glucose tolerance." | 3.79 | Polycystic ovary syndrome and combined oral contraceptive use: a comparison of clinical practice in the United States to treatment guidelines. ( Bird, ST; Brophy, JM; Delaney, JA; Etminan, M; Hartzema, AG, 2013) |
| "Metformin has been reported to reduce the risk of gestational diabetes (GD) in women with polycystic ovarian syndrome (PCOS)." | 3.79 | How metformin acts in PCOS pregnant women: insights into insulin secretion and peripheral action at each trimester of gestation. ( Busacca, M; Campagna, G; De Cicco, S; Gagliano, D; Guido, M; Lanzone, A; Romualdi, D, 2013) |
| "The study aim was to evaluate our personal experience regarding the use and the reproductive effect of metformin administration in a large population of infertile patients with polycystic ovary syndrome (PCOS) undergoing gonadotropins ovarian stimulation for in vitro fertilization (IVF)." | 3.78 | Metformin administration in patients with polycystic ovary syndrome who receive gonadotropins for in vitro fertilization cycles: 10-year experience in a large infertile population. ( Cappiello, F; Di Cello, A; Falbo, A; Morelli, M; Orio, F; Palomba, S; Russo, T; Tolino, A; Zullo, F, 2012) |
| "To evaluate the ovarian function during early infancy in daughters of women with polycystic ovary syndrome (PCOS) treated with metformin throughout pregnancy (PCOSd+M), as a means to reduce androgen and insulin levels, compared with daughters of nontreated PCOS women (PCOSd-M) and daughters of women who belong to a healthy comparison group (HCd)." | 3.78 | Improvement of hyperandrogenism and hyperinsulinemia during pregnancy in women with polycystic ovary syndrome: possible effect in the ovarian follicular mass of their daughters. ( Crisosto, N; Echiburú, B; Ladrón de Guevara, A; Maliqueo, M; Pérez, V; Preisler, J; Sánchez, F; Sir-Petermann, T, 2012) |
| "To evaluate retrospectively the prevalence of gestational diabetes (GD) in pregnancies obtained with myo-inositol administration in women with polycystic ovary syndrome." | 3.78 | Myo-inositol may prevent gestational diabetes in PCOS women. ( Corrado, F; D'Anna, R; Di Benedetto, A; Di Benedetto, V; Interdonato, ML; Raffone, E; Rizzo, P, 2012) |
| "We studied patient persistence with oral contraceptive pills (OCPs) compared to metformin for treatment of polycystic ovary syndrome (PCOS) in an urban university clinic population." | 3.78 | Persistence with oral contraceptive pills versus metformin in women with polycystic ovary syndrome. ( Cheang, KI; Karjane, NW; Mandolesi, GA; Stovall, DW, 2012) |
| "Serum hsCRP improved with lifestyle modification and metformin therapy for 3 months in overweight subjects from India with PCOS, along with serum total cholesterol, triglycerides, and HDL-C." | 3.78 | Effect of lifestyle modification and metformin therapy on emerging cardiovascular risk factors in overweight Indian women with polycystic ovary syndrome. ( Bitla, A; P V L N Rao, S; Rajagopal, G; Reddy, AP; Sachan, A; Suresh, V; Venkata Harinarayan, C, 2012) |
| "Metformin (an insulin sensitizer) and spironolactone (an antiandrogen) are both used for treatment of polycystic ovary syndrome." | 3.78 | Effect of metformin and spironolactone therapy on OGTT in patients with polycystic ovarian syndrome - a retrospective analysis. ( Ammini, AC; Ganie, MA; Gupta, N; Kulshreshtha, B, 2012) |
| "We aimed to compare the effects of metformin and metformin-rosuvastatin combination therapies on hyperandrogenism in patients with polycystic ovary syndrome (PCOS)." | 3.78 | Effects of metformin plus rosuvastatin on hyperandrogenism in polycystic ovary syndrome patients with hyperlipidemia and impaired glucose tolerance. ( Acbay, O; Celik, O, 2012) |
| "The objective was to explore the effects of metformin on the expression of endometrial glucose transporter 4 (GLUT4) and analyze the related factors of GLUT4 in patients with polycystic ovary syndrome (PCOS)." | 3.78 | Effects of metformin on the expression of GLUT4 in endometrium of obese women with polycystic ovary syndrome. ( Jiang, QH; Liu, CX; Sun, YP; Tian, ZR; Zhai, J, 2012) |
| " Of the available agents affecting insulin sensitivity, metformin has been the most widely used but despite an enormous literature reporting beneficial effects on reproductive, cutaneous and metabolic manifestations of PCOS, its efficacy is unproven apart from in those subjects with impaired glucose tolerance or frank diabetes." | 3.77 | When should an insulin sensitizing agent be used in the treatment of polycystic ovary syndrome? ( Franks, S, 2011) |
| "Metformin is a promising medication for the prevention or reduction of the incidence of GDM and pre-eclampsia in PCOS women." | 3.77 | Can metformin reduce the incidence of gestational diabetes mellitus in pregnant women with polycystic ovary syndrome? Prospective cohort study. ( Aboul Foutouh, I; Ashmawi, HS; Khattab, S; Mohsen, IA; Mohsen, MN; van der Veen, F; van Wely, M; Youssef, MA, 2011) |
| "To assess the effect of metformin administration on thyroid function in overweight women with polycystic ovarian syndrome (PCOS)." | 3.77 | Metformin decreases thyrotropin in overweight women with polycystic ovarian syndrome and hypothyroidism. ( Fatemi, S; Morteza Taghavi, S; Rokni, H, 2011) |
| " The aim of the study was to assess serum vaspin levels in PCOS and the effects on vaspin levels of metformin or of weight loss." | 3.77 | The effect of weight loss and treatment with metformin on serum vaspin levels in women with polycystic ovary syndrome. ( Delkos, D; Dinas, K; Kalaitzakis, E; Kandaraki, EA; Katsikis, I; Koiou, E; Panidis, D; Tziomalos, K, 2011) |
| "A high rate of GD or IGT already was observed in the first weeks of pregnancy in our cohort under metformin treatment." | 3.77 | Early onset and high prevalence of gestational diabetes in PCOS and insulin resistant women before and after assisted reproduction. ( Bals-Pratsch, M; Grosser, B; Ortmann, O; Seifarth, C; Seifert, B, 2011) |
| "Treatment with metformin three times 500 mg daily had been advised since 2002, to patients suffering from the polycystic ovary syndrome diagnosed by the Rotterdam criteria and who did not want to take contraceptive pills." | 3.77 | [Metformin treatment with or without life style changes in patients with polycystic ovary syndrome]. ( Petrányi, G; Zaoura-Petrányi, M, 2011) |
| "To search for predictors of metformin response in women with polycystic ovary syndrome (PCOS) through a detailed analysis of clinical and laboratory parameters." | 3.77 | Influence of LH and high-density lipoprotein cholesterol (HDL-C) on metformin response in women with polycystic ovary syndrome. ( Baracat, EC; da Costa, LC; da Fonseca, AM; Hayashida, SA; Maciel, GA; Marcondes, JA; Soares, JM, 2011) |
| "The use of metformin throughout gestation by pregnant women with polycystic ovary syndrome (PCOS) significantly reduces the number of first trimester spontaneous abortions and the rate of occurrence of gestational diabetes." | 3.77 | Metformin pharmacokinetics in nondiabetic pregnant women with polycystic ovary syndrome. ( Cavalli, RC; Dantas Moisés, EC; Dantes Moisés, EC; de Jesus Antunes, N; de Jesus Ponte Carvalho, TM; de Oliveira Baraldi, C; Duarte, G; Lanchote, VL, 2011) |
| "The objective of this study is to determine the ability of metformin treatment in reducing the prevalence of metabolic syndrome (MS) and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome (PCOS)." | 3.77 | Long-term metformin treatment is able to reduce the prevalence of metabolic syndrome and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome. ( Apa, R; Cefalo, C; Ciardulli, A; Gangale, MF; Grieco, A; Lanzone, A; Martinez, D; Miele, L; Morciano, A; Moro, F; Palla, C; Pompili, M; Sagnella, F; Tropea, A, 2011) |
| "Metformin has failed to gain wide acceptance as a first-line treatment option for women with anovulatory infertility related to polycystic ovary syndrome." | 3.77 | Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS-related ovulation dysfunction in a randomised controlled trial. ( Bontekoe, S; Johnson, NP; Stewart, AW, 2011) |
| "To evaluate serum visfatin levels and to determine the effects of metformin treatment on visfatin levels in patients with polycystic ovary syndrome (PCOS)." | 3.76 | Effect of metformin on serum visfatin levels in patients with polycystic ovary syndrome. ( Cakal, E; Engin-Ustun, Y; Ozkaya, M; Ustun, Y, 2010) |
| "To evaluate whether the administration of metformin exerts any effects on serum homocysteine (Hcy) levels in patients with polycystic ovary syndrome (PCOS) and whether supplementation with folate enhances the positive effects of metformin on the structure and function of the vascular endothelium." | 3.76 | Effects of metformin with or without supplementation with folate on homocysteine levels and vascular endothelium of women with polycystic ovary syndrome. ( Colao, A; Falbo, A; Giallauria, F; Orio, F; Palomba, S; Russo, T; Tolino, A; Zullo, F, 2010) |
| "Several data have demonstrated the efficacy of metformin in inducing ovulation in patients with polycystic ovary syndrome (PCOS), however, the exact mechanism by which this drug acts remains unknown." | 3.76 | Systemic and local effects of metformin administration in patients with polycystic ovary syndrome (PCOS): relationship to the ovulatory response. ( Falbo, A; Orio, F; Palomba, S; Russo, T; Tolino, A; Zullo, F, 2010) |
| "Abstract Objective: To evaluate the effects of oral contraceptives and metformin on the outcome of in vitro maturation (IVM) in infertile women with polycystic ovary syndrome (PCOS)." | 3.76 | Effects of oral contraceptives and metformin on the outcome of in vitro maturation in infertile women with polycystic ovary syndrome. ( Huang, XF; Huang, YP; Lin, JJ; Yang, HY; Zhang, W; Zhao, JZ, 2010) |
| " The variables evaluated were first-line methods of weight reduction used, proportion of women with PCOS seen that were obese, whether the patients had tried other weight reduction methods before seeking help, the optimal dietary advice and optimal composition, the optimal duration and frequency of exercise suggested, BMI used for suggesting weight loss, percentage of women in whom weight loss worked, length of time allowed prior to suggesting another method, methods considered most effective by patients, use of metformin for weight loss, criteria used for prescribing metformin, first-line anti-obesity drugs preferred if any, second- and third-line methods used, referral to other specialists and criteria for referral for bariatric surgery." | 3.76 | National survey on management of weight reduction in PCOS women in the United Kingdom. ( Atiomo, W; Sharma, A; Walker, DM, 2010) |
| "The pregnancy in polycystic ovary syndrome (PPCOS) study was a prospective, multi-center, randomized clinical trial comparing three ovulation induction regimens: clomiphene citrate (CC), metformin and the combination of the two." | 3.76 | Decision trees for identifying predictors of treatment effectiveness in clinical trials and its application to ovulation in a study of women with polycystic ovary syndrome. ( Brzyski, RG; Casson, PR; Chen, X; Christman, GM; Coutifaris, C; Diamond, MP; Eisenberg, E; Huang, H; Krawetz, SA; Legro, RS; Santoro, N; Schlaff, WD; Zhang, H; Zhang, J; Zhang, L, 2010) |
| " Women who had elective cryopreservation due to ovarian hyperstimulation syndrome risk were found to have significantly higher LBRs if metformin was taken in the fresh IVF/ICSI cycle (A = 44." | 3.76 | Effect of metformin taken in the 'fresh' in vitro fertilization/intracytoplasmic sperm injection cycle upon subsequent frozen embryo replacement in women with polycystic ovary syndrome. ( Acharya, S; Balen, A; Brewer, C; Tang, T; Thake, F, 2010) |
| "To evaluate the effects of metformin on the ovarian stromal blood perfusion in the patients with polycystic ovary syndrome (PCOS)." | 3.75 | The effect of metformin treatment on ovarian stromal blood flow in women with polycystic ovary syndrome. ( Ciftci, FC; Ozcimen, EE; Uckuyu, A; Zeyneloglu, HB, 2009) |
| "To evaluate the effect of metformin addition during ovarian hyperstimulation on cycle parameters and outcome of in vitro fertilization (IVF) treatment in polycystic ovary syndrome (PCOS) patients with a body mass index (BMI) <28 kg/m(2)." | 3.75 | Efficacy of metformin supplementation during ovarian stimulation of lean PCOS patients undergoing in vitro fertilization. ( Kahraman, S; Kumbak, B, 2009) |
| "The aim of the present study was to assess whether continuation of metformin therapy throughout pregnancy can reduce the development of gestational diabetes in women with polycystic ovarian syndrome (PCOS)." | 3.75 | Prevention of gestational diabetes mellitus by continuing metformin therapy throughout pregnancy in women with polycystic ovary syndrome. ( Begum, A; Begum, MR; Begum, MS; Ferdous, J; Khan, F; Khanam, NN; Quadir, E, 2009) |
| "This study aimed to assess the perinatal outcome, especially foetal growth, following the continuation of metformin during the first trimester of pregnancy." | 3.75 | Continuation of metformin in the first trimester of women with polycystic ovarian syndrome is not associated with increased perinatal morbidity. ( Bolton, S; Cleary, B; Dempsey, E; Turner, MJ; Walsh, J, 2009) |
| "Most research confirms that metformin therapy has a positive influence on cardiovascular risk factors (CVRF) such as dyslipidemia, insulin resistance and hyperandrogenism in polycystic ovary syndrome (PCOS)." | 3.74 | Plasma cytokines in obese women with polycystic ovary syndrome, before and after metformin treatment. ( Bednarek-Tupikowska, G; Bohdanowicz-Pawlak, A; Demissie, M; Jakubowska, J; Milewicz, A; Szymczak, J, 2008) |
| "To date, among insulin-sensitizing drugs, only metformin should be used to improve reproductive function in well selected polycystic ovary syndrome patients." | 3.74 | Insulin-sensitizing agents and reproductive function in polycystic ovary syndrome patients. ( Falbo, A; Orio, F; Palomba, S; Zullo, F, 2008) |
| " We present a case of psychosis associated with the menstrual cycle in a patient with polycystic ovary syndrome, a disorder typically characterized by anovulatory cycles, in whom the restoration of normal menstruation with use of metformine led to significant improvement of psychotic symptoms." | 3.74 | Metformine for psychosis associated with the menstrual cycle in a patient with polycystic ovary syndrome. ( Andreou, C; Karavatos, A; Syngelakis, M, 2008) |
| "In women with PCOS, continuous use of metformin during pregnancy significantly reduced the rate of miscarriage, gestational diabetes requiring insulin treatment and fetal growth restriction." | 3.74 | Does continuous use of metformin throughout pregnancy improve pregnancy outcomes in women with polycystic ovarian syndrome? ( Khalid, R; Naru, T; Nawaz, FH; Rizvi, J, 2008) |
| "Metformin therapy in polycystic ovary syndrome (PCOS) improves metabolic and hormonal profiles." | 3.74 | Effect of metformin administration on plasma advanced glycation end product levels in women with polycystic ovary syndrome. ( Aessopos, A; Alexandraki, K; Diamanti-Kandarakis, E; Katsikis, I; Panidis, D; Paterakis, T; Piperi, C, 2007) |
| "To evaluate the acute effects of metformin therapy on biochemical markers and polycystic ovarian morphology among insulin-resistant (IR) and noninsulin-resistant (NIR) patients with polycystic ovary syndrome (PCOS)." | 3.74 | Acute effects of metformin therapy include improvement of insulin resistance and ovarian morphology. ( Bayrak, A; Mor, E; Paulson, RJ; Stanczyk, FZ; Terbell, H; Urwitz-Lane, R, 2007) |
| " There is no evidence-based schema for achieving pregnancy in women with PCOS, though lifestyle modification, clomiphene citrate, and metformin are the current front line therapies." | 3.74 | Pregnancy considerations in women with polycystic ovary syndrome. ( Legro, RS, 2007) |
| " We evaluated serum CRP level, before and after metformin therapy in obese women with polycystic ovarian syndrome (PCOS)." | 3.74 | C-reactive protein in obese PCOS women and the effect of metformin therapy. ( Velija-Asimi, Z, 2007) |
| " In a university teaching hospital, a total of 38 patients with polycystic ovarian syndrome were treated by metformin before undergoing an IVM cycle." | 3.74 | Controlled natural cycle IVF: a novel approach for a dominant follicle during an in-vitro maturation cycle. ( Fanchin, R; Frydman, N; Frydman, R; Kadoch, IJ; Le Du, A, 2007) |
| "There are conflicting data regarding the effects of metformin in lean women with polycystic ovary syndrome (PCOS)." | 3.74 | The effects of metformin on metabolic and cardiovascular risk factors in nonobese women with polycystic ovary syndrome. ( Aygen, E; Kelestimur, F; Sahin, Y; Unluhizarci, K; Yikilmaz, A; Yilmazsoy, A, 2007) |
| "To compare the incidence of multiple gestation following treatment with clomiphene citrate (CC), metformin (MET) or gonadotropins in polycystic ovary syndrome (PCOS) patients undergoing ovulation induction." | 3.74 | Risk of multiple gestation after ovulation induction in polycystic ovary syndrome. ( Kraja, A; Odem, RR; Pauls, RN; Pinto, AB; Ratts, VS; Williams, DB, 2007) |
| "The effect of 6 months of metformin treatment was prospectively assessed in 188 PCOS patients, divided into three groups according to body mass index (BMI; lean: BMI<25 kg/m2, overweight: BMI 25-29 kg/m2, and obese: BMI30 kg/m2)." | 3.74 | Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance. ( Benson, S; Dietz, T; Elsenbruch, S; Hahn, S; Janssen, OE; Kimmig, R; Lahner, H; Mann, K; Moeller, LC; Schmidt, M; Tan, S, 2007) |
| " We sought to characterize patients with biochemical hyperandrogenism in respect of tumor versus non-tumor etiologies, explore possible links between non-tumor hyperandrogenism and metabolic syndrome, and ascertain whether metformin therapy can elicit diagnostic reductions in serum testosterone (T)." | 3.74 | The investigation and management of severe hyperandrogenism pre- and postmenopause: non-tumor disease is strongly associated with metabolic syndrome and typically responds to insulin-sensitization with metformin. ( Advani, A; Al-Ozairi, E; Ball, SG; James, RA; Lim, E; Quinton, R; Vaikkakara, S, 2008) |
| " In this study, therefore, we aimed (1) to determine the circulating ADMA concentrations in 44 women with PCOS and 22 age- and BMI-matched healthy controls, (2) to evaluate its correlations with insulin resistance, gonadotrophins, and androgen secretion, and (3) to compare effects of metformin and ethinyl estradiol-cyproterone acetate (EE/CPA) treatments on circulating ADMA concentrations." | 3.74 | Metformin and oral contraceptive treatments reduced circulating asymmetric dimethylarginine (ADMA) levels in patients with polycystic ovary syndrome (PCOS). ( Baser, I; Dede, M; Erbil, MK; Kenar, L; Oktenli, C; Ozgurtas, T; Sanisoglu, SY; Tapan, S; Yenen, MC; Yesilova, Z, 2008) |
| "This study evaluated the use of metformin as first line treatment for patients with polycystic ovary syndrome." | 3.74 | The use of metformin as first line treatment in polycystic ovary syndrome. ( Abbas, M; Gannon, M, 2008) |
| " It has been suggested that metformin in combination with clomiphene can restore ovulation to some clomiphene-resistant anovulators with polycystic ovary syndrome (PCOS)." | 3.74 | Extended-release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome. ( Barnhart, HX; Carr, BR; Carson, SA; Cataldo, NA; Coutifaris, C; Diamond, MP; Giudice, LC; Gosman, G; Legro, RS; McGovern, PG; Myers, ER; Nestler, JE; Schlaff, WD; Steinkampf, MP, 2008) |
| "We prospectively assessed whether metabolic and menstrual benefits of metformin-diet were equally realized in women with polycystic ovary syndrome (PCOS), categorized by pretreatment top (n = 32) and bottom (n = 35) quintile homeostasis model assessment insulin resistance (IR)." | 3.73 | Metformin-diet benefits in women with polycystic ovary syndrome in the bottom and top quintiles for insulin resistance. ( Glueck, CJ; Goldenberg, N; Loftspring, M; Sherman, A; Wang, P, 2005) |
| "Metformin had differential effects on fasting insulin levels, insulin resistance as demonstrated by homeostasis model assessment (HOMA), LH, total testosterone, dehydroepiandrosterone sulphate and free testosterone index on the basis of IRS genotype." | 3.73 | The importance of IRS-1 Gly972Arg polymorphism in evaluating the response to metformin treatment in polycystic ovary syndrome. ( Aktas, A; Dilek, S; Erdal, EM; Ertunc, D; Tok, EC, 2005) |
| "This study was carried out to compare ovulation and pregnancy rates in response to metformin therapy in lean and obese women with polycystic ovary syndrome (PCOS)." | 3.73 | Metformin monotherapy in lean women with polycystic ovary syndrome. ( Abdel-Wareth, LO; Al Haija, SA; Alvares, M; Haq, A; Jayasundaram, R; Kumari, AS, 2005) |
| "Based on the favourable international experience with metformin in the most common female endocrine disease, the polycystic ovary syndrome, which has insulin resistance in the background, the author's treatment advice has been this in such cases since early 2002: for sexually active women who do not want to become pregnant for the time being, anti-androgenic contraceptive pill; for those who do not want to take contraceptives, contraceptives are contraindicated, or who do want to conceive, metformin." | 3.73 | [Treatment experience with metformin in polycystic ovary syndrome]. ( Petrányi, G, 2005) |
| "Recent data indicate that women affected by the polycystic ovary syndrome (PCOS) are at greater risk for cardiovascular disease and that metformin may improve the metabolic alterations in these patients." | 3.73 | Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: results of a 6-month study. ( Azziz, R; Cascella, T; Colao, A; De Simone, B; Lombardi, G; Manguso, F; Orio, F; Palomba, S; Russo, T; Savastano, S; Tolino, A; Zullo, F, 2005) |
| "In women with polycystic ovary syndrome, metformin administration, not laparoscopic ovarian drilling, reduces plasminogen activator inhibitor 1 (PAI-1) activity." | 3.73 | Plasminogen activator inhibitor 1 and miscarriage after metformin treatment and laparoscopic ovarian drilling in patients with polycystic ovary syndrome. ( Falbo, A; Orio, F; Palomba, S; Russo, T; Tolino, A; Zullo, F, 2005) |
| "Our data showed that both metformin and rosiglitazone increased insulin sensitivity in obese patients with PCOS as expected, and in lean patients as well." | 3.73 | The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome. ( Arslan, M; Ayvaz, G; Bingöl, B; Biri, A; Cakir, N; Karakoç, A; Tiras, B; Törüner, F; Yilmaz, M, 2005) |
| "Plasma androgen levels were decreased significantly by metformin treatment, as were plasma LH and allopregnanolone levels and insulin resistance." | 3.73 | Metformin administration modulates neurosteroids secretion in non-obese amenorrhoic patients with polycystic ovary syndrome. ( Baraldi, E; Casarosa, E; Genazzani, AD; Genazzani, AR; Lanzoni, C; Luisi, M; Mehmeti, H; Ricchieri, F; Strucchi, C, 2006) |
| "A pregnant patient with polycystic ovary syndrome asked me whether continuing metformin, which she was taking to treat infertility before her pregnancy, is safe for her fetus." | 3.73 | Metformin use during the first trimester of pregnancy. Is it safe? ( Gilbert, C; Koren, G; Valois, M, 2006) |
| "To analyze pregnancy complications and outcome in patients with polycystic ovary syndrome (PCOS) treated with metformin." | 3.73 | Pregnancy outcome in infertile patients with polycystic ovary syndrome who were treated with metformin. ( Jackson, EM; Thatcher, SS, 2006) |
| "To report the effect of metformin treatment on a patient with recurrent miscarriage (RM) and polycystic ovary syndrome (PCOS)." | 3.73 | Metformin hydrochloride and recurrent miscarriage in a woman with polycystic ovary syndrome. ( Falbo, A; Orio, F; Palomba, S; Russo, T; Tolino, A; Zullo, F, 2006) |
| "The present study supports the notion that metformin may be considered as a prophylactic therapy lowering cardiovascular risk factors in hyperinsulinemic women with polycystic ovary syndrome." | 3.73 | Lipids in polycystic ovary syndrome: role of hyperinsulinemia and effects of metformin. ( Banaszewska, B; Duleba, AJ; Pawelczyk, L; Spaczynski, RZ, 2006) |
| "The objective of this study was to review the first 50 clinical pregnancies of women with polycystic ovarian syndrome (PCOS) who had ovulation induced either with metformin alone, or in combination with clomifene." | 3.73 | Outcome of clinical pregnancies after ovulation induction using metformin. ( Byrne, KM; Farah, N; Langan, H; Murphy, C; Turner, MJ; Walsh, J, 2006) |
| "55 g metformin per day throughout pregnancy and lactation." | 3.73 | Growth, motor, and social development in breast- and formula-fed infants of metformin-treated women with polycystic ovary syndrome. ( Glueck, CJ; Salehi, M; Sieve, L; Wang, P, 2006) |
| " Metformin therapy reduces whole-body insulin resistance (IR) in patients with type-2 diabetes mellitus (DM)." | 3.73 | Metformin therapy improves coronary microvascular function in patients with polycystic ovary syndrome and insulin resistance. ( Caliskan, M; Erdogan, D; Gullu, H; Muderrisoglu, H; Ozcimen, EE; Tok, D; Topcu, S; Uckuyu, A; Zeyneloglu, H, 2006) |
| "To determine whether women with polycystic ovary syndrome (PCOS) and abnormal insulin levels treated with metformin had different rates of ovulation and pregnancy from women with PCOS and normal insulin levels." | 3.73 | Use of metformin for ovulation induction in women who have polycystic ovary syndrome with or without evidence of insulin resistance. ( Liu, KE; Sagle, M; Tataryn, IV, 2006) |
| "The mean birth weight percentile of neonates exposed to metformin in utero during the first trimester was significantly lower than that of neonates delivered to normal healthy matched controls." | 3.73 | Neonatal outcome in polycystic ovarian syndrome patients treated with metformin during pregnancy. ( Glezerman, M; Gur, D; Kovo, M; Levran, D; Rotmensch, S; Weissman, A, 2006) |
| "In 74 women with polycystic ovary syndrome, treated for 4 years with metformin (MET) and diet, we prospectively assessed whether, and to what degree, weight loss, reduction of insulin resistance, and amelioration of coronary heart disease risk factors could be sustained." | 3.73 | Sustainability of 8% weight loss, reduction of insulin resistance, and amelioration of atherogenic-metabolic risk factors over 4 years by metformin-diet in women with polycystic ovary syndrome. ( Agloria, M; Aregawi, D; Glueck, CJ; Sieve, L; Wang, P; Winiarska, M, 2006) |
| "In an observational study of 13 women with polycystic ovary syndrome (PCOS) not optimally responsive to metformin diet, we assessed the efficacy and safety of addition of pioglitazone." | 3.72 | Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin. ( Glueck, CJ; Goldenberg, N; Moreira, A; Sieve, L; Wang, P, 2003) |
| "The purpose of this review is to provide a critical summary of recent studies on the clinical effects of metformin in polycystic ovary syndrome." | 3.72 | The role of metformin in the management of polycystic ovary syndrome. ( Prelevic, GM; Tsilchorozidou, T, 2003) |
| "To evaluate the effects of metformin on gonadotropin-induced ovulation in patients with polycystic ovary syndrome (PCOS)." | 3.72 | [Effects of metformin on gonadotropin-induced ovulation in patients with polycystic ovary syndrome]. ( Chi, HH; Lin, JJ; Lin, WQ; Ye, BL; Zhao, JZ, 2003) |
| "Women with polycystic ovary syndrome (PCOS) are increasingly being treated with metformin as an insulin sensitizing agent to reduce symptoms of hyperandrogenism and promote fertility." | 3.72 | Women with polycystic ovary syndrome (PCOS) often undergo protracted treatment with metformin and are disinclined to stop: indications for a change in licensing arrangements? ( Fleming, R; Muth, S; Norman, J; Sattar, N, 2004) |
| "The aim of this study was to assess the efficacy of metformin on induction of ovulation in Asian women with clomiphene citrate (CC)-resistant polycystic ovary syndrome (PCOS)." | 3.72 | Efficacy of metformin on ovulation induction in Asian women with polycystic ovary syndrome. ( Choktanasiri, W; Rojanasakul, A; Sophonsritsuk, A; Tingthanatikul, Y; Wansumrith, S; Weerakiet, S, 2004) |
| "We sought to determine whether metformin, which had facilitated conception in 72 oligoamenorrhoeic women with polycystic ovary syndrome (PCOS), would safely reduce the rate of first trimester spontaneous abortion (SAB) and increase the number of live births without teratogenicity." | 3.71 | Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. ( Glueck, CJ; Goldenberg, N; Sieve-Smith, L; Wang, P, 2002) |
| "To determine if metformin therapy improves in vitro fertilization (IVF) outcomes in patients with clomiphene-resistant polycystic ovarian syndrome (PCOS)." | 3.71 | Metformin treatment of patients with polycystic ovary syndrome undergoing in vitro fertilization improves outcomes and is associated with modulation of the insulin-like growth factors. ( Riehl, RM; Stadtmauer, LA; Talbert, LM; Toma, SK, 2001) |
| "Long-term metformin treatment reduced various steroid enzymatic activities both in the ovary and the adrenal glands, without apparent changes in basal steroid levels and in insulin sensitivity." | 3.71 | The effects of long-term metformin treatment on adrenal and ovarian steroidogenesis in women with polycystic ovary syndrome. ( Bendlová, B; Cibula, D; Hill, M; Snajderová, M; Stárka, L; Sulcová, J; Vondra, K; Vrbíková, J, 2001) |
| " Metformin, an oral hypoglycaemic agent that increases insulin sensitivity, has been shown to reduce serum concentrations of insulin and androgens, to reduce hirsutism, and to improve ovulation rates." | 3.71 | Metformin and intervention in polycystic ovary syndrome. Endocrine Society of Australia, the Australian Diabetes Society and the Australian Paediatric Endocrine Group. ( Cuneo, RC; Kidson, WJ; Norman, RJ; Zacharin, MR, 2001) |
| "We evaluated the fertility promoting effect of metformin in infertile patients with polycystic ovary syndrome." | 3.71 | Metformin improves ovulation and pregnancy rates in patients with polycystic ovary syndrome. ( Batukan, C; Baysal, B, 2001) |
| "The aim of the present study was to investigate the steroidogenic response pattern to HCG in obese women with polycystic ovary syndrome (PCOS) and the possible effects of metformin treatment on it." | 3.71 | Ovarian steroidogenic response to human chorionic gonadotrophin in obese women with polycystic ovary syndrome: effect of metformin. ( Koivunen, RM; Martikainen, HK; Morin-Papunen, LC; Ruokonen, A; Tapanainen, JS, 2001) |
| "Basing on the key role of the hyperinsulinemia in the etiopathogenesis of the Polycystic ovary syndrome, the authors treat the affected women with Metformin." | 3.71 | [Our experience in the treatment of polycystic ovary syndrome with Metformin]. ( Mitkov, M; Pekhlivanov, B; Simeonov, S; Velchev, G, 2001) |
| "Long-term therapy with metformin led to the improvement in menstrual cyclicity, without significant change in basal steroid levels or parameters of insulin resistance." | 3.71 | [Effect of long-term treatment with metformin on steroid levels and parameters of insulin resistance in women with polycystic ovary syndrome]. ( Bendlová, B; Cibula, D; Hill, M; Snajderová, M; Stárka, L; Sulcová, J; Vondra, K; Vrbíková, J, 2001) |
| "To evaluate the long-term effects of metformin on biochemical variables and body weight in polycystic ovary syndrome (PCOS)." | 3.71 | Biochemical and body weight changes with metformin in polycystic ovary syndrome. ( Batukan, C; Batukan, M; Baysal, B, 2001) |
| "Before metformin therapy, after covariance adjustment for age, the two cohorts did not differ in height, weight, basal metabolic index, insulin, insulin resistance, or insulin secretion." | 3.71 | Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. ( Glueck, CJ; Kobayashi, S; Phillips, H; Sieve-Smith, L; Wang, P, 2002) |
| " In the present study we tested the hypothesis that metformin therapy in obese adolescents with PCOS will attenuate the adrenal steroidogenic response to ACTH, with reduction of insulin resistance/insulinemia." | 3.71 | Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. ( Arslanian, SA; Danadian, K; Lewy, V; Saad, R, 2002) |
| "To assess pregnancy outcome in anovulatory infertility patients diagnosed with polycystic ovary syndrome (PCOS) who were treated with metformin." | 3.71 | Pregnancies following use of metformin for ovulation induction in patients with polycystic ovary syndrome. ( Buster, JE; Carson, SA; Heard, MJ; Pierce, A, 2002) |
| "To assess the therapeutic effects of metformin in patients with polycystic ovary syndrome (PCOS) and clomiphene (CC) resistant cases." | 3.71 | [Effects of metformin on the plasminogen activator system, endocrine, metabolic profiles in patients with polycystic ovary syndrome and clomiphene resistant cases]. ( Huang, Z; Li, J; Shen, H; Song, J; Zhang, Y, 2002) |
| "The objective of the study was to find predictors of a successful therapy with metformin in polycystic ovary syndrome." | 3.71 | Prediction of the effect of metformin treatment in patients with polycystic ovary syndrome. ( Hill, M; Stárka, L; Vondra, K; Vrbíková, J, 2002) |
| " Metformin therapy resulted in some improvement in insulin sensitivity and reduced the basal and post-glucose load insulin levels." | 3.70 | The treatment of insulin resistance does not improve adrenal cytochrome P450c17alpha enzyme dysregulation in polycystic ovary syndrome. ( Bayram, F; Keleştimur, F; Sahin, Y; Unlühizarci, K, 1999) |
| " Metformin therapy improved menstrual disturbances in 25% of the women with PCOS and also resulted in some improvement in insulin sensitivity and reduced basal and post glucose load insulin levels." | 3.70 | The effects of metformin on insulin resistance and ovarian steroidogenesis in women with polycystic ovary syndrome. ( Bayram, F; Keleştimur, F; Sahin, Y; Tutuş, A; Unlühizarci, K, 1999) |
| "The objective of the present study was to investigate whether metformin affected plasma concentrations of insulin-like growth factor (IGF) I and IGF-binding protein I (IGFBP-I) in polycystic ovary syndrome (PCOS) patients." | 3.70 | Effect of metformin on insulin-like growth factor (IGF) I and IGF-binding protein I in polycystic ovary syndrome. ( De Leo, V; La Marca, A; Morgante, G; Orvieto, R, 2000) |
| " Metformin, a medication that improves insulin sensitivity and decreases serum insulin levels, restores menstrual cyclicity and ovulatory function and may improve fertility rates in women with PCOS." | 3.70 | Association of metformin and pregnancy in the polycystic ovary syndrome. A report of three cases. ( Neal, GS; Robinson, RD; Seale, FG, 2000) |
| "Measures of thrombophilia, hypofibrinolysis, reproductive hormones, and androgenic steroids before and after metformin therapy." | 3.70 | Polycystic ovary syndrome, infertility, familial thrombophilia, familial hypofibrinolysis, recurrent loss of in vitro fertilized embryos, and miscarriage. ( Awadalla, SG; Cameron, D; Fontaine, RN; Glueck, CJ; Phillips, H; Wang, P, 2000) |
| "To observe the efficacy of Chinese herbal formula "Tiangui Fang" (TGF) in hyperandrogenism and hyperinsulinism patients of polycystic ovarian syndrome (PCOS), and compare with western medicine metformin." | 3.70 | [Study on treatment of hyperandrogenism and hyperinsulinism in polycystic ovary syndrome with Chinese herbal formula "tiangui fang"]. ( Hou, J; Wei, M; Yu, J, 2000) |
| "Using polycystic ovary syndrome (PCOS) as a model of insulin resistance and hyperandrogenism, our specific aim was to assess the effect of Metformin on lipoproteins, sex hormones, gonadotropins, and blood pressure in 26 women with PCOS who were studied at baseline, received Metformin 1." | 3.69 | Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. ( Glueck, CJ; Hamer, T; Mendoza, S; Sosa, F; Velazquez, EM, 1994) |
| "Insulin sensitivity, the mean fasting serum levels of glucose, insulin, total cholesterol, triglyceride, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, total T, free T, androstenedione, DHEAS, and LH:FSH ratio, and the areas under the curve for plasma glucose and insulin during OGTT were not changed by either placebo or metformin treatment." | 3.69 | Can metformin reduce insulin resistance in polycystic ovary syndrome? ( Açbay, O; Gündoğdu, S, 1996) |
| "Sixteen nondiabetic women with polycystic ovary syndrome (PCOS) aged 18 to 33 years were studied before and after 8 weeks on metformin (1." | 3.69 | Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome. ( Glueck, CJ; Mendoza, SG; Velazquez, EM; Wang, P, 1997) |
| "Chronic low-grade inflammation has emerged as a key contributor to the pathogenesis of Polycystic Ovary Syndrome (PCOS)." | 3.11 | Effect of aerobic exercise on inflammatory markers in polycystic ovary syndrome: a randomized controlled trial. ( Abdelbasset, WK; Eid, MM; Elbandrawy, AM; Elkholi, SM; Ewais, NF; Morgan, EN; Yousef, AM, 2022) |
| " This study investigates the clinical efficacy of Bushen Huatan Decoction combined with Baduanjin in IR-PCOS, to form a specific TCM-behaviour intervention plan in the treatment of IR-PCOS." | 3.01 | Efficacy of Bushen Huatan Decoction combined with Baduanjin in the treatment of polycystic ovary syndrome with insulin resistance (IR-PCOS), kidney deficiency and phlegm dampness: study protocol for a randomized controlled trial. ( Cui, L; Qian, H; Tang, M; Wang, J; Wang, L; Wang, R; Wei, M; Xu, W, 2021) |
| "To evaluate the risk of miscarriage in IVF cycles in women with PCOS." | 3.01 | Polycystic ovarian syndrome and miscarriage in IVF: systematic revision of the literature and meta-analysis. ( Díaz-Nuñez, M; Laínz, L; Matorras, R; Moreira, D; Pérez-Fernandez, S; Pijoan, JI; Sainz, H, 2023) |
| "Metformin is an established staple drug in the management of Type 2 diabetes mellitus." | 3.01 | A systematic review of the uses of metformin in dermatology. ( Al-Niaimi, F; Ali, FR; Raza, S, 2023) |
| "Polycystic Ovary Syndrome is the most prevalent hormonal disorder in females." | 3.01 | Effects of myo-inositol vs. metformin on hormonal and metabolic parameters in women with PCOS: a meta-analysis. ( Adnan, A; Faheem, S; Fatima, K; Jamil, Z; Javaid, SS; Mohiuddin, N; Naeem, H; Ochani, S; Sajid, A, 2023) |
| "The optimal drug for treatment with polycystic ovary syndrome (PCOS) was in debate." | 3.01 | Comparison of different drug for reducing testosterone levels in women with polycystic ovary syndrome: A systematic review and network meta-analysis. ( Hao, SL; Meng, XY; Zhang, CL, 2023) |
| " In this meta-analysis, we aimed to compare the effectiveness and safety of exenatide alone or in combination with metformin versus metformin in patients suffering from PCOS." | 3.01 | Comparison of exenatide alone or combined with metformin versus metformin in the treatment of polycystic ovaries: a systematic review and meta-analysis. ( Guo, Y; Hamiti, S; Hu, Y; Ma, Y; Song, X; Wang, X; Yusufu, M; Zhang, K, 2023) |
| " Co-supplementation of high dosage VD with spironolactone or pioglitazone are more effective in reducing plasma leptin levels than metformin, and thus might prove to be better therapeutic strategies for women with PCOS." | 2.94 | Differential Impact of Insulin Sensitizers vs. Anti-Androgen on Serum Leptin Levels in Vitamin D Replete PCOS Women: A Six Month Open Labeled Randomized Study. ( Bhat, GA; Ganie, MA; Rashid, A; Shah, ZA; Shaheen, F; Shrivastava, M; Wani, IA, 2020) |
| "Treatment with metformin is associated with a time-dependent decrease in mtDNA-CN in patients with PCOS who are treated over the course of one year." | 2.94 | Changes in peripheral mitochondrial DNA copy number in metformin-treated women with polycystic ovary syndrome: a longitudinal study. ( Chang, CH; Chen, MJ; Chen, SU; Chou, CH; Ho, HN; Yang, PK, 2020) |
| "In view of the high incidence of polycystic ovary syndrome (PCOS) and the unsatisfactory therapeutic effects of dimethyldiguanide or clomifene citrate alone, our study aimed to investigate the therapeutic effects of dimethyldiguanide combined with clomifene citrate in the treatment of PCOS." | 2.90 | Therapeutic effects of dimethyldiguanide combined with clomifene citrate in the treatment of polycystic ovary syndrome. ( Gao, S; Jiang, J; Zhang, Y, 2019) |
| "Metformin is one of the treatments used for PCOS pathology decreasing body weight, plasma androgen, FSH and glucose levels." | 2.90 | Metformin induces lipid changes on sphingolipid species and oxidized lipids in polycystic ovary syndrome women. ( Bañuls, C; Hernandez-Mijares, A; Jové, M; Naudí, A; Pamplona, R; Pradas, I; Rocha, M; Rovira-Llopis, S; Victor, VM, 2019) |
| "Empagliflozin is a sodium-glucose-cotransporter-2 inhibitor that improves cardiovascular risk and promotes weight loss in patients with type-2 diabetes." | 2.90 | Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: A randomized controlled study. ( Abbas, J; Atkin, SL; Deshmukh, H; Javed, Z; Khan, AY; Kilpatrick, ES; Papageorgiou, M; Qamar, U; Rigby, AS; Sathyapalan, T, 2019) |
| "Treatment with metformin and NAC significantly increased ovulation and pregnancy rates in CC-resistant PCOS patients." | 2.84 | Comparison of metformin and N-acetyl cysteine, as an adjuvant to clomiphene citrate, in clomiphene-resistant women with polycystic ovary syndrome. ( Heidari, B; Nemati, M; Nemati, S; Taheri, AM, 2017) |
| "Metformin treatment was also associated with a significant decrease in LH and oestradiol levels, androgens and anti-müllerian hormone levels." | 2.84 | Metformin vs myoinositol: which is better in obese polycystic ovary syndrome patients? A randomized controlled crossover study. ( De Cicco, S; Di Florio, C; Guido, M; Immediata, V; Lanzone, A; Romualdi, D; Tagliaferri, V, 2017) |
| "This review provides an update on gestational diabetes (GDM) and other adverse pregnancy outcomes in individuals with polycystic ovary syndrome (PCOS), one of the most common metabolic disorders and causes of infertility." | 2.82 | Gestational diabetes and other adverse pregnancy outcomes in polycystic ovary syndrome. ( Powe, CE; Selen, DJ, 2022) |
| " This study aimed to compare the different effects of drospirenone (DRP)-containing COCs with cyproterone acetate (CPA)-containing COCs, combined with metformin and lifestyle modifications in women with PCOS and metabolic disorders." | 2.82 | Comparison of Drospirenone- with Cyproterone Acetate-Containing Oral Contraceptives, Combined with Metformin and Lifestyle Modifications in Women with Polycystic Ovary Syndrome and Metabolic Disorders: A Prospective Randomized Control Trial. ( Feng, GM; Huang, W; Song, Y; Wang, QS; Wang, QY; Xiao, L, 2016) |
| "Both metformin and statin have been used as methods to ameliorate symptoms and improve prognosis." | 2.80 | Inadequacy of initiating rosuvastatin then metformin on biochemical profile of polycystic ovarian syndrome patients. ( Abbas, HA; Awwad, J; Ghazeeri, G; Harajly, S; Skaff, B, 2015) |
| "Metformin has beneficial effects on insulin resistance and endothelial functions." | 2.80 | Metformin improves endothelial function and carotid intima media thickness in patients with PCOS. ( Akpek, M; Calapkorur, B; Kaya, MG; Kelestimur, F; Unluhizarci, K; Yildirim, S, 2015) |
| "The objective of the study was to evaluate whether treatment with metformin (M) or M combined with oral contraceptive pills (OCPs) resulted in a more advantageous body composition than treatment with OCP alone." | 2.79 | Body composition is improved during 12 months' treatment with metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. ( Altinok, ML; Andersen, M; Glintborg, D; Hermann, AP; Mumm, H; Ravn, P, 2014) |
| "Chronic low-grade inflammation is a common feature of insulin resistant states, including obesity and type 2 diabetes." | 2.78 | Inflammatory cytokines and chemokines, skeletal muscle and polycystic ovary syndrome: effects of pioglitazone and metformin treatment. ( Aroda, V; Ciaraldi, TP; Henry, RR; Mudaliar, SR, 2013) |
| "Berberine (BBR) is an isoquinoline derivative alkaloid extracted from Chinese medicinal herbs that has been used as an insulin sensitizer." | 2.77 | A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. ( Deng, H; Guan, Y; Liang, K; Ma, Y; Sui, M; Wang, A; Wei, W; Zhang, H; Zhang, Y; Zhao, H, 2012) |
| "In boys, birth weight was negatively correlated to the AMH levels." | 2.77 | Androgens and antimüllerian hormone in mothers with polycystic ovary syndrome and their newborns. ( Carlsen, SM; Vanky, E, 2012) |
| "Vitamin D deficiency was recompensed in 74% of the PCOS patients who had taken calcium & vitamin D supplementation." | 2.77 | Therapeutic effects of calcium & vitamin D supplementation in women with PCOS. ( Aflatoonian, A; Firouzabadi, Rd; Modarresi, S; MohammadTaheri, S; Sekhavat, L, 2012) |
| "Treatment with metformin significantly reduced IL-6, especially in PCOS patients with IRS-2 homozygous Asp variant." | 2.76 | Interleukin-6 as an early chronic inflammatory marker in polycystic ovary syndrome with insulin receptor substrate-2 polymorphism. ( Huang, MF; Lin, MW; Lin, YS; Tsai, SJ; Wu, MH; Yang, CT, 2011) |
| "The objective of this study was to assess the efficacy and safety of metformin at the dosage of 2,500 mg/day in the treatment of obese women with PCOS and also to evaluate its effect on weight, hormones, and lipid profile." | 2.75 | Metformin 2,500 mg/day in the treatment of obese women with polycystic ovary syndrome and its effect on weight, hormones, and lipid profile. ( Aghahosseini, M; Aleyaseen, A; Kashani, L; Moddaress-Hashemi, S; Mofid, B; Safdarian, L, 2010) |
| " No adverse maternal-fetal side effects were reported on enoxaparin alone or enoxaparin-metformin." | 2.74 | Enoxaparin-metformin and enoxaparin alone may safely reduce pregnancy loss. ( Glueck, CJ; Goldenberg, N; Khan, N; Ramidi, G; Wang, P, 2009) |
| "Metformin treatment increases serum TSP-1 in these women." | 2.74 | Metformin decreases angiogenesis via NF-kappaB and Erk1/2/Erk5 pathways by increasing the antiangiogenic thrombospondin-1. ( Adya, R; Chen, J; Farhatullah, S; Heutling, D; Lehnert, H; Mitchell, D; Randeva, HS; Tan, BK, 2009) |
| "Metformin treatment decreases serum chemerin in these women." | 2.74 | Insulin and metformin regulate circulating and adipose tissue chemerin. ( Adya, R; Chen, J; Farhatullah, S; Heutling, D; Kaur, J; Lehnert, H; Lewandowski, KC; O'Hare, JP; Randeva, HS; Tan, BK, 2009) |
| "Simvastatin treatment was superior to metformin alone, whereas a combination of simvastatin and metformin was not significantly superior to simvastatin alone." | 2.74 | Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. ( Banaszewska, B; Duleba, AJ; Pawelczyk, L; Spaczynski, RZ, 2009) |
| "Metformin therapy has many useful effects in these patients." | 2.73 | Metformin therapy in girls with polycystic ovary syndrome: a self-controlled clinical trial. ( Bayat, R; Hamedi, M; Nazari, T, 2007) |
| "Oral metformin 850mg bid was administered to PCOS patients." | 2.73 | Evaluation of endothelial function in women with polycystic ovary syndrome. ( Blumenfeld, Z; Damti, A; Lowenstein, L; Pillar, G; Shott, S, 2007) |
| "Metformin treatment induced a significant decrease in insulin levels (P < 0." | 2.73 | Alteration of ghrelin-neuropeptide Y network in obese patients with polycystic ovary syndrome: role of hyperinsulinism. ( Campagna, G; De Marinis, L; Guido, M; Lanzone, A; Proto, C; Romualdi, D, 2008) |
| "Metformin is an established insulin receptor sensitising antihyperglycemic agent, is highly affordable, and has superior safety and efficacy profiles." | 2.72 | Metformin turns 62 in pharmacotherapy: Emergence of non-glycaemic effects and potential novel therapeutic applications. ( Driver, C; Gcwensa, SK; Mbara, KC; Mcobothi, EN; Mkhombo, NT; Mofo Mato, PE; Nzuza, S; Owira, PM, 2021) |
| "Metformin was then given at a dose of 500 mg three times a day for 8 weeks, after which time the pretreatment study was repeated." | 2.71 | Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome. ( Dehghan-Kooshkghazi, M; Kazerooni, T, 2003) |
| "Flutamide-metformin treatment (n = 30) was followed within 3 months by marked decreases in hirsutism score and serum androgens, by a more than 50% increase in insulin sensitivity and by a less atherogenic lipid profile (all P < 0." | 2.71 | Low-dose flutamide-metformin therapy reverses insulin resistance and reduces fat mass in nonobese adolescents with ovarian hyperandrogenism. ( Amin, R; de Zegher, F; Dunger, D; Ferrer, A; Ibáñez, L; Ong, K, 2003) |
| "Hirsutism is a common and distressing symptom frequently encountered in women with polycystic ovary syndrome (PCOS), who also show relative insulin resistance." | 2.71 | Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome. ( Fleming, R; Harborne, L; Lyall, H; Norman, J; Sattar, N, 2003) |
| "In metformin-treated girls, all these abnormalities significantly reversed within 6 months, and body composition continued to improve between 6 and 12 months." | 2.71 | Insulin sensitization early after menarche prevents progression from precocious pubarche to polycystic ovary syndrome. ( Amin, R; de Zegher, F; Dunger, D; Ferrer, A; Ibáñez, L; Ong, K, 2004) |
| "The results suggest that hyperinsulinemia/insulin resistance may be responsible for low progesterone levels during the luteal phase in PCOS." | 2.71 | Effects of metformin treatment on luteal phase progesterone concentration in polycystic ovary syndrome. ( Agarwal, S; Krishna, A; Meenakumari, KJ; Pandey, LK, 2004) |
| "In conclusion, metformin treatment improved insulin sensitivity and decreased androgen levels, and flutamide decreased androgen levels but failed to improve insulin sensitivity in the non-obese women with PCOS." | 2.71 | Metformin versus flutamide in the treatment of metabolic consequences of non-obese young women with polycystic ovary syndrome: a randomized prospective study. ( Aral, Y; Culha, C; Demirbas, B; Karakurt, F; Kosar, F; Sahin, I; Serter, R; Taskapan, C, 2004) |
| "Metformin was well tolerated except for one case of flatulence." | 2.69 | Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. ( Bergiele, A; Diamanti-Kandarakis, E; Kouli, C; Tsianateli, T, 1998) |
| "Metformin is an oral hypoglycemic agent extensively used as first-line therapy for type 2 diabetes." | 2.66 | Metformin: Up to Date. ( De Pergola, G; Giagulli, VA; Grimaldi, F; Guastamacchia, E; Iacoviello, M; Licchelli, B; Sciannimanico, S; Triggiani, V; Vescini, F, 2020) |
| "Insulin resistance is becoming an increasingly studied target for therapy, most evidence stemming from the time-honored metformin use." | 2.66 | Current treatment for polycystic ovary syndrome: focus on adolescence. ( Catellani, C; Cirillo, F; Dauriz, M; Lazzeroni, P; Moghetti, P; Sartori, C; Street, ME, 2020) |
| "Obesity is responsible for an increased risk of sub-fecundity and infertility." | 2.66 | Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists. ( Cena, H; Chiovato, L; Nappi, RE, 2020) |
| "Polycystic Ovary Syndrome is a very complex syndrome, with typical hormonal and metabolic features." | 2.66 | Polycystic ovary syndrome (PCOS) and adolescence: How can we manage it? ( Capozzi, A; Lello, S; Scambia, G, 2020) |
| "Metformin is a widely used drug that results in clear benefits in relation to glucose metabolism and diabetes-related complications." | 2.66 | The clinical application of metformin in children and adolescents: A short update. ( Alaaraj, N; De Sanctis, V; Hamed, N; Soliman, A, 2020) |
| "Metformin is a safe medication used in PCOS for 25 years that is currently recommended in select PCOS subpopulations, such as adolescents, women with metabolic disorders, and infertility infertile women undergoing ovarian hyperstimulation." | 2.61 | Current and future aspects of several adjunctive treatment strategies in polycystic ovary syndrome. ( Banaszewska, B; Pawelczyk, L; Spaczynski, R, 2019) |
| "When metformin was compared with CC, data for live birth were inconclusive, and the findings were limited by lack of evidence." | 2.61 | Metformin for ovulation induction (excluding gonadotrophins) in women with polycystic ovary syndrome. ( Balen, AH; Morley, LC; Norman, RJ; Sharpe, A; Tang, T, 2019) |
| "Metformin was associated with generally mild gastrointestinal adverse events." | 2.61 | Effect of the combined oral contraceptive pill and/or metformin in the management of polycystic ovary syndrome: A systematic review with meta-analyses. ( Costello, M; Joham, A; Malhotra, J; McAllister, V; Misso, ML; Mol, BW; Peña, A; Piltonen, T; Romualdi, D; Tassone, EC; Teede, H; Thondan, M; Witchel, SF, 2019) |
| "Metformin is a biguanide drug that has been used to treat type 2 diabetes mellitus for more than 60 years." | 2.58 | Metformin: An Old Drug with New Applications. ( Li, L; Massey, S; Story, D; Zhou, J, 2018) |
| "Recently, fatty liver index and NAFLD fatty liver score analyzed in large cohorts of PCOS women have been shown as accurate markers of liver damage in this metabolically vulnerable population." | 2.55 | MANAGEMENT OF ENDOCRINE DISEASE: Polycystic ovary syndrome and nonalcoholic fatty liver disease. ( Bjekić-Macut, J; Božić-Antić, I; Macut, D; Tziomalos, K, 2017) |
| "Pioglitazone was used to treat patients of PCOS in many researches, but the treatment has not been recognized by public or recommended by all the guidelines." | 2.55 | Comparison of the effect between pioglitazone and metformin in treating patients with PCOS:a meta-analysis. ( Huang, Q; Wu, Y; Xu, Y, 2017) |
| "The increased risk of type 2 diabetes and cardiovascular disease in PCOS is closely associated with BMI." | 2.55 | Medical comorbidity in polycystic ovary syndrome with special focus on cardiometabolic, autoimmune, hepatic and cancer diseases: an updated review. ( Andersen, M; Glintborg, D, 2017) |
| "Polycystic ovary syndrome is characterized by an excess in androgen levels, ovarian dysfunction, and polycystic ovarian morphology but is also associated with metabolic dysfunction and risk factors for cardiovascular disease." | 2.53 | Treatment Considerations for the Cardiometabolic Signs of Polycystic Ovary Syndrome: A Review of the Literature Since the 2013 Endocrine Society Clinical Practice Guidelines. ( Fields, EL; Trent, ME, 2016) |
| "Hirsutism affects 5-25% women, and the condition is most often caused by polycystic ovary syndrome (PCOS)." | 2.53 | Endocrine and metabolic characteristics in polycystic ovary syndrome. ( Glintborg, D, 2016) |
| "The link between NAFLD/NASH and PCOS is not just a coincidence." | 2.53 | Hepatic manifestations of women with polycystic ovary syndrome. ( Chen, MJ; Ho, HN, 2016) |
| "It has also been widely used in the treatment of polycystic ovary syndrome (PCOS) and gestational diabetes mellitus." | 2.53 | Role of Metformin in Women's Health: Review of Its Current Place in Clinical Practice and Emerging Indications for Future. ( Sinai Talaulikar, V; Tang, T; Yasmin, E, 2016) |
| "Metformin and OCPs were similar in terms of impact on hirsutism." | 2.53 | Metformin or Oral Contraceptives for Adolescents With Polycystic Ovarian Syndrome: A Meta-analysis. ( Al Khalifah, RA; Bassilious, E; Dennis, B; Florez, ID; Thabane, L, 2016) |
| "It is also used to delay the onset of type 2 diabetes mellitus, in treating gestational diabetes, and in women with polycystic ovary syndrome." | 2.53 | Metformin: From Research to Clinical Practice. ( Alquraini, H; MacEachern, M; Mizokami-Stout, K; Tan, MH, 2016) |
| "Obesity is now a major international health concern." | 2.52 | Obesity and polycystic ovary syndrome. ( Boyle, J; De Courten, B; Joham, A; Naderpoor, N; Shorakae, S; Teede, HJ, 2015) |
| "Insulin resistance is prevalent in women with polycystic ovary syndrome (PCOS), and plays a critical pathophysiologic role in both the metabolic and reproductive complications of PCOS." | 2.52 | Polycystic ovary syndrome and insulin: our understanding in the past, present and future. ( Evans, WS; Mayer, SB; Nestler, JE, 2015) |
| " The secondary outcome measures include acne scores, prevalence of dysglycaemia, BMI, lipid profile, total testosterone level, and adverse events." | 2.52 | The effectiveness and safety of treatments used for polycystic ovarian syndrome management in adolescents: a systematic review and network meta-analysis protocol. ( Al Khalifah, RA; Bassilious, E; Dennis, B; Flórez, ID; Neupane, B; Thabane, L, 2015) |
| "Polycystic ovary syndrome is recognized as the most common hormonal and metabolic disorder likely to affect women." | 2.52 | [Evidence-based therapy of polycystic ovarian syndrome]. ( Csenteri, OK; Gődény, S, 2015) |
| "Ovarian hyperstimulation syndrome is an important condition with considerable morbidity and a small risk of mortality, which most commonly results as an iatrogenic condition following follicular stimulation of the ovaries." | 2.52 | Consensus statement on prevention and detection of ovarian hyperstimulation syndrome. ( Andreadis, N; Boothroyd, C; Chapman, M; Johnson, N; Karia, S; Rombauts, L, 2015) |
| "Polycystic ovary syndrome is the most common hormonal and metabolic disorder likely to affect women." | 2.52 | [Prevention and treatment of the complications of polycystic ovarian syndrome--the significance of evidence-based, interdisciplinary management]. ( Csenteri, OK; Gődény, S, 2015) |
| "Metformin is an insulin sensitising agent which is safe, widely available and currently licensed for type-2 diabetes." | 2.50 | Preventing endometrial cancer risk in polycystic ovarian syndrome (PCOS) women: could metformin help? ( Abu, J; Ariffin, R; Atiomo, W; Barrett, DA; Chapman, C; Deen, S; Khan, G; Nunns, D; Seedhouse, C; Shafiee, MN, 2014) |
| "In particular, when obesity is present, lifestyle intervention should be always considered, and if necessary combined with pharmacotherapy." | 2.50 | Therapy in endocrine disease: treatment of hirsutism in the polycystic ovary syndrome. ( Gambineri, A; Pasquali, R, 2014) |
| " Currently, there is no evidence that cardiovascular morbidity is decreased by long-term use of insulin sensitizers in PCOS women." | 2.50 | Metformin and other insulin sensitizers in polycystic ovary syndrome. ( Bhagavath, B; Hoeger, K; Queenan, J; Vitek, W, 2014) |
| "Metformin is an effective insulin sensitizer treating type 2 diabetes mellitus." | 2.50 | Effect of metformin intervention during pregnancy on the gestational diabetes mellitus in women with polycystic ovary syndrome: a systematic review and meta-analysis. ( Wang, A; Yu, H; Zhuo, Z, 2014) |
| "Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the Western world comprising a spectrum of liver damage from fatty liver infiltration to end-stage liver disease, in patients without significant alcohol consumption." | 2.50 | Nonalcoholic fatty liver disease and polycystic ovary syndrome. ( Vassilatou, E, 2014) |
| "Metformin is a first-line drug in the treatment of overweight and obese type 2 diabetic patients, offering a selective pathophysiological approach by its effect on insulin resistance." | 2.50 | The therapy of insulin resistance in other diseases besides type 2 diabetes. ( Barbaro, V; Dicembrini, I; Pala, L; Rotella, CM, 2014) |
| "Metformin is an oral insulin-sensitizing anti-diabetic drug." | 2.50 | [Metformin in pregnancy]. ( Bijok, J; Bińkowska, M; Jakiel, G, 2014) |
| "Polycystic ovarian syndrome is one of the most frequent endocrine dysfunctions in women in their fertile age." | 2.48 | Diagnosis and therapy of polycystic ovarian syndrome: results of a survey among German gynecologists with a review on literature. ( Buhling, KJ; Doll, I; Doll, R, 2012) |
| "Obesity is also a feature of this syndrome and contributes to associated metabolic abnormalities." | 2.48 | Polycystic ovarian syndrome management options. ( Bates, GW; Propst, AM, 2012) |
| "Polycystic ovarian syndrome is the major cause of anovulation and is generally associated with obesity." | 2.48 | Evaluation and treatment of anovulatory and unexplained infertility. ( Bates, GW; Propst, AM, 2012) |
| "Insulin resistance is linked to polycystic ovary syndrome." | 2.47 | Current perspectives of insulin resistance and polycystic ovary syndrome. ( Legro, RS; Pauli, JM; Raja-Khan, N; Wu, X, 2011) |
| "Hirsutism is defined as excess hair growth in androgen-dependent areas of the body in women." | 2.46 | Hirsutism: Diagnosis and management. ( Brodell, LA; Mercurio, MG, 2010) |
| "Metformin treatment was shown to improve these features, although conflicting results were also reported." | 2.46 | Insulin-sensitizing agents in the treatment of polycystic ovary syndrome: an update. ( Hatzitolios, AI; Katsiki, N, 2010) |
| "Metformin has been introduced as a therapeutic option in PCOS, targeting of cardiometabolic and reproductive abnormalities on the basis of its action on the reduction of glucose levels and the attenuation of insulin resistance." | 2.46 | Metformin in polycystic ovary syndrome. ( Christakou, C; Diamanti-Kandarakis, E; Economou, F; Palimeri, S, 2010) |
| "Metformin is an insulin sensitizer widely used for the treatment of patients affected by type 2 diabetes mellitus." | 2.45 | Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. ( Falbo, A; Orio, F; Palomba, S; Zullo, F, 2009) |
| "Metformin is an insulin-sensitizing agent that may lower androgen levels." | 2.45 | The effects of metformin on endogenous androgens and SHBG in women: a systematic review and meta-analysis. ( Akl, EA; Barba, M; Guyatt, G; Musicco, F; Muti, P; Schünemann, HJ; Sperati, F, 2009) |
| "Metformin was also associated with a significantly higher incidence of gastrointestinal disturbance, but no serious adverse effects were reported." | 2.45 | WITHDRAWN: Insulin-sensitising drugs for polycystic ovary syndrome. ( Balen, AH; Lord, JM; Norman, RJ; Tang, T; Yasmin, E, 2009) |
| "Metabolic syndrome is a chronic low-grade inflammatory condition in which adipokines play a major role." | 2.45 | Adipose tissue, metabolic syndrome and polycystic ovary syndrome: from pathophysiology to treatment. ( Damato, AB; Depalo, R; Garruti, G; Giampetruzzi, F; Giorgino, F; Lorusso, F; Vita, MG, 2009) |
| "Metformin was less effective than the OCP in improving menstrual pattern (Peto odds ratio (OR) 0." | 2.44 | Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. ( Costello, M; Eden, J; Johnson, N; Shrestha, B; Sjoblom, P, 2007) |
| "Polycystic ovary syndrome is estimated to affect 5-10% of premenopausal women." | 2.44 | Polycystic ovary syndrome update in adolescence. ( Gordon, CM; Hassan, A, 2007) |
| "Polycystic ovarian syndrome is the commonest endocrine disorder of reproductive-age women." | 2.44 | Polycystic ovarian syndrome--prognosis and treatment outcomes. ( Hart, R, 2007) |
| "Polycystic ovary syndrome is a diagnosis of exclusion of other causes of hyperandrogenism." | 2.43 | Polycystic ovary syndrome--a management update. ( Costello, MF, 2005) |
| "Polycystic ovary syndrome is characterized among other things by oligo-amenorrhea and may account for more than 75% of cases with anoluvatory infertility." | 2.43 | Is metformin therapy for polycystic ovary syndrome safe during pregnancy? ( Brock, B; Ovesen, P; Rungby, J; Schmitz, O; Smidt, K, 2005) |
| "Hyperinsulinemia has been causally linked with all features of the syndrome, such as hyperandrogenism, reproductive disorders, and metabolic disturbances." | 2.43 | Metformin treatment of PCOS during adolescence and the reproductive period. ( Artensio, AC; La Marca, A; Stabile, G; Volpe, A, 2005) |
| "Metformin has proven to be effective in the management of the metabolic disturbances, anovulation and hirsutism and is now a widely accepted therapy." | 2.43 | [Polycystic ovary syndrome. New pathophysiological discoveries--therapeutic consequences]. ( Madsbad, S; Nilas, L; Nørgaard, K; Svendsen, PF, 2005) |
| "Although insulin resistance is not part of the diagnostic criteria for PCOS, its importance in the pathogenesis of PCOS can not be denied." | 2.43 | Insulin resistance in polycystic ovarian disease. ( Bhatia, V, 2005) |
| "The finding that insulin resistance has important implications in the pathogenesis of polycystic ovarian disease has elicit the concept of a therapeutic approach of insulin-sensitizing drugs." | 2.43 | [Insulin sensitizers in the treatment of polycystic ovary]. ( Ayala, AR; Hernández Marín, I; Ortiz Núñez, DA, 2005) |
| "The management of polycystic ovary syndrome is now complex and includes life style modifications, dietary-induced weight loss, oral contraceptives, clomiphene citrate, gonadotropins, antiandrogens and insulin-sensitising agents." | 2.43 | [Advance in treatment of polycystic ovary syndrome]. ( Herman, ZS; Krysiak, R; Okopień, B, 2005) |
| "Hypogonadotropic anovulation is treated with exogenous gonadotropins, and little has changed in its management." | 2.43 | Ovulatory disorders and infertility. ( Urman, B; Yakin, K, 2006) |
| " Evidence for the long-term use of metformin to protect against adverse cardiovascular outcomes and for the use of metformin throughout pregnancy to reduce the risk of miscarriage, gestational diabetes, pre-eclampsia and fetal macrosomia is still lacking." | 2.43 | Polycystic ovarian syndrome--prognosis and outcomes. ( Hart, R; Norman, R, 2006) |
| "Polycystic ovary syndrome is a multi-system endocrinopathy with long-term metabolic and cardiovascular health consequences." | 2.43 | Contemporary medical therapy for polycystic ovary syndrome. ( Domino, SE; Lanham, MS; Lebovic, DI, 2006) |
| "Insulin resistance is an important pathophysiological feature of the polycystic ovary syndrome (PCOS)." | 2.43 | Is metformin a primary ovulatory agent in patients with polycystic ovary syndrome? ( Cheang, KI; Nestler, JE; Sharma, ST, 2006) |
| "The mechanism of anovulation is uncertain but there is evidence that arrested antral follicle development is associated with the abnormal endocrine profile, in particular the interaction of insulin and LH on granulosa cell differentiation." | 2.43 | Infertility in polycystic ovary syndrome: focus on low-dose gonadotropin treatment. ( Franks, S; Gorry, A; White, DM, 2006) |
| "Metformin is a widely used drug in the therapy of patients affected by diabetes mellitus." | 2.43 | Metformin beyond diabetes: new life for an old drug. ( Mannucci, E; Monami, M; Rotella, CM, 2006) |
| "Metformin has been shown to reduce ovarian production, enhance ovulatory cycles and in some cases increase fertility." | 2.42 | [Insulin resistance and polycystic ovary syndrome]. ( Basille, C; Bernard, L; Chabbert-Buffet, N; Christin-Maître, S, 2003) |
| "Polycystic ovary syndrome is a frequent endocrine disorder often associated with insulin resistance and hyperinsulinaemia which may play a role in hyperandrogenism and anovulation." | 2.42 | [Should infertile women with polycystic ovarian syndrome be treated with metformine?]. ( Basille, C; Bry-Gauillard, H; Cédrin-Durnerin, I; Galey, J; Hugues, JN; Massin, N; Théron-Gérard, L, 2003) |
| "Metformin, a biguanide, has been available in the US for the treatment of type 2 diabetes mellitus for nearly 8 years." | 2.42 | Metformin: new understandings, new uses. ( Hundal, RS; Inzucchi, SE, 2003) |
| "Insulin resistance is a common feature of PCOS and is more marked in obese women, suggesting that PCOS and obesity have a synergistic effect on the magnitude of the insulin disorder." | 2.42 | Insulin-lowering agents in the management of polycystic ovary syndrome. ( De Leo, V; la Marca, A; Petraglia, F, 2003) |
| " However, a significant proportion of women with PCOS fail to ovulate with the use of standard dosage of CC and are called CC-resistant PCOS." | 2.42 | Minireview: Up-date management of non responder to clomiphene citrate in polycystic ovary syndrome. ( Abd el-Aal, G; Abdel-Kareem, O; Amin, M; Maruo, T; Moriyama, T; Takekida, S, 2003) |
| "Insulin resistance is a central feature of polycystic ovary syndrome (PCOS)." | 2.42 | Should insulin-sensitizing drugs be used in the treatment of polycystic ovary syndrome? ( Cheang, KI; Nestler, JE, 2004) |
| "While the treatment of hyperandrogenism makes use of different drugs already studied, the debate about the use of insulin sensitizing drugs is still open." | 2.42 | Which treatment options should be used in adolescents with polycystic ovary syndrome? ( Barini, A; Di Sebastiano, F; Fulghesu, AM; Lanzone, A; Rossodivita, A; Sagnella, F; Villa, P, 2004) |
| "Metformin is a first-line drug in the treatment of overweight and obese type 2 diabetic patients, offering a selective pathophysiological approach by its effect on insulin resistance." | 2.42 | Current indications for metformin therapy. ( Tankova, T, 2003) |
| "Insulin resistance is a prominent feature of polycystic ovarian syndrome (PCOS), and women with the disorder are at increased risk for the development of other diseases that have been linked to insulin resistance-namely, type 2 diabetes and cardiovascular disease." | 2.41 | Should patients with polycystic ovarian syndrome be treated with metformin?: an enthusiastic endorsement. ( Nestler, JE, 2002) |
| "The patient also had untreated Polycystic Ovarian Syndrome (PCOS)." | 2.41 | Common treatment of polycystic ovarian syndrome and major depressive disorder: case report and review. ( Bauer, M; Carter, MS; Elman, S; Korenman, SG; Love, M; Rasgon, NL, 2002) |
| "Women with severe insulin resistance are a unique subset of polycystic ovary syndrome." | 2.41 | Induction of ovulation in infertile women with hyperandrogenism and insulin resistance. ( Barbieri, RL, 2000) |
| "Treatment with metformin, alone or in combination with clomiphene citrate, may also be beneficial." | 2.41 | Polycystic ovary syndrome and ovulation induction. ( Phipps, WR, 2001) |
| "Polycystic ovary syndrome is one of the most common endocrinopathies worldwide and for many years it was one of the most difficult to elucidate." | 2.41 | Polycystic ovary syndrome: not ovarian, not simple, unkind. ( Fox, R; Ryan, A, 2002) |
| "Metformin is an insulin-sensitizing agent with potent antihyperglycemic properties." | 2.41 | Metformin: an update. ( Kirpichnikov, D; McFarlane, SI; Sowers, JR, 2002) |
| " They also suggest that long term administration of metformin might be helpful in treating insulin resistance, thus reducing risks of type 2 (non-insulin-dependent) diabetes and cardiovascular disease in these patients." | 2.40 | Insulin resistance, polycystic ovary syndrome and metformin. ( Ducluzeau, PH; Pugeat, M, 1999) |
| "Metformin was used as a positive control." | 1.91 | Pioglitazone can improve liver sex hormone-binding globulin levels and lipid metabolism in polycystic ovary syndrome by regulating hepatocyte nuclear factor-4α. ( He, B; Lv, B; Wang, D; Wang, X; Xing, C; Zhao, H, 2023) |
| "Metformin is a commonly used drug of PCOS but few studies on whether metformin can improve the follicle development and ovarian function in PCOS." | 1.91 | Metformin improves polycystic ovary syndrome in mice by inhibiting ovarian ferroptosis. ( Chang, Q; Chen, X; He, R; Hei, C; Li, G; Liang, X; Liu, H; Liu, X; Ouyang, J; Peng, Q; Ren, S; Sun, M; Sun, Y; Wang, C; Wang, Q; Wu, X; Xie, H, 2023) |
| "Metformin has been shown to protect against PCOS by reducing insulin resistance in women, whereas its role in OGC pyroptosis is unknown." | 1.91 | Metformin inhibits ovarian granular cell pyroptosis through the miR-670-3p/NOX2/ROS pathway. ( Hao, JY; Huang, Y; Li, J; Xu, XH; Zhang, JN; Zhou, LH; Zou, H, 2023) |
| "Treatment with metformin also resulted in a decrease in body mass index, blood glucose, insulin, and HOMA-IR." | 1.91 | METFORMIN EFFECTS ON BLOOD LEVELS OF GREMLIN-1 IN POLYCYSTIC OVARIAN WOMEN. ( Allow, S; Sarhat, E, 2023) |
| "Gut microbiota dysbiosis is critical in the etiology of polycystic ovary syndrome (PCOS)." | 1.72 | Gut microbiota dysbiosis-derived macrophage pyroptosis causes polycystic ovary syndrome via steroidogenesis disturbance and apoptosis of granulosa cells. ( Chen, P; Huang, J; Liang, Q; Liang, X; Liu, J; Wu, T; Xiang, Y; Zeng, H; Zeng, Y; Zhou, C, 2022) |
| " This study aimed to investigate the effect of letrozole and metformin combined with targeted nursing on ovarian function, LH, and FSH in infertile patients with PCOS." | 1.72 | The Effects of Letrozole and Metformin Combined with Targeted Nursing Care on Ovarian Function, LH, and FSH in Infertile Patients with Polycystic Ovary Syndrome. ( Jiang, S; Li, R; Sheng, Y; Tang, T; Xu, H, 2022) |
| "Metformin (MTF) treatment improves insulin signaling in endometrial tissues, but its mechanism is not fully understood." | 1.72 | Metformin Treatment Regulates the Expression of Molecules Involved in Adiponectin and Insulin Signaling Pathways in Endometria from Women with Obesity-Associated Insulin Resistance and PCOS. ( Astorga, I; Carvajal, R; García, V; Oróstica, ML; Plaza-Parrochia, F; Poblete, C; Romero, C; Vega, M, 2022) |
| "Metformin is an orally effective insulin-sensitizing drug widely prescribed for treating type 2 diabetes mellitus (T2DM)." | 1.72 | Lipids Alterations Associated with Metformin in Healthy Subjects: An Investigation Using Mass Spectrometry Shotgun Approach. ( Abdel Rahman, AM; Alfadda, AA; AlMalki, RH; Arafat, T; Benabdelkamel, H; Dahabiyeh, LA; Mujammami, M, 2022) |
| "Letrozole (1 mg/kg/day) was administered to female Sprague-Dawley (SD) rats for 21 days to induce PCOS." | 1.72 | Kelulut Honey Improves Folliculogenesis, Steroidogenic, and Aromatase Enzyme Profiles and Ovarian Histomorphology in Letrozole-Induced Polycystic Ovary Syndrome Rats. ( Ibrahim, SF; Kamal, DAM; Mokhtar, MH; Ugusman, A; Zaid, SSM, 2022) |
| "Metformin is a drug that has been widely used around the world for many years." | 1.72 | Use of metformin in patients who require intravascular administration of a contrast agent. ( Rokicka, D; Stołtny, D; Strojek, K; Wróbel, M, 2022) |
| "Polycystic ovary syndrome affects 7% of women of reproductive ages." | 1.62 | Repurposing new drug candidates and identifying crucial molecules underlying PCOS Pathogenesis Based On Bioinformatics Analysis. ( Dehghan, Z; Mirmotalebisohi, SA; Mohammadi-Yeganeh, S; Salehi, M; Sameni, M; Zali, H, 2021) |
| "Metformin is an appropriate medical option to improve ovulation rates for women who cannot take combined hormone contraception or whom are attempting conception." | 1.62 | Menstrual Dysfunction in PCOS. ( Decherney, AH; Saunders, R; Walker, K, 2021) |
| "A rat model of PCOS-IR was established using a high-fat diet (49 d) combined with letrozole (1 mg/kg·d, for 28 d)." | 1.62 | Effects of total flavonoids from Eucommia ulmoides Oliv. leaves on polycystic ovary syndrome with insulin resistance model rats induced by letrozole combined with a high-fat diet. ( Li, CX; Li, M; Miao, MS; Peng, MF; Ren, Z; Song, YG; Tian, S, 2021) |
| "Berberine is a monomer from Chinese herbs such as Coptis chinensis, whose effect on improving ovulation and endometrial receptivity of PCOS is uncertain." | 1.62 | Berberine improves ovulation and endometrial receptivity in polycystic ovary syndrome. ( Dong, H; Nie, K; Su, H; Tang, Y; Wang, H; Wang, Z; Xu, X, 2021) |
| "Treatment with dapsone and metformin reversed the effects of testosterone in the DAP and MET groups." | 1.62 | The effect of dapsone in testosterone enanthate-induced polycystic ovary syndrome in rat. ( Dehpour, AR; Khaledi, E; Khazaei, M; Noori, T; Sadeghi, F; Shirooie, S; Sobarzo-Sánchez, E, 2021) |
| "Myo-inositol (MYO) is an insulin-sensitizing compound used in PCOS patients; however, its insulin-sensitizing mechanism is unclear." | 1.56 | The insulin-sensitizing mechanism of myo-inositol is associated with AMPK activation and GLUT-4 expression in human endometrial cells exposed to a PCOS environment. ( Cabrera-Cruz, H; Oróstica, L; Plaza-Parrochia, F; Romero, C; Torres-Pinto, I; Vega, M, 2020) |
| "Metformin treatment elevates serum MANF levels and alleviates insulin resistance and hyperandrogenism in PCOS women." | 1.56 | Decreased Circulating MANF in Women with PCOS is Elevated by Metformin Therapy and is Inversely Correlated with Insulin Resistance and Hyperandrogenism. ( Deng, W; Jia, Y; Li, Y; Liu, D; Long, M; Wang, C; Wei, J; Yang, G, 2020) |
| "Letrozole (1 mg/kg) was administered orally for a period of 28 days to induce PCOS." | 1.56 | The effects of thylakoid-rich spinach extract and aqueous extract of caraway (Carum carvi L.) in letrozole-induced polycystic ovarian syndrome rats. ( Ekramzadeh, M; Golmakani, MT; Koohpeyma, F; Sherafatmanesh, S; Tanideh, N, 2020) |
| "Polycystic ovary syndrome is one of the most common causes of female infertility, affecting 5-10% of the population." | 1.51 | Ocimum kilimandscharicum L. restores ovarian functions in letrozole - induced Polycystic Ovary Syndrome (PCOS) in rats: Comparison with metformin. ( AbdelMaksoud, S; El-Bahy, AA; Handoussa, H; Khaled, N; Radwan, R, 2019) |
| " Long-term use of OCPs needs to be considered carefully for PCOS patients who are already burdened with associated risk factors." | 1.51 | Oral contraceptive use increases risk of inflammatory and coagulatory disorders in women with Polycystic Ovarian Syndrome: An observational study. ( Amin, S; Bhat, IA; Fatima, Q; Ganie, MA; Jeelani, H; Kawa, IA; Manzoor, S; Rashid, F; Shah, ZA; Yousuf, SD, 2019) |
| "Metformin and combined treatment groups reduced the body and ovary weights compared to the PCOS group." | 1.48 | Effect of resveratrol and metformin on ovarian reserve and ultrastructure in PCOS: an experimental study. ( Ceylan, S; Eraldemır, C; Furat Rencber, S; Guzel, E; Kum, T; Kurnaz Ozbek, S; Sezer, Z, 2018) |
| "Letrozole-treated patients required a significantly lower amount of gonadotropins units (p < 0." | 1.48 | Mild ovarian stimulation with letrozole plus fixed dose human menopausal gonadotropin prior to IVF/ICSI for infertile non-obese women with polycystic ovarian syndrome being pre-treated with metformin: a pilot study. ( Cantatore, C; Caringella, AM; Caroppo, E; D'Amato, G; Palini, S; Stanziano, A, 2018) |
| "Insulin resistance was assessed by 3-h oral glucose tolerance test (OGTT)." | 1.46 | Metabolic and androgen profile in underweight women with polycystic ovary syndrome. ( Anastasiou, OE; Canbay, A; Fuhrer, D; Reger-Tan, S, 2017) |
| "Metformin was originally shown to lower testosterone levels in women with PCOS in the 1990s, an effect presumably related to its insulin sensitising actions." | 1.46 | Metformin therapy for the reproductive and metabolic consequences of polycystic ovary syndrome. ( Ehrmann, DA; Sam, S, 2017) |
| "Metformin is an antidiabetic drug, which inhibits mitochondrial respiratory-chain-complex I and thereby seems to affect the cellular metabolism in many ways." | 1.46 | Combined transcriptome and metabolome analyses of metformin effects reveal novel links between metabolic networks in steroidogenic systems. ( Diserens, G; Flück, CE; Hertig, D; Legeza, B; Marti, N; Nuoffer, JM; Udhane, SS; Vermathen, P, 2017) |
| "Polycystic ovary syndrome is the most common endocrinopathy among reproductive-aged women in the United States, affecting approximately 7% of female patients." | 1.43 | Diagnosis and Treatment of Polycystic Ovary Syndrome. ( Mortada, R; Porter, S; Williams, T, 2016) |
| "Metformin was also given as a standard control to one of the rat groups." | 1.43 | Ameliorative effects of rutin against metabolic, biochemical and hormonal disturbances in polycystic ovary syndrome in rats. ( Afsar, T; Ain, QU; Almajwal, A; Jahan, S; Mehboob, A; Munir, F; Razak, S; Shaheen, G; Ullah, H, 2016) |
| "Metformin was added according to its indication." | 1.42 | Metabolic profile of Diane-35 versus Diane-35 plus metformin in Chinese PCOS women under standardized life-style changes. ( Jin, J; Mueck, AO; Ruan, X; Wu, H, 2015) |
| "Insulin resistance is a prevalent condition commonly associated with unhealthy lifestyles." | 1.42 | [Second Consensus of the Chilean Society of Endocrinology and Diabetes about insulin resistance]. ( Araya, V; Arrese, M; Aylwin, CG; Bezanilla, CG; Carrasco, E; Carrasco, F; Codner, E; Díaz, E; Durruty, P; Galgani, J; García, H; Lahsen, R; Lanas, A; Liberman, C; López, G; Maíz, A; Mujica, V; Pollak, F; Poniachik, J; Sapunar, J; Sir, T; Soto, N; Valderas, J; Villaseca, P; Zavala, C, 2015) |
| "Treatment with metformin resulted in progressive improvement of metabolic status, while blood pressure values normalized with atenolol therapy." | 1.40 | LMNA gene mutation as a model of cardiometabolic dysfunction: from genetic analysis to treatment response. ( Amorini, M; Arrigo, T; Briuglia, S; Chirico, V; Ferraù, V; Lacquaniti, A; Loddo, I; Salpietro, C; Salpietro, V, 2014) |
| "The treatment with metformin or Diane-35 was continued for 6 months and all subjects were evaluated with clinical and biochemical parameters 6 months later." | 1.40 | The platelet activating factor acetyl hydrolase, oxidized low-density lipoprotein, paraoxonase 1 and arylesterase levels in treated and untreated patients with polycystic ovary syndrome. ( Armutcu, F; Carlioglu, A; Gumus, II; Karakurt, F; Kasapoglu, B; Kaygusuz, I; Keskin, EA; Koca, C; Uysal, A; Uysal, S, 2014) |
| "To compare the incidence of gestational diabetes mellitus (GDM) in Iranian infertile women with polycystic ovary syndrome (PCOS) and women without PCOS after pregnancies resulting from either assisted reproductive technology (ART) or spontaneous as well as to determine the risk factors of GDM in PCOS women." | 1.40 | Gestational diabetes mellitus risk factors in women with polycystic ovary syndrome (PCOS). ( Arabipoor, A; Ashrafi, M; Hosseini, R; Nourbakhsh, F; Sheikhan, F; Zolfaghari, Z, 2014) |
| "Metformin has antitumor activity in monotherapy and also synergistically with other anticancer agents." | 1.39 | [Metformin--new treatment strategies for gynecologic neoplasms]. ( Kiałka, M; Krzysiek, J; Milewicz, T; Mrozińska, S; Ociepka, A, 2013) |
| "Metformin treatment after 6 and 12 months significantly reduced weight, BMI, waist circumference, insulin and HOMA-IR (p=0." | 1.39 | Evaluation of endocrine changes in women with the polycystic ovary syndrome during metformin treatment. ( Velija-Ašimi, Z, 2013) |
| "Metformin treatment increases serum cartonectin levels in these women and in omental AT explants." | 1.39 | Metformin increases the novel adipokine cartonectin/CTRP3 in women with polycystic ovary syndrome. ( Adya, R; Amar, O; Chen, J; Hu, J; Lehnert, H; Mattu, HS; Patel, V; Ramanjaneya, M; Randeva, HS; Tan, BK, 2013) |
| "Metformin treatment, lead to a significant decrease in serum insulin (p = 0." | 1.39 | Effects of metformin on serum insulin and anti-Mullerian hormone levels and on hyperandrogenism in patients with polycystic ovary syndrome. ( Ferriani, RA; Japur de Sá Rosa-e-Silva, AC; Nascimento, AD; Reis, RM; Silva Lara, LA, 2013) |
| "Metformin has been shown to be effective therapy and could be used more widely in obese adolescents with hyperandrogenemia, a forerunner of PCOS." | 1.38 | Should all women with PCOS be treated for insulin resistance? ( Dunaif, A; Marshall, JC, 2012) |
| "Treated with metformin (n = 17) or metformin and antiandrogen (n = 21)." | 1.38 | Effect of antiandrogen treatment on bone density and bone geometry in adolescents with polycystic ovary syndrome. ( Bechtold, S; Buckel, M; Dalla Pozza, R; Putzker, S; Roeb, J; Schmidt, H; Weissenbacher, C, 2012) |
| "Metformin has beneficial effects on insulin resistance and endothelial functions." | 1.38 | The effects of treatment with drospirenone/ethinyl oestradiol alone or in combination with metformin on elastic properties of aorta in women with polycystic ovary syndrome. ( Akpek, M; Calapkorur, B; Celik, A; Karaca, Z; Kaya, MG; Kelestimur, F; Unluhizarci, K; Yildirim, S, 2012) |
| "Metformin treatment was only effective to increase serum 25-hydroxyvitamin D levels in PCOS patients carrying the homozygous 1521G/1012A haplotype." | 1.38 | Vitamin D receptor 1a promotor -1521 G/C and -1012 A/G polymorphisms in polycystic ovary syndrome. ( Chou, PY; Huang, MF; Lin, MW; Sun, HS; Tsai, SJ; Wu, MH, 2012) |
| "Insulin resistance was diagnosed in 90." | 1.38 | [Metformin efficiency for the adolescent PCOS treatment]. ( Boyadzhieva, M; Kedikova, S; Sirakov, M, 2012) |
| "Metformin treatment decreases serum ASAA in these women." | 1.37 | The anti-atherogenic aspect of metformin treatment in insulin resistant women with the polycystic ovary syndrome: role of the newly established pro-inflammatory adipokine Acute-phase Serum Amyloid A; evidence of an adipose tissue-monocyte axis. ( Adya, R; Aghilla, M; Keay, SD; Lehnert, H; Randeva, HS; Shan, X; Tan, BK, 2011) |
| "Metformin is widely used in women with Type 2 diabetes of child-bearing age, many of whom become pregnant." | 1.36 | Metformin treatment for Type 2 diabetes in pregnancy? ( Simmons, D, 2010) |
| "Hypertension is a common comorbidity (34%), whereas early nephropathy appears to be rare (4%)." | 1.35 | Management and 1 year outcome for UK children with type 2 diabetes. ( Barrett, TG; Haines, L; Lynn, R; Shield, JP; Wan, KC, 2009) |
| "When metformin was administered together with DHEA uterine histology and apoptosis did not differ when compared with controls." | 1.35 | The effects of metformin on uterine tissue of hyperandrogenized BALB/c mice. ( Belgorosky, D; Elia, EM; Faut, M; Luigi, D; Motta, AB; Pustovrh, C; Vighi, S, 2009) |
| "The preferred treatment for polycystic ovary syndrome, which affects women of fertile age, is diet and lifestyle interventions - especially in association with overweight." | 1.35 | [Use of metformin in polycystic ovary syndrome]. ( Carlsen, SM, 2009) |
| "Insulin resistance is a central feature of the PCOS and may increase cardiovascular risk." | 1.35 | Long-term effect of metformin on metabolic parameters in the polycystic ovary syndrome. ( Best, AM; Cheang, KI; Essah, PA; Huszar, JM; Nestler, JE; Sharma, S, 2009) |
| "Metformin treatment led to improvement of hormonal and metabolic parameters and decreased ADMA levels possibly independent of BMI and metabolic changes." | 1.35 | Asymmetrical dimethylarginine, inflammatory and metabolic parameters in women with polycystic ovary syndrome before and after metformin treatment. ( Heutling, D; Kaltwasser, P; Kleinstein, J; Krzyzanowska, K; Lehnert, H; Mittermayer, F; Nickel, I; Randeva, H; Schernthaner, G; Schulz, H; Westphal, S; Wolzt, M, 2008) |
| "For women in whom weight loss is not possible, or for lean women with PCOS, clomiphene citrate is an effective first-line method of ovulation induction." | 1.34 | Ovulation induction management of PCOS. ( Guzick, DS, 2007) |
| "Metformin is a logical treatment in these circumstances but there has always been concern about its safety for the fetus, particularly as it crosses the placenta and it may increase the risk of teratogenesis." | 1.33 | Metformin use and diabetic pregnancy-has its time come? ( Hawthorne, G, 2006) |
| "When metformin was administered together with DHEA, serum insulin, E and P levels, and ovarian PGE values did not differ when compared with controls." | 1.33 | Role of the N, N'-dimethylbiguanide metformin in the treatment of female prepuberal BALB/c mice hyperandrogenized with dehydroepiandrosterone. ( Di Girolamo, G; Elia, E; Gonzalez, C; Luchetti, CG; Motta, AB; Sander, V; Solano, ME, 2006) |
| "When metformin was administered together with DHEA, the ovarian GSH content, NOS activity and PGE production did not differ when compared with controls." | 1.33 | The mechanisms involved in the action of metformin in regulating ovarian function in hyperandrogenized mice. ( Di Girolamo, G; Elia, E; Gonzalez, C; Luchetti, CG; Motta, AB; Sander, V; Solano, ME, 2006) |
| "Metformin treatment significantly improved hyperandrogenism, menstrual cyclicity, body weight, and insulin resistance independent of GNAS1 genotype." | 1.33 | The CC genotype of the GNAS T393C polymorphism is associated with obesity and insulin resistance in women with polycystic ovary syndrome. ( Frey, UH; Hahn, S; Janssen, OE; Mann, K; Siffert, W; Tan, S, 2006) |
| "To compare the effects of 3 therapeutic regimens widely used in practice--OHC alone and in combination with metformin or rosiglitazone on body weight and anthropometric proportions, hormonal and metabolic alterations." | 1.33 | [Effect of 6-month treatment with oral antiandrogen alone and in combination with insulin sensitizers on body composition, hormonal and metabolic parameters in women with polycystic ovary syndrome (PCOS) in order to determine therapeutic strategy]. ( Atanasova, I; Genchev, G; Kamenov, Z; Khristov, V; Kolarov, G; Milcheva, B; Orbetsova, M; Shigarminova, R; Zakharieva, S, 2006) |
| "The metabolic syndrome was present in 64 (46%) of the women with PCOS." | 1.32 | Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome. ( Glueck, CJ; Goldenberg, N; Papanna, R; Sieve-Smith, L; Wang, P, 2003) |
| "Hirsutism is the manifestation of hyperandrogenemia in PCOS." | 1.32 | The treatment of polycystic ovary syndrome. ( Ajossa, S; Guerriero, S; Melis, GB; Orrù, M; Paoletti, AM, 2004) |
| "Metformin treatment also significantly decreased testosterone (by 37%, P = 0." | 1.32 | Metformin therapy increases insulin-like growth factor binding protein-1 in hyperinsulinemic women with polycystic ovary syndrome. ( Banaszewska, B; Duleba, AJ; Pawelczyk, L; Spaczynski, RZ, 2004) |
| "Insulin sensitivity was assessed by homeostasis model assessment (HOMA) and continuous infusion of glucose with model assessment (CIGMA) in all patients." | 1.31 | Circulating ghrelin levels in patients with polycystic ovary syndrome. ( Brabant, G; Horn, R; Müller, MJ; Schill, T; Schlösser, HW; Schöfl, C, 2002) |
| "Metformin treatment was associated with significant reduction in basal free testosterone plasma levels, insulin plasma levels, and insulin response to oral glucose tolerance testing." | 1.31 | Insulin-lowering treatment reduces aromatase activity in response to follicle-stimulating hormone in women with polycystic ovary syndrome. ( Cianci, A; De Leo, V; la Marca, A; Morgante, G; Palumbo, M; Petraglia, F, 2002) |
| "Polycystic ovary syndrome is considered the most frequent endocrine abnormality during the fertile age." | 1.31 | [Effects of metformin on insulin resistance and on ovarian steroidogenesis in women with polycystic ovary syndrome]. ( De Conciliis, B; Passannanti, G; Romano, L; Santarpia, R, 2001) |
| "Polycystic ovary syndrome is the most common form of female infertility in the United States." | 1.31 | Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. ( Iuorno, MJ; Jakubowicz, DJ; Jakubowicz, S; Nestler, JE; Roberts, KA, 2002) |
| "Treatment with metformin in women with PCOS can lead to the increase in homocysteine levels--a risk factor for atherosclerosis." | 1.31 | Homocysteine and steroids levels in metformin treated women with polycystic ovary syndrome. ( Bicíková, M; Hill, M; Stárka, L; Tallová, J; Vrbíková, J, 2002) |
| "Polycystic ovary syndrome is a heterogeneous disorder characterized by signs and symptoms of hyperandrogenism and insulin resistance." | 1.30 | Ovarian responses to hCG stimulation: insulin resistance/hyperinsulinaemia vs. insulin deficiency. ( Arslanian, S; Witchel, SF, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 28 (2.08) | 18.2507 |
| 2000's | 512 (38.12) | 29.6817 |
| 2010's | 565 (42.07) | 24.3611 |
| 2020's | 238 (17.72) | 2.80 |
| Authors | Studies |
|---|---|
| Xing, C | 7 |
| Lv, B | 2 |
| Zhao, H | 7 |
| Wang, D | 3 |
| Li, X | 13 |
| He, B | 8 |
| Dehghan, Z | 1 |
| Mohammadi-Yeganeh, S | 1 |
| Sameni, M | 1 |
| Mirmotalebisohi, SA | 1 |
| Zali, H | 1 |
| Salehi, M | 2 |
| Xie, Y | 2 |
| Xiao, L | 2 |
| Li, S | 6 |
| Hanem, LGE | 5 |
| Salvesen, Ø | 10 |
| Madsen, A | 1 |
| Sagen, JV | 1 |
| Mellgren, G | 1 |
| Juliusson, PB | 3 |
| Carlsen, SM | 30 |
| Vanky, E | 41 |
| Ødegård, R | 6 |
| Cao, Q | 1 |
| Hu, Y | 3 |
| Fu, J | 1 |
| Huang, X | 3 |
| Wu, L | 3 |
| Zhang, J | 10 |
| Huang, W | 5 |
| Rajasekaran, K | 1 |
| Malhotra, N | 1 |
| Mahey, R | 4 |
| Khadgawat, R | 3 |
| Kalaivani, M | 1 |
| Hameed, L | 1 |
| Farooq, AD | 1 |
| Qureshi, T | 1 |
| Amani Abkenari, S | 1 |
| Safdarian, L | 3 |
| Amidi, F | 2 |
| Hosseini, A | 1 |
| Aryanpour, R | 1 |
| Salahi, E | 1 |
| Sobhani, A | 2 |
| Soldat-Stanković, V | 1 |
| Popović-Pejičić, S | 1 |
| Stanković, S | 1 |
| Prtina, A | 1 |
| Malešević, G | 1 |
| Bjekić-Macut, J | 4 |
| Livadas, S | 3 |
| Ognjanović, S | 1 |
| Mastorakos, G | 3 |
| Micić, D | 3 |
| Macut, D | 4 |
| Abdalla, MA | 3 |
| Shah, N | 3 |
| Deshmukh, H | 4 |
| Sahebkar, A | 4 |
| Östlundh, L | 3 |
| Al-Rifai, RH | 3 |
| Atkin, SL | 17 |
| Sathyapalan, T | 13 |
| Duan, X | 1 |
| Zhou, M | 2 |
| Zhou, G | 1 |
| Zhu, Q | 1 |
| Li, W | 4 |
| Cai, M | 2 |
| Shao, X | 2 |
| Xing, F | 1 |
| Zhang, Y | 16 |
| Gao, X | 1 |
| Zeng, Q | 1 |
| Dilimulati, D | 1 |
| Qu, S | 1 |
| Zhang, M | 1 |
| Ma, RL | 2 |
| Deng, Y | 4 |
| Wang, YF | 1 |
| Zhu, SY | 2 |
| Ding, XS | 2 |
| Sun, AJ | 2 |
| Song, Y | 3 |
| Wang, H | 8 |
| Zhu, Z | 2 |
| Huang, H | 5 |
| Lin, W | 1 |
| Feng, J | 2 |
| Zhou, H | 3 |
| Chen, X | 7 |
| Diao, W | 1 |
| Ma, P | 1 |
| Qian, H | 1 |
| Xu, W | 1 |
| Cui, L | 1 |
| Wang, R | 2 |
| Wang, J | 5 |
| Tang, M | 1 |
| Wei, M | 2 |
| Wang, L | 5 |
| Varikasuvu, SR | 1 |
| Pérez-López, FR | 1 |
| Thangappazham, B | 1 |
| Raj, H | 1 |
| Vykunta, A | 1 |
| Hernández-Jiménez, JL | 1 |
| Barrera, D | 1 |
| Espinoza-Simón, E | 1 |
| González, J | 1 |
| Ortíz-Hernández, R | 1 |
| Escobar, L | 1 |
| Echeverría, O | 1 |
| Torres-Ramírez, N | 1 |
| Zhao, YX | 1 |
| Wang, LJ | 2 |
| Gong, FY | 1 |
| Pan, H | 2 |
| Miao, H | 1 |
| Duan, L | 1 |
| Yang, HB | 1 |
| Zhu, HJ | 1 |
| Molin, J | 2 |
| Løvvik, TS | 4 |
| Dehlin, E | 1 |
| Bixo, M | 3 |
| Tulipano, G | 1 |
| Wen, Q | 3 |
| Hu, M | 7 |
| Lai, M | 2 |
| Li, J | 11 |
| Hu, Z | 3 |
| Quan, K | 1 |
| Liu, J | 8 |
| Liu, H | 5 |
| Meng, Y | 1 |
| Wang, S | 4 |
| Wen, X | 1 |
| Yu, C | 3 |
| Huang, S | 1 |
| Zheng, Y | 2 |
| Lin, H | 1 |
| Liang, X | 3 |
| Lu, L | 2 |
| Mai, Z | 1 |
| Zhang, C | 5 |
| Wu, T | 3 |
| Ng, EHY | 1 |
| Stener-Victorin, E | 7 |
| Ma, H | 3 |
| Espnes, KA | 1 |
| Hønnås, A | 1 |
| Gundersen, POM | 1 |
| Naavik, A | 1 |
| Skogvoll, E | 1 |
| Westin, AA | 1 |
| Spigset, O | 2 |
| Garzia, E | 1 |
| Galiano, V | 1 |
| Marfia, G | 1 |
| Navone, S | 1 |
| Grossi, E | 1 |
| Marconi, AM | 1 |
| Walter, K | 1 |
| Liu, Y | 10 |
| Wang, Y | 11 |
| Yao, D | 1 |
| Zhang, F | 1 |
| Feng, Y | 3 |
| Grindheim, S | 1 |
| Ebbing, C | 1 |
| Karlsen, HO | 1 |
| Skulstad, SM | 1 |
| Real, FG | 1 |
| Lønnebotn, M | 2 |
| Løvvik, T | 1 |
| Kessler, J | 1 |
| Czika, A | 2 |
| Yang, Y | 3 |
| Yang, JP | 1 |
| Adu-Gyamfi, EA | 2 |
| Ullah, A | 2 |
| Ruan, LL | 1 |
| Chen, XM | 1 |
| Wang, YX | 2 |
| Wang, MJ | 2 |
| Ding, YB | 1 |
| Fornes, R | 1 |
| Simin, J | 1 |
| Nguyen, MH | 1 |
| Cruz, G | 2 |
| Crisosto, N | 3 |
| van der Schaaf, M | 1 |
| Engstrand, L | 1 |
| Brusselaers, N | 1 |
| Magzoub, R | 1 |
| Kheirelseid, EAH | 1 |
| Perks, C | 1 |
| Lewis, S | 1 |
| Notaro, ALG | 1 |
| Neto, FTL | 1 |
| Herman, R | 1 |
| Kravos, NA | 2 |
| Jensterle, M | 8 |
| Janež, A | 8 |
| Dolžan, V | 1 |
| Rashid, R | 2 |
| Mir, SA | 1 |
| Kareem, O | 1 |
| Ali, T | 1 |
| Ara, R | 1 |
| Malik, A | 1 |
| Amin, F | 1 |
| Bader, GN | 2 |
| Daneshjou, D | 4 |
| Mehranjani, MS | 3 |
| Zadehmodarres, S | 1 |
| Shariatzadeh, SMA | 1 |
| Mofarahe, ZS | 1 |
| Trouva, A | 3 |
| Alvarsson, M | 1 |
| Calissendorff, J | 1 |
| Åsvold, BO | 1 |
| Hirschberg, AL | 4 |
| Palomba, S | 37 |
| Huang, J | 1 |
| Chen, P | 1 |
| Xiang, Y | 1 |
| Liang, Q | 1 |
| Zeng, Y | 1 |
| Zeng, H | 2 |
| Zhou, C | 1 |
| Ilias, I | 1 |
| Rizzo, M | 1 |
| Zabuliene, L | 1 |
| Meun, C | 1 |
| Oostingh, E | 1 |
| Louwers, Y | 1 |
| Laven, J | 1 |
| Zhang, JQ | 1 |
| Jiang, S | 1 |
| Tang, T | 13 |
| Sheng, Y | 1 |
| Li, R | 4 |
| Xu, H | 2 |
| Oróstica, ML | 1 |
| Astorga, I | 1 |
| Plaza-Parrochia, F | 2 |
| Poblete, C | 1 |
| Carvajal, R | 2 |
| García, V | 1 |
| Romero, C | 3 |
| Vega, M | 3 |
| Froment, P | 1 |
| Plotton, I | 1 |
| Giulivi, C | 1 |
| Fabre, S | 1 |
| Khoueiry, R | 1 |
| Mourad, NI | 1 |
| Horman, S | 1 |
| Ramé, C | 1 |
| Rouillon, C | 1 |
| Grandhaye, J | 1 |
| Bigot, Y | 1 |
| Chevaleyre, C | 1 |
| Le Guevel, R | 1 |
| Mallegol, P | 1 |
| Andriantsitohaina, R | 1 |
| Guerif, F | 1 |
| Tamburini, J | 1 |
| Viollet, B | 2 |
| Foretz, M | 2 |
| Dupont, J | 2 |
| Jethaliya, H | 1 |
| Gajjar, N | 1 |
| Patel, V | 4 |
| Deshpande, S | 1 |
| Patel, R | 3 |
| El Leithy, AA | 1 |
| Al-Karmalawy, AA | 1 |
| Youssif, OM | 1 |
| Ebrahim, YA | 1 |
| Khalifa, AS | 1 |
| Elkaeed, EB | 1 |
| Abo-Zeid, FS | 1 |
| Zhao, Y | 4 |
| Chen, L | 5 |
| Ning, Y | 2 |
| Zhu, X | 3 |
| Hu, L | 2 |
| Ma, L | 1 |
| Xia, X | 1 |
| Ying, T | 2 |
| Zou, S | 1 |
| Yu, H | 2 |
| Yin, J | 1 |
| Pan, ML | 3 |
| Chen, LR | 3 |
| Chen, KH | 3 |
| Farhadi-Azar, M | 1 |
| Ghahremani, M | 1 |
| Mahboobifard, F | 1 |
| Noroozzadeh, M | 1 |
| Yaghmaei, P | 1 |
| Tehrani, FR | 1 |
| Miao, K | 1 |
| Zhao, Q | 1 |
| He, J | 1 |
| Manique, MES | 1 |
| Ferreira, AMAP | 1 |
| Elbandrawy, AM | 1 |
| Yousef, AM | 1 |
| Morgan, EN | 1 |
| Ewais, NF | 1 |
| Eid, MM | 1 |
| Elkholi, SM | 1 |
| Abdelbasset, WK | 1 |
| Cui, YY | 1 |
| Jiajue, JRZ | 1 |
| Chen, MP | 1 |
| Yu, M | 1 |
| Yin, WW | 1 |
| Huang, CC | 2 |
| Chen, YR | 1 |
| Yu, DQ | 1 |
| Jin, M | 1 |
| Feng, C | 1 |
| Ghasemian, F | 1 |
| Esmaeilnezhad, S | 1 |
| Xiao, N | 1 |
| Wang, T | 2 |
| Xiong, X | 1 |
| Zhou, J | 2 |
| Su, X | 2 |
| Peng, J | 1 |
| Yang, C | 1 |
| Lin, G | 1 |
| Lu, G | 1 |
| Gong, F | 1 |
| Cheng, L | 1 |
| Smirnov, VV | 1 |
| Beeraka, NM | 1 |
| Butko, DY | 1 |
| Nikolenko, VN | 1 |
| Bondarev, SA | 1 |
| Achkasov, EE | 1 |
| Sinelnikov, MY | 1 |
| Vikram, PRH | 1 |
| Mai, T | 2 |
| Zheng, S | 2 |
| Kong, WY | 1 |
| Liu, ZA | 2 |
| Zhang, N | 1 |
| Wu, X | 5 |
| Zhao, XB | 1 |
| Yan, L | 2 |
| Kayacık Günday, Ö | 1 |
| Özdemir Erdoğan, M | 1 |
| Pehlivan, A | 1 |
| Yılmazer, M | 1 |
| Pervaz, S | 1 |
| Guo, M | 1 |
| Joham, AE | 2 |
| Norman, RJ | 20 |
| Legro, RS | 29 |
| Franks, S | 6 |
| Moran, LJ | 5 |
| Boyle, J | 3 |
| Teede, HJ | 14 |
| Selen, DJ | 1 |
| Powe, CE | 1 |
| Manzoor, F | 1 |
| Nisa, MU | 1 |
| Shakoor, A | 1 |
| Hussain, L | 1 |
| Mahmood, A | 1 |
| Younas, A | 1 |
| Matorras, R | 1 |
| Pijoan, JI | 1 |
| Laínz, L | 1 |
| Díaz-Nuñez, M | 1 |
| Sainz, H | 1 |
| Pérez-Fernandez, S | 1 |
| Moreira, D | 1 |
| Ji, X | 2 |
| Chen, J | 12 |
| Xu, P | 1 |
| Shen, S | 3 |
| Bi, Y | 3 |
| Lan, Y | 2 |
| Yang, L | 3 |
| Li, H | 1 |
| Long, C | 1 |
| Wang, M | 1 |
| Xie, Q | 2 |
| Li, Z | 3 |
| Wu, J | 3 |
| Yang, S | 3 |
| Zhao, L | 2 |
| He, W | 1 |
| Mi, Y | 1 |
| Cheng, X | 2 |
| Dong, H | 2 |
| Ma, R | 2 |
| Zou, Y | 1 |
| Wang, W | 2 |
| Zheng, Q | 2 |
| Tan, Z | 1 |
| Zeng, X | 3 |
| Gu, B | 1 |
| Sun, A | 2 |
| Hassan, S | 1 |
| Shah, M | 4 |
| Malik, MO | 3 |
| Ehtesham, E | 3 |
| Habib, SH | 2 |
| Rauf, B | 2 |
| Dahabiyeh, LA | 1 |
| Mujammami, M | 1 |
| AlMalki, RH | 1 |
| Arafat, T | 1 |
| Benabdelkamel, H | 1 |
| Alfadda, AA | 1 |
| Abdel Rahman, AM | 1 |
| Unanyan, A | 1 |
| Pivazyan, L | 1 |
| Krylova, E | 1 |
| Eskin, A | 1 |
| Zakaryan, A | 1 |
| Sarkisova, A | 1 |
| Ishchenko, A | 1 |
| Kamal, DAM | 3 |
| Ibrahim, SF | 3 |
| Ugusman, A | 3 |
| Zaid, SSM | 1 |
| Mokhtar, MH | 3 |
| Cui, D | 1 |
| Xu, Z | 1 |
| Qiu, S | 1 |
| Sun, Y | 6 |
| Chan, LE | 3 |
| Casiraghi, E | 3 |
| Laraway, B | 3 |
| Coleman, B | 3 |
| Blau, H | 3 |
| Zaman, A | 3 |
| Harris, NL | 3 |
| Wilkins, K | 3 |
| Antony, B | 3 |
| Gargano, M | 3 |
| Valentini, G | 3 |
| Sahner, D | 3 |
| Haendel, M | 3 |
| Robinson, PN | 3 |
| Bramante, C | 3 |
| Reese, J | 3 |
| Jiang, XL | 3 |
| Tai, H | 3 |
| Xiao, XS | 3 |
| Zhang, SY | 3 |
| Cui, SC | 3 |
| Qi, SB | 3 |
| Hu, DD | 3 |
| Zhang, LN | 3 |
| Kuang, JS | 3 |
| Meng, XS | 3 |
| Li, SM | 3 |
| Rokicka, D | 3 |
| Wróbel, M | 2 |
| Stołtny, D | 2 |
| Strojek, K | 3 |
| Ahmed, AF | 2 |
| Sharkawi, SS | 2 |
| AbdelHameed, SS | 2 |
| Bayoumi, AM | 2 |
| Moussa, RS | 2 |
| Alhakamy, NA | 2 |
| Al Sadoun, H | 2 |
| Mansouri, RA | 2 |
| El-Moselhy, MA | 2 |
| El-Daly, M | 2 |
| Anter, AF | 2 |
| Onal, T | 1 |
| Tulay, P | 1 |
| Vatansever, HS | 1 |
| Zehra, SA | 1 |
| Shah, HH | 1 |
| Hancke, K | 2 |
| Liu, X | 4 |
| Ding, Q | 1 |
| Yin, S | 1 |
| Yang, H | 1 |
| Yang, PK | 3 |
| Huang, YS | 1 |
| Chen, SU | 3 |
| Yang, YS | 1 |
| Chen, MJ | 4 |
| Raza, S | 1 |
| Al-Niaimi, F | 1 |
| Ali, FR | 1 |
| Garcia-Beltran, C | 6 |
| Bassols, J | 4 |
| Carreras-Badosa, G | 2 |
| López Bermejo, A | 1 |
| Ibáñez, L | 28 |
| de Zegher, F | 26 |
| Kamboj, P | 1 |
| Kaushik, A | 1 |
| Handa, S | 1 |
| Dutta, P | 1 |
| Saikia, UN | 1 |
| Pal, A | 1 |
| De, D | 1 |
| Rabah, HM | 1 |
| Mohamed, DA | 1 |
| Mariah, RA | 1 |
| Abd El-Khalik, SR | 1 |
| Khattab, HA | 1 |
| AbuoHashish, NA | 2 |
| Abdelsattar, AM | 1 |
| Raslan, MA | 1 |
| Farghal, EE | 1 |
| Eltokhy, AK | 1 |
| Diaz, M | 13 |
| Puerto-Carranza, E | 1 |
| Oliver-Vila, C | 1 |
| Casano, P | 1 |
| Franco, CA | 1 |
| Malpique, R | 5 |
| López-Bermejo, A | 12 |
| Greff, D | 1 |
| Juhász, AE | 1 |
| Váncsa, S | 1 |
| Váradi, A | 1 |
| Sipos, Z | 1 |
| Szinte, J | 1 |
| Park, S | 1 |
| Hegyi, P | 1 |
| Nyirády, P | 1 |
| Ács, N | 1 |
| Várbíró, S | 1 |
| Horváth, EM | 1 |
| Abolhassani, N | 1 |
| Winterfeld, U | 1 |
| Kaplan, YC | 1 |
| Jaques, C | 1 |
| Minder Wyssmann, B | 1 |
| Del Giovane, C | 1 |
| Panchaud, A | 1 |
| Wang, X | 4 |
| Peng, Q | 1 |
| Ouyang, J | 1 |
| Wang, Q | 4 |
| Ren, S | 1 |
| Xie, H | 1 |
| Wang, C | 4 |
| Hei, C | 1 |
| Sun, M | 1 |
| Chang, Q | 1 |
| Li, G | 1 |
| He, R | 1 |
| Fontes, AFS | 1 |
| Reis, FM | 2 |
| Cândido, AL | 2 |
| Gomes, KB | 2 |
| Tosatti, JAG | 1 |
| Lin, K | 1 |
| Wei, T | 1 |
| Song, L | 1 |
| Hua, Y | 1 |
| Ni, Z | 1 |
| Yuan, Z | 1 |
| Yu, J | 2 |
| Zhang, D | 3 |
| Yao, R | 1 |
| Zhou, L | 2 |
| Elshamy, AM | 1 |
| Shatat, D | 1 |
| Safa, MAE | 1 |
| Elgharbawy, N | 1 |
| Ibrahim, HA | 1 |
| Barhoma, RAE | 1 |
| Eltabaa, EF | 1 |
| Ahmed, AS | 1 |
| Shalaby, AM | 1 |
| Alabiad, MA | 1 |
| Alorini, M | 1 |
| Ibrahim, RR | 1 |
| Gao, R | 1 |
| Qin, L | 1 |
| Min, W | 1 |
| Peng, G | 1 |
| Yan, Z | 1 |
| Ma, J | 1 |
| Tong, N | 1 |
| Ryssdal, M | 1 |
| Stokkeland, LMT | 1 |
| Jarmund, AH | 1 |
| Steinkjer, B | 1 |
| Madssen, TS | 1 |
| Iversen, AC | 1 |
| Giskeødegård, GF | 1 |
| Belani, MA | 1 |
| Shah, P | 1 |
| Banker, M | 1 |
| Gupta, SS | 1 |
| Ye, ZR | 1 |
| Yan, CQ | 1 |
| Liao, N | 1 |
| Wen, SH | 1 |
| Modarres, SZ | 1 |
| Ali Shariatzadeh, SM | 1 |
| García-Gómez, E | 1 |
| Gómez-Viais, YI | 1 |
| Cruz-Aranda, MM | 1 |
| Martínez-Razo, LD | 1 |
| Reyes-Mayoral, C | 1 |
| Ibarra-González, L | 1 |
| Montoya-Estrada, A | 1 |
| Osorio-Caballero, M | 1 |
| Perichart-Perera, O | 1 |
| Camacho-Arroyo, I | 1 |
| Cerbón, M | 1 |
| Reyes-Muñoz, E | 1 |
| Vázquez-Martínez, ER | 1 |
| Borzan, V | 1 |
| Riedl, R | 1 |
| Obermayer-Pietsch, B | 4 |
| DiVall, SA | 1 |
| Fatima, K | 1 |
| Jamil, Z | 1 |
| Faheem, S | 1 |
| Adnan, A | 1 |
| Javaid, SS | 1 |
| Naeem, H | 1 |
| Mohiuddin, N | 1 |
| Sajid, A | 1 |
| Ochani, S | 1 |
| Zhong, X | 1 |
| Li, Y | 5 |
| Liang, W | 1 |
| Hu, Q | 1 |
| Zeng, A | 1 |
| Ding, M | 1 |
| Chen, D | 1 |
| Xie, M | 1 |
| Tripathi, R | 1 |
| Singh, A | 1 |
| Sarkar, S | 1 |
| Kawale, A | 1 |
| Gupta, S | 1 |
| Gupta, RK | 1 |
| Jha, RK | 1 |
| Alsoghachi, H | 1 |
| Althanoon, Z | 1 |
| Huang, Y | 3 |
| Liu, D | 6 |
| Xie, T | 1 |
| Chen, Z | 2 |
| Huang, Q | 4 |
| Zhou, X | 3 |
| Lai, X | 1 |
| Zhou, LH | 1 |
| Zou, H | 1 |
| Hao, JY | 1 |
| Zhang, JN | 1 |
| Xu, XH | 1 |
| Nazirudeen, R | 1 |
| Sridhar, S | 1 |
| Priyanka, R | 1 |
| Sumathi, B | 1 |
| Natarajan, V | 1 |
| Subbiah, E | 1 |
| Raghavan, KS | 1 |
| Sangumani, J | 1 |
| Gan, J | 1 |
| Ali Fadlalmola, H | 1 |
| Elhusein, AM | 1 |
| Al-Sayaghi, KM | 1 |
| Albadrani, MS | 1 |
| Swamy, DV | 1 |
| Mamanao, DM | 1 |
| El-Amin, EI | 1 |
| Ibrahim, SE | 1 |
| Abbas, SM | 1 |
| Fang, S | 1 |
| Liang, Y | 1 |
| Tian, Y | 1 |
| Chen, Y | 4 |
| Yuan, J | 1 |
| Chen, Q | 3 |
| Tawfeq, M | 1 |
| Sarhat, E | 2 |
| Allow, S | 1 |
| Zhou, Z | 1 |
| Chen, H | 3 |
| Chu, L | 1 |
| Zou, Q | 1 |
| Yang, J | 1 |
| Ou, X | 1 |
| Sciacca, L | 1 |
| Bianchi, C | 1 |
| Burlina, S | 1 |
| Formoso, G | 1 |
| Manicardi, E | 1 |
| Sculli, MA | 1 |
| Resi, V | 1 |
| Tosti, G | 1 |
| Barberio, A | 1 |
| Tartaglione, L | 1 |
| Rizzi, A | 1 |
| Di Leo, M | 1 |
| Viti, L | 1 |
| Sirico, A | 1 |
| De Carolis, S | 1 |
| Pontecorvi, A | 1 |
| Lanzone, A | 14 |
| Pitocco, D | 1 |
| Xiong, T | 1 |
| Fraison, E | 1 |
| Kolibianaki, E | 1 |
| Costello, MF | 11 |
| Venetis, C | 1 |
| Kostova, EB | 1 |
| Guarano, A | 1 |
| Capozzi, A | 2 |
| Cristodoro, M | 1 |
| Di Simone, N | 1 |
| Lello, S | 2 |
| Melin, J | 1 |
| Forslund, M | 1 |
| Alesi, S | 1 |
| Piltonen, T | 3 |
| Romualdi, D | 12 |
| Spritzer, PM | 7 |
| Tay, CT | 2 |
| Pena, A | 2 |
| Witchel, SF | 3 |
| Mousa, A | 1 |
| Teede, H | 5 |
| Omar, HS | 1 |
| Ibrahim, OA | 1 |
| Sayed, MG | 1 |
| Faruk, EM | 1 |
| Fouad, H | 1 |
| Safwat, M | 1 |
| Schweighofer, N | 2 |
| Strasser, M | 1 |
| Obermayer, A | 1 |
| Trummer, O | 2 |
| Sourij, H | 1 |
| Sourij, C | 1 |
| Tang, Z | 1 |
| Guan, J | 1 |
| Mao, JH | 1 |
| Han, L | 1 |
| Zhang, JJ | 1 |
| Chen, R | 1 |
| Jiao, Z | 1 |
| Kadhem, AH | 1 |
| Gholizadeh, A | 1 |
| Khalaj-Kondori, M | 1 |
| Andersen, MS | 3 |
| Bas, F | 1 |
| Darendeliler, F | 1 |
| Dieris, B | 1 |
| Fanelli, F | 1 |
| Fröhlich-Reiterer, E | 1 |
| Gambineri, A | 13 |
| Glintborg, D | 10 |
| Mann, C | 1 |
| Marin, S | 1 |
| Ravn, P | 5 |
| Reinehr, T | 1 |
| Renzulli, M | 1 |
| Salvador, C | 1 |
| Singer, V | 1 |
| Torres, JV | 1 |
| Yildiz, M | 2 |
| Hao, SL | 1 |
| Zhang, CL | 1 |
| Meng, XY | 1 |
| Anbar, HS | 1 |
| Vahora, NY | 1 |
| Shah, HL | 1 |
| Azam, MM | 1 |
| Islam, T | 1 |
| Hersi, F | 1 |
| Omar, HA | 1 |
| Dohle, W | 1 |
| Potter, BVL | 1 |
| El-Gamal, MI | 1 |
| Qu, H | 1 |
| Shou, L | 1 |
| Song, X | 1 |
| Hamiti, S | 1 |
| Ma, Y | 3 |
| Yusufu, M | 1 |
| Zhang, K | 1 |
| Guo, Y | 1 |
| Mahmoud, MM | 1 |
| Rashed, LA | 1 |
| Soliman, SA | 1 |
| Sayed, SM | 1 |
| Kamel, O | 1 |
| Kamar, SS | 1 |
| Hussien, RES | 1 |
| Ujvari, D | 1 |
| Shang, J | 1 |
| Zhou, W | 1 |
| Stefanaki, C | 1 |
| Bacopoulou, F | 1 |
| Kandaraki, E | 2 |
| Boschiero, D | 1 |
| Diamandi-Kandarakis, E | 1 |
| Tao, X | 2 |
| Cai, L | 1 |
| Ge, S | 1 |
| Deng, X | 1 |
| Banaszewska, B | 7 |
| Pawelczyk, L | 8 |
| Spaczynski, R | 2 |
| Underdal, MO | 3 |
| Henriksen, AH | 1 |
| Andersen, M | 8 |
| Jiang, J | 1 |
| Gao, S | 1 |
| Bordewijk, EM | 2 |
| Zhang, H | 8 |
| Gao, J | 1 |
| Morin-Papunen, L | 9 |
| Homburg, R | 7 |
| König, TE | 1 |
| Moll, E | 4 |
| Kar, S | 1 |
| Johnson, NP | 5 |
| Amer, SA | 1 |
| Vegetti, W | 1 |
| Falbo, A | 29 |
| Özmen, Ü | 1 |
| Nazik, H | 1 |
| Williams, CD | 1 |
| Federica, G | 1 |
| Lord, J | 3 |
| Sahin, Y | 5 |
| Bhattacharya, S | 1 |
| van Wely, M | 4 |
| Mol, BW | 3 |
| Sciannimanico, S | 1 |
| Grimaldi, F | 1 |
| Vescini, F | 1 |
| De Pergola, G | 2 |
| Iacoviello, M | 1 |
| Licchelli, B | 1 |
| Guastamacchia, E | 1 |
| Giagulli, VA | 1 |
| Triggiani, V | 1 |
| Ali, DE | 1 |
| Ali, A | 2 |
| Rehman, F | 1 |
| Badshah, H | 2 |
| Vitale, SG | 1 |
| Pradas, I | 1 |
| Rovira-Llopis, S | 3 |
| Naudí, A | 1 |
| Bañuls, C | 3 |
| Rocha, M | 3 |
| Hernandez-Mijares, A | 3 |
| Pamplona, R | 1 |
| Victor, VM | 3 |
| Jové, M | 1 |
| Carvalho, MJ | 1 |
| Subtil, S | 1 |
| Rodrigues, Â | 1 |
| Oliveira, J | 1 |
| Figueiredo-Dias, M | 1 |
| Ganie, MA | 7 |
| Rashid, A | 2 |
| Sood, M | 1 |
| Sofi, NY | 1 |
| Wani, IA | 4 |
| Nisar, S | 2 |
| Butt, TP | 1 |
| Gupta, N | 4 |
| Bhat, D | 1 |
| Choh, N | 1 |
| Masoodi, SR | 1 |
| Tan, J | 1 |
| Duan, C | 1 |
| Xie, YJ | 1 |
| Liu, YT | 1 |
| Long, SL | 1 |
| Mo, ZC | 1 |
| Heidari, B | 2 |
| Lerman, A | 1 |
| Lalia, AZ | 1 |
| Lerman, LO | 1 |
| Chang, AY | 1 |
| Sharpe, A | 1 |
| Morley, LC | 3 |
| Balen, AH | 17 |
| Cabrera-Cruz, H | 1 |
| Oróstica, L | 1 |
| Torres-Pinto, I | 1 |
| Piltonen, TT | 2 |
| Ruokojärvi, M | 1 |
| Karro, H | 1 |
| Kujanpää, L | 1 |
| Tapanainen, JS | 8 |
| Sundrström-Poromaa, I | 1 |
| Mellembakken, JR | 1 |
| Steingrimsdottir, T | 1 |
| Gibson-Helm, M | 1 |
| Arffman, RK | 1 |
| Falah-Hassani, K | 1 |
| Vatopoulou, A | 1 |
| Tziomalos, K | 6 |
| Alahmadi, AA | 1 |
| Alzahrani, AA | 1 |
| Ali, SS | 1 |
| Alahmadi, BA | 1 |
| Arab, RA | 1 |
| El-Shitany, NAE | 1 |
| Weng, S | 1 |
| Luo, Y | 1 |
| Zhang, Z | 3 |
| Peng, D | 1 |
| Chen, SF | 2 |
| Yang, YC | 2 |
| Hsu, CY | 3 |
| Shen, YC | 2 |
| Arya, S | 1 |
| Hansen, KR | 1 |
| Wild, RA | 2 |
| Greger, HK | 1 |
| Østgård, HF | 1 |
| Bhat, GA | 1 |
| Shaheen, F | 1 |
| Shrivastava, M | 1 |
| Shah, ZA | 4 |
| Wei, J | 2 |
| Yang, G | 4 |
| Jia, Y | 1 |
| Deng, W | 1 |
| Long, M | 1 |
| Papadakis, E | 2 |
| Sarigianni, M | 1 |
| Mavromatidis, G | 1 |
| Panidis, D | 8 |
| Cereijo, R | 1 |
| Quesada-López, T | 1 |
| Villarroya, F | 2 |
| Cui, P | 5 |
| Brännström, M | 5 |
| Shao, LR | 4 |
| Billig, H | 6 |
| Ding, Z | 1 |
| Chen, A | 2 |
| Yao, Y | 1 |
| Cai, H | 1 |
| Sun, H | 2 |
| Gao, Y | 1 |
| Xu, S | 1 |
| Shen, Y | 1 |
| Liao, T | 1 |
| Hu, S | 1 |
| Zhou, S | 1 |
| Almalki, HH | 1 |
| Alshibani, TM | 1 |
| Alhifany, AA | 1 |
| Almohammed, OA | 1 |
| O'Brien, B | 1 |
| Dahiya, R | 1 |
| Kimble, R | 1 |
| Nejabati, HR | 1 |
| Samadi, N | 1 |
| Shahnazi, V | 1 |
| Mihanfar, A | 2 |
| Fattahi, A | 1 |
| Latifi, Z | 1 |
| Bahrami-Asl, Z | 1 |
| Roshangar, L | 2 |
| Nouri, M | 2 |
| Nayak, G | 1 |
| Salian, SR | 1 |
| Agarwal, P | 1 |
| Suresh Poojary, P | 1 |
| Rao, A | 1 |
| Kumari, S | 1 |
| Kalthur, SG | 1 |
| Shreya, AB | 1 |
| Mutalik, S | 1 |
| Adiga, SK | 1 |
| Kalthur, G | 1 |
| Jin, J | 2 |
| Tong, X | 1 |
| Yang, W | 1 |
| Dai, Y | 1 |
| Pan, Y | 1 |
| Ren, P | 1 |
| Liu, L | 1 |
| Fan, HY | 1 |
| Zhang, S | 4 |
| Kim, CH | 1 |
| Chon, SJ | 1 |
| Lee, SH | 1 |
| Krupej-Kędzierska, J | 1 |
| Cichocka, E | 1 |
| Kędzierski, L | 1 |
| Okopień, B | 3 |
| Gumprecht, J | 1 |
| Guo, QJ | 1 |
| Shan, J | 1 |
| Xu, YF | 1 |
| Hu, YY | 1 |
| Huo, CL | 1 |
| Song, JY | 1 |
| Wang, CQ | 1 |
| Yu, CQ | 2 |
| Street, ME | 1 |
| Cirillo, F | 1 |
| Catellani, C | 1 |
| Dauriz, M | 1 |
| Lazzeroni, P | 1 |
| Sartori, C | 1 |
| Moghetti, P | 4 |
| Cena, H | 1 |
| Chiovato, L | 2 |
| Nappi, RE | 2 |
| Li, C | 2 |
| Tu, H | 1 |
| Yao, J | 1 |
| Le, J | 1 |
| Jiang, Z | 1 |
| Tang, Q | 1 |
| Zhang, R | 1 |
| Huo, P | 1 |
| Lei, X | 1 |
| Scambia, G | 1 |
| Battaglia, C | 3 |
| Battaglia, B | 1 |
| Casadio, P | 1 |
| Rizzo, R | 1 |
| Artini, PG | 2 |
| Papaetis, GS | 1 |
| Filippou, PK | 1 |
| Constantinidou, KG | 1 |
| Stylianou, CS | 1 |
| Chou, CH | 1 |
| Chang, CH | 1 |
| Ho, HN | 3 |
| Zadeh Modarres, S | 2 |
| Soleimani Mehranjani, M | 2 |
| Shariat Zadeh, SMA | 1 |
| Wu, Y | 4 |
| Tu, M | 1 |
| Morgante, G | 12 |
| Massaro, MG | 3 |
| Scolaro, V | 1 |
| Cappelli, V | 4 |
| Luddi, A | 2 |
| Troìa, L | 1 |
| De Leo, V | 16 |
| De Diego, MV | 1 |
| Gómez-Pardo, O | 1 |
| Groar, JK | 1 |
| López-Escobar, A | 1 |
| Martín-Estal, I | 1 |
| Castilla-Cortázar, I | 1 |
| Rodríguez-Zambrano, MÁ | 1 |
| Fu, XP | 1 |
| Xu, L | 2 |
| Fu, BB | 1 |
| Wei, KN | 1 |
| Liao, BQ | 1 |
| He, SW | 1 |
| Wang, YL | 1 |
| Chen, MH | 1 |
| Lin, YH | 1 |
| Li, FP | 1 |
| Hong, ZW | 1 |
| Huang, XH | 1 |
| Xu, CL | 1 |
| Wang, HL | 1 |
| Sherafatmanesh, S | 1 |
| Ekramzadeh, M | 1 |
| Tanideh, N | 1 |
| Golmakani, MT | 1 |
| Koohpeyma, F | 1 |
| Andræ, F | 2 |
| Abbott, D | 1 |
| Stridsklev, S | 7 |
| Schmedes, AV | 1 |
| Odsæter, IH | 1 |
| Alenzi, EO | 1 |
| Gupta, M | 2 |
| Bansiwal, R | 1 |
| Sethi, A | 2 |
| Soliman, A | 1 |
| De Sanctis, V | 1 |
| Alaaraj, N | 1 |
| Hamed, N | 1 |
| Prabhakar, P | 1 |
| Kachhawa, G | 2 |
| Sharma, JB | 1 |
| Vanamail, P | 2 |
| Kumari, R | 1 |
| Bhatla, N | 1 |
| Carbonetto, B | 1 |
| González-Torres, P | 1 |
| Henares, D | 1 |
| Brotons, P | 1 |
| Muñoz-Almagro, C | 1 |
| Tao, T | 2 |
| Zhu, YC | 1 |
| Fu, JR | 1 |
| Wang, YY | 1 |
| Cai, J | 1 |
| Ma, JY | 1 |
| Xu, Y | 4 |
| Gao, YN | 1 |
| Fan, W | 1 |
| Liu, W | 2 |
| Yen, H | 1 |
| Chang, YT | 1 |
| Yee, FJ | 1 |
| Huang, YC | 1 |
| Shariatzadeh, MA | 2 |
| Yaylalı, A | 1 |
| Bakacak, M | 1 |
| Bakacak, Z | 1 |
| Giudice, LC | 6 |
| He, S | 1 |
| Meng, J | 1 |
| Zhu, Y | 2 |
| Sferruzzi-Perri, AN | 1 |
| Ferrer, MJ | 1 |
| Silva, AF | 1 |
| Abruzzese, GA | 1 |
| Velázquez, ME | 1 |
| Motta, AB | 9 |
| Vukašin, T | 1 |
| Velija-Ašimi, Z | 3 |
| Bureković, A | 1 |
| Zdravković, M | 1 |
| Andrić, Z | 1 |
| Branković, M | 1 |
| Crevar-Marinović, S | 1 |
| Madić, T | 1 |
| Stanojlović, O | 1 |
| Milutinović, DV | 1 |
| Walker, K | 1 |
| Decherney, AH | 1 |
| Saunders, R | 1 |
| Chang, C | 2 |
| Chang, S | 2 |
| Poles, J | 1 |
| Popov, V | 1 |
| Naseri, L | 1 |
| Khazaei, MR | 1 |
| Khazaei, M | 2 |
| Mbara, KC | 1 |
| Mofo Mato, PE | 1 |
| Driver, C | 1 |
| Nzuza, S | 1 |
| Mkhombo, NT | 1 |
| Gcwensa, SK | 1 |
| Mcobothi, EN | 1 |
| Owira, PM | 1 |
| Peng, MF | 1 |
| Tian, S | 1 |
| Song, YG | 1 |
| Li, CX | 1 |
| Miao, MS | 1 |
| Ren, Z | 1 |
| Li, M | 7 |
| Raperport, C | 1 |
| Chronopoulou, E | 1 |
| Fang, Z | 1 |
| Yang, X | 2 |
| Bai, Y | 1 |
| Wang, F | 4 |
| Dorgham, N | 1 |
| Sharobim, A | 1 |
| Haggag, H | 1 |
| El-Kalioby, M | 1 |
| Dorgham, D | 1 |
| Celotto, S | 1 |
| Pizzol, D | 1 |
| Gasevic, D | 1 |
| Ji, MM | 1 |
| Barnini, T | 1 |
| Solmi, M | 1 |
| Stubbs, B | 1 |
| Smith, L | 1 |
| López Sánchez, GF | 1 |
| Pesolillo, G | 1 |
| Yu, Z | 1 |
| Tzoulaki, I | 1 |
| Theodoratou, E | 1 |
| Ioannidis, JPA | 1 |
| Veronese, N | 1 |
| Demurtas, J | 1 |
| Villarroya, J | 1 |
| Cairó, M | 1 |
| Torres-Zegarra, C | 1 |
| Sundararajan, D | 1 |
| Benson, J | 1 |
| Seagle, H | 1 |
| Witten, M | 1 |
| Walders-Abramson, N | 1 |
| Simon, SL | 1 |
| Huguelet, P | 1 |
| Nokoff, NJ | 1 |
| Cree-Green, M | 1 |
| Ouyang, H | 1 |
| Al-Mureish, A | 1 |
| Wu, N | 1 |
| Kathuria, D | 1 |
| Raul, AD | 1 |
| Wanjari, P | 1 |
| Bharatam, PV | 1 |
| Sohrevardi, SM | 1 |
| Heydari, B | 1 |
| Azarpazhooh, MR | 1 |
| Teymourzadeh, M | 1 |
| Simental-Mendía, LE | 1 |
| Karimi-Zarchi, M | 1 |
| Ebrahimi, F | 1 |
| Rostami, S | 1 |
| Nekoonam, S | 1 |
| Rashidi, Z | 1 |
| Azizi Kutenaei, M | 1 |
| Hosseini Teshnizi, S | 1 |
| Ghaemmaghami, P | 1 |
| Eini, F | 1 |
| Roozbeh, N | 1 |
| Garcia-Hernandez, SC | 1 |
| Porchia, LM | 1 |
| Pacheco-Soto, BT | 1 |
| López-Bayghen, E | 1 |
| Gonzalez-Mejia, ME | 1 |
| Siamashvili, M | 1 |
| Davis, SN | 1 |
| Hu, H | 1 |
| Zou, G | 1 |
| Ma, Z | 1 |
| Li, F | 1 |
| Tauqir, S | 1 |
| Israr, M | 1 |
| Shah, FA | 1 |
| Usman, M | 1 |
| Raza, MA | 1 |
| Shah, I | 1 |
| Ohara, M | 1 |
| Yoshida-Komiya, H | 2 |
| Ono-Okutsu, M | 1 |
| Yamaguchi-Ito, A | 1 |
| Takahashi, T | 1 |
| Fujimori, K | 2 |
| Elkind-Hirsch, KE | 2 |
| Chappell, N | 1 |
| Seidemann, E | 1 |
| Storment, J | 1 |
| Bellanger, D | 1 |
| Ding, X | 1 |
| Yuan, L | 1 |
| Wu, H | 3 |
| Qin, A | 1 |
| Khan, L | 1 |
| Ran, Y | 1 |
| Kong, L | 1 |
| Geng, L | 1 |
| Hu, J | 3 |
| Qi, H | 1 |
| Khadem-Ansari, MH | 1 |
| Wang, Z | 3 |
| Nie, K | 1 |
| Su, H | 1 |
| Tang, Y | 2 |
| Xu, X | 3 |
| Shao, Y | 1 |
| Xie, J | 2 |
| Zhu, G | 1 |
| Shirooie, S | 1 |
| Khaledi, E | 1 |
| Dehpour, AR | 1 |
| Noori, T | 1 |
| Sadeghi, F | 1 |
| Sobarzo-Sánchez, E | 1 |
| Ge, JJ | 1 |
| Wang, DJ | 1 |
| Song, W | 1 |
| Shen, SM | 1 |
| Ge, WH | 1 |
| Goricar, K | 2 |
| Meng, F | 1 |
| Sun, X | 3 |
| Morina, N | 1 |
| Wu, XK | 2 |
| Shao, R | 2 |
| Tsao, HM | 2 |
| Deng, H | 2 |
| Li, N | 1 |
| Xu, D | 1 |
| Jamilian, M | 2 |
| Farhat, P | 1 |
| Foroozanfard, F | 3 |
| Afshar Ebrahimi, F | 3 |
| Aghadavod, E | 2 |
| Bahmani, F | 2 |
| Badehnoosh, B | 1 |
| Jamilian, H | 2 |
| Asemi, Z | 3 |
| LE, TN | 1 |
| Wickham, EP | 1 |
| Nestler, JE | 35 |
| Anastasiou, OE | 1 |
| Canbay, A | 1 |
| Fuhrer, D | 1 |
| Reger-Tan, S | 1 |
| Rahelić, D | 1 |
| Doknić, M | 1 |
| Božić-Antić, I | 1 |
| Nemati, M | 1 |
| Nemati, S | 1 |
| Taheri, AM | 1 |
| Dawson, AJ | 1 |
| Kilpatrick, ES | 12 |
| Coady, AM | 10 |
| Elshewehy, AMM | 1 |
| Dakroury, Y | 2 |
| Ahmed, L | 2 |
| Del Río, L | 2 |
| Sebastiani, G | 1 |
| Pozo, ÓJ | 1 |
| Nas, K | 1 |
| Tűű, L | 1 |
| Riahi, SM | 1 |
| Mokhayeri, Y | 1 |
| Sam, S | 1 |
| Ehrmann, DA | 6 |
| Carvalho, LML | 1 |
| Ferreira, CN | 1 |
| Sóter, MO | 1 |
| Sales, MF | 1 |
| Silva, IFO | 1 |
| Nunes, FFC | 1 |
| Scioscia, M | 1 |
| Fascilla, F | 1 |
| Bettocchi, S | 1 |
| Udhane, SS | 1 |
| Legeza, B | 1 |
| Marti, N | 1 |
| Hertig, D | 1 |
| Diserens, G | 1 |
| Nuoffer, JM | 1 |
| Vermathen, P | 1 |
| Flück, CE | 1 |
| Wróbel, MP | 1 |
| Marek, B | 1 |
| Kajdaniuk, D | 1 |
| Szymborska-Kajanek, A | 1 |
| Medina, G | 1 |
| Maliqueo, M | 3 |
| Echiburú, B | 2 |
| Sir-Petermann, T | 3 |
| Lara, HE | 1 |
| Pedersen, AJT | 1 |
| Stage, TB | 1 |
| Christensen, MMH | 1 |
| Di Sabatino, A | 4 |
| Wang, YW | 1 |
| He, SJ | 1 |
| Feng, X | 2 |
| Cheng, J | 2 |
| Luo, YT | 1 |
| Tian, L | 2 |
| Alpañés, M | 2 |
| Álvarez-Blasco, F | 7 |
| Fernández-Durán, E | 1 |
| Luque-Ramírez, M | 10 |
| Escobar-Morreale, HF | 11 |
| Zhu, L | 2 |
| Hu, K | 2 |
| Xu, J | 1 |
| Zhou, D | 1 |
| Chu, S | 1 |
| Zeng, L | 1 |
| Yang, K | 1 |
| Rezk, M | 1 |
| Shaheen, AE | 1 |
| Saif El-Nasr, I | 1 |
| Lepine, S | 1 |
| Jo, J | 1 |
| Metwally, M | 2 |
| Cheong, YC | 1 |
| Hjorth-Hansen, A | 1 |
| Engen Hanem, LG | 1 |
| Eggebø, T | 1 |
| Salvesen, KÅ | 6 |
| Song, J | 3 |
| Ruan, X | 3 |
| Gu, M | 2 |
| Mueck, AO | 3 |
| Yasmin, E | 7 |
| Hibberd, R | 1 |
| Raine-Fenning, N | 2 |
| Thornton, J | 1 |
| Pundir, J | 2 |
| Psaroudakis, D | 1 |
| Savnur, P | 1 |
| Bhide, P | 1 |
| Sabatini, L | 1 |
| Coomarasamy, A | 1 |
| Thangaratinam, S | 2 |
| Dos Santos, IK | 1 |
| de Lima Nunes, R | 1 |
| Soares, GM | 1 |
| de Oliveira Maranhão, TM | 1 |
| Dantas, PMS | 1 |
| Pal Singh Kochar, I | 1 |
| Ramachandran, S | 1 |
| Lai, MY | 1 |
| Li, ZR | 1 |
| Chen, CH | 1 |
| Sebastian, MR | 1 |
| Wiemann, CM | 1 |
| Bacha, F | 1 |
| Alston Taylor, SJ | 1 |
| Prado Correia, LE | 1 |
| de Almeida, BC | 1 |
| de Jesus Simões, M | 2 |
| Abi Haidar, M | 2 |
| Berguio Vidotti, D | 1 |
| Silva, I | 1 |
| Wu, P | 1 |
| Roelants, M | 1 |
| Mahamed, RR | 1 |
| Maganhin, CC | 1 |
| Sasso, GRS | 1 |
| Baracat, MCP | 1 |
| Baracat, EC | 7 |
| Soares-, JM | 1 |
| Zhao, W | 1 |
| Guo, X | 1 |
| Vestin, E | 2 |
| Malik, M | 1 |
| Tasnim, N | 1 |
| Mahmud, G | 1 |
| Greenhill, C | 1 |
| Abdalmageed, OS | 1 |
| Farghaly, TA | 1 |
| Abdelaleem, AA | 1 |
| Abdelmagied, AE | 1 |
| Ali, MK | 1 |
| Abbas, AM | 1 |
| Altinok, ML | 4 |
| Oppen, IH | 1 |
| Høgetveit, K | 1 |
| Salamun, V | 2 |
| Vrtacnik Bokal, E | 2 |
| Hiam, DS | 1 |
| Gadalla, MA | 1 |
| Bodur, S | 1 |
| Dundar, O | 1 |
| Kanat-Pektas, M | 1 |
| Kinci, MF | 1 |
| Tutuncu, L | 1 |
| Zhao, J | 1 |
| Zhang, W | 6 |
| Castillo-Castro, C | 1 |
| Gonzalez-Velazquez, C | 1 |
| Rodriguez-Gutierrez, R | 1 |
| Furat Rencber, S | 1 |
| Kurnaz Ozbek, S | 1 |
| Eraldemır, C | 1 |
| Sezer, Z | 1 |
| Kum, T | 1 |
| Ceylan, S | 1 |
| Guzel, E | 1 |
| Hyer, S | 1 |
| Balani, J | 1 |
| Shehata, H | 1 |
| Scherneck, S | 1 |
| Schlinke, N | 1 |
| Beck, E | 1 |
| Grupe, K | 1 |
| Weber-Schoendorfer, C | 1 |
| Schaefer, C | 1 |
| Seyam, E | 1 |
| Hefzy, E | 1 |
| Dragamestianos, C | 1 |
| Messini, CI | 2 |
| Antonakis, PT | 1 |
| Zacharouli, K | 1 |
| Kostopoulou, E | 1 |
| Makrigiannakis, A | 2 |
| Georgoulias, P | 1 |
| Anifandis, G | 2 |
| Dafopoulos, K | 2 |
| Garas, A | 1 |
| Daponte, A | 1 |
| Messinis, IE | 2 |
| Marciniak, A | 3 |
| Lejman-Larysz, K | 1 |
| Nawrocka-Rutkowska, J | 3 |
| Brodowska, A | 3 |
| Songin, D | 1 |
| Otto-Buczkowska, E | 1 |
| Grzyb, K | 1 |
| Jainta, N | 1 |
| Shah, G | 2 |
| Aldobeaban, S | 1 |
| Mzahim, B | 1 |
| Alshehri, AA | 1 |
| Kupreeva, M | 1 |
| Diane, A | 1 |
| Lehner, R | 1 |
| Watts, R | 1 |
| Ghosh, M | 1 |
| Proctor, S | 1 |
| Vine, D | 1 |
| Erensoy, H | 1 |
| Niafar, M | 1 |
| Ghafarzadeh, S | 1 |
| Aghamohammadzadeh, N | 1 |
| Nader, ND | 1 |
| D'Amato, G | 1 |
| Caringella, AM | 1 |
| Stanziano, A | 1 |
| Cantatore, C | 1 |
| Palini, S | 1 |
| Caroppo, E | 1 |
| Massey, S | 1 |
| Story, D | 1 |
| Li, L | 4 |
| Karateke, A | 1 |
| Dokuyucu, R | 2 |
| Dogan, H | 1 |
| Ozgur, T | 2 |
| Tas, ZA | 1 |
| Tutuk, O | 1 |
| Agturk, G | 1 |
| Tumer, C | 1 |
| Sahu, A | 1 |
| Tripathy, P | 1 |
| Mohanty, J | 1 |
| Nagy, A | 1 |
| Álvarez, D | 1 |
| Ceballo, K | 1 |
| Olguín, S | 1 |
| Martinez-Pinto, J | 1 |
| Fernandois, D | 1 |
| Sotomayor-Zárate, R | 1 |
| Uliassi, N | 1 |
| Sullivan, S | 1 |
| Damle, L | 1 |
| Gomez-Lobo, V | 3 |
| Showell, MG | 1 |
| Mackenzie-Proctor, R | 1 |
| Jordan, V | 1 |
| Hodgson, R | 1 |
| Farquhar, C | 1 |
| Scheen, AJ | 1 |
| Philips, JC | 1 |
| Kridelka, F | 1 |
| Zhai, J | 2 |
| Yao, GD | 1 |
| Wang, JY | 1 |
| Yang, QL | 1 |
| Chang, ZY | 1 |
| Sun, YP | 2 |
| Shokrpour, M | 1 |
| Vahedpoor, Z | 1 |
| Ghaderi, A | 1 |
| Friden, C | 1 |
| Li, D | 1 |
| Huo, Z | 1 |
| Linden-Hirschberg, A | 1 |
| Qiao, J | 2 |
| Facchinetti, F | 1 |
| Orrù, B | 1 |
| Grandi, G | 1 |
| Unfer, V | 1 |
| Agrawal, A | 1 |
| Kriplani, A | 2 |
| Huang, YL | 1 |
| Shen, J | 1 |
| Sánchez-Infantes, D | 1 |
| Taxerås, SD | 1 |
| Tiwari, N | 1 |
| Pasrija, S | 1 |
| Jain, S | 1 |
| Gu, YY | 1 |
| Jing, F | 1 |
| Yu, CX | 1 |
| Guan, QB | 1 |
| Nossum, MCF | 1 |
| Vaage, MØ | 1 |
| Abbott, DH | 1 |
| Tang, L | 1 |
| Ye, J | 1 |
| Shi, Y | 1 |
| Cheng, HY | 1 |
| Ko, KT | 1 |
| Tzang, RF | 1 |
| Steffensen, B | 1 |
| Gómez-Real, F | 1 |
| Hestvold, KV | 1 |
| Zabielska, R | 1 |
| Thorarinsdottir, S | 1 |
| Hjelle, S | 2 |
| Berg, AH | 2 |
| Poromaa, IS | 1 |
| Mohlin, J | 1 |
| Underdal, M | 1 |
| El Sharkwy, I | 1 |
| Sharaf El-Din, M | 1 |
| Pourghasem, S | 1 |
| Bazarganipour, F | 1 |
| Taghavi, SA | 1 |
| Kutenaee, MA | 1 |
| Mokaberinejad, R | 1 |
| Rampisheh, Z | 1 |
| Aliasl, J | 1 |
| Akhtari, E | 1 |
| Javed, Z | 2 |
| Papageorgiou, M | 1 |
| Rigby, AS | 1 |
| Qamar, U | 1 |
| Abbas, J | 1 |
| Khan, AY | 1 |
| Wang, A | 4 |
| Mo, T | 1 |
| Li, Q | 1 |
| Shen, C | 1 |
| Liu, M | 1 |
| Liu, E | 1 |
| Long, T | 1 |
| Gong, Y | 1 |
| Shen, H | 3 |
| Lin, R | 1 |
| Xu, Q | 1 |
| Yousuf, SD | 2 |
| Jeelani, S | 1 |
| Mudassar, S | 1 |
| Zargar, MA | 2 |
| Amin, S | 2 |
| Rashid, F | 2 |
| Wei, H | 1 |
| Zhao, X | 1 |
| Xin, X | 1 |
| Peng, L | 2 |
| Zhang, Q | 1 |
| Schmedes, A | 1 |
| Zimmerman, LD | 1 |
| Setton, R | 1 |
| Pereira, N | 1 |
| Rosenwaks, Z | 2 |
| Morotti, E | 1 |
| Giovanni Artini, P | 1 |
| Persico, N | 1 |
| Tassone, EC | 1 |
| Malhotra, J | 1 |
| Joham, A | 2 |
| McAllister, V | 1 |
| Thondan, M | 1 |
| Costello, M | 2 |
| Misso, ML | 5 |
| Masaeli, A | 1 |
| Nayeri, H | 1 |
| Mirzaee, M | 1 |
| Chiakpo, E | 1 |
| Han, Y | 1 |
| Wang, QQ | 1 |
| Guo, XC | 1 |
| Gao, ZH | 1 |
| Ji, M | 1 |
| Lin, L | 1 |
| Chen, MX | 1 |
| Mo, ZW | 1 |
| Fang, TY | 1 |
| Quan, HB | 1 |
| Xue, J | 1 |
| Liu, P | 1 |
| Li, K | 1 |
| Sha, L | 1 |
| Dong, Y | 1 |
| Zhang, L | 2 |
| Lei, H | 1 |
| Zhang, X | 5 |
| Dong, X | 1 |
| Ayub, M | 1 |
| Gul, S | 1 |
| Zehra, F | 1 |
| Khaled, N | 1 |
| El-Bahy, AA | 1 |
| Radwan, R | 1 |
| Handoussa, H | 1 |
| AbdelMaksoud, S | 1 |
| Long, J | 1 |
| Cheng, W | 1 |
| Chen, M | 1 |
| Manzoor, S | 1 |
| Bhat, IA | 1 |
| Jeelani, H | 1 |
| Kawa, IA | 1 |
| Fatima, Q | 1 |
| Haugen, AG | 1 |
| Mohiyiddeen, L | 1 |
| Watson, AJ | 2 |
| Apostolopoulos, NV | 1 |
| Berry, R | 1 |
| Alexandraki, KI | 1 |
| Jude, EB | 1 |
| Muneyyirci-Delale, O | 1 |
| Kaplan, J | 1 |
| Joulak, I | 1 |
| Von Gizycki, H | 1 |
| Nacharaju, VL | 1 |
| Karakas, SE | 1 |
| Spaczynski, RZ | 6 |
| Duleba, A | 1 |
| Tauchert, S | 3 |
| Ludwig, AK | 1 |
| Diedrich, K | 3 |
| Weiss, JM | 4 |
| Zheng, J | 1 |
| Shan, PF | 1 |
| Gu, W | 1 |
| Rosas, C | 1 |
| Kohan, K | 1 |
| Gabler, F | 1 |
| Vantman, D | 1 |
| Hosseini, MA | 1 |
| Alleyassin, A | 1 |
| Sarvi, F | 1 |
| Kokab, A | 1 |
| Fanisalek, M | 1 |
| Bozdag, G | 1 |
| Yildiz, BO | 3 |
| Helseth, R | 2 |
| Salvesen, O | 1 |
| Zheng, YH | 1 |
| Wang, XH | 2 |
| Lai, MH | 1 |
| Yao, H | 1 |
| Ma, HX | 1 |
| Michael, AE | 1 |
| Glenn, C | 1 |
| Wood, PJ | 1 |
| Webb, RJ | 1 |
| Pellatt, L | 2 |
| Mason, HD | 2 |
| Moro, F | 2 |
| Morciano, A | 2 |
| Tropea, A | 2 |
| Sagnella, F | 3 |
| Palla, C | 2 |
| Scarinci, E | 1 |
| Ciardulli, A | 2 |
| Martinez, D | 2 |
| Familiari, A | 1 |
| Liuzzo, G | 1 |
| Tritarelli, A | 1 |
| Cosentino, N | 1 |
| Niccoli, G | 1 |
| Crea, F | 1 |
| Apa, R | 2 |
| Auble, B | 1 |
| Elder, D | 1 |
| Gross, A | 1 |
| Hillman, JB | 1 |
| Mazza, A | 1 |
| Fruci, B | 1 |
| Guzzi, P | 1 |
| D'Orrico, B | 1 |
| Malaguarnera, R | 1 |
| Veltri, P | 1 |
| Fava, A | 1 |
| Belfiore, A | 1 |
| Rice, S | 1 |
| Elia, A | 1 |
| Jawad, Z | 1 |
| Khurana, ML | 2 |
| Shah, PA | 1 |
| Kulshrestha, B | 1 |
| Wani, TA | 1 |
| Mudasir, S | 1 |
| Mir, FA | 1 |
| Taing, S | 1 |
| Greibe, E | 1 |
| Trolle, B | 4 |
| Bor, MV | 1 |
| Lauszus, FF | 4 |
| Nexo, E | 1 |
| An, Y | 1 |
| Sun, Z | 1 |
| Liu, B | 1 |
| Guan, Y | 2 |
| Lu, M | 2 |
| Hamed, HO | 2 |
| Milewicz, T | 3 |
| Kiałka, M | 3 |
| Mrozińska, S | 1 |
| Ociepka, A | 2 |
| Krzysiek, J | 1 |
| Lautatzis, ME | 1 |
| Goulis, DG | 2 |
| Vrontakis, M | 1 |
| Ayaz, A | 1 |
| Alwan, Y | 1 |
| Farooq, MU | 1 |
| Tan, BK | 11 |
| Adya, R | 9 |
| Ramanjaneya, M | 3 |
| Randeva, HS | 11 |
| Musacchio, MC | 5 |
| Orvieto, R | 2 |
| Ciaraldi, TP | 1 |
| Aroda, V | 1 |
| Mudaliar, SR | 1 |
| Henry, RR | 1 |
| Xia, Yj | 1 |
| Yi, L | 1 |
| Gao, Q | 1 |
| Bajuk Studen, K | 1 |
| Jensterle Sever, M | 1 |
| Pfeifer, M | 4 |
| Pasquali, R | 16 |
| Katsikis, I | 6 |
| Ciećwież, S | 1 |
| Wiśniewska, B | 1 |
| Kotlega, D | 1 |
| Starczewski, A | 3 |
| Domecq, JP | 1 |
| Prutsky, G | 1 |
| Mullan, RJ | 1 |
| Sundaresh, V | 1 |
| Wang, AT | 1 |
| Erwin, PJ | 1 |
| Welt, C | 1 |
| Ehrmann, D | 1 |
| Montori, VM | 1 |
| Murad, MH | 1 |
| Amar, O | 2 |
| Mattu, HS | 2 |
| Lehnert, H | 9 |
| Shafiee, MN | 2 |
| Khan, G | 1 |
| Ariffin, R | 1 |
| Abu, J | 1 |
| Chapman, C | 2 |
| Deen, S | 1 |
| Nunns, D | 1 |
| Barrett, DA | 1 |
| Seedhouse, C | 2 |
| Atiomo, W | 3 |
| Milewicz, A | 3 |
| Makled, AK | 1 |
| El Sherbiny, M | 1 |
| Elkabarity, R | 1 |
| La Sala, GB | 4 |
| Barthelmess, EK | 1 |
| Naz, RK | 1 |
| Materazzo, C | 1 |
| Orio, F | 29 |
| Sultan, C | 1 |
| Clemens, I | 1 |
| Gómez-Pérez, AM | 1 |
| Fernández-García, JC | 1 |
| Mancha Doblas, I | 1 |
| Tinahones, FJ | 1 |
| Ferreira, GD | 1 |
| Germeyer, A | 3 |
| de Barros Machado, A | 1 |
| do Nascimento, TL | 1 |
| Strowitzki, T | 3 |
| Brum, IS | 1 |
| von Eye Corleta, H | 3 |
| Capp, E | 3 |
| Chirico, V | 1 |
| Ferraù, V | 1 |
| Loddo, I | 1 |
| Briuglia, S | 1 |
| Amorini, M | 1 |
| Salpietro, V | 1 |
| Lacquaniti, A | 1 |
| Salpietro, C | 1 |
| Arrigo, T | 1 |
| Ke, RW | 1 |
| Kocer, D | 1 |
| Bayram, F | 4 |
| Diri, H | 2 |
| Lerchbaum, E | 1 |
| Schwetz, V | 1 |
| Pieber, T | 1 |
| Kruszyńska, A | 1 |
| Słowińska-Srzednicka, J | 1 |
| Jeske, W | 1 |
| Zgliczyński, W | 1 |
| Dardzińska, JA | 1 |
| Rachoń, D | 1 |
| Kuligowska-Jakubowska, M | 1 |
| Aleksandrowicz-Wrona, E | 1 |
| Płoszyński, A | 1 |
| Wyrzykowski, B | 1 |
| Lysiak-Szydłowska, W | 1 |
| Grigoryan, O | 1 |
| Absatarova, J | 1 |
| Andreeva, E | 1 |
| Melnichenko, G | 1 |
| Dedov, I | 1 |
| Vogt, C | 1 |
| Pau, CT | 2 |
| Keefe, C | 1 |
| Duran, J | 1 |
| Welt, CK | 2 |
| Soares Junior, JM | 3 |
| Sa, MF | 1 |
| Nathan, N | 1 |
| Sullivan, SD | 2 |
| Mumm, H | 3 |
| Hermann, AP | 1 |
| Chen, B | 1 |
| Kabiri, N | 1 |
| Tabandeh, MR | 1 |
| Tabatabaie, SR | 1 |
| Kocjan, T | 3 |
| Carlioglu, A | 2 |
| Kaygusuz, I | 1 |
| Karakurt, F | 2 |
| Gumus, II | 1 |
| Uysal, A | 1 |
| Kasapoglu, B | 1 |
| Armutcu, F | 1 |
| Uysal, S | 1 |
| Keskin, EA | 1 |
| Koca, C | 1 |
| Lin, JF | 1 |
| Richelsen, B | 1 |
| Bruun, JM | 1 |
| Renato, P | 1 |
| Lemos, AJ | 1 |
| Peixoto, CA | 1 |
| Teixeira, AA | 1 |
| Luna, RL | 1 |
| Rocha, SW | 1 |
| Santos, HM | 1 |
| Silva, AK | 1 |
| Nunes, AK | 1 |
| Wanderley-Teixeira, V | 1 |
| Bhagavath, B | 1 |
| Vitek, W | 2 |
| Queenan, J | 1 |
| Hoeger, K | 2 |
| Stuckey, BG | 1 |
| Opie, N | 1 |
| Cussons, AJ | 1 |
| Watts, GF | 1 |
| Burke, V | 1 |
| Zhang, YY | 1 |
| Hou, LQ | 1 |
| Zhao, TY | 1 |
| Liu, Q | 1 |
| Quan, H | 1 |
| Zhuo, Z | 1 |
| Leanza, V | 1 |
| Coco, L | 1 |
| Grasso, F | 1 |
| Leanza, G | 1 |
| Zarbo, G | 1 |
| Palumbo, M | 2 |
| Wu, QF | 1 |
| Hu, MH | 1 |
| Vassilatou, E | 1 |
| Conway, G | 1 |
| Dewailly, D | 2 |
| Diamanti-Kandarakis, E | 14 |
| Kelestimur, F | 9 |
| Pignatelli, D | 1 |
| Pugeat, M | 3 |
| Yildiz, B | 2 |
| Pala, L | 1 |
| Barbaro, V | 1 |
| Dicembrini, I | 1 |
| Rotella, CM | 2 |
| Roberts, TK | 1 |
| Fantz, CR | 1 |
| Krysiak, R | 2 |
| Du, C | 1 |
| Piomboni, P | 3 |
| Focarelli, R | 1 |
| Capaldo, A | 1 |
| Stendardi, A | 1 |
| Cianci, A | 5 |
| La Marca, A | 10 |
| Bijok, J | 1 |
| Bińkowska, M | 1 |
| Jakiel, G | 1 |
| Fantus, IG | 1 |
| Maruthini, D | 2 |
| Harris, SE | 2 |
| Barth, JH | 4 |
| Campbell, BK | 1 |
| Picton, HM | 3 |
| Ashrafi, M | 2 |
| Sheikhan, F | 1 |
| Arabipoor, A | 1 |
| Hosseini, R | 2 |
| Nourbakhsh, F | 1 |
| Zolfaghari, Z | 1 |
| Ito-Yamaguchi, A | 1 |
| Suganuma, R | 1 |
| Kumagami, A | 1 |
| Hashimoto, S | 1 |
| El-Sharkawy, AA | 1 |
| Abdelmotaleb, GS | 1 |
| Aly, MK | 1 |
| Kabel, AM | 1 |
| Zhang, T | 3 |
| Zou, X | 1 |
| Su, S | 1 |
| Li, T | 1 |
| Wan, J | 1 |
| Gu, J | 1 |
| Christiansen, SC | 1 |
| Klungland, H | 1 |
| Stafne, SN | 1 |
| Mørkved, S | 1 |
| Sæther, M | 1 |
| Wang, JQ | 2 |
| Huang, LP | 1 |
| Kurzthaler, D | 1 |
| Hadziomerovic-Pekic, D | 2 |
| Wildt, L | 2 |
| Seeber, BE | 2 |
| Basios, G | 1 |
| Trakakis, E | 1 |
| Chrelias, Ch | 1 |
| Panagopoulos, P | 1 |
| Vaggopoulos, V | 1 |
| Skarpas, P | 1 |
| Kassanos, D | 1 |
| Dimitriadis, G | 1 |
| Hatziagelaki, E | 1 |
| Kabil Kucur, S | 1 |
| Gozukara, I | 1 |
| Aksoy, A | 1 |
| Uludag, EU | 1 |
| Keskin, H | 1 |
| Kamalak, Z | 1 |
| Tso, LO | 4 |
| Albuquerque, LE | 3 |
| Andriolo, RB | 3 |
| Macedo, CR | 2 |
| Naderpoor, N | 2 |
| Shorakae, S | 2 |
| De Courten, B | 2 |
| Buzney, E | 1 |
| Sheu, J | 1 |
| Buzney, C | 1 |
| Reynolds, RV | 1 |
| Cheraghi, E | 1 |
| Esfahani, MH | 1 |
| Ebrahimi, Z | 1 |
| Malik, DA | 1 |
| Yunos, RI | 1 |
| Omar, MH | 1 |
| Ghani, NA | 1 |
| Hatta, AZ | 1 |
| Mokhtar, NM | 1 |
| Nardo, LG | 3 |
| El-Toukhy, T | 1 |
| Stewart, J | 1 |
| Potdar, N | 1 |
| Vitagliano, A | 1 |
| Noventa, M | 1 |
| Gizzo, S | 1 |
| Powers, SE | 1 |
| Uliassi, NW | 1 |
| Tuchman, LK | 1 |
| Mehra, R | 1 |
| Di Pietro, M | 1 |
| Parborell, F | 1 |
| Irusta, G | 1 |
| Pascuali, N | 1 |
| Bas, D | 1 |
| Bianchi, MS | 1 |
| Tesone, M | 1 |
| Abramovich, D | 1 |
| Fernandez, H | 2 |
| Cedrin-Durnerin, I | 2 |
| Gallot, V | 1 |
| Rongieres, C | 1 |
| Watrelot, A | 1 |
| Mayenga-Mankezi, JM | 1 |
| Arnoux, A | 1 |
| Guo, J | 1 |
| Christianson, MS | 1 |
| Yemini, M | 1 |
| Leong, M | 1 |
| Shoham, Z | 1 |
| Yang, M | 1 |
| Fang, X | 1 |
| Hu, W | 1 |
| Zhu, W | 1 |
| Ghazeeri, G | 1 |
| Abbas, HA | 1 |
| Skaff, B | 1 |
| Harajly, S | 1 |
| Awwad, J | 1 |
| Alur, S | 1 |
| Hoeger, KM | 2 |
| Madsen, HN | 1 |
| Ingerslev, HJ | 1 |
| Tørring, N | 1 |
| Mayer, SB | 1 |
| Evans, WS | 3 |
| Al-Zubeidi, H | 1 |
| Klein, KO | 1 |
| Kaya, MG | 2 |
| Yildirim, S | 2 |
| Calapkorur, B | 2 |
| Akpek, M | 2 |
| Unluhizarci, K | 7 |
| Cahill, DJ | 1 |
| O'Brien, K | 1 |
| Sun, J | 1 |
| Yuan, Y | 1 |
| Cai, R | 1 |
| Zhou, Y | 2 |
| Wang, P | 30 |
| Huang, R | 1 |
| Xia, W | 1 |
| Ainuddin, JA | 1 |
| Kazi, S | 1 |
| Aftab, S | 1 |
| Kamran, A | 1 |
| Padmanabhan, V | 2 |
| Veiga-Lopez, A | 1 |
| Herkimer, C | 1 |
| Abi Salloum, B | 1 |
| Moeller, J | 1 |
| Beckett, E | 1 |
| Sreedharan, R | 1 |
| Saleh, BO | 1 |
| Ibraheem, WF | 1 |
| Ameen, NS | 1 |
| Abu Hashim, H | 6 |
| Foda, O | 1 |
| Ghayaty, E | 1 |
| Moreno, LE | 1 |
| Bonnell, A | 1 |
| Neher, JO | 1 |
| Safranek, S | 1 |
| Randriamboavonjy, V | 1 |
| Mann, WA | 1 |
| Elgheznawy, A | 1 |
| Popp, R | 1 |
| Rogowski, P | 1 |
| Dornauf, I | 1 |
| Dröse, S | 1 |
| Fleming, I | 1 |
| Macedo, LA | 1 |
| Carbonel, AA | 1 |
| Simões, RS | 1 |
| Fuchs, LF | 1 |
| do Amaral, VC | 1 |
| Simoncini, T | 1 |
| Simões, MJ | 1 |
| Maria Soares, J | 1 |
| Marjoribanks, J | 1 |
| Hecht Baldauff, N | 1 |
| Arslanian, S | 2 |
| Lin, XF | 2 |
| Wu, RR | 1 |
| Du, J | 1 |
| Liao, YC | 1 |
| Du, Y | 1 |
| Ye, Y | 1 |
| Zhang, XB | 1 |
| Wu, C | 1 |
| Al-Biate, MA | 1 |
| Diaz-Morales, N | 2 |
| Lopez-Domenech, S | 1 |
| Escribano-López, I | 1 |
| Rios-Navarro, C | 1 |
| Alvarez, A | 1 |
| Gomez, M | 2 |
| Sidelmann, JJ | 1 |
| Pollak, F | 1 |
| Araya, V | 1 |
| Lanas, A | 1 |
| Sapunar, J | 1 |
| Arrese, M | 1 |
| Aylwin, CG | 1 |
| Bezanilla, CG | 1 |
| Carrasco, E | 1 |
| Carrasco, F | 1 |
| Codner, E | 1 |
| Díaz, E | 1 |
| Durruty, P | 1 |
| Galgani, J | 1 |
| García, H | 1 |
| Lahsen, R | 1 |
| Liberman, C | 1 |
| López, G | 1 |
| Maíz, A | 1 |
| Mujica, V | 1 |
| Poniachik, J | 1 |
| Sir, T | 1 |
| Soto, N | 1 |
| Valderas, J | 1 |
| Villaseca, P | 1 |
| Zavala, C | 1 |
| Maged, AM | 1 |
| Elsawah, H | 1 |
| Abdelhafez, A | 1 |
| Bakry, A | 1 |
| Mostafa, WA | 1 |
| Tal, R | 1 |
| Lv, F | 1 |
| Yu, X | 1 |
| Castelló, R | 2 |
| Falcón, R | 1 |
| Hurliman, A | 1 |
| Keller Brown, J | 1 |
| Maille, N | 1 |
| Mandala, M | 1 |
| Casson, P | 2 |
| Osol, G | 1 |
| Ge, SQ | 1 |
| Zhang, EH | 1 |
| Zhang, B | 1 |
| Karaburgu, S | 1 |
| Acmaz, B | 1 |
| Tanriverdi, F | 1 |
| Karaca, Z | 2 |
| Sokhal, D | 1 |
| Kraus, C | 1 |
| Cheng, F | 1 |
| Huang, T | 1 |
| Jia, F | 1 |
| Chen, C | 1 |
| Al Khalifah, RA | 2 |
| Flórez, ID | 2 |
| Dennis, B | 2 |
| Neupane, B | 1 |
| Thabane, L | 2 |
| Bassilious, E | 2 |
| Zhou, R | 1 |
| Lu, Q | 1 |
| Miao, Y | 1 |
| Zhao, C | 1 |
| Wei, L | 1 |
| Feng, L | 1 |
| Wan, ZH | 1 |
| Hu, D | 1 |
| Du, YK | 1 |
| Kong, W | 1 |
| Niu, X | 1 |
| Zeng, T | 1 |
| Vrbíková, J | 6 |
| Feng, W | 2 |
| Jia, YY | 1 |
| Zhang, DY | 1 |
| Shi, HR | 1 |
| Goodman, NF | 1 |
| Cobin, RH | 1 |
| Futterweit, W | 1 |
| Glueck, JS | 1 |
| Carmina, E | 5 |
| Gozukara, IO | 1 |
| Pınar, N | 1 |
| Ozcan, O | 1 |
| Kurt, RK | 1 |
| Kucur, SK | 1 |
| Aksoy, AN | 1 |
| Gődény, S | 2 |
| Csenteri, OK | 2 |
| Trisno, R | 1 |
| Worsley, R | 1 |
| Kulkarni, J | 1 |
| Mesbah, F | 1 |
| Moslem, M | 1 |
| Vojdani, Z | 1 |
| Mirkhani, H | 1 |
| Boothroyd, C | 2 |
| Karia, S | 1 |
| Andreadis, N | 1 |
| Rombauts, L | 3 |
| Johnson, N | 4 |
| Chapman, M | 2 |
| El-khayat, W | 1 |
| Abdel Moety, G | 1 |
| Al Mohammady, M | 1 |
| Hamed, D | 1 |
| Tannus, S | 1 |
| Burke, YZ | 1 |
| Kol, S | 1 |
| Pedersen, KD | 1 |
| Bülow, NS | 1 |
| Aaboe, K | 1 |
| Galsgaard, J | 1 |
| Odgaard, HS | 1 |
| Mathiesen, ER | 2 |
| Lauenborg, J | 1 |
| Javanmanesh, F | 1 |
| Kashanian, M | 1 |
| Rahimi, M | 1 |
| Sheikhansari, N | 1 |
| Dursun, F | 1 |
| Güven, A | 1 |
| Shigiyama, F | 1 |
| Kumashiro, N | 1 |
| Rikitake, T | 1 |
| Usui, S | 1 |
| Saegusa, M | 1 |
| Kitamura, M | 1 |
| Uchino, H | 1 |
| Hirose, T | 1 |
| Tomczyk, R | 1 |
| Migacz, K | 1 |
| Kowalczuk, A | 1 |
| Klocek, M | 1 |
| Shetelig Løvvik, T | 1 |
| Martins, WP | 1 |
| Sun, L | 1 |
| Ji, C | 1 |
| Jin, L | 1 |
| Li, P | 1 |
| Zhu, D | 1 |
| De Sousa, SM | 1 |
| Kulshreshtha, B | 2 |
| Arora, A | 1 |
| Pahuja, I | 1 |
| Sharma, N | 1 |
| Pant, S | 1 |
| Gundelach, T | 1 |
| Rodewald, M | 1 |
| Bekes, I | 1 |
| Janni, W | 1 |
| Fruzzetti, F | 3 |
| Ghiadoni, L | 1 |
| Virdis, A | 1 |
| De Negri, F | 1 |
| Perini, D | 3 |
| Bucci, F | 2 |
| Giannarelli, C | 1 |
| Gadducci, A | 2 |
| Taddei, S | 1 |
| Fields, EL | 1 |
| Trent, ME | 1 |
| Wang, QY | 1 |
| Wang, QS | 1 |
| Feng, GM | 1 |
| Saini, N | 1 |
| Sodhi, RK | 1 |
| Bajaj, L | 1 |
| Pandey, RS | 1 |
| Jain, UK | 1 |
| Katare, OP | 1 |
| Madan, J | 1 |
| Poulton, A | 1 |
| Indran, IR | 1 |
| Lee, BH | 1 |
| Yong, EL | 1 |
| Seow, KM | 1 |
| Lee, WL | 1 |
| Wang, PH | 1 |
| Ou, HT | 2 |
| Chen, PC | 2 |
| Wu, MH | 4 |
| Andrade, C | 1 |
| Birch Petersen, K | 1 |
| Pedersen, NG | 1 |
| Pedersen, AT | 1 |
| Lauritsen, MP | 1 |
| la Cour Freiesleben, N | 1 |
| Sinai Talaulikar, V | 1 |
| Graff, SK | 1 |
| Mario, FM | 1 |
| Ziegelmann, P | 1 |
| Elshewehy, AM | 1 |
| Ding, T | 1 |
| Baio, G | 1 |
| Hardiman, PJ | 1 |
| Petersen, I | 1 |
| Sammon, C | 1 |
| Williams, T | 1 |
| Mortada, R | 2 |
| Porter, S | 1 |
| Dravecká, I | 3 |
| Figurová, J | 2 |
| Javorský, M | 2 |
| Petríková, J | 2 |
| Vaľková, M | 1 |
| Lazúrová, I | 3 |
| Misso, M | 1 |
| Wijeyaratne, CN | 1 |
| Fauser, BC | 2 |
| Sztefko, K | 1 |
| Rogatko, I | 1 |
| Majewska, R | 1 |
| Lin, CY | 1 |
| Bucher, KG | 1 |
| Wiltz, SA | 1 |
| Zeng, XL | 1 |
| Zhang, YF | 1 |
| Tian, Q | 1 |
| Xue, Y | 2 |
| An, RF | 1 |
| Tan, X | 1 |
| Chang, Y | 1 |
| Fang, C | 1 |
| Russo, M | 1 |
| Zahra, M | 1 |
| Rahim, R | 1 |
| Jacob, SL | 1 |
| Brewer, C | 2 |
| Tan, MH | 1 |
| Alquraini, H | 1 |
| Mizokami-Stout, K | 1 |
| MacEachern, M | 1 |
| Sumarac-Dumanovic, M | 1 |
| Apostolovic, M | 1 |
| Janjetovic, K | 1 |
| Jeremic, D | 1 |
| Popadic, D | 1 |
| Ljubic, A | 1 |
| Micic, J | 1 |
| Dukanac-Stamenkovic, J | 1 |
| Tubic, A | 1 |
| Stevanovic, D | 1 |
| Trajkovic, V | 1 |
| Ren, J | 1 |
| Sun, W | 1 |
| Jahan, S | 1 |
| Munir, F | 1 |
| Razak, S | 1 |
| Mehboob, A | 1 |
| Ain, QU | 1 |
| Ullah, H | 1 |
| Afsar, T | 1 |
| Shaheen, G | 1 |
| Almajwal, A | 1 |
| Mosbruger, T | 1 |
| Saxena, R | 1 |
| Tagliaferri, V | 3 |
| Immediata, V | 1 |
| De Cicco, S | 3 |
| Di Florio, C | 2 |
| Guido, M | 9 |
| Nahuis, M | 1 |
| Van der Veen, F | 5 |
| Freis, A | 1 |
| Renke, T | 1 |
| Kämmerer, U | 1 |
| Jauckus, J | 1 |
| Paterson, MS | 1 |
| Seidemann, EL | 1 |
| Gutowski, HC | 1 |
| Haas, J | 1 |
| Bentov, Y | 1 |
| Kalem, MN | 1 |
| Kalem, Z | 1 |
| Gurgan, T | 1 |
| Ng, EH | 2 |
| Xie, C | 1 |
| Su, N | 1 |
| Cui, N | 1 |
| Zhao, Z | 1 |
| Hao, G | 1 |
| Jakimiuk, AJ | 1 |
| Elizur, SE | 1 |
| Tulandi, T | 3 |
| Cho, LW | 4 |
| Keevil, BG | 1 |
| Solano, ME | 3 |
| Sander, V | 3 |
| Wald, MR | 1 |
| Ma, F | 1 |
| Qiao, L | 1 |
| Yue, H | 1 |
| Xie, S | 1 |
| Jiang, M | 1 |
| Qi, J | 1 |
| Xu, K | 1 |
| Glueck, CJ | 30 |
| Goldenberg, N | 18 |
| Sieve, L | 10 |
| Preiss, D | 1 |
| Sattar, N | 8 |
| Harborne, L | 4 |
| Norman, J | 5 |
| Fleming, R | 7 |
| Mendieta-Azcona, C | 2 |
| Costantini, B | 2 |
| Selvaggi, L | 5 |
| Giuliani, M | 3 |
| Cristello, F | 2 |
| Macrì, F | 1 |
| Bompiani, A | 1 |
| Jiang, Y | 1 |
| Cao, Y | 2 |
| Cocksedge, KA | 1 |
| Li, TC | 1 |
| Saravelos, SH | 1 |
| Jakubowska, J | 1 |
| Bohdanowicz-Pawlak, A | 1 |
| Szymczak, J | 1 |
| Bednarek-Tupikowska, G | 1 |
| Demissie, M | 1 |
| Fougner, KJ | 2 |
| Sebestjen, M | 1 |
| Prezelj, J | 2 |
| Keber, I | 1 |
| Zullo, F | 29 |
| Motta, DA | 1 |
| Goodarzi, MO | 2 |
| Azziz, R | 3 |
| Semple, RK | 1 |
| Forlani, G | 1 |
| Genghini, S | 2 |
| Grassi, I | 1 |
| Hyden, CS | 1 |
| Pagotto, U | 5 |
| O'Rahilly, S | 1 |
| Andreou, C | 1 |
| Syngelakis, M | 1 |
| Karavatos, A | 1 |
| Nawaz, FH | 2 |
| Khalid, R | 1 |
| Naru, T | 1 |
| Rizvi, J | 2 |
| Shield, JP | 1 |
| Lynn, R | 1 |
| Wan, KC | 1 |
| Haines, L | 1 |
| Barrett, TG | 1 |
| Drown, DJ | 1 |
| Jing, Z | 1 |
| Liang-Zhi, X | 1 |
| Tai-Xiang, W | 1 |
| Yu-Jian, J | 1 |
| Meyer, C | 5 |
| Hutchison, SK | 5 |
| Zoungas, S | 4 |
| McGrath, BP | 2 |
| Hart, R | 5 |
| Mathur, R | 1 |
| Alexander, CJ | 1 |
| Yano, J | 1 |
| Trivax, B | 1 |
| Rezvanian, H | 1 |
| Adibi, N | 1 |
| Siavash, M | 1 |
| Kachuei, A | 1 |
| Shojaee-Moradie, F | 1 |
| Asilian, A | 1 |
| Ramidi, G | 1 |
| Khan, N | 1 |
| Ozkaya, M | 1 |
| Cakal, E | 1 |
| Ustun, Y | 1 |
| Engin-Ustun, Y | 1 |
| Ozcimen, EE | 2 |
| Uckuyu, A | 2 |
| Ciftci, FC | 1 |
| Zeyneloglu, HB | 3 |
| del Rey Sánchez, JM | 1 |
| Matíes, M | 1 |
| Benson, S | 3 |
| Arck, PC | 1 |
| Tan, S | 4 |
| Hahn, S | 5 |
| Mann, K | 5 |
| Rifaie, N | 1 |
| Janssen, OE | 5 |
| Schedlowski, M | 2 |
| Elsenbruch, S | 4 |
| Haydardedeoglu, B | 3 |
| Simsek, E | 2 |
| Kilicdag, EB | 3 |
| Bagis, T | 5 |
| Barba, M | 1 |
| Schünemann, HJ | 1 |
| Sperati, F | 1 |
| Akl, EA | 1 |
| Musicco, F | 1 |
| Guyatt, G | 1 |
| Muti, P | 1 |
| Tsilchorozidou, T | 3 |
| Mohamed-Ali, V | 1 |
| Conway, GS | 2 |
| Economou, FN | 2 |
| Tantalaki, E | 1 |
| Piperi, C | 4 |
| Papavassiliou, AG | 1 |
| Fulghesu, AM | 4 |
| Kumbak, B | 1 |
| Kahraman, S | 1 |
| Kebapcilar, L | 3 |
| Taner, CE | 2 |
| Kebapcilar, AG | 2 |
| Alacacioglu, A | 1 |
| Sari, I | 3 |
| Freitas, V | 1 |
| Svendsen, PF | 2 |
| Nilas, L | 2 |
| Madsbad, S | 2 |
| Holst, JJ | 1 |
| Siebert, TI | 3 |
| Kruger, TF | 3 |
| Lombard, C | 1 |
| Farhatullah, S | 4 |
| Heutling, D | 4 |
| Mitchell, D | 1 |
| Meldrum, DR | 1 |
| Chang, RJ | 1 |
| de Ziegler, D | 1 |
| Schoolcraft, WB | 1 |
| Scott, RT | 1 |
| Pellicer, A | 1 |
| Cahill, D | 1 |
| Wisniewski, M | 1 |
| Petersen, M | 1 |
| Karimzadeh, MA | 1 |
| Javedani, M | 1 |
| Elia, EM | 1 |
| Belgorosky, D | 1 |
| Faut, M | 1 |
| Vighi, S | 1 |
| Pustovrh, C | 1 |
| Luigi, D | 1 |
| Cho, L | 1 |
| Le Roux, CW | 1 |
| Kaur, J | 1 |
| Lewandowski, KC | 1 |
| O'Hare, JP | 1 |
| Ben Ayed, B | 1 |
| Dammak dit Mlik, S | 1 |
| Ben Arab, H | 1 |
| Trabelssi, H | 1 |
| Chahtour, H | 1 |
| Mathlouthi, N | 1 |
| Dhuib, M | 1 |
| Kassis, M | 1 |
| Saiidane, D | 1 |
| Trabelssi, K | 1 |
| Guermazi, M | 1 |
| Billa, E | 1 |
| Kapolla, N | 1 |
| Nicopoulou, SC | 1 |
| Koukkou, E | 1 |
| Venaki, E | 1 |
| Milingos, S | 1 |
| Antsaklis, A | 1 |
| Adamopoulos, DA | 1 |
| Pagidas, K | 1 |
| Carson, SA | 9 |
| McGovern, PG | 9 |
| Barnhart, HX | 6 |
| Myers, ER | 9 |
| Diamond, MP | 10 |
| Carr, BR | 10 |
| Schlaff, WD | 9 |
| Coutifaris, C | 10 |
| Steinkampf, MP | 9 |
| Cataldo, NA | 9 |
| Gosman, G | 4 |
| Chaudhury, K | 1 |
| Chaudhury, S | 1 |
| Chowdhury, S | 1 |
| Kazerooni, T | 3 |
| Ghaffarpasand, F | 2 |
| Kazerooni, Y | 2 |
| Kazerooni, M | 1 |
| Setoodeh, S | 1 |
| Rashidi, B | 1 |
| Haghollahi, F | 2 |
| Shariat, M | 2 |
| Zayerii, F | 1 |
| Lord, JM | 6 |
| Bilgir, O | 2 |
| Taner, C | 1 |
| Bilgir, F | 1 |
| Kebapcilar, A | 1 |
| Bozkaya, G | 2 |
| Yildiz, Y | 2 |
| Yuksel, A | 1 |
| Katsiki, N | 2 |
| Georgiadou, E | 1 |
| Hatzitolios, AI | 2 |
| Aubuchon, M | 2 |
| Lieman, H | 1 |
| Stein, D | 1 |
| Cohen, HW | 1 |
| Isaac, B | 1 |
| Adel, G | 1 |
| Weitzman, V | 1 |
| Tetrokalashvili, M | 1 |
| Polotsky, AJ | 1 |
| Santoro, N | 3 |
| Leeman, L | 1 |
| Acharya, U | 2 |
| Begum, MR | 1 |
| Khanam, NN | 1 |
| Quadir, E | 1 |
| Ferdous, J | 1 |
| Begum, MS | 1 |
| Khan, F | 1 |
| Begum, A | 1 |
| Ashrafinia, M | 1 |
| Moini, A | 1 |
| Eslami, B | 1 |
| Asgari, Z | 1 |
| Shokeir, T | 1 |
| Badawy, A | 1 |
| Gowri, V | 1 |
| Jain, R | 1 |
| Qublan, HS | 5 |
| Al-Khaderei, S | 1 |
| Abu-Salem, AN | 1 |
| Al-Zpoon, A | 1 |
| Al-Khateeb, M | 1 |
| Al-Ibrahim, N | 1 |
| Megdadi, M | 1 |
| Al-Ahmad, N | 1 |
| Chi, H | 1 |
| Harris-Glocker, M | 1 |
| Davidson, K | 1 |
| Kochman, L | 2 |
| Guzick, D | 1 |
| Klein, F | 1 |
| Christakou, CD | 1 |
| Bao, WF | 1 |
| Duleba, AJ | 8 |
| Hasan, AF | 1 |
| Ahmed, OG | 1 |
| Ahmed, MA | 1 |
| Sieradzki, J | 1 |
| Tendera-Małecka, E | 1 |
| Skałba, P | 1 |
| Jedrzejuk, D | 1 |
| Garruti, G | 1 |
| Depalo, R | 1 |
| Vita, MG | 1 |
| Lorusso, F | 2 |
| Giampetruzzi, F | 1 |
| Damato, AB | 1 |
| Giorgino, F | 1 |
| Lazzarini, V | 1 |
| Parrini, D | 1 |
| Gambacciani, M | 1 |
| Genazzani, AR | 3 |
| Giallauria, F | 2 |
| Russo, T | 19 |
| Tolino, A | 20 |
| Colao, A | 9 |
| Sienkiewicz, R | 1 |
| Szydłowska, I | 1 |
| Agarwal, N | 2 |
| Rice, SP | 1 |
| Bolusani, H | 1 |
| Luzio, SD | 1 |
| Dunseath, G | 1 |
| Ludgate, M | 1 |
| Rees, DA | 2 |
| Oppelt, PG | 1 |
| Mueller, A | 1 |
| Jentsch, K | 1 |
| Kronawitter, D | 1 |
| Reissmann, C | 1 |
| Dittrich, R | 1 |
| Beckmann, MW | 1 |
| Cupisti, S | 1 |
| Palermo, V | 1 |
| Petraglia, F | 4 |
| Duranteau, L | 1 |
| Lefevre, P | 1 |
| Jeandidier, N | 1 |
| Simon, T | 1 |
| Christin-Maitre, S | 2 |
| Shojaei-Baghini, A | 1 |
| Dehbashi, S | 2 |
| Asadi, N | 1 |
| Battista, L | 1 |
| Venturella, R | 1 |
| Nader, S | 2 |
| Zhao, JZ | 3 |
| Lin, JJ | 3 |
| Yang, HY | 2 |
| Huang, XF | 1 |
| Huang, YP | 1 |
| Fux Otta, C | 1 |
| Wior, M | 1 |
| Iraci, GS | 1 |
| Kaplan, R | 1 |
| Torres, D | 1 |
| Gaido, MI | 1 |
| Wyse, EP | 1 |
| Oride, A | 1 |
| Kanasaki, H | 1 |
| Purwana, IN | 1 |
| Miyazaki, K | 1 |
| Di Berardino, OM | 1 |
| Simi, G | 1 |
| Papini, F | 1 |
| Ruggiero, M | 1 |
| Monteleone, P | 1 |
| Cela, V | 1 |
| Frystyk, J | 1 |
| Flyvbjerg, A | 2 |
| Raffone, E | 2 |
| Rizzo, P | 2 |
| Benedetto, V | 1 |
| Langmár, Z | 1 |
| Moeller, K | 1 |
| Mattle, V | 1 |
| Cheang, KI | 5 |
| Huszar, JM | 1 |
| Best, AM | 1 |
| Sharma, S | 1 |
| Essah, PA | 3 |
| Brodell, LA | 1 |
| Mercurio, MG | 1 |
| Stewart, AW | 2 |
| Falkiner, J | 1 |
| Farquhar, CM | 1 |
| Milsom, S | 1 |
| Singh, VP | 1 |
| Okonkwo, QL | 1 |
| Buckingham, KL | 1 |
| Sohrabvand, F | 2 |
| Bagheri, B | 1 |
| Jungheim, ES | 1 |
| Odibo, AO | 1 |
| Ott, J | 1 |
| Kurz, C | 1 |
| Nouri, K | 1 |
| Wirth, S | 1 |
| Vytiska-Binstorfer, E | 1 |
| Huber, JC | 1 |
| Mayerhofer, K | 1 |
| Baran, S | 1 |
| Api, M | 1 |
| Goksedef, BP | 1 |
| Cetin, A | 1 |
| Marsh, KA | 1 |
| Steinbeck, KS | 1 |
| Atkinson, FS | 1 |
| Petocz, P | 1 |
| Brand-Miller, JC | 1 |
| Enríquez, G | 1 |
| Fábregues, F | 1 |
| Castelo-Branco, C | 1 |
| Carmona, F | 1 |
| Guimerá, M | 1 |
| Casamitjana, R | 1 |
| Balasch, J | 1 |
| Boudhrâa, K | 1 |
| Jellouli, MA | 1 |
| Amri, M | 1 |
| Farhat, M | 1 |
| Torkhani, F | 1 |
| Gara, MF | 1 |
| Tomlinson, J | 1 |
| Millward, A | 1 |
| Stenhouse, E | 1 |
| Pinkney, J | 1 |
| Wafa, A | 1 |
| El Rakhawy, M | 1 |
| Aghahosseini, M | 1 |
| Aleyaseen, A | 1 |
| Moddaress-Hashemi, S | 1 |
| Mofid, B | 1 |
| Kashani, L | 2 |
| Genazzani, AD | 5 |
| Ricchieri, F | 3 |
| Lanzoni, C | 3 |
| Chierchia, E | 1 |
| Rattighieri, E | 1 |
| Santagni, S | 1 |
| Casarosa, E | 3 |
| Luisi, M | 2 |
| Hanjalic-Beck, A | 1 |
| Gabriel, B | 1 |
| Schaefer, W | 1 |
| Zahradnik, HP | 1 |
| Schories, M | 1 |
| Tempfer, C | 1 |
| Keck, C | 1 |
| Denschlag, D | 1 |
| Tomassoni, F | 2 |
| Gasparini, DI | 1 |
| Di Rocco, A | 1 |
| Mantovani, V | 1 |
| Altieri, P | 1 |
| Sanna, S | 2 |
| Sharma, A | 1 |
| Walker, DM | 1 |
| Naka, KK | 1 |
| Kalantaridou, SN | 1 |
| Kravariti, M | 1 |
| Bechlioulis, A | 1 |
| Kazakos, N | 1 |
| Calis, KA | 1 |
| Katsouras, CS | 1 |
| Chrousos, GP | 1 |
| Tsatsoulis, A | 1 |
| Michalis, LK | 1 |
| Petry, CJ | 1 |
| Casson, PR | 1 |
| Krawetz, SA | 1 |
| Brzyski, RG | 1 |
| Christman, GM | 1 |
| Eisenberg, E | 2 |
| Simmons, D | 2 |
| Georgopoulos, NA | 1 |
| Piouka, A | 1 |
| Saltamavros, AD | 1 |
| Decavalas, G | 1 |
| Economou, F | 1 |
| Palimeri, S | 1 |
| Christakou, C | 1 |
| Vause, TD | 1 |
| Cheung, AP | 2 |
| Sierra, S | 1 |
| Claman, P | 1 |
| Graham, J | 1 |
| Guillemin, JA | 1 |
| Lapensée, L | 1 |
| Steward, S | 1 |
| Wong, BC | 2 |
| Acharya, S | 1 |
| Thake, F | 1 |
| Balen, A | 1 |
| Shan, X | 1 |
| Aghilla, M | 1 |
| Keay, SD | 2 |
| Marcos, MV | 3 |
| Heimstad, R | 2 |
| Romundstad, P | 4 |
| Skogøy, K | 1 |
| Kleggetveit, O | 1 |
| von Brandis, P | 1 |
| Eikeland, T | 1 |
| Flo, K | 1 |
| Berg, KF | 1 |
| Bunford, G | 1 |
| Lund, A | 1 |
| Bjerke, C | 1 |
| Almås, I | 1 |
| Danielson, A | 1 |
| Lahmami, G | 1 |
| de la Fuente-Valero, J | 1 |
| Zapardiel-Gutiérrez, I | 1 |
| Orensanz-Fernández, I | 1 |
| Alvarez-Alvarez, P | 1 |
| Engels-Calvo, V | 1 |
| Bajo-Arenas, JM | 1 |
| Anwar, K | 1 |
| El-Fatah, RA | 1 |
| Li, XJ | 1 |
| Yu, YX | 1 |
| Liu, CQ | 1 |
| Zhang, HJ | 1 |
| Yan, B | 1 |
| Wang, LY | 1 |
| Yang, SY | 1 |
| Zhang, SH | 1 |
| Duval, DL | 1 |
| Kilic, S | 1 |
| Yilmaz, N | 1 |
| Zulfikaroglu, E | 1 |
| Erdogan, G | 1 |
| Aydin, M | 1 |
| Batioglu, S | 1 |
| El Lakany, N | 1 |
| Sherief, L | 1 |
| Tarkun, I | 1 |
| Dikmen, E | 1 |
| Cetinarslan, B | 1 |
| Cantürk, Z | 1 |
| Sant Cassia, LJ | 1 |
| Gebel, E | 1 |
| Ladson, G | 2 |
| Dodson, WC | 3 |
| Sweet, SD | 2 |
| Archibong, AE | 2 |
| Kunselman, AR | 5 |
| Demers, LM | 3 |
| Williams, NI | 3 |
| Coney, P | 2 |
| Khattab, S | 3 |
| Mohsen, IA | 3 |
| Aboul Foutouh, I | 1 |
| Ashmawi, HS | 1 |
| Mohsen, MN | 1 |
| Youssef, MA | 1 |
| Morteza Taghavi, S | 1 |
| Rokni, H | 1 |
| Fatemi, S | 1 |
| Glanville, J | 3 |
| Barth, J | 1 |
| Grover, A | 1 |
| Yialamas, MA | 1 |
| Proto, C | 3 |
| Alfarouk, KO | 1 |
| Bashir, AH | 1 |
| Koiou, E | 2 |
| Dinas, K | 1 |
| Kalaitzakis, E | 2 |
| Delkos, D | 2 |
| Kandaraki, EA | 2 |
| Birnbaum, MJ | 1 |
| Shaw, RJ | 1 |
| Brufani, C | 1 |
| Fintini, D | 1 |
| Nobili, V | 1 |
| Patera, PI | 1 |
| Cappa, M | 1 |
| Brufani, M | 1 |
| Bals-Pratsch, M | 1 |
| Grosser, B | 1 |
| Seifert, B | 1 |
| Ortmann, O | 3 |
| Seifarth, C | 1 |
| Wassell, J | 1 |
| Michail, M | 1 |
| Soliman, N | 1 |
| Wardle, PG | 1 |
| Karakas, S | 1 |
| Fellow, C | 1 |
| Petrányi, G | 2 |
| Zaoura-Petrányi, M | 1 |
| Ghandi, S | 1 |
| Aflatoonian, A | 2 |
| Tabibnejad, N | 1 |
| Moghaddam, MH | 1 |
| Berent-Spillson, A | 1 |
| Love, T | 1 |
| Pop-Busui, R | 1 |
| Sowers, M | 1 |
| Persad, CC | 1 |
| Pennington, KP | 1 |
| Eyvazaddeh, AD | 1 |
| Zubieta, JK | 1 |
| Smith, YR | 1 |
| Morin-Surruca, M | 1 |
| Torre, A | 1 |
| Faivre, E | 1 |
| Deffieux, X | 1 |
| Gervaise, A | 1 |
| Weerakiet, S | 2 |
| Sophonsritsuk, A | 2 |
| Lertvikool, S | 1 |
| Satirapot, C | 1 |
| Leelaphiwat, S | 1 |
| Jultanmas, R | 1 |
| Liao, L | 1 |
| Tian, YJ | 1 |
| Zhao, JJ | 1 |
| Xin, Y | 1 |
| Xing, HY | 1 |
| Dong, JJ | 1 |
| Rotondi, M | 1 |
| Cappelli, C | 1 |
| Magri, F | 1 |
| Botta, R | 1 |
| Dionisio, R | 1 |
| Iacobello, C | 1 |
| De Cata, P | 1 |
| Castellano, M | 1 |
| Maciel, GA | 3 |
| Hayashida, SA | 1 |
| da Costa, LC | 1 |
| Marcondes, JA | 3 |
| da Fonseca, AM | 1 |
| Soares, JM | 2 |
| de Oliveira Baraldi, C | 2 |
| Lanchote, VL | 2 |
| de Jesus Antunes, N | 2 |
| de Jesus Ponte Carvalho, TM | 2 |
| Dantas Moisés, EC | 1 |
| Dantes Moisés, EC | 1 |
| Duarte, G | 2 |
| Cavalli, RC | 2 |
| Gangale, MF | 1 |
| Miele, L | 1 |
| Pompili, M | 1 |
| Cefalo, C | 1 |
| Grieco, A | 1 |
| Swanton, A | 1 |
| Lighten, A | 1 |
| Granne, I | 1 |
| McVeigh, E | 1 |
| Lavery, S | 1 |
| Trew, G | 1 |
| Talmor, A | 1 |
| Jayaprakasan, K | 1 |
| Child, T | 1 |
| Lázaro, I | 1 |
| Cabré, A | 1 |
| Masana, L | 1 |
| Kjøtrød, SB | 5 |
| Rasmussen, PE | 1 |
| Holst-Larsen, T | 1 |
| Mellembakken, J | 1 |
| Thurin-Kjellberg, A | 1 |
| Haapaniemikouru, K | 1 |
| Humaidan, P | 1 |
| Sunde, A | 3 |
| von Düring, V | 4 |
| Huang, Z | 2 |
| Lv, J | 1 |
| Bontekoe, S | 1 |
| Lee, PA | 1 |
| Arrowood, JA | 1 |
| Adawadkar, SS | 1 |
| Stovall, DW | 3 |
| Serdyńska-Szuster, M | 1 |
| Vosnakis, C | 1 |
| Hsia, Y | 1 |
| Dawoud, D | 1 |
| Sutcliffe, AG | 1 |
| Viner, RM | 1 |
| Kinra, S | 1 |
| Wong, IC | 1 |
| Di Cello, A | 3 |
| Morelli, M | 1 |
| Cappiello, F | 3 |
| Lin, YS | 1 |
| Tsai, SJ | 2 |
| Lin, MW | 2 |
| Yang, CT | 1 |
| Huang, MF | 2 |
| Doll, I | 1 |
| Doll, R | 1 |
| Buhling, KJ | 1 |
| Oner, G | 1 |
| Muderris, II | 1 |
| Gosman, GG | 5 |
| Isik, S | 1 |
| Ozcan, HN | 1 |
| Ozuguz, U | 1 |
| Berker, D | 1 |
| Tutuncu, Y | 1 |
| Akbaba, G | 1 |
| Guler, S | 1 |
| Kuek, S | 1 |
| Wang, WJ | 1 |
| Gui, SQ | 1 |
| Weickert, MO | 2 |
| Tomova, A | 1 |
| Deepinder, F | 1 |
| Robeva, R | 1 |
| Kirilov, G | 1 |
| Mechandjiev, Z | 1 |
| Kumanov, P | 1 |
| Pauli, JM | 1 |
| Raja-Khan, N | 1 |
| Smith, KA | 1 |
| Raval, AD | 1 |
| Hunter, T | 1 |
| Stuckey, B | 1 |
| Hart, RJ | 1 |
| Carrillo, L | 1 |
| Villani, MT | 1 |
| Capasso, S | 1 |
| Mastrantonio, P | 1 |
| Cittadini, E | 1 |
| Wei, W | 1 |
| Sui, M | 1 |
| Liang, K | 1 |
| Kostev, K | 1 |
| Richter, H | 1 |
| Pérez, V | 1 |
| Ladrón de Guevara, A | 1 |
| Preisler, J | 1 |
| Sánchez, F | 1 |
| Guigas, B | 1 |
| Sanz Garcia, N | 1 |
| Leclerc, J | 1 |
| Andreelli, F | 1 |
| D'Anna, R | 1 |
| Di Benedetto, V | 1 |
| Interdonato, ML | 1 |
| Corrado, F | 1 |
| Di Benedetto, A | 1 |
| Marshall, JC | 2 |
| Dunaif, A | 2 |
| Vinaixa, M | 1 |
| Rodriguez, MA | 1 |
| Samino, S | 1 |
| Beltran, A | 1 |
| Mallol, R | 1 |
| Bladé, C | 1 |
| Correig, X | 1 |
| Yanes, O | 1 |
| Navali, N | 1 |
| Pourabolghasem, S | 1 |
| Fouladi, RF | 1 |
| Nikpour, MA | 1 |
| Bechtold, S | 1 |
| Dalla Pozza, R | 1 |
| Putzker, S | 1 |
| Roeb, J | 1 |
| Buckel, M | 1 |
| Weissenbacher, C | 1 |
| Schmidt, H | 1 |
| Curi, DD | 1 |
| Fonseca, AM | 1 |
| Almeida, JA | 1 |
| Bagnoli, VR | 1 |
| Anwary, SA | 1 |
| Alfazzaman, M | 1 |
| Bari, N | 1 |
| Islam, MR | 1 |
| Karjane, NW | 1 |
| Mandolesi, GA | 1 |
| Le Donne, M | 1 |
| Alibrandi, A | 1 |
| Giarrusso, R | 1 |
| Lo Monaco, I | 1 |
| Muraca, U | 1 |
| Ghazeeri, GS | 1 |
| Nassar, AH | 1 |
| Younes, Z | 1 |
| Awwad, JT | 1 |
| Hodges, P | 1 |
| Rantala, AS | 1 |
| Unkila-Kallio, L | 1 |
| Tiitinen, A | 1 |
| Hippeläinen, M | 1 |
| Perheentupa, A | 2 |
| Tinkanen, H | 1 |
| Bloigu, R | 1 |
| Puukka, K | 1 |
| Ruokonen, A | 9 |
| Curry, A | 1 |
| Ziaee, A | 1 |
| Oveisi, S | 1 |
| Abedini, A | 1 |
| Hashemipour, S | 1 |
| Karimzadeh, T | 1 |
| Ghorbani, A | 1 |
| Pepene, CE | 1 |
| Du, Q | 2 |
| Wang, YJ | 2 |
| Wu, B | 1 |
| Han, P | 1 |
| Zhao, YY | 1 |
| Rajagopal, G | 1 |
| Reddy, AP | 1 |
| Venkata Harinarayan, C | 1 |
| Suresh, V | 1 |
| Bitla, A | 1 |
| P V L N Rao, S | 1 |
| Sachan, A | 1 |
| Ammini, AC | 2 |
| Motta, EL | 1 |
| Domingues, TS | 1 |
| Firouzabadi, Rd | 1 |
| Modarresi, S | 1 |
| Sekhavat, L | 1 |
| MohammadTaheri, S | 1 |
| Cinar, N | 1 |
| Harmanci, A | 1 |
| Bayraktar, M | 1 |
| Viola, MI | 1 |
| Steyn, DW | 2 |
| Celik, O | 1 |
| Acbay, O | 2 |
| Kruger, M | 1 |
| Schlaff, W | 1 |
| Brzyski, R | 1 |
| Christman, G | 1 |
| Carson, S | 1 |
| Myers, EE | 1 |
| Celik, A | 1 |
| Liu, CX | 1 |
| Tian, ZR | 1 |
| Jiang, QH | 1 |
| Berstein, LM | 1 |
| Roth, LW | 1 |
| Gao, L | 1 |
| Zhao, FL | 1 |
| Li, SC | 1 |
| Wong, J | 2 |
| Melder, A | 1 |
| Minerba, L | 1 |
| Xiao, J | 1 |
| Chen, S | 1 |
| Nordskar, JJ | 1 |
| Leithe, H | 1 |
| Hjorth-Hansen, AK | 1 |
| Martinussen, M | 1 |
| Bonny, AE | 1 |
| Appelbaum, H | 1 |
| Connor, EL | 2 |
| Cromer, B | 1 |
| DiVasta, A | 1 |
| Harel, Z | 1 |
| Huppert, J | 1 |
| Sucato, G | 1 |
| Veilleux-Lemieux, M | 1 |
| DiVasta, AD | 1 |
| Shepherd, J | 1 |
| Lansdown, A | 1 |
| Lambalk, CB | 4 |
| Bossuyt, PM | 3 |
| Bredella, MA | 1 |
| McManus, S | 1 |
| Misra, M | 1 |
| Koivunen, R | 3 |
| Melder, AM | 1 |
| Jakubowicz, D | 1 |
| Wainstein, J | 1 |
| Omidvar, T | 1 |
| Farazmand, B | 1 |
| Modabbernia, A | 1 |
| Ramzanzadeh, F | 1 |
| Tehraninejad, ES | 1 |
| Tabrizi, M | 1 |
| Akhondzadeh, S | 1 |
| Moisés, EC | 1 |
| Martinussen, MP | 1 |
| Sinawat, S | 2 |
| Buppasiri, P | 2 |
| Lumbiganon, P | 2 |
| Pattanittum, P | 2 |
| Geier, LM | 1 |
| Bekx, MT | 1 |
| Usadi, RS | 1 |
| Sova, H | 1 |
| Puistola, U | 1 |
| Karihtala, P | 1 |
| Elkattan, E | 1 |
| Nabil, H | 1 |
| Wang, LL | 1 |
| Ren, W | 1 |
| Cheng, QF | 1 |
| Fan, XD | 1 |
| Mahmood, K | 1 |
| Naeem, M | 1 |
| Rahimnajjad, NA | 1 |
| Bates, GW | 2 |
| Propst, AM | 2 |
| Nascimento, AD | 1 |
| Silva Lara, LA | 1 |
| Japur de Sá Rosa-e-Silva, AC | 1 |
| Ferriani, RA | 2 |
| Reis, RM | 1 |
| Pranikoff, J | 4 |
| Khan, Z | 1 |
| Padda, J | 1 |
| Lawrence, JM | 1 |
| Andrade, SE | 1 |
| Avalos, LA | 1 |
| Beaton, SJ | 1 |
| Chiu, VY | 1 |
| Davis, RL | 1 |
| Dublin, S | 1 |
| Pawloski, PA | 1 |
| Raebel, MA | 1 |
| Smith, DH | 1 |
| Toh, S | 1 |
| Kaplan, S | 1 |
| Amini, T | 1 |
| Hampp, C | 1 |
| Hammad, TA | 1 |
| Scott, PE | 1 |
| Cheetham, TC | 1 |
| Yawn, V | 1 |
| Chou, PY | 1 |
| Sun, HS | 1 |
| Esfahanian, F | 1 |
| Zamani, MM | 1 |
| Heshmat, R | 1 |
| Moini nia, F | 1 |
| Bird, ST | 1 |
| Hartzema, AG | 1 |
| Etminan, M | 1 |
| Brophy, JM | 1 |
| Delaney, JA | 1 |
| Gagliano, D | 1 |
| Busacca, M | 1 |
| Campagna, G | 3 |
| Neagu, M | 1 |
| Cristescu, C | 1 |
| Abd Elgafor, I | 1 |
| Cakiroglu, Y | 1 |
| Vural, B | 1 |
| Isgoren, S | 1 |
| Williams, RM | 1 |
| Ong, KK | 1 |
| Dunger, DB | 2 |
| Kedikova, S | 1 |
| Sirakov, M | 1 |
| Boyadzhieva, M | 1 |
| Kelly, CJ | 1 |
| Gordon, D | 1 |
| Martikainen, H | 2 |
| Loverro, G | 1 |
| Nicolardi, V | 1 |
| Mei, L | 1 |
| Awartani, KA | 1 |
| Seli, E | 3 |
| Leclair, C | 1 |
| Patton, PE | 1 |
| Goldstein, DB | 1 |
| Schöfl, C | 1 |
| Horn, R | 1 |
| Schill, T | 1 |
| Schlösser, HW | 1 |
| Müller, MJ | 1 |
| Brabant, G | 1 |
| Morelli, EM | 1 |
| Grazi, RV | 1 |
| Robinson, K | 1 |
| Sieve-Smith, L | 6 |
| Yarali, H | 3 |
| Luttrull, S | 1 |
| Streicher, P | 2 |
| Stadtmauer, LA | 2 |
| Oehninger, S | 1 |
| Vicennati, V | 2 |
| Heiman, ML | 1 |
| Tschöp, M | 1 |
| Rasgon, NL | 1 |
| Carter, MS | 1 |
| Elman, S | 1 |
| Bauer, M | 1 |
| Love, M | 1 |
| Korenman, SG | 2 |
| Vauhkonen, I | 2 |
| Eden, JA | 1 |
| Quint, EH | 1 |
| George, SS | 1 |
| George, K | 1 |
| Irwin, C | 1 |
| Job, V | 1 |
| Selvakumar, R | 1 |
| Jeyaseelan, V | 1 |
| Seshadri, MS | 1 |
| Haas, DA | 1 |
| Attia, GR | 1 |
| Barbieri, RL | 5 |
| Bernard, L | 1 |
| Basille, C | 2 |
| Chabbert-Buffet, N | 1 |
| Dehghan-Kooshkghazi, M | 1 |
| Chou, KH | 2 |
| Dean, H | 1 |
| Tasdemir, S | 1 |
| Ficicioglu, C | 1 |
| Yalti, S | 1 |
| Gurbuz, B | 1 |
| Basaran, T | 1 |
| Yildirim, G | 1 |
| Ciçek, MN | 1 |
| Bala, A | 1 |
| Celik, C | 1 |
| Akyürek, C | 1 |
| Massin, N | 1 |
| Galey, J | 1 |
| Théron-Gérard, L | 1 |
| Bry-Gauillard, H | 1 |
| Hugues, JN | 1 |
| Lyall, H | 2 |
| Ong, K | 3 |
| Ferrer, A | 2 |
| Amin, R | 2 |
| Dunger, D | 2 |
| Baillargeon, JP | 3 |
| Iuorno, MJ | 7 |
| Cardone, VS | 1 |
| Malkawi, HY | 3 |
| Hamaideh, AH | 1 |
| Fedorcsák, P | 1 |
| Dale, PO | 1 |
| Storeng, R | 1 |
| Abyholm, T | 1 |
| Tanbo, T | 1 |
| Papanna, R | 1 |
| Moreira, A | 1 |
| Perry, CG | 1 |
| Connell, JM | 1 |
| Visnová, H | 1 |
| Ventruba, P | 1 |
| Crha, I | 1 |
| Záková, J | 1 |
| Pirwany, I | 1 |
| Flight, IH | 2 |
| Hundal, RS | 1 |
| Inzucchi, SE | 1 |
| Frank-Raue, K | 1 |
| Schulze, E | 1 |
| Pfeifer, SM | 1 |
| Rautio, K | 2 |
| Hedberg, P | 1 |
| Puukka, M | 1 |
| Eagleson, CA | 1 |
| Bellows, AB | 1 |
| Gingrich, MB | 1 |
| Prelevic, GM | 1 |
| Amin, M | 1 |
| Abdel-Kareem, O | 1 |
| Takekida, S | 1 |
| Moriyama, T | 1 |
| Abd el-Aal, G | 1 |
| Maruo, T | 1 |
| Ye, BL | 2 |
| Lin, WQ | 2 |
| Chi, HH | 1 |
| Malavasi, B | 1 |
| Strucchi, C | 2 |
| Tortolani, F | 1 |
| Gamba, O | 1 |
| Jakubowicz, DJ | 7 |
| Apridonidze, T | 2 |
| He, N | 1 |
| Pelusi, C | 1 |
| Morselli-Labate, AM | 3 |
| Cacciari, M | 2 |
| Schröder, AK | 2 |
| McCarthy, EA | 1 |
| Walker, SP | 1 |
| McLachlan, K | 1 |
| Permezel, M | 1 |
| Alves da Motta, EL | 1 |
| de Lima, GR | 1 |
| Maesel, A | 1 |
| Bjerve, KS | 1 |
| Kauffman, MM | 1 |
| Kauffman, RP | 1 |
| Ajossa, S | 1 |
| Guerriero, S | 1 |
| Paoletti, AM | 1 |
| Orrù, M | 1 |
| Melis, GB | 1 |
| Gargiulo, AR | 1 |
| Loftspring, M | 3 |
| Sherman, A | 2 |
| Belosi, C | 1 |
| Yirmibeş, U | 1 |
| Aygen, E | 2 |
| Salmi, DJ | 1 |
| Zisser, HC | 1 |
| Jovanovic, L | 2 |
| Walters, BN | 1 |
| Rowan, JA | 2 |
| McIntyre, HD | 1 |
| Wang, JX | 1 |
| Hague, W | 1 |
| Quadbeck, B | 1 |
| Gärtner, R | 1 |
| Finke, R | 1 |
| Heymann, WR | 1 |
| Eunice, M | 1 |
| Gulati, M | 1 |
| Dwivedi, SN | 1 |
| Saleh, AM | 1 |
| Khalil, HS | 1 |
| Al-Fadhli, R | 1 |
| Villa, P | 1 |
| Di Sebastiano, F | 2 |
| Rossodivita, A | 1 |
| Barini, A | 1 |
| Szilágyi, A | 1 |
| Szabó, I | 1 |
| Gomel, V | 1 |
| Ben-Haroush, A | 1 |
| Yogev, Y | 1 |
| Fisch, B | 1 |
| Bornovali, S | 1 |
| Dharashivkar, S | 1 |
| Wixom, N | 1 |
| Craig, K | 1 |
| Miller, RK | 1 |
| Guzick, DS | 3 |
| Stoesser, K | 1 |
| Mitkov, M | 6 |
| Pekhlivanov, B | 4 |
| Terzieva, D | 3 |
| Valls, C | 2 |
| Cabré, S | 1 |
| Kashyap, S | 1 |
| Wells, GA | 1 |
| Muth, S | 1 |
| Corea, D | 1 |
| Doldo, P | 1 |
| Lombardi, G | 5 |
| Jakubowicz, S | 3 |
| Zhang, YW | 1 |
| Xue, YM | 1 |
| Chen, LX | 1 |
| Cai, Q | 1 |
| Cui, QH | 1 |
| Ge, J | 1 |
| Yuan, T | 1 |
| Sönmez, AS | 1 |
| Yasar, L | 1 |
| Savan, K | 1 |
| Koç, S | 1 |
| Ozcan, J | 1 |
| Toklar, A | 1 |
| Yazicioğu, F | 1 |
| Akgün, A | 1 |
| Sut, N | 1 |
| Meenakumari, KJ | 1 |
| Agarwal, S | 1 |
| Krishna, A | 1 |
| Pandey, LK | 1 |
| Tankova, T | 1 |
| Wilkin, T | 2 |
| Kraus, V | 1 |
| Petrovicova, J | 1 |
| Jayagopal, V | 1 |
| Holding, S | 1 |
| Jennings, PE | 1 |
| Lobo, RA | 1 |
| Aruna, J | 1 |
| Mittal, S | 1 |
| Kumar, S | 1 |
| Misra, R | 1 |
| Dadhwal, V | 1 |
| Vimala, N | 1 |
| Cibula, D | 3 |
| Fanta, M | 1 |
| Stanicka, S | 1 |
| Dvorakova, K | 1 |
| Hill, M | 5 |
| Skrha, J | 1 |
| Zivny, J | 1 |
| Skrenkova, J | 1 |
| Ortega-González, C | 2 |
| Luna, S | 1 |
| Hernández, L | 1 |
| Crespo, G | 1 |
| Aguayo, P | 1 |
| Arteaga-Troncoso, G | 2 |
| Parra, A | 2 |
| Tarim, E | 2 |
| Aslan, E | 2 |
| Erkanli, S | 2 |
| Santana, LF | 1 |
| de Sá, MF | 1 |
| de Moura, MD | 1 |
| Foss, MC | 1 |
| dos Reis, RM | 1 |
| Lam, PM | 1 |
| Cheung, LP | 1 |
| Haines, C | 1 |
| Cascella, T | 4 |
| Cardoza, L | 1 |
| Coutiño, B | 1 |
| Hidalgo, R | 1 |
| MacLaughlin, DT | 1 |
| Ling, D | 1 |
| Seifer, DB | 1 |
| Pehlivanov, B | 2 |
| Ertunc, D | 1 |
| Tok, EC | 1 |
| Aktas, A | 1 |
| Erdal, EM | 1 |
| Dilek, S | 1 |
| Andy, C | 1 |
| Flake, D | 1 |
| French, L | 1 |
| Sahin, I | 1 |
| Serter, R | 1 |
| Demirbas, B | 1 |
| Culha, C | 1 |
| Taskapan, C | 1 |
| Kosar, F | 1 |
| Aral, Y | 1 |
| Berker, B | 1 |
| Emral, R | 1 |
| Demirel, C | 1 |
| Corapcioglu, D | 1 |
| Unlu, C | 1 |
| Kose, K | 1 |
| Kumari, AS | 1 |
| Haq, A | 1 |
| Jayasundaram, R | 1 |
| Abdel-Wareth, LO | 1 |
| Al Haija, SA | 1 |
| Alvares, M | 1 |
| Tingthanatikul, Y | 1 |
| Choktanasiri, W | 1 |
| Wansumrith, S | 1 |
| Rojanasakul, A | 1 |
| Morin-Papunen, LC | 5 |
| Stout, DL | 1 |
| Fugate, SE | 1 |
| Kuscu, E | 1 |
| Manguso, F | 7 |
| Al-Inany, H | 4 |
| Zahlsen, K | 1 |
| Alexandraki, K | 3 |
| Protogerou, A | 1 |
| Papamichael, C | 1 |
| Aessopos, A | 3 |
| Lekakis, J | 1 |
| Mavrikakis, M | 1 |
| Harborne, LR | 1 |
| Norman, JE | 1 |
| Brock, B | 1 |
| Smidt, K | 1 |
| Ovesen, P | 1 |
| Schmitz, O | 1 |
| Rungby, J | 1 |
| Silva, SG | 1 |
| Hafley, G | 1 |
| Hwu, YM | 1 |
| Lin, SY | 1 |
| Huang, WY | 1 |
| Lin, MH | 1 |
| Lee, RK | 1 |
| Onalan, G | 3 |
| Selam, B | 1 |
| Baran, Y | 1 |
| Cincik, M | 2 |
| Onalan, R | 2 |
| Gündüz, U | 1 |
| Ural, AU | 1 |
| Pabuccu, R | 3 |
| Artensio, AC | 1 |
| Stabile, G | 1 |
| Volpe, A | 1 |
| Annamaria, C | 1 |
| Dale, B | 1 |
| Turner, MJ | 3 |
| Langan, H | 2 |
| Farah, N | 2 |
| Byrne, K | 1 |
| Cleary, B | 2 |
| Hoo, P | 1 |
| Shaw, R | 1 |
| Lv, L | 1 |
| Tan, K | 1 |
| Nørgaard, K | 1 |
| De Simone, B | 1 |
| Savastano, S | 1 |
| Yilmaz, M | 3 |
| Bukan, N | 1 |
| Ayvaz, G | 3 |
| Karakoç, A | 3 |
| Törüner, F | 2 |
| Cakir, N | 3 |
| Arslan, M | 3 |
| Vaughan, TB | 1 |
| Bell, DS | 2 |
| van Santbrink, EJ | 1 |
| Eijkemans, MJ | 1 |
| Laven, JS | 1 |
| Goktolga, U | 2 |
| Ceyhan, T | 2 |
| Hayden, CJ | 1 |
| White, D | 1 |
| Allen, HF | 1 |
| Mazzoni, C | 1 |
| Heptulla, RA | 1 |
| Murray, MA | 1 |
| Miller, N | 1 |
| Koenigs, L | 1 |
| Reiter, EO | 1 |
| Bhatia, V | 1 |
| Suriano, R | 1 |
| Tienforti, D | 1 |
| Hasan, JA | 1 |
| Memon, GU | 1 |
| Ortiz Núñez, DA | 1 |
| Hernández Marín, I | 1 |
| Ayala, AR | 2 |
| Törüner, FB | 1 |
| Tiras, B | 2 |
| Caterina, G | 1 |
| Eisenhardt, S | 1 |
| Schwarzmann, N | 1 |
| Henschel, V | 1 |
| von Wolff, M | 1 |
| Hamann, A | 1 |
| Yazdani, A | 1 |
| Brown, FM | 1 |
| Wyckoff, J | 1 |
| Sacks, DA | 1 |
| Briggs, GG | 1 |
| Conway, U | 1 |
| Ansari, Sh | 1 |
| Bagheri, M | 1 |
| Misugi, T | 1 |
| Ozaki, K | 1 |
| El Beltagy, K | 1 |
| Tokuyama, O | 1 |
| Honda, K | 1 |
| Ishiko, O | 1 |
| Biri, A | 1 |
| Bingöl, B | 1 |
| Zhu, B | 1 |
| Hawthorne, G | 1 |
| Paterakis, T | 2 |
| Katsilambros, N | 1 |
| Kreatsas, G | 1 |
| Hjorth-Hansen, H | 2 |
| Bjerve, K | 1 |
| Orsi, N | 1 |
| Luchetti, CG | 2 |
| Elia, E | 2 |
| Di Girolamo, G | 2 |
| Gonzalez, C | 2 |
| Bridger, T | 1 |
| MacDonald, S | 1 |
| Baltzer, F | 1 |
| Rodd, C | 1 |
| Herman, ZS | 1 |
| Baraldi, E | 2 |
| Mehmeti, H | 1 |
| Koren, G | 2 |
| Gilbert, C | 2 |
| Valois, M | 2 |
| Pleger, K | 1 |
| van Halteren, WB | 1 |
| Kimmig, R | 2 |
| Khorram, O | 1 |
| Helliwell, JP | 1 |
| Katz, S | 1 |
| Bonpane, CM | 1 |
| Jaramillo, L | 1 |
| Thatcher, SS | 1 |
| Jackson, EM | 1 |
| Rouzi, AA | 1 |
| Ardawi, MS | 1 |
| Golnik, KC | 2 |
| Aregawi, D | 5 |
| Walsh, J | 2 |
| Byrne, KM | 1 |
| Murphy, C | 1 |
| Urman, B | 1 |
| Yakin, K | 1 |
| Liu, JH | 1 |
| Bill, AH | 1 |
| Kocak, I | 1 |
| Ustün, C | 1 |
| Norman, R | 1 |
| Korevaar, JC | 2 |
| Sharma, ST | 2 |
| Doldi, N | 1 |
| Persico, P | 1 |
| Marsiglio, E | 1 |
| Ferrari, A | 1 |
| Ulloa-Aguirre, A | 1 |
| Portocarrero, L | 1 |
| Zariñán, T | 1 |
| Olivares, A | 1 |
| Carranza-Lira, S | 1 |
| Veldhuis, JD | 1 |
| López-Alvarenga, JC | 1 |
| Lilja, AE | 1 |
| Topcu, S | 1 |
| Tok, D | 1 |
| Caliskan, M | 1 |
| Gullu, H | 1 |
| Erdogan, D | 1 |
| Zeyneloglu, H | 1 |
| Muderrisoglu, H | 1 |
| Thomas, R | 1 |
| Fox, B | 1 |
| Shi, XB | 1 |
| Zhou, LY | 1 |
| Fu, SX | 1 |
| Chen, JL | 1 |
| Krstevska, B | 1 |
| Dimitrovski, Ch | 1 |
| Pemovska, G | 1 |
| Misevska, S | 1 |
| Dimova, Z | 1 |
| Simeonova, S | 1 |
| Ahmeti, I | 1 |
| Patton, L | 1 |
| Vaccina, A | 1 |
| Cavazza, C | 1 |
| Winiarska, M | 2 |
| Agloria, M | 2 |
| Luo, G | 1 |
| Liu, KE | 1 |
| Tataryn, IV | 1 |
| Sagle, M | 1 |
| Kovo, M | 1 |
| Weissman, A | 1 |
| Gur, D | 1 |
| Levran, D | 1 |
| Rotmensch, S | 1 |
| Glezerman, M | 1 |
| Guidice, LC | 1 |
| Leppert, PC | 4 |
| Jothilakshmi, PK | 1 |
| Jude, E | 1 |
| Elhadd, TA | 1 |
| Fiad, T | 1 |
| Meer, L | 1 |
| Nosarka, S | 1 |
| Lanham, MS | 1 |
| Lebovic, DI | 1 |
| Domino, SE | 1 |
| Hoppin, AG | 1 |
| Katz, ES | 1 |
| Kaplan, LM | 1 |
| Lauwers, GY | 1 |
| Lambrinoudaki, I | 1 |
| Creatsas, G | 1 |
| Manno, M | 1 |
| Tomei, F | 1 |
| Marchesan, E | 1 |
| Frey, UH | 1 |
| Siffert, W | 1 |
| Neveu, N | 1 |
| Granger, L | 1 |
| St-Michel, P | 1 |
| Lavoie, HB | 1 |
| Foutouh, IA | 1 |
| Ramadan, A | 1 |
| Moaz, M | 1 |
| Kavŭrdzhikova, S | 1 |
| Gorry, A | 1 |
| White, DM | 1 |
| Homan, G | 1 |
| Moran, L | 1 |
| Noakes, M | 1 |
| Bayrak, A | 1 |
| Terbell, H | 1 |
| Urwitz-Lane, R | 1 |
| Mor, E | 1 |
| Stanczyk, FZ | 1 |
| Paulson, RJ | 1 |
| Shrestha, B | 2 |
| Eden, J | 2 |
| Sjoblom, P | 2 |
| Shibahara, H | 1 |
| Kikuchi, K | 1 |
| Hirano, Y | 1 |
| Suzuki, T | 1 |
| Takamizawa, S | 1 |
| Suzuki, M | 1 |
| Dronavalli, S | 1 |
| Elnashar, A | 1 |
| Fahmy, M | 1 |
| Mansour, A | 1 |
| Ibrahim, K | 1 |
| Schachter, M | 1 |
| Raziel, A | 1 |
| Strassburger, D | 1 |
| Rotem, C | 1 |
| Ron-El, R | 1 |
| Friedler, S | 1 |
| Seibel, SA | 1 |
| Kjøtrød, S | 1 |
| Nazari, T | 1 |
| Bayat, R | 1 |
| Hamedi, M | 1 |
| Lowenstein, L | 1 |
| Damti, A | 1 |
| Pillar, G | 1 |
| Shott, S | 1 |
| Blumenfeld, Z | 1 |
| Reckelhoff, JF | 1 |
| Zaino, RJ | 1 |
| Gnatuk, CL | 1 |
| Botella-Carretero, JI | 2 |
| Martínez-Bermejo, E | 2 |
| Lasunción, MA | 1 |
| Bruno, RV | 1 |
| de Avila, MA | 1 |
| Neves, FB | 1 |
| Nardi, AE | 1 |
| Crespo, CM | 1 |
| Sobrinho, AT | 1 |
| Jasonni, VM | 1 |
| Orbetsova, M | 1 |
| Kamenov, Z | 1 |
| Kolarov, G | 1 |
| Zakharieva, S | 1 |
| Khristov, V | 1 |
| Atanasova, I | 1 |
| Shigarminova, R | 1 |
| Milcheva, B | 1 |
| Genchev, G | 1 |
| Nawrocka, J | 1 |
| Geberhiwot, T | 1 |
| Jones, AF | 1 |
| Kadoch, IJ | 1 |
| Fanchin, R | 1 |
| Frydman, N | 1 |
| Le Du, A | 1 |
| Frydman, R | 1 |
| De Feo, P | 1 |
| Sanchón, R | 1 |
| San Millán, JL | 1 |
| Pillai, A | 1 |
| Bang, H | 1 |
| Green, C | 1 |
| Yamashita, SA | 1 |
| Halpern, A | 1 |
| Di Biase, S | 1 |
| Labella, D | 1 |
| Clapauch, R | 1 |
| Mattos, TM | 1 |
| Check, JH | 1 |
| Hassan, A | 1 |
| Gordon, CM | 1 |
| Cento, R | 1 |
| Yilmazsoy, A | 1 |
| Yikilmaz, A | 1 |
| Thaler, CJ | 1 |
| Ma, LK | 1 |
| Jin, LN | 1 |
| Yu, Q | 1 |
| Kesmodel, U | 1 |
| Galindo, CG | 1 |
| Hernández, I | 1 |
| Rutherford, AJ | 1 |
| Lebinger, TG | 1 |
| Yannakoula, EK | 1 |
| Al-Qudah, MA | 1 |
| El-Uri, FI | 1 |
| Ratts, VS | 2 |
| Pauls, RN | 1 |
| Pinto, AB | 1 |
| Kraja, A | 1 |
| Williams, DB | 1 |
| Odem, RR | 1 |
| Dietz, T | 1 |
| Lahner, H | 1 |
| Moeller, LC | 1 |
| Schmidt, M | 1 |
| Schulz, H | 1 |
| Nickel, I | 1 |
| Kleinstein, J | 1 |
| Kaltwasser, P | 1 |
| Westphal, S | 1 |
| Mittermayer, F | 1 |
| Wolzt, M | 1 |
| Krzyzanowska, K | 1 |
| Randeva, H | 1 |
| Schernthaner, G | 1 |
| Wu, JH | 1 |
| Zhou, QL | 1 |
| Ewens, KG | 1 |
| Spielman, RS | 1 |
| Wei, Z | 1 |
| Cong, L | 1 |
| Zhou, P | 1 |
| Tien, JC | 1 |
| Tan, TY | 1 |
| Oktenli, C | 2 |
| Ozgurtas, T | 2 |
| Dede, M | 2 |
| Sanisoglu, YS | 1 |
| Yenen, MC | 2 |
| Yesilova, Z | 2 |
| Kenar, L | 2 |
| Kurt, YG | 1 |
| Baser, I | 2 |
| Smith, J | 1 |
| Cianflone, K | 1 |
| Nelson, SM | 1 |
| Vaikkakara, S | 1 |
| Al-Ozairi, E | 2 |
| Lim, E | 1 |
| Advani, A | 2 |
| Ball, SG | 1 |
| James, RA | 1 |
| Quinton, R | 2 |
| Monami, M | 1 |
| Mannucci, E | 1 |
| Schaefer-Graf, UM | 1 |
| Kleinwechter, H | 1 |
| Aylwin, S | 1 |
| Al-Zaman, Y | 1 |
| De Marinis, L | 1 |
| Glueck, C | 1 |
| Tollino, A | 1 |
| Tapan, S | 1 |
| Sanisoglu, SY | 1 |
| Erbil, MK | 1 |
| Mascitelli, L | 2 |
| Pezzetta, F | 2 |
| Zain, MM | 1 |
| Jamaluddin, R | 1 |
| Ibrahim, A | 1 |
| Mlinar, B | 1 |
| Marc, J | 1 |
| Tosca, L | 1 |
| Chabrolle, C | 1 |
| Oppedisano, R | 1 |
| Uriol Rivera, MG | 1 |
| Kennedy, CR | 1 |
| Creanga, AA | 1 |
| Bradley, HM | 1 |
| McCormick, C | 1 |
| Witkop, CT | 1 |
| Kumar, HK | 1 |
| Harrison, C | 1 |
| Stepto, N | 1 |
| Raskauskas, TA | 1 |
| Batterham, RL | 1 |
| Fisken, RA | 1 |
| Targher, G | 1 |
| Lippi, G | 1 |
| Goldstein, MR | 1 |
| Abbas, M | 1 |
| Gannon, M | 1 |
| Elkind-Hirsch, K | 1 |
| Marrioneaux, O | 1 |
| Bhushan, M | 1 |
| Vernor, D | 1 |
| Bhushan, R | 1 |
| Kircher, C | 1 |
| Smith, KP | 1 |
| Bolton, S | 1 |
| Dempsey, E | 1 |
| Velazquez, EM | 2 |
| Mendoza, S | 1 |
| Hamer, T | 1 |
| Sosa, F | 1 |
| Gündoğdu, S | 1 |
| Utiger, RD | 1 |
| Cavaghan, MK | 1 |
| Imperial, J | 1 |
| Sturis, J | 1 |
| Rosenfield, RL | 1 |
| Polonsky, KS | 1 |
| Mendoza, SG | 2 |
| Velázquez, E | 1 |
| Acosta, A | 1 |
| Zárate, A | 1 |
| Hernández, M | 1 |
| Fonseca, ME | 1 |
| Ochoa, R | 1 |
| van Montfrans, JM | 1 |
| van Hooff, MH | 1 |
| Hompes, PG | 1 |
| Kouli, C | 3 |
| Tsianateli, T | 2 |
| Bergiele, A | 2 |
| Koivunen, RM | 4 |
| Martikainen, HK | 4 |
| Hopkinson, ZE | 1 |
| Greer, IA | 1 |
| Tomás, C | 1 |
| Fontaine, R | 2 |
| Tracy, T | 2 |
| Sarlis, NJ | 1 |
| Weil, SJ | 1 |
| Nelson, LM | 1 |
| Ditto, A | 1 |
| Tutuş, A | 1 |
| Ducluzeau, PH | 1 |
| Paglia, T | 2 |
| Ciotta, L | 1 |
| Gandar, R | 1 |
| Spizzo, M | 1 |
| Collin, D | 1 |
| Egbe, TO | 1 |
| Ciani, A | 1 |
| Negri, C | 1 |
| Tosi, F | 1 |
| Perrone, F | 1 |
| Caputo, M | 1 |
| Zanolin, E | 1 |
| Muggeo, M | 1 |
| Lu, C | 1 |
| Zapanti, E | 1 |
| Kim, LH | 1 |
| Taylor, AE | 2 |
| Kolodziejczyk, B | 1 |
| Sills, ES | 1 |
| Perloe, M | 1 |
| Palermo, GD | 1 |
| Seale, FG | 1 |
| Robinson, RD | 1 |
| Neal, GS | 1 |
| Awadalla, SG | 1 |
| Phillips, H | 3 |
| Cameron, D | 2 |
| Fontaine, RN | 1 |
| Biscotti, D | 1 |
| Gagliardi, L | 1 |
| Colitta, D | 1 |
| Fiorini, S | 1 |
| Cognigni, GE | 1 |
| Filicori, M | 1 |
| Vandermolen, DT | 1 |
| Kauma, SW | 1 |
| Seppälä, M | 1 |
| Rodriguez-Armas, O | 1 |
| Rivas-Santiago, A | 1 |
| Koistinen, H | 1 |
| Koistinen, R | 1 |
| Toma, SK | 1 |
| Riehl, RM | 1 |
| Talbert, LM | 1 |
| Phipps, WR | 1 |
| Kowalska, I | 1 |
| Kinalski, M | 1 |
| Straczkowski, M | 1 |
| Wolczyski, S | 1 |
| Kinalska, I | 1 |
| Stárka, L | 4 |
| Bendlová, B | 2 |
| Vondra, K | 3 |
| Sulcová, J | 2 |
| Snajderová, M | 2 |
| De Conciliis, B | 1 |
| Passannanti, G | 1 |
| Romano, L | 1 |
| Santarpia, R | 1 |
| Kidson, WJ | 1 |
| Cuneo, RC | 1 |
| Zacharin, MR | 1 |
| Wat, NM | 1 |
| Ho, PC | 1 |
| Batukan, C | 2 |
| Baysal, B | 2 |
| Parsanezhad, ME | 1 |
| Alborzi, S | 1 |
| Zarei, A | 1 |
| Omrani, G | 1 |
| Spina, G | 1 |
| Migdalis, I | 1 |
| Rai, R | 1 |
| Kocak, M | 1 |
| Caliskan, E | 1 |
| Simsir, C | 1 |
| Haberal, A | 1 |
| Simeonov, S | 1 |
| Velchev, G | 1 |
| Hou, J | 1 |
| De Sloover Koch, Y | 1 |
| Ernst, ME | 1 |
| Stovall, D | 1 |
| Akhter, N | 1 |
| Demirol, A | 1 |
| Yiğit, N | 1 |
| Bükülmez, O | 1 |
| Koray, Z | 1 |
| Roberts, KA | 1 |
| Batukan, M | 1 |
| Kent, SC | 1 |
| Lee, F | 1 |
| Patel, HR | 1 |
| Copland, P | 1 |
| Kahn, L | 1 |
| Kobayashi, S | 1 |
| Fox, R | 1 |
| Ryan, A | 1 |
| Bicíková, M | 1 |
| Tallová, J | 1 |
| Arslanian, SA | 1 |
| Lewy, V | 1 |
| Danadian, K | 1 |
| Saad, R | 1 |
| Heard, MJ | 1 |
| Pierce, A | 1 |
| Buster, JE | 1 |
| Laboureau-Soares Barbosa, S | 1 |
| Rodien, P | 1 |
| Rohmer, V | 1 |
| Sturrock, ND | 1 |
| Lannon, B | 1 |
| Fay, TN | 1 |
| Mulchahey, KM | 1 |
| Trent, M | 1 |
| Kirpichnikov, D | 1 |
| McFarlane, SI | 1 |
| Sowers, JR | 1 |
| Elter, K | 1 |
| Imir, G | 1 |
| Durmusoglu, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Study on the Effect of Metformin vs Metformin Combined With GLP-1 RA (Exenatide) on Overweight/Obese Patients With Polycystic Ovary Syndrome (PCOS)[NCT04029272] | Phase 4 | 80 participants (Anticipated) | Interventional | 2019-07-20 | Recruiting | ||
| Semaglutide Improves Metabolic Abnormalities and Fertility in Obese Infertile Women With Polycystic Ovary Syndrome: a Prospective, Randomized, Open, Controlled Study[NCT05702905] | Phase 4 | 75 participants (Anticipated) | Interventional | 2023-04-30 | Not yet recruiting | ||
| The Effect of Acupuncture on Insulin Sensitivity of Women With Polycystic Ovary Syndrome and Insulin Resistance: a Randomized Controlled Trial[NCT02491333] | Phase 3 | 342 participants (Actual) | Interventional | 2015-08-31 | Completed | ||
| Metformin Treatment of Pregnant Women With Polycystic Ovary Syndrome (PCOS)[NCT00159536] | Phase 3 | 257 participants (Actual) | Interventional | 2005-02-28 | Completed | ||
| Metformin Treatment of Pregnant Women With Polycystic Ovary Syndrome: a Pilot Study[NCT03259919] | Phase 2 | 40 participants (Actual) | Interventional | 2000-10-31 | Completed | ||
| Canagliflozin Administration in Non-diabetic Women With Polycystic Ovarian Syndrome[NCT04973891] | Phase 1/Phase 2 | 52 participants (Actual) | Interventional | 2021-04-07 | Completed | ||
| Effects of Combined Resveratrol and Myo-inositol on Altered Metabolic, Endocrine Parameters and Perceived Stress in Patients With Polycystic Ovarian Syndrome[NCT04867252] | Phase 2 | 88 participants (Actual) | Interventional | 2021-05-03 | Completed | ||
| Effect of Metformin on Healthy Live Birth After In-vitro Fertilization in Women With Prediabetes Mellitus: a Multicenter Double-blind Placebo Controlled Randomized Trial[NCT06064669] | 988 participants (Anticipated) | Interventional | 2023-10-01 | Not yet recruiting | |||
| Effects of Metformin on Metabolic and Reproductive Outcomes in Chinese PCOS Patients[NCT05463627] | 1,440 participants (Anticipated) | Observational | 2016-01-01 | Recruiting | |||
| Effectiveness of the Combination Liraglutide and Metformin on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With Polycystic Ovarian Syndrome, Obesity and Infertility[NCT05952882] | Phase 3 | 188 participants (Anticipated) | Interventional | 2023-11-01 | Not yet recruiting | ||
| Targeting Pathophysiologic Pathways in Polycystic Ovary Syndrome Using a Response to Metformin Phenotype[NCT02086526] | Phase 1 | 68 participants (Actual) | Interventional | 2014-03-31 | Completed | ||
| Abnormalities of the Endometrium Persist Despite Adequate Progesterone Supplementation in the Polycystic Ovary Syndrome[NCT05062135] | 36 participants (Actual) | Interventional | 2014-02-10 | Completed | |||
| [NCT00172523] | 0 participants | Observational | 2004-10-31 | Recruiting | |||
| Comparing the Therapeutic Effect of Sitagliptin/Metformin and Metformin on Biochemical Factors and Expression of GDF-9 and BMP-15 Genes in Patients With Classic PCOS Undergoing Intra-cytoplasmic Sperm Injection (ICSI)[NCT04268563] | Phase 1/Phase 2 | 80 participants (Anticipated) | Interventional | 2020-01-10 | Recruiting | ||
| Research of Exenatide for Management of Reproductive and Metabolic Dysfunction in Overweight/Obese PCOS Patients With Impaired Glucose Regulation[NCT03352869] | Phase 4 | 183 participants (Actual) | Interventional | 2017-11-28 | Completed | ||
| Effects of Triple Drug Cocktail Therapy on Metabolic, Endocrine Alterations and Perceived Stress Response in Patients With PCOS: A Double Blind Randomized Clinical Trial[NCT04113889] | Phase 2 | 147 participants (Actual) | Interventional | 2019-10-15 | Completed | ||
| The Effects of Acetyl L--Carnitine and Myo/Chiro-Inositol on Improving Ovulation, Pregnancy Rate, Ovarian Function and Perceived Stress Response in Patients With PCOS[NCT05767515] | 120 participants (Anticipated) | Interventional | 2023-04-15 | Not yet recruiting | |||
| Comparison of Dapagliflozin (DAPA) and Once-weekly Exenatide (EQW), Co-administered or Alone, DAPA/ Glucophage (DAPA/MET ER) and Phentermine/Topiramate (PHEN/TPM) ER on Metabolic Profiles and Body Composition in Obese PCOS Women[NCT02635386] | Phase 3 | 119 participants (Actual) | Interventional | 2016-03-22 | Completed | ||
| Randomized Clinical Trial to Evaluate The Effect of Metformin-GLP-1 Receptor Agonist Versus Oral Contraceptive (OC) Therapy on Reproductive Disorders and Cardiovascular Risks in Overweight Polycystic Ovarian Syndrome (PCOS) Patients[NCT03151005] | Phase 4 | 70 participants (Actual) | Interventional | 2017-07-01 | Completed | ||
| The Change in Microbiome Following Treatment of Women With Polycystic Ovaries[NCT04836910] | 40 participants (Anticipated) | Observational | 2024-09-01 | Recruiting | |||
| A Multi-center, Prospective, Cohort Study to Elucidate the Effects of Metformin Treatment on Steroid Hormones and Social Behavior. Linking Autistic Behaviorial Symptoms to Changes in Steroid Hormone Availability[NCT04930471] | 45 participants (Anticipated) | Observational | 2021-06-30 | Not yet recruiting | |||
| Independent and Additive Effects Of Micronutrients With Metformin In Patients With PCOS:A Double Blind Randomized Placebo Controlled Trial[NCT05653895] | 250 participants (Anticipated) | Interventional | 2022-12-07 | Recruiting | |||
| Impact of Metformin on In Vitro Fertilization Outcomes in Overweight and Obese Polycystic Ovary Syndrome Women; A Quasi Experimental Study[NCT02910817] | 102 participants (Actual) | Interventional | 2015-01-31 | Completed | |||
| Maternal and Fetal Outcome With Metformin Therapy for Obese Pregnant Women a Randomized Control Trial.[NCT05554679] | Phase 4 | 178 participants (Anticipated) | Interventional | 2021-02-01 | Recruiting | ||
| Effects of Inositols on Insulin Resistance in Children With Obesity (ONIRICO Trial)[NCT05701813] | 56 participants (Anticipated) | Interventional | 2023-02-01 | Not yet recruiting | |||
| Acupuncture or Metformin for Insulin Resistance in Women With Polycystic Ovary Syndrome: A Randomized Controlled Trial[NCT02647827] | Phase 2 | 303 participants (Anticipated) | Interventional | 2015-12-31 | Recruiting | ||
| A Prospective, Randomized, Double-blind, Multi-centre Study, Where the Possible Effect of Metformin to Prevent Late Miscarriage and Preterm Delivery is Studied in Women With Polycystic Ovary Syndrome (PCOS)[NCT01587378] | 489 participants (Actual) | Interventional | 2012-10-31 | Completed | |||
| The Effect of Empagliflozin Versus Metformin on Hormonal, Metabolic and Cardiovascular Risk Factors in Patients With Polycystic Ovary Syndrome (PCOS) - a Randomised Open-label Parallel Study.[NCT03008551] | Phase 2/Phase 3 | 40 participants (Actual) | Interventional | 2017-08-18 | Completed | ||
| The Efficacy of Canagliflozin Versus Metformin in Women With Polycystic Ovary Syndrome: A Randomized, Open Label Trial[NCT04700839] | Phase 4 | 68 participants (Actual) | Interventional | 2020-05-01 | Completed | ||
| Randomized Clinical Trial, Effect of Metformin and Rosiglitazone Over Glucose Homeoastasis in no Diabetic With Metabolic Syndrome Patients.[NCT04148183] | Phase 2/Phase 3 | 30 participants (Actual) | Interventional | 2004-01-01 | Completed | ||
| Is the Co-administration of Metformine and CC as Compared to Placebo and CC Superior to Induce Ovulation in PCOS Patients With a Confirmed insulin-resistant-a Double Blind Randomized Clinical Trial[NCT02523898] | Phase 2 | 388 participants (Anticipated) | Interventional | 2015-11-30 | Enrolling by invitation | ||
| Prevention of Pre-eclampsia Using Metformin: a Randomized Control Trial[NCT04855513] | 414 participants (Anticipated) | Interventional | 2022-03-24 | Not yet recruiting | |||
| Effect of Acupuncture on Insulin Sensitivity in Women With Polycystic Ovary Syndrome and Insulin Resistance: Study Protocol of a Prospective Observational Study[NCT02026323] | 112 participants (Anticipated) | Interventional | 2014-01-31 | Enrolling by invitation | |||
| Effect of Acupuncture Pre-treatment Combined With Letrozole on Live Birth in Infertile Women With Polycystic Ovary Syndrome[NCT02491320] | Phase 3 | 384 participants (Actual) | Interventional | 2015-08-31 | Completed | ||
| Metformin Versus Metfotmin Plus Low-dose Spironolactone in the Treatment of Overweight/Obese Patients With Polycystic Ovary Syndrome: a Randomized Study[NCT01526616] | 56 participants (Actual) | Interventional | 2010-05-31 | Completed | |||
| Randomized, Cross-over Trial With Metformin in Women With Polycystic Ovary Syndrome[NCT02280057] | Phase 4 | 56 participants (Actual) | Interventional | 2001-09-30 | Completed | ||
| Ultrasonographic Evaluation of Ovarian Stroma in PCOS Women[NCT05418595] | 42 participants (Actual) | Observational | 2022-06-13 | Completed | |||
| Uterine Artery Blood Flow in Pregnant Women With Polycystic Ovary Syndrome(PCOS)Treated With Metformin - a Substudy to The PregMet Study[NCT00466622] | Phase 3 | 48 participants (Actual) | Interventional | 2007-04-30 | Completed | ||
| Metabolic Responses of Metformin and Genetic Polymorphisms (rs628031 and rs2282143) of Solute Carrier Family 22 Member 1 Gene in Polycystic Ovary Syndrome[NCT05680805] | Phase 4 | 100 participants (Anticipated) | Interventional | 2023-05-27 | Recruiting | ||
| Effects of Different Therapies on Surrogate Markers of Cardiovascular Risk in Women With Polycystic Ovary Syndrome (PCOS)[NCT01798875] | Phase 4 | 50 participants (Anticipated) | Interventional | 2012-04-30 | Recruiting | ||
| Effects of Metformin on Mitochondrial Function in Polycystic Ovary Syndrome[NCT02198417] | 20 participants (Anticipated) | Interventional | 2014-07-31 | Active, not recruiting | |||
| Polycystic Ovary Syndrome Genetics and Treatment Response[NCT01389778] | 200 participants (Anticipated) | Interventional | 2011-06-30 | Active, not recruiting | |||
| Metformin and Oral Contraceptives in PCOS[NCT00451568] | Phase 4 | 90 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| Use of Metformin in Prevention and Treatment of Cardiac Fibrosis in PAI-1 Deficient Population[NCT05317806] | Phase 4 | 15 participants (Anticipated) | Interventional | 2022-10-10 | Active, not recruiting | ||
| Pilot Randomized Controlled Trial of Spironolactone in Young Women With Nonalcoholic Steatohepatitis (NASH)[NCT03576755] | Phase 1/Phase 2 | 20 participants (Actual) | Interventional | 2019-01-09 | Completed | ||
| Effects of Metformin and Combination of Metformin and Pioglitazone on Plasma Interleukin-6 and Interleukin-8 Levels in Polycystic Ovarian Syndrome[NCT03117517] | Early Phase 1 | 106 participants (Actual) | Interventional | 2017-03-20 | Completed | ||
| Effect of Metformin and Combination of Olive Oil Plus Nutritional Supplements on Inflammatory Markers IL-6 and IL-8 in PCOS.[NCT05952349] | Phase 2 | 88 participants (Anticipated) | Interventional | 2023-07-01 | Recruiting | ||
| A Pilot Study: Metformin as an Inflammatory Modulating Therapy in Older Adults Without Diabetes[NCT03772964] | Phase 1/Phase 2 | 32 participants (Actual) | Interventional | 2019-01-22 | Completed | ||
| Short-term Treatment With PDE-4 Inhibitor Roflumilast or GLP-1 Agonist Liraglutide or Metformin in Treatment Naive Obese Women With Polycystic Ovary Syndrome[NCT02187250] | Phase 4 | 45 participants (Actual) | Interventional | 2014-03-31 | Completed | ||
| Pregnancy in Polycystic Ovary Syndrome: A 30 Week Double-Blind Randomized Trial of Clomiphene Citrate, Metformin XR, and Combined Clomiphene Citrate/Metformin XR For the Treatment of Infertility in Women With Polycystic Ovary Syndrome[NCT00068861] | Phase 3 | 678 participants | Interventional | 2002-11-30 | Completed | ||
| The Efficacy of Levonorgestrel Intrauterine System Versus Oral Megesterol Acetate in Treatment of Atypical Endometrial Hyperplasia. A Randomized Controlled Trial.[NCT04385667] | Phase 2/Phase 3 | 143 participants (Actual) | Interventional | 2020-05-20 | Completed | ||
| Combined Letrozole-metformin-pioglitazone Versus Combined Clomiphene Citrate-metformin-pioglitazone in Clomiphene Citrate-resistant Women With Polycystic Ovary Syndrome[NCT01909141] | Early Phase 1 | 100 participants (Actual) | Interventional | 2013-08-31 | Completed | ||
| Investigation of the Effect of Calisthenic Exercise Training Combined With Aerobic Exercise on Exercise Tolerance, Physical Fitness and Plasma Lipid Profile in Patients With Dyslipidemia[NCT06008912] | 24 participants (Anticipated) | Interventional | 2024-01-01 | Not yet recruiting | |||
| The Angiotensin-Melatonin Axis in Poor and Hyper Responders for IVF Treatment[NCT05298657] | 200 participants (Anticipated) | Observational [Patient Registry] | 2022-09-01 | Not yet recruiting | |||
| A Multicenter Randomized Trial of Personalized Acupuncture, Fixed Acupuncture, Letrozole and Placebo on Live Birth for Infertility in Women With Polycystic Ovary Syndrome[NCT03625531] | Phase 3 | 1,100 participants (Anticipated) | Interventional | 2018-08-13 | Recruiting | ||
| [NCT02909933] | Phase 4 | 30 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| Metabolic and Endocrine Effects of Combination of Metformin and DPP-4 Inhibitor Saxagliptin Compared to Saxagliptin or Metformin XR Monotherapy in Patients With PCOS and Impaired Glucose Regulation: A Single-blinded Randomized Pilot Study[NCT02022007] | Phase 3 | 38 participants (Actual) | Interventional | 2014-03-31 | Completed | ||
| Phase II Randomized Study of Neoadjuvant Metformin Plus Letrozole vs Placebo Plus Letrozole for ER-positive Postmenopausal Breast Cancer[NCT01589367] | Phase 2 | 208 participants (Actual) | Interventional | 2012-05-31 | Completed | ||
| The Cardiovascular Risk Profile Associated With The Polycystic Ovary Syndrome And With Ovulatory Hyperandrogenism, And Its Changes During Treatment With Metformin Or Oral Contraceptives[NCT00428311] | Phase 4 | 50 participants | Interventional | 2004-04-30 | Completed | ||
| Effect of Myoinositol on Serum Asprosin Levels in PCOS Patients[NCT05951309] | 30 participants (Actual) | Interventional | 2021-09-01 | Completed | |||
| A Comparison of a Pulse-Based Diet and the Therapeutic Lifestyle Changes Diet on Reproductive and Metabolic Parameters in Women With Polycystic Ovary Syndrome[NCT05428566] | 110 participants (Anticipated) | Interventional | 2022-01-01 | Recruiting | |||
| The Effects of Contraceptive Pill and Hormonal Vaginal Ring on Hormonal, Inflammatory and Metabolic Parameters in Women of Reproductive Age With Polycystic Ovary Syndrome (PCOS).[NCT01588873] | Phase 4 | 42 participants (Anticipated) | Interventional | 2012-04-30 | Recruiting | ||
| Clomiphene Citrate Plus HPuFSH Versus Letrozole Plus HPuFSH in Clomid Resistant Infertile PCOS Women[NCT01793038] | 160 participants (Anticipated) | Interventional | 2013-03-31 | Recruiting | |||
| Clomiphene Citrate Co-treatment With Low Dose HP Urinary FSH vs. HP Urinary FSH Step-up Protocol for Clomiphene-citrate Resistant PCOS Anovulatory Infertility: Randomized Controlled Trial[NCT01212263] | 174 participants (Actual) | Interventional | 2010-01-31 | Completed | |||
| Effect of Simvastatin and Metformin on Clinical, Endocrine, Metabolic and Endothelial Function of Women With Polycystic Ovary Syndrome: Prospective Randomised Trial[NCT00396513] | 0 participants | Interventional | 2005-09-30 | Recruiting | |||
| Effects of Metformin With or Without Folate Supplementation on Homocysteine Levels and Endothelium in Women With Polycystic Ovary Syndrome[NCT00953355] | Phase 4 | 50 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| Effect of Metformin on Insulin Sensitivity and Pan-Arterial Vascular Function in Adults With Metabolic Syndrome[NCT02633488] | 19 participants (Actual) | Interventional | 2014-06-30 | Completed | |||
| A Randomized Trial of Metformin as Adjunct Therapy for Overweight Adolescents With Type 1 Diabetes[NCT01881828] | Phase 3 | 164 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| Clinical Metabolic and Endocrine Parameters in Response to Metformin and Lifestyle Intervention in Women With Polycystic Ovary Syndrome: A Phase 4 Randomized, Double- Blind and Placebo Control Trial[NCT00679679] | Phase 4 | 30 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| [NCT01514942] | Phase 4 | 0 participants | Interventional | Completed | |||
| Multi-Centre Randomised Controlled Trial of the Effectiveness of Metformin and Clomiphene Citrate for Treating Anovulatory Infertility in Women With Polycystic Ovary Syndrome[NCT00795808] | Phase 4 | 171 participants (Actual) | Interventional | 2003-08-31 | Completed | ||
| A Multicenter, Prospective, Randomized Study to Assess the Effect of Metformin Supplementation on IVF Outcome and Intrafollicular Environment in Patients With Polycystic Ovarian Syndrome Undergoing In Vitro Fertilization/Embryo Transfer[NCT03086005] | Phase 3 | 24 participants (Actual) | Interventional | 2011-10-12 | Completed | ||
| The Effect of Combination Therapy With Lifestyle Intervention and Metformin in Females With Polycystic Ovary Syndrome[NCT00151411] | Phase 2 | 114 participants (Actual) | Interventional | 2004-10-31 | Completed | ||
| Influence of Insulin Resistance on Cognitive, Emotional and Opioid System Functioning in Women With Polycystic Ovary Syndrome[NCT00670800] | 14 participants (Actual) | Interventional | 2008-01-31 | Completed | |||
| Preventing Recurrent Gestational Diabetes Mellitus With Early Metformin Intervention[NCT02394158] | Phase 4 | 112 participants (Anticipated) | Interventional | 2015-01-27 | Recruiting | ||
| Metformin Treatment Before IVF in Women With Ultrasound Evidence of Polycystic Ovaries; a Prospective, Randomised, Double Blind, Placebo Study[NCT01046032] | 134 participants (Actual) | Interventional | 2005-12-31 | Completed | |||
| Metformin Treatment Before IVF / ICSI in Non-obese Women With Polycystic Ovarian Syndrome[NCT00159575] | Phase 4 | 150 participants (Actual) | Interventional | 2005-03-31 | Terminated (stopped due to Slow patient recruitment and expiry of study medication(aug2009)) | ||
| Combination Metformin and Oral Contraception for Polycystic Ovary Syndrome (PCOS)[NCT00682890] | Phase 4 | 28 participants (Actual) | Interventional | 2005-11-30 | Terminated (stopped due to Lack of recruitment) | ||
| Effects of Metformin on the Ovarian Response to Gonadotropins for in Vitro Fertilization Treatment in Patients With Polycystic Ovary Syndrome and Predictors of Poor Ovarian Response[NCT01208740] | Phase 4 | 88 participants (Actual) | Interventional | 2009-01-31 | Terminated (stopped due to Concerns about safety at the first interim analysis) | ||
| Metformin Addition to Gonadotropins Ovarian Stimulation in High Responder Patients With PCOS Undergoing In-vitro Fertilization[NCT01233206] | Phase 4 | 120 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma[NCT02978547] | Phase 2 | 20 participants (Anticipated) | Interventional | 2019-01-31 | Not yet recruiting | ||
| Metformin Pharmacology in Human Cancers[NCT03477162] | Early Phase 1 | 18 participants (Actual) | Interventional | 2018-05-15 | Terminated (stopped due to Enrollment was closed as efforts had become more challenging, and the lab indicated that they were able to obtain their primary objective with the number that had already been enrolled.) | ||
| Assessing the Efficacy and Safety of Metformin in Treatment of Moderate Psoriasis: A Prospective Randomized Double Blind Controlled Study[NCT02644954] | Phase 3 | 40 participants (Anticipated) | Interventional | 2016-01-31 | Not yet recruiting | ||
| [NCT01511822] | Phase 4 | 0 participants | Interventional | Completed | |||
| Reduction of Insulin Therapy Under Myo-inositol for the Treatment of Gestational Diabetes Mellitus: a Randomized Multicenter and Prospective Trial. MYO-GDM Study[NCT03875755] | 1,080 participants (Anticipated) | Interventional | 2020-03-04 | Recruiting | |||
| Role Of Dydrogesterone Towards Oocyte and Embryo Quality in Polycystic Ovarian Syndrome (PCOS)[NCT04175990] | Phase 1 | 155 participants (Actual) | Interventional | 2018-05-10 | Completed | ||
| Effects of Inositol Alone or Associated With Alpha-lipoic Acid in Polycystic Ovary Syndrome Treatment[NCT04881851] | 90 participants (Anticipated) | Interventional | 2015-05-07 | Recruiting | |||
| Effects of Metformin on Fertility and Pregnancy in Women With Polycystic Ovary Syndrome: a Randomized, Prospective, Placebo-controlled Multicenter Study[NCT00994812] | Phase 3 | 326 participants (Actual) | Interventional | 2002-08-31 | Completed | ||
| [NCT01594697] | 60 participants (Actual) | Interventional | Completed | ||||
| PCOS and IVF: A Comparison Between Standard Long Protocol Versus an Antagonist Protocol Starting on Day 1[NCT00883766] | 172 participants (Anticipated) | Interventional | 2009-04-30 | Terminated | |||
| Double-blind, Randomized Clinical Trial to Evaluate Effect of Combination Therapy of Metformin and Sibutramine Versus Metformin or Sibutramine Monotherapy Over Weight, Adiposity, Glucose Metabolism and Inflammatory State in Obese Patients[NCT00941382] | Phase 3 | 60 participants (Anticipated) | Interventional | 2008-11-30 | Active, not recruiting | ||
| Gut-Brain-axis: Targets for Improvement of Cognition in the Elderly[NCT04841668] | 136 participants (Anticipated) | Observational | 2021-04-10 | Recruiting | |||
| Metabolic Syndrome in PCOS: Precursors and Interventions[NCT00442689] | 97 participants (Actual) | Interventional | 2006-07-31 | Completed | |||
| Efficacy and Safety of Furocyst in Patients With Poly Cystic Ovary Syndrome[NCT02789488] | Phase 4 | 50 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| Does Metformin Improve Pregnancy Outcomes (Incidence of LGA (≥90% Birth Weight Centile) Babies, Onset of Maternal GDM, Hypertension, PET, Macrosomia, Shoulder Dystocia, Admission to SCBU) in Obese Non-diabetic Women?[NCT01273584] | Phase 2/Phase 3 | 450 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| Vigorous Exercise Versus Moderate Exercise to Improve Glucose Metabolism and Metabolic Parameters in Women With Polycystic Ovary Syndrome and Insulin Resistance: A Prospective Randomized Pilot Study[NCT02303470] | 47 participants (Actual) | Interventional | 2015-03-31 | Active, not recruiting | |||
| Laparoscopic Ovarian Diathermy or Metformin Plus Clomiphene Citrate Administration as Second-Line Treatment for Infertile Anovulatory Patients With Polycystic Ovary Syndrome: a Randomized Controlled Trial[NCT00558077] | Phase 4 | 50 participants (Actual) | Interventional | 2003-02-28 | Completed | ||
| Descriptive, Transversal Study of Evaluation of Cardiovascular Risks Factors and Prevalence of Metabolic Syndrome in the Different Phenotypes of Women With Polycystic Ovary Syndrome[NCT00784615] | 80 participants (Anticipated) | Observational | 2007-12-31 | Recruiting | |||
| Anxiety and Sexual Malfunction in Infertile Polycystic Ovarian Syndrome Patients[NCT05056272] | 128 participants (Anticipated) | Observational | 2022-01-01 | Recruiting | |||
| The Impact of Continuous Aerobic Exercise and High-Intensity Interval Training on Reproductive Outcomes in Polycystic Ovary Syndrome: A Pilot Randomized Controlled Trial.[NCT03362918] | 60 participants (Actual) | Interventional | 2018-01-01 | Completed | |||
| Adipose Tissue Angiogenesis in Polycystic Ovary Syndrome (PCOS)[NCT01745471] | 36 participants (Anticipated) | Observational | 2012-12-06 | Active, not recruiting | |||
| Clomiphene Citrate Versus Metformin as First-Line Approach for the Treatment of Anovulation in Infertile Patients With Polycystic Ovary Syndrome[NCT00471523] | Phase 4 | 80 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| Efficacy of Long- Versus Short-term Metformin Protocol in Infertile Anovulatory PCOS Patients[NCT00501904] | Phase 4 | 20 participants (Anticipated) | Interventional | 2012-04-30 | Recruiting | ||
| Comparison of Three Different Strategies for Treating Infertility in Anovulatory Women With Polycystic Ovary Syndrome: a Multicentre Randomized Controlled Clinical Trial[NCT00461643] | Phase 4 | 552 participants (Anticipated) | Interventional | 2007-01-31 | Recruiting | ||
| How Long Should First-line Treatment be Continued in Infertile PCOS Patients Who Ovulate Under Clomiphene Citrate? A Randomized Controlled Clinical Study.[NCT00501839] | Phase 4 | 0 participants (Actual) | Interventional | 2008-08-31 | Withdrawn | ||
| What is the Following Step to Improve Fertility in Infertile PCOS Patients Ovulating Under Clomiphene Citrate or Metformin? A Randomized Controlled Clinical Study.[NCT00502229] | Phase 4 | 0 participants (Actual) | Interventional | 2010-01-31 | Withdrawn | ||
| Circulating Anti-mullerian Hormone as Predictor of Ovarian Response to Clomiphene Citrate in Women With Polycystic Ovary Syndrome[NCT03316469] | 40 participants (Anticipated) | Interventional | 2018-07-31 | Not yet recruiting | |||
| Pilot Trial of Bicalutamide Versus Placebo in Reproductive-Aged Women With Nonalcoholic Fatty Liver Disease (NAFLD) and Polycystic Ovary Syndrome (PCOS)[NCT05979389] | Phase 1 | 50 participants (Anticipated) | Interventional | 2023-12-31 | Not yet recruiting | ||
| Letrozole Versus Combined Metformin and Clomiphene Citrate for Ovulation Induction in Clomiphene-Resistant Women With Polycystic Ovary Syndrome[NCT00911313] | 250 participants (Actual) | Interventional | 2006-06-30 | Completed | |||
| Combined Metformin and Clomiphene Citrate Versus Laparoscopic Ovarian Diathermy for Ovulation Induction in Clomiphene-resistant Women With Polycystic Ovary Syndrome[NCT00969631] | 282 participants (Actual) | Interventional | 2005-09-30 | Completed | |||
| N-acetyl Cysteine Plus Clomiphene Citrate Versus Metformin and Clomiphene Citrate in Treatment of Clomiphene-resistant Polycystic Ovary Syndrome[NCT01008046] | 192 participants (Actual) | Interventional | 2007-04-30 | Completed | |||
| Pilot Study on the Effects of Fasting Mimicking Diet (FMD) in Women With Polycystic[NCT05196568] | 100 participants (Anticipated) | Interventional | 2021-07-01 | Active, not recruiting | |||
| PCOS, Sleep Apnea and Metabolic Risk in Women[NCT00696111] | 80 participants (Anticipated) | Interventional | 2007-12-31 | Active, not recruiting | |||
| Assessment of a Peripheral Endothelial Dysfunction in COPD (Chronic Obstructive Pulmonary Disease)[NCT02593357] | 137 participants (Actual) | Interventional | 2012-12-17 | Completed | |||
| Peripheral Endothelial Function in Asthmatic Patients[NCT02593344] | 113 participants (Actual) | Interventional | 2012-12-13 | Completed | |||
| Bioequivalence Study of 2 mg Cyproterone Acetate and 0.035 mg Ethinyl Estradiol in Indonesian Healthy Females[NCT04964193] | 24 participants (Actual) | Interventional | 2019-03-12 | Completed | |||
| The Experience of Living With Polycystic Ovary Syndrome in the Military[NCT03876665] | 24 participants (Actual) | Observational | 2019-08-15 | Completed | |||
| The Effect of Semaglutide Compared to Metformin in Obese Women With Polycystic Ovary Syndrome (PCOS): a Randomised Controlled Study (Semaglutide-PCOS Trial).[NCT05646199] | Phase 2/Phase 3 | 60 participants (Anticipated) | Interventional | 2024-03-01 | Not yet recruiting | ||
| Comparison of the Effects of Monotherapy With Exenatide or Metformin to Combined Exenatide and Metformin Therapy on Menstrual Cyclicity in Overweight Women With Polycystic Ovary Syndrome[NCT00344851] | Phase 2 | 60 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| "Randomized, Double-blind, Placebo-controlled Study to Assess the Effect of Metformin, an Activator of AMPK, on Cognitive Measures of Progression in Huntington's Disease Patients"[NCT04826692] | Phase 3 | 60 participants (Anticipated) | Interventional | 2021-12-10 | Recruiting | ||
| [NCT01626443] | Phase 4 | 46 participants (Actual) | Interventional | 2014-01-31 | Completed | ||
| Pulsatile GnRH in Anovulatory Infertility[NCT00383656] | Phase 2 | 270 participants (Anticipated) | Interventional | 1989-01-31 | Recruiting | ||
| Different Variables Predicting Ovulatory Response Among Clomiphene Citrate Resistance and Clomiphene Citrate Sensitive Patients With Polycystic Ovarian Syndrome.[NCT04887402] | 100 participants (Anticipated) | Observational [Patient Registry] | 2021-01-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Treatment effect on body weight at 24 weeks of treatment (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | kilogram (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 100.4 |
| Dapagliflozin (DAPA) | 102.6 |
| EQW Plus DAPA | 99 |
| Dapagliflozin Plus Glucophage (MET ER) | 101.2 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 97 |
treatment impact on measure of central adiposity as determined by android/gynoid ratio (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | ratio (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 1.07 |
| Dapagliflozin (DAPA) | 1.02 |
| EQW Plus DAPA | 1.04 |
| Dapagliflozin Plus Glucophage (MET ER) | 1.04 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 1.03 |
Treatment efficacy in reducing body mass at 24 weeks of treatment (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | kilogram/meter squared (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 37.3 |
| Dapagliflozin (DAPA) | 37.4 |
| EQW Plus DAPA | 36.7 |
| Dapagliflozin Plus Glucophage (MET ER) | 37 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 35.3 |
Treatment effect on loss of central adiposity after 24 weeks (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | centimeters (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 104 |
| Dapagliflozin (DAPA) | 101 |
| EQW Plus DAPA | 106 |
| Dapagliflozin Plus Glucophage (MET ER) | 101.3 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 97 |
Treatment effect on change in percent body weight from baseline (NCT02635386)
Timeframe: Change from baseline (time 0) to study end (24 weeks)
| Intervention | percentage change in body weight (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 3.8 |
| Dapagliflozin (DAPA) | 1.5 |
| EQW Plus DAPA | 6.9 |
| Dapagliflozin Plus Glucophage (MET ER) | 1.7 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 8.1 |
Treatment effect on insulin secretion from 0 to 30 minutes after glucose load corrected for by fasting insulin sensitivity. A higher score shows improved first phase insulin secretion in response to glucose (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | index score (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 1.03 |
| Dapagliflozin (DAPA) | 0.6 |
| EQW Plus DAPA | 0.91 |
| Dapagliflozin Plus Glucophage (MET ER) | 0.7 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 1.1 |
Treatment effect on blood concentrations of DHEA-S (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | mcg/dL (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 165 |
| Dapagliflozin (DAPA) | 187 |
| EQW Plus DAPA | 169 |
| Dapagliflozin Plus Glucophage (MET ER) | 189 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 201 |
Treatment effect on DBP after 24 weeks (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | mmHg (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 81 |
| Dapagliflozin (DAPA) | 79.8 |
| EQW Plus DAPA | 76 |
| Dapagliflozin Plus Glucophage (MET ER) | 82 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 83.6 |
Treatment impact on fasting concentration of glucose in the blood (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | mg/dL (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 91 |
| Dapagliflozin (DAPA) | 93 |
| EQW Plus DAPA | 86.5 |
| Dapagliflozin Plus Glucophage (MET ER) | 89 |
| Phentermine /Topiramate (PHEN/ TPM ER | 91.4 |
Treatment effect on the ratio HOMA-IR which is insulin resistance measure derived from fasting blood glucose and insulin and is calculated by insulin (mU/ml)*glucose (mmol/L)/22,5. The higher thenumber the more insulin resistant. (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | index score (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 3.7 |
| Dapagliflozin (DAPA) | 3.6 |
| EQW Plus DAPA | 2.6 |
| Dapagliflozin Plus Glucophage (MET ER) | 3.3 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 3.4 |
Treatment effect on FAI calculated from total testosterone divided by sex hormone binding globulin (SHBG) levels. A higher score indicates a worse outcome. (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | index score (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 5.3 |
| Dapagliflozin (DAPA) | 4.7 |
| EQW Plus DAPA | 5.2 |
| Dapagliflozin Plus Glucophage (MET ER) | 5.7 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 5 |
The SI IOGTT is a measure of peripheral insulin sensitivity derived from the values of Insulin (microunits per milliliter) and Glucose (milligrams per deciliter) obtained from the OGTT and the corresponding fasting values. SI (OGTT) = 10,000/ [(G fasting x I fasting) x (G OGTTmean x I OGTTmean)], where fasting glucose and insulin data are taken from time 0 of the OGTT and mean data represent the average glucose and insulin values obtained during the entire OGTT. The square root is used to correct for nonlinear distribution of insulin, and 10,000 is a scaling factor in the equation. The higher value, the more sensitive to insulin. (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | index score (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 3.1 |
| Dapagliflozin (DAPA) | 3.6 |
| EQW Plus DAPA | 3.9 |
| Dapagliflozin Plus Glucophage (MET ER) | 4.8 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 4.7 |
Treatment effect on MBG measured during the oral glucose tolerance test (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | mg/dL (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 118 |
| Dapagliflozin (DAPA) | 126.4 |
| EQW Plus DAPA | 112 |
| Dapagliflozin Plus Glucophage (MET ER) | 119 |
| Phentermine /Topiramate (PHEN/ TPM ER | 113 |
An estimation of β-cell compensatory function, the insulin secretion-sensitivity index (IS-SI) will be derived by applying the concept of the oral disposition index to measurements obtained during the 2-h OGTT and calculated as the index of insulin secretion factored by insulin sensitivity (ΔINS/ΔPG 30 x Matsuda SIOGTT) from the OGTT. A higher score shows improved pancreatic insulin responsiveness relative to resistance. (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | index score (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 471 |
| Dapagliflozin (DAPA) | 311 |
| EQW Plus DAPA | 503 |
| Dapagliflozin Plus Glucophage (MET ER) | 395 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 545 |
Treatment effect on SBP after 24 weeks of treatment (NCT02635386)
Timeframe: 24 weeks treatment
| Intervention | mmHg (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 123.6 |
| Dapagliflozin (DAPA) | 123 |
| EQW Plus DAPA | 122 |
| Dapagliflozin Plus Glucophage (MET ER) | 128 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 124 |
Treatment impact on percent total body fat by DEXA (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | percent fat mass (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 46.1 |
| Dapagliflozin (DAPA) | 46.4 |
| EQW Plus DAPA | 45.8 |
| Dapagliflozin Plus Glucophage (MET ER) | 46.1 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 45.2 |
Treatment effect on blood concentrations of total cholesterol (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | mg/dL (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 189 |
| Dapagliflozin (DAPA) | 186 |
| EQW Plus DAPA | 185 |
| Dapagliflozin Plus Glucophage (MET ER) | 192 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 178 |
Treatment impact on total fat mass by DEXA (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | kilogram (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 47.6 |
| Dapagliflozin (DAPA) | 47.8 |
| EQW Plus DAPA | 45.9 |
| Dapagliflozin Plus Glucophage (MET ER) | 48 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 44.5 |
Treatment effect on blood concentrations of total testosterone (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | ng/dL (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 38.8 |
| Dapagliflozin (DAPA) | 35 |
| EQW Plus DAPA | 42.6 |
| Dapagliflozin Plus Glucophage (MET ER) | 39.5 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 45.5 |
Treatment effect on blood concentrations of triglycerides (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | mg/dL (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 130 |
| Dapagliflozin (DAPA) | 132 |
| EQW Plus DAPA | 112 |
| Dapagliflozin Plus Glucophage (MET ER) | 105 |
| Phentermine /Topiramate (PHEN/ TPM) ER | 110 |
Treatment impact on trunk/limb ratio (measure of central adiposity) by DEXA (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | ratio (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | 1.03 |
| Dapagliflozin (DAPA) | .95 |
| EQW Plus DAPA | .93 |
| Dapagliflozin Plus Glucophage (MET ER) | .98 |
| Phentermine /Topiramate (PHEN/ TPM) ER | .99 |
Treatment impact on WHtR which is a measure of central adiposity (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | ratio (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | .64 |
| Dapagliflozin (DAPA) | .61 |
| EQW Plus DAPA | .65 |
| Dapagliflozin Plus Glucophage (MET ER) | .61 |
| Phentermine /Topiramate (PHEN/ TPM) ER | .59 |
Treatment impact on central adiposity after 24 weeks (NCT02635386)
Timeframe: 24 weeks of treatment
| Intervention | ratio (Mean) |
|---|---|
| Exenatide Once Weekly (EQW ) | .83 |
| Dapagliflozin (DAPA) | .79 |
| EQW Plus DAPA | .86 |
| Dapagliflozin Plus Glucophage (MET ER) | .83 |
| Phentermine /Topiramate (PHEN/ TPM) ER | .81 |
Systolic blood pressure was measured in mmHg. (NCT03151005)
Timeframe: 12 weeks
| Intervention | mmHg (Mean) |
|---|---|
| Metformin-GLP-1 Receptor Agonist | 122.83 |
| Metformin-Oral Contraceptive(OC) | 122.40 |
Alanine transaminase was measured in IU/L. (NCT03151005)
Timeframe: 12 weeks
| Intervention | IU/L (Mean) |
|---|---|
| Metformin-GLP-1 Receptor Agonist | 39.09 |
| Metformin-Oral Contraceptive(OC) | 36.73 |
Changes in testosterone levels were measured (NCT03151005)
Timeframe: 12 weeks
| Intervention | nmol/L (Mean) |
|---|---|
| Metformin-GLP-1 Receptor Agonist | 1.82 |
| Metformin-Oral Contraceptive(OC) | 2.14 |
Concentration of LH was measured in mIU/ml. (NCT03151005)
Timeframe: 12 weeks
| Intervention | mIU/ml (Mean) |
|---|---|
| Metformin-GLP-1 Receptor Agonist | 5.52 |
| Metformin-Oral Contraceptive(OC) | 5.33 |
Weight and height will be combined to report BMI in kg/m^2. (NCT03151005)
Timeframe: 12 weeks
| Intervention | kg/m^2 (Mean) |
|---|---|
| Metformin-GLP-1 Receptor Agonist | 26.26 |
| Metformin-Oral Contraceptive(OC) | 27.12 |
IL-6 and IL-8 levels by ELISA method using commercially available kits. (NCT03117517)
Timeframe: Baseline and after 3 Months
| Intervention | pg/ml (Geometric Mean) | |||
|---|---|---|---|---|
| IL-6 levels at baseline | IL-6 levels after 3 months of treatment | IL-8 Llevels at baseline | IL-8 Llevels after treatment | |
| Metformin | 14.60 | 12.65 | 61.92 | 32.70 |
| Metformin, Pioglitazone | 14.12 | 11.12 | 41.86 | 22.00 |
Serum level of LH was measure at baseline and after 3 months of treatment (NCT03117517)
Timeframe: Baseine and after 3 Months
| Intervention | mIU/ml (Geometric Mean) | |
|---|---|---|
| LH level at baseline | LH level after treatment | |
| Metformin | 5.79 | 4.92 |
| Metformin, Pioglitazone | 6.625 | 5.16 |
Insulin resistance was measure by calculating HOMA-IR from the data of insulin and sugar levels. (NCT03117517)
Timeframe: Baseline and after 3 months
| Intervention | unitless (Mean) | |
|---|---|---|
| HOMA-IR at baseline | HOMA-IR after treatment | |
| Metformin | 7.19 | 3.97 |
| Metformin, Pioglitazone | 6.22 | 3.84 |
Grip strength over time. (NCT03772964)
Timeframe: Day 0 (baseline), 90, and 120 (30 days post metformin exposure)
| Intervention | mmHg (Mean) | ||
|---|---|---|---|
| 0 days | 90 days, compared to 0 days | 120 days, compared to 0 days | |
| 1000mg Exposure | 28.9 | -0.4 | 1.1 |
| 1500mg Exposure | 25.7 | -.2 | .3 |
| 500mg Exposure | 28.2 | -5.3 | .1 |
| Placebo | 25.7 | -.3 | -.6 |
The SPPB is a group of measures that combines the results of the gait speed, chair stand and balance tests. The minimum is zero (worse performance) and the maximum is 12 (best performance). (NCT03772964)
Timeframe: Day 0 (baseline), 90, and 120 (30 days post metformin exposure)
| Intervention | Units on a scale (Mean) | ||
|---|---|---|---|
| 0d | 90d, change from 0d | 120d, change from 0d | |
| 1000mg Exposure | 10.8 | 0.4 | 0.2 |
| 1500mg Exposure | 11.1 | 0.4 | 0.3 |
| 500mg Exposure | 11.2 | -0.3 | 0 |
| Placebo | 10.6 | 1.0 | 0.5 |
Aggregometry area under the curve with the Y-axis being % aggregometry and the X-axis time in minutes. (NCT03772964)
Timeframe: Day 0 (baseline), 30, 60, 90, and 120 (30 days post metformin exposure)
| Intervention | arbitrary units*mins (Mean) | ||||
|---|---|---|---|---|---|
| 0 days | 30 day change from day 0 | 60 days change from day 0 | 90 days change from day 0 | 120 days change from day 0 | |
| 1000mg Exposure | 67 | 8.9 | -23.5 | 2.4 | 1.0 |
| 1500mg Exposure | 196 | -166.7 | -139.8 | -222.5 | -196.7 |
| 500mg Exposure | 56.3 | -34.7 | -28.3 | 1.6 | -49.2 |
| Placebo | 83.3 | -29.6 | -49.4 | -66.6 | -47.6 |
"Bacterial communities using 16S rRNA sequencing in relationship to metformin dosing over time. Species richness or diversity in the sample is measured by Choa1 metric. Chao1 is an estimate of how many species are present in an ecosystem. In general, having more species is considered to be healthier and these values typically range from 100-200 for fecal samples. The Chao1 index over numerous samples across time are explored to understand treatment effects." (NCT03772964)
Timeframe: Day 0 (baseline), 30, 60, 90, and 120 (30 days post metformin exposure)
| Intervention | Index (Mean) | ||||
|---|---|---|---|---|---|
| Day 0 | Day 30 | Day 60 | Day 90 | Day 120 | |
| 1000mg Exposure | 107.6 | 130.7 | 137.9 | 135 | 142.2 |
| 1500mg Exposure | 128.1 | 128.1 | 128.6 | 138.2 | 144.2 |
| 500mg Exposure | 136.5 | 139.9 | 121.4 | 137.8 | 134 |
| Placebo | 141.5 | 144.75 | 134.3 | 152 | 159.2 |
(NCT01909141)
Timeframe: 3 months
| Intervention | mm (Mean) |
|---|---|
| Arm 1:Letrozole-pioglitazone -Metformin Group | 10.56 |
| Arm 2: Clomiphene Citrate-pioglitazone-metformin | 9.68 |
(NCT01909141)
Timeframe: 3 months
| Intervention | follicles (Mean) |
|---|---|
| Arm 1:Letrozole-pioglitazone -Metformin Group | 1.44 |
| Arm 2: Clomiphene Citrate-pioglitazone-metformin | 1.5 |
(NCT01909141)
Timeframe: 3 months
| Intervention | percentage of all cycles (Number) |
|---|---|
| Arm 1:Letrozole-pioglitazone -Metformin Group | 93 |
| Arm 2: Clomiphene Citrate-pioglitazone-metformin | 108 |
(NCT01909141)
Timeframe: 3 months
| Intervention | participants (Number) |
|---|---|
| Arm 1:Letrozole-pioglitazone -Metformin Group | 28 |
| Arm 2: Clomiphene Citrate-pioglitazone-metformin | 24 |
serum creatinine was measured at the end of the study period (after 3 months) in both groups. (NCT01909141)
Timeframe: 3 months
| Intervention | mg/dL (Mean) |
|---|---|
| Arm 1:Letrozole-pioglitazone -Metformin Group | 0.62 |
| Arm 2: Clomiphene Citrate-pioglitazone-metformin | 0.57 |
Height and weight measurements were used to calculate body mass index (BMI), defined as kg/m2. (NCT02022007)
Timeframe: 16 weeks
| Intervention | kg/mg2 (Mean) |
|---|---|
| Metformin XR | 42 |
| Saxagliptin | 36.7 |
| Saxagliptin-Metformin XR | 42 |
Post-treatment fasting glucose levels (NCT02022007)
Timeframe: 16 weeks
| Intervention | mmol/L (Mean) |
|---|---|
| Metformin XR | 5.4 |
| Saxagliptin | 5.3 |
| Saxagliptin-Metformin XR | 5.0 |
Hyperandrogenism is measured by a combination of total testosterone (T) and sex hormone binding globulin (SHBG). The FAI was calculated as the quotient 100 x T/SHBG; hyperandrogenism was defined by a FAI value >3.85. (NCT02022007)
Timeframe: 16 weeks
| Intervention | index (Mean) |
|---|---|
| Metformin XR | 6.3 |
| Saxagliptin | 5.5 |
| Saxagliptin-Metformin XR | 4.3 |
Glucose metabolic secretory status after drug treatment (normal, impaired or diabetic). We used the American Diabetes Association (ADA) definition of impairment which is fasting glucose greater than 100 mg/dL and/or 2 hour glucose greater than 140 mg/dL. (NCT02022007)
Timeframe: 16 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Metformin XR | 3 |
| Saxagliptin | 6 |
| Saxagliptin-Metformin XR | 10 |
Post-treatment insulin sensitivity index. The Matsuda index of whole-body insulin sensitivity is calculated from an oral glucose tolerance test (10,000/square root of [fasting glucose x fasting insulin] x [mean glucose x mean insulin during OGTT]), and is highly correlated with the rate of whole-body glucose disposal during the euglycemic insulin clamp (NCT02022007)
Timeframe: 16 weeks
| Intervention | Index (Mean) |
|---|---|
| Metformin XR | 2.5 |
| Saxagliptin | 3.5 |
| Saxagliptin-Metformin XR | 4.1 |
Post-treatment mean blood glucose levels. Mean blood glucose (MBG) concentrations were calculated by summing glucose values obtained at 0,30,60 and 120 minutes during the OGTT and dividing by 4. (NCT02022007)
Timeframe: 16 weeks
| Intervention | mmol/L (Mean) |
|---|---|
| Metformin XR | 7.9 |
| Saxagliptin | 7.1 |
| Saxagliptin-Metformin XR | 6.2 |
The number of menstrual cycles during the previous year was recorded and the average menstrual interval calculated by dividing 365 by the number of menstrual cycles in the previous year . During the study period, the patients in a menstrual diary recorded vaginal bleeding over 16 weeks. The effects of treatment intervention on menstrual cycle interval was calculated evaluated by dividing 112 days by the number of menstrual cycles recorded in each patient's menstrual cycle diary. (NCT02022007)
Timeframe: 16 weeks
| Intervention | days between menstrual cycles (Mean) |
|---|---|
| Metformin XR | 81 |
| Saxagliptin | 58 |
| Saxagliptin-Metformin XR | 36 |
The safety criteria will include laboratory values for liver enzymes and document the absence of pregnancy in all participants during the trial (NCT02022007)
Timeframe: 16 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Metformin XR | 0 |
| Saxagliptin | 0 |
| Saxagliptin-Metformin XR | 0 |
Post-treatment in insulin-sensitivity-secretion index . The insulin secretion-sensitivity index (IS-SI) provides an estimate of β-cell compensation relative to the prevailing insulin resistance, not absolute insulin secretion. It is derived by applying the concept of the disposition index (DI) to measurements obtained during the 2-h OGTT. The IS-SI, a surrogate measure of the DI derived from the OGTT (IGI multiplied by the SIOGTT], was calculated as the product of acute β-cell response [IGI] and Matsuda index (SIOGTT) based on the existence of the predicted hyperbolic relationship between these two measures (NCT02022007)
Timeframe: 16 weeks
| Intervention | index (Mean) |
|---|---|
| Metformin XR | 208 |
| Saxagliptin | 359 |
| Saxagliptin-Metformin XR | 532 |
Post-treatment corrected early phase insulin secretion index (IGI/HOMA-IR). . Early pancreatic β-cell response is estimated as the insulinogenic index (IGI) derived from the ratio of the increment of insulin to that of glucose 30 minutes after a glucose load (insulin 30 min - insulin 0 min/glucose 30 min - glucose 0 min) corrected for by the relative level of insulin resistance (IGI/HOMA-IR which is estimated by homeostasis model assessment of insulin resistance using fasting insulin and glucose levels). (NCT02022007)
Timeframe: 16 weeks
| Intervention | Ratio (Mean) |
|---|---|
| Metformin XR | 0.46 |
| Saxagliptin | 1.4 |
| Saxagliptin-Metformin XR | 1.03 |
The measure of TRG levels and HDL- cholesterol levels are used as an estimate of insulin sensitivity. A TRG/HDL-C ratio of greater than 3.0 is used as an indirect measure of insulin resistance (NCT02022007)
Timeframe: 16 weeks
| Intervention | Ratio (Mean) |
|---|---|
| Metformin XR | 4.2 |
| Saxagliptin | 2.9 |
| Saxagliptin-Metformin XR | 3.0 |
The circumference measurement was taken in the upright position using a 15-mm width flexible metric tape held close to the body but not tight enough to indent the skin. Waist circumference (WC) was measured in centimeters at the narrowest level midway between the lowest ribs and the iliac crest. (NCT02022007)
Timeframe: 16 weeks
| Intervention | centimeters (Mean) |
|---|---|
| Metformin XR | 109 |
| Saxagliptin | 99.6 |
| Saxagliptin-Metformin XR | 106 |
brachial artery ultrasonography % flow-mediated dilatation (FMD) for assessing endothelial function before and after an insulin clamp to assess insulin's effect on the vasculature (NCT02633488)
Timeframe: before and after 12 weeks on placebo or metformin
| Intervention | percentage of artery dilation (Mean) |
|---|---|
| Pre and Post Placebo 12 Weeks | 6.1 |
| Pre and Post Metformin 12 Weeks | 6.2 |
Change in percent body fat (NCT01881828)
Timeframe: 0-26 weeks
| Intervention | percentage of change (Mean) |
|---|---|
| Metformin | -0 |
| Oral Placebo | 1 |
(NCT01881828)
Timeframe: 0-26 weeks
| Intervention | percentile (Mean) |
|---|---|
| Metformin | -1 |
| Oral Placebo | 1 |
(NCT01881828)
Timeframe: 0-26 weeks
| Intervention | insulin per kg (Mean) |
|---|---|
| Metformin | -0.1 |
| Oral Placebo | -0.0 |
(NCT01881828)
Timeframe: 0-26 weeks
| Intervention | centimeters (Mean) |
|---|---|
| Metformin | -0 |
| Oral Placebo | 1 |
(NCT01881828)
Timeframe: 0-26 weeks
| Intervention | mm Hg (Mean) | |
|---|---|---|
| Change in Systolic | Change in Diastolic | |
| Metformin | 0 | 0 |
| Oral Placebo | -0 | 0 |
Hemoglobin A1c is a measure of glycemic control over approximately the past 3 months (NCT01881828)
Timeframe: 0-26 weeks
| Intervention | percentage (Mean) | |
|---|---|---|
| HbA1c | Change from Baseline to 26 Weeks | |
| Metformin | 9.0 | 0.2 |
| Oral Placebo | 8.9 | 0.2 |
Hemoglobin A1c is a measure of glycemic control over approximately the past 3 months (NCT01881828)
Timeframe: 0-26 weeks
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| HbA1c Decrease ≥0.5% | HbA1c Increase ≥0.5% | HbA1c <7.5% | |
| Metformin | 19 | 44 | 3 |
| Oral Placebo | 18 | 35 | 4 |
(NCT01881828)
Timeframe: 0-26 weeks
| Intervention | mg/dL (Mean) | ||||
|---|---|---|---|---|---|
| Change in LDL | Change in VLDL | Change in HDL | Change in Triglycerides | Change in Total Cholesterol | |
| Metformin | -6 | -0 | -0 | 4 | -5 |
| Oral Placebo | 2 | 1 | -1 | 6 | 3 |
(NCT00151411)
Timeframe: baseline and 6 months
| Intervention | index (Least Squares Mean) |
|---|---|
| Metformin | 1.9 |
| Placebo | -2.7 |
(NCT00151411)
Timeframe: baseline and 6 months
| Intervention | ng/dL (Least Squares Mean) |
|---|---|
| Metformin | -2.1 |
| Placebo | -6.4 |
"Mu-opioid binding potential in left amygdala measured before and after 4 months of Metformin treatment.~Mu-opioid binding potential is measured in vivo with C11-carfentanil positron emission tomography in women with PCOS before and after 4 months of metformin treatment.~Binding Potential is measured by the ratio of Mu-opioid receptor concentration (Bmax)/Receptor radiotracer (C11-carfentanil) affinity (Kd.)" (NCT00670800)
Timeframe: Baseline and after 4 months
| Intervention | ratio (Mean) |
|---|---|
| PCOS Affected Women Pre-Metformin (Baseline) | 2.28 |
| PCOS Affected Women Post-Metformin (After 4 Months) | 2.08 |
| Normal Controls | 2.03 |
"Mu-opioid binding potential in left nucleus accumbens is measured before and after 4 months of Metformin treatment.~Mu-opioid binding potential is measured in vivo with C11-carfentanil positron emission tomography in women with PCOS before and after 4 months of metformin treatment.~Binding Potential is measured by the ratio of Mu-opioid receptor concentration (Bmax)/Receptor radiotracer (C11-carfentanil) affinity (Kd.)~Control group was measured at baseline only." (NCT00670800)
Timeframe: Baseline and after 4 months
| Intervention | ratio (Mean) |
|---|---|
| PCOS Affected Women Pre-Metformin (Baseline) | 1.95 |
| PCOS Affected Women Post-Metformin (After 4 Months) | 1.65 |
| Normal Controls | 1.53 |
"Mu-opioid binding potential in right amygdala measured before and after 4 months of Metformin treatment.~Mu-opioid binding potential is measured in vivo with C11-carfentanil positron emission tomography in women with PCOS before and after 4 months of metformin treatment.~Binding Potential is measured by the ratio of Mu-opioid receptor concentration (Bmax)/Receptor radiotracer (C11-carfentanil) affinity (Kd.)~Control group was measured at baseline only." (NCT00670800)
Timeframe: Baseline and 4 months
| Intervention | ratio (Mean) |
|---|---|
| PCOS Affected Women Pre-Metformin (Baseline) | 2.28 |
| PCOS Affected Women Post-Metformin (After 4 Months) | 2.11 |
| Normal Controls | 2.06 |
"Mu-opioid binding potential in right nucleus accumbens measured before and after 4 months of Metformin treatment.~Mu-opioid binding potential is measured in vivo with C11-carfentanil positron emission tomography in women with PCOS before and after 4 months of metformin treatment.~Binding Potential is measured by the ratio of Mu-opioid receptor concentration (Bmax)/Receptor radiotracer (C11-carfentanil) affinity (Kd.)~Control group was measured at baseline only." (NCT00670800)
Timeframe: Baseline and after 4 months
| Intervention | ratio (Mean) |
|---|---|
| PCOS Affected Women Pre-Metformin (Baseline) | 2.40 |
| PCOS Affected Women Post-Metformin (After 4 Months) | 2.11 |
| Normal Control Women | 2.05 |
Insulin sensitivity as measured by a combination of insulin sensitivity index (ISI) which should go up after 3 month treatment period to show improvement, and insulin sensitivity (SI) which should go down after 3 month treatment period to show improvement. Note that the ISI as developed by Matsuda and DeFronzo from a calculation based on results from a standard oral glucose tolerance test (OGTT) (doi: 10.2337/diacare.22.9.1462 Diabetes Care September 1999 vol. 22 no. 9 1462-1470) is recorded as units on an arbitrary scale. SI data is based on a calculation derived from analysis of results of frequently sampled intravenous glucose tolerance test (FSIVGTT) by Bergman et al (doi:10.1172/JCI112886/J Clin Invest. 1987;79(3):790-800) and is reported with units min-1/(µlU/L). (NCT00682890)
Timeframe: baseline and 3 months
| Intervention | min-1/(µlU/L) (Mean) | ||
|---|---|---|---|
| SI at baseline | SI at 3 months | SI change vs baseline | |
| Metformin | 3.83 | 2.11 | -1.72 |
| Placebo | 2.26 | 2.8 | 0.544 |
Insulin sensitivity as measured by a combination of insulin sensitivity index (ISI) which should go up after 3 month treatment period to show improvement, and insulin sensitivity (SI) which should go down after 3 month treatment period to show improvement. Note that the ISI as developed by Matsuda and DeFronzo from a calculation based on results from a standard oral glucose tolerance test (OGTT) (doi: 10.2337/diacare.22.9.1462 Diabetes Care September 1999 vol. 22 no. 9 1462-1470) is recorded as units on an arbitrary scale. SI data is based on a calculation derived from analysis of results of frequently sampled intravenous glucose tolerance test (FSIVGTT) by Bergman et al (doi:10.1172/JCI112886/J Clin Invest. 1987;79(3):790-800) and is reported with units min-1/(µlU/L). (NCT00682890)
Timeframe: baseline and 3 months
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| ISI at baseline | ISI at month 3 | ISI change vs baseline | |
| Metformin | 7.3 | 5.9 | -1.4 |
| Placebo | 4.7 | 4.4 | -0.3 |
To determine the concentration of metformin in adipose tissue. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/g (Median) |
|---|---|
| Metformin | 70 |
To determine the concentration of metformin in plasma. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/mL (Median) |
|---|---|
| Metformin | 450 |
To determine the concentration of metformin in tumor-adjacent normal tissue. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/g (Median) |
|---|---|
| Metformin | 749 |
To determine the concentration of metformin in whole blood. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/mL (Median) |
|---|---|
| Metformin | 514 |
To determine the intra-tumor concentrations of metformin, with a standard deviation ≤25% of the mean, in patients with solid tumors of thoracic origin administered metformin extended release. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/g (Median) |
|---|---|
| Metformin | 1290 |
Change in disposition index (DI, insulin secretion corrected for insulin secretion) as measured by frequently-sampled IV glucose tolerance test (DI at study endpoint - baseline DI) (NCT00442689)
Timeframe: 6 months
| Intervention | min^-1 (Mean) |
|---|---|
| Oral Contraceptive - 1 | 1653 |
| Flutamide - 2 | 194 |
| Placebo - 3 | -184 |
Change in fat percentage as measured by DEXA scan over the study period (Fat percentage at study endpoint - baseline fat percentage) (NCT00442689)
Timeframe: 6 months
| Intervention | percentage of body mass (Mean) |
|---|---|
| Oral Contraceptive - 1 | 0.4 |
| Flutamide - 2 | -1.9 |
| Placebo - 3 | -1.9 |
Change in high-density lipoprotein (HDL) levels during study period (HDL level at study endpoint - baseline HDL) (NCT00442689)
Timeframe: 6 months
| Intervention | mg/dL (Mean) |
|---|---|
| Oral Contraceptive - 1 | 6 |
| Flutamide - 2 | -5 |
| Placebo - 3 | -2 |
Change in low-density lipoprotein (LDL) levels over the study period (LDL level at study endpoint - baseline LDL level) (NCT00442689)
Timeframe: 6 months
| Intervention | mg/dL (Mean) |
|---|---|
| Oral Contraceptive - 1 | -6 |
| Flutamide - 2 | -9 |
| Placebo - 3 | -7 |
Change in maximal aerobic exercise capacity (VO2 max) over the study period (VO2 max at study endpoint - baseline VO2 max) (NCT00442689)
Timeframe: 6 months
| Intervention | L/min (Mean) |
|---|---|
| Oral Contraceptive - 1 | -0.5 |
| Flutamide - 2 | -1.6 |
| Placebo - 3 | 1.1 |
Change in resting energy expenditure (REE) over the study period (REE at study endpoint - baseline REE) (NCT00442689)
Timeframe: 6 months
| Intervention | Kcal/day (Mean) |
|---|---|
| Oral Contraceptive - 1 | 7 |
| Flutamide - 2 | -79 |
| Placebo - 3 | -88 |
Change in visceral adipose tissue (VAT) volume as measured by MRI (VAT at study endpoint - baseline VAT) (NCT00442689)
Timeframe: 6 months
| Intervention | L (Mean) |
|---|---|
| Oral Contraceptive - 1 | -0.1 |
| Flutamide - 2 | -0.1 |
| Placebo - 3 | 0.1 |
Area Under Curve from 0 to 72 hours (AUCt) (NCT04964193)
Timeframe: before dosing (0 h) and at 15, 30, 45 min, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 15, 24, 36, 48 and 72 hours after dosing
| Intervention | pg*hr/mL (Mean) | |
|---|---|---|
| AUC0-t of Cyproterone Acetate | AUC0-t of Ethinyl Estradiol | |
| Diane-35 Sugar-coated Tablet | 127.54 | 842.56 |
| Elzsa Film-coated Tablet | 132.56 | 870.45 |
Maximum plasma concentration (Cmax) (NCT04964193)
Timeframe: before dosing (0 h) and at 15, 30, 45 min, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 15, 24, 36, 48 and 72 hours after dosing
| Intervention | pg/mL (Mean) | |
|---|---|---|
| Cmax of Cyproterone Acetate | Cmax of Ethinyl Estradiol | |
| Diane-35 Sugar-coated Tablet | 16.20 | 93.61 |
| Elzsa Film-coated Tablet | 17.39 | 103.69 |
379 reviews available for metformin and Polycystic Ovarian Syndrome
| Article | Year |
|---|---|
Gestational metformin administration in women with polycystic ovary syndrome: A systematic review and meta-analysis of randomized control studies.
Topics: Bayes Theorem; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Infant, Newborn; Metformi | 2021 |
Impact of pharmacological interventions on insulin resistance in women with polycystic ovary syndrome: A systematic review and meta-analysis of randomized controlled trials.
Topics: Acarbose; Diabetes Mellitus, Type 2; Exenatide; Female; Humans; Insulin; Insulin Resistance; Metform | 2022 |
Effect of metformin on adiponectin in PCOS: A meta-analysis and a systematic review.
Topics: Adiponectin; Body Mass Index; C-Reactive Protein; Female; Humans; Metformin; Polycystic Ovary Syndro | 2021 |
Effects of Metformin and Exercise in Polycystic Ovary Syndrome: Systematic Review and Meta-Analysis.
Topics: Exercise; Exercise Therapy; Female; Humans; Metformin; Polycystic Ovary Syndrome | 2021 |
Therapeutic efficacy of clomiphene citrate combined with metformin in patients with polycystic ovary syndrome.
Topics: Clomiphene; Female; Fertility Agents, Female; Humans; Infertility, Female; Metformin; Ovulation Indu | 2022 |
Effect of metformin intervention on circulating irisin levels in polycystic ovary syndrome: a systematic review and collaborative meta-analysis.
Topics: Female; Humans; Metformin; Polycystic Ovary Syndrome | 2022 |
Polycystic ovarian syndrome: signs and feedback effects of hyperandrogenism and insulin resistance.
Topics: Androgens; Electron Transport; Feedback, Physiological; Female; Humans; Hyperandrogenism; Hyperinsul | 2022 |
Integrated or Independent Actions of Metformin in Target Tissues Underlying Its Current Use and New Possible Applications in the Endocrine and Metabolic Disorder Area.
Topics: Animals; Antineoplastic Agents; Diabetes Mellitus, Type 2; Female; Gluconeogenesis; Humans; Hypoglyc | 2021 |
Impact of pharmacological interventions on anthropometric indices in women with polycystic ovary syndrome: A systematic review and meta-analysis of randomized controlled trials.
Topics: Acarbose; Body Weight; Female; Humans; Hypoglycemic Agents; Metformin; Orlistat; Pioglitazone; Polyc | 2022 |
Does metformin improve reproduction outcomes for non-obese, infertile women with polycystic ovary syndrome? Meta-analysis and systematic review.
Topics: Clomiphene; Female; Fertility Agents, Female; Humans; Infertility, Female; Live Birth; Metformin; Ov | 2022 |
The use of metformin in women with polycystic ovary syndrome: an updated review.
Topics: Clomiphene; Female; Fertility Agents, Female; Humans; Hypoglycemic Agents; Infertility, Female; Insu | 2022 |
Metformin and Insulin Resistance: A Review of the Underlying Mechanisms behind Changes in GLUT4-Mediated Glucose Transport.
Topics: Animals; Female; Gene Expression; Glucose; Glucose Transport Proteins, Facilitative; Glucose Transpo | 2022 |
Polycystic ovarian syndrome-current pharmacotherapy and clinical implications.
Topics: Acupuncture; Anovulation; Eflornithine; Female; Herbal Medicine; Hirsutism; Humans; Hydroxymethylglu | 2022 |
Metformin: Sex/Gender Differences in Its Uses and Effects-Narrative Review.
Topics: COVID-19 Drug Treatment; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Metfo | 2022 |
Short period-administration of myo-inositol and metformin on hormonal and glycolipid profiles in patients with polycystic ovary syndrome: a systematic review and updated meta-analysis of randomized controlled trials.
Topics: Female; Glycolipids; Humans; Hypoglycemic Agents; Inositol; Metformin; Polycystic Ovary Syndrome; Ra | 2022 |
Impact of pharmacological interventions on biochemical hyperandrogenemia in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomised controlled trials.
Topics: Androgens; Dexamethasone; Female; Flutamide; Humans; Hyperandrogenism; Metformin; Polycystic Ovary S | 2023 |
Efficacy of Myo-inositol on Anthropometric, Metabolic, and Endocrine Outcomes in PCOS Patients: a Meta-analysis of Randomized Controlled Trial.
Topics: Female; Folic Acid; Humans; Inositol; Insulin; Insulin Resistance; Metformin; Polycystic Ovary Syndr | 2022 |
Effect of statins combined or not combined with metformin on polycystic ovary syndrome: A systematic review and meta-analysis.
Topics: Cholesterol; Female; Follicle Stimulating Hormone; Humans; Hydroxymethylglutaryl-CoA Reductase Inhib | 2022 |
Efficacy and safety of metformin in pregnant women with polycystic ovary syndrome: a systematic review with meta-analysis of randomized and non-randomized controlled trials.
Topics: Abortion, Spontaneous; Clinical Trials as Topic; Female; Humans; Hypoglycemic Agents; Infant, Newbor | 2022 |
The effect of medication on serum anti-müllerian hormone (AMH) levels in women of reproductive age: a meta-analysis.
Topics: Anti-Mullerian Hormone; Dehydroepiandrosterone; Female; Gonadotropin-Releasing Hormone; Humans; Metf | 2022 |
Updates on Molecular Targets and Epigenetic-Based Therapies for PCOS.
Topics: Female; Humans; Hyperandrogenism; Infertility; Insulin Resistance; Metformin; Polycystic Ovary Syndr | 2023 |
Polycystic ovary syndrome.
Topics: Female; Humans; Hyperandrogenism; Insulin Resistance; Metformin; Obesity; Polycystic Ovary Syndrome | 2022 |
Gestational diabetes and other adverse pregnancy outcomes in polycystic ovary syndrome.
Topics: Diabetes, Gestational; Female; Humans; Infertility; Metformin; Polycystic Ovary Syndrome; Pregnancy; | 2022 |
Polycystic ovarian syndrome and miscarriage in IVF: systematic revision of the literature and meta-analysis.
Topics: Abortion, Spontaneous; Female; Fertilization in Vitro; Humans; Metformin; Polycystic Ovary Syndrome; | 2023 |
Acupuncture combined with metformin versus metformin alone to improve pregnancy rate in polycystic ovary syndrome: A systematic review and meta-analysis.
Topics: Acupuncture Therapy; Female; Humans; Insulin Resistance; Metformin; Polycystic Ovary Syndrome; Pregn | 2022 |
The Effect of Oral Antidiabetic Drugs on Improving the Endocrine and Metabolic States in Women with Polycystic Ovary Syndrome: A Systematic Review and Network Meta-analysis.
Topics: Bayes Theorem; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucagon-Like Peptide-1 Receptor; Humans; | 2022 |
Effectiveness of inositol, metformin and their combination in women with PCOS undergoing assisted reproduction: systematic review and meta-analysis.
Topics: Female; Humans; Hypoglycemic Agents; Inositol; Live Birth; Metformin; Polycystic Ovary Syndrome; Pre | 2022 |
A systematic review of the uses of metformin in dermatology.
Topics: Acne Vulgaris; Dermatology; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Metformi | 2023 |
Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials.
Topics: Female; Humans; Hypoglycemic Agents; Inositol; Insulins; Metformin; Polycystic Ovary Syndrome; Rando | 2023 |
Major malformations risk following early pregnancy exposure to metformin: a systematic review and meta-analysis.
Topics: Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Pregnancy | 2023 |
Influence of metformin on hyperandrogenism in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized clinical trials.
Topics: Female; Humans; Hyperandrogenism; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Randomi | 2023 |
Oral contraceptives (OCs) in combination with metformin versus OCs alone on metabolism in nonobese polycystic ovary syndrome: A meta-analysis and systematic review of randomized controlled trials.
Topics: Contraceptives, Oral; Female; Humans; Hypoglycemic Agents; Insulin; Metformin; Polycystic Ovary Synd | 2023 |
The effects of first-line pharmacological treatments for reproductive outcomes in infertile women with PCOS: a systematic review and network meta-analysis.
Topics: Abortion, Spontaneous; Clomiphene; Female; Humans; Infertility, Female; Live Birth; Metformin; Netwo | 2023 |
The Effectiveness and Safety of Exenatide Versus Metformin in Patients with Polycystic Ovary Syndrome: A Meta-Analysis of Randomized Controlled Trials.
Topics: Exenatide; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Pregnancy; Pre | 2023 |
Practical considerations for diagnosis and treatment of polycystic ovary syndrome in adolescence - distilling guidelines into clinical practice.
Topics: Adolescent; Adult; Female; Humans; Hyperandrogenism; Life Style; Menstruation Disturbances; Metformi | 2023 |
Effects of myo-inositol vs. metformin on hormonal and metabolic parameters in women with PCOS: a meta-analysis.
Topics: Blood Glucose; Female; Follicle Stimulating Hormone; Humans; Hypoglycemic Agents; Inositol; Metformi | 2023 |
Efficacy of resveratrol in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized clinical trials.
Topics: Female; Humans; Metformin; Polycystic Ovary Syndrome; Randomized Controlled Trials as Topic; Resvera | 2023 |
The effects of metformin on anti-Müllerian hormone levels in patients with polycystic ovary syndrome: a systematic review and meta-analysis.
Topics: Anti-Mullerian Hormone; Databases, Factual; Female; Humans; Metformin; Polycystic Ovary Syndrome; Pu | 2023 |
Position paper of the Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), and the Italian Study Group of Diabetes in pregnancy: Metformin use in pregnancy.
Topics: Child; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Infant | 2023 |
Lights and shadows on the use of metformin in pregnancy: from the preconception phase to breastfeeding and beyond.
Topics: Abortion, Spontaneous; Breast Feeding; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Hum | 2023 |
Statins for women with polycystic ovary syndrome not actively trying to conceive.
Topics: Acne Vulgaris; Contraceptives, Oral; Female; Hirsutism; Humans; Hydroxymethylglutaryl-CoA Reductase | 2023 |
Alpha Lipoic Acid Efficacy in PCOS Treatment: What Is the Truth?
Topics: Antioxidants; Diabetes Mellitus, Type 2; Female; Humans; Inositol; Insulin; Insulin Resistance; Metf | 2023 |
The impact of metformin with or without lifestyle modification versus placebo on polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials.
Topics: Adult; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Life Style; Metformin; Polycystic Ov | 2023 |
Identification of Novel Intronic SNPs in Transporter Genes Associated with Metformin Side Effects.
Topics: Diabetes Mellitus, Type 2; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Introns; | 2023 |
Quantitative risk-benefit profiles of oral contraceptives, insulin sensitizers and antiandrogens for women with polycystic ovary syndrome: A model-based meta-analysis.
Topics: Androgen Antagonists; Androgens; Contraceptives, Oral; Female; Hirsutism; Humans; Hypoglycemic Agent | 2023 |
Comparison of different drug for reducing testosterone levels in women with polycystic ovary syndrome: A systematic review and network meta-analysis.
Topics: Atorvastatin; Female; Humans; Metformin; Network Meta-Analysis; Polycystic Ovary Syndrome; Simvastat | 2023 |
Effects of GLP1RAs on pregnancy rate and menstrual cyclicity in women with polycystic ovary syndrome: a meta-analysis and systematic review.
Topics: Female; Humans; Insulin Resistance; Metformin; Periodicity; Polycystic Ovary Syndrome; Pregnancy; Pr | 2023 |
Comparison of exenatide alone or combined with metformin versus metformin in the treatment of polycystic ovaries: a systematic review and meta-analysis.
Topics: Exenatide; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Pregnancy; Pre | 2023 |
Current and future aspects of several adjunctive treatment strategies in polycystic ovary syndrome.
Topics: Antioxidants; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; I | 2019 |
First-line ovulation induction for polycystic ovary syndrome: an individual participant data meta-analysis.
Topics: Birth Rate; Clomiphene; Female; Fertility Agents, Female; Gonadotropins; Humans; Infertility, Female | 2019 |
Metformin: Up to Date.
Topics: Antineoplastic Agents; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Humans; Hypergl | 2020 |
Controversial association between polycystic ovary syndrome and breast cancer.
Topics: Androgens; Anovulation; Aromatase Inhibitors; Breast Neoplasms; Clomiphene; Contraceptives, Oral, Co | 2019 |
Polycystic ovarian syndrome: Correlation between hyperandrogenism, insulin resistance and obesity.
Topics: Androgens; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; Insulin Resistance; Metformin; Obe | 2020 |
Comparison of the efficacy between NAC and metformin in treating PCOS patients: a meta-analysis.
Topics: Acetylcysteine; Body Mass Index; Female; Follicle Stimulating Hormone; Free Radical Scavengers; Huma | 2020 |
Metformin for ovulation induction (excluding gonadotrophins) in women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Birth Rate; Body Mass Index; Clomiphene; Female; Fertility Agents, Female; Hu | 2019 |
Metformin for ovulation induction (excluding gonadotrophins) in women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Birth Rate; Body Mass Index; Clomiphene; Female; Fertility Agents, Female; Hu | 2019 |
Metformin for ovulation induction (excluding gonadotrophins) in women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Birth Rate; Body Mass Index; Clomiphene; Female; Fertility Agents, Female; Hu | 2019 |
Metformin for ovulation induction (excluding gonadotrophins) in women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Birth Rate; Body Mass Index; Clomiphene; Female; Fertility Agents, Female; Hu | 2019 |
Management of obesity in adolescents with polycystic ovary syndrome.
Topics: Adolescent; Female; Humans; Hyperandrogenism; Insulin Resistance; Life Style; Metformin; Pediatric O | 2020 |
Effects of metformin on blood lipid profiles in nondiabetic adults: a meta-analysis of randomized controlled trials.
Topics: Adult; Cholesterol, HDL; Female; Humans; Lipids; Metformin; Polycystic Ovary Syndrome; Randomized Co | 2020 |
Effects of lifestyle modification in polycystic ovary syndrome compared to metformin only or metformin addition: A systematic review and meta-analysis.
Topics: Biomarkers; Body Weights and Measures; Female; Humans; Hypoglycemic Agents; Infertility, Female; Lif | 2020 |
Metformin therapy in pregnancy [Zastosowanie metforminy w ciąży].
Topics: Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Pr | 2020 |
Current treatment for polycystic ovary syndrome: focus on adolescence.
Topics: Adolescent; Contraceptives, Oral, Hormonal; Female; Gene-Environment Interaction; Humans; Hypoglycem | 2020 |
Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists.
Topics: Drug Therapy, Combination; Female; Glucagon-Like Peptide-1 Receptor; Humans; Incretins; Infertility, | 2020 |
Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists.
Topics: Drug Therapy, Combination; Female; Glucagon-Like Peptide-1 Receptor; Humans; Incretins; Infertility, | 2020 |
Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists.
Topics: Drug Therapy, Combination; Female; Glucagon-Like Peptide-1 Receptor; Humans; Incretins; Infertility, | 2020 |
Obesity, Polycystic Ovary Syndrome, and Infertility: A New Avenue for GLP-1 Receptor Agonists.
Topics: Drug Therapy, Combination; Female; Glucagon-Like Peptide-1 Receptor; Humans; Incretins; Infertility, | 2020 |
Insulin Sensitizers for Improving the Endocrine and Metabolic Profile in Overweight Women With PCOS.
Topics: Adult; Androstenedione; Blood Glucose; Female; Glucagon-Like Peptide-1 Receptor; Hormones; Humans; H | 2020 |
Polycystic ovary syndrome (PCOS) and adolescence: How can we manage it?
Topics: Adolescent; Adult; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Poly | 2020 |
Liraglutide: New Perspectives for the Treatment of Polycystic Ovary Syndrome.
Topics: Adult; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; | 2020 |
Association of Metformin With Pregnancy Outcomes in Women With Polycystic Ovarian Syndrome Undergoing In Vitro Fertilization: A Systematic Review and Meta-analysis.
Topics: Adult; Body Mass Index; Female; Fertilization in Vitro; Humans; Hypoglycemic Agents; Metformin; Midd | 2020 |
The clinical application of metformin in children and adolescents: A short update.
Topics: Adolescent; Child; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Resistanc | 2020 |
Metformin Therapy for Acne in Patients with Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis.
Topics: Acne Vulgaris; Androgen Antagonists; Drug Therapy, Combination; Female; Humans; Metformin; Non-Rando | 2021 |
Endometrial function in women with polycystic ovary syndrome: a comprehensive review.
Topics: Endometrium; Female; Humans; Infertility, Female; Insulin Resistance; Metformin; Polycystic Ovary Sy | 2021 |
Effects of metformin on body weight in polycystic ovary syndrome patients: model-based meta-analysis.
Topics: Body Mass Index; Body Weight; Dose-Response Relationship, Drug; Female; Humans; Hypoglycemic Agents; | 2021 |
Efficacy of simvastatin plus metformin for polycystic ovary syndrome: A meta-analysis of randomized controlled trials.
Topics: Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Randomized Controlled Tri | 2021 |
Lipid Metabolism and Relevant Disorders to Female Reproductive Health.
Topics: Diet, Reducing; Female; Humans; Insulin Resistance; Lipid Metabolism; Metformin; Obesity; Polycystic | 2021 |
Polycystic Ovary Syndrome: A Contemporary Clinical Approach.
Topics: Female; Humans; Hyperandrogenism; Insulin Resistance; Metabolic Syndrome; Metformin; Polycystic Ovar | 2021 |
The Impact of Bariatric Surgery Compared to Metformin Therapy on Pregnancy Outcomes in Patients with Polycystic Ovarian Syndrome: a Systematic Review and Meta-analysis.
Topics: Bariatric Surgery; Female; Humans; Metformin; Polycystic Ovary Syndrome; Pregnancy; Pregnancy Outcom | 2021 |
Metformin turns 62 in pharmacotherapy: Emergence of non-glycaemic effects and potential novel therapeutic applications.
Topics: Animals; Anti-Infective Agents; Antineoplastic Agents; Cardiovascular Diseases; COVID-19; COVID-19 D | 2021 |
Effects of metformin treatment on pregnancy outcomes in patients with polycystic ovary syndrome.
Topics: Female; Humans; Hypoglycemic Agents; Live Birth; Metformin; Polycystic Ovary Syndrome; Pregnancy; Pr | 2021 |
The effect of metformin on homocysteine levels in patients with polycystic ovary syndrome: A systematic review and meta-analysis.
Topics: Female; Folic Acid; Homocysteine; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome | 2021 |
Metformin and health outcomes: An umbrella review of systematic reviews with meta-analyses.
Topics: Body Mass Index; Cardiovascular Diseases; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Fema | 2021 |
Research progress of metformin in gestational diabetes mellitus: a narrative review.
Topics: Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Pr | 2021 |
Biguanides: Species with versatile therapeutic applications.
Topics: Anti-Infective Agents; Antineoplastic Agents; Biguanides; Diabetes Mellitus, Type 2; Female; Humans; | 2021 |
The effects of myo-inositol vs. metformin on the ovarian function in the polycystic ovary syndrome: a systematic review and meta-analysis.
Topics: Female; Fertilization in Vitro; Humans; Hypoglycemic Agents; Inositol; Metformin; Polycystic Ovary S | 2021 |
Metformin does not improve insulin sensitivity over hypocaloric diets in women with polycystic ovary syndrome: a systematic review of 12 studies.
Topics: Blood Glucose; Caloric Restriction; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance | 2021 |
Update on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome.
Topics: Exenatide; Female; Glucagon-Like Peptide-1 Receptor; Heart Disease Risk Factors; Humans; Hypoglycemi | 2021 |
The function of metformin in endometrial receptivity (ER) of patients with polycyclic ovary syndrome (PCOS): a systematic review and meta-analysis.
Topics: Endometrium; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Pregnancy; R | 2021 |
The efficacy and safety of metformin combined with simvastatin in the treatment of polycystic ovary syndrome: A meta-analysis and systematic review.
Topics: Blood Glucose; Cholesterol; Drug Therapy, Combination; Female; Gonadal Steroid Hormones; Humans; Ins | 2021 |
Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis.
Topics: Berberine; Clinical Decision-Making; Female; Humans; Hypoglycemic Agents; Inositol; Insulin; Insulin | 2021 |
The effectiveness and safety of liraglutide in treating overweight/obese patients with polycystic ovary syndrome: a meta-analysis.
Topics: Drug Synergism; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; | 2022 |
Impact of metformin on C-reactive protein levels in women with polycystic ovary syndrome: a meta-analysis.
Topics: Adult; Androgens; C-Reactive Protein; Female; Humans; Metformin; Obesity; Polycystic Ovary Syndrome; | 2017 |
Insulin sensitizers in adolescents with polycystic ovary syndrome.
Topics: Adolescent; Adult; Age Factors; Contraceptives, Oral, Hormonal; Female; Humans; Hypoglycemic Agents; | 2017 |
Insulin and the polycystic ovary syndrome.
Topics: Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Polycystic Ovary Syndro | 2017 |
Insulin and the polycystic ovary syndrome.
Topics: Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Polycystic Ovary Syndro | 2017 |
Insulin and the polycystic ovary syndrome.
Topics: Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Polycystic Ovary Syndro | 2017 |
Insulin and the polycystic ovary syndrome.
Topics: Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Polycystic Ovary Syndro | 2017 |
MANAGEMENT OF ENDOCRINE DISEASE: Polycystic ovary syndrome and nonalcoholic fatty liver disease.
Topics: Female; Humans; Hypoglycemic Agents; Insulin Resistance; Liraglutide; Metformin; Non-alcoholic Fatty | 2017 |
Comparison of the effect between pioglitazone and metformin in treating patients with PCOS:a meta-analysis.
Topics: Blood Glucose; Female; Humans; Hypoglycemic Agents; Metformin; Ovulation; Ovulation Induction; Piogl | 2017 |
Comparison of the effect between pioglitazone and metformin in treating patients with PCOS:a meta-analysis.
Topics: Blood Glucose; Female; Humans; Hypoglycemic Agents; Metformin; Ovulation; Ovulation Induction; Piogl | 2017 |
Comparison of the effect between pioglitazone and metformin in treating patients with PCOS:a meta-analysis.
Topics: Blood Glucose; Female; Humans; Hypoglycemic Agents; Metformin; Ovulation; Ovulation Induction; Piogl | 2017 |
Comparison of the effect between pioglitazone and metformin in treating patients with PCOS:a meta-analysis.
Topics: Blood Glucose; Female; Humans; Hypoglycemic Agents; Metformin; Ovulation; Ovulation Induction; Piogl | 2017 |
Metformin - a new old drug.
Topics: Diabetes Mellitus, Type 2; Female; Glucose; Humans; Insulin Resistance; Liver; Metformin; Polycystic | 2017 |
Therapeutic approach for metabolic disorders and infertility in women with PCOS.
Topics: Androgen Antagonists; Anovulation; Clomiphene; Contraceptives, Oral, Hormonal; Female; Gonadotropins | 2018 |
Metformin: a review of its potential indications.
Topics: Aging; Antineoplastic Agents; Blood Glucose; Cardiotonic Agents; Diabetes Mellitus, Type 2; Female; | 2017 |
Role of metformin for ovulation induction in infertile patients with polycystic ovary syndrome (PCOS): a guideline.
Topics: Comorbidity; Evidence-Based Medicine; Female; Humans; Infertility, Female; Metformin; Ovulation Indu | 2017 |
Medical comorbidity in polycystic ovary syndrome with special focus on cardiometabolic, autoimmune, hepatic and cancer diseases: an updated review.
Topics: Body Mass Index; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Fatty Liver; Femal | 2017 |
Effects of metformin treatment on serum levels of C-reactive protein and interleukin-6 in women with polycystic ovary syndrome: a meta-analysis: A PRISMA-compliant article.
Topics: C-Reactive Protein; Female; Humans; Hypoglycemic Agents; Interleukin-6; Metformin; Patient Outcome A | 2017 |
Effectiveness of myoinositol for polycystic ovary syndrome: a systematic review and meta-analysis.
Topics: Estradiol; Female; Humans; Inositol; Metformin; Polycystic Ovary Syndrome; Randomized Controlled Tri | 2018 |
Ovarian surgery for symptom relief in women with polycystic ovary syndrome.
Topics: Acne Vulgaris; Clomiphene; Female; Gonadotropins; Hirsutism; Humans; Laparoscopy; Letrozole; Menstru | 2017 |
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
Topics: Abortion, Spontaneous; Anovulation; Clomiphene; Female; Humans; Hypoglycemic Agents; Infertility, Fe | 2017 |
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
Topics: Abortion, Spontaneous; Anovulation; Clomiphene; Female; Humans; Hypoglycemic Agents; Infertility, Fe | 2017 |
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
Topics: Abortion, Spontaneous; Anovulation; Clomiphene; Female; Humans; Hypoglycemic Agents; Infertility, Fe | 2017 |
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
Topics: Abortion, Spontaneous; Anovulation; Clomiphene; Female; Humans; Hypoglycemic Agents; Infertility, Fe | 2017 |
Pharmacological and surgical treatment of nonreproductive outcomes in polycystic ovary syndrome: An overview of systematic reviews.
Topics: Contraceptives, Oral, Combined; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; Metformin; Po | 2018 |
The Effect of Metformin Therapy for Preventing Gestational Diabetes Mellitus in Women with Polycystic Ovary Syndrome: A Meta-Analysis.
Topics: Adult; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Metformin; Outcome Assessment, He | 2020 |
Metformin in Pregnancy: Mechanisms and Clinical Applications.
Topics: Adult; Animals; Child; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Insulin; Me | 2018 |
[Polycystic ovary syndrome - current state of knowledge].
Topics: Adult; Clomiphene; Diabetes Mellitus, Type 2; Female; Fertility Agents, Female; Humans; Infertility, | 2018 |
Polycystic ovary syndrome (PCOS) and the accompanying disorders of glucose homeostasis among girls at the time of puberty.
Topics: Adolescent; Diabetes Mellitus, Type 1; Female; Homeostasis; Humans; Hyperinsulinism; Hypoglycemic Ag | 2018 |
Metformin: An Old Drug with New Applications.
Topics: Animals; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Metabolic Syndrome; Metform | 2018 |
Inositol for subfertile women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Administration, Oral; Birth Rate; Clomiphene; Combined Modality Therapy; Fema | 2018 |
[Role of metformin in gynaecology and obstetrics].
Topics: Breast Neoplasms; Diabetes, Gestational; Endometrial Neoplasms; Female; Humans; Hypoglycemic Agents; | 2018 |
Short-term effects of metformin and myo-inositol in women with polycystic ovarian syndrome (PCOS): a meta-analysis of randomized clinical trials.
Topics: Female; Humans; Hypoglycemic Agents; Inositol; Metformin; Off-Label Use; Polycystic Ovary Syndrome; | 2019 |
The Effect of Statins on Levels of Dehydroepiandrosterone (DHEA) in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis.
Topics: Adult; Atorvastatin; China; Dehydroepiandrosterone; Female; Humans; Hydroxymethylglutaryl-CoA Reduct | 2019 |
The effectiveness of metformin, oral contraceptives, and lifestyle modification in improving the metabolism of overweight women with polycystic ovary syndrome: a network meta-analysis.
Topics: Contraceptives, Oral, Hormonal; Diet, Reducing; Female; Humans; Hypoglycemic Agents; Life Style; Met | 2019 |
Long-term effects of prenatal exposure to metformin on the health of children based on follow-up studies of randomized controlled trials: a systematic review and meta-analysis.
Topics: Child; Diabetes, Gestational; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Long Term Adve | 2019 |
Contemporary Management of Polycystic Ovarian Syndrome.
Topics: Androgen Antagonists; Aromatase Inhibitors; Biomarkers; Clomiphene; Contraceptives, Oral, Combined; | 2019 |
Effect of the combined oral contraceptive pill and/or metformin in the management of polycystic ovary syndrome: A systematic review with meta-analyses.
Topics: Contraceptives, Oral, Combined; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syn | 2019 |
GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis.
Topics: Adult; Androgens; Blood Glucose; Female; Glucagon-Like Peptide-1 Receptor; Homeostasis; Humans; Metf | 2019 |
GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis.
Topics: Adult; Androgens; Blood Glucose; Female; Glucagon-Like Peptide-1 Receptor; Homeostasis; Humans; Metf | 2019 |
GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis.
Topics: Adult; Androgens; Blood Glucose; Female; Glucagon-Like Peptide-1 Receptor; Homeostasis; Humans; Metf | 2019 |
GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis.
Topics: Adult; Androgens; Blood Glucose; Female; Glucagon-Like Peptide-1 Receptor; Homeostasis; Humans; Metf | 2019 |
Effect of metformin on ovulation and reproductive outcomes in women with polycystic ovary syndrome: a meta-analysis of randomized controlled trials.
Topics: Clomiphene; Confidence Intervals; Female; Fertility Agents, Female; Humans; Infertility, Female; Liv | 2013 |
Overweight in polycystic ovary syndrome. An update on evidence based advice on diet, exercise and metformin use for weight loss.
Topics: Body Mass Index; Caloric Restriction; Evidence-Based Medicine; Exercise; Female; Humans; Hypoglycemi | 2013 |
The efficacy of metformin in pregnant women with polycystic ovary syndrome: a meta-analysis of clinical trials.
Topics: Clinical Trials as Topic; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; | 2013 |
The efficacy of metformin in pregnant women with polycystic ovary syndrome: a meta-analysis of clinical trials.
Topics: Clinical Trials as Topic; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; | 2013 |
The efficacy of metformin in pregnant women with polycystic ovary syndrome: a meta-analysis of clinical trials.
Topics: Clinical Trials as Topic; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; | 2013 |
The efficacy of metformin in pregnant women with polycystic ovary syndrome: a meta-analysis of clinical trials.
Topics: Clinical Trials as Topic; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; | 2013 |
Interventions for the metabolic dysfunction in polycystic ovary syndrome.
Topics: Diabetes Mellitus; Diet; Dyslipidemias; Exercise; Female; Humans; Hypoglycemic Agents; Metformin; Ob | 2013 |
Efficacy and safety of metformin during pregnancy in women with gestational diabetes mellitus or polycystic ovary syndrome: a systematic review.
Topics: Adult; Clinical Trials as Topic; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Insulin | 2013 |
Cardiovascular risk and subclinical cardiovascular disease in polycystic ovary syndrome.
Topics: Adolescent; Adult; Androstenes; Atherosclerosis; Cardiovascular Diseases; Carotid Intima-Media Thick | 2013 |
Insulin sensitizers in polycystic ovary syndrome.
Topics: Animals; Clomiphene; Diabetes Mellitus, Type 2; Female; Humans; Hyperandrogenism; Hyperinsulinism; I | 2013 |
Adverse effects of the common treatments for polycystic ovary syndrome: a systematic review and meta-analysis.
Topics: Androgen Antagonists; Contraceptives, Oral; Evidence-Based Medicine; Female; Flutamide; Humans; Hypo | 2013 |
Preventing endometrial cancer risk in polycystic ovarian syndrome (PCOS) women: could metformin help?
Topics: Endometrial Hyperplasia; Endometrial Neoplasms; Female; Humans; Metformin; Polycystic Ovary Syndrome | 2014 |
Therapy in endocrine disease: treatment of hirsutism in the polycystic ovary syndrome.
Topics: Androgen Antagonists; Androgens; Bariatric Surgery; Female; Hair Removal; Hirsutism; Humans; Metform | 2014 |
Metformin and gonadotropins for ovulation induction in patients with polycystic ovary syndrome: a systematic review with meta-analysis of randomized controlled trials.
Topics: Birth Rate; Female; Fertility Agents, Female; Gonadotropins; Humans; Infertility, Female; Metformin; | 2014 |
Polycystic ovary syndrome: current status and future perspective.
Topics: Androgens; Disease Management; Female; Humans; Hyperandrogenism; Infertility, Female; Insulin Resist | 2014 |
Metformin, oral contraceptives or both to manage oligo-amenorrhea in adolescents with polycystic ovary syndrome? A clinical review.
Topics: Adolescent; Amenorrhea; Contraceptives, Oral; Female; Humans; Metformin; Polycystic Ovary Syndrome | 2014 |
Endocrine basis for recurrent pregnancy loss.
Topics: Abortion, Habitual; Female; Humans; Hyperinsulinism; Hyperprolactinemia; Hypoglycemic Agents; Lutein | 2014 |
The utility of metformin therapy in reproductive-aged women with polycystic ovary syndrome (PCOS).
Topics: Animals; Clomiphene; Female; Fertility Agents, Female; Humans; Hypoglycemic Agents; Letrozole; Metfo | 2014 |
Polycystic ovary syndrome: reviewing diagnosis and management of metabolic disturbances.
Topics: Adolescent; Female; Humans; Insulin Resistance; Life Style; Menopause; Metabolic Syndrome; Metformin | 2014 |
Direct effects of metformin in the endometrium: a hypothetical mechanism for the treatment of women with PCOS and endometrial carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma; Endometrial Neoplasms; Endometrium; Female; Humans; Metfo | 2014 |
Metformin and other insulin sensitizers in polycystic ovary syndrome.
Topics: Blood Glucose; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Polycyst | 2014 |
Effects of acarbose on polycystic ovary syndrome: a meta-analysis.
Topics: Acarbose; Body Mass Index; Female; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Lipo | 2014 |
Vitamin B12 status in metformin treated patients: systematic review.
Topics: Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome | 2014 |
Effect of metformin intervention during pregnancy on the gestational diabetes mellitus in women with polycystic ovary syndrome: a systematic review and meta-analysis.
Topics: Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Metformin; Multicenter Studies as Topic; | 2014 |
Nonalcoholic fatty liver disease and polycystic ovary syndrome.
Topics: Adiposity; Animals; Caloric Restriction; Comorbidity; Exercise; Female; Humans; Hypoglycemic Agents; | 2014 |
The therapy of insulin resistance in other diseases besides type 2 diabetes.
Topics: Fatty Liver; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Obesity; Polycystic | 2014 |
Effect of metformin on serum interleukin-6 levels in polycystic ovary syndrome: a systematic review.
Topics: Female; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Interleukin-6; Metformin; Pol | 2014 |
Effect of metformin on serum interleukin-6 levels in polycystic ovary syndrome: a systematic review.
Topics: Female; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Interleukin-6; Metformin; Pol | 2014 |
Effect of metformin on serum interleukin-6 levels in polycystic ovary syndrome: a systematic review.
Topics: Female; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Interleukin-6; Metformin; Pol | 2014 |
Effect of metformin on serum interleukin-6 levels in polycystic ovary syndrome: a systematic review.
Topics: Female; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Interleukin-6; Metformin; Pol | 2014 |
[Metformin in pregnancy].
Topics: Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Polycysti | 2014 |
Metformin in women with PCOS, cons.
Topics: Adult; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome | 2015 |
Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome.
Topics: Female; Fertilization in Vitro; Humans; Hyperandrogenism; Hyperinsulinism; Hypoglycemic Agents; Live | 2014 |
Obesity and polycystic ovary syndrome.
Topics: Adipokines; Bariatric Surgery; Combined Modality Therapy; Comorbidity; Diet, Reducing; Exercise Ther | 2015 |
Polycystic ovary syndrome: a review for dermatologists: Part II. Treatment.
Topics: 5-alpha Reductase Inhibitors; Acne Vulgaris; Alopecia; Androgen Antagonists; Contraceptives, Oral, C | 2014 |
Off-label drug use in the treatment of polycystic ovary syndrome.
Topics: Clomiphene; Contraceptives, Oral; Female; Humans; Hypoglycemic Agents; Inositol; Metformin; Off-Labe | 2015 |
Polycystic ovary syndrome and insulin: our understanding in the past, present and future.
Topics: Androgens; Anovulation; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Humans; Hypoglyc | 2015 |
Novel strategies in the management of polycystic ovary syndrome.
Topics: Adult; Clomiphene; Contraceptives, Oral, Combined; Female; Fertility Agents, Female; Fertilization i | 2015 |
An investigation into the therapeutic effects of statins with metformin on polycystic ovary syndrome: a meta-analysis of randomised controlled trials.
Topics: C-Reactive Protein; Cholesterol, LDL; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutar | 2015 |
Combined metformin-clomiphene in clomiphene-resistant polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials.
Topics: Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; Hypoglycemic Agents | 2015 |
Clinical Inquiry: What therapies alleviate symptoms of polycystic ovary syndrome?
Topics: Body Mass Index; Contraceptives, Oral; Diuretics; Female; Humans; Hydroxymethylglutaryl-CoA Reductas | 2015 |
Metformin treatment before and during in vitro fertilization or intracytoplasmic sperm injection in women with polycystic ovary syndrome: summary of a Cochrane review.
Topics: Chi-Square Distribution; Female; Fertility; Fertilization in Vitro; Humans; Hypoglycemic Agents; Inf | 2015 |
Optimal management of polycystic ovary syndrome in adolescence.
Topics: Adolescent; Contraceptives, Oral, Hormonal; Diagnosis, Differential; Disease Management; Female; Hir | 2015 |
Adolescence and polycystic ovary syndrome: current concepts on diagnosis and treatment.
Topics: Adolescent; Androgen Antagonists; Contraceptives, Oral; Female; Hirsutism; Hormones; Humans; Hyperan | 2015 |
A systematic review and meta-analysis of metformin among patients with polycystic ovary syndrome undergoing assisted reproductive technology procedures.
Topics: Abortion, Spontaneous; Adult; Female; Humans; Hypoglycemic Agents; Live Birth; Metformin; Ovarian Hy | 2015 |
The effectiveness and safety of treatments used for polycystic ovarian syndrome management in adolescents: a systematic review and network meta-analysis protocol.
Topics: Adolescent; Androgen Antagonists; Contraceptives, Oral; Diet; Drug Therapy, Combination; Exercise; F | 2015 |
Efficacy of metformin on pregnancy complications in women with polycystic ovary syndrome: a meta-analysis.
Topics: Abortion, Spontaneous; Case-Control Studies; Diabetes, Gestational; Female; Humans; Hypoglycemic Age | 2015 |
Impact of Treatment with Metformin on Adipocytokines in Patients with Polycystic Ovary Syndrome: A Meta-Analysis.
Topics: Adiponectin; Cytokines; Female; Gene Expression Regulation; Humans; Leptin; Metformin; Nicotinamide | 2015 |
[Polycystic ovary syndrome].
Topics: Androgen Antagonists; Anovulation; Combined Modality Therapy; Contraceptives, Oral, Hormonal; Diabet | 2015 |
[Evidence-based therapy of polycystic ovarian syndrome].
Topics: Amenorrhea; Androgen Antagonists; Anovulation; Anti-Obesity Agents; Chorionic Gonadotropin; Contrace | 2015 |
Consensus statement on prevention and detection of ovarian hyperstimulation syndrome.
Topics: Consensus; Cryopreservation; Embryo, Mammalian; Evidence-Based Medicine; Female; Follicle Stimulatin | 2015 |
Treatment strategies for the infertile polycystic ovary syndrome patient.
Topics: Anovulation; Antineoplastic Agents; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, | 2015 |
[Prevention and treatment of the complications of polycystic ovarian syndrome--the significance of evidence-based, interdisciplinary management].
Topics: Biomarkers; Counseling; Dermatology; Diabetes Mellitus, Type 2; Disease Management; Endocrinology; E | 2015 |
[Metformin and the obstetric patient].
Topics: Breast Feeding; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ov | 2015 |
Twenty years of ovulation induction with metformin for PCOS; what is the best available evidence?
Topics: Evidence-Based Practice; Female; Humans; Infertility, Female; Metformin; Ovulation Induction; Polycy | 2016 |
Metabolic syndrome, diet and exercise.
Topics: Bariatric Surgery; Diet; Diet Therapy; Exercise; Exercise Therapy; Female; Humans; Hydroxymethylglut | 2016 |
[Metformin for the treatment of polycystic ovary syndrome].
Topics: Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Polycystic Ovary Syndrome | 2016 |
Treatment Considerations for the Cardiometabolic Signs of Polycystic Ovary Syndrome: A Review of the Literature Since the 2013 Endocrine Society Clinical Practice Guidelines.
Topics: Adolescent; Adult; Cardiovascular Diseases; Estrogen Replacement Therapy; Exercise Therapy; Female; | 2016 |
Endocrine and metabolic characteristics in polycystic ovary syndrome.
Topics: Biomarkers; Female; Hirsutism; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metabolic S | 2016 |
Hepatic manifestations of women with polycystic ovary syndrome.
Topics: Alanine Transaminase; Androgen Antagonists; Aspartate Aminotransferases; Contraceptives, Oral, Hormo | 2016 |
Cellular and Animal Studies: Insights into Pathophysiology and Therapy of PCOS.
Topics: Androgens; Animals; Death Domain Receptor Signaling Adaptor Proteins; Decanoic Acids; Disease Models | 2016 |
Major malformation risk, pregnancy outcomes, and neurodevelopmental outcomes associated with metformin use during pregnancy.
Topics: Abnormalities, Drug-Induced; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Infan | 2016 |
Mono-ovulation in women with polycystic ovary syndrome: a clinical review on ovulation induction.
Topics: Adult; Anovulation; Body Weight; Clomiphene; Female; Fertility Agents, Female; Gonadotropins; Humans | 2016 |
Role of Metformin in Women's Health: Review of Its Current Place in Clinical Practice and Emerging Indications for Future.
Topics: Anticarcinogenic Agents; Clomiphene; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Ferti | 2016 |
Effects of orlistat vs. metformin on weight loss-related clinical variables in women with PCOS: systematic review and meta-analysis.
Topics: Anti-Obesity Agents; Female; Humans; Lactones; Metformin; Obesity, Morbid; Orlistat; Polycystic Ovar | 2016 |
Metformin or Oral Contraceptives for Adolescents With Polycystic Ovarian Syndrome: A Meta-analysis.
Topics: Acne Vulgaris; Adolescent; Body Mass Index; Contraceptives, Oral; Female; Glucose Metabolism Disorde | 2016 |
The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance.
Topics: Anovulation; Aromatase Inhibitors; Clomiphene; Consensus; Female; Fertility Agents, Female; Fertiliz | 2016 |
Effects of metformin on pregnancy outcomes in women with polycystic ovary syndrome: A meta-analysis.
Topics: Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Pregnancy; Pregnancy Outc | 2016 |
Effect of metformin treatment during pregnancy on women with PCOS: a systematic review and meta-analysis.
Topics: Abortion, Spontaneous; Birth Weight; Diabetes, Gestational; Evidence-Based Medicine; Female; Humans; | 2016 |
Effect of metformin treatment during pregnancy on women with PCOS: a systematic review and meta-analysis.
Topics: Abortion, Spontaneous; Birth Weight; Diabetes, Gestational; Evidence-Based Medicine; Female; Humans; | 2016 |
Effect of metformin treatment during pregnancy on women with PCOS: a systematic review and meta-analysis.
Topics: Abortion, Spontaneous; Birth Weight; Diabetes, Gestational; Evidence-Based Medicine; Female; Humans; | 2016 |
Effect of metformin treatment during pregnancy on women with PCOS: a systematic review and meta-analysis.
Topics: Abortion, Spontaneous; Birth Weight; Diabetes, Gestational; Evidence-Based Medicine; Female; Humans; | 2016 |
Metformin: From Research to Clinical Practice.
Topics: Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Metformin; Po | 2016 |
Ovulation induction in polycystic ovary syndrome: Current options.
Topics: Anovulation; Anti-Obesity Agents; Aromatase Inhibitors; Bariatric Surgery; Clomiphene; Diet Therapy; | 2016 |
A comparative systematic review of Yasmin (drospirenone pill) versus standard treatment options for symptoms of polycystic ovary syndrome.
Topics: Androgen Antagonists; Androstenes; Cyproterone Acetate; Female; Humans; Hypoglycemic Agents; Metform | 2017 |
Effect of metformin on clinical, metabolic and endocrine outcomes in women with polycystic ovary syndrome: a meta-analysis of randomized controlled trials.
Topics: Female; Follicle Stimulating Hormone; Humans; Hypoglycemic Agents; Lipoproteins, HDL; Lipoproteins, | 2017 |
Metformin during ovulation induction with gonadotrophins followed by timed intercourse or intrauterine insemination for subfertility associated with polycystic ovary syndrome.
Topics: Coitus; Combined Modality Therapy; Drug Therapy, Combination; Female; Fertility Agents, Female; Fert | 2017 |
[Metformin therapy in polycystic ovary syndrome].
Topics: Clomiphene; Drug Administration Schedule; Drug Therapy, Combination; Female; Fertility Agents, Femal | 2008 |
Drugs in infertility and fetal safety.
Topics: Clomiphene; Estrogens; Female; Fertility Agents, Female; Fetus; Gonadotropins; Humans; Infertility, | 2008 |
Metformin in the treatment of polycystic ovary syndrome.
Topics: Clinical Trials as Topic; Female; Glucose; Humans; Hypoglycemic Agents; Insulin Resistance; Metformi | 2008 |
Clomiphene citrate, metformin or both as first-step approach in treating anovulatory infertility in patients with polycystic ovary syndrome (PCOS): a systematic review of head-to-head randomized controlled studies and meta-analysis.
Topics: Anovulation; Clomiphene; Drug Therapy, Combination; Female; Humans; Infertility, Female; Metformin; | 2009 |
Effect of preconceptional metformin on abortion risk in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials.
Topics: Abortion, Spontaneous; Adult; Algorithms; Female; Humans; Hypoglycemic Agents; Metformin; Ovulation | 2009 |
Use of insulin-sensitizing agents in the treatment of polycystic ovary syndrome.
Topics: Drug Resistance; Female; Glucose Tolerance Test; Health Planning Guidelines; Humans; Hyperinsulinism | 2008 |
The effects of Diane-35 and metformin in treatment of polycystic ovary syndrome: an updated systematic review.
Topics: Algorithms; Androgen Antagonists; Cyproterone Acetate; Drug Combinations; Ethinyl Estradiol; Female; | 2008 |
Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review.
Topics: Anovulation; Cardiovascular Diseases; Endometrial Neoplasms; Endometrium; Evidence-Based Medicine; F | 2009 |
Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review.
Topics: Anovulation; Cardiovascular Diseases; Endometrial Neoplasms; Endometrium; Evidence-Based Medicine; F | 2009 |
Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review.
Topics: Anovulation; Cardiovascular Diseases; Endometrial Neoplasms; Endometrium; Evidence-Based Medicine; F | 2009 |
Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review.
Topics: Anovulation; Cardiovascular Diseases; Endometrial Neoplasms; Endometrium; Evidence-Based Medicine; F | 2009 |
PCOS and infertility.
Topics: Clomiphene; Female; Fertility Agents, Female; Gonadotropin-Releasing Hormone; Humans; Hypoglycemic A | 2008 |
Use of metformin in polycystic ovary syndrome.
Topics: Adolescent; Adult; Clomiphene; Dose-Response Relationship, Drug; Drug Administration Schedule; Femal | 2008 |
The effects of metformin on endogenous androgens and SHBG in women: a systematic review and meta-analysis.
Topics: Androgens; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; | 2009 |
Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome.
Topics: Female; Fertilization in Vitro; Humans; Hyperandrogenism; Hyperinsulinism; Hypoglycemic Agents; Live | 2009 |
PCOS.
Topics: Diabetes Mellitus, Type 2; Flutamide; Hair Removal; Hirsutism; Humans; Metformin; Polycystic Ovary S | 2009 |
WITHDRAWN: Insulin-sensitising drugs for polycystic ovary syndrome.
Topics: Anovulation; Chromans; Female; Humans; Hypoglycemic Agents; Inositol; Metformin; Ovulation Induction | 2009 |
The role of insulin-sensitizing agents in the treatment of polycystic ovary syndrome.
Topics: Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Polycystic Ovary Syndro | 2009 |
The use of metformin in the management of polycystic ovary syndrome and associated anovulatory infertility: the current evidence.
Topics: Anovulation; Female; Humans; Hypoglycemic Agents; Infertility, Female; Metformin; Patient Selection; | 2009 |
Mechanisms involved in metformin action in the treatment of polycystic ovary syndrome.
Topics: Animals; Female; Glucose; Humans; Hypoglycemic Agents; Metformin; Ovulation Induction; Polycystic Ov | 2009 |
Management strategies for ovulation induction in women with polycystic ovary syndrome and known clomifene citrate resistance.
Topics: Acetylcysteine; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bromocriptine; Clomiphene; De | 2009 |
Management strategies for ovulation induction in women with polycystic ovary syndrome and known clomifene citrate resistance.
Topics: Acetylcysteine; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bromocriptine; Clomiphene; De | 2009 |
Management strategies for ovulation induction in women with polycystic ovary syndrome and known clomifene citrate resistance.
Topics: Acetylcysteine; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bromocriptine; Clomiphene; De | 2009 |
Management strategies for ovulation induction in women with polycystic ovary syndrome and known clomifene citrate resistance.
Topics: Acetylcysteine; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bromocriptine; Clomiphene; De | 2009 |
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
Topics: Anovulation; Clomiphene; Female; Humans; Hypoglycemic Agents; Inositol; Metformin; Ovulation Inducti | 2009 |
Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome.
Topics: Female; Humans; Hypoglycemic Agents; Infertility, Female; Insulin Resistance; Metformin; Polycystic | 2010 |
Adipose tissue, metabolic syndrome and polycystic ovary syndrome: from pathophysiology to treatment.
Topics: Adipokines; Adipose Tissue; Animals; Female; Humans; Insulin Resistance; Metabolic Syndrome; Metform | 2009 |
Polycystic ovary syndrome and metabolic comorbidities: therapeutic options.
Topics: Comorbidity; Diabetes Mellitus, Type 2; Female; Humans; Hyperlipidemias; Hypoglycemic Agents; Insuli | 2009 |
Should physicians prescribe metformin to women with polycystic ovary syndrome PCOS?
Topics: Adult; Body Mass Index; Clomiphene; Diabetes Mellitus; Diabetes, Gestational; Female; Fertility Agen | 2010 |
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
Topics: Anovulation; Clomiphene; Female; Humans; Hypoglycemic Agents; Inositol; Insulin Resistance; Live Bir | 2010 |
Best methods for identification and treatment of PCOS.
Topics: Androgens; Aromatase Inhibitors; Clomiphene; Contraceptives, Oral, Hormonal; Diagnosis, Differential | 2010 |
Dehydroepiandrosterone to induce murine models for the study of polycystic ovary syndrome.
Topics: Androgens; Animals; Dehydroepiandrosterone; Disease Models, Animal; Embryo Loss; Female; Humans; Hyp | 2010 |
Hirsutism: Diagnosis and management.
Topics: 5-alpha Reductase Inhibitors; Adrenal Hyperplasia, Congenital; Causality; Contraceptives, Oral; Diag | 2010 |
Fertility treatment in women with polycystic ovary syndrome: a decision analysis of different oral ovulation induction agents.
Topics: Administration, Oral; Adult; Algorithms; Clomiphene; Decision Support Techniques; Drug Combinations; | 2010 |
Type 2 diabetes and cardiovascular disease in polycystic ovary syndrome: what are the risks and can they be reduced?
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Fasting; Female; Glucose Toleranc | 2010 |
Use of metformin in the treatment of polycystic ovary syndrome.
Topics: Adaptation, Psychological; Body Mass Index; Endocrine System; Female; Humans; Hyperandrogenism; Hypo | 2010 |
Insulin-sensitizing agents in the treatment of polycystic ovary syndrome: an update.
Topics: Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Metformin; Pioglitazone; Polycystic | 2010 |
Metformin in polycystic ovary syndrome.
Topics: Cardiovascular Diseases; Female; Humans; Hypoglycemic Agents; Infertility, Female; Metabolic Disease | 2010 |
Metformin vs thiazolidinediones for treatment of clinical, hormonal and metabolic characteristics of polycystic ovary syndrome: a meta-analysis.
Topics: Dehydroepiandrosterone Sulfate; Diarrhea; Female; Humans; Hypoglycemic Agents; Metformin; Nausea; Pi | 2011 |
Use of metformin in pediatric age.
Topics: Adolescent; Antipsychotic Agents; Child; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Fatty | 2011 |
Metformin is a reasonable first-line treatment option for non-obese women with infertility related to anovulatory polycystic ovary syndrome--a meta-analysis of randomised trials.
Topics: Anovulation; Body Mass Index; Clomiphene; Drug Therapy, Combination; Female; Humans; Infertility, Fe | 2011 |
Ovarian drilling for surgical treatment of polycystic ovarian syndrome: a comprehensive review.
Topics: Clomiphene; Female; Humans; Infertility, Female; Laparoscopy; Metformin; Ovary; Ovulation Induction; | 2011 |
Diagnosis and therapy of polycystic ovarian syndrome: results of a survey among German gynecologists with a review on literature.
Topics: Contraceptives, Oral; Diabetes Mellitus; Female; Germany; Glucocorticoids; Health Care Surveys; Huma | 2012 |
Metformin and/or clomiphene do not adversely affect liver or renal function in women with polycystic ovary syndrome.
Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Bilirubin; Clomiphene; Double-Blind Method | 2011 |
Current perspectives of insulin resistance and polycystic ovary syndrome.
Topics: Adipose Tissue; Cardiovascular Diseases; Female; Fertility; Humans; Hypoglycemic Agents; Insulin Res | 2011 |
Statins for women with polycystic ovary syndrome not actively trying to conceive.
Topics: Adult; Atorvastatin; Female; Heptanoic Acids; Hirsutism; Humans; Hydroxymethylglutaryl-CoA Reductase | 2011 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Cellular and molecular mechanisms of metformin: an overview.
Topics: Animals; Cardiovascular System; Circadian Clocks; Diabetic Nephropathies; Female; Humans; Hypoglycem | 2012 |
Pregnancy outcomes and the effect of metformin treatment in women with polycystic ovary syndrome: an overview.
Topics: Abortion, Spontaneous; Diabetes, Gestational; Female; Humans; Hyperandrogenism; Hyperinsulinism; Hyp | 2012 |
Neuroendocrine and endocrine dysfunction in the hyperinsulinemic PCOS patient: the role of metformin.
Topics: Adipokines; Androgens; Endocrine System; Fatty Acids, Nonesterified; Fatty Liver; Female; Hormones; | 2012 |
A systematic review and meta-analysis of randomized controlled trials comparing pioglitazone versus metformin in the treatment of polycystic ovary syndrome.
Topics: Blood Glucose; Body Mass Index; Female; Hirsutism; Humans; Hyperinsulinism; Insulin Resistance; Metf | 2012 |
Is metformin indicated as primary ovulation induction agent in women with PCOS? A systematic review and meta-analysis.
Topics: Clomiphene; Drug Resistance; Drug Therapy, Combination; Female; Humans; Infertility, Female; Live Bi | 2012 |
Metformin in obesity, cancer and aging: addressing controversies.
Topics: Aging; Animals; Body Weight; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Metform | 2012 |
Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
Topics: Anovulation; Clomiphene; Female; Humans; Hypoglycemic Agents; Infertility, Female; Inositol; Insulin | 2012 |
Statin is a reasonable treatment option for patients with Polycystic Ovary Syndrome: a meta-analysis of randomized controlled trials.
Topics: Algorithms; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyp | 2012 |
The treatment of infertility in polycystic ovary syndrome: a brief update.
Topics: Adult; Anovulation; Clomiphene; Evidence-Based Medicine; Female; Fertility Agents, Female; Gonadotro | 2012 |
The effectiveness of metformin ovulation induction treatment in patients with PCOS: a systematic review and meta-analysis.
Topics: Abortion, Spontaneous; Clomiphene; Drug Therapy, Combination; Estrogen Antagonists; Evidence-Based M | 2012 |
The sympathetic nervous system in polycystic ovary syndrome: a novel therapeutic target?
Topics: Animals; Continuous Positive Airway Pressure; Electroacupuncture; Female; Heart Rate; Humans; Insuli | 2012 |
[Treatment of infertility].
Topics: Anovulation; Aromatase Inhibitors; Clomiphene; Female; Fertility Agents, Female; Fertilization in Vi | 2012 |
Status of clomiphene citrate and metformin for infertility in PCOS.
Topics: Clomiphene; Female; Humans; Infertility, Female; Metformin; Ovulation Induction; Polycystic Ovary Sy | 2012 |
Comparative efficacy of thiazolidinediones and metformin for polycystic ovary syndrome.
Topics: Body Mass Index; China; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Polycyst | 2012 |
On the potential of metformin to prevent preterm delivery in women with polycystic ovary syndrome - an epi-analysis.
Topics: Adolescent; Adult; Female; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Polycystic Ovary Syn | 2012 |
Long versus short course treatment with metformin and clomiphene citrate for ovulation induction in women with PCOS.
Topics: Clomiphene; Drug Administration Schedule; Drug Therapy, Combination; Female; Fertility Agents, Femal | 2012 |
Ovulation induction in the management of anovulatory polycystic ovary syndrome.
Topics: Anovulation; Aromatase Inhibitors; Clomiphene; Female; Gonadotropins; Humans; Hypoglycemic Agents; I | 2013 |
Reproductive impact of polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Clomiphene; Female; Fertilization in Vitro; Humans; Infant, Newborn; Infertil | 2012 |
[Therapeutic effect of metformin for clomiphene-resistant infertility patients with polycystic ovary syndrome: a systematic analysis].
Topics: Clomiphene; Drug Resistance; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; In | 2012 |
Metformin: the hidden chronicles of a magic drug.
Topics: Animals; Female; Humans; Hypoglycemic Agents; Inflammation; Male; Metabolic Syndrome; Metformin; Neo | 2013 |
Polycystic ovarian syndrome management options.
Topics: Clomiphene; Contraceptives, Oral, Hormonal; Estrogen Antagonists; Exercise; Female; Humans; Infertil | 2012 |
Evaluation and treatment of anovulatory and unexplained infertility.
Topics: Anovulation; Clomiphene; Diet; Evidence-Based Medicine; Exercise; Female; Fertility Agents, Female; | 2012 |
Effects of metformin in women with polycystic ovary syndrome treated with gonadotrophins for in vitro fertilisation and intracytoplasmic sperm injection cycles: a systematic review and meta-analysis of randomised controlled trials.
Topics: Abortion, Spontaneous; Dinoprostone; Embryo Implantation; Female; Fertility Agents, Female; Fertiliz | 2013 |
PCOS: metabolic impact and long-term management.
Topics: Adolescent; Adult; Antihypertensive Agents; Cardiovascular Diseases; Child; Comorbidity; Diabetes Me | 2012 |
Should patients with polycystic ovarian syndrome be treated with metformin?: an enthusiastic endorsement.
Topics: Contraceptives, Oral; Diabetes Mellitus, Type 2; Female; Glucose Intolerance; Humans; Hypoglycemic A | 2002 |
[When and how should polycystic ovary syndrome be treated?].
Topics: Androgen Antagonists; Contraceptives, Oral, Hormonal; Female; Humans; Hypoglycemic Agents; Infertili | 2001 |
Metformin and polycystic ovary syndrome: a literature review.
Topics: Androgens; Body Mass Index; Female; Hirsutism; Humans; Hypoglycemic Agents; Insulin Resistance; Lipi | 2002 |
Should patients with polycystic ovarian syndrome be treated with metformin?
Topics: Abortion, Spontaneous; Cardiovascular Diseases; Diabetes Mellitus; Female; Humans; Hypoglycemic Agen | 2002 |
Advances in polycystic ovary syndrome treatment: metformin and ovarian diathermy.
Topics: Algorithms; Anovulation; Clomiphene; Combined Modality Therapy; Diathermy; Female; Humans; Hyperinsu | 2002 |
The contentious nature of gestational diabetes: diet, insulin, glyburide and metformin.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Glyburide; Human | 2002 |
Should patients with polycystic ovary syndrome be treated with metformin? Benefits of insulin sensitizing drugs in polycystic ovary syndrome--beyond ovulation induction.
Topics: Androgens; Cardiovascular Diseases; Female; Fertilization in Vitro; Gonadotropins; Humans; Hypoglyce | 2002 |
Common treatment of polycystic ovarian syndrome and major depressive disorder: case report and review.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Drug Therapy, Combinati | 2002 |
Detection of insulin resistance and its treatment in adolescents with polycystic ovary syndrome.
Topics: Adolescent; Blood Glucose; Diabetes Mellitus; Female; Glucose Tolerance Test; Humans; Insulin Resist | 2002 |
A systematic review of the reproductive system effects of metformin in patients with polycystic ovary syndrome.
Topics: Clomiphene; Drug Therapy, Combination; Female; Fertilization in Vitro; Follicle Stimulating Hormone; | 2003 |
Effects of metformin on body mass index, menstrual cyclicity, and ovulation induction in women with polycystic ovary syndrome.
Topics: Body Mass Index; Clomiphene; Diet; Female; Humans; Hypoglycemic Agents; Menotropins; Menstrual Cycle | 2003 |
Metformin for the treatment of polycystic ovary syndrome.
Topics: Clinical Trials as Topic; Clomiphene; Drug Therapy, Combination; Education, Medical, Continuing; Fem | 2003 |
[Insulin resistance and polycystic ovary syndrome].
Topics: Female; Humans; Hyperandrogenism; Hypoglycemic Agents; Infertility, Female; Insulin Resistance; Metf | 2003 |
Metformin use in adolescent with PCOS--an invited editorial from the pediatric endocrinology perspective.
Topics: Adolescent; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome | 2003 |
[Should infertile women with polycystic ovarian syndrome be treated with metformine?].
Topics: Clomiphene; Drug Synergism; Estrogen Antagonists; Female; Fertility Agents, Female; Humans; Hyperand | 2003 |
[Treatment of PCOS without IVF: weight loss, insulin-sensitizing agents].
Topics: Acarbose; Chromans; Enzyme Inhibitors; Female; Glucose Intolerance; Glucosidases; Humans; Hypoglycem | 2003 |
Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome.
Topics: Cardiovascular Diseases; Female; Humans; Hypoglycemic Agents; Metformin; Ovulation; Polycystic Ovary | 2003 |
Insulin sensitizers for polycystic ovary syndrome.
Topics: Chromans; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Polycystic Ovary Syndr | 2003 |
GnRH antagonists for treatment of polycystic ovarian syndrome.
Topics: Female; Gonadotropin-Releasing Hormone; Humans; Menstrual Cycle; Metformin; Polycystic Ovary Syndrom | 2003 |
Metformin and gestational diabetes.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Glucose; Humans; | 2003 |
Key developments in endocrinology.
Topics: Addison Disease; Adjuvants, Immunologic; Dehydroepiandrosterone; Endocrine System Diseases; Female; | 2003 |
Laparoscopic treatment of polycystic ovaries: is it time to relinquish the procedure?
Topics: Coronary Disease; Diabetes Mellitus, Type 2; Female; Gynecologic Surgical Procedures; Humans; Hypogl | 2003 |
The importance of insulin resistance in polycystic ovary syndrome.
Topics: Arteriosclerosis; Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metfor | 2003 |
Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome.
Topics: Anovulation; Chromans; Female; Humans; Hypoglycemic Agents; Inositol; Metformin; Ovulation Induction | 2003 |
Metformin: new understandings, new uses.
Topics: Anti-Obesity Agents; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Fatty Liver; Female; HIV I | 2003 |
Metformin: new understandings, new uses.
Topics: Anti-Obesity Agents; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Fatty Liver; Female; HIV I | 2003 |
Metformin: new understandings, new uses.
Topics: Anti-Obesity Agents; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Fatty Liver; Female; HIV I | 2003 |
Metformin: new understandings, new uses.
Topics: Anti-Obesity Agents; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Fatty Liver; Female; HIV I | 2003 |
Insulin-lowering agents in the management of polycystic ovary syndrome.
Topics: Female; Humans; Insulin; Insulin Resistance; Metformin; Obesity; Polycystic Ovary Syndrome; Pregnanc | 2003 |
Metformin in polycystic ovary syndrome: systematic review and meta-analysis.
Topics: Blood Pressure; Body Weight; Double-Blind Method; Female; Fertility Agents, Female; Humans; Insulin; | 2003 |
Minireview: Up-date management of non responder to clomiphene citrate in polycystic ovary syndrome.
Topics: Anovulation; Chromans; Clomiphene; Drug Resistance; Drug Therapy, Combination; Female; Gynecologic S | 2003 |
[Insulin resistance in polycystic ovary syndrome].
Topics: Adolescent; Adult; Body Mass Index; Cardiovascular Diseases; Chromans; Controlled Clinical Trials as | 2003 |
Metformin in obstetric and gynecologic practice: a review.
Topics: Abortion, Spontaneous; Anovulation; Diabetes Mellitus, Type 2; Female; Gastrointestinal Tract; Human | 2004 |
Treatment of PCOS with metformin and other insulin-sensitizing agents.
Topics: Female; Humans; Hypoglycemic Agents; Inositol Phosphates; Metformin; Polycystic Ovary Syndrome; Poly | 2004 |
Polycystic ovary syndrome--a complex disorder among women.
Topics: Androgen Antagonists; Female; Gonadotropin-Releasing Hormone; Humans; Hypoglycemic Agents; Metformin | 2003 |
Metformin for the treatment of the polycystic ovary syndrome.
Topics: Adolescent; Adult; Amenorrhea; Clinical Trials as Topic; Clomiphene; Diabetes Mellitus, Type 2; Diab | 2004 |
Polycystic ovary syndrome in adolescence--a therapeutic conundrum.
Topics: Adolescent; Female; Humans; Hypoglycemic Agents; Metformin; Obesity; Polycystic Ovary Syndrome | 2004 |
Screening for and treatment of polycystic ovary syndrome in teenagers.
Topics: Adolescent; Combined Modality Therapy; Contraceptives, Oral; Diet; Exercise; Female; Humans; Metform | 2004 |
Metformin therapy and diabetes in pregnancy.
Topics: Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Metformin; Po | 2004 |
Should we continue or stop insulin sensitizing drugs during pregnancy?
Topics: Abortion, Spontaneous; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Metformin; Polycy | 2004 |
Should insulin-sensitizing drugs be used in the treatment of polycystic ovary syndrome?
Topics: Abortion, Spontaneous; Anovulation; Clomiphene; Drug Therapy, Combination; Female; Humans; Hypoglyce | 2004 |
Review of nonsurgical and surgical treatment and the role of insulin-sensitizing agents in the management of infertile women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Drug Resistance; Electrocoagulation; Female; Fertility Agents, Femal | 2004 |
Laparoscopic treatment of polycystic ovaries: is its place diminishing?
Topics: Female; Humans; Hypoglycemic Agents; Laparoscopy; Metformin; Ovary; Polycystic Ovary Syndrome; Pregn | 2004 |
Which treatment options should be used in adolescents with polycystic ovary syndrome?
Topics: Adolescent; Adolescent Health Services; Adult; Androgen Antagonists; Estrogens; Female; Flutamide; H | 2004 |
Endocrine characteristics of polycystic ovary syndrome (PCOS).
Topics: Contraceptives, Oral, Hormonal; Endocrine System; Female; Humans; Metformin; Mineralocorticoid Recep | 2003 |
Insulin resistance and metformin in polycystic ovary syndrome.
Topics: Cardiovascular Diseases; Diabetes Mellitus; Female; Humans; Hyperinsulinism; Hypoglycemic Agents; In | 2004 |
Insulin-sensitizing agents as primary therapy for patients with polycystic ovarian syndrome.
Topics: Clomiphene; Cohort Studies; Female; Fertility Agents, Female; Humans; Hypoglycemic Agents; Infertili | 2004 |
Editorial: Metformin--comparison with other therapies in ovulation induction in polycystic ovary syndrome.
Topics: Female; Humans; Hypoglycemic Agents; Metformin; Ovulation Induction; Polycystic Ovary Syndrome | 2004 |
Current indications for metformin therapy.
Topics: Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin R | 2003 |
Metformin in polycystic ovary syndrome.
Topics: Anovulation; Body Weight; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female; G | 2004 |
Revisit of metformin treatment in polycystic ovarian syndrome.
Topics: Cardiovascular Diseases; Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Insulin Resistance; | 2004 |
Is ovulation induction still a therapeutic problem in patients with polycystic ovary syndrome?
Topics: Aromatase Inhibitors; Clomiphene; Diet; Female; Fertility Agents, Female; Humans; Hypoglycemic Agent | 2004 |
Clinical inquiries. Do insulin-sensitizing drugs increase ovulation rates for women with PCOS?
Topics: Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Ovulation; Polycystic Ovary Synd | 2005 |
Thiazolidinediones for treatment of polycystic ovary syndrome.
Topics: Adult; Chromans; Clinical Trials as Topic; Clomiphene; Contraceptives, Oral; Female; Fertility Agent | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Cardiovascular Diseases; Chromans; Contraceptives, Oral; Diabet | 2005 |
Polycystic ovary syndrome--a management update.
Topics: Contraceptives, Oral; Family Practice; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Inf | 2005 |
Polycystic ovary syndrome.
Topics: Androgen Antagonists; Cyproterone Acetate; Drug Therapy, Combination; Ethinyl Estradiol; Female; Fin | 2004 |
Is metformin therapy for polycystic ovary syndrome safe during pregnancy?
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Anencephaly; Animals; Anophthalmos; Blastocyst; | 2005 |
Metformin treatment of PCOS during adolescence and the reproductive period.
Topics: Adolescent; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studie | 2005 |
[Metformin for the treatment of polycystic ovary syndrome].
Topics: Female; Humans; Hyperinsulinism; Hypoglycemic Agents; Infertility, Female; Insulin Resistance; Metfo | 2005 |
The patient with polycystic ovary syndrome.
Topics: Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Prognosis; Weight Loss | 2005 |
[Polycystic ovary syndrome. New pathophysiological discoveries--therapeutic consequences].
Topics: Contraceptives, Oral; Diabetes Mellitus, Type 2; Female; Genetic Predisposition to Disease; Humans; | 2005 |
Patient-tailored conventional ovulation induction algorithms in anovulatory infertility.
Topics: Algorithms; Anovulation; Clomiphene; Electrocoagulation; Female; Fertilization in Vitro; Follicle St | 2005 |
Insulin resistance in polycystic ovarian disease.
Topics: Cardiovascular Diseases; Female; Follicle Stimulating Hormone; Humans; Hypoglycemic Agents; Inflamma | 2005 |
Insulin-sensitisers in the treatment of polycystic ovary syndrome.
Topics: Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diet; Drug Approval; Exercise; Fema | 2005 |
[Insulin sensitizers in the treatment of polycystic ovary].
Topics: Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Polycystic Ovary Syndrome; Thiaz | 2005 |
Higher-order multiple pregnancy associated with metformin in women with polycystic ovary syndrome: two cases and review of the literature.
Topics: Adult; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; Hypoglycemic | 2006 |
A systematic review and meta-analysis of randomized controlled trials on metformin co-administration during gonadotrophin ovulation induction or IVF in women with polycystic ovary syndrome.
Topics: Adult; Female; Fertilization in Vitro; Gonadotropins; Humans; Metformin; Odds Ratio; Ovulation Induc | 2006 |
[Advance in treatment of polycystic ovary syndrome].
Topics: Androgen Antagonists; Clomiphene; Estrogen Antagonists; Female; Gonadotropins; Humans; Hypoglycemic | 2005 |
Ovulation induction in infertile patients with polycystic ovary syndrome.
Topics: Aromatase Inhibitors; Clomiphene; Decision Trees; Diet; Drug Therapy, Combination; Female; Gonadotro | 2006 |
Polycystic ovary syndrome.
Topics: Cyproterone Acetate; Drug Therapy, Combination; Ethinyl Estradiol; Female; Finasteride; Flutamide; H | 2005 |
Insulin-sensitizing agents in polycystic ovary syndrome.
Topics: Androgen Antagonists; Contraceptives, Oral; Drug Therapy, Combination; Female; Humans; Hypoglycemic | 2006 |
Ovulatory disorders and infertility.
Topics: Anovulation; Clomiphene; Female; Fertility Agents, Female; Glucocorticoids; Gonadotropin-Releasing H | 2006 |
Polycystic ovarian syndrome--prognosis and outcomes.
Topics: Adolescent; Anovulation; Cardiovascular Diseases; Clomiphene; Contraceptives, Oral; Diabetes Mellitu | 2006 |
Prevention of diabetes and cardiovascular disease in women with PCOS: treatment with insulin sensitizers.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Res | 2006 |
Pregnancy complications in PCOS.
Topics: Abortion, Spontaneous; Diabetes, Gestational; Female; Humans; Hyperinsulinism; Hypertension, Pregnan | 2006 |
Polycystic ovary syndrome and metformin in pregnancy.
Topics: Drug Administration Schedule; Female; Humans; Metformin; Ovulation Induction; Polycystic Ovary Syndr | 2006 |
Pregnancy outcome after first-trimester exposure to metformin: a meta-analysis.
Topics: Abnormalities, Drug-Induced; Canada; Comorbidity; Female; Humans; Hypoglycemic Agents; Incidence; Me | 2006 |
Is the addition of metformin efficacious in the treatment of clomiphene citrate-resistant patients with polycystic ovary syndrome? A structured literature review.
Topics: Clomiphene; Drug Combinations; Drug Resistance; Female; Fertility Agents, Female; Humans; Infertilit | 2006 |
Is the addition of metformin efficacious in the treatment of clomiphene citrate-resistant patients with polycystic ovary syndrome? A structured literature review.
Topics: Clomiphene; Drug Combinations; Drug Resistance; Female; Fertility Agents, Female; Humans; Infertilit | 2006 |
Is the addition of metformin efficacious in the treatment of clomiphene citrate-resistant patients with polycystic ovary syndrome? A structured literature review.
Topics: Clomiphene; Drug Combinations; Drug Resistance; Female; Fertility Agents, Female; Humans; Infertilit | 2006 |
Is the addition of metformin efficacious in the treatment of clomiphene citrate-resistant patients with polycystic ovary syndrome? A structured literature review.
Topics: Clomiphene; Drug Combinations; Drug Resistance; Female; Fertility Agents, Female; Humans; Infertilit | 2006 |
Is the addition of metformin efficacious in the treatment of clomiphene citrate-resistant patients with polycystic ovary syndrome? A structured literature review.
Topics: Clomiphene; Drug Combinations; Drug Resistance; Female; Fertility Agents, Female; Humans; Infertilit | 2006 |
Is the addition of metformin efficacious in the treatment of clomiphene citrate-resistant patients with polycystic ovary syndrome? A structured literature review.
Topics: Clomiphene; Drug Combinations; Drug Resistance; Female; Fertility Agents, Female; Humans; Infertilit | 2006 |
Is the addition of metformin efficacious in the treatment of clomiphene citrate-resistant patients with polycystic ovary syndrome? A structured literature review.
Topics: Clomiphene; Drug Combinations; Drug Resistance; Female; Fertility Agents, Female; Humans; Infertilit | 2006 |
Is the addition of metformin efficacious in the treatment of clomiphene citrate-resistant patients with polycystic ovary syndrome? A structured literature review.
Topics: Clomiphene; Drug Combinations; Drug Resistance; Female; Fertility Agents, Female; Humans; Infertilit | 2006 |
Is the addition of metformin efficacious in the treatment of clomiphene citrate-resistant patients with polycystic ovary syndrome? A structured literature review.
Topics: Clomiphene; Drug Combinations; Drug Resistance; Female; Fertility Agents, Female; Humans; Infertilit | 2006 |
Contemporary medical therapy for polycystic ovary syndrome.
Topics: Acne Vulgaris; Adult; Clomiphene; Estrogen Antagonists; Female; Hirsutism; Humans; Hypoglycemic Agen | 2006 |
Polycystic ovary syndrome in adolescents: current and future treatment options.
Topics: Adolescent; Anti-Obesity Agents; Female; Hormones; Humans; Hypoglycemic Agents; Metformin; Polycysti | 2006 |
Use of insulin sensitizing agents in the treatment of polycystic ovary syndrome.
Topics: Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Polycystic Ovary Syndrome; Thiaz | 2006 |
Is metformin a primary ovulatory agent in patients with polycystic ovary syndrome?
Topics: Anovulation; Clinical Trials as Topic; Female; Fertility Agents, Female; Humans; Infertility, Female | 2006 |
Infertility in polycystic ovary syndrome: focus on low-dose gonadotropin treatment.
Topics: Adult; Anovulation; Clomiphene; Female; Gonadotropins; Humans; Infertility, Female; Metformin; Ovula | 2006 |
Lifestyle choices, diet, and insulin sensitizers in polycystic ovary syndrome.
Topics: Age Factors; Alcohol Drinking; Body Weight; Caffeine; Female; Humans; Hypoglycemic Agents; Infertili | 2006 |
Lifestyle choices, diet, and insulin sensitizers in polycystic ovary syndrome.
Topics: Age Factors; Alcohol Drinking; Body Weight; Caffeine; Female; Humans; Hypoglycemic Agents; Infertili | 2006 |
Lifestyle choices, diet, and insulin sensitizers in polycystic ovary syndrome.
Topics: Age Factors; Alcohol Drinking; Body Weight; Caffeine; Female; Humans; Hypoglycemic Agents; Infertili | 2006 |
Lifestyle choices, diet, and insulin sensitizers in polycystic ovary syndrome.
Topics: Age Factors; Alcohol Drinking; Body Weight; Caffeine; Female; Humans; Hypoglycemic Agents; Infertili | 2006 |
Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome.
Topics: Acne Vulgaris; Cardiovascular Diseases; Contraceptives, Oral, Combined; Endometrial Neoplasms; Femal | 2007 |
Metformin versus oral contraceptive pill in polycystic ovary syndrome: a Cochrane review.
Topics: Acne Vulgaris; Adult; Cardiovascular Diseases; Contraceptives, Oral, Combined; Female; Hirsutism; Hu | 2007 |
Metformin before and during pregnancy and lactation in polycystic ovary syndrome.
Topics: Female; Humans; Infant; Lactation; Metformin; Polycystic Ovary Syndrome; Pregnancy; Time Factors | 2007 |
Is metformin the treatment of choice for anovulation in polycystic ovary syndrome?
Topics: Anovulation; Female; Humans; Metformin; Overweight; Polycystic Ovary Syndrome; Risk Reduction Behavi | 2007 |
Metformin and glitazones: do they really help PCOS patients?
Topics: Clinical Trials as Topic; Evidence-Based Medicine; Female; Humans; Hypoglycemic Agents; Metformin; P | 2007 |
Triplet pregnancy after metformin in a woman with polycystic ovary syndrome.
Topics: Adult; Female; Humans; Hypoglycemic Agents; Infertility, Female; Metformin; Polycystic Ovary Syndrom | 2008 |
Polycystic ovary syndrome update in adolescence.
Topics: Adolescent; Algorithms; Androgen Antagonists; Disease Progression; Female; Humans; Hypoglycemic Agen | 2007 |
The management of insulin resistance in polycystic ovary syndrome.
Topics: Female; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Metformin; Models, Biologi | 2007 |
Polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Aromatase Inhibitors; Clomiphene; Female; Fertility Agents, Fem | 2008 |
Managing anovulatory infertility and polycystic ovary syndrome.
Topics: Anovulation; Female; Humans; Hypoglycemic Agents; Infertility, Female; Metformin; Obesity; Ovulation | 2007 |
Obesity and the polycystic ovary syndrome.
Topics: Adrenal Glands; Adult; Androgens; Cardiovascular Diseases; Contraceptives, Oral, Hormonal; Diet; Fem | 2007 |
Metformin and polycystic ovary syndrome.
Topics: Female; Humans; Hyperinsulinism; Insulin Resistance; Metformin; Polycystic Ovary Syndrome | 2007 |
Polycystic ovarian syndrome--prognosis and treatment outcomes.
Topics: Anovulation; Cardiovascular Diseases; Combined Modality Therapy; Contraceptives, Oral; Diabetes Mell | 2007 |
Non-surgical interventions for threatened and recurrent miscarriages.
Topics: Abortion, Habitual; Abortion, Threatened; Antiphospholipid Syndrome; Aspirin; Bed Rest; Chorionic Go | 2007 |
Cardiovascular risk in women with polycystic ovary syndrome.
Topics: Atherosclerosis; Biomarkers; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Exerci | 2007 |
Metformin for the treatment of the polycystic ovary syndrome.
Topics: Adult; Cholesterol, LDL; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Obesity | 2008 |
Metformin beyond diabetes: new life for an old drug.
Topics: Anti-Obesity Agents; Blood Glucose; Diabetes Mellitus, Type 2; Fatty Liver; Female; Humans; Hypoglyc | 2006 |
Diagnosis and new approaches in the therapy of gestational diabetes mellitus.
Topics: Blood Glucose; Diabetes, Gestational; Female; Fetal Development; Fetus; Glyburide; Humans; Hypoglyce | 2006 |
Emerging concepts in the medical and surgical treatment of obesity.
Topics: Adipose Tissue; Amyloid; Anticonvulsants; Antidepressive Agents; Anxiety; Appetite Regulation; Baria | 2008 |
Long versus short course treatment with Metformin and Clomiphene Citrate for ovulation induction in women with PCOS.
Topics: Clomiphene; Drug Administration Schedule; Drug Therapy, Combination; Female; Fertility Agents, Femal | 2008 |
Ovulation induction in polycystic ovary syndrome.
Topics: Adult; Anovulation; Aromatase Inhibitors; Body Mass Index; Clomiphene; Diathermy; Female; Fertility | 2008 |
Medical therapy in women with polycystic ovarian syndrome before and during pregnancy and lactation.
Topics: Adult; Clomiphene; Diabetes, Gestational; Drug Therapy, Combination; Female; Fertility Agents, Femal | 2008 |
Role of metformin in patients with polycystic ovary syndrome: the state of the art.
Topics: Clomiphene; Comorbidity; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Fertility Age | 2008 |
[AMPK: a link between metabolism and reproduction?].
Topics: Adenylate Kinase; Adipokines; Animals; Energy Metabolism; Female; Ghrelin; Gonadal Steroid Hormones; | 2008 |
Outlook: metformin use in infertile patients with polycystic ovary syndrome: an evidence-based overview.
Topics: Female; Gonadotropins; Humans; Hypoglycemic Agents; Infertility, Female; Insulin Resistance; Meta-An | 2008 |
Drug insight: insulin-sensitizing drugs in the treatment of polycystic ovary syndrome--a reappraisal.
Topics: Clomiphene; Female; Fertility Agents, Female; Humans; Hyperandrogenism; Infertility; Insulin Resista | 2008 |
Drug insight: insulin-sensitizing drugs in the treatment of polycystic ovary syndrome--a reappraisal.
Topics: Clomiphene; Female; Fertility Agents, Female; Humans; Hyperandrogenism; Infertility; Insulin Resista | 2008 |
Drug insight: insulin-sensitizing drugs in the treatment of polycystic ovary syndrome--a reappraisal.
Topics: Clomiphene; Female; Fertility Agents, Female; Humans; Hyperandrogenism; Infertility; Insulin Resista | 2008 |
Drug insight: insulin-sensitizing drugs in the treatment of polycystic ovary syndrome--a reappraisal.
Topics: Clomiphene; Female; Fertility Agents, Female; Humans; Hyperandrogenism; Infertility; Insulin Resista | 2008 |
Use of metformin in polycystic ovary syndrome: a meta-analysis.
Topics: Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; Hypoglycemic Agents | 2008 |
Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications.
Topics: Adrenal Glands; Androgens; Anovulation; Chromans; Diazoxide; Female; Humans; Hyperinsulinism; Hypogl | 1997 |
Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications.
Topics: Adrenal Glands; Androgens; Anovulation; Chromans; Diazoxide; Female; Humans; Hyperinsulinism; Hypogl | 1997 |
Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications.
Topics: Adrenal Glands; Androgens; Anovulation; Chromans; Diazoxide; Female; Humans; Hyperinsulinism; Hypogl | 1997 |
Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications.
Topics: Adrenal Glands; Androgens; Anovulation; Chromans; Diazoxide; Female; Humans; Hyperinsulinism; Hypogl | 1997 |
Treatment of hyperinsulinaemia in polycystic ovary syndrome?
Topics: Chromans; Diazoxide; Female; Humans; Hyperinsulinism; Hypoglycemic Agents; Metformin; Polycystic Ova | 1998 |
Attenuation of hyperinsulinemia in polycystic ovary syndrome: what are the options?
Topics: Chromans; Female; Humans; Hyperinsulinism; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome | 1998 |
Insulin-lowering therapeutic modalities for polycystic ovary syndrome.
Topics: Female; Glucose Intolerance; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin; Insulin Secretio | 1999 |
Insulin resistance, polycystic ovary syndrome and metformin.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Res | 1999 |
[Diagnosis and treatment of polycystic ovary syndrome].
Topics: Anovulation; Clomiphene; Diagnosis, Differential; Female; Humans; Hyperinsulinism; Insulin Resistanc | 1999 |
Correction of hyperinsulinemia in oligoovulatory women with clomiphene-resistant polycystic ovary syndrome: a review of therapeutic rationale and reproductive outcomes.
Topics: Clomiphene; Drug Resistance; Female; Humans; Hyperinsulinism; Hypoglycemic Agents; Metformin; Ovulat | 2000 |
Insulin-lowering medications in polycystic ovary syndrome.
Topics: Diazoxide; Female; Humans; Hyperandrogenism; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistanc | 2000 |
Induction of ovulation in infertile women with hyperandrogenism and insulin resistance.
Topics: Acanthosis Nigricans; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; Infertility, Female; In | 2000 |
The polycystic ovary syndrome: treatment with insulin sensitizing agents.
Topics: Chromans; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Obesity; Ovar | 1999 |
Polycystic ovary syndrome and ovulation induction.
Topics: Clomiphene; Female; Fertility Agents, Female; Humans; Hypoglycemic Agents; Metformin; Ovulation Indu | 2001 |
Metformin therapy in the management of polycystic ovary syndrome: endocrine, metabolic and reproductive effects.
Topics: Endocrine System; Female; Humans; Hyperandrogenism; Hyperinsulinism; Hypoglycemic Agents; Menstrual | 2001 |
Use of metformin in polycystic ovary syndrome.
Topics: Female; Humans; Hypoglycemic Agents; Menstruation Disturbances; Metformin; Polycystic Ovary Syndrome | 2001 |
Strategies for the use of insulin-sensitizing drugs to treat infertility in women with polycystic ovary syndrome.
Topics: Algorithms; Clomiphene; Female; Fertility Agents, Female; Humans; Hypoglycemic Agents; Infertility, | 2002 |
Polycystic ovary syndrome in adolescents.
Topics: Adolescent; Anovulation; Diabetes Mellitus, Type 2; Diagnosis, Differential; Female; Glucose Intoler | 2002 |
Polycystic ovary syndrome: not ovarian, not simple, unkind.
Topics: Female; Humans; Metformin; Polycystic Ovary Syndrome | 2002 |
Should patients with polycystic ovarian syndrome be treated with metformin? A note of cautious optimism.
Topics: Anovulation; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Gastrointestin | 2002 |
[Polycystic ovary syndrome: treatment with insulin-sensitizing agents].
Topics: Androgens; Chromans; Female; Hirsutism; Humans; Hypoglycemic Agents; Insulin Resistance; Luteinizing | 2002 |
Optimizing ovulation induction in women with polycystic ovary syndrome.
Topics: Clinical Trials as Topic; Clomiphene; Female; Fertility Agents, Female; Humans; Metformin; Ovulation | 2002 |
Polycystic ovary syndrome. Long term sequelae and management.
Topics: Adult; Blood Glucose; Cardiovascular Diseases; Contraceptives, Oral; Diabetes Mellitus, Type 2; Diag | 2002 |
In support of metformin use in adolescent polycystic ovary syndrome.
Topics: Adolescent; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Treatment Out | 2002 |
Metformin in adolescents with polycystic ovary syndrome: opposed.
Topics: Adolescent; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Treatment Out | 2002 |
Metformin: an update.
Topics: Animals; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Huma | 2002 |
452 trials available for metformin and Polycystic Ovarian Syndrome
| Article | Year |
|---|---|
Maternal PCOS status and metformin in pregnancy: Steroid hormones in 5-10 years old children from the PregMet randomized controlled study.
Topics: Child; Female; Glucose; Homeostasis; Humans; Male; Metformin; Polycystic Ovary Syndrome; Pregnancy; | 2021 |
Myoinositol
Topics: Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone; Humans; Inositol; Metformin; Ovarian | 2022 |
Analysis of Unani coded formulation on the hormonal parameters of patients with polycystic ovarian syndrome.
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Antioxidants; Cinnamomum zeylanicum; Female; Flax; Foll | 2021 |
The effect of metformin and myoinositol on metabolic outcomes in women with polycystic ovary syndrome: role of body mass and adiponectin in a randomized controlled trial.
Topics: Adiponectin; Adult; Blood Glucose; Body Composition; Body Mass Index; Female; Gonadal Steroid Hormon | 2022 |
Efficacy of canagliflozin versus metformin in women with polycystic ovary syndrome: A randomized, open-label, noninferiority trial.
Topics: Adolescent; Adult; Canagliflozin; China; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resis | 2022 |
Short-term combined treatment with exenatide and metformin for overweight/obese women with polycystic ovary syndrome.
Topics: Exenatide; Female; Humans; Metformin; Obesity; Overweight; Polycystic Ovary Syndrome | 2021 |
Short-term combined treatment with exenatide and metformin for overweight/obese women with polycystic ovary syndrome.
Topics: Exenatide; Female; Humans; Metformin; Obesity; Overweight; Polycystic Ovary Syndrome | 2021 |
Short-term combined treatment with exenatide and metformin for overweight/obese women with polycystic ovary syndrome.
Topics: Exenatide; Female; Humans; Metformin; Obesity; Overweight; Polycystic Ovary Syndrome | 2021 |
Short-term combined treatment with exenatide and metformin for overweight/obese women with polycystic ovary syndrome.
Topics: Exenatide; Female; Humans; Metformin; Obesity; Overweight; Polycystic Ovary Syndrome | 2021 |
Efficacy of Bushen Huatan Decoction combined with Baduanjin in the treatment of polycystic ovary syndrome with insulin resistance (IR-PCOS), kidney deficiency and phlegm dampness: study protocol for a randomized controlled trial.
Topics: Female; Humans; Insulin; Insulin Resistance; Kidney; Metabolic Syndrome; Metformin; Polycystic Ovary | 2021 |
[Effects of orlistat and metformin on metabolism and gonadal function in overweight or obese patients with polycystic ovary syndrome].
Topics: Body Mass Index; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Obesity; Orlist | 2021 |
Effect of acupuncture and metformin on insulin sensitivity in women with polycystic ovary syndrome and insulin resistance: a three-armed randomized controlled trial.
Topics: Acupuncture Therapy; Diabetes Mellitus, Type 2; Female; Humans; Insulin; Insulin Resistance; Male; M | 2022 |
Hyperandrogenism and menstrual imbalance are the best predictors of metformin response in PCOS patients.
Topics: Adult; Biomarkers, Pharmacological; Blood Glucose; Female; Humans; Hyperandrogenism; Hypoglycemic Ag | 2022 |
Metformin exposure, maternal PCOS status and fetal venous liver circulation: A randomized, placebo-controlled study.
Topics: Adult; Double-Blind Method; Female; Fetus; Humans; Liver Circulation; Metformin; Polycystic Ovary Sy | 2022 |
Sitagliptin/metformin improves the fertilization rate and embryo quality in polycystic ovary syndrome patients through increasing the expression of GDF9 and BMP15: A new alternative to metformin (a randomized trial).
Topics: Bone Morphogenetic Protein 15; Female; Fertilization; Growth Differentiation Factor 9; Humans; Lepti | 2022 |
Thyroid Status During Pregnancy in Women With Polycystic Ovary Syndrome and the Effect of Metformin.
Topics: Diabetes, Gestational; Female; Humans; Hypothyroidism; Metformin; Pilot Projects; Polycystic Ovary S | 2022 |
Thyroid Status During Pregnancy in Women With Polycystic Ovary Syndrome and the Effect of Metformin.
Topics: Diabetes, Gestational; Female; Humans; Hypothyroidism; Metformin; Pilot Projects; Polycystic Ovary S | 2022 |
Thyroid Status During Pregnancy in Women With Polycystic Ovary Syndrome and the Effect of Metformin.
Topics: Diabetes, Gestational; Female; Humans; Hypothyroidism; Metformin; Pilot Projects; Polycystic Ovary S | 2022 |
Thyroid Status During Pregnancy in Women With Polycystic Ovary Syndrome and the Effect of Metformin.
Topics: Diabetes, Gestational; Female; Humans; Hypothyroidism; Metformin; Pilot Projects; Polycystic Ovary S | 2022 |
Efficacy of Bariatric Surgery in the Treatment of Women With Obesity and Polycystic Ovary Syndrome.
Topics: Adolescent; Adult; Bariatric Surgery; Female; Humans; Metformin; Obesity; Polycystic Ovary Syndrome; | 2022 |
Effect of aerobic exercise on inflammatory markers in polycystic ovary syndrome: a randomized controlled trial.
Topics: Biomarkers; C-Reactive Protein; Exercise; Female; Humans; Inflammation; Interleukin-6; Metformin; Po | 2022 |
Effect of metformin and exenatide on pregnancy rate and pregnancy outcomes in overweight or obese infertility PCOS women: long-term follow-up of an RCT.
Topics: Exenatide; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Infertility, Female; Metformin; O | 2022 |
A Prospective Cohort Study of Metformin as an Adjuvant Therapy for Infertile Women With Endometrial Complex Hyperplasia/Complex Atypical Hyperplasia and Their Subsequent Assisted Reproductive Technology Outcomes.
Topics: Endometrial Hyperplasia; Female; Humans; Hyperplasia; Infertility, Female; Metformin; Polycystic Ova | 2022 |
Effect of sodium alginate supplementation on weight management and reproductive hormones in polycystic females.
Topics: Adult; Alginates; Blood Glucose; Body Mass Index; Dietary Fiber; Dietary Supplements; Estrogens; Fem | 2022 |
Effect of metformin versus metformin plus liraglutide on gonadal and metabolic profiles in overweight patients with polycystic ovary syndrome.
Topics: Female; Follicle Stimulating Hormone; Glucose; Humans; Liraglutide; Metabolome; Metformin; Obesity; | 2022 |
Effect of probiotics combined with metformin on improvement of menstrual and metabolic patterns in women with polycystic ovary syndrome: a randomized clinical trial.
Topics: Female; Humans; Hypoglycemic Agents; Menstruation; Metformin; Polycystic Ovary Syndrome; Probiotics | 2022 |
Canagliflozin combined with metformin versus metformin monotherapy for endocrine and metabolic profiles in overweight and obese women with polycystic ovary syndrome: A single-center, open-labeled prospective randomized controlled trial.
Topics: Adolescent; Adult; Blood Glucose; Canagliflozin; Female; Humans; Insulin; Insulin Resistance; Metabo | 2022 |
Treatment with combined resveratrol and myoinositol ameliorates endocrine, metabolic alterations and perceived stress response in women with PCOS: a double-blind randomized clinical trial.
Topics: Adiponectin; Adult; Female; Follicle Stimulating Hormone; Humans; Inositol; Insulin; Luteinizing Hor | 2023 |
Cangfudaotan decoction inhibits mitochondria-dependent apoptosis of granulosa cells in rats with polycystic ovarian syndrome.
Topics: Animals; Apoptosis; Female; Granulosa Cells; Humans; Metformin; Mitochondria; Polycystic Ovary Syndr | 2022 |
Cangfudaotan decoction inhibits mitochondria-dependent apoptosis of granulosa cells in rats with polycystic ovarian syndrome.
Topics: Animals; Apoptosis; Female; Granulosa Cells; Humans; Metformin; Mitochondria; Polycystic Ovary Syndr | 2022 |
Cangfudaotan decoction inhibits mitochondria-dependent apoptosis of granulosa cells in rats with polycystic ovarian syndrome.
Topics: Animals; Apoptosis; Female; Granulosa Cells; Humans; Metformin; Mitochondria; Polycystic Ovary Syndr | 2022 |
Cangfudaotan decoction inhibits mitochondria-dependent apoptosis of granulosa cells in rats with polycystic ovarian syndrome.
Topics: Animals; Apoptosis; Female; Granulosa Cells; Humans; Metformin; Mitochondria; Polycystic Ovary Syndr | 2022 |
Effects of half-dose spiomet treatment in girls with early puberty and accelerated bone maturation: a multicenter, randomized, placebo-controlled study protocol.
Topics: Adiponectin; Female; Humans; Hypoglycemic Agents; Metformin; Multicenter Studies as Topic; Polycysti | 2023 |
Circulating follistatin concentrations in adolescent PCOS: Divergent effects of randomized treatments.
Topics: Adolescent; Cyproterone Acetate; Diabetes Mellitus, Type 2; Female; Follistatin; Humans; Hypoglycemi | 2023 |
Comparative evaluation of metformin & sitaformin in classic PCOS patients undergoing intracytoplasmic sperm injection: A randomized controlled pilot study.
Topics: Female; Humans; Insulin; Male; Metformin; Pilot Projects; Polycystic Ovary Syndrome; Semen; Sperm In | 2023 |
Probiotic vs. placebo and metformin: probiotic dietary intervention in polycystic ovary syndrome - A randomized controlled trial.
Topics: Double-Blind Method; Female; Humans; Metformin; Polycystic Ovary Syndrome; Probiotics | 2023 |
A randomized controlled trial comparing myoinositol with metformin versus metformin monotherapy in polycystic ovary syndrome.
Topics: Female; Humans; Hypoglycemic Agents; Inositol; Insulin; Insulin Resistance; Metformin; Polycystic Ov | 2023 |
Short-term effect of beinaglutide combined with metformin versus metformin alone on weight loss and metabolic profiles in obese patients with polycystic ovary syndrome: a pilot randomized trial.
Topics: Female; Humans; Insulin Resistance; Metformin; Obesity; Pilot Projects; Polycystic Ovary Syndrome; W | 2023 |
SPIOMET4HEALTH-efficacy, tolerability and safety of lifestyle intervention plus a fixed dose combination of spironolactone, pioglitazone and metformin (SPIOMET) for adolescent girls and young women with polycystic ovary syndrome: study protocol for a mult
Topics: Adolescent; Carotid Intima-Media Thickness; Clinical Trials, Phase II as Topic; Female; Humans; Insu | 2023 |
Maternal serum levels of prokineticin-1 related to pregnancy complications and metformin use in women with polycystic ovary syndrome: a post hoc analysis of two prospective, randomised, placebo-controlled trials.
Topics: Female; Gastrointestinal Hormones; Humans; Hyperandrogenism; Hypoglycemic Agents; Infant, Newborn; M | 2023 |
Impaired Respiratory Function in Women With PCOS Compared With Matched Controls From a Population-Based Study.
Topics: Adult; Asthma; Case-Control Studies; Cohort Studies; Female; Follow-Up Studies; Humans; Metformin; P | 2020 |
Impaired Respiratory Function in Women With PCOS Compared With Matched Controls From a Population-Based Study.
Topics: Adult; Asthma; Case-Control Studies; Cohort Studies; Female; Follow-Up Studies; Humans; Metformin; P | 2020 |
Impaired Respiratory Function in Women With PCOS Compared With Matched Controls From a Population-Based Study.
Topics: Adult; Asthma; Case-Control Studies; Cohort Studies; Female; Follow-Up Studies; Humans; Metformin; P | 2020 |
Impaired Respiratory Function in Women With PCOS Compared With Matched Controls From a Population-Based Study.
Topics: Adult; Asthma; Case-Control Studies; Cohort Studies; Female; Follow-Up Studies; Humans; Metformin; P | 2020 |
Therapeutic effects of dimethyldiguanide combined with clomifene citrate in the treatment of polycystic ovary syndrome.
Topics: Adult; Cervix Mucus; Clomiphene; Drug Therapy, Combination; Endometrium; Female; Fertility Agents, F | 2019 |
Treatment with Metformin and Combination of Metformin Plus Pioglitazone on Serum Levels of IL-6 and IL-8 in Polycystic Ovary Syndrome: A Randomized Clinical Trial.
Topics: Adult; Biomarkers; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypoglycemic Agents | 2019 |
Metformin induces lipid changes on sphingolipid species and oxidized lipids in polycystic ovary syndrome women.
Topics: Female; Humans; Metformin; Oxidation-Reduction; Oxidative Stress; Polycystic Ovary Syndrome; Sphingo | 2019 |
Coadministration of metformin or spironolactone enhances efficacy of rosiglitazone in management of PCOS.
Topics: Adolescent; Adult; Drug Synergism; Drug Therapy, Combination; Female; Humans; Hyperandrogenism; Indi | 2020 |
Comparing the individual effects of metformin and rosiglitazone and their combination in obese women with polycystic ovary syndrome: a randomized controlled trial.
Topics: Adult; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Insulin Re | 2020 |
Low Circulating Levels of miR-451a in Girls with Polycystic Ovary Syndrome: Different Effects of Randomized Treatments.
Topics: Adolescent; Biomarkers; Contraceptives, Oral; Drug Therapy, Combination; Female; Humans; Hypoglycemi | 2020 |
Effect of Metformin on Microvascular Endothelial Function in Polycystic Ovary Syndrome.
Topics: Adult; Endothelium, Vascular; Female; Humans; Hypoglycemic Agents; Manometry; Metformin; Polycystic | 2019 |
Cognitive function in metformin exposed children, born to mothers with PCOS - follow-up of an RCT.
Topics: Adult; Child; Child, Preschool; Cognition; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; I | 2020 |
Differential Impact of Insulin Sensitizers vs. Anti-Androgen on Serum Leptin Levels in Vitamin D Replete PCOS Women: A Six Month Open Labeled Randomized Study.
Topics: Adult; Blood Glucose; Female; Humans; Insulin; Insulin Resistance; Leptin; Metformin; Pioglitazone; | 2020 |
Reduced circulating levels of chemokine CXCL14 in adolescent girls with polycystic ovary syndrome: normalization after insulin sensitization.
Topics: Adipocytes; Adipogenesis; Adipose Tissue, Brown; Adolescent; Arrhythmias, Cardiac; Biomarkers; Chemo | 2020 |
Pioglitazone Metformin Complex Improves Polycystic Ovary Syndrome Comorbid Psychological Distress via Inhibiting NLRP3 Inflammasome Activation: A Prospective Clinical Study.
Topics: Adult; Anxiety; Comorbidity; Depression; Female; Humans; Inflammasomes; Metformin; NLR Family, Pyrin | 2020 |
Changes in peripheral mitochondrial DNA copy number in metformin-treated women with polycystic ovary syndrome: a longitudinal study.
Topics: Adolescent; Adult; Body Mass Index; DNA Copy Number Variations; DNA, Mitochondrial; Female; Humans; | 2020 |
Sustained Maternal Hyperandrogenism During PCOS Pregnancy Reduced by Metformin in Non-obese Women Carrying a Male Fetus.
Topics: Adult; Androgens; Body Mass Index; Female; Fetal Blood; Fetus; Humans; Hyperandrogenism; Male; Metfo | 2020 |
Impact of myoinositol with metformin and myoinositol alone in infertile PCOS women undergoing ovulation induction cycles - randomized controlled trial.
Topics: Adult; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Infertility, Female; Inositol | 2021 |
Exenatide, Metformin, or Both for Prediabetes in PCOS: A Randomized, Open-label, Parallel-group Controlled Study.
Topics: Adolescent; Adult; Blood Glucose; China; Drug Therapy, Combination; Exenatide; Female; Glucose Intol | 2021 |
Adding Combined Oral Contraceptives or Metformin to Laser Treatment in Polycystic Ovarian Syndrome Hirsute Patients.
Topics: Administration, Oral; Adolescent; Adult; Combined Modality Therapy; Contraceptives, Oral, Combined; | 2021 |
The relative deficit of GDF15 in adolescent girls with PCOS can be changed into an abundance that reduces liver fat.
Topics: Adolescent; Adult; Case-Control Studies; Child; Fatty Liver; Female; Growth Differentiation Factor 1 | 2021 |
Therapeutic Effect of Curcumin in Women with Polycystic Ovary Syndrome Receiving Metformin: A Randomized Controlled Trial.
Topics: Blood Glucose; Curcumin; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin | 2021 |
Therapeutic effects of puerarin on polycystic ovary syndrome: A randomized trial in Chinese women.
Topics: Administration, Oral; Adolescent; Adult; China; Cholesterol; Cyproterone Acetate; Drug Administratio | 2021 |
Acetyl-L-Carnitine Ameliorates Metabolic and Endocrine Alterations in Women with PCOS: A Double-Blind Randomized Clinical Trial.
Topics: Acetylcarnitine; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Polycy | 2021 |
Acetyl-L-Carnitine Ameliorates Metabolic and Endocrine Alterations in Women with PCOS: A Double-Blind Randomized Clinical Trial.
Topics: Acetylcarnitine; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Polycy | 2021 |
Acetyl-L-Carnitine Ameliorates Metabolic and Endocrine Alterations in Women with PCOS: A Double-Blind Randomized Clinical Trial.
Topics: Acetylcarnitine; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Polycy | 2021 |
Acetyl-L-Carnitine Ameliorates Metabolic and Endocrine Alterations in Women with PCOS: A Double-Blind Randomized Clinical Trial.
Topics: Acetylcarnitine; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Polycy | 2021 |
Exenatide, Dapagliflozin, or Phentermine/Topiramate Differentially Affect Metabolic Profiles in Polycystic Ovary Syndrome.
Topics: Adolescent; Adult; Benzhydryl Compounds; Blood Glucose; Drug Therapy, Combination; Exenatide; Female | 2021 |
Add on DPP-4 inhibitor alogliptin alone or in combination with pioglitazone improved β-cell function and insulin sensitivity in metformin treated PCOS.
Topics: Adult; Body Mass Index; Cohort Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitor | 2017 |
Comparison of myo-inositol and metformin on clinical, metabolic and genetic parameters in polycystic ovary syndrome: A randomized controlled clinical trial.
Topics: Adolescent; Adult; C-Reactive Protein; Cytokines; Female; Gene Expression; Humans; Inositol; Interle | 2017 |
Comparison of metformin and N-acetyl cysteine, as an adjuvant to clomiphene citrate, in clomiphene-resistant women with polycystic ovary syndrome.
Topics: Acetylcysteine; Adjuvants, Pharmaceutic; Adult; Clomiphene; Drug Administration Schedule; Drug Resis | 2017 |
Endocannabinoid receptor blockade reduces alanine aminotransferase in polycystic ovary syndrome independent of weight loss.
Topics: Alanine Transaminase; Anti-Obesity Agents; Body Mass Index; Cannabinoid Receptor Antagonists; Case-C | 2017 |
Normalizing Ovulation Rate by Preferential Reduction of Hepato-Visceral Fat in Adolescent Girls With Polycystic Ovary Syndrome.
Topics: Adolescent; Body Mass Index; Contraceptives, Oral, Combined; Drug Combinations; Ethinyl Estradiol; F | 2017 |
The Pharmacogenetics of Metformin in Women with Polycystic Ovary Syndrome: A Randomized Trial.
Topics: Adult; Ataxia Telangiectasia Mutated Proteins; Biomarkers; Blood Glucose; Contraceptives, Oral, Horm | 2018 |
Combined oral contraceptives plus spironolactone compared with metformin in women with polycystic ovary syndrome: a one-year randomized clinical trial.
Topics: Adult; Contraceptives, Oral, Combined; Drug Administration Schedule; Female; Hirsutism; Humans; Hypo | 2017 |
Comparison of myo-inositol and metformin on mental health parameters and biomarkers of oxidative stress in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Anxiety; Biomarkers; Depression; Double-Blind Method; Female; Humans; Hypoglycemic Agents; In | 2018 |
Clomiphene citrate combined with metformin versus letrozole for induction of ovulation in clomiphene-resistant polycystic ovary syndrome: a randomized clinical trial.
Topics: Adult; Clomiphene; Female; Fertility Agents, Female; Humans; Letrozole; Metformin; Nitriles; Ovulati | 2018 |
Fetal Growth and Birth Anthropometrics in Metformin-Exposed Offspring Born to Mothers With PCOS.
Topics: Adult; Birth Weight; Double-Blind Method; Female; Fetal Development; Humans; Infant, Newborn; Metfor | 2018 |
The Efficacy of 24-Month Metformin for Improving Menses, Hormones, and Metabolic Profiles in Polycystic Ovary Syndrome.
Topics: Adult; Anthropometry; Body Mass Index; Drug Administration Schedule; Female; Humans; Hypoglycemic Ag | 2018 |
Comparison of glycemic control and β-cell function in new onset T2DM patients with PCOS of metformin and saxagliptin monotherapy or combination treatment.
Topics: Adamantane; Adult; Age of Onset; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; D | 2018 |
Metformin Use in PCOS Pregnancies Increases the Risk of Offspring Overweight at 4 Years of Age: Follow-Up of Two RCTs.
Topics: Body Mass Index; Child, Preschool; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypoglyce | 2018 |
Metformin Use in PCOS Pregnancies Increases the Risk of Offspring Overweight at 4 Years of Age: Follow-Up of Two RCTs.
Topics: Body Mass Index; Child, Preschool; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypoglyce | 2018 |
Metformin Use in PCOS Pregnancies Increases the Risk of Offspring Overweight at 4 Years of Age: Follow-Up of Two RCTs.
Topics: Body Mass Index; Child, Preschool; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypoglyce | 2018 |
Metformin Use in PCOS Pregnancies Increases the Risk of Offspring Overweight at 4 Years of Age: Follow-Up of Two RCTs.
Topics: Body Mass Index; Child, Preschool; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypoglyce | 2018 |
Effect of Metformin Alone Compared with Metformin Plus Simvastatin on Polycystic Ovarian Syndrome in Pakistani Women.
Topics: Adolescent; Adult; Drug Therapy, Combination; Female; Follicle Stimulating Hormone; Humans; Hydroxym | 2018 |
Impact of Metformin on IVF Outcomes in Overweight and Obese Women With Polycystic Ovary Syndrome: A Randomized Double-Blind Controlled Trial.
Topics: Adult; Double-Blind Method; Female; Fertilization in Vitro; Humans; Hypoglycemic Agents; Infertility | 2019 |
Effect of Diane-35, alone or in combination with orlistat or metformin in Chinese polycystic ovary syndrome patients.
Topics: Adipose Tissue; Adult; Androgen Antagonists; Androgens; Cyproterone Acetate; Drug Combinations; Ethi | 2018 |
Effect of 12-month treatment with metformin and/or oral contraceptives on health-related quality of life in polycystic ovary syndrome.
Topics: Adolescent; Adult; Contraceptives, Oral, Hormonal; Female; Humans; Hypoglycemic Agents; Metformin; P | 2018 |
Does Metformin Treatment During Pregnancy Modify the Future Metabolic Profile in Women With PCOS?
Topics: Adult; Blood Glucose; Blood Pressure; Body Mass Index; Female; Follow-Up Studies; Humans; Hypoglycem | 2018 |
Does Metformin Treatment During Pregnancy Modify the Future Metabolic Profile in Women With PCOS?
Topics: Adult; Blood Glucose; Blood Pressure; Body Mass Index; Female; Follow-Up Studies; Humans; Hypoglycem | 2018 |
Does Metformin Treatment During Pregnancy Modify the Future Metabolic Profile in Women With PCOS?
Topics: Adult; Blood Glucose; Blood Pressure; Body Mass Index; Female; Follow-Up Studies; Humans; Hypoglycem | 2018 |
Does Metformin Treatment During Pregnancy Modify the Future Metabolic Profile in Women With PCOS?
Topics: Adult; Blood Glucose; Blood Pressure; Body Mass Index; Female; Follow-Up Studies; Humans; Hypoglycem | 2018 |
Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study.
Topics: Adult; Drug Therapy, Combination; Female; Fertilization in Vitro; Humans; Hypoglycemic Agents; Infer | 2018 |
Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study.
Topics: Adult; Drug Therapy, Combination; Female; Fertilization in Vitro; Humans; Hypoglycemic Agents; Infer | 2018 |
Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study.
Topics: Adult; Drug Therapy, Combination; Female; Fertilization in Vitro; Humans; Hypoglycemic Agents; Infer | 2018 |
Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study.
Topics: Adult; Drug Therapy, Combination; Female; Fertilization in Vitro; Humans; Hypoglycemic Agents; Infer | 2018 |
The effects of different therapeutic modalities on cardiovascular risk factors in women with polycystıc ovary syndrome: A randomızed controlled study.
Topics: Adult; Androstenes; Apolipoproteins B; Blood Glucose; C-Reactive Protein; Cardiovascular Diseases; D | 2018 |
Long-term effects of combined simvastatin and metformin treatment on the clinical abnormalities and ovulation dysfunction in single young women with polycystic ovary syndrome.
Topics: Adolescent; Anticholesteremic Agents; Double-Blind Method; Drug Therapy, Combination; Female; Humans | 2018 |
Doppler analysis of ovarian stromal blood flow changes after treatment with metformin versus ethinyl estradiol-cyproterone acetate in women with polycystic ovarian syndrome: A randomized controlled trial.
Topics: Adult; Androgen Antagonists; Androgens; Body Mass Index; Contraceptives, Oral, Combined; Cyproterone | 2019 |
Comparison of myo-inositol and metformin on glycemic control, lipid profiles, and gene expression related to insulin and lipid metabolism in women with polycystic ovary syndrome: a randomized controlled clinical trial.
Topics: Adolescent; Adult; Blood Glucose; Female; Gene Expression; Humans; Hypoglycemic Agents; Inositol; In | 2019 |
Acupuncture or metformin to improve insulin resistance in women with polycystic ovary syndrome: study protocol of a combined multinational cross sectional case-control study and a randomised controlled trial.
Topics: Acupuncture Therapy; Blood Glucose; Case-Control Studies; China; Combined Modality Therapy; Cross-Se | 2019 |
Comparison of metformin plus myoinositol vs metformin alone in PCOS women undergoing ovulation induction cycles: randomized controlled trial.
Topics: Adult; Birth Rate; Drug Synergism; Drug Therapy, Combination; Female; Fertility Agents, Female; Fert | 2019 |
[Effect of Qilin Pill Combined Metformin on Polycystic Ovaries Induced Infertility Patients].
Topics: Drugs, Chinese Herbal; Female; Humans; Hypoglycemic Agents; Infertility, Female; Luteinizing Hormone | 2016 |
Towards a circulating marker of hepato-visceral fat excess: S100A4 in adolescent girls with polycystic ovary syndrome - Evidence from randomized clinical trials.
Topics: Adolescent; Adult; Biomarkers; Body Mass Index; Contraceptives, Oral; Drug Therapy, Combination; Fem | 2019 |
Randomised controlled trial to study the efficacy of exercise with and without metformin on women with polycystic ovary syndrome.
Topics: Adult; Body Mass Index; Combined Modality Therapy; Exercise Therapy; Female; Glucose Tolerance Test; | 2019 |
Intrauterine metformin exposure and offspring cardiometabolic risk factors (PedMet study): a 5-10 year follow-up of the PregMet randomised controlled trial.
Topics: Adult; Body Mass Index; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Hypoglycemic Age | 2019 |
Use of metformin to treat pregnant women with polycystic ovary syndrome (PregMet2): a randomised, double-blind, placebo-controlled trial.
Topics: Abortion, Spontaneous; Adolescent; Adult; Biomarkers; Blood Glucose; Diabetes, Gestational; Double-B | 2019 |
Use of metformin to treat pregnant women with polycystic ovary syndrome (PregMet2): a randomised, double-blind, placebo-controlled trial.
Topics: Abortion, Spontaneous; Adolescent; Adult; Biomarkers; Blood Glucose; Diabetes, Gestational; Double-B | 2019 |
Use of metformin to treat pregnant women with polycystic ovary syndrome (PregMet2): a randomised, double-blind, placebo-controlled trial.
Topics: Abortion, Spontaneous; Adolescent; Adult; Biomarkers; Blood Glucose; Diabetes, Gestational; Double-B | 2019 |
Use of metformin to treat pregnant women with polycystic ovary syndrome (PregMet2): a randomised, double-blind, placebo-controlled trial.
Topics: Abortion, Spontaneous; Adolescent; Adult; Biomarkers; Blood Glucose; Diabetes, Gestational; Double-B | 2019 |
l-Carnitine plus metformin in clomiphene-resistant obese PCOS women, reproductive and metabolic effects: a randomized clinical trial.
Topics: Adult; Blood Glucose; Carnitine; Clomiphene; Drug Resistance; Female; Fertility Agents, Female; Horm | 2019 |
The effectiveness of inositol and metformin on infertile polycystic ovary syndrome women with resistant to letrozole.
Topics: Adult; Female; Folic Acid; Humans; Infertility, Female; Inositol; Letrozole; Metformin; Ovulation In | 2019 |
The comparison of fennel infusion plus dry cupping versus metformin in management of oligomenorrhoea in patients with polycystic ovary syndrome: a randomised clinical trial.
Topics: Acupuncture Therapy; Adult; Body Mass Index; Cupping Therapy; Dysmenorrhea; Female; Foeniculum; Huma | 2019 |
Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: A randomized controlled study.
Topics: Adolescent; Adult; Anthropometry; Benzhydryl Compounds; Body Composition; Cardiovascular Diseases; D | 2019 |
Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: A randomized controlled study.
Topics: Adolescent; Adult; Anthropometry; Benzhydryl Compounds; Body Composition; Cardiovascular Diseases; D | 2019 |
Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: A randomized controlled study.
Topics: Adolescent; Adult; Anthropometry; Benzhydryl Compounds; Body Composition; Cardiovascular Diseases; D | 2019 |
Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: A randomized controlled study.
Topics: Adolescent; Adult; Anthropometry; Benzhydryl Compounds; Body Composition; Cardiovascular Diseases; D | 2019 |
Circulating zinc-α2-glycoprotein is reduced in women with polycystic ovary syndrome, but can be increased by exenatide or metformin treatment.
Topics: Adipokines; Adult; Biomarkers; Blood Glucose; Carrier Proteins; Exenatide; Female; Glycoproteins; Hu | 2019 |
Screening for a Simple and Effective Indicator of Insulin Resistance in Chinese Reproductive-Aged Women, with the Insulin Clamp Technique as a Reference.
Topics: Adolescent; Adult; Age Factors; Biomarkers; Body Mass Index; China; Cross-Sectional Studies; Diagnos | 2019 |
Effects of low-dose metformin and rosiglitazone on biochemical, clinical, metabolic and biophysical outcomes in polycystic ovary syndrome.
Topics: Adult; Drug Therapy, Combination; Endothelium, Vascular; Female; Humans; Hypoglycemic Agents; Metfor | 2013 |
Serum free fatty acid levels in PCOS patients treated with glucophage, magnesium oxide and spironolactone.
Topics: Adolescent; Adult; Aldosterone; Drug Therapy, Combination; Fatty Acids, Nonesterified; Female; Human | 2013 |
Free fatty acid binding protein-4 and retinol binding protein-4 in polycystic ovary syndrome: response to simvastatin and metformin therapies.
Topics: Adult; Drug Therapy, Combination; Fatty Acid-Binding Proteins; Female; Humans; Hydroxymethylglutaryl | 2013 |
Metformin treatment in different phenotypes of polycystic ovary syndrome.
Topics: Adult; Female; Folic Acid; Humans; Hypoglycemic Agents; Insemination, Artificial; Metformin; Ovulati | 2013 |
Gestational diabetes mellitus among Norwegian women with polycystic ovary syndrome: prevalence and risk factors according to the WHO and the modified IADPSG criteria.
Topics: Adult; Analysis of Variance; Diabetes, Gestational; Double-Blind Method; Female; Humans; Hypoglycemi | 2013 |
Effectiveness of abdominal acupuncture for patients with obesity-type polycystic ovary syndrome: a randomized controlled trial.
Topics: Abdomen; Acupuncture Therapy; Adult; Blood Glucose; Fasting; Female; Hormones; Humans; Hypoglycemic | 2013 |
Effectiveness of abdominal acupuncture for patients with obesity-type polycystic ovary syndrome: a randomized controlled trial.
Topics: Abdomen; Acupuncture Therapy; Adult; Blood Glucose; Fasting; Female; Hormones; Humans; Hypoglycemic | 2013 |
Effectiveness of abdominal acupuncture for patients with obesity-type polycystic ovary syndrome: a randomized controlled trial.
Topics: Abdomen; Acupuncture Therapy; Adult; Blood Glucose; Fasting; Female; Hormones; Humans; Hypoglycemic | 2013 |
Effectiveness of abdominal acupuncture for patients with obesity-type polycystic ovary syndrome: a randomized controlled trial.
Topics: Abdomen; Acupuncture Therapy; Adult; Blood Glucose; Fasting; Female; Hormones; Humans; Hypoglycemic | 2013 |
Effects of drospirenone-ethinylestradiol and/or metformin on CD4(+)CD28(null) T lymphocytes frequency in women with hyperinsulinemia having polycystic ovary syndrome: a randomized clinical trial.
Topics: Adolescent; Adult; Analysis of Variance; Androstenes; Cardiovascular Diseases; CD28 Antigens; CD4 Ly | 2013 |
In PCOS patients the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism than metformin alone.
Topics: Adult; Androstenedione; Dehydroepiandrosterone; Dose-Response Relationship, Drug; Female; Hirsutism; | 2014 |
Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study.
Topics: Adolescent; Adult; Blood Glucose; Blood Pressure; Body Composition; Body Mass Index; Drug Therapy, C | 2013 |
Metformin lowers serum cobalamin without changing other markers of cobalamin status: a study on women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Biomarkers; Body Mass Index; Cohort Studies; Cross-Over Studies; Female; Humans; | 2013 |
The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment.
Topics: Adult; Berberine; Female; Fertilization in Vitro; Humans; Hypoglycemic Agents; Infertility, Female; | 2014 |
Efficacy of combined metformin-clomiphene citrate in comparison with clomiphene citrate alone in infertile women with polycystic ovarian syndrome (PCOS).
Topics: Adult; Clomiphene; Drug Therapy, Combination; Female; Humans; Infertility, Female; Metformin; Polycy | 2013 |
Inflammatory cytokines and chemokines, skeletal muscle and polycystic ovary syndrome: effects of pioglitazone and metformin treatment.
Topics: Adult; Biomarkers; Chemokines; Cytokines; Drug Therapy, Combination; Female; Glucose Clamp Technique | 2013 |
[Evaluation of a new association between insulin-sensitizers and α-lipoic acid in obese women affected by PCOS].
Topics: Adult; Antioxidants; Blood Glucose; Body Mass Index; Drug Therapy, Combination; Electron Transport; | 2013 |
Midpregnancy Doppler ultrasound of the uterine artery in metformin- versus placebo-treated PCOS women: a randomized trial.
Topics: Adolescent; Adult; Female; Humans; Hypoglycemic Agents; Metformin; Middle Aged; Placebos; Polycystic | 2014 |
Proinsulin, adiponectin and hsCRP in reproductive age women with polycystic ovary syndrome (PCOS)--the effect of metformin treatment.
Topics: Adiponectin; Adolescent; Adult; C-Reactive Protein; Female; Humans; Insulin Resistance; Metformin; O | 2014 |
Effects of metformin or an oral contraceptive containing cyproterone acetate on serum c-reactive protein, interleukin-6 and soluble vascular cell adhesion molecule-1 concentrations in women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Androgen Antagonists; C-Reactive Protein; Contraceptives, Oral; Cross-Sectional S | 2014 |
Effect of metformin on the level of anti-Mullerian hormone in therapy of polycystic ovary syndrome in obese women.
Topics: Adult; Anti-Mullerian Hormone; Body Mass Index; Female; Humans; Hypoglycemic Agents; Insulin; Metfor | 2014 |
Maternal and fetal insulin levels at birth in women with polycystic ovary syndrome: data from a randomized controlled study on metformin.
Topics: Adult; Double-Blind Method; Female; Fetal Blood; Humans; Hyperinsulinism; Hypoglycemic Agents; Insul | 2014 |
Metformin improves glucose effectiveness, not insulin sensitivity: predicting treatment response in women with polycystic ovary syndrome in an open-label, interventional study.
Topics: Adult; Blood Glucose; Female; Follicle Stimulating Hormone; Glucose Tolerance Test; Humans; Hypoglyc | 2014 |
Metformin improves glucose effectiveness, not insulin sensitivity: predicting treatment response in women with polycystic ovary syndrome in an open-label, interventional study.
Topics: Adult; Blood Glucose; Female; Follicle Stimulating Hormone; Glucose Tolerance Test; Humans; Hypoglyc | 2014 |
Metformin improves glucose effectiveness, not insulin sensitivity: predicting treatment response in women with polycystic ovary syndrome in an open-label, interventional study.
Topics: Adult; Blood Glucose; Female; Follicle Stimulating Hormone; Glucose Tolerance Test; Humans; Hypoglyc | 2014 |
Metformin improves glucose effectiveness, not insulin sensitivity: predicting treatment response in women with polycystic ovary syndrome in an open-label, interventional study.
Topics: Adult; Blood Glucose; Female; Follicle Stimulating Hormone; Glucose Tolerance Test; Humans; Hypoglyc | 2014 |
Body composition is improved during 12 months' treatment with metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome.
Topics: Adolescent; Adult; Body Composition; Contraceptives, Oral, Combined; Desogestrel; Drug Therapy, Comb | 2014 |
Phosphodiesterase 4 inhibition as a potential new therapeutic target in obese women with polycystic ovary syndrome.
Topics: Adult; Aminopyridines; Benzamides; Body Weight; Cyclopropanes; Drug-Related Side Effects and Adverse | 2014 |
Adiponectin, interleukin-6, monocyte chemoattractant protein-1, and regional fat mass during 12-month randomized treatment with metformin and/or oral contraceptives in polycystic ovary syndrome.
Topics: Abdominal Fat; Absorptiometry, Photon; Adiponectin; Adiposity; Adolescent; Adult; Body Mass Index; C | 2014 |
Ovulation induction with clomiphene citrate and metformin in women with polycystic ovary syndrome.
Topics: Adult; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; Hypoglycemic | 2014 |
The effect of metformin on the hypothalamic-pituitary-thyroid axis in women with polycystic ovary syndrome and subclinical hypothyroidism.
Topics: Adult; Female; Humans; Hypothalamo-Hypophyseal System; Hypothyroidism; Metformin; Middle Aged; Polyc | 2015 |
The effect of exercise and metformin treatment on circulating free DNA in pregnancy.
Topics: Adolescent; Adult; DNA; Exercise; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary S | 2014 |
Therapeutic effects of metformin and laparoscopic ovarian drilling in treatment of clomiphene and insulin-resistant polycystic ovary syndrome.
Topics: Adult; Clomiphene; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Laparoscopy; Me | 2015 |
Metformin induces a prompt decrease in LH-stimulated testosterone response in women with PCOS independent of its insulin-sensitizing effects.
Topics: Adrenal Cortex; Adult; Body Mass Index; Double-Blind Method; Female; Follow-Up Studies; Humans; Hype | 2014 |
The impact of metformin treatment on adiponectin and resistin levels in women with polycystic ovary syndrome: a prospective clinical study.
Topics: Adiponectin; Adult; Body Mass Index; Female; Humans; Insulin; Insulin Resistance; Metformin; Polycys | 2015 |
N-Acetylcysteine improves oocyte and embryo quality in polycystic ovary syndrome patients undergoing intracytoplasmic sperm injection: an alternative to metformin.
Topics: Academic Medical Centers; Acetylcysteine; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antioxidan | 2016 |
[Using an ovarian drilling by hydrolaparoscopy or recombinant follicle stimulating hormone plus metformin to treat polycystic ovary syndrome: Why a randomized controlled trial fail?].
Topics: Adult; Clomiphene; Female; Fertility Agents, Female; Follicle Stimulating Hormone; Humans; Hypoglyce | 2015 |
Elevated circulating levels of irisin and the effect of metformin treatment in women with polycystic ovary syndrome.
Topics: Adult; Cross-Sectional Studies; Female; Fibronectins; Glucose Tolerance Test; Humans; Hypoglycemic A | 2015 |
Inadequacy of initiating rosuvastatin then metformin on biochemical profile of polycystic ovarian syndrome patients.
Topics: Adult; Blood Glucose; Dehydroepiandrosterone; Double-Blind Method; Drug Therapy, Combination; Female | 2015 |
Impact of metformin on anti-Müllerian hormone in women with polycystic ovary syndrome: a secondary analysis of a randomized controlled trial.
Topics: Adolescent; Adult; Anti-Mullerian Hormone; Body Mass Index; Cohort Studies; Cross-Over Studies; Doub | 2015 |
Randomized clinical trial evaluating metformin versus oral contraceptive pills in the treatment of adolescents with polycystic ovarian syndrome.
Topics: Adolescent; Androgens; Body Mass Index; Child; Chromatography, Liquid; Contraceptives, Oral, Combine | 2015 |
Metformin improves endothelial function and carotid intima media thickness in patients with PCOS.
Topics: Adolescent; Adult; Androstenes; Brachial Artery; Carotid Arteries; Carotid Intima-Media Thickness; C | 2015 |
Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study.
Topics: Adult; Aminopyridines; Benzamides; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclopropanes; Fema | 2015 |
Pregnancy in polycystic ovary syndrome I: lessons from a pragmatic explanatory with repository clinical trial.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Fertility Agents, Female; Humans; Hypog | 2015 |
Metformin modulates human leukocyte/endothelial cell interactions and proinflammatory cytokines in polycystic ovary syndrome patients.
Topics: Adolescent; Adult; Biomarkers; Cell Adhesion; Cell Adhesion Molecules; Cells, Cultured; Coculture Te | 2015 |
Increased thrombin generation in women with polycystic ovary syndrome: A pilot study on the effect of metformin and oral contraceptives.
Topics: Adolescent; Adult; C-Reactive Protein; Contraceptives, Oral; Desogestrel; Ethinyl Estradiol; Female; | 2015 |
The adjuvant effect of metformin and N-acetylcysteine to clomiphene citrate in induction of ovulation in patients with Polycystic Ovary Syndrome.
Topics: Acetylcysteine; Adult; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female; Huma | 2015 |
Comparison of spironolactone and spironolactone plus metformin in the treatment of polycystic ovary syndrome.
Topics: Adolescent; Adult; Blood Glucose; Body Mass Index; Dehydroepiandrosterone Sulfate; Drug Therapy, Com | 2016 |
Serum vascular endothelial growth factor B is elevated in women with polycystic ovary syndrome and can be decreased with metformin treatment.
Topics: Adult; Body Mass Index; Cross-Sectional Studies; Female; Gonadal Steroid Hormones; Humans; Hypoglyce | 2016 |
A randomized controlled trial of clomifene citrate, metformin, and pioglitazone versus letrozole, metformin, and pioglitazone for clomifene-citrate-resistant polycystic ovary syndrome.
Topics: Adult; Clomiphene; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Egypt; Female; F | 2016 |
A comparison between the effects of metformin and N-acetyl cysteine (NAC) on some metabolic and endocrine characteristics of women with polycystic ovary syndrome.
Topics: Acetylcysteine; Adult; Blood Glucose; Double-Blind Method; Female; Free Radical Scavengers; Humans; | 2016 |
[Effect of Qingre Yangyin Recipe on Endocrine and Metabolism of Polycystic Ovary Syndrome Patients].
Topics: Adiponectin; Blood Glucose; Body Mass Index; Drugs, Chinese Herbal; Estradiol; Female; Follicle Stim | 2015 |
Cervical Length and Androgens in Pregnant Women With Polycystic Ovary Syndrome: Has Metformin Any Effect?
Topics: Adolescent; Adult; Androgens; Androstenedione; Cervical Length Measurement; Dehydroepiandrosterone S | 2016 |
Comparison of Drospirenone- with Cyproterone Acetate-Containing Oral Contraceptives, Combined with Metformin and Lifestyle Modifications in Women with Polycystic Ovary Syndrome and Metabolic Disorders: A Prospective Randomized Control Trial.
Topics: Adolescent; Adult; Androstenes; Carbohydrate Metabolism; Contraceptives, Oral; Cyproterone Acetate; | 2016 |
Endocannabinoid receptor blockade increases hepatocyte growth factor and reduces insulin levels in obese women with polycystic ovary syndrome.
Topics: Body Mass Index; Cannabinoid Receptor Antagonists; Cytokines; Female; Hepatocyte Growth Factor; Huma | 2016 |
The effect of alfacalcidiol and metformin on phenotype manifestations in women with polycystic ovary syndrome - a preliminary study.
Topics: Adult; Female; Humans; Hydroxycholecalciferols; Hyperandrogenism; Hypoglycemic Agents; Insulin Resis | 2016 |
Endocannabinoid receptor blockade increases vascular endothelial growth factor and inflammatory markers in obese women with polycystic ovary syndrome.
Topics: Biomarkers; Cannabinoid Receptor Antagonists; Cytokines; Female; Humans; Hyperandrogenism; Inflammat | 2017 |
Comparison of two insulin sensitizers, metformin and myo-inositol, in women with polycystic ovary syndrome (PCOS).
Topics: Adolescent; Adult; Female; Humans; Hypoglycemic Agents; Inositol; Insulin Resistance; Metformin; Out | 2017 |
Effects of Metformin on Endocrine and Metabolic Parameters in Patients with Polycystic Ovary Syndrome.
Topics: Demography; Endocrine System; Female; Hemodynamics; Hormones; Humans; Metformin; Organ Size; Ovary; | 2017 |
A short course of metformin does not reduce OHSS in a GnRH antagonist cycle for women with PCOS undergoing IVF: a randomised placebo-controlled trial.
Topics: Adult; Female; Gonadotropin-Releasing Hormone; Hormone Antagonists; Humans; Infertility, Female; Met | 2016 |
Metformin vs myoinositol: which is better in obese polycystic ovary syndrome patients? A randomized controlled crossover study.
Topics: Adult; Cross-Over Studies; Female; Humans; Hypoglycemic Agents; Inositol; Metformin; Obesity; Outcom | 2017 |
Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial.
Topics: Adult; Biomarkers; Blood Glucose; Body Weight; Drug Therapy, Combination; Female; Follow-Up Studies; | 2017 |
Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial.
Topics: Adult; Biomarkers; Blood Glucose; Body Weight; Drug Therapy, Combination; Female; Follow-Up Studies; | 2017 |
Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial.
Topics: Adult; Biomarkers; Blood Glucose; Body Weight; Drug Therapy, Combination; Female; Follow-Up Studies; | 2017 |
Short-term effectiveness of low dose liraglutide in combination with metformin versus high dose liraglutide alone in treatment of obese PCOS: randomized trial.
Topics: Adult; Biomarkers; Blood Glucose; Body Weight; Drug Therapy, Combination; Female; Follow-Up Studies; | 2017 |
The effect of alfacalcidiol and metformin on metabolic disturbances in women with polycystic ovary syndrome.
Topics: Adult; Biomarkers; Blood Glucose; Body Mass Index; Bone Density Conservation Agents; Female; Follow- | 2017 |
Short-term therapy with combination dipeptidyl peptidase-4 inhibitor saxagliptin/metformin extended release (XR) is superior to saxagliptin or metformin XR monotherapy in prediabetic women with polycystic ovary syndrome: a single-blind, randomized, pilot
Topics: Adamantane; Adiposity; Adolescent; Adult; Androgens; Biomarkers; Blood Glucose; Delayed-Action Prepa | 2017 |
Acupuncture treatment for insulin sensitivity of women with polycystic ovary syndrome and insulin resistance: a study protocol for a randomized controlled trial.
Topics: Acupuncture Therapy; Adolescent; Adult; Biomarkers; Blood Glucose; China; Clinical Protocols; Combin | 2017 |
Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome.
Topics: Adult; Anti-Obesity Agents; Body Mass Index; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; | 2009 |
An observational study of reduction of insulin resistance and prevention of development of type 2 diabetes mellitus in women with polycystic ovary syndrome treated with metformin and diet.
Topics: Adult; Blood Glucose; Body Mass Index; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diabete | 2008 |
The effects of 8 months of metformin on circulating GGT and ALT levels in obese women with polycystic ovarian syndrome.
Topics: Adult; Alanine Transaminase; Analysis of Variance; Anti-Obesity Agents; Biomarkers; Female; gamma-Gl | 2008 |
Effects of metformin versus ethinyl-estradiol plus cyproterone acetate on ambulatory blood pressure monitoring and carotid intima media thickness in women with the polycystic ovary syndrome.
Topics: Adult; Androgen Antagonists; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Carotid Arteries | 2009 |
Metformin improves endothelial function in normoinsulinemic PCOS patients: a new prospective.
Topics: Adult; Androgens; Body Weight; Brachial Artery; Endothelium, Vascular; Female; Humans; Insulin; Metf | 2008 |
Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
Topics: Adult; Contraceptives, Oral, Combined; Cyproterone Acetate; Drug Therapy, Combination; Ethinyl Estra | 2008 |
Metformin has no major effects on glucose homeostasis in pregnant women with PCOS: results of a randomized double-blind study.
Topics: Adolescent; Adult; Diabetes, Gestational; Double-Blind Method; Female; Glucose; Homeostasis; Humans; | 2008 |
Improvement of endothelial function with metformin and rosiglitazone treatment in women with polycystic ovary syndrome.
Topics: Androgens; Brachial Artery; C-Reactive Protein; Cardiovascular Diseases; Endothelium, Vascular; Fema | 2008 |
Antiandrogenic contraceptives increase serum adiponectin in obese polycystic ovary syndrome patients.
Topics: Adipocytes; Adiponectin; Adipose Tissue; Adult; Androgen Antagonists; Area Under Curve; Body Weight; | 2009 |
Endothelial function and insulin resistance in polycystic ovary syndrome: the effects of medical therapy.
Topics: Adult; Arginine; Biomarkers; Blood Glucose; C-Reactive Protein; Contraceptives, Oral, Combined; Cont | 2010 |
Increased insulin sensitivity by metformin enhances intense-pulsed-light-assisted hair removal in patients with polycystic ovary syndrome.
Topics: Adult; Female; Hair Removal; Hirsutism; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; | 2009 |
Enoxaparin-metformin and enoxaparin alone may safely reduce pregnancy loss.
Topics: Abortion, Habitual; Abortion, Spontaneous; Adult; Anticoagulants; Blood Coagulation Disorders; Dose- | 2009 |
Metformin maintains the weight loss and metabolic benefits following rimonabant treatment in obese women with polycystic ovary syndrome (PCOS).
Topics: Adult; Androgens; Female; Humans; Insulin Resistance; Metformin; Piperidines; Polycystic Ovary Syndr | 2009 |
Effects of an antiandrogenic oral contraceptive pill compared with metformin on blood coagulation tests and endothelial function in women with the polycystic ovary syndrome: influence of obesity and smoking.
Topics: Adult; Androgen Antagonists; Blood Coagulation; Blood Platelets; Case-Control Studies; Contraceptive | 2009 |
Disturbed stress responses in women with polycystic ovary syndrome.
Topics: Adult; Anxiety; Blood Pressure; Female; Heart Rate; Humans; Hypoglycemic Agents; Hypothalamo-Hypophy | 2009 |
Metabolic and endocrine effects of metformin and metformin plus cyclic medroxyprogesterone acetate in women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Body Mass Index; Cholesterol; Contraceptive Agents, Female; Drug Therapy, Combina | 2009 |
Determinants of interleukin-6 and C-reactive protein vary in polycystic ovary syndrome, as do effects of short- and long-term metformin therapy.
Topics: Adiposity; Adult; C-Reactive Protein; Case-Control Studies; Cross-Sectional Studies; Diabetes Mellit | 2009 |
Hyperreninemia characterizing women with polycystic ovary syndrome improves after metformin therapy.
Topics: Adult; Aldosterone; Androgens; Area Under Curve; Blood Glucose; Case-Control Studies; Female; Humans | 2009 |
Metformin effects on ovarian ultrasound appearance and steroidogenic function in normal-weight normoinsulinemic women with polycystic ovary syndrome: a randomized double-blind placebo-controlled clinical trial.
Topics: Adult; Double-Blind Method; Female; Gonadal Steroid Hormones; Humans; Hypoglycemic Agents; Ideal Bod | 2010 |
Comparison of four different treatment regimens on coagulation parameters, hormonal and metabolic changes in women with polycystic ovary syndrome.
Topics: Adult; Blood Coagulation; Cyproterone Acetate; Estrogens; Ethinyl Estradiol; Female; Fibrin Fibrinog | 2010 |
Anti-Müllerian hormone concentrations in androgen-suppressed women with polycystic ovary syndrome.
Topics: Adult; Androgens; Anti-Mullerian Hormone; Dexamethasone; Double-Blind Method; Drug Therapy, Combinat | 2009 |
Evaluating the equivalence of clomiphene citrate with and without metformin in ovulation induction in PCOS patients.
Topics: Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; Metformin; Ovulatio | 2009 |
Metformin decreases angiogenesis via NF-kappaB and Erk1/2/Erk5 pathways by increasing the antiangiogenic thrombospondin-1.
Topics: Adult; Case-Control Studies; Cell Movement; Cells, Cultured; Culture Media, Conditioned; Down-Regula | 2009 |
An assessment of lifestyle modification versus medical treatment with clomiphene citrate, metformin, and clomiphene citrate-metformin in patients with polycystic ovary syndrome.
Topics: Adult; Clomiphene; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Life Style; Metfo | 2010 |
An assessment of lifestyle modification versus medical treatment with clomiphene citrate, metformin, and clomiphene citrate-metformin in patients with polycystic ovary syndrome.
Topics: Adult; Clomiphene; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Life Style; Metfo | 2010 |
An assessment of lifestyle modification versus medical treatment with clomiphene citrate, metformin, and clomiphene citrate-metformin in patients with polycystic ovary syndrome.
Topics: Adult; Clomiphene; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Life Style; Metfo | 2010 |
An assessment of lifestyle modification versus medical treatment with clomiphene citrate, metformin, and clomiphene citrate-metformin in patients with polycystic ovary syndrome.
Topics: Adult; Clomiphene; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Life Style; Metfo | 2010 |
Effect of rimonabant and metformin on glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 in obese women with polycystic ovary syndrome.
Topics: Drug Therapy, Combination; Female; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; | 2010 |
Insulin and metformin regulate circulating and adipose tissue chemerin.
Topics: Adipose Tissue; Adolescent; Adult; Androstenedione; Dehydroepiandrosterone Sulfate; Dose-Response Re | 2009 |
Metformin effects on clomifene-induced ovulation in the polycystic ovary syndrome.
Topics: Adult; Clomiphene; Female; Fertility Agents, Female; Humans; Hypoglycemic Agents; Metformin; Ovulati | 2009 |
Metformin administration was associated with a modification of LH, prolactin and insulin secretion dynamics in women with polycystic ovarian syndrome.
Topics: Adolescent; Adult; Androgens; Anovulation; Female; Glucose Tolerance Test; Hormones; Humans; Hypogly | 2009 |
Intercourse compliance, ovulation, and treatment success in the National Institute of Child Health and Human Development-Reproductive Medicine Network's Pregnancy in Polycystic Ovary Syndrome (PPCOS) Trial.
Topics: Adult; Clomiphene; Coitus; Female; Fertility Agents, Female; Humans; Infertility, Female; Metformin; | 2010 |
Does metformin augment the ovulation inducing effects of clomiphene in non-obese women with polycystic ovary syndrome?
Topics: Adult; Clomiphene; Female; Fertility Agents, Female; Humans; Hypoglycemic Agents; Metformin; Ovulati | 2008 |
Short-term metformin treatment for clomiphene citrate-resistant women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Blood Glucose; Body Mass Index; Clomiphene; Double-Blind Method; Drug Resistance; | 2009 |
The effects of calcium-vitamin D and metformin on polycystic ovary syndrome: a pilot study.
Topics: Administration, Oral; Adult; Calcium; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; | 2009 |
The effect of ethinylestradiol (EE)/cyproterone acetate (CA) and EE/CA plus metformin treatment on adhesion molecules in cases with polycystic ovary syndrome (PCOS).
Topics: Adult; Antineoplastic Agents; Cell Adhesion Molecules; Cyproterone Acetate; Drug Therapy, Combinatio | 2009 |
Atorvastatin pretreatment augments the effect of metformin in patients with polycystic ovary syndrome (PCOS).
Topics: Adult; Atorvastatin; C-Reactive Protein; Drug Synergism; Female; Heptanoic Acids; Humans; Hydroxymet | 2010 |
Metformin does not improve the reproductive or metabolic profile in women with polycystic ovary syndrome (PCOS).
Topics: Adolescent; Adult; Cross-Over Studies; Double-Blind Method; Female; Follicle Stimulating Hormone; Hu | 2009 |
Comparison of metformin treatment and laparoscopic ovarian diathermy in patients with polycystic ovary syndrome.
Topics: Adult; Clomiphene; Diathermy; Female; Fertility Agents, Female; Hirsutism; Humans; Hypoglycemic Agen | 2009 |
RETRACTED: Letrozole versus combined metformin and clomiphene citrate for ovulation induction in clomiphene-resistant women with polycystic ovary syndrome: a randomized controlled trial.
Topics: Adult; Algorithms; Clomiphene; Drug Combinations; Drug Resistance; Female; Fertility Agents, Female; | 2010 |
Metformin in the treatment of clomiphene citrate-resistant women with polycystic ovary syndrome undergoing in vitro fertilisation treatment: a randomised controlled trial.
Topics: Adult; Clomiphene; Female; Fertility Agents, Female; Fertilization in Vitro; Humans; Hypoglycemic Ag | 2009 |
The role of family history in clinical symptoms and therapeutic outcomes of women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Area Under Curve; Blood Glucose; Contraceptives, Oral; Female; Follow-Up Studies; | 2010 |
Improvement in quality-of-life questionnaire measures in obese adolescent females with polycystic ovary syndrome treated with lifestyle changes and oral contraceptives, with or without metformin.
Topics: Adolescent; Combined Modality Therapy; Contraceptives, Oral; Female; Humans; Hypoglycemic Agents; Li | 2010 |
Novel inflammatory markers in overweight women with and without polycystic ovary syndrome and following pharmacological intervention.
Topics: Adiponectin; Adiposity; Aldosterone; Biomarkers; Body Mass Index; Cross-Sectional Studies; Female; H | 2010 |
[Advantages of Chinese medicine for treatment of blood sugar and lipid metabolic disorders in patients with polycystic ovarian syndrome].
Topics: Adolescent; Adult; Blood Glucose; Cholesterol, HDL; Cyproterone; Drugs, Chinese Herbal; Female; Huma | 2009 |
Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial.
Topics: Adult; Cardiovascular Diseases; Dehydroepiandrosterone Sulfate; Drug Therapy, Combination; Female; H | 2009 |
Metformin versus laparoscopic ovarian drilling in clomiphene- and insulin-resistant women with polycystic ovary syndrome.
Topics: Adult; Clomiphene; Female; Fertility Agents, Female; Hormones; Humans; Hypoglycemic Agents; Insulin | 2010 |
Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome.
Topics: Administration, Oral; Adolescent; Adult; Androgens; Androstenes; Blood Pressure; Cardiovascular Dise | 2010 |
Metformin-diet ameliorates coronary heart disease risk factors and facilitates resumption of regular menses in adolescents with polycystic ovary syndrome.
Topics: Adolescent; Combined Modality Therapy; Coronary Disease; Diet, Reducing; Female; Humans; Hypoglycemi | 2009 |
Leptin concentrations in patients with polycystic ovary syndrome before and after met-formin treatment depending on insulin resistance, body mass index and androgen con-centrations--introductory report.
Topics: Androgens; Body Mass Index; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Leptin; Metform | 2009 |
Metformin reduces arterial stiffness and improves endothelial function in young women with polycystic ovary syndrome: a randomized, placebo-controlled, crossover trial.
Topics: Adenylate Kinase; Adult; Aorta; Cross-Over Studies; Endothelium, Vascular; Female; Humans; Hypoglyce | 2010 |
Metformin reduces arterial stiffness and improves endothelial function in young women with polycystic ovary syndrome: a randomized, placebo-controlled, crossover trial.
Topics: Adenylate Kinase; Adult; Aorta; Cross-Over Studies; Endothelium, Vascular; Female; Humans; Hypoglyce | 2010 |
Metformin reduces arterial stiffness and improves endothelial function in young women with polycystic ovary syndrome: a randomized, placebo-controlled, crossover trial.
Topics: Adenylate Kinase; Adult; Aorta; Cross-Over Studies; Endothelium, Vascular; Female; Humans; Hypoglyce | 2010 |
Metformin reduces arterial stiffness and improves endothelial function in young women with polycystic ovary syndrome: a randomized, placebo-controlled, crossover trial.
Topics: Adenylate Kinase; Adult; Aorta; Cross-Over Studies; Endothelium, Vascular; Female; Humans; Hypoglyce | 2010 |
The effect of metformin treatment for 2 years without caloric restriction on endocrine and metabolic parameters in women with polycystic ovary syndrome.
Topics: Blood Glucose; Caloric Restriction; Drug Administration Schedule; Endocrine System; Female; Follow-U | 2010 |
Metformin influence on hormone levels at birth, in PCOS mothers and their newborns.
Topics: Adult; Androgens; Androstane-3,17-diol; Estradiol; Estrone; Female; Fetal Blood; Humans; Hypoglycemi | 2010 |
Continuation of metformin reduces early pregnancy loss in obese Pakistani women with polycystic ovarian syndrome.
Topics: Abortion, Habitual; Adult; Body Mass Index; Case-Control Studies; Diabetes, Gestational; Female; Fet | 2010 |
Effects of metformin plus simvastatin on polycystic ovary syndrome: a prospective, randomized, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Anticholesteremic Agents; Cholesterol, HDL; Double-Blind Method; Drug Therapy, Co | 2010 |
Laparoscopic ovarian diathermy vs clomiphene citrate plus metformin as second-line strategy for infertile anovulatory patients with polycystic ovary syndrome: a randomized controlled trial.
Topics: Abortion, Spontaneous; Anovulation; Body Mass Index; Clomiphene; Diathermy; Drug Therapy, Combinatio | 2010 |
Clinical, metabolic, and endocrine parameters in response to metformin and lifestyle intervention in women with polycystic ovary syndrome: a randomized, double-blind, and placebo control trial.
Topics: Adult; Blood Pressure; Body Mass Index; Cholesterol; Double-Blind Method; Female; Follicle Stimulati | 2010 |
Adiponectin levels in women with polycystic ovary syndrome: impact of metformin treatment in a randomized controlled study.
Topics: Adiponectin; Adolescent; Adult; Cross-Over Studies; Double-Blind Method; Female; Humans; Hypoglycemi | 2010 |
Insulin sensitiser agents alone and in co-treatment with r-FSH for ovulation induction in PCOS women.
Topics: Adult; Anovulation; Dietary Supplements; Drug Therapy, Combination; Female; Fertility Agents, Female | 2010 |
Metformin, naltrexone, or the combination of prednisolone and antiandrogenic oral contraceptives as first-line therapy in hyperinsulinemic women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Androgen Antagonists; Antineoplastic Agents; Contraceptives, Oral; Drug Therapy, | 2010 |
PCOSMIC: a multi-centre randomized trial in women with PolyCystic Ovary Syndrome evaluating Metformin for Infertility with Clomiphene.
Topics: Anovulation; Clomiphene; Female; Humans; Hypoglycemic Agents; Infertility, Female; Metformin; Ovulat | 2010 |
Effect of metformin on miscarriage in pregnant patients with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Adult; Drug Administration Schedule; Female; Humans; Hypoglycemic Agents; Met | 2009 |
Comparison of metformin and clomiphene citrate therapy for induction of ovulation in the polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Female; Fertility Agents, Female; Humans; Hypoglycemic Agents; Infer | 2010 |
Low-dose pioglitazone, flutamide, metformin plus an estro-progestagen for non-obese young women with polycystic ovary syndrome: increasing efficacy and persistent safety over 30 months.
Topics: Adolescent; Alanine Transaminase; Androgens; Androstenes; Aspartate Aminotransferases; Blood Glucose | 2010 |
The effect of different hormone therapies on anti-müllerian hormone serum levels in anovulatory women of reproductive age.
Topics: Adult; Anovulation; Anti-Mullerian Hormone; Biomarkers; Contraceptives, Oral; Female; Gonadotropins; | 2011 |
[Indication of metformin in the management of hormonal dysfunction secondary to polycystic ovarian syndrome: prospective comparative study of 63 cases].
Topics: Adult; Clomiphene; Female; Fertility Agents, Female; Humans; Hypoglycemic Agents; Infertility, Femal | 2010 |
Metformin plus oral contraceptive may decrease plasma sCD40 ligand in women with PCOS patients.
Topics: Adult; Androgen Antagonists; Body Mass Index; CD40 Antigens; Contraceptives, Oral; Cyproterone Aceta | 2011 |
Combined metformin and clomiphene citrate versus highly purified FSH for ovulation induction in clomiphene-resistant PCOS women: a randomised controlled trial.
Topics: Adult; Chi-Square Distribution; Clomiphene; Drug Resistance; Female; Fertility Agents, Female; Folli | 2011 |
Metformin 2,500 mg/day in the treatment of obese women with polycystic ovary syndrome and its effect on weight, hormones, and lipid profile.
Topics: Adult; Body Weight; Female; Hormones; Humans; Hypoglycemic Agents; Lipids; Metformin; Obesity; Polyc | 2010 |
Metformin administration restores allopregnanolone response to adrenocorticotropic hormone (ACTH) stimulation in overweight hyperinsulinemic patients with PCOS.
Topics: Adrenocorticotropic Hormone; Adult; Dehydroepiandrosterone Sulfate; Drug Synergism; Drug Therapy, Co | 2010 |
Metformin versus acarbose therapy in patients with polycystic ovary syndrome (PCOS): a prospective randomised double-blind study.
Topics: Acarbose; Adolescent; Adult; Algorithms; Dehydroepiandrosterone Sulfate; Double-Blind Method; Female | 2010 |
Organic cation transporter 1 polymorphisms predict the metabolic response to metformin in women with the polycystic ovary syndrome.
Topics: Administration, Oral; Adolescent; Adult; Biomarkers, Pharmacological; Dose-Response Relationship, Dr | 2010 |
Effect of the insulin sensitizers metformin and pioglitazone on endothelial function in young women with polycystic ovary syndrome: a prospective randomized study.
Topics: Adolescent; Adult; Brachial Artery; Cardiovascular Diseases; Endothelium, Vascular; Female; Humans; | 2011 |
Efficacy of metformin therapy in adolescent girls with androgen excess: relation to sex hormone-binding globulin and androgen receptor polymorphisms.
Topics: Adolescent; Androgens; Biomarkers, Pharmacological; Child; Female; Humans; Hyperandrogenism; Hypogly | 2010 |
Treatment of polycystic ovary syndrome (PCOS) with metformin ameliorates insulin resistance in parallel with the decrease of serum interleukin-6 concentrations.
Topics: Adult; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Interleukin-18; Interleukin-6; Metfo | 2010 |
The impact of oral contraceptives and metformin on anti-Müllerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia.
Topics: Adolescent; Adult; Androgen Antagonists; Androstenes; Anti-Mullerian Hormone; Blood Glucose; Body Ma | 2011 |
Early metformin therapy to delay menarche and augment height in girls with precocious pubarche.
Topics: Body Height; Child; Female; Humans; Hypoglycemic Agents; Infant, Low Birth Weight; Infant, Newborn; | 2011 |
Metformin versus placebo from first trimester to delivery in polycystic ovary syndrome: a randomized, controlled multicenter study.
Topics: Adult; Blood Pressure; Delivery, Obstetric; Diabetes, Gestational; Double-Blind Method; Female; Hear | 2010 |
[Sonographic ovarian vascularization and volume in women with polycystic ovary syndrome treated with clomiphene citrate and metformin].
Topics: Adult; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; Hyperglycemi | 2010 |
N-acetyl cysteine plus clomiphene citrate versus metformin and clomiphene citrate in treatment of clomiphene-resistant polycystic ovary syndrome: a randomized controlled trial.
Topics: Abortion, Spontaneous; Acetylcysteine; Adult; Clomiphene; Drug Resistance; Drug Therapy, Combination | 2010 |
Inflammatory-metabolic parameters in obese and nonobese normoandrogenemic polycystic ovary syndrome during metformin and oral contraceptive treatment.
Topics: Adult; Arginine; Body Mass Index; Cardiovascular Diseases; Contraceptives, Oral; Female; Homocystein | 2011 |
Combined metformin and clomiphene citrate versus laparoscopic ovarian diathermy for ovulation induction in clomiphene-resistant women with polycystic ovary syndrome: a randomized controlled trial.
Topics: Anovulation; Clomiphene; Drug Resistance; Electrocoagulation; Endometrium; Female; Humans; Laparosco | 2011 |
Impact of treatment with metformin on adipokines in patients with polycystic ovary syndrome.
Topics: Adipokines; Adult; Blood Chemical Analysis; Female; Humans; Hypoglycemic Agents; Metformin; Polycyst | 2010 |
The effects of metformin with lifestyle therapy in polycystic ovary syndrome: a randomized double-blind study.
Topics: Adult; Caloric Restriction; Diet, Reducing; Double-Blind Method; Exercise; Female; Glycemic Index; H | 2011 |
Role of decreased circulating hepcidin concentrations in the iron excess of women with the polycystic ovary syndrome.
Topics: Adult; Androgen Antagonists; Anthropometry; Antimicrobial Cationic Peptides; Case-Control Studies; F | 2011 |
Effect of dose escalation of metformin on clinical features, insulin sensitivity and androgen profile in polycystic ovary syndrome.
Topics: Adult; Algorithms; Androgens; Body Mass Index; Cohort Studies; Dose-Response Relationship, Drug; Fem | 2011 |
The effects of metformin or orlistat on obese women with polycystic ovary syndrome: a prospective randomized open-label study.
Topics: Adult; Anti-Obesity Agents; Body Mass Index; Body Weight; Female; Humans; Hypoglycemic Agents; Lacto | 2011 |
Randomized controlled trial of different doses of metformin for ovulation induction in infertile women with polycystic ovary syndrome.
Topics: Adult; Clomiphene; Dose-Response Relationship, Drug; Female; Fertility Agents, Female; Humans; Hyper | 2011 |
Metformin versus metformin plus rosiglitazone in women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Luteinizing Hormone; Met | 2011 |
Thyroidal effect of metformin treatment in patients with polycystic ovary syndrome.
Topics: Adult; Female; Humans; Hypoglycemic Agents; Hypothyroidism; Metformin; Polycystic Ovary Syndrome; Th | 2011 |
The administration of metformin during pregnancy reduces polycystic ovary syndrome related gestational complications.
Topics: Abortion, Spontaneous; Adult; Blood Glucose; Diabetes, Gestational; Female; Humans; Hyperinsulinism; | 2011 |
The administration of metformin during pregnancy reduces polycystic ovary syndrome related gestational complications.
Topics: Abortion, Spontaneous; Adult; Blood Glucose; Diabetes, Gestational; Female; Humans; Hyperinsulinism; | 2011 |
The administration of metformin during pregnancy reduces polycystic ovary syndrome related gestational complications.
Topics: Abortion, Spontaneous; Adult; Blood Glucose; Diabetes, Gestational; Female; Humans; Hyperinsulinism; | 2011 |
The administration of metformin during pregnancy reduces polycystic ovary syndrome related gestational complications.
Topics: Abortion, Spontaneous; Adult; Blood Glucose; Diabetes, Gestational; Female; Humans; Hyperinsulinism; | 2011 |
Do women with ovaries of polycystic morphology without any other features of PCOS benefit from short-term metformin co-treatment during IVF? A double-blind, placebo-controlled, randomized trial.
Topics: Double-Blind Method; Female; Fertilization in Vitro; Humans; Live Birth; Metformin; Ovarian Hypersti | 2011 |
Fatty acid-binding protein-4 plasma levels are associated to metabolic abnormalities and response to therapy in girls and young women with androgen excess.
Topics: Adolescent; Androgen Antagonists; Biomarkers; Body Mass Index; Child; Contraceptives, Oral, Combined | 2011 |
Use of metformin before and during assisted reproductive technology in non-obese young infertile women with polycystic ovary syndrome: a prospective, randomized, double-blind, multi-centre study.
Topics: Adult; Double-Blind Method; Female; Humans; Infertility, Female; Metformin; Polycystic Ovary Syndrom | 2011 |
Prognostic value of total testosterone for pregnancy during treatment in patients with clomiphene-citrate-resistant polycystic ovary syndrome: a pilot study.
Topics: Adult; Chorionic Gonadotropin; Clomiphene; Drug Resistance; Drug Therapy, Combination; Estradiol; Fe | 2011 |
Early metformin therapy (age 8-12 years) in girls with precocious pubarche to reduce hirsutism, androgen excess, and oligomenorrhea in adolescence.
Topics: Adolescent; Child; Female; Follow-Up Studies; Hirsutism; Humans; Hyperandrogenism; Hypoglycemic Agen | 2011 |
Effects of metformin in adolescents with polycystic ovary syndrome undertaking lifestyle therapy: a pilot randomized double-blind study.
Topics: Adolescent; Biomarkers; Caloric Restriction; Combined Modality Therapy; Double-Blind Method; Exercis | 2011 |
Effect of combined metformin and oral contraceptive therapy on metabolic factors and endothelial function in overweight and obese women with polycystic ovary syndrome.
Topics: Analysis of Variance; Biomarkers; Blood Glucose; Contraceptives, Oral, Combined; Contraceptives, Ora | 2011 |
[Effects of metformin therapy on markers of coagulation disorders in hyperinsulinemic women with polycystic ovary syndrome].
Topics: Adult; Blood Coagulation Factors; Body Mass Index; Female; Humans; Hyperinsulinism; Hypoglycemic Age | 2011 |
Weight loss significantly reduces serum lipocalin-2 levels in overweight and obese women with polycystic ovary syndrome.
Topics: Acute-Phase Proteins; Adolescent; Adult; Anti-Obesity Agents; Caloric Restriction; Combined Modality | 2012 |
Interleukin-6 as an early chronic inflammatory marker in polycystic ovary syndrome with insulin receptor substrate-2 polymorphism.
Topics: Adolescent; Adult; Case-Control Studies; Female; Homozygote; Humans; Hypoglycemic Agents; Inflammati | 2011 |
Clinical, endocrine and metabolic effects of metformin vs N-acetyl-cysteine in women with polycystic ovary syndrome.
Topics: Acetylcysteine; Adolescent; Adult; Anticholesteremic Agents; Antioxidants; Body Mass Index; Female; | 2011 |
Metformin and/or clomiphene do not adversely affect liver or renal function in women with polycystic ovary syndrome.
Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Bilirubin; Clomiphene; Double-Blind Method | 2011 |
Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment.
Topics: Adult; C-Reactive Protein; Drug Therapy, Combination; Female; Hirsutism; Humans; Hydroxymethylglutar | 2011 |
Impaired gallbladder motility and the effect of metformin therapy in patients with polycystic ovary syndrome.
Topics: Adult; Blood Glucose; Estradiol; Fasting; Female; Follicle Stimulating Hormone; Follow-Up Studies; G | 2012 |
Efficacy of Chinese patent medicine Tian Gui Capsule in patients with polycystic ovary syndrome: a randomized controlled trial.
Topics: Adolescent; Adult; Androgen Antagonists; Cyproterone Acetate; Drug Combinations; Drugs, Chinese Herb | 2011 |
Does metformin affect the ovarian response to gonadotropins for in vitro fertilization treatment in patients with polycystic ovary syndrome and reduced ovarian reserve? A randomized controlled trial.
Topics: Adult; Chi-Square Distribution; Double-Blind Method; Early Termination of Clinical Trials; Female; F | 2011 |
Anti-Müllerian hormone in women with polycystic ovary syndrome before and after therapy with metformin.
Topics: Adolescent; Adult; Anti-Mullerian Hormone; Case-Control Studies; Female; Humans; Metformin; Polycyst | 2011 |
Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study.
Topics: Adrenal Glands; Adult; Androstenedione; Atorvastatin; Dehydroepiandrosterone; Dehydroepiandrosterone | 2012 |
Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial.
Topics: Administration, Oral; Adult; Double-Blind Method; Down-Regulation; Drug Administration Schedule; Fem | 2011 |
A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome.
Topics: Berberine; Cholesterol; Cholesterol, LDL; Female; Humans; Insulin Resistance; Metformin; Polycystic | 2012 |
Androgens and antimüllerian hormone in mothers with polycystic ovary syndrome and their newborns.
Topics: Adult; Androgens; Anti-Mullerian Hormone; Biomarkers; Birth Weight; Chi-Square Distribution; Double- | 2012 |
Metabolomics reveals reduction of metabolic oxidation in women with polycystic ovary syndrome after pioglitazone-flutamide-metformin polytherapy.
Topics: Abdominal Fat; Biomarkers; Carotid Intima-Media Thickness; Chromatography, Gas; Chromatography, Liqu | 2011 |
Therapeutic effects of biguanide vs. statin in polycystic ovary syndrome: a randomized clinical trial.
Topics: Adult; Anticholesteremic Agents; Biguanides; Blood Glucose; Double-Blind Method; Female; Humans; Hyp | 2011 |
Metformin versus lifestyle changes in treating women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Body Mass Index; Female; Humans; Hypoglycemic Agents; Life Style; Logistic Models | 2012 |
[Diet, metformin and inositol in overweight and obese women with polycystic ovary syndrome: effects on body composition].
Topics: Adolescent; Adult; Body Composition; Combined Modality Therapy; Drug Therapy, Combination; Female; H | 2012 |
Metformin improves pregnancy and live-birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double-blind, placebo-controlled randomized trial.
Topics: Abortion, Spontaneous; Adult; Birth Rate; Double-Blind Method; Female; Humans; Infertility, Female; | 2012 |
Effect of metformin and pioglitazone treatment on cardiovascular risk profile in polycystic ovary syndrome.
Topics: Adult; Biomarkers; Blood Glucose; Body Mass Index; Cholesterol; Drug Administration Schedule; Female | 2012 |
Therapeutic effects of calcium & vitamin D supplementation in women with PCOS.
Topics: Adult; Calcium; Case-Control Studies; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; | 2012 |
Endometrial shedding effect on conception and live birth in women with polycystic ovary syndrome.
Topics: Adult; Clomiphene; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Fer | 2012 |
Altering hirsutism through ovulation induction in women with polycystic ovary syndrome.
Topics: Adult; Clomiphene; Double-Blind Method; Drug Therapy, Combination; Female; Fertility Agents, Female; | 2012 |
Is there a dose-response relationship of metformin treatment in patients with polycystic ovary syndrome? Results from a multicentric study.
Topics: Adult; Body Mass Index; Dose-Response Relationship, Drug; Female; Glucose Tolerance Test; Humans; Hy | 2012 |
Breast size increment during pregnancy and breastfeeding in mothers with polycystic ovary syndrome: a follow-up study of a randomised controlled trial on metformin versus placebo.
Topics: Body Composition; Body Mass Index; Breast; Breast Feeding; Female; Follow-Up Studies; Humans; Hypogl | 2012 |
Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome.
Topics: Adult; Atorvastatin; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA | 2012 |
Health-related quality of life in women with newly diagnosed polycystic ovary syndrome randomized between clomifene citrate plus metformin or clomifene citrate plus placebo.
Topics: Adult; Anxiety; Clomiphene; Depression; Double-Blind Method; Female; Fertility Agents, Female; Human | 2012 |
Does pioglitazone improve depression through insulin-sensitization? Results of a randomized double-blind metformin-controlled trial in patients with polycystic ovarian syndrome and comorbid depression.
Topics: Adolescent; Adult; Antidepressive Agents; Biomarkers; Depressive Disorder, Major; Double-Blind Metho | 2013 |
Effect of type 2 diabetes mellitus on the pharmacokinetics of metformin in obese pregnant women.
Topics: Adult; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Metformin; Obesity; Polycysti | 2012 |
Metformin's effect on first-year weight gain: a follow-up study.
Topics: Adult; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Infant; Infant, | 2012 |
Metformin decreases serum 8-hydroxy-2'-deoxyguanosine levels in polycystic ovary syndrome.
Topics: Adult; Biomarkers; Deoxyadenosines; Double-Blind Method; Down-Regulation; Female; Humans; Hypoglycem | 2013 |
Effects of metformin-diet intervention before and throughout pregnancy on obstetric and neonatal outcomes in patients with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Adult; Diabetes, Gestational; Female; Fetal Macrosomia; Humans; Hypoglycemic | 2013 |
Effect of metformin compared with hypocaloric diet on serum C-reactive protein level and insulin resistance in obese and overweight women with polycystic ovary syndrome.
Topics: Adult; Body Mass Index; C-Reactive Protein; Diet, Reducing; Female; Humans; Hypoglycemic Agents; Ins | 2013 |
Efficacy of combined metformin-letrozole in comparison with bilateral ovarian drilling in clomiphene-resistant infertile women with polycystic ovarian syndrome.
Topics: Adult; Aromatase Inhibitors; Blood Glucose; Clomiphene; Drug Therapy, Combination; Female; Fertility | 2013 |
The effects of drospirenone-ethinyl estradiol and drospirenone-ethinyl estradiol + metformin on ovarian ultrasonographic markers, body fat mass index, leptin, and ghrelin.
Topics: Abdominal Fat; Adiposity; Adolescent; Adult; Androstenes; Body Mass Index; Drug Therapy, Combination | 2013 |
The effect of metformin on hirsutism in polycystic ovary syndrome.
Topics: Body Constitution; Body Height; Body Weight; Double-Blind Method; Female; Hair; Hirsutism; Humans; H | 2002 |
Clinical and endocrinological effects of 6 months of metformin treatment in young hyperinsulinemic patients affected by polycystic ovary syndrome.
Topics: Adolescent; Adult; Androstenedione; Apolipoprotein A-I; Apolipoproteins B; Body Constitution; Body M | 2002 |
Plasma ghrelin, obesity, and the polycystic ovary syndrome: correlation with insulin resistance and androgen levels.
Topics: Adult; Androgens; Androstenedione; Diet, Reducing; Female; Ghrelin; Homeostasis; Humans; Hypoglycemi | 2002 |
Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study.
Topics: Adult; Contraceptives, Oral; Cyproterone Acetate; Drug Combinations; Energy Metabolism; Estradiol Co | 2003 |
Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study.
Topics: Adult; Contraceptives, Oral; Cyproterone Acetate; Drug Combinations; Energy Metabolism; Estradiol Co | 2003 |
Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study.
Topics: Adult; Contraceptives, Oral; Cyproterone Acetate; Drug Combinations; Energy Metabolism; Estradiol Co | 2003 |
Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study.
Topics: Adult; Contraceptives, Oral; Cyproterone Acetate; Drug Combinations; Energy Metabolism; Estradiol Co | 2003 |
Low-dose combination of flutamide, metformin and an oral contraceptive for non-obese, young women with polycystic ovary syndrome.
Topics: Adult; Androgen Antagonists; Cohort Studies; Contraceptives, Oral; Dose-Response Relationship, Drug; | 2003 |
Sequential treatment of metformin and clomiphene citrate in clomiphene-resistant women with polycystic ovary syndrome: a randomized, controlled trial.
Topics: Adult; Clomiphene; Cost-Benefit Analysis; Drug Resistance; Drug Therapy, Combination; Fasting; Femal | 2003 |
Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome.
Topics: Acne Vulgaris; Adolescent; Adult; Blood Glucose; Body Mass Index; Dehydroepiandrosterone Sulfate; Fa | 2003 |
Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double-blind and placebo-controlled trial.
Topics: Adolescent; Adult; Blood Pressure; Body Mass Index; Double-Blind Method; Female; Follicle Stimulatin | 2003 |
The effect of metformin treatment to ovarian response in cases with PCOS.
Topics: Adult; Female; Fertility Agents; Gonadotropins; Humans; Metformin; Ovulation; Polycystic Ovary Syndr | 2004 |
The comparison of clinical and hormonal parameters in PCOS patients treated with metformin and GnRH analogue.
Topics: Adult; Female; Gonadotropin-Releasing Hormone; Goserelin; Hormones; Humans; Hypoglycemic Agents; Met | 2003 |
Low-dose flutamide-metformin therapy reverses insulin resistance and reduces fat mass in nonobese adolescents with ovarian hyperandrogenism.
Topics: Adipose Tissue; Androgen Antagonists; Child; Dose-Response Relationship, Drug; Drug Therapy, Combina | 2003 |
Medical vs. surgical treatment for clomiphene citrate-resistant women with polycystic ovary syndrome.
Topics: Adult; Clomiphene; Drug Resistance; Female; Fertility Agents, Female; Humans; Laparoscopy; Menstrual | 2003 |
The effect of metformin on ovarian stimulation and in vitro fertilization in insulin-resistant women with polycystic ovary syndrome: an open-label randomized cross-over trial.
Topics: Adult; Buserelin; Cross-Over Studies; Female; Fertilization in Vitro; Follicle Stimulating Hormone; | 2003 |
[Importance of sensitization of insulin receptors in the prevention of ovarian hyperstimulation syndrome].
Topics: Adult; Female; Humans; Infertility, Female; Insulin Resistance; Metformin; Ovarian Hyperstimulation | 2003 |
Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome.
Topics: Acne Vulgaris; Androgen Antagonists; Anthropometry; Blood Glucose; Blood Pressure; Body Mass Index; | 2003 |
Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome.
Topics: Adult; C-Reactive Protein; Cyproterone Acetate; Estradiol Congeners; Ethinyl Estradiol; Female; Huma | 2003 |
Obese patients with polycystic ovary syndrome: evidence that metformin does not restore sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by ovarian steroids.
Topics: Adult; Androstenedione; Estrone; Feedback, Physiological; Female; Gonadal Steroid Hormones; Gonadotr | 2003 |
Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome.
Topics: 17-alpha-Hydroxyprogesterone; Adult; Androstenedione; Area Under Curve; Blood Glucose; C-Peptide; Es | 2004 |
Metformin therapy increases insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator in women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Area Under Curve; Body Mass Index; Body Weight; Female; Glucose Tolerance Test; H | 2004 |
Insulin sensitization early after menarche prevents progression from precocious pubarche to polycystic ovary syndrome.
Topics: Adolescent; Body Composition; Body Constitution; Body Mass Index; Child; Disease Progression; Female | 2004 |
Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome.
Topics: Adult; Analysis of Variance; Androgen Antagonists; Combined Modality Therapy; Diet, Reducing; Drug T | 2004 |
Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome.
Topics: Adult; Analysis of Variance; Androgen Antagonists; Combined Modality Therapy; Diet, Reducing; Drug T | 2004 |
Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome.
Topics: Adult; Analysis of Variance; Androgen Antagonists; Combined Modality Therapy; Diet, Reducing; Drug T | 2004 |
Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome.
Topics: Adult; Analysis of Variance; Androgen Antagonists; Combined Modality Therapy; Diet, Reducing; Drug T | 2004 |
[Endocrine and metabolic effects of metformin in combination with compound cyproterone acetate in women with polycystic ovarian syndrome].
Topics: Adult; Antineoplastic Agents; Cholesterol, HDL; Cyproterone Acetate; Dehydroepiandrosterone; Drug Th | 2003 |
[The use of oral antidiabetic drugs in the treatment of polycystic ovary syndrome].
Topics: Acarbose; Administration, Oral; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Met | 2003 |
Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin.
Topics: Administration, Oral; Adult; Body Mass Index; Body Weight; Double-Blind Method; Female; Hormones; Hu | 2004 |
Dexamethasone reduces androgen levels in metformin-treated patients with polycystic ovary syndrome.
Topics: Androgens; Antineoplastic Agents, Hormonal; Blood Glucose; Bromocriptine; Dexamethasone; Double-Blin | 2004 |
Metformin during pregnancy reduces insulin, insulin resistance, insulin secretion, weight, testosterone and development of gestational diabetes: prospective longitudinal assessment of women with polycystic ovary syndrome from preconception throughout preg
Topics: Adult; Body Weight; Cohort Studies; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Insu | 2004 |
Six-month treatment with low-dose dexamethasone further reduces androgen levels in PCOS women treated with diet and lifestyle advice, and metformin.
Topics: Adult; Androgen Antagonists; Androgens; Counseling; Dexamethasone; Dose-Response Relationship, Drug; | 2004 |
The effects of metformin on insulin resistance, clomiphene-induced ovulation and pregnancy rates in women with polycystic ovary syndrome.
Topics: Adult; Clomiphene; Endometrium; Female; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Inferti | 2004 |
Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity.
Topics: Adiponectin; Adipose Tissue; Adolescent; Adult; Androgen Antagonists; Androstenes; Drug Therapy, Com | 2004 |
Height, weight, and motor-social development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on and continued metformin through pregnancy.
Topics: Adult; Body Height; Body Weight; Child Development; Diabetes, Gestational; Female; Humans; Hypoglyce | 2004 |
Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study.
Topics: Adult; Double-Blind Method; Drug Administration Schedule; Female; Fertilization; Fertilization in Vi | 2004 |
[Metformin, an efficacious drug in the treatment of polycystic ovary syndrome].
Topics: Adolescent; Adult; Body Mass Index; Data Interpretation, Statistical; Female; Follow-Up Studies; Glu | 2004 |
Metformin reduces pregnancy complications without affecting androgen levels in pregnant polycystic ovary syndrome women: results of a randomized study.
Topics: Adult; Androgens; Birth Weight; Diabetes, Gestational; Female; Gestational Age; Glucose Tolerance Te | 2004 |
Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open-labeled study.
Topics: Adolescent; Adult; Body Mass Index; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Metformi | 2004 |
Effects of metformin on clinical and biochemical parameters in polycystic ovary syndrome.
Topics: Adolescent; Adult; Female; Humans; Hypoglycemic Agents; Infertility, Female; Insulin; Insulin Resist | 2004 |
Flutamide-metformin plus an oral contraceptive (OC) for young women with polycystic ovary syndrome: switch from third- to fourth-generation OC reduces body adiposity.
Topics: Abdomen; Adipose Tissue; Adolescent; Adult; Androgen Antagonists; Contraceptives, Oral; Drug Therapy | 2004 |
A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study.
Topics: Adipose Tissue; Adult; Blood Glucose; Body Composition; Body Mass Index; Double-Blind Method; Electr | 2004 |
[Combined use of metformin and Diane35 in polycystic ovary syndrome].
Topics: Administration, Oral; Adolescent; Adult; Androgen Antagonists; Cyproterone Acetate; Drug Administrat | 2004 |
Insulin sensitization for girls with precocious pubarche and with risk for polycystic ovary syndrome: effects of prepubertal initiation and postpubertal discontinuation of metformin treatment.
Topics: Adiponectin; Body Composition; Child; Female; Humans; Hypoglycemic Agents; Insulin; Intercellular Si | 2004 |
Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of early, low-dose flutamide.
Topics: Adiponectin; Adolescent; Androstenes; Arteriosclerosis; Drug Therapy, Combination; Ethinyl Estradiol | 2004 |
Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate-resistant women with polycystic ovary syndrome: a prospective parallel randomized double-blind placebo-controlled trial.
Topics: Adult; Ambulatory Surgical Procedures; Clomiphene; Double-Blind Method; Drug Resistance; Electrocoag | 2004 |
Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity.
Topics: Adolescent; Adult; Blood Glucose; Dehydroepiandrosterone Sulfate; Double-Blind Method; Drug Therapy, | 2004 |
Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity.
Topics: Adolescent; Adult; Blood Glucose; Dehydroepiandrosterone Sulfate; Double-Blind Method; Drug Therapy, | 2004 |
Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity.
Topics: Adolescent; Adult; Blood Glucose; Dehydroepiandrosterone Sulfate; Double-Blind Method; Drug Therapy, | 2004 |
Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity.
Topics: Adolescent; Adult; Blood Glucose; Dehydroepiandrosterone Sulfate; Double-Blind Method; Drug Therapy, | 2004 |
Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of metformin at the start and after more than one year of therapy.
Topics: Adolescent; Adult; Androstenes; Arteriosclerosis; Drug Therapy, Combination; Ethinyl Estradiol; Fema | 2005 |
Pregnancy loss, polycystic ovary syndrome, thrombophilia, hypofibrinolysis, enoxaparin, metformin.
Topics: Abortion, Habitual; Abortion, Spontaneous; Adult; Blood Coagulation Disorders; Case-Control Studies; | 2004 |
[Clinical study on treating insulin resistance and promoting ovulation in polycystic ovary syndrome].
Topics: Adult; Body Mass Index; Clomiphene; Drug Therapy, Combination; Female; Humans; Insulin Resistance; M | 2004 |
Comparison of the effects of acarbose and metformin use on ovulation rates in clomiphene citrate-resistant polycystic ovary syndrome.
Topics: Acarbose; Adult; Blood Glucose; Clomiphene; Drug Resistance; Female; Follicle Stimulating Hormone; H | 2005 |
Effects of metformin treatment on luteal phase progesterone concentration in polycystic ovary syndrome.
Topics: Adolescent; Adult; Analysis of Variance; Case-Control Studies; Clomiphene; Female; Fertility Agents, | 2004 |
Metformin versus sibutramine in the treatment of hyperinsulinemia in chronically anovulating women.
Topics: Adult; Anovulation; Appetite Depressants; Body Mass Index; Chronic Disease; Cyclobutanes; Diet, Redu | 2004 |
Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome.
Topics: Adult; Blood Pressure; Body Mass Index; Body Weight; Cholesterol; Enzyme Inhibitors; Female; Humans; | 2005 |
Does metformin induce ovulation in normoandrogenic anovulatory women?
Topics: Adult; Drug Administration Schedule; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; Insulin; | 2004 |
Metformin therapy in women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Body Mass Index; Cholesterol; Female; Follicle Stimulating Hormone; Glucose Toler | 2004 |
The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients.
Topics: Adult; Androgens; Contraceptives, Oral, Combined; Female; Humans; Hypoglycemic Agents; Insulin Resis | 2005 |
The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients.
Topics: Adult; Androgens; Contraceptives, Oral, Combined; Female; Humans; Hypoglycemic Agents; Insulin Resis | 2005 |
The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients.
Topics: Adult; Androgens; Contraceptives, Oral, Combined; Female; Humans; Hypoglycemic Agents; Insulin Resis | 2005 |
The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients.
Topics: Adult; Androgens; Contraceptives, Oral, Combined; Female; Humans; Hypoglycemic Agents; Insulin Resis | 2005 |
Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Androgens; Blood Glucose; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; | 2005 |
Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Androgens; Blood Glucose; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; | 2005 |
Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Androgens; Blood Glucose; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; | 2005 |
Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Androgens; Blood Glucose; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; | 2005 |
Homocysteine levels in women with polycystic ovary syndrome treated with metformin versus rosiglitazone: a randomized study.
Topics: Adult; Anovulation; Blood Glucose; Body Weight; Female; Folic Acid; Homocysteine; Humans; Hypoglycem | 2005 |
Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome.
Topics: Adult; Area Under Curve; Blood Glucose; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resist | 2005 |
Metformin reduces serum mullerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment.
Topics: Adult; Androstenedione; Anti-Mullerian Hormone; Female; Glycoproteins; Humans; Hypoglycemic Agents; | 2005 |
Combined use of metformin and ethinyl estradiol-cyproterone acetate in polycystic ovary syndrome.
Topics: Adult; Androgen Antagonists; Body Mass Index; Cyproterone Acetate; Dehydroepiandrosterone Sulfate; D | 2005 |
Metformin versus flutamide in the treatment of metabolic consequences of non-obese young women with polycystic ovary syndrome: a randomized prospective study.
Topics: Adolescent; Adult; Blood Glucose; Body Mass Index; Dehydroepiandrosterone Sulfate; Female; Flutamide | 2004 |
Increased insulin-like growth factor-I levels in women with polycystic ovary syndrome, and beneficial effects of metformin therapy.
Topics: 17-alpha-Hydroxyprogesterone; Adult; Body Mass Index; Dehydroepiandrosterone Sulfate; Estradiol; Fem | 2004 |
Effects of metformin and ethinyl estradiol-cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome.
Topics: Adult; Androgen Antagonists; Cardiovascular Diseases; Cholesterol; Cyproterone Acetate; Ethinyl Estr | 2005 |
Administration of B-group vitamins reduces circulating homocysteine in polycystic ovarian syndrome patients treated with metformin: a randomized trial.
Topics: Adolescent; Adult; Blood Glucose; Body Weight; Dose-Response Relationship, Drug; Female; Folic Acid; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Prospective parallel randomized, double-blind, double-dummy controlled clinical trial comparing clomiphene citrate and metformin as the first-line treatment for ovulation induction in nonobese anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; | 2005 |
Metformin administration improves endothelial function in women with polycystic ovary syndrome.
Topics: Adult; Brachial Artery; Endothelin-1; Endothelium, Vascular; Female; Glucose Intolerance; Humans; Hy | 2005 |
Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses.
Topics: Administration, Oral; Androstenedione; Blood Glucose; Dehydroepiandrosterone Sulfate; Female; Humans | 2005 |
Estimating live birth rates after ovulation induction in polycystic ovary syndrome: sample size calculations for the pregnancy in polycystic ovary syndrome trial.
Topics: Adolescent; Adult; Anovulation; Birth Rate; Clomiphene; Drug Therapy, Combination; Female; Humans; M | 2005 |
Ultra-short metformin pretreatment for clomiphene citrate-resistant polycystic ovary syndrome.
Topics: Adult; Clomiphene; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; Female; | 2005 |
Serum and follicular fluid levels of soluble Fas, soluble Fas ligand and apoptosis of luteinized granulosa cells in PCOS patients undergoing IVF.
Topics: Adult; Apoptosis; Biomarkers; Fas Ligand Protein; fas Receptor; Female; Fertilization in Vitro; Foll | 2005 |
A randomized controlled trial evaluating metformin pre-treatment and co-administration in non-obese insulin-resistant women with polycystic ovary syndrome treated with controlled ovarian stimulation plus timed intercourse or intrauterine insemination.
Topics: Adult; Area Under Curve; Chorionic Gonadotropin; Female; Follicle Stimulating Hormone; Gonadotropins | 2005 |
A randomized controlled trial evaluating metformin pre-treatment and co-administration in non-obese insulin-resistant women with polycystic ovary syndrome treated with controlled ovarian stimulation plus timed intercourse or intrauterine insemination.
Topics: Adult; Area Under Curve; Chorionic Gonadotropin; Female; Follicle Stimulating Hormone; Gonadotropins | 2005 |
A randomized controlled trial evaluating metformin pre-treatment and co-administration in non-obese insulin-resistant women with polycystic ovary syndrome treated with controlled ovarian stimulation plus timed intercourse or intrauterine insemination.
Topics: Adult; Area Under Curve; Chorionic Gonadotropin; Female; Follicle Stimulating Hormone; Gonadotropins | 2005 |
A randomized controlled trial evaluating metformin pre-treatment and co-administration in non-obese insulin-resistant women with polycystic ovary syndrome treated with controlled ovarian stimulation plus timed intercourse or intrauterine insemination.
Topics: Adult; Area Under Curve; Chorionic Gonadotropin; Female; Follicle Stimulating Hormone; Gonadotropins | 2005 |
A randomized controlled trial evaluating metformin pre-treatment and co-administration in non-obese insulin-resistant women with polycystic ovary syndrome treated with controlled ovarian stimulation plus timed intercourse or intrauterine insemination.
Topics: Adult; Area Under Curve; Chorionic Gonadotropin; Female; Follicle Stimulating Hormone; Gonadotropins | 2005 |
A randomized controlled trial evaluating metformin pre-treatment and co-administration in non-obese insulin-resistant women with polycystic ovary syndrome treated with controlled ovarian stimulation plus timed intercourse or intrauterine insemination.
Topics: Adult; Area Under Curve; Chorionic Gonadotropin; Female; Follicle Stimulating Hormone; Gonadotropins | 2005 |
A randomized controlled trial evaluating metformin pre-treatment and co-administration in non-obese insulin-resistant women with polycystic ovary syndrome treated with controlled ovarian stimulation plus timed intercourse or intrauterine insemination.
Topics: Adult; Area Under Curve; Chorionic Gonadotropin; Female; Follicle Stimulating Hormone; Gonadotropins | 2005 |
A randomized controlled trial evaluating metformin pre-treatment and co-administration in non-obese insulin-resistant women with polycystic ovary syndrome treated with controlled ovarian stimulation plus timed intercourse or intrauterine insemination.
Topics: Adult; Area Under Curve; Chorionic Gonadotropin; Female; Follicle Stimulating Hormone; Gonadotropins | 2005 |
A randomized controlled trial evaluating metformin pre-treatment and co-administration in non-obese insulin-resistant women with polycystic ovary syndrome treated with controlled ovarian stimulation plus timed intercourse or intrauterine insemination.
Topics: Adult; Area Under Curve; Chorionic Gonadotropin; Female; Follicle Stimulating Hormone; Gonadotropins | 2005 |
Effects of metformin combined with cyproterone acetate on clinical features, endocrine and metabolism of non-obese women with polycystic ovarian syndrome.
Topics: Adolescent; Adult; Androgen Antagonists; Androstenedione; Body Mass Index; Cyproterone Acetate; Drug | 2005 |
The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome.
Topics: Adult; Androgens; Antioxidants; Blood Glucose; Body Mass Index; Body Weight; Female; Homeostasis; Ho | 2005 |
Metformin treatment in patients with polycystic ovary syndrome undergoing in vitro fertilization: a prospective randomized trial.
Topics: Adult; Female; Fertilization in Vitro; Humans; Live Birth; Metformin; Polycystic Ovary Syndrome; Pre | 2005 |
Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study.
Topics: Adult; Anthropometry; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Insulin Resistance; | 2006 |
Randomized controlled trial evaluating response to metformin versus standard therapy in the treatment of adolescents with polycystic ovary syndrome.
Topics: Adolescent; Adult; Androgens; Child; Contraceptives, Oral; Female; Humans; Hyperinsulinism; Hypoglyc | 2005 |
Uterine effects of metformin administration in anovulatory women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Endometrium; Female; Fertility Agents; Humans; Menstruation-Inducing Agents; Met | 2006 |
Impact of metformin therapy in patients with polycystic ovarian syndrome.
Topics: Adult; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome | 2005 |
Predictive value of glucose-insulin ratio in PCOS and profile of women who will benefit from metformin therapy: obese, lean, hyper or normoinsulinemic?
Topics: Adiposity; Adult; Blood Glucose; Body Mass Index; Double-Blind Method; Female; Humans; Hyperinsulini | 2005 |
The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome.
Topics: Adult; Androstenedione; Female; Glucose Tolerance Test; Hirsutism; Humans; Hypoglycemic Agents; Insu | 2005 |
Metformin administration and laparoscopic ovarian drilling improve ovarian response to clomiphene citrate (CC) in oligo-anovulatory CC-resistant women with polycystic ovary syndrome.
Topics: Adult; Clomiphene; Combined Modality Therapy; Female; Fertility Agents, Female; Humans; Hypoglycemic | 2005 |
Early effects of metformin in women with polycystic ovary syndrome: a prospective randomized, double-blind, placebo-controlled trial.
Topics: Adult; Anovulation; Blood Glucose; Body Mass Index; Double-Blind Method; Female; Humans; Hypoglycemi | 2006 |
Metformin versus rosiglitazone in the treatment of polycystic ovary syndrome.
Topics: Adult; Body Mass Index; Dehydroepiandrosterone Sulfate; Female; Humans; Hyperandrogenism; Hypoglycem | 2006 |
Efficacy of combined metformin-letrozole in comparison with metformin-clomiphene citrate in clomiphene-resistant infertile women with polycystic ovarian disease.
Topics: Adult; Aromatase Inhibitors; Clomiphene; Drug Resistance; Drug Therapy, Combination; Endometrium; Fe | 2006 |
Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin.
Topics: Adult; C-Reactive Protein; Case-Control Studies; Cell Adhesion Molecules; E-Selectin; Female; Humans | 2006 |
Beneficial effect of metformin on pregnancy outcome in women with polycystic ovary syndrome is not associated with major changes in C-reactive protein levels or indices of coagulation.
Topics: Activated Protein C Resistance; Adult; Antithrombin III; Blood Coagulation; C-Reactive Protein; Fema | 2006 |
The use of metformin for women with PCOS undergoing IVF treatment.
Topics: Adult; Female; Fertilization in Vitro; Follicle Stimulating Hormone; Gonadotropin-Releasing Hormone; | 2006 |
The use of metformin for women with PCOS undergoing IVF treatment.
Topics: Adult; Female; Fertilization in Vitro; Follicle Stimulating Hormone; Gonadotropin-Releasing Hormone; | 2006 |
The use of metformin for women with PCOS undergoing IVF treatment.
Topics: Adult; Female; Fertilization in Vitro; Follicle Stimulating Hormone; Gonadotropin-Releasing Hormone; | 2006 |
The use of metformin for women with PCOS undergoing IVF treatment.
Topics: Adult; Female; Fertilization in Vitro; Follicle Stimulating Hormone; Gonadotropin-Releasing Hormone; | 2006 |
Randomized placebo-controlled trial of metformin for adolescents with polycystic ovary syndrome.
Topics: Adolescent; Cholesterol, HDL; Double-Blind Method; Female; Glucose Tolerance Test; Humans; Hypoglyce | 2006 |
Two weeks of metformin improves clomiphene citrate-induced ovulation and metabolic profiles in women with polycystic ovary syndrome.
Topics: Adult; Clomiphene; Drug Administration Schedule; Drug Combinations; Female; Fertility Agents, Female | 2006 |
A randomized controlled trial of the efficacy of rosiglitazone and clomiphene citrate versus metformin and clomiphene citrate in women with clomiphene citrate-resistant polycystic ovary syndrome.
Topics: Adult; Clomiphene; Drug Resistance; Drug Therapy, Combination; Female; Fertility Agents, Female; Hor | 2006 |
No more surrogate end-points in randomised trials: the PCOSMIC trial protocol for women with polycystic ovary syndrome using metformin for infertility with clomiphene.
Topics: Adult; Clomiphene; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedu | 2006 |
Effects of short-term and long-term metformin treatment on menstrual cyclicity in women with polycystic ovary syndrome.
Topics: Adult; Female; Humans; Hyperinsulinism; Hypoglycemic Agents; Longitudinal Studies; Menstrual Cycle; | 2006 |
Effects of metformin on insulin resistance, androgen concentration, ovulation and pregnancy rates in women with polycystic ovary syndrome following laparoscopic ovarian drilling.
Topics: Adult; Androgens; Blood Glucose; Combined Modality Therapy; Electrocoagulation; Female; Humans; Hypo | 2006 |
Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial.
Topics: Adult; Clomiphene; Double-Blind Method; Drug Therapy, Combination; Female; Fertility Agents, Female; | 2006 |
Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial.
Topics: Adult; Clomiphene; Double-Blind Method; Drug Therapy, Combination; Female; Fertility Agents, Female; | 2006 |
Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial.
Topics: Adult; Clomiphene; Double-Blind Method; Drug Therapy, Combination; Female; Fertility Agents, Female; | 2006 |
Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial.
Topics: Adult; Clomiphene; Double-Blind Method; Drug Therapy, Combination; Female; Fertility Agents, Female; | 2006 |
Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial.
Topics: Adult; Clomiphene; Double-Blind Method; Drug Therapy, Combination; Female; Fertility Agents, Female; | 2006 |
Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial.
Topics: Adult; Clomiphene; Double-Blind Method; Drug Therapy, Combination; Female; Fertility Agents, Female; | 2006 |
Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial.
Topics: Adult; Clomiphene; Double-Blind Method; Drug Therapy, Combination; Female; Fertility Agents, Female; | 2006 |
Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial.
Topics: Adult; Clomiphene; Double-Blind Method; Drug Therapy, Combination; Female; Fertility Agents, Female; | 2006 |
Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial.
Topics: Adult; Clomiphene; Double-Blind Method; Drug Therapy, Combination; Female; Fertility Agents, Female; | 2006 |
Gonadotropin-releasing hormone antagonist and metformin for treatment of polycystic ovary syndrome patients undergoing in vitro fertilization-embryo transfer.
Topics: Chorionic Gonadotropin; Estradiol; Female; Fertilization in Vitro; Follicle Stimulating Hormone; Gon | 2006 |
Metformin treatment is effective in obese teenage girls with PCOS.
Topics: Adolescent; Estradiol; Female; Follicle Stimulating Hormone; Humans; Hypoglycemic Agents; Insulin Re | 2006 |
The effect of metformin on fat distribution and the metabolic syndrome in women with polycystic ovary syndrome--a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Anovulation; Cholesterol; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Intra-Abd | 2006 |
Metformin improves menstrual patterns, endocrine and metabolic profile in obese hyperinsulinemic women with a polycystic ovary syndrome.
Topics: Adult; Blood Glucose; Female; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin; Lipids; Menstru | 2006 |
Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study.
Topics: Adipose Tissue; Adult; Diet, Reducing; Drug Therapy, Combination; Energy Intake; Female; Flutamide; | 2006 |
Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study.
Topics: Adipose Tissue; Adult; Diet, Reducing; Drug Therapy, Combination; Energy Intake; Female; Flutamide; | 2006 |
Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study.
Topics: Adipose Tissue; Adult; Diet, Reducing; Drug Therapy, Combination; Energy Intake; Female; Flutamide; | 2006 |
Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study.
Topics: Adipose Tissue; Adult; Diet, Reducing; Drug Therapy, Combination; Energy Intake; Female; Flutamide; | 2006 |
Metformin-diet ameliorates coronary heart disease risk factors and facilitates resumption of regular menses in adolescents with polycystic ovary syndrome.
Topics: Adolescent; Adult; Cholesterol; Coronary Disease; Diet; Female; Humans; Insulin; Insulin Resistance; | 2006 |
Is metformin or clomiphene citrate more effective for ovulation induction in polycystic ovary syndrome?
Topics: Adult; Clomiphene; Double-Blind Method; Female; Humans; Metformin; Ovulation Induction; Polycystic O | 2006 |
The Pregnancy in Polycystic Ovary Syndrome study: baseline characteristics of the randomized cohort including racial effects.
Topics: Adolescent; Adult; Age Distribution; Clomiphene; Double-Blind Method; Drug Combinations; Female; Fer | 2006 |
Effects of metformin and clomiphene citrate on ovarian vascularity in patients with polycystic ovary syndrome.
Topics: Adult; Blood Flow Velocity; Clomiphene; Cohort Studies; Female; Humans; Infertility, Female; Metform | 2006 |
Comparison of clomiphene citrate, metformin, or the combination of both for first-line ovulation induction and achievement of pregnancy in 154 women with polycystic ovary syndrome.
Topics: Adult; Canada; Clomiphene; Comorbidity; Drug Combinations; Female; Fertility Agents, Female; Humans; | 2007 |
Changes in weight, papilledema, headache, visual field, and life status in response to diet and metformin in women with idiopathic intracranial hypertension with and without concurrent polycystic ovary syndrome or hyperinsulinemia.
Topics: Adolescent; Adult; Body Mass Index; Body Weight; Combined Modality Therapy; Diet, Reducing; Female; | 2006 |
Metformin reduces abortion in pregnant women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Adult; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndr | 2006 |
[Clinical, hormonal and biochemical changes after treatment with metformin and weight reduction in women with polycystic ovary syndrome].
Topics: Adolescent; Adult; Caloric Restriction; Exercise; Female; Hormones; Humans; Hypoglycemic Agents; Ins | 2006 |
Increase of multiple pregnancies caused by ovulation induction with gonadotropin in combination with metformin in infertile women with polycystic ovary syndrome.
Topics: Adult; Drug Therapy, Combination; Female; Gonadotropins; Humans; Infertility, Female; Metformin; Pol | 2007 |
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome.
Topics: Adult; Birth Rate; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; | 2007 |
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome.
Topics: Adult; Birth Rate; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; | 2007 |
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome.
Topics: Adult; Birth Rate; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; | 2007 |
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome.
Topics: Adult; Birth Rate; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; | 2007 |
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome.
Topics: Adult; Birth Rate; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; | 2007 |
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome.
Topics: Adult; Birth Rate; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; | 2007 |
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome.
Topics: Adult; Birth Rate; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; | 2007 |
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome.
Topics: Adult; Birth Rate; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; | 2007 |
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome.
Topics: Adult; Birth Rate; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; | 2007 |
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome.
Topics: Adult; Birth Rate; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; | 2007 |
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome.
Topics: Adult; Birth Rate; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; | 2007 |
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome.
Topics: Adult; Birth Rate; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; | 2007 |
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome.
Topics: Adult; Birth Rate; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; | 2007 |
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome.
Topics: Adult; Birth Rate; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; | 2007 |
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome.
Topics: Adult; Birth Rate; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; | 2007 |
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome.
Topics: Adult; Birth Rate; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; | 2007 |
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome.
Topics: Adult; Birth Rate; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; | 2007 |
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome.
Topics: Adult; Birth Rate; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; | 2007 |
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome.
Topics: Adult; Birth Rate; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; | 2007 |
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome.
Topics: Adult; Birth Rate; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; | 2007 |
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome.
Topics: Adult; Birth Rate; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; | 2007 |
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome.
Topics: Adult; Birth Rate; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; | 2007 |
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome.
Topics: Adult; Birth Rate; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; | 2007 |
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome.
Topics: Adult; Birth Rate; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; | 2007 |
Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome.
Topics: Adult; Birth Rate; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; | 2007 |
Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome.
Topics: Adult; Area Under Curve; Body Mass Index; Cardiovascular Physiological Phenomena; Contraceptives, Or | 2007 |
Metformin treatment in pregnant women with polycystic ovary syndrome--is reduced complication rate mediated by changes in the uteroplacental circulation?
Topics: Adult; Chi-Square Distribution; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Metformin; | 2007 |
N-acetyl cysteine vs. metformin in treatment of clomiphene citrate-resistant polycystic ovary syndrome: a prospective randomized controlled study.
Topics: Acetylcysteine; Adolescent; Adult; Blood Glucose; Clomiphene; Drug Resistance; Female; Humans; Insul | 2007 |
Prospective, randomized trial of metformin and vitamins for the reduction of plasma homocysteine in insulin-resistant polycystic ovary syndrome.
Topics: Adult; Female; Homocysteine; Humans; Insulin Resistance; Metformin; Polycystic Ovary Syndrome; Prosp | 2007 |
Effect of metformin on IGF-1 and IGFBP-1 levels in obese patients with polycystic ovary syndrome.
Topics: Female; Humans; Hypoglycemic Agents; Insulin-Like Growth Factor Binding Protein 1; Insulin-Like Grow | 2008 |
Homocysteine levels are unaffected by metformin treatment in both nonpregnant and pregnant women with polycystic ovary syndrome.
Topics: Female; Folic Acid; Homocysteine; Humans; Hypoglycemic Agents; Metformin; Methylenetetrahydrofolate | 2007 |
Metformin therapy in girls with polycystic ovary syndrome: a self-controlled clinical trial.
Topics: Adolescent; Adult; Dehydroepiandrosterone; Female; Follicle Stimulating Hormone; Humans; Hypoglycemi | 2007 |
Evaluation of endothelial function in women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Case-Control Studies; Endothelium, Vascular; Female; Follicular Phase; Humans; Hy | 2007 |
Evaluation of endothelial function in women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Case-Control Studies; Endothelium, Vascular; Female; Follicular Phase; Humans; Hy | 2007 |
Evaluation of endothelial function in women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Case-Control Studies; Endothelium, Vascular; Female; Follicular Phase; Humans; Hy | 2007 |
Evaluation of endothelial function in women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Case-Control Studies; Endothelium, Vascular; Female; Follicular Phase; Humans; Hy | 2007 |
The effects of metformin and rosiglitazone, alone and in combination, on the ovary and endometrium in polycystic ovary syndrome.
Topics: Adult; Biopsy, Needle; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, | 2007 |
Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome.
Topics: Administration, Oral; Adult; Androgen Antagonists; Androgens; Blood Glucose; Cardiovascular Diseases | 2007 |
Comparison of two doses of metformin (2.5 and 1.5 g/day) for the treatment of polycystic ovary syndrome and their effect on body mass index and waist circumference.
Topics: Adult; Body Mass Index; Body Weight; Dose-Response Relationship, Drug; Drug Administration Schedule; | 2007 |
Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia.
Topics: Adolescent; Adult; Amenorrhea; Female; Glucose Tolerance Test; Humans; Hyperandrogenism; Hyperinsuli | 2007 |
Effects of metformin treatment in women with polycystic ovary syndrome depends on insulin resistance.
Topics: Adult; Body Mass Index; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Polycyst | 2007 |
Insulin sensitivity after metformin suspension in normal-weight women with polycystic ovary syndrome.
Topics: Adult; Area Under Curve; Body Mass Index; Body Weight; Female; Glucose Clamp Technique; Hormones; Hu | 2007 |
Increased body iron stores of obese women with polycystic ovary syndrome are a consequence of insulin resistance and hyperinsulinism and are not a result of reduced menstrual losses.
Topics: Adolescent; Adult; Androgen Antagonists; Cyproterone Acetate; Drug Combinations; Ethinyl Estradiol; | 2007 |
C-reactive protein levels are unaffected by metformin during pretreatment and an IVF cycle in women with polycystic ovary syndrome.
Topics: Adult; Androgens; Biomarkers; Body Mass Index; C-Peptide; C-Reactive Protein; Double-Blind Method; F | 2008 |
Metformin in normal-weight hirsute women with polycystic ovary syndrome with normal insulin sensitivity.
Topics: Adolescent; Adult; Blood Glucose; Body Weight; Female; Hirsutism; Hormones; Humans; Hypoglycemic Age | 2007 |
Clomiphene citrate versus metformin as first-line approach for the treatment of anovulation in infertile patients with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Female; Fertility Agents, Female; Humans; Infertility, Female; Menst | 2007 |
Clomiphene citrate versus metformin as first-line approach for the treatment of anovulation in infertile patients with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Female; Fertility Agents, Female; Humans; Infertility, Female; Menst | 2007 |
Clomiphene citrate versus metformin as first-line approach for the treatment of anovulation in infertile patients with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Female; Fertility Agents, Female; Humans; Infertility, Female; Menst | 2007 |
Clomiphene citrate versus metformin as first-line approach for the treatment of anovulation in infertile patients with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Female; Fertility Agents, Female; Humans; Infertility, Female; Menst | 2007 |
Clomiphene citrate versus metformin as first-line approach for the treatment of anovulation in infertile patients with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Female; Fertility Agents, Female; Humans; Infertility, Female; Menst | 2007 |
Clomiphene citrate versus metformin as first-line approach for the treatment of anovulation in infertile patients with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Female; Fertility Agents, Female; Humans; Infertility, Female; Menst | 2007 |
Clomiphene citrate versus metformin as first-line approach for the treatment of anovulation in infertile patients with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Female; Fertility Agents, Female; Humans; Infertility, Female; Menst | 2007 |
Clomiphene citrate versus metformin as first-line approach for the treatment of anovulation in infertile patients with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Female; Fertility Agents, Female; Humans; Infertility, Female; Menst | 2007 |
Clomiphene citrate versus metformin as first-line approach for the treatment of anovulation in infertile patients with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Female; Fertility Agents, Female; Humans; Infertility, Female; Menst | 2007 |
Metformin administration improves leukocyte count in women with polycystic ovary syndrome: a 6-month prospective study.
Topics: Adolescent; Adult; C-Reactive Protein; Drug Administration Schedule; Female; Humans; Hypoglycemic Ag | 2007 |
Metformin treatment does not affect total leptin levels and free leptin index in obese patients with polycystic ovary syndrome.
Topics: Adult; Female; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin; Leptin; Metformin; Obesity; Po | 2008 |
[Effect of lifestyle adjustment, metformin and rosiglitazone in polycystic ovary syndrome].
Topics: Adult; Body Mass Index; Drug Therapy, Combination; Exercise; Female; Humans; Insulin; Life Style; Li | 2007 |
Prevention of gestational diabetes by metformin plus diet in patients with polycystic ovary syndrome.
Topics: Adult; Blood Glucose; Body Weight; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Insul | 2008 |
Efficacy of metformin in obese and non-obese women with polycystic ovary syndrome: a randomized, double-blinded, placebo-controlled cross-over trial.
Topics: Adolescent; Adult; Body Weight; Cross-Over Studies; Double-Blind Method; Female; Humans; Insulin; Me | 2007 |
[Clinical effects of metformin in patients with polcystic ovarian syndrome].
Topics: Adult; Female; Humans; Metformin; Polycystic Ovary Syndrome; Prospective Studies | 2007 |
Dietary intervention versus metformin to improve the reproductive outcome in women with polycystic ovary syndrome. A prospective comparative study.
Topics: Adult; Chi-Square Distribution; Diet, Reducing; Female; Humans; Hypoglycemic Agents; Menstruation; M | 2007 |
Ovulatory response to treatment of polycystic ovary syndrome is associated with a polymorphism in the STK11 gene.
Topics: Adult; AMP-Activated Protein Kinase Kinases; Body Mass Index; Double-Blind Method; Female; Genotype; | 2008 |
Effect of metformin pretreatment on pregnancy outcome of in vitro matured oocytes retrieved from women with polycystic ovary syndrome.
Topics: Adult; Female; Fertilization in Vitro; Humans; Hypoglycemic Agents; Infertility, Female; Metformin; | 2008 |
Medication adherence and treatment success in the National Institute of Child Health and Human Development-Reproductive Medicine Network's Pregnancy in Polycystic Ovary Syndrome Trial.
Topics: Clomiphene; Community Networks; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; | 2008 |
Alteration of ghrelin-neuropeptide Y network in obese patients with polycystic ovary syndrome: role of hyperinsulinism.
Topics: Adult; Female; Ghrelin; Glucose Tolerance Test; Humans; Hyperinsulinism; Hypoglycemic Agents; Insuli | 2008 |
Possible metformin effect on adrenal androgens during pretreatment and IVF cycle in women with polycystic ovary syndrome.
Topics: Adrenal Glands; Adult; Androgens; Body Mass Index; Chorionic Gonadotropin; Dehydroepiandrosterone Su | 2009 |
Comparison of clomiphene citrate, metformin, or the combination of both for first-line ovulation induction, achievement of pregnancy, and live birth in Asian women with polycystic ovary syndrome: a randomized controlled trial.
Topics: Adult; Anovulation; Asian People; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, F | 2009 |
Impact of metformin and rosiglitazone treatment on glucose transporter 4 mRNA expression in women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Analysis of Variance; Androgens; Female; Gene Expression; Glucose Transporter Typ | 2008 |
Serum uric acid concentration as non-classic cardiovascular risk factor in women with polycystic ovary syndrome: effect of treatment with ethinyl-estradiol plus cyproterone acetate versus metformin.
Topics: Adolescent; Adult; Body Mass Index; Cross-Sectional Studies; Cyproterone Acetate; Drug Combinations; | 2008 |
Retinol-binding protein 4 and insulin resistance in polycystic ovary syndrome.
Topics: Adult; Body Mass Index; Contraceptives, Oral; Cyproterone; Ethinyl Estradiol; Female; Glucose Tolera | 2008 |
A comparison between rimonabant and metformin in reducing biochemical hyperandrogenaemia and insulin resistance in patients with polycystic ovary syndrome (PCOS): a randomized open-label parallel study.
Topics: Adult; Female; Humans; Hyperandrogenism; Insulin Resistance; Metformin; Piperidines; Polycystic Ovar | 2008 |
Metformin increases fasting plasma peptide tyrosine tyrosine (PYY) in women with polycystic ovarian syndrome (PCOS).
Topics: Adult; Fasting; Female; Humans; Metformin; Peptide YY; Polycystic Ovary Syndrome; Waist Circumferenc | 2008 |
Efficacy predictors for metformin and clomiphene citrate treatment in anovulatory infertile patients with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Estradiol; Female; Fertility Agents; Follicle Stimulating Hormone; H | 2009 |
Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome.
Topics: Adiponectin; Adult; Body Weight; Drug Therapy, Combination; Exenatide; Female; Humans; Lipids; Menst | 2008 |
Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome.
Topics: Adiponectin; Adult; Body Weight; Drug Therapy, Combination; Exenatide; Female; Humans; Lipids; Menst | 2008 |
Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome.
Topics: Adiponectin; Adult; Body Weight; Drug Therapy, Combination; Exenatide; Female; Humans; Lipids; Menst | 2008 |
Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome.
Topics: Adiponectin; Adult; Body Weight; Drug Therapy, Combination; Exenatide; Female; Humans; Lipids; Menst | 2008 |
Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome.
Topics: Adiponectin; Adult; Body Weight; Drug Therapy, Combination; Exenatide; Female; Humans; Lipids; Menst | 2008 |
Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome.
Topics: Adiponectin; Adult; Body Weight; Drug Therapy, Combination; Exenatide; Female; Humans; Lipids; Menst | 2008 |
Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome.
Topics: Adiponectin; Adult; Body Weight; Drug Therapy, Combination; Exenatide; Female; Humans; Lipids; Menst | 2008 |
Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome.
Topics: Adiponectin; Adult; Body Weight; Drug Therapy, Combination; Exenatide; Female; Humans; Lipids; Menst | 2008 |
Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome.
Topics: Adiponectin; Adult; Body Weight; Drug Therapy, Combination; Exenatide; Female; Humans; Lipids; Menst | 2008 |
Does adding metformin to clomifene citrate lead to higher pregnancy rates in a subset of women with polycystic ovary syndrome?
Topics: Adult; Anovulation; Clomiphene; Drug Therapy, Combination; Female; Humans; Infertility, Female; Metf | 2008 |
Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome.
Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adult; Blood Glucose; Female; Humans; Hydroxyprogesterones | 1996 |
Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome.
Topics: Adult; Androgens; Female; Glucose; Glucose Tolerance Test; Gonadotropins; Humans; Hypoglycemic Agent | 1997 |
Menstrual cyclicity after metformin therapy in polycystic ovary syndrome.
Topics: Adult; Female; Humans; Menstruation; Metformin; Periodicity; Polycystic Ovary Syndrome; Prospective | 1997 |
Treatment of hyperinsulinaemia in polycystic ovary syndrome?
Topics: Chromans; Diazoxide; Female; Humans; Hyperinsulinism; Hypoglycemic Agents; Metformin; Polycystic Ova | 1998 |
Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome.
Topics: Adult; Androstenedione; Blood Glucose; Female; Glucose Clamp Technique; Humans; Hyperandrogenism; Hy | 1998 |
Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome.
Topics: 17-alpha-Hydroxyprogesterone; Adult; Androstenedione; Blood Glucose; Cohort Studies; Dehydroepiandro | 1998 |
Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome.
Topics: Adult; Clomiphene; Female; Fertility Agents, Female; Humans; Hyperinsulinism; Hypoglycemic Agents; M | 1998 |
Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome.
Topics: Adult; Clomiphene; Female; Fertility Agents, Female; Humans; Hyperinsulinism; Hypoglycemic Agents; M | 1998 |
Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome.
Topics: Adult; Clomiphene; Female; Fertility Agents, Female; Humans; Hyperinsulinism; Hypoglycemic Agents; M | 1998 |
Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome.
Topics: Adult; Clomiphene; Female; Fertility Agents, Female; Humans; Hyperinsulinism; Hypoglycemic Agents; M | 1998 |
Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome.
Topics: Adult; Clomiphene; Female; Fertility Agents, Female; Humans; Hyperinsulinism; Hypoglycemic Agents; M | 1998 |
Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome.
Topics: Adult; Clomiphene; Female; Fertility Agents, Female; Humans; Hyperinsulinism; Hypoglycemic Agents; M | 1998 |
Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome.
Topics: Adult; Clomiphene; Female; Fertility Agents, Female; Humans; Hyperinsulinism; Hypoglycemic Agents; M | 1998 |
Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome.
Topics: Adult; Clomiphene; Female; Fertility Agents, Female; Humans; Hyperinsulinism; Hypoglycemic Agents; M | 1998 |
Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome.
Topics: Adult; Clomiphene; Female; Fertility Agents, Female; Humans; Hyperinsulinism; Hypoglycemic Agents; M | 1998 |
Decreased serum leptin concentrations during metformin therapy in obese women with polycystic ovary syndrome.
Topics: Adult; Analysis of Variance; Drug Administration Schedule; Female; Humans; Hypoglycemic Agents; Lept | 1998 |
Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome.
Topics: Adult; Amenorrhea; Blood Glucose; Blood Pressure; Body Mass Index; Female; Hormones; Humans; Hypogly | 1999 |
Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome.
Topics: Adult; Androstenedione; Clomiphene; Drug Therapy, Combination; Estradiol; Female; Fertility Agents, | 1999 |
Effects of metformin on adrenal steroidogenesis in women with polycystic ovary syndrome.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Adult; Female; Humans; Hypoglycemic Agents; Me | 1999 |
Metformin treatment reduces ovarian cytochrome P-450c17alpha response to human chorionic gonadotrophin in women with insulin resistance-related polycystic ovary syndrome.
Topics: 17-alpha-Hydroxyprogesterone; Adult; Chorionic Gonadotropin; Female; Humans; Hyperinsulinism; Hypogl | 2000 |
Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.
Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adult; Blood Glucose; Buserelin; Cholesterol; Double-Blind | 2000 |
Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.
Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adult; Blood Glucose; Buserelin; Cholesterol; Double-Blind | 2000 |
Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.
Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adult; Blood Glucose; Buserelin; Cholesterol; Double-Blind | 2000 |
Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.
Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adult; Blood Glucose; Buserelin; Cholesterol; Double-Blind | 2000 |
[Role of hyperinsulinemia in pathogenesis of polycystic ovary syndrome and treatment by reduction of insulin secretion].
Topics: Adult; Androgens; Female; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin; Metformin; Polycyst | 1998 |
Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome.
Topics: Administration, Oral; Adult; Fasting; Female; Humans; Hyperandrogenism; Hyperinsulinism; Hypoglycemi | 2000 |
Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.
Topics: Abdomen; Adipose Tissue; Adult; Androgens; Body Composition; Combined Modality Therapy; Diet, Reduci | 2000 |
Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study.
Topics: Adult; Androgen Antagonists; Area Under Curve; Blood Glucose; Calorimetry; Cyproterone Acetate; Estr | 2000 |
Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study.
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Adult; Birth Weight; Female; Health Status Indic | 2001 |
Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone.
Topics: Adolescent; Adult; Androstenedione; Body Mass Index; Clomiphene; Dehydroepiandrosterone Sulfate; Dou | 2001 |
Insulin reduction with metformin increases luteal phase serum glycodelin and insulin-like growth factor-binding protein 1 concentrations and enhances uterine vascularity and blood flow in the polycystic ovary syndrome.
Topics: Adult; Blood Flow Velocity; Clomiphene; Female; Follicular Phase; Glycodelin; Glycoproteins; Humans; | 2001 |
Insulin, leptin, IGF-I and insulin-dependent protein concentrations after insulin-sensitizing therapy in obese women with polycystic ovary syndrome.
Topics: Adult; Blood Glucose; Diet, Reducing; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistan | 2001 |
Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene-resistant polycystic ovaries: a randomized, double-blinded placebo-controlled trial.
Topics: Adult; Body Mass Index; Clomiphene; Double-Blind Method; Drug Resistance; Female; Fertility Agents, | 2001 |
Metformin to restore normal menses in oligo-amenorrheic teenage girls with polycystic ovary syndrome (PCOS).
Topics: Adolescent; Amenorrhea; Blood Glucose; Case-Control Studies; Cohort Studies; Dietary Carbohydrates; | 2001 |
Insulin resistance in clomiphene responders and non-responders with polycystic ovarian disease and therapeutic effects of metformin.
Topics: Adult; Analysis of Variance; Blood Glucose; Body Mass Index; Clomiphene; Female; Fertility Agents, F | 2001 |
Insulin resistance in clomiphene responders and non-responders with polycystic ovarian disease and therapeutic effects of metformin.
Topics: Adult; Analysis of Variance; Blood Glucose; Body Mass Index; Clomiphene; Female; Fertility Agents, F | 2001 |
Insulin resistance in clomiphene responders and non-responders with polycystic ovarian disease and therapeutic effects of metformin.
Topics: Adult; Analysis of Variance; Blood Glucose; Body Mass Index; Clomiphene; Female; Fertility Agents, F | 2001 |
Insulin resistance in clomiphene responders and non-responders with polycystic ovarian disease and therapeutic effects of metformin.
Topics: Adult; Analysis of Variance; Blood Glucose; Body Mass Index; Clomiphene; Female; Fertility Agents, F | 2001 |
Metformin therapy improves ovulatory rates, cervical scores, and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome.
Topics: Adult; Clomiphene; Double-Blind Method; Drug Resistance; Female; Fertility Agents, Female; Gonadal S | 2002 |
Co-administration of metformin during rFSH treatment in patients with clomiphene citrate-resistant polycystic ovarian syndrome: a prospective randomized trial.
Topics: Adult; Clomiphene; Dose-Response Relationship, Drug; Drug Resistance; Drug Therapy, Combination; Fem | 2002 |
Metformin does not enhance ovulation induction in clomiphene resistant polycystic ovary syndrome in clinical practice.
Topics: Adult; Clomiphene; Cross-Over Studies; Double-Blind Method; Drug Resistance; Female; Fertility Agent | 2002 |
The effect of metformin plus clomiphene citrate on ovulation and pregnancy rates in clomiphene-resistant women with polycystic ovary syndrome.
Topics: Adult; Clomiphene; Drug Resistance; Drug Therapy, Combination; Female; Fertility Agents, Female; Hum | 2002 |
Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study.
Topics: Adolescent; Adult; Androstenedione; Body Constitution; Body Mass Index; Cyproterone Acetate; Drug Th | 2002 |
514 other studies available for metformin and Polycystic Ovarian Syndrome
| Article | Year |
|---|---|
Metformin and exenatide upregulate hepatocyte nuclear factor-4α, sex hormone binding globulin levels and improve hepatic triglyceride deposition in polycystic ovary syndrome with insulin resistance rats.
Topics: Animals; Body Weight; Estrous Cycle; Exenatide; Female; Glucose Tolerance Test; Hepatocyte Nuclear F | 2021 |
Repurposing new drug candidates and identifying crucial molecules underlying PCOS Pathogenesis Based On Bioinformatics Analysis.
Topics: Computational Biology; Databases, Protein; Drug Repositioning; Female; Gene Expression Regulation; H | 2021 |
Effects of Metformin on Reproductive, Endocrine, and Metabolic Characteristics of Female Offspring in a Rat Model of Letrozole-Induced Polycystic Ovarian Syndrome With Insulin Resistance.
Topics: Animals; Animals, Newborn; Antineoplastic Agents; Female; Hyperinsulinism; Hypoglycemic Agents; Insu | 2021 |
Metformin improves epigenetic modification involved in oocyte growth and embryo development in polycystic ovary syndrome mice model.
Topics: Animals; Dehydroepiandrosterone; Embryonic Development; Epigenesis, Genetic; Female; Metformin; Mice | 2021 |
Gestational weight gain, appetite regulating hormones, and metformin treatment in polycystic ovary syndrome: A longitudinal, placebo-controlled study.
Topics: Appetite; Body Mass Index; Cohort Studies; Female; Gestational Weight Gain; Ghrelin; Humans; Leptin; | 2022 |
Metformin serum concentrations during pregnancy and post partum - A clinical study in patients with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Female; Humans; Hypoglycemic Agents; Infant, Newborn; Metformin; Polycystic O | 2022 |
What Is Polycystic Ovary Syndrome?
Topics: Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Pregnancy; Symptom Assess | 2022 |
Diane-35 and Metformin Induce Autophagy and Apoptosis in Polycystic Ovary Syndrome Women with Early-Stage Endometrial Carcinoma.
Topics: Androgen Antagonists; Animals; Apoptosis; Autophagy; Cyproterone Acetate; Drug Combinations; Drug Th | 2022 |
A decrease in cluster of differentiation 2 expression on natural killer cells is associated with polycystic ovary syndrome but not influenced by metformin in a mouse model†.
Topics: Animals; Disease Models, Animal; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Killer Cel | 2022 |
Pregnancy, perinatal and childhood outcomes in women with and without polycystic ovary syndrome and metformin during pregnancy: a nationwide population-based study.
Topics: Adult; Child; Child, Preschool; Cohort Studies; Diabetes, Gestational; Female; Humans; Infant, Newbo | 2022 |
Large randomized controlled trials in reproductive medicine: another battle won by biases and confounders?
Topics: Acupuncture Therapy; Bias; Female; Humans; Insulin Resistance; Metformin; Polycystic Ovary Syndrome; | 2022 |
Acupuncture for insulin sensitivity in women with polycystic ovary syndrome.
Topics: Acupuncture Therapy; Female; Glucose Tolerance Test; Humans; Insulin Resistance; Metformin; Polycyst | 2022 |
Gut microbiota dysbiosis-derived macrophage pyroptosis causes polycystic ovary syndrome via steroidogenesis disturbance and apoptosis of granulosa cells.
Topics: Animals; Apoptosis; Dehydroepiandrosterone; Disulfiram; DNA, Ribosomal; Dysbiosis; Estrogens; Female | 2022 |
The influence of ethnicity on outcomes of ovulation induction with clomifene citrate in women with PCOS.
Topics: Citrates; Clomiphene; Ethnicity; Female; Fertility Agents, Female; Humans; Infertility, Female; Male | 2022 |
The Effects of Letrozole and Metformin Combined with Targeted Nursing Care on Ovarian Function, LH, and FSH in Infertile Patients with Polycystic Ovary Syndrome.
Topics: Female; Follicle Stimulating Hormone; Humans; Infertility, Female; Letrozole; Metformin; Polycystic | 2022 |
Metformin Treatment Regulates the Expression of Molecules Involved in Adiponectin and Insulin Signaling Pathways in Endometria from Women with Obesity-Associated Insulin Resistance and PCOS.
Topics: Adiponectin; Endometrium; Female; Humans; Insulin; Insulin Resistance; Metformin; Obesity; Polycysti | 2022 |
At the crossroads of fertility and metabolism: the importance of AMPK-dependent signaling in female infertility associated with hyperandrogenism.
Topics: AMP-Activated Protein Kinases; Animals; Anti-Mullerian Hormone; Biological Phenomena; Female; Fertil | 2022 |
Spirulina therapeutic potentiality in polycystic ovarian syndrome management using DHEA-induced rat model.
Topics: Animals; bcl-2-Associated X Protein; Dehydroepiandrosterone; Disease Models, Animal; Female; Humans; | 2022 |
Role of metformin in functional endometrial hyperplasia and polycystic ovary syndrome involves the regulation of MEG3/miR‑223/GLUT4 and SNHG20/miR‑4486/GLUT4 signaling.
Topics: Animals; Carcinoma, Hepatocellular; Endometrial Hyperplasia; Endometrium; Female; Glucose Transporte | 2022 |
Prepregnancy Polycystic Ovary Syndrome as a Risk Factor of Subsequent Preterm Labor: A National Population-Based Cohort Study.
Topics: Cohort Studies; Female; Humans; Infant, Newborn; Metformin; Polycystic Ovary Syndrome; Pregnancy; Pr | 2022 |
Effects of Rosa damascena on reproductive improvement, metabolic parameters, liver function and insulin-like growth factor-1 gene expression in estradiol valerate induced polycystic ovarian syndrome in Wistar rats.
Topics: Animals; Estradiol; Female; Gene Expression; Humans; Insulin-Like Growth Factor I; Liver; Metformin; | 2023 |
Polycystic Ovary Syndrome in Adolescence: Challenges in Diagnosis and Management.
Topics: Adolescent; Female; Humans; Hyperandrogenism; Life Style; Menstruation Disturbances; Metformin; Poly | 2022 |
[The 495th case: young female-hyperandrogenemia-severe insulin resistance].
Topics: Acanthosis Nigricans; Adult; Diabetes Mellitus; Female; Hirsutism; Humans; Insulin; Insulin Resistan | 2022 |
Metformin, clomiphene citrate and flutamide effects on oocyte ultrastructure status and quality in PCOS mouse model.
Topics: Animals; Body Weight; Clomiphene; Female; Fertility Agents, Female; Flutamide; Humans; Infertility, | 2022 |
Metformin abrogates pathological TNF-α-producing B cells through mTOR-dependent metabolic reprogramming in polycystic ovary syndrome.
Topics: Animals; Dehydroepiandrosterone; Disease Models, Animal; Female; Humans; Metformin; Mice; Polycystic | 2022 |
The effect of metformin treatment on leukocyte telomere length in patients with polycystic ovary syndrome: a prospective case-control study.
Topics: Body Mass Index; C-Reactive Protein; Case-Control Studies; Female; Humans; Leukocytes; Metformin; Po | 2022 |
CXCL13 and CXCR5 are upregulated in PCOS mice ovaries but downregulated following metformin administration.
Topics: Animals; Chemokine CXCL13; Female; Humans; Metformin; Mice; Polycystic Ovary Syndrome; Receptors, CX | 2022 |
The Disparity in the Management of Polycystic Ovary Syndrome between Obstetrician-Gynecologists in Different-Level Hospitals under the Hierarchical Medical System.
Topics: Androgens; Blood Glucose; Female; Hospitals; Humans; Insulin Resistance; Letrozole; Lipids; Metformi | 2022 |
Lipids Alterations Associated with Metformin in Healthy Subjects: An Investigation Using Mass Spectrometry Shotgun Approach.
Topics: Arachidonic Acid; Diabetes Mellitus, Type 2; Female; Glycerophospholipids; Healthy Volunteers; Human | 2022 |
Kelulut Honey Improves Folliculogenesis, Steroidogenic, and Aromatase Enzyme Profiles and Ovarian Histomorphology in Letrozole-Induced Polycystic Ovary Syndrome Rats.
Topics: Animals; Aromatase; Clomiphene; Female; Honey; Letrozole; Metformin; Polycystic Ovary Syndrome; Rats | 2022 |
Nasturtium officinale L. and metformin alleviate the estradiol- induced polycystic ovary syndrome with synergistic effects through modulation of Bax/Bcl-2/p53/caspase-3 signaling pathway and anti-inflammatory and anti-oxidative effects.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; bcl-2-Associated X Protein; Caspase 3; Cytokines; E | 2022 |
Metformin is associated with reduced COVID-19 severity in patients with prediabetes.
Topics: COVID-19; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Prediabetic Sta | 2022 |
Metformin is associated with reduced COVID-19 severity in patients with prediabetes.
Topics: COVID-19; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Prediabetic Sta | 2022 |
Metformin is associated with reduced COVID-19 severity in patients with prediabetes.
Topics: COVID-19; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Prediabetic Sta | 2022 |
Metformin is associated with reduced COVID-19 severity in patients with prediabetes.
Topics: COVID-19; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Prediabetic Sta | 2022 |
Metformin is associated with reduced COVID-19 severity in patients with prediabetes.
Topics: COVID-19; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Prediabetic Sta | 2022 |
Metformin is associated with reduced COVID-19 severity in patients with prediabetes.
Topics: COVID-19; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Prediabetic Sta | 2022 |
Metformin is associated with reduced COVID-19 severity in patients with prediabetes.
Topics: COVID-19; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Prediabetic Sta | 2022 |
Metformin is associated with reduced COVID-19 severity in patients with prediabetes.
Topics: COVID-19; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Prediabetic Sta | 2022 |
Metformin is associated with reduced COVID-19 severity in patients with prediabetes.
Topics: COVID-19; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Prediabetic Sta | 2022 |
Kelulut Honey Regulates Sex Steroid Receptors in a Polycystic Ovary Syndrome Rat Model.
Topics: Animals; Clomiphene; Female; Gonadal Steroid Hormones; Honey; Humans; Letrozole; Metformin; Polycyst | 2022 |
Kelulut Honey Regulates Sex Steroid Receptors in a Polycystic Ovary Syndrome Rat Model.
Topics: Animals; Clomiphene; Female; Gonadal Steroid Hormones; Honey; Humans; Letrozole; Metformin; Polycyst | 2022 |
Kelulut Honey Regulates Sex Steroid Receptors in a Polycystic Ovary Syndrome Rat Model.
Topics: Animals; Clomiphene; Female; Gonadal Steroid Hormones; Honey; Humans; Letrozole; Metformin; Polycyst | 2022 |
Kelulut Honey Regulates Sex Steroid Receptors in a Polycystic Ovary Syndrome Rat Model.
Topics: Animals; Clomiphene; Female; Gonadal Steroid Hormones; Honey; Humans; Letrozole; Metformin; Polycyst | 2022 |
Use of metformin in patients who require intravascular administration of a contrast agent.
Topics: Contrast Media; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Resistance; | 2022 |
Use of metformin in patients who require intravascular administration of a contrast agent.
Topics: Contrast Media; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Resistance; | 2022 |
Use of metformin in patients who require intravascular administration of a contrast agent.
Topics: Contrast Media; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Resistance; | 2022 |
Use of metformin in patients who require intravascular administration of a contrast agent.
Topics: Contrast Media; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Resistance; | 2022 |
Ketogenic diet restores hormonal, apoptotic/proliferative balance and enhances the effect of metformin on a letrozole-induced polycystic ovary model in rats.
Topics: Animals; Diet, Ketogenic; Female; Humans; Letrozole; Metformin; Polycystic Ovary Syndrome; Rats | 2023 |
Ketogenic diet restores hormonal, apoptotic/proliferative balance and enhances the effect of metformin on a letrozole-induced polycystic ovary model in rats.
Topics: Animals; Diet, Ketogenic; Female; Humans; Letrozole; Metformin; Polycystic Ovary Syndrome; Rats | 2023 |
Ketogenic diet restores hormonal, apoptotic/proliferative balance and enhances the effect of metformin on a letrozole-induced polycystic ovary model in rats.
Topics: Animals; Diet, Ketogenic; Female; Humans; Letrozole; Metformin; Polycystic Ovary Syndrome; Rats | 2023 |
Ketogenic diet restores hormonal, apoptotic/proliferative balance and enhances the effect of metformin on a letrozole-induced polycystic ovary model in rats.
Topics: Animals; Diet, Ketogenic; Female; Humans; Letrozole; Metformin; Polycystic Ovary Syndrome; Rats | 2023 |
Does Pten have an impact on oogenesis of PCOS mouse models?
Topics: Animals; Clomiphene; Female; Metformin; Mice; Oogenesis; Ovulation Induction; Phosphatidylinositol 3 | 2023 |
Gestational weight gain, appetite-regulating hormones and metformin treatment in polycystic ovary syndrome: The importance of exclusion criteria.
Topics: Appetite; Female; Gestational Weight Gain; Hormones; Humans; Hypoglycemic Agents; Metformin; Polycys | 2023 |
[PCOS - desire for children and pregnancy].
Topics: Anovulation; Child; Female; Humans; Hyperandrogenism; Life Style; Metformin; Polycystic Ovary Syndro | 2023 |
Acupuncture combined with metformin for polycystic ovary syndrome: A protocol for systematic review and meta-analysis.
Topics: Acupuncture Therapy; Female; Humans; Hypoglycemic Agents; Meta-Analysis as Topic; Metformin; Polycys | 2022 |
The role of circulating miRNAs in mechanism of action and prediction of therapeutic responses of metformin in polycystic ovarian syndrome.
Topics: Anovulation; Cohort Studies; Female; Humans; Metformin; MicroRNAs; Polycystic Ovary Syndrome | 2023 |
Raised Thyroid-Stimulating Hormone in Girls with Polycystic Ovary Syndrome: Effects of Randomized Interventions.
Topics: Adolescent; Female; Humans; Metformin; Pioglitazone; Polycystic Ovary Syndrome; Randomized Controlle | 2023 |
Effects of metformin on clinical, hormonal and relevant gene expression parameters in patients with acne: an observational study.
Topics: Acne Vulgaris; Female; Gene Expression; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; In | 2023 |
Novel insights into the synergistic effects of selenium nanoparticles and metformin treatment of letrozole - induced polycystic ovarian syndrome: targeting PI3K/Akt signalling pathway, redox status and mitochondrial dysfunction in ovarian tissue.
Topics: Animals; Female; Humans; Insulin Resistance; Letrozole; Lipids; Metformin; Mitochondria; Nanoparticl | 2023 |
Pioglitazone can improve liver sex hormone-binding globulin levels and lipid metabolism in polycystic ovary syndrome by regulating hepatocyte nuclear factor-4α.
Topics: Animals; Female; Hepatocyte Nuclear Factors; Humans; Insulin; Insulin Resistance; Lipid Metabolism; | 2023 |
Metformin improves polycystic ovary syndrome in mice by inhibiting ovarian ferroptosis.
Topics: AMP-Activated Protein Kinases; Animals; Body Weight; Female; Ferroptosis; Humans; Insulin Resistance | 2023 |
Past and present: a bibliometric study on polycystic ovary syndrome.
Topics: Bibliometrics; Female; Humans; Insulin Resistance; Metformin; Obesity; Polycystic Ovary Syndrome | 2023 |
Ameliorative effect of sesame oil on experimentally induced polycystic ovary syndrome: A cross-link between XBP-1/PPAR-1, regulatory proteins for lipogenesis/steroids.
Topics: Animals; Disease Models, Animal; Female; Humans; Letrozole; Lipogenesis; Metformin; Peroxisome Proli | 2023 |
The homeostasis model assessment of insulin resistance is a judgment criterion for metformin pre-treatment before IVF/ICSI and embryo transfer cycles in patients with polycystic ovarian syndrome.
Topics: Embryo Transfer; Female; Fertilization in Vitro; Homeostasis; Humans; Insulin Resistance; Judgment; | 2023 |
Immunomodulatory Effects of Metformin Treatment in Pregnant Women With PCOS.
Topics: Abortion, Spontaneous; Cytokines; Female; Humans; Hypoglycemic Agents; Infant, Newborn; Metformin; P | 2023 |
Investigating the potential role of swertiamarin on insulin resistant and non-insulin resistant granulosa cells of poly cystic ovarian syndrome patients.
Topics: Female; Granulosa Cells; Humans; Insulin; Insulin Resistance; Metformin; Polycystic Ovary Syndrome | 2023 |
The Effect of Metformin and Carbohydrate-Controlled Diet on DNA Methylation and Gene Expression in the Endometrium of Women with Polycystic Ovary Syndrome.
Topics: Adult; Diet; DNA Methylation; Endometrium; Female; Gene Expression; Humans; Metformin; Polycystic Ov | 2023 |
Free leptin index, excessive weight gain, and metformin treatment during pregnancy in polycystic ovary syndrome: What about inflammation?
Topics: Female; Humans; Hypoglycemic Agents; Leptin; Metformin; Polycystic Ovary Syndrome; Pregnancy; Weight | 2023 |
Clinical and metabolic characteristics of endometrial lesions in polycystic ovary syndrome at reproductive age.
Topics: Contraceptives, Oral; Female; Gonadal Steroid Hormones; Humans; Metformin; Obesity; Polycystic Ovary | 2023 |
Naringenin improves ovarian health by reducing the serum androgen and eliminating follicular cysts in letrozole-induced polycystic ovary syndrome in the Sprague Dawley rats.
Topics: Androgens; Animals; Disease Models, Animal; Female; Follicular Cyst; Humans; Letrozole; Metformin; P | 2023 |
THE THERAPEUTIC EFFECT OF ORAL INSULIN SENSITIZER METFORMIN ON LIPID PROFILE IN WOMEN WITH POLYCYSTIC OVARY SYNDROME.
Topics: Case-Control Studies; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; P | 2023 |
Interaction between OCT1 and LPIN1 polymorphisms and response to pioglitazone-metformin tablets in patients with polycystic ovary syndrome.
Topics: Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Phosphatidate Phosphatase; Piogl | 2023 |
Metformin inhibits ovarian granular cell pyroptosis through the miR-670-3p/NOX2/ROS pathway.
Topics: Animals; Caspase 1; Female; Humans; Metformin; Mice; MicroRNAs; NLR Family, Pyrin Domain-Containing | 2023 |
Metagenomics study on taxonomic and functional change of gut microbiota in patients with obesity with PCOS treated with exenatide combination with metformin or metformin alone.
Topics: Exenatide; Female; Gastrointestinal Microbiome; Humans; Metagenomics; Metformin; Obesity; Polycystic | 2023 |
METFORMIN EFFECTS ON NEUREGULIN-1 IN POLYCYSTIC OVARIAN WOMEN.
Topics: Blood Glucose; Cross-Sectional Studies; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Insu | 2023 |
METFORMIN EFFECTS ON BLOOD LEVELS OF GREMLIN-1 IN POLYCYSTIC OVARIAN WOMEN.
Topics: Blood Glucose; Body Mass Index; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; In | 2023 |
Non-coding RNA genes modulate PI3K/AKT signaling pathway in polycystic ovary syndrome.
Topics: Female; Glucose; Humans; Insulin; Insulin Resistance; Metformin; MicroRNAs; Phosphatidylinositol 3-K | 2023 |
Effects of
Topics: Female; Follicle Stimulating Hormone, Human; Humans; Iraq; Kisspeptins; Metformin; Polycystic Ovary | 2023 |
Promising drug candidates for the treatment of polycystic ovary syndrome (PCOS) as alternatives to the classical medication metformin.
Topics: Animals; Female; Humans; Letrozole; Metformin; Polycystic Ovary Syndrome; Rats; Rats, Wistar | 2023 |
SGLT-2 inhibitors enhance the effect of metformin to ameliorate hormonal changes and inflammatory markers in a rat PCOS model.
Topics: Animals; Female; Gonadal Steroid Hormones; Humans; Insulin; Insulin Resistance; Metformin; Polycysti | 2023 |
Metformin and sitagliptin combination therapy ameliorates polycystic ovary syndrome with insulin resistance through upregulation of lncRNA H19.
Topics: Animals; Apoptosis; Cells, Cultured; DNA (Cytosine-5-)-Methyltransferase 1; Drug Therapy, Combinatio | 2019 |
Lean Women on Metformin and Oral Contraceptives for Polycystic Ovary Syndrome Demonstrate a Dehydrated Osteosarcopenic Phenotype: A Pilot Study.
Topics: Adult; Body Composition; Contraceptives, Oral; Female; Humans; Hypoglycemic Agents; Metformin; Pilot | 2019 |
Effects of metformin and Exenatide on insulin resistance and AMPKα-SIRT1 molecular pathway in PCOS rats.
Topics: AMP-Activated Protein Kinases; Androgens; Animals; Blood Glucose; Disease Models, Animal; Exenatide; | 2019 |
Polycystic ovary syndrome in adolescent girls.
Topics: Adolescent; Female; Humans; Metformin; Pioglitazone; Polycystic Ovary Syndrome; Spironolactone | 2020 |
The insulin-sensitizing mechanism of myo-inositol is associated with AMPK activation and GLUT-4 expression in human endometrial cells exposed to a PCOS environment.
Topics: Adult; AMP-Activated Protein Kinases; Cells, Cultured; Endometrium; Enzyme Activation; Female; Gluco | 2020 |
Awareness of polycystic ovary syndrome among obstetrician-gynecologists and endocrinologists in Northern Europe.
Topics: Adult; Comorbidity; Contraceptives, Oral; Cross-Sectional Studies; Endocrinologists; Europe; Female; | 2019 |
Both
Topics: Animals; Antioxidants; Chamomile; Female; Hypothyroidism; Matricaria; Metformin; Oxidative Stress; P | 2020 |
Risk of bipolar disorder in patients with polycystic ovary syndrome: A nationwide population-based cohort study.
Topics: Bipolar Disorder; Clomiphene; Cohort Studies; Female; Humans; Metformin; Polycystic Ovary Syndrome | 2020 |
Metformin, rosiglitazone, or both for obese women with polycystic ovary syndrome?
Topics: Female; Humans; Hypoglycemic Agents; Metformin; Obesity; Polycystic Ovary Syndrome; Rosiglitazone | 2020 |
Decreased Circulating MANF in Women with PCOS is Elevated by Metformin Therapy and is Inversely Correlated with Insulin Resistance and Hyperandrogenism.
Topics: Adult; Blood Glucose; Cross-Sectional Studies; Female; Glucose Tolerance Test; Humans; Hyperandrogen | 2020 |
Oral contraceptives increase platelet microparticle levels in normal-weight women with polycystic ovary syndrome.
Topics: Adult; Androgen Antagonists; Blood Platelets; Cell-Derived Microparticles; Contraceptives, Oral, Hor | 2020 |
Risk of schizophrenia in patients with polycystic ovary syndrome: a nationwide population-based cohort study from Taiwan.
Topics: Cohort Studies; Female; Humans; Metformin; Polycystic Ovary Syndrome; Schizophrenia; Taiwan | 2021 |
Alterations of endometrial epithelial-mesenchymal transition and MAPK signalling components in women with PCOS are partially modulated by metformin in vitro.
Topics: Adult; Case-Control Studies; Cells, Cultured; Endometrium; Epithelial-Mesenchymal Transition; Female | 2020 |
Study of the effect of metformin on expression levels of TNF-α and IL-18 in animal models of polycystic ovary syndrome.
Topics: Animals; Carboxymethylcellulose Sodium; Disease Models, Animal; Down-Regulation; Estradiol; Estrous | 2021 |
Metformin and acupuncture for polycystic ovary syndrome: A protocol for a systematic review and meta-analysis.
Topics: Acupuncture Therapy; Combined Modality Therapy; Female; Humans; Hypoglycemic Agents; Meta-Analysis a | 2020 |
Comparative efficacy of statins, metformin, spironolactone and combined oral contraceptives in reducing testosterone levels in women with polycystic ovary syndrome: a network meta-analysis of randomized clinical trials.
Topics: Contraceptives, Oral, Combined; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypo | 2020 |
Hyperandrogenism, insulin resistance and acanthosis nigricans (HAIR-AN syndrome): an extreme subphenotype of polycystic ovary syndrome.
Topics: Acanthosis Nigricans; Child; Contraceptives, Oral, Hormonal; Female; Humans; Hyperandrogenism; Insul | 2020 |
Nicotinamide and its metabolite N1-Methylnicotinamide alleviate endocrine and metabolic abnormalities in adipose and ovarian tissues in rat model of Polycystic Ovary Syndrome.
Topics: Adipose Tissue; AMP-Activated Protein Kinases; Animals; Cytokines; Estrous Cycle; Female; Gene Expre | 2020 |
Antidiabetic drug metformin affects the developmental competence of cleavage-stage embryos.
Topics: Adult; Animals; Blastocyst; Blood Glucose; Diabetes, Gestational; Disease Models, Animal; Embryonic | 2020 |
Metformin inhibits testosterone-induced endoplasmic reticulum stress in ovarian granulosa cells via inactivation of p38 MAPK.
Topics: Animals; China; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Endoribonucleases | 2020 |
Combined use of Diane-35 and metformin improves the ovulation in the PCOS rat model possibly via regulating glycolysis pathway.
Topics: Androgen Antagonists; Animals; Apoptosis; Body Weight; Cyproterone Acetate; Disease Models, Animal; | 2020 |
Metformin metabolic and vascular effects in normal weight hyperinsulinemic polycystic ovary syndrome patients treated with contraceptive vaginal ring. A pilot study.
Topics: Adult; Blood Glucose; Brachial Artery; Contraceptive Agents, Hormonal; Contraceptive Devices, Female | 2020 |
Comparing the effect of sitagliptin and metformin on the oocyte and embryo quality in classic PCOS patients undergoing ICSI.
Topics: Adult; Female; Humans; Metformin; Oocytes; Polycystic Ovary Syndrome; Sitagliptin Phosphate; Sperm I | 2021 |
Metformin doses and body mass index: clinical outcomes in insulin resistant polycystic ovary syndrome women.
Topics: Adult; Body Mass Index; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Hypoglycem | 2020 |
Metabolic impact of current therapeutic strategies in Polycystic Ovary Syndrome: a preliminary study.
Topics: Adolescent; Adult; Blood Glucose; Contraceptives, Oral, Combined; Female; Glycated Hemoglobin; Human | 2020 |
Pachymic acid protects oocyte by improving the ovarian microenvironment in polycystic ovary syndrome mice†.
Topics: Animals; Dehydroepiandrosterone; Disease Models, Animal; Female; Metformin; Mice; Oocytes; Ovary; Po | 2020 |
The effects of thylakoid-rich spinach extract and aqueous extract of caraway (Carum carvi L.) in letrozole-induced polycystic ovarian syndrome rats.
Topics: Animals; Biomarkers; Carum; Disease Models, Animal; Female; Hypoglycemic Agents; Iran; Letrozole; Me | 2020 |
Cost-effectiveness analysis of polycystic ovary syndrome management and the risk of gestational diabetes in pregnant women: a decision-tree model.
Topics: Adult; Cohort Studies; Cost-Benefit Analysis; Decision Trees; Diabetes, Gestational; Disease Progres | 2021 |
Successful IVF outcome after repeat laparoscopic ovarian drilling in a case of resistant PCOS.
Topics: Abortion, Habitual; Adult; Female; Fertilization in Vitro; Glucose Metabolism Disorders; Humans; Hyp | 2020 |
Gut microbiota in adolescent girls with polycystic ovary syndrome: Effects of randomized treatments.
Topics: Adolescent; Female; Gastrointestinal Microbiome; Humans; Metformin; Pioglitazone; Polycystic Ovary S | 2021 |
Sitagliptin/Metformin: A New Medical Treatment in Polycystic Ovary Syndrome.
Topics: Female; Humans; Menstrual Cycle; Metformin; Ovulation; Polycystic Ovary Syndrome; Sitagliptin Phosph | 2020 |
The efficacy of different insulin-sensitizing agents on treatment outcomes in patients with polycystic ovary syndrome who underwent in-vitro fertilization: A retrospective, record-based, comparative study.
Topics: Adult; Case-Control Studies; Cell Count; Chorionic Gonadotropin; Female; Fertilization in Vitro; Hum | 2021 |
TLR4-Associated IRF-7 and NFκB Signaling Act as a Molecular Link Between Androgen and Metformin Activities and Cytokine Synthesis in the PCOS Endometrium.
Topics: Adult; Androgens; Cytokines; Endometrial Hyperplasia; Endometrium; Female; Humans; Interferon Regula | 2021 |
Menstrual Dysfunction in PCOS.
Topics: Female; Humans; Menstruation Disturbances; Metformin; Ovulation; Ovulation Induction; Polycystic Ova | 2021 |
Synergic effect of bee pollen and metformin on proliferation and apoptosis of granulosa cells: Rat model of polycystic ovary syndrome.
Topics: Animals; Apoptosis; Bees; Cell Proliferation; Female; Granulosa Cells; Humans; Ki-67 Antigen; Metfor | 2022 |
Effects of total flavonoids from Eucommia ulmoides Oliv. leaves on polycystic ovary syndrome with insulin resistance model rats induced by letrozole combined with a high-fat diet.
Topics: Animals; Body Weight; Diet, High-Fat; Disease Models, Animal; Eucommiaceae; Female; Flavonoids; Gona | 2021 |
Care for Adolescents With Polycystic Ovary Syndrome: Development and Prescribing Patterns of a Multidisciplinary Clinic.
Topics: Adolescent; Adult; Alopecia; Child; Female; Hirsutism; Humans; Metformin; Polycystic Ovary Syndrome; | 2021 |
The Effect of Astaxanthin and Metformin on Oxidative Stress in Granulosa Cells of BALB C Mouse Model of Polycystic Ovary Syndrome.
Topics: Animals; Dehydroepiandrosterone; Female; Granulosa Cells; Metformin; Mice; Mice, Inbred BALB C; Oxid | 2021 |
Metformin reduces androgen receptor and upregulates homeobox A10 expression in uterine endometrium in women with polycystic ovary syndrome.
Topics: Adult; Cell Line; Embryo Implantation; Endometrium; Female; Homeobox A10 Proteins; Humans; Hypoglyce | 2021 |
The therapeutic effects of glucagon-like peptide-1 receptor agonists and metformin on polycystic ovary syndrome: A protocol for systematic review and meta-analysis.
Topics: Female; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Insulin Resistance; Meta-Anal | 2021 |
Polycystic Ovarian Syndrome in Adolescents: Keys to Diagnosis and Management.
Topics: Adolescent; Androgen Antagonists; Contraceptives, Oral; Female; Humans; Life Style; Metformin; Polyc | 2021 |
Decreased SFRP5 correlated with excessive metabolic inflammation in polycystic ovary syndrome could be reversed by metformin: implication of its role in dysregulated metabolism.
Topics: Adaptor Proteins, Signal Transducing; Adult; Case-Control Studies; Female; Humans; Inflammation; Met | 2021 |
Ameliorative effects of fisetin in letrozole-induced rat model of polycystic ovary syndrome.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents, Phytogenic; Blood Glucose; Carboxymet | 2021 |
Berberine improves ovulation and endometrial receptivity in polycystic ovary syndrome.
Topics: Animals; Berberine; Endometrium; Female; Metformin; Ovulation; Polycystic Ovary Syndrome; Rats | 2021 |
The effect of dapsone in testosterone enanthate-induced polycystic ovary syndrome in rat.
Topics: Androgens; Animals; Cytokines; Dapsone; Female; Inflammation; Metformin; Ovary; Polycystic Ovary Syn | 2021 |
Metformin Ameliorates Uterine Defects in a Rat Model of Polycystic Ovary Syndrome.
Topics: Animals; Chorionic Gonadotropin; Disease Models, Animal; Embryo Implantation; Estradiol; Estrous Cyc | 2017 |
Polycystic ovarian syndrome and the risk of subsequent primary ovarian insufficiency: a nationwide population-based study.
Topics: Adolescent; Adult; Databases, Factual; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ov | 2017 |
Metabolic and androgen profile in underweight women with polycystic ovary syndrome.
Topics: Adult; Androgens; Diabetes Mellitus, Type 2; Female; Glucose Tolerance Test; Humans; Hypoglycemic Ag | 2017 |
A comparative study between myo-inositol and metformin in the treatment of insulin-resistant women.
Topics: Adult; Body Mass Index; Fasting; Female; Folic Acid; Humans; Inositol; Insulin; Insulin Resistance; | 2017 |
Methodological issues in a meta-analysis.
Topics: Female; Humans; Metformin; Polycystic Ovary Syndrome; Randomized Controlled Trials as Topic; Researc | 2017 |
Metformin therapy for the reproductive and metabolic consequences of polycystic ovary syndrome.
Topics: Body Composition; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Polycystic Ova | 2017 |
Metformin reduces total microparticles and microparticles-expressing tissue factor in women with polycystic ovary syndrome.
Topics: Adult; Cell-Derived Microparticles; Female; Hemostatics; Humans; Hypoglycemic Agents; Metformin; Pol | 2017 |
Re: Inositol treatment of anovulation in women with polycystic ovary syndrome: a meta-analysis of randomised trials.
Topics: Anovulation; Female; Humans; Hypoglycemic Agents; Inositol; Metformin; Polycystic Ovary Syndrome | 2018 |
Combined transcriptome and metabolome analyses of metformin effects reveal novel links between metabolic networks in steroidogenic systems.
Topics: Adrenal Glands; Biomarkers; Cell Line; Female; Gene Expression Profiling; Gene Expression Regulation | 2017 |
Metformin increases norepinephrine transporter expression in placenta of patients with polycystic ovary syndrome.
Topics: Adult; Case-Control Studies; Female; Humans; Hypoglycemic Agents; Metformin; Norepinephrine Plasma M | 2017 |
Metformin Therapy for the Management of Infertility in Women with Polycystic Ovary Syndrome: Scientific Impact Paper No. 13.
Topics: Androgen Antagonists; Female; Humans; Infertility, Female; Insulin Resistance; Metformin; Polycystic | 2017 |
Beneficial effects of Heqi san on rat model of polycystic ovary syndrome through the PI3K/AKT pathway.
Topics: Animals; Dehydroepiandrosterone; Disease Models, Animal; DNA-Binding Proteins; Drugs, Chinese Herbal | 2017 |
Effect of orlistat or metformin in overweight and obese polycystic ovary syndrome patients with insulin resistance.
Topics: Adult; Anti-Obesity Agents; Cyproterone Acetate; Drug Combinations; Drug Therapy, Combination; Ethin | 2018 |
Re: Inositol treatment of anovulation in women with polycystic ovary syndrome: a meta-analysis of randomised trials.
Topics: Anovulation; Clomiphene; Female; Humans; Inositol; Metformin; Polycystic Ovary Syndrome | 2018 |
Authors' reply re: Inositol treatment of anovulation in women with polycystic ovary syndrome: a meta-analysis of randomised trials.
Topics: Anovulation; Clomiphene; Female; Humans; Inositol; Metformin; Polycystic Ovary Syndrome | 2018 |
Exercise and reproductive function in polycystic ovary syndrome: protocol of a systematic review.
Topics: Diet; Exercise; Female; Fertility; Humans; Hyperandrogenism; Insulin Resistance; Menstrual Cycle; Me | 2017 |
Metformin in Adolescent PCOS: The Way Forward.
Topics: Adolescent; Adult; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; Metformin; Polycystic Ovar | 2017 |
Diagnostic Evaluation, Comorbidity Screening, and Treatment of Polycystic Ovary Syndrome in Adolescents in 3 Specialty Clinics.
Topics: Adolescent; Adolescent Medicine; Androgen Antagonists; Child; Comorbidity; Contraceptives, Oral, Hor | 2018 |
IGF-1R and Leptin Expression Profile and the Effects of Metformin Treatment on Metabolic and Endocrine Parameters in PCOS Mice.
Topics: Animals; Blood Glucose; Body Weight; Female; Gene Expression Regulation; Humans; Hypoglycemic Agents | 2017 |
Metformin improves ovarian follicle dynamics by reducing theca cell proliferation and CYP-17 expression in an androgenized rat model.
Topics: Animals; Biomarkers; Cell Proliferation; Cytochrome P450 Family 17; Disease Models, Animal; Female; | 2018 |
Uterine progesterone signaling is a target for metformin therapy in PCOS-like rats.
Topics: Animals; Chorionic Gonadotropin; Disease Models, Animal; Embryo Implantation; Female; Gene Expressio | 2018 |
PCOS: Metformin risk for offspring.
Topics: Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Metformin; Overweight; Polycystic Ovary Synd | 2018 |
Letter to the Editor: "Metformin Use in PCOS Pregnancies Increases the Risk of Offspring Overweight at 4 Years of Age: Follow-Up of Two RCTs".
Topics: Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Metformin; Overweight; Polycystic Ovary Synd | 2018 |
Response to Letter to the Editor: "Metformin Use in PCOS Pregnancies Increases the Risk of Offspring Overweight at 4 Years of Age: Follow-Up of Two RCTs".
Topics: Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Metformin; Overweight; Polycystic Ovary Synd | 2018 |
Effect of resveratrol and metformin on ovarian reserve and ultrastructure in PCOS: an experimental study.
Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Cell Count; Dehydroepiandrosterone; Disease Model | 2018 |
Pregnancy outcome after first-trimester exposure to metformin: A prospective cohort study.
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Adolescent; Adult; Diabetes Mellitus, Type 2; Fe | 2018 |
The Effect of Metformin on the Endometrium of Women with Polycystic Ovary Syndrome.
Topics: Adult; Corticotropin-Releasing Hormone; Drug Therapy, Combination; Endometrium; Estradiol; Estrogens | 2019 |
Insulin Sensitizers Modulate GnRH Receptor Expression in PCOS Rats.
Topics: Animals; Body Weight; Carboxymethylcellulose Sodium; Diet, High-Fat; Female; Glucose Tolerance Test; | 2018 |
Recurrent hypoglycemia secondary to metformin toxicity in the absence of co-ingestions: a case report.
Topics: Acidosis, Lactic; Anti-Obesity Agents; Female; Humans; Hypoglycemia; Metformin; Polycystic Ovary Syn | 2018 |
Effect of metformin and flutamide on insulin, lipogenic and androgen-estrogen signaling, and cardiometabolic risk in a PCOS-prone metabolic syndrome rodent model.
Topics: Androgen Antagonists; Animals; Apolipoprotein B-100; Apolipoprotein B-48; Apolipoproteins B; Blood G | 2019 |
A pilot trial of metformin for insulin resistance and mood disturbances in adolescent and adult women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Anxiety; Blood Glucose; Body Mass Index; Depression; Female; Humans; Hypoglycemic | 2019 |
Mild ovarian stimulation with letrozole plus fixed dose human menopausal gonadotropin prior to IVF/ICSI for infertile non-obese women with polycystic ovarian syndrome being pre-treated with metformin: a pilot study.
Topics: Adult; Female; Gonadotropins; Humans; Infertility, Female; Letrozole; Metformin; Nitriles; Oocyte Re | 2018 |
Investigation of Therapeutic Effects of Erdosteine on Polycystic Ovary Syndrome in a Rat Model.
Topics: Analysis of Variance; Animals; Blood Glucose; Cholesterol; Disease Models, Animal; Estrone; Expector | 2018 |
Prenatal metformin treatment improves ovarian function in offspring of obese rats.
Topics: Animals; Diet, High-Fat; Drug Evaluation, Preclinical; Female; Hypoglycemic Agents; Lactation; Metfo | 2018 |
Trends, in Diagnosis and Treatment of Polycystic Ovarian Syndrome by Specialty.
Topics: Adolescent; Adult; Contraceptives, Oral, Hormonal; Diagnostic Tests, Routine; Diuretics; Endocrinolo | 2016 |
Metformin Regulates Key MicroRNAs to Improve Endometrial Receptivity Through Increasing Implantation Marker Gene Expression in Patients with PCOS Undergoing IVF/ICSI.
Topics: Adult; Embryo Implantation; Endometrium; Female; Fertilization in Vitro; Gene Expression; Genetic Ma | 2019 |
Metformin use in polycystic ovary syndrome pregnancy impacts on offspring obesity.
Topics: Cardiovascular Diseases; Female; Follow-Up Studies; Humans; Metformin; Obesity; Polycystic Ovary Syn | 2019 |
Association between CD16
Topics: Adult; Biomarkers; Case-Control Studies; China; Cross-Sectional Studies; Cyproterone Acetate; Drug C | 2019 |
Metformin-induced first-episode psychosis in patient with polycystic ovary syndrome using drospirenone.
Topics: Adult; Androstenes; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Metformin; Miner | 2019 |
Differential Expression Patterns of Glycolytic Enzymes and Mitochondria-Dependent Apoptosis in PCOS Patients with Endometrial Hyperplasia, an Early Hallmark of Endometrial Cancer,
Topics: Adult; Apoptosis; Blotting, Western; Endometrial Hyperplasia; Endometrial Neoplasms; Endometrium; Fe | 2019 |
Exploring the use of metformin in pregnant women with polycystic ovary syndrome: new evidence, new wisdom.
Topics: Double-Blind Method; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Preg | 2019 |
Effect of six-month use of oral contraceptive pills on plasminogen activator inhibitor-1 & factor VIII among women with polycystic ovary syndrome: An observational pilot study.
Topics: Adult; Blood Glucose; Contraceptives, Oral; Contraceptives, Oral, Combined; Factor VIII; Female; Hum | 2018 |
Metformin treatment alleviates polycystic ovary syndrome by decreasing the expression of MMP-2 and MMP-9 via H19/miR-29b-3p and AKT/mTOR/autophagy signaling pathways.
Topics: Adenylate Kinase; Animals; Autophagy; Base Sequence; Cell Line; Down-Regulation; Female; Matrix Meta | 2019 |
Prolactin and breast increase during pregnancy in PCOS: linked to long-term metabolic health?
Topics: Adolescent; Adult; Blood Pressure; Body Mass Index; Breast; Female; Follow-Up Studies; Gestational A | 2019 |
Metformin metabolic and vascular effects in overweight/moderately obese hyperinsulinemic PCOS patients treated with contraceptive vaginal ring: a pilot study.
Topics: Adolescent; Adult; Blood Glucose; Body Mass Index; Contraceptive Devices, Female; Female; Glucose To | 2019 |
Effect of Metformin Treatment on Insulin Resistance Markers, and Circulating Irisin in Women with Polycystic Ovarian Syndrome (PCOS).
Topics: Adult; Biomarkers; Female; Fibronectins; Humans; Insulin; Insulin Resistance; Lipoproteins, LDL; Met | 2019 |
"I'm Sticking With You, Doc".
Topics: Delivery, Obstetric; Family Practice; Female; Fertility; Humans; Hypoglycemic Agents; Hypoplastic Le | 2019 |
Treatment with metformin and sorafenib alleviates endometrial hyperplasia in polycystic ovary syndrome by promoting apoptosis via synergically regulating autophagy.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Drug Synergism; Endometrial Hyperplasi | 2020 |
[Pulse administration of gonadotropin-releasing hormone combined with metformin for fertility in a non-obese woman with polycystic ovary syndrome].
Topics: Female; Fertility; Fertility Agents, Female; Gonadotropin-Releasing Hormone; Humans; Injections, Int | 2019 |
Inulin and metformin ameliorate polycystic ovary syndrome via anti-inflammation and modulating gut microbiota in mice.
Topics: Animals; Anti-Inflammatory Agents; Bacteria; Biomarkers; Cytokines; Dehydroepiandrosterone; Diet, Hi | 2019 |
Report: Metformin potential in predisposing arthralgia, type II cross reactivity secondary to group A streptococcus infection & other comorbidities in treating PCOS.
Topics: Analgesics; Arthralgia; Drug Hypersensitivity; Female; Humans; Hyperuricemia; Metformin; Migraine Di | 2019 |
Ocimum kilimandscharicum L. restores ovarian functions in letrozole - induced Polycystic Ovary Syndrome (PCOS) in rats: Comparison with metformin.
Topics: Aged; Animals; Antioxidants; Aromatase Inhibitors; Blood Glucose; Body Weight; Chromatography, High | 2019 |
Oral contraceptive use increases risk of inflammatory and coagulatory disorders in women with Polycystic Ovarian Syndrome: An observational study.
Topics: Adult; Body Mass Index; Coagulation Protein Disorders; Contraceptives, Oral; Ethinyl Estradiol; Fema | 2019 |
Treatment strategies in PCOS patients.
Topics: Clomiphene; Diabetes Mellitus; Diet; Exercise; Female; Fertility Agents, Female; Humans; Hypoglycemi | 2005 |
Metformin augments the levels of molecules that regulate the expression of the insulin-dependent glucose transporter GLUT4 in the endometria of hyperinsulinemic PCOS patients.
Topics: Adult; AMP-Activated Protein Kinases; Case-Control Studies; Endometrium; Female; Gene Expression Reg | 2013 |
Ovarian 11β-hydroxysteroid dehydrogenase (11βHSD) activity is suppressed in women with anovulatory polycystic ovary syndrome (PCOS): apparent role for ovarian androgens.
Topics: 11-beta-Hydroxysteroid Dehydrogenases; Adult; Androgens; Anovulation; Cortisone; Dose-Response Relat | 2013 |
Differences in the management of adolescents with polycystic ovary syndrome across pediatric specialties.
Topics: Adolescent; Adolescent Medicine; Androgen Antagonists; Contraceptives, Oral, Hormonal; Diabetes Mell | 2013 |
Metformin inhibits follicle-stimulating hormone (FSH) action in human granulosa cells: relevance to polycystic ovary syndrome.
Topics: Aromatase; Cell Line, Tumor; Colforsin; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Female; Fo | 2013 |
Role of adiponectin and its receptor in prediction of reproductive outcome of metformin treatment in patients with polycystic ovarian syndrome.
Topics: Adiponectin; Adult; Case-Control Studies; Cohort Studies; Female; Humans; Hypoglycemic Agents; Insul | 2013 |
[Metformin--new treatment strategies for gynecologic neoplasms].
Topics: Antineoplastic Agents; Drug Synergism; Female; Genital Neoplasms, Female; Humans; Lactoylglutathione | 2013 |
Metformin increases the novel adipokine adipolin/CTRP12: role of the AMPK pathway.
Topics: Adipokines; Adult; AMP-Activated Protein Kinases; Body Mass Index; Case-Control Studies; Female; Glu | 2013 |
Alterations in thyroid function among the different polycystic ovary syndrome phenotypes.
Topics: Adult; Body Mass Index; Drug Therapy, Combination; Female; Hospitals, University; Humans; Hypoglycem | 2013 |
Dehydroepiandrosterone induces ovarian and uterine hyperfibrosis in female rats.
Topics: Animals; Dehydroepiandrosterone; Female; Fibrosis; Hypoglycemic Agents; Hypolipidemic Agents; Metfor | 2013 |
Evaluation of endocrine changes in women with the polycystic ovary syndrome during metformin treatment.
Topics: Adult; Anovulation; Anthropometry; Body Mass Index; Endocrine System; Estradiol; Female; Follicle St | 2013 |
Infertility treatment in polycystic ovary syndrome: lifestyle interventions, medications and surgery.
Topics: Clomiphene; Exercise; Female; Fertilization in Vitro; Humans; Infertility, Female; Life Style; Metfo | 2013 |
Insulin resistance assessment in patients with polycystic ovary syndrome using different diagnostic criteria--impact of metformin treatment.
Topics: Adult; Blood Glucose; Body Mass Index; Female; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin | 2013 |
Metformin increases the novel adipokine cartonectin/CTRP3 in women with polycystic ovary syndrome.
Topics: Adipokines; Adult; Biomarkers; Body Mass Index; C-Reactive Protein; Cardiovascular Diseases; Carotid | 2013 |
Metformin for polycystic ovary syndrome.
Topics: Algorithms; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; Metformin; Off-Label Use; Ovulati | 2013 |
Assessment of ovarian stromal blood flow after metformin treatment in women with polycystic ovary syndrome.
Topics: Adult; Body Mass Index; Case-Control Studies; Female; Humans; Hypoglycemic Agents; Imaging, Three-Di | 2014 |
[Liraglutide in polycystic ovary syndrome].
Topics: Adult; Diabetes Mellitus, Type 2; Drug Synergism; Female; Glucagon-Like Peptide 1; Hirsutism; Humans | 2014 |
Metformin modulates PI3K and GLUT4 expression and Akt/PKB phosphorylation in human endometrial stromal cells after stimulation with androgen and insulin.
Topics: Adult; Androgens; Cells, Cultured; Endometrium; Extracellular Signal-Regulated MAP Kinases; Female; | 2014 |
LMNA gene mutation as a model of cardiometabolic dysfunction: from genetic analysis to treatment response.
Topics: Adolescent; Amenorrhea; Body Fat Distribution; Cardiovascular Diseases; DNA Mutational Analysis; Fem | 2014 |
The effects of metformin on endothelial dysfunction, lipid metabolism and oxidative stress in women with polycystic ovary syndrome.
Topics: Adult; Apolipoprotein A-I; Apolipoproteins B; Aryldialkylphosphatase; Case-Control Studies; Choleste | 2014 |
Metformin resistance alleles in polycystic ovary syndrome: pattern and association with glucose metabolism.
Topics: Adult; Ataxia Telangiectasia Mutated Proteins; C-Peptide; Drug Resistance; Female; Genetic Associati | 2014 |
Circulatory changes of the novel adipokine adipolin/CTRP12 in response to metformin treatment and an oral glucose challenge in humans.
Topics: Adipokines; Adult; Blood Glucose; Carotid Intima-Media Thickness; Case-Control Studies; Cross-Sectio | 2014 |
[Should insulin resistance be always treated in Polycystic Ovary Syndrome?].
Topics: Female; Humans; Hypoglycemic Agents; Metabolic Syndrome; Metformin; Polycystic Ovary Syndrome | 2014 |
A retrospective survey of quality of reporting on randomized controlled trials of metformin for polycystic ovary syndrome.
Topics: Female; Guideline Adherence; Humans; Intention to Treat Analysis; Metformin; Polycystic Ovary Syndro | 2014 |
Beneficial effects of pioglitazone and metformin in murine model of polycystic ovaries via improvement of chemerin gene up-regulation.
Topics: Adipokines; Animals; Chemokines; Disease Models, Animal; Drug Combinations; Drug Resistance; Female; | 2014 |
Reproductive endocrinology: Maternal and fetal insulin levels at birth in women with PCOS.
Topics: Female; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin; Metformin; Polycystic Ovary Syndrome; | 2014 |
The platelet activating factor acetyl hydrolase, oxidized low-density lipoprotein, paraoxonase 1 and arylesterase levels in treated and untreated patients with polycystic ovary syndrome.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Androgen Antagonists; Aryldialkylphosphatase; | 2014 |
Metformin in women with PCOS, pros.
Topics: Adolescent; Adult; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome | 2015 |
Effect of the combination of metformin hydrochloride and melatonin on oxidative stress before and during pregnancy, and biochemical and histopathological analysis of the livers of rats after treatment for polycystic ovary syndrome.
Topics: Animals; Antioxidants; Drug Therapy, Combination; Female; Liver; Melatonin; Metformin; Oxidative Str | 2014 |
Clustering of metabolic and cardiovascular risk factors in the polycystic ovary syndrome: a principal component analysis.
Topics: Adult; Cardiovascular Diseases; Cluster Analysis; Cohort Studies; Female; Humans; Hypoglycemic Agent | 2014 |
Treatment of polycystic ovarian syndrome with insulin resistance by insulin-sensitizer.
Topics: Adolescent; Adult; Blood Glucose; Body Mass Index; C-Reactive Protein; Cholesterol, HDL; Cholesterol | 2014 |
European survey of diagnosis and management of the polycystic ovary syndrome: results of the ESE PCOS Special Interest Group's Questionnaire.
Topics: Adult; Androgens; Biomarkers; Clomiphene; Contraceptives, Oral; Diagnosis, Differential; Endocrinolo | 2014 |
Easy bruising in a patient with secondary amenorrhea.
Topics: Acne Vulgaris; Adult; Amenorrhea; Contusions; Female; Hormones; Humans; Metformin; Polycystic Ovary | 2014 |
Protein modification as oxidative stress marker in follicular fluid from women with polycystic ovary syndrome: the effect of inositol and metformin.
Topics: Adult; Biomarkers; Female; Fertilization in Vitro; Follicular Fluid; Gonadotropins; Humans; Inositol | 2014 |
Is metformin ready for prime time in pregnancy? Probably not yet.
Topics: Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Metformin; Po | 2015 |
The effect of metformin treatment in vivo on acute and long-term energy metabolism and progesterone production in vitro by granulosa cells from women with polycystic ovary syndrome.
Topics: Adult; Case-Control Studies; Cell Proliferation; Cells, Cultured; Female; Follicular Fluid; Glucose; | 2014 |
Gestational diabetes mellitus risk factors in women with polycystic ovary syndrome (PCOS).
Topics: Adult; Cross-Sectional Studies; Diabetes, Gestational; Female; Fertilization; Humans; Hypoglycemic A | 2014 |
Effects of metformin on endocrine, metabolic milieus and endometrial expression of androgen receptor in patients with polycystic ovary syndrome.
Topics: Adult; Blood Glucose; Body Mass Index; Endometrium; Female; Follicle Stimulating Hormone; Humans; Hy | 2015 |
Effect of metformin on sleep disorders in adolescent girls with polycystic ovarian syndrome.
Topics: Adolescent; Blood Glucose; Body Mass Index; Body Weight; Child; Female; Hirsutism; Humans; Hypoglyce | 2014 |
[Effects of visfatin and metformin on insulin resistance and reproductive endocrine in rats with polycystic ovary syndrome].
Topics: Animals; Female; Humans; Insulin Resistance; Metformin; Nicotinamide Phosphoribosyltransferase; Poly | 2014 |
How medical treatment affects mean platelet volume as a cardiovascular risk marker in polycystic ovary syndrome?
Topics: Adolescent; Adult; Androgen Antagonists; Biomarkers; Blood Platelets; Body Mass Index; C-Reactive Pr | 2015 |
Polycystic ovaries and obesity.
Topics: Adipokines; Adiponectin; Female; Humans; Hyperandrogenism; Hyperinsulinism; Hypoglycemic Agents; Inf | 2015 |
The effect of Metformin on endometrial tumor-regulatory genes and systemic metabolic parameters in polycystic ovarian syndrome--a proof-of-concept study.
Topics: Adult; Biopsy; Body Mass Index; Cohort Studies; Cyclin D2; Endometrial Neoplasms; Endometrium; Femal | 2015 |
British Fertility Society Policy and Practice Committee: adjuvants in IVF: evidence for good clinical practice.
Topics: Chemotherapy, Adjuvant; Evidence-Based Medicine; Female; Fertility; Fertilization in Vitro; Humans; | 2015 |
Is it time to consider patients suffering from endometriosis-related infertility as "novel candidates" for targeted peri-conceptional D-chiro inositol supplementation? Hypothesis, rationale and some considerations.
Topics: Biomarkers; Female; Humans; Inositol; Metformin; Oxidative Stress; Polycystic Ovary Syndrome; Protei | 2015 |
Trends in standard workup performed by pediatric subspecialists for the diagnosis of adolescent polycystic ovary syndrome.
Topics: Adolescent; Adolescent Medicine; Androgens; Child; Contraceptives, Oral; Endocrinology; Female; Gyne | 2015 |
Metformin regulates ovarian angiogenesis and follicular development in a female polycystic ovary syndrome rat model.
Topics: Angiogenesis Modulating Agents; Angiopoietin-1; Angiopoietin-2; Animals; Dehydroepiandrosterone; Fem | 2015 |
[Association between levels of serum leptin and insulin resistance in patients with polycystic ovary syndrome].
Topics: Body Mass Index; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Leptin; Metformin | 2014 |
Metformin use in patients undergoing in vitro fertilization treatment: results of a worldwide web-based survey.
Topics: Abortion, Spontaneous; Female; Fertilization in Vitro; Humans; Hypoglycemic Agents; Insulin Resistan | 2015 |
Polycystic ovary syndrome (PCOS): metformin.
Topics: Androgen Antagonists; Cyproterone Acetate; Drug Combinations; Ethinyl Estradiol; Female; Humans; Hyp | 2015 |
Metformin for preventing gestational diabetes in women with polycystic ovarian syndrome.
Topics: Adolescent; Adult; Diabetes, Gestational; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Me | 2015 |
Developmental Programming: Prenatal and Postnatal Androgen Antagonist and Insulin Sensitizer Interventions Prevent Advancement of Puberty and Improve LH Surge Dynamics in Prenatal Testosterone-Treated Sheep.
Topics: Androgen Antagonists; Androgens; Animals; Estrous Cycle; Female; Fetal Development; Flutamide; Hypog | 2015 |
The role of anti-Mullerian hormone and inhibin B in the assessment of metformin therapy in women with polycystic ovarian syndrome.
Topics: Adolescent; Adult; Anti-Mullerian Hormone; Biomarkers; Cross-Sectional Studies; Female; Humans; Inhi | 2015 |
Metformin reduces hyper-reactivity of platelets from patients with polycystic ovary syndrome by improving mitochondrial integrity.
Topics: Adult; AMP-Activated Protein Kinases; Blood Platelets; Case-Control Studies; Cell Line; Dose-Respons | 2015 |
Metabolic profile of Diane-35 versus Diane-35 plus metformin in Chinese PCOS women under standardized life-style changes.
Topics: Adolescent; Adult; Androgen Antagonists; China; Cyproterone Acetate; Drug Combinations; Drug Therapy | 2015 |
Effects of metformin on the adrenal cortex of androgenized rats.
Topics: Adrenal Cortex; Androstenedione; Animals; Female; Hypoglycemic Agents; Metformin; Organ Size; Polycy | 2015 |
Can Animal Models of PCOS Help Point the Way Towards Early and Effective Therapeutic Intervention in Women With the Syndrome?
Topics: Androgen Antagonists; Animals; Contraceptives, Oral, Hormonal; Disease Models, Animal; Disease Progr | 2015 |
Exploring the significance of sex hormone-binding globulin examination in the treament of women with polycystic ovarian syndrome (PCOS).
Topics: Abortion, Spontaneous; Adult; Androgen Antagonists; Blood Glucose; Body Mass Index; Clomiphene; Cypr | 2015 |
Effect of metformin on early pregnancy loss in women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Adult; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndr | 2015 |
[Second Consensus of the Chilean Society of Endocrinology and Diabetes about insulin resistance].
Topics: Chile; Delphi Technique; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Life Style; Metfor | 2015 |
Evaluation of Apelin and Insulin Resistance in Patients with PCOS and Therapeutic Effect of Drospirenone-Ethinylestradiol Plus Metformin.
Topics: Adult; Androstenes; Apelin; Blood Glucose; Body Mass Index; Case-Control Studies; Drug Therapy, Comb | 2015 |
Effects of metformin on mitochondrial function of leukocytes from polycystic ovary syndrome patients with insulin resistance.
Topics: Adult; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Interleukin-6; Metformin; Mitochondr | 2015 |
Hyperandrogenism and Insulin Resistance, Not Changes in Body Weight, Mediate the Development of Endothelial Dysfunction in a Female Rat Model of Polycystic Ovary Syndrome (PCOS).
Topics: Androgen Antagonists; Androgens; Animals; Arteries; Blood Pressure; Body Weight; Dihydrotestosterone | 2015 |
Expression of SIRT1 in the ovaries of rats with polycystic ovary syndrome before and after therapeutic intervention with exenatide.
Topics: Animals; Dehydroepiandrosterone; Disease Models, Animal; Exenatide; Female; Gene Expression Regulati | 2015 |
Insulin Sensitizers for Treatment of Menstrual Irregularities Associated with PCOS.
Topics: Comparative Effectiveness Research; Contraceptives, Oral; Evidence-Based Practice; Female; Humans; H | 2015 |
Prognostic factors of oncological and reproductive outcomes in fertility-sparing treatment of complex atypical hyperplasia and low-grade endometrial cancer using oral progestin in Chinese patients.
Topics: Administration, Oral; Adult; Antineoplastic Agents, Hormonal; China; Endometrial Hyperplasia; Endome | 2015 |
Relationship between Polycystic Ovarian Syndrome and Subsequent Gestational Diabetes Mellitus: A Nationwide Population-Based Study.
Topics: Adolescent; Adult; Comorbidity; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Metformi | 2015 |
Management of polycystic ovarian syndrome with Diane-35 or Diane-35 plus metformin.
Topics: Adult; Androgen Antagonists; Cyproterone Acetate; Drug Combinations; Ethinyl Estradiol; Female; Huma | 2016 |
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME--PART 1.
Topics: Adolescent; Alopecia; Androgen Antagonists; Androgens; Anovulation; Diagnostic Techniques, Endocrine | 2015 |
Effect of colchicine on polycystic ovary syndrome: an experimental study.
Topics: Androstenedione; Animals; C-Reactive Protein; Colchicine; Disease Models, Animal; Dose-Response Rela | 2016 |
Borderline personality disorder and polycystic ovary syndrome.
Topics: Borderline Personality Disorder; Estradiol; Estrogens; Female; Humans; Hypoglycemic Agents; Metformi | 2016 |
Does metformin improve in vitro maturation and ultrastructure of oocytes retrieved from estradiol valerate polycystic ovary syndrome-induced rats.
Topics: Animals; Blood Glucose; Body Weight; Contraceptive Agents; Cumulus Cells; Disease Models, Animal; Es | 2015 |
Assessment of Anti-Müllerian Hormone Level in Management of Adolescents with Polycystic Ovary Syndrome.
Topics: Adolescent; Androgens; Anti-Mullerian Hormone; Biomarkers; Contraceptives, Oral, Combined; Disease M | 2016 |
A case of lean polycystic ovary syndrome with early stage of type 1 diabetes successfully treated with metformin.
Topics: Adult; Diabetes Mellitus, Type 1; Disease Progression; Female; Humans; Hypoglycemic Agents; Metformi | 2016 |
[Metformin and changes in blood pressure and heart rate in lean patients with polycystic ovary syndrome (PCOS)--preliminary study].
Topics: Adolescent; Blood Pressure; Body Weight; Female; Heart Rate; Humans; Hypoglycemic Agents; Metformin; | 2015 |
Reply: Metformin for women with hyperandrogenic anovulation.
Topics: Anovulation; Female; Hirsutism; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome | 2016 |
Metformin for women with hyperandrogenic anovulation.
Topics: Anovulation; Female; Hirsutism; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome | 2016 |
Effects of Exenatide on Metabolic Changes, Sexual Hormones, Inflammatory Cytokines, Adipokines, and Weight Change in a DHEA-Treated Rat Model.
Topics: Adipokines; Animals; Body Weight; Cytokines; Dehydroepiandrosterone; Disease Models, Animal; Exenati | 2016 |
Presence of type 1 diabetes in women with polycystic ovary syndrome: Does it have any impact on anti-Müllerian hormone concentrations?
Topics: Anti-Mullerian Hormone; Biomarkers; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Female; Hu | 2016 |
Menstrual cyclicity post OC withdrawal in PCOS: Use of non-hormonal options.
Topics: Adolescent; Adult; Contraceptives, Oral, Hormonal; Female; Humans; Hypoglycemic Agents; Menstrual Cy | 2016 |
Adolescents with Classical Polycystic Ovary Syndrome Have Alterations in the Surrogate Markers of Cardiovascular Disease but Not in the Endothelial Function. The Possible Benefits of Metformin.
Topics: Adolescent; Adult; Biomarkers; Blood Glucose; C-Reactive Protein; Cardiovascular Diseases; Carotid I | 2016 |
Intravaginal administration of metformin hydrochloride loaded cationic niosomes amalgamated with thermosensitive gel for the treatment of polycystic ovary syndrome: In vitro and in vivo studies.
Topics: Adhesiveness; Administration, Intravaginal; Animals; Cations; Chitosan; Drug Liberation; Female; Gel | 2016 |
Does Metformin Really Increase Height or Is There Some Problem With the Controls?
Topics: Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome | 2016 |
A challenge in the management of women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Anti-Mullerian Hormone; Female; Ferritins; Humans; Hypoglycemic Agents; Insul | 2016 |
Effect of metformin by employing 2-hour postload insulin for measuring insulin resistance in Taiwanese women with polycystic ovary syndrome.
Topics: Adult; Blood Glucose; Body Mass Index; Female; Glucose Tolerance Test; Humans; Insulin Antagonists; | 2017 |
Diagnosis and management of polycystic ovary syndrome in the UK (2004-2014): a retrospective cohort study.
Topics: Acne Vulgaris; Adolescent; Adult; Contraceptives, Oral, Combined; Drug Prescriptions; Female; Humans | 2016 |
Diagnosis and Treatment of Polycystic Ovary Syndrome.
Topics: Aromatase Inhibitors; Clomiphene; Female; Fertility Agents, Female; Humans; Hyperandrogenism; Hypogl | 2016 |
Metformin increases pressure pain threshold in lean women with polycystic ovary syndrome.
Topics: Female; Humans; Metformin; Pain Threshold; Polycystic Ovary Syndrome | 2016 |
Metformin improved health-related quality of life in ethnic Chinese women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Asian People; Ethnicity; Female; Follow-Up Studies; Health Status Indicators; Hum | 2016 |
Alternatives to Metformin for Patients with PCOS.
Topics: Evidence-Based Medicine; Family Practice; Female; Humans; Metformin; Polycystic Ovary Syndrome; Rosi | 2016 |
Downregulation of autophagy gene expression in endometria from women with polycystic ovary syndrome.
Topics: Adult; Autophagy; Case-Control Studies; Down-Regulation; Endometrium; Female; Gene Expression Profil | 2017 |
Ameliorative effects of rutin against metabolic, biochemical and hormonal disturbances in polycystic ovary syndrome in rats.
Topics: Animals; Antioxidants; Aromatase Inhibitors; Biomarkers; Blood Glucose; Body Weights and Measures; C | 2016 |
Phenotype and Tissue Expression as a Function of Genetic Risk in Polycystic Ovary Syndrome.
Topics: Biomarkers; Case-Control Studies; Female; Follicle Stimulating Hormone; Gene Expression; Gene Expres | 2017 |
Effects of a hyperandrogenaemic state on the proliferation and decidualization potential in human endometrial stromal cells.
Topics: Adult; Cell Proliferation; Decidua; Dexamethasone; Embryo Implantation; Endometrium; Epithelial Cell | 2017 |
Should metformin be included in fertility treatment of PCOS patients?
Topics: Adenosine Triphosphate; Diabetes Mellitus, Type 2; Diabetes, Gestational; Electron Transport; Female | 2017 |
Effect of metformin and oral contraceptives on polycystic ovary syndrome and IVF cycles.
Topics: Adult; Contraceptives, Oral; Drug Therapy, Combination; Female; Fertilization in Vitro; Humans; Hypo | 2017 |
Restored Plasma Anandamide and Endometrial Expression of Fatty Acid Amide Hydrolase in Women With Polycystic Ovary Syndrome by the Combination Use of Diane-35 and Metformin.
Topics: Adult; Amidohydrolases; Androgen Antagonists; Arachidonic Acids; Cyproterone Acetate; Drug Combinati | 2017 |
Dehydroepiandrosterone and metformin regulate proliferation of murine T lymphocytes.
Topics: Animals; Antioxidants; Apoptosis; Cell Proliferation; Cell Survival; Cells, Cultured; Dehydroepiandr | 2008 |
Metformin in the treatment of infertility in polycystic ovarian syndrome: an alternative perspective.
Topics: Clomiphene; Drug Administration Schedule; Drug Therapy, Combination; Female; Fertility Agents, Femal | 2008 |
Homeostasis model assessment-insulin resistance (HOMA-IR), a key role for assessing the ovulation function in polycystic ovary syndrome (PCOS) patients with insulin resistance.
Topics: Cyproterone Acetate; Drug Combinations; Ethinyl Estradiol; Female; Homeostasis; Humans; Hypoglycemic | 2008 |
A reappraisal of the role of polycystic ovary syndrome in recurrent miscarriage.
Topics: Abortion, Habitual; Androgens; Anovulation; Female; Gonadotropins; Humans; Infertility, Female; Insu | 2008 |
Plasma cytokines in obese women with polycystic ovary syndrome, before and after metformin treatment.
Topics: Adiponectin; Adult; Body Mass Index; C-Reactive Protein; Cytokines; Fasting; Female; Humans; Insulin | 2008 |
Insulin-sensitizing agents and reproductive function in polycystic ovary syndrome patients.
Topics: Female; Humans; Hypoglycemic Agents; Metformin; Ovulation Induction; Polycystic Ovary Syndrome; Preg | 2008 |
Is pharmacogenomics our future? Metformin, ovulation and polymorphism of the STK11 gene in polycystic ovary syndrome.
Topics: AMP-Activated Protein Kinase Kinases; Female; Humans; Metformin; Multicenter Studies as Topic; Ovula | 2008 |
Metformin use in polycystic ovary syndrome: metabolic benefits and diabetes prevention.
Topics: Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome | 2008 |
Monogenic polycystic ovary syndrome due to a mutation in the lamin A/C gene is sensitive to thiazolidinediones but not to metformin.
Topics: Adolescent; Adult; Drug Resistance; Female; Humans; Hypoglycemic Agents; Lamin Type A; Metabolic Syn | 2008 |
Metformine for psychosis associated with the menstrual cycle in a patient with polycystic ovary syndrome.
Topics: Aggression; Female; Humans; Hypoglycemic Agents; Menstruation; Metformin; Polycystic Ovary Syndrome; | 2008 |
Does continuous use of metformin throughout pregnancy improve pregnancy outcomes in women with polycystic ovarian syndrome?
Topics: Adult; Case-Control Studies; Female; Humans; Hypoglycemic Agents; Infant, Newborn; Metformin; Polycy | 2008 |
Management and 1 year outcome for UK children with type 2 diabetes.
Topics: Adolescent; Body Mass Index; Child; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Epidemiolo | 2009 |
Metformin: effective in the prevention of new-onset type 2 diabetes?
Topics: Diabetes Mellitus, Type 2; Early Diagnosis; Female; Humans; Hypoglycemic Agents; Insulin Resistance; | 2008 |
Impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women: do we need a new drug?
Topics: Adolescent; Behavior Therapy; Contraceptives, Oral, Hormonal; Female; Humans; Hypoglycemic Agents; L | 2008 |
Effect of metformin on serum visfatin levels in patients with polycystic ovary syndrome.
Topics: Adult; Blood Glucose; Body Mass Index; Cross-Sectional Studies; Cytokines; Diabetes Mellitus, Type 2 | 2010 |
The effect of metformin treatment on ovarian stromal blood flow in women with polycystic ovary syndrome.
Topics: Adult; Female; Humans; Hypoglycemic Agents; Metformin; Ovary; Polycystic Ovary Syndrome; Prospective | 2009 |
Efficacy of metformin supplementation during ovarian stimulation of lean PCOS patients undergoing in vitro fertilization.
Topics: Adult; Blood Glucose; Body Mass Index; Case-Control Studies; Chorionic Gonadotropin; Dinoprostone; E | 2009 |
Incretin hormone secretion in women with polycystic ovary syndrome: roles of obesity, insulin sensitivity, and treatment with metformin.
Topics: Adult; Blood Glucose; Cross-Sectional Studies; Female; Gastric Inhibitory Polypeptide; Glucagon-Like | 2009 |
Adjuncts for ovarian stimulation: when do we adopt "orphan indications" for approved drugs?
Topics: Androgens; Aspirin; Contraceptives, Oral; Dopamine Agonists; Estrogens; Female; Fertilization in Vit | 2009 |
Is metformin beneficial for the treatment of infertility in women with PCOS?
Topics: Adult; Female; Humans; Hypoglycemic Agents; Infertility, Female; Metformin; Polycystic Ovary Syndrom | 2009 |
The effects of metformin on uterine tissue of hyperandrogenized BALB/c mice.
Topics: Animals; Blotting, Western; Catalase; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cycloo | 2009 |
Prevention of gestational diabetes mellitus by continuing metformin therapy throughout pregnancy in women with polycystic ovary syndrome.
Topics: Adult; Apgar Score; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Infant, Newborn; Met | 2009 |
[Use of metformin in polycystic ovary syndrome].
Topics: Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Treatment Outcome | 2009 |
Investigating infertility.
Topics: Antineoplastic Agents; Dermoid Cyst; Female; Humans; Infertility, Female; Medical History Taking; Me | 2009 |
[Polycystic ovary syndrome. Diet helps control hormone chaos].
Topics: Acne Vulgaris; Adolescent; Adult; Androgens; Child; Combined Modality Therapy; Female; Hirsutism; Hu | 2009 |
The renaissance of metformin in endocrine clinical practice.
Topics: Climacteric; Diabetes Mellitus, Type 2; Endocrinology; Female; Humans; Hypoglycemic Agents; Metformi | 2009 |
Effects of metformin with or without supplementation with folate on homocysteine levels and vascular endothelium of women with polycystic ovary syndrome.
Topics: Adult; Body Mass Index; Brachial Artery; Double-Blind Method; Endothelin-1; Endothelium, Vascular; E | 2010 |
Androgen excess in women: not just a cosmetic problem.
Topics: Adrenal Hyperplasia, Congenital; Androgen Antagonists; Androgens; Female; Hirsutism; Humans; Hyperan | 2010 |
Reproductive endocrinology: live birth prediction in polycystic ovary syndrome.
Topics: Adult; Clomiphene; Female; Humans; Hypoglycemic Agents; Infertility, Female; Live Birth; Metformin; | 2010 |
Systemic and local effects of metformin administration in patients with polycystic ovary syndrome (PCOS): relationship to the ovulatory response.
Topics: Adult; Androgens; Case-Control Studies; Female; Follicular Fluid; Humans; Hypoglycemic Agents; Insul | 2010 |
Effects of oral contraceptives and metformin on the outcome of in vitro maturation in infertile women with polycystic ovary syndrome.
Topics: Adult; Contraceptives, Oral; Female; Fertilization in Vitro; Humans; In Vitro Oocyte Maturation Tech | 2010 |
Effects of metformin administration on plasma gonadotropin levels in women with infertility, with an in vitro study of the direct effects on the pituitary gonadotrophs.
Topics: Adult; Cell Line; Female; Follicle Stimulating Hormone; Gonadotrophs; Gonadotropin-Releasing Hormone | 2010 |
[Diagnosis and treatment of polycystic ovary syndrome].
Topics: Acne Vulgaris; Alopecia; Amenorrhea; Androgens; Clomiphene; Diabetes Complications; Diagnosis, Diffe | 2010 |
Long-term effect of metformin on metabolic parameters in the polycystic ovary syndrome.
Topics: Adult; Blood Pressure; Body Mass Index; Cholesterol, HDL; Female; Humans; Hypoglycemic Agents; Insul | 2009 |
Pregnancy outcome in women with polycystic ovary syndrome comparing the effects of laparoscopic ovarian drilling and clomiphene citrate stimulation in women pre-treated with metformin: a retrospective study.
Topics: Adult; Clomiphene; Drug Administration Schedule; Female; Fertility Agents, Female; Gynecologic Surgi | 2010 |
Effect of a low glycemic index compared with a conventional healthy diet on polycystic ovary syndrome.
Topics: Adolescent; Adult; Blood Glucose; Body Composition; Body Mass Index; Cardiovascular Diseases; Diet; | 2010 |
Metabolism and karyotype analysis of oocytes from patients with polycystic ovary syndrome.
Topics: Adult; Carbohydrate Metabolism; Cell Differentiation; Cells, Cultured; Chromosome Aberrations; Chrom | 2010 |
National survey on management of weight reduction in PCOS women in the United Kingdom.
Topics: Anti-Obesity Agents; Body Mass Index; Diet, Reducing; Exercise; Female; Guideline Adherence; Health | 2010 |
Decision trees for identifying predictors of treatment effectiveness in clinical trials and its application to ovulation in a study of women with polycystic ovary syndrome.
Topics: Age Factors; Androgens; Anovulation; Body Mass Index; Clomiphene; Decision Trees; Drug Therapy, Comb | 2010 |
Metformin treatment for Type 2 diabetes in pregnancy?
Topics: Adult; Breast Feeding; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Humans; Hypoglycemi | 2010 |
Ovulation induction in polycystic ovary syndrome: No. 242, May 2010.
Topics: Aromatase Inhibitors; Clomiphene; Female; Fertility Agents, Female; Fertilization in Vitro; Gonadotr | 2010 |
Effect of metformin taken in the 'fresh' in vitro fertilization/intracytoplasmic sperm injection cycle upon subsequent frozen embryo replacement in women with polycystic ovary syndrome.
Topics: Adult; Birth Rate; Cryopreservation; Embryo Transfer; Female; Fertilization in Vitro; Humans; Hyperi | 2010 |
Metformin treatment may increase omentin-1 levels in women with polycystic ovary syndrome.
Topics: Adult; Blood Glucose; Capillaries; Cell Movement; Cholesterol; Cytokines; Endothelium, Vascular; Fem | 2010 |
The anti-atherogenic aspect of metformin treatment in insulin resistant women with the polycystic ovary syndrome: role of the newly established pro-inflammatory adipokine Acute-phase Serum Amyloid A; evidence of an adipose tissue-monocyte axis.
Topics: Adipokines; Adipose Tissue; Adult; Animals; Atherosclerosis; Case-Control Studies; Female; Humans; I | 2011 |
PRKA/AMPK: integrating energy status with fertility in pituitary gonadotrophs.
Topics: AMP-Activated Protein Kinases; Animals; Cyclic AMP-Dependent Protein Kinases; Energy Metabolism; Fem | 2011 |
When should an insulin sensitizing agent be used in the treatment of polycystic ovary syndrome?
Topics: Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Polycystic Ovary Syndro | 2011 |
Metformin during pregnancy in polycystic ovary syndrome: another vitamin bites the dust.
Topics: Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Pr | 2010 |
Metformin treatment exerts antiinvasive and antimetastatic effects in human endometrial carcinoma cells.
Topics: Adult; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Movement; Cyclic AMP; Cyclic | 2011 |
A new shine on an old med. The story of metformin's past, present, and possible future.
Topics: Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Polyc | 2010 |
Phosphoprotein enriched in diabetes gene product (Ped/pea-15) is increased in omental adipose tissue of women with the polycystic ovary syndrome: ex vivo regulation of ped/pea-15 by glucose, insulin and metformin.
Topics: Adipose Tissue; Adult; Apoptosis Regulatory Proteins; Biomarkers; Female; Glucose; Humans; Insulin; | 2011 |
Can metformin reduce the incidence of gestational diabetes mellitus in pregnant women with polycystic ovary syndrome? Prospective cohort study.
Topics: Abdominal Pain; Adult; Cohort Studies; Diabetes, Gestational; Egypt; Female; Fertilization in Vitro; | 2011 |
Metformin decreases thyrotropin in overweight women with polycystic ovarian syndrome and hypothyroidism.
Topics: Female; Humans; Hypoglycemic Agents; Hypothyroidism; Metformin; Overweight; Polycystic Ovary Syndrom | 2011 |
Metformin or thiazolidinedione therapy in PCOS?
Topics: Female; Humans; Metformin; Polycystic Ovary Syndrome; Thiazolidinediones | 2011 |
The metabolic status modulates the effect of metformin on the antimullerian hormone-androgens-insulin interplay in obese women with polycystic ovary syndrome.
Topics: 17-alpha-Hydroxyprogesterone; Adult; Androgens; Androstenedione; Anti-Mullerian Hormone; Body Mass I | 2011 |
Diabetes mellitus type 2 through oncology lens.
Topics: Diabetes Complications; Diabetes Mellitus, Type 2; Disease Progression; Female; Humans; Insulin; Isc | 2011 |
The effect of weight loss and treatment with metformin on serum vaspin levels in women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Body Mass Index; Cyclobutanes; Diet, Reducing; Female; Humans; Lactones; Metformi | 2011 |
Genomics: Drugs, diabetes and cancer.
Topics: Adenylate Kinase; AMP-Activated Protein Kinase Kinases; Animals; Ataxia Telangiectasia Mutated Prote | 2011 |
Early onset and high prevalence of gestational diabetes in PCOS and insulin resistant women before and after assisted reproduction.
Topics: Adult; Age of Onset; Cohort Studies; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Inf | 2011 |
The value of sex hormone binding globulin (SHBG) in predicting treatment response in polycystic ovary syndrome (PCOS).
Topics: Adult; Biomarkers; Case-Control Studies; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic | 2011 |
In search of the "LINK": Acute Phase Serum Amyloid A.
Topics: Animals; Female; Humans; Insulin Resistance; Metformin; Polycystic Ovary Syndrome | 2011 |
[Metformin treatment with or without life style changes in patients with polycystic ovary syndrome].
Topics: Acne Vulgaris; Adult; Body Mass Index; Caloric Restriction; Case-Control Studies; Drug Administratio | 2011 |
Insulin resistance influences central opioid activity in polycystic ovary syndrome.
Topics: Adult; beta-Endorphin; Binding Sites; Brain; Carbon Radioisotopes; Case-Control Studies; Female; Fen | 2011 |
Influence of LH and high-density lipoprotein cholesterol (HDL-C) on metformin response in women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Biomarkers; Blood Glucose; Cholesterol, HDL; Dose-Response Relationship, Drug; Fe | 2011 |
Metformin pharmacokinetics in nondiabetic pregnant women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Female; Fetal Blood; Humans; Hypoglycemic Agents; Maternal-Fetal Exchange; Metfor | 2011 |
Long-term metformin treatment is able to reduce the prevalence of metabolic syndrome and its hepatic involvement in young hyperinsulinaemic overweight patients with polycystic ovarian syndrome.
Topics: Adult; Female; Humans; Hyperinsulinism; Hypoglycemic Agents; Liver; Metabolic Syndrome; Metformin; O | 2011 |
Metformin as adjuvant therapy to IVF in women with PCOS: when is intention-to-treat unintentional?
Topics: Female; Humans; Infertility, Female; Metformin; Polycystic Ovary Syndrome; Pregnancy | 2011 |
Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS-related ovulation dysfunction in a randomised controlled trial.
Topics: Anovulation; Body Mass Index; Clomiphene; Female; Fertility Agents, Female; Humans; Infertility, Fem | 2011 |
Unlicensed use of metformin in children and adolescents in the UK.
Topics: Adolescent; Child; Child, Preschool; Cohort Studies; Diabetes Mellitus; Drug Prescriptions; Drug Uti | 2012 |
Metformin administration in patients with polycystic ovary syndrome who receive gonadotropins for in vitro fertilization cycles: 10-year experience in a large infertile population.
Topics: Adult; Cohort Studies; Female; Fertility Agents, Female; Fertilization in Vitro; Gonadotropins; Huma | 2012 |
Improved gall bladder motility in PCOS women treated with metformin--interaction of free fatty acids with circulating cholecystokinin?
Topics: Female; Gallbladder; Gallbladder Emptying; Humans; Metformin; Polycystic Ovary Syndrome | 2012 |
Unlicensed use of metformin in children and adolescents in Germany and France.
Topics: Diabetes Mellitus; Drug Prescriptions; Female; Humans; Hypoglycemic Agents; Male; Metformin; Obesity | 2012 |
Improvement of hyperandrogenism and hyperinsulinemia during pregnancy in women with polycystic ovary syndrome: possible effect in the ovarian follicular mass of their daughters.
Topics: Adult; Anti-Mullerian Hormone; Birth Weight; Diabetes, Gestational; Female; Fertility Agents, Female | 2012 |
Myo-inositol may prevent gestational diabetes in PCOS women.
Topics: Adult; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Inositol; Metformin; Polycystic O | 2012 |
Myo-inositol may prevent gestational diabetes in PCOS women.
Topics: Adult; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Inositol; Metformin; Polycystic O | 2012 |
Myo-inositol may prevent gestational diabetes in PCOS women.
Topics: Adult; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Inositol; Metformin; Polycystic O | 2012 |
Myo-inositol may prevent gestational diabetes in PCOS women.
Topics: Adult; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Inositol; Metformin; Polycystic O | 2012 |
For what reasons should metformin be used in the management of polycystic ovary syndrome?
Topics: Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome | 2012 |
Should all women with PCOS be treated for insulin resistance?
Topics: Female; Glucose Intolerance; Humans; Hyperinsulinism; Hypoglycemic Agents; Insulin Resistance; Metab | 2012 |
Effect of antiandrogen treatment on bone density and bone geometry in adolescents with polycystic ovary syndrome.
Topics: Adolescent; Androgen Antagonists; Bone Density; Cohort Studies; Drug Therapy, Combination; Female; F | 2012 |
Outcome of metformin treatment in polycystic ovary syndrome.
Topics: Adult; Aromatase Inhibitors; Clomiphene; Drug Therapy, Combination; Estrogen Antagonists; Female; Hu | 2012 |
Persistence with oral contraceptive pills versus metformin in women with polycystic ovary syndrome.
Topics: Adult; Anthropometry; Body Mass Index; Contraceptives, Oral, Combined; Female; Humans; Hypoglycemic | 2012 |
Better care for PCOS. Studying women's genes to find out what works.
Topics: Diabetes Mellitus, Type 2; Drug Resistance; Female; Humans; Hypoglycemic Agents; Metformin; Polycyst | 2012 |
Soluble platelet/endothelial cell adhesion molecule (sPECAM)-1 is increased in polycystic ovary syndrome and related to endothelial dysfunction.
Topics: Androstenes; Case-Control Studies; Endothelium, Vascular; Ethinyl Estradiol; Female; Humans; Hypogly | 2012 |
Effect of lifestyle modification and metformin therapy on emerging cardiovascular risk factors in overweight Indian women with polycystic ovary syndrome.
Topics: Adolescent; Adult; C-Reactive Protein; Cardiovascular Diseases; Female; Homeostasis; Homocysteine; H | 2012 |
Effect of metformin and spironolactone therapy on OGTT in patients with polycystic ovarian syndrome - a retrospective analysis.
Topics: Adolescent; Adult; Androgen Antagonists; Female; Glucose Intolerance; Hirsutism; Humans; Hyperglycem | 2012 |
[Use of insulin sensitizers in the treatment of infertility in patients with polycystic ovary syndrome (POS)].
Topics: Female; Humans; Hypoglycemic Agents; Infertility, Female; Insulin Resistance; Metformin; Polycystic | 2012 |
Ethinyl estradiol-drospirenone vs ethinyl estradiol-drospirenone plus metformin in the treatment of lean women with polycystic ovary syndrome.
Topics: Androstenes; Ethinyl Estradiol; Female; Humans; Male; Metformin; Middle Aged; Polycystic Ovary Syndr | 2013 |
Effects of metformin plus rosuvastatin on hyperandrogenism in polycystic ovary syndrome patients with hyperlipidemia and impaired glucose tolerance.
Topics: Adult; Blood Glucose; Body Mass Index; Drug Combinations; Female; Fluorobenzenes; Follow-Up Studies; | 2012 |
Reproductive endocrinology: Infertility treatment in PCOS--is metformin in from the cold?
Topics: Comorbidity; Female; Humans; Infertility, Female; Metformin; Obesity; Polycystic Ovary Syndrome; Tre | 2012 |
The effects of treatment with drospirenone/ethinyl oestradiol alone or in combination with metformin on elastic properties of aorta in women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Androstenes; Aorta; Body Mass Index; Drug Therapy, Combination; Ethinyl Estradiol | 2012 |
Effects of metformin on the expression of GLUT4 in endometrium of obese women with polycystic ovary syndrome.
Topics: Adult; Body Mass Index; Case-Control Studies; Endometrium; Female; Glucose Transporter Type 4; Human | 2012 |
Clinical variability in approaches to polycystic ovary syndrome.
Topics: Adolescent; Contraceptives, Oral; Cross-Sectional Studies; Data Collection; Exercise; Feeding Behavi | 2012 |
Severe hyperandrogenemia and insulin resistance in a 12-year-old girl.
Topics: Child; Estrogens; Ethinyl Estradiol; Female; Humans; Hyperandrogenism; Hyperinsulinism; Hypoglycemic | 2012 |
Impact of metformin monotherapy versus metformin with oestrogen-progesterone on lipids in adolescent girls with polycystic ovarian syndrome.
Topics: Adolescent; Estrogens; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Metformin; | 2013 |
The link between polycystic ovarian syndrome and type 2 diabetes: preventive and therapeutic approach in Israel.
Topics: Comorbidity; Diabetes Mellitus, Type 2; Female; Humans; Hyperinsulinism; Hypoglycemic Agents; Insuli | 2012 |
Factors contributing to initial weight loss among adolescents with polycystic ovary syndrome.
Topics: Adolescent; Adult; Behavior Therapy; Body Mass Index; Child; Dietetics; Endocrinology; Feeding Behav | 2012 |
Effect of metformin treatment on endometrial vascular indices in anovulatory obese/overweight women with polycystic ovarian syndrome using three-dimensional power doppler ultrasonography.
Topics: Adult; Case-Control Studies; Endometrium; Female; Humans; Hypoglycemic Agents; Imaging, Three-Dimens | 2013 |
Effects of metformin on serum insulin and anti-Mullerian hormone levels and on hyperandrogenism in patients with polycystic ovary syndrome.
Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adult; Anti-Mullerian Hormone; Female; Follicular Phase; H | 2013 |
Prevalence, trends, and patterns of use of antidiabetic medications among pregnant women, 2001-2007.
Topics: Adolescent; Adult; Child; Diabetes, Gestational; Female; Humans; Hyperglycemia; Hypoglycemic Agents; | 2013 |
Polycystic ovarian syndrome.
Topics: Clomiphene; Comorbidity; Contraceptives, Oral; Diagnosis, Differential; Endocrine System Diseases; F | 2012 |
Vitamin D receptor 1a promotor -1521 G/C and -1012 A/G polymorphisms in polycystic ovary syndrome.
Topics: Adolescent; Adult; Body Mass Index; Case-Control Studies; Female; Heterozygote; Homozygote; Humans; | 2012 |
Polycystic ovary syndrome and combined oral contraceptive use: a comparison of clinical practice in the United States to treatment guidelines.
Topics: Androgen Antagonists; Contraceptives, Oral, Combined; Databases, Factual; Drug Prescriptions; Female | 2013 |
How metformin acts in PCOS pregnant women: insights into insulin secretion and peripheral action at each trimester of gestation.
Topics: Adolescent; Adult; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Metformin; Polyc | 2013 |
Anti-Műllerian hormone--a prognostic marker for metformin therapy efficiency in the treatment of women with infertility and polycystic ovary syndrome.
Topics: Anti-Mullerian Hormone; Biomarkers; Female; Humans; Infertility, Female; Metformin; Polycystic Ovary | 2012 |
Polycystic ovarian syndrome during puberty and adolescence.
Topics: Adolescent; Androgen Antagonists; Contraceptives, Oral, Hormonal; Female; Humans; Hypoglycemic Agent | 2013 |
[Metformin efficiency for the adolescent PCOS treatment].
Topics: Adolescent; Body Mass Index; Bulgaria; Female; Humans; Hypoglycemic Agents; Incidence; Insulin Resis | 2012 |
Metformin and FSH for induction of ovulation in women with polycystic ovarian syndrome.
Topics: Female; Follicle Stimulating Hormone; Humans; Metformin; Ovulation Induction; Polycystic Ovary Syndr | 2002 |
Clomid versus metformin for ovulation induction--let's not have any "hanging chads"!
Topics: Clomiphene; Female; Fertility Agents, Female; Humans; Infertility, Female; Metformin; Ovulation Indu | 2002 |
Circulating ghrelin levels in patients with polycystic ovary syndrome.
Topics: Adult; Female; Follicle Stimulating Hormone; Gastrectomy; Ghrelin; Gonadal Steroid Hormones; Homeost | 2002 |
Metformin and BMI?
Topics: Body Mass Index; Female; Humans; Infertility, Female; Metformin; Ovulation Induction; Polycystic Ova | 2002 |
'Off-label' use of metformin warranted.
Topics: Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Polycystic Ovary Syndrome | 2001 |
Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin.
Topics: Abortion, Spontaneous; Birth Weight; Body Height; Child Development; Female; Follow-Up Studies; Huma | 2002 |
Metformin and FSH for induction of ovulation in women with polycystic ovary syndrome.
Topics: Female; Follicle Stimulating Hormone; Hormones; Humans; Metformin; Ovulation Induction; Polycystic O | 2002 |
Be wary of recommending off-label use of meds.
Topics: Drug Approval; Drug Labeling; Drug Prescriptions; Drug Utilization; Female; Humans; Metformin; Nurse | 2001 |
Insulin-lowering treatment reduces aromatase activity in response to follicle-stimulating hormone in women with polycystic ovary syndrome.
Topics: Adult; Androstenedione; Aromatase; Aromatase Inhibitors; Estradiol; Female; Follicle Stimulating Hor | 2002 |
Hirsutism and adnexal masses in a teenager.
Topics: Abdominal Pain; Adolescent; Contraceptives, Oral, Combined; Diagnosis, Differential; Female; Hirsuti | 2002 |
Insulin-sensitizing drugs for polycystic ovary syndrome.
Topics: Adult; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Pregnancy; Pregnan | 2003 |
Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome.
Topics: Adult; Blood Glucose; Blood Pressure; Body Constitution; Cholesterol, HDL; Diabetes Mellitus, Type 2 | 2003 |
Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin.
Topics: Adolescent; Adult; Diet, Reducing; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; M | 2003 |
[Hirsutism].
Topics: Adolescent; Adrenal Hyperplasia, Congenital; Adult; Androgen Antagonists; Anti-Inflammatory Agents; | 2003 |
Polycystic ovary syndrome.
Topics: Androgen Antagonists; Contraceptives, Oral, Combined; Feeding Behavior; Female; Hair Removal; Humans | 2003 |
The role of metformin in the management of polycystic ovary syndrome.
Topics: Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Polycystic Ovary Syndrome; Repro | 2003 |
[Effects of metformin on gonadotropin-induced ovulation in patients with polycystic ovary syndrome].
Topics: Adult; Female; Follicle Stimulating Hormone; Gonadotropins; Humans; Insulin; Leptin; Metformin; Ovul | 2003 |
The treatment of polycystic ovary syndrome.
Topics: Adult; Androgen Antagonists; Cabergoline; Cardiovascular Diseases; Clomiphene; Cyproterone Acetate; | 2004 |
Longitudinal metabolic observation of metformin effects during pregnancy in hyperinsulinemic women with polycystic ovary syndrome: a case report.
Topics: Adult; Blood Glucose; Diabetes, Gestational; Female; Glucose Tolerance Test; Humans; Hyperinsulinism | 2004 |
Metformin therapy increases insulin-like growth factor binding protein-1 in hyperinsulinemic women with polycystic ovary syndrome.
Topics: Adult; Body Constitution; Body Mass Index; Female; Humans; Hyperinsulinism; Hypoglycemic Agents; Ins | 2004 |
Hyperandrogenism and the skin.
Topics: Acne Vulgaris; Adrenal Hyperplasia, Congenital; Female; Humans; Hyperandrogenism; Male; Metformin; P | 2004 |
Surgical treatment of polycystic ovary syndrome associated with infertility.
Topics: Clomiphene; Female; Gonadotropins; Gynecologic Surgical Procedures; Humans; Hyperandrogenism; Infert | 2004 |
Metformin, pre-eclampsia, and pregnancy outcomes in women with polycystic ovary syndrome.
Topics: Adult; Birth Weight; Body Weight; Diabetes, Gestational; Female; Gestational Age; HELLP Syndrome; Hu | 2004 |
Treatment of polycystic ovary syndrome in adolescents.
Topics: Adolescent; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome | 2004 |
Women with polycystic ovary syndrome (PCOS) often undergo protracted treatment with metformin and are disinclined to stop: indications for a change in licensing arrangements?
Topics: Clinical Trials as Topic; Female; Humans; Infertility, Female; Metformin; Patient Participation; Pat | 2004 |
Are laparoscopic ovarian diathermy and gonadotropin administration the only therapeutic second-steps in clomiphene-citrate resistant women with polycystic ovary syndrome?
Topics: Clomiphene; Electrocoagulation; Female; Fertility Agents, Female; Follicle Stimulating Hormone; Gona | 2004 |
[Current concept of polycystic ovary syndrome].
Topics: Body Mass Index; Female; Humans; Insulin Resistance; Leptin; Metformin; Obesity; Polycystic Ovary Sy | 2004 |
Metformin-diet benefits in women with polycystic ovary syndrome in the bottom and top quintiles for insulin resistance.
Topics: Blood Pressure; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Menstruation; Metf | 2005 |
Effect of metformin on the clinical and metabolic assessment of women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Blood Glucose; Body Mass Index; Body Weight; Female; Glucose Tolerance Test; Huma | 2004 |
The importance of IRS-1 Gly972Arg polymorphism in evaluating the response to metformin treatment in polycystic ovary syndrome.
Topics: Adult; Androgens; Arginine; Female; Glycine; Humans; Hypoglycemic Agents; Insulin Receptor Substrate | 2005 |
Metformin monotherapy in lean women with polycystic ovary syndrome.
Topics: Adult; Female; Humans; Hypoglycemic Agents; Metformin; Obesity; Polycystic Ovary Syndrome; Thinness | 2005 |
Efficacy of metformin on ovulation induction in Asian women with polycystic ovary syndrome.
Topics: Adult; Androstenedione; Body Mass Index; Clomiphene; Coitus; Female; Humans; Hypoglycemic Agents; In | 2004 |
Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome.
Topics: Adult; Aging; Androstenedione; Anti-Mullerian Hormone; Case-Control Studies; Estradiol; Female; Foll | 2005 |
Placental passage of metformin in women with polycystic ovary syndrome.
Topics: Female; Humans; Maternal-Fetal Exchange; Metformin; Placenta; Polycystic Ovary Syndrome; Pregnancy | 2005 |
[Treatment experience with metformin in polycystic ovary syndrome].
Topics: Adolescent; Adult; Body Mass Index; Female; Hirsutism; Humans; Hypoglycemic Agents; Insulin Resistan | 2005 |
Metformin: an advance in ovulation induction.
Topics: Adult; Anovulation; Clomiphene; Female; Fertility Agents, Female; Humans; Hypoglycemic Agents; Infer | 2005 |
Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: results of a 6-month study.
Topics: Area Under Curve; Cardiovascular Diseases; Endothelin-1; Endothelium, Vascular; Female; Humans; Hypo | 2005 |
Stockpiling of ovarian follicles and the response to rosiglitazone.
Topics: Female; Humans; Hypoglycemic Agents; Infant, Newborn; Metformin; Middle Aged; Ovarian Follicle; Poly | 2005 |
Metformin in the treatment of clomiphene citrate-resistant women with high BMI and primary infertility: clinical results and reproductive outcome.
Topics: Adult; Body Mass Index; Clomiphene; Drug Resistance; Female; Humans; Hypoglycemic Agents; Infertilit | 2005 |
Plasminogen activator inhibitor 1 and miscarriage after metformin treatment and laparoscopic ovarian drilling in patients with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Female; Humans; Laparoscopy; Metformin; Ovary; Plasminogen Activator Inhibito | 2005 |
Effect of metformin on the growth hormone response to growth hormone-releasing hormone in obese women with polycystic ovary syndrome.
Topics: Adolescent; Adult; Female; Growth Hormone; Growth Hormone-Releasing Hormone; Humans; Metformin; Obes | 2005 |
Metformin in pregnancy: its time has not yet come.
Topics: Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Pr | 2006 |
Insulin-lowering agents inhibit synthesis of testosterone in ovaries of DHEA-induced PCOS rats.
Topics: 17-Hydroxysteroid Dehydrogenases; Adjuvants, Immunologic; Animals; Chromans; Dehydroepiandrosterone; | 2006 |
The effects of rosiglitazone and metformin on insulin resistance and serum androgen levels in obese and lean patients with polycystic ovary syndrome.
Topics: Adult; Androgens; Blood Glucose; Body Mass Index; Fasting; Female; Follicle Stimulating Hormone; Glu | 2005 |
Plasminogen activator inhibitor activity, 4G5G polymorphism of the plasminogen activator inhibitor 1 gene, and first-trimester miscarriage in women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Body Mass Index; Case-Control Studies; Female; Genotype; Humans; Insulin Resi | 2006 |
Metformin use and diabetic pregnancy-has its time come?
Topics: Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Fetus; Humans; Hypoglycemic Agents; Insuli | 2006 |
Role of the N, N'-dimethylbiguanide metformin in the treatment of female prepuberal BALB/c mice hyperandrogenized with dehydroepiandrosterone.
Topics: Androgens; Animals; Blood Glucose; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Dehydroep | 2006 |
Metformin administration modulates neurosteroids secretion in non-obese amenorrhoic patients with polycystic ovary syndrome.
Topics: Adult; Analysis of Variance; Androgens; Female; Glucose Tolerance Test; Gonadotropins, Pituitary; Hu | 2006 |
Metformin use during the first trimester of pregnancy. Is it safe?
Topics: Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Pregnancy; Pregnancy Comp | 2006 |
Metformin treatment of polycystic ovary syndrome improves health-related quality-of-life, emotional distress and sexuality.
Topics: Adult; Female; Humans; Metformin; Polycystic Ovary Syndrome; Prospective Studies; Quality of Life; S | 2006 |
Pregnancy outcome in infertile patients with polycystic ovary syndrome who were treated with metformin.
Topics: Adolescent; Adult; Female; Humans; Infant, Newborn; Infertility, Female; Male; Metformin; Polycystic | 2006 |
Response to diet and metformin in women with idiopathic intracranial hypertension with and without concurrent polycystic ovary syndrome or hyperinsulinemia.
Topics: Diet Therapy; Female; Humans; Hyperinsulinism; Hypoglycemic Agents; Metformin; Polycystic Ovary Synd | 2005 |
Metformin hydrochloride and recurrent miscarriage in a woman with polycystic ovary syndrome.
Topics: Abortion, Habitual; Adult; Diabetes, Gestational; Female; Humans; Hypoglycemic Agents; Metformin; Po | 2006 |
Lipids in polycystic ovary syndrome: role of hyperinsulinemia and effects of metformin.
Topics: Adult; Case-Control Studies; Cholesterol; Female; Humans; Hyperinsulinism; Hypoglycemic Agents; Insu | 2006 |
Outcome of clinical pregnancies after ovulation induction using metformin.
Topics: Adult; Drug Administration Schedule; Drug Therapy, Combination; Female; Fertility Agents, Female; Fo | 2006 |
Expanding applications for metformin in polycystic ovarian syndrome.
Topics: Child Development; Female; Humans; Hypoglycemic Agents; Infant, Newborn; Metformin; Polycystic Ovary | 2006 |
Growth, motor, and social development in breast- and formula-fed infants of metformin-treated women with polycystic ovary syndrome.
Topics: Adult; Bottle Feeding; Breast Feeding; Child Development; Female; Follow-Up Studies; Humans; Hypogly | 2006 |
Effects of metformin on inappropriate LH release in women with polycystic ovarian syndrome and insulin resistance.
Topics: Adolescent; Adult; Blood Glucose; Cluster Analysis; Female; Gonadal Steroid Hormones; Gonadotropin-R | 2006 |
Drugs for anovulatory infertility in polycystic ovary syndrome.
Topics: Anovulation; Clomiphene; Drug Resistance; Female; Fertility Agents, Female; Humans; Infertility, Fem | 2006 |
Ovulation induction in women with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Diathermy; Drug Therapy, Combination; Female; Fertility Agents, Fema | 2006 |
Insulin-sensitizing agents in women with polycystic ovary syndrome.
Topics: Adult; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Polycystic Ovary Syndrome | 2006 |
Prenatal growth restraint followed by catch-up of weight: a hyperinsulinemic pathway to polycystic ovary syndrome.
Topics: Aging; Androgen Antagonists; Body Weight; Child; Drug Therapy, Combination; Female; Fetal Developmen | 2006 |
The mechanisms involved in the action of metformin in regulating ovarian function in hyperandrogenized mice.
Topics: Adjuvants, Immunologic; Administration, Oral; AMP-Activated Protein Kinases; Animals; Catalase; Cycl | 2006 |
Metformin therapy improves coronary microvascular function in patients with polycystic ovary syndrome and insulin resistance.
Topics: Adult; Blood Flow Velocity; Case-Control Studies; Coronary Circulation; Diastole; Echocardiography, | 2006 |
[Clinical analysis of 4 treatments for woman polycystic ovarian syndrome with infertility].
Topics: Adult; Chorionic Gonadotropin; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Fema | 2006 |
Use of metformin for ovulation induction in women who have polycystic ovary syndrome with or without evidence of insulin resistance.
Topics: Adult; Blood Glucose; Cohort Studies; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Insuli | 2006 |
Neonatal outcome in polycystic ovarian syndrome patients treated with metformin during pregnancy.
Topics: Adult; Birth Weight; Case-Control Studies; Diabetes, Gestational; Female; Humans; Hyperbilirubinemia | 2006 |
Metformin and early pregnancy?
Topics: Adolescent; Adult; Female; Humans; Infant, Newborn; Infertility, Female; Male; Metformin; Polycystic | 2006 |
Acute alopecia due to metformin treatment for polycystic ovarian syndrome.
Topics: Adult; Alopecia; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome | 2006 |
Ovarian stockpiling in polycystic ovary syndrome, infertility, and the combined use of rosiglitazone and metformin.
Topics: Adult; Diabetes Mellitus, Type 2; Female; Humans; Infertility, Female; Metformin; Polycystic Ovary S | 2006 |
Case records of the Massachusetts General Hospital. Case 31-2006. A 15-year-old girl with severe obesity.
Topics: Acanthosis Nigricans; Adolescent; Body Mass Index; Diabetes Mellitus, Type 2; Fatty Liver; Female; G | 2006 |
Polycystic ovary-related miscarriage: should metformin be proposed to such frustrated women?
Topics: Abortion, Habitual; Adult; Female; Humans; Metformin; Polycystic Ovary Syndrome; Pregnancy | 2007 |
The CC genotype of the GNAS T393C polymorphism is associated with obesity and insulin resistance in women with polycystic ovary syndrome.
Topics: Androgens; Body Weight; Chromogranins; Female; Genotype; GTP-Binding Protein alpha Subunits, Gs; Hum | 2006 |
Sustainability of 8% weight loss, reduction of insulin resistance, and amelioration of atherogenic-metabolic risk factors over 4 years by metformin-diet in women with polycystic ovary syndrome.
Topics: Atherosclerosis; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Energy Intake; Female; Humans; | 2006 |
Effect of metformin administration on plasma advanced glycation end product levels in women with polycystic ovary syndrome.
Topics: Adult; Blood Glucose; Cholesterol; Female; Glycation End Products, Advanced; Humans; Hypoglycemic Ag | 2007 |
Acute effects of metformin therapy include improvement of insulin resistance and ovarian morphology.
Topics: Adult; Anti-Mullerian Hormone; Female; Follicle Stimulating Hormone; Glycoproteins; Humans; Hypoglyc | 2007 |
Treating the polycystic ovary syndrome the old-fashioned way.
Topics: Birth Rate; Clomiphene; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; Hypogly | 2007 |
Pharmacologic therapy of polycystic ovary syndrome.
Topics: Amenorrhea; Contraceptives, Oral, Hormonal; Drug Therapy, Combination; Female; Humans; Hyperandrogen | 2007 |
Ovulation induction management of PCOS.
Topics: Aromatase Inhibitors; Clomiphene; Endometrial Neoplasms; Female; Fertility Agents, Female; Glucocort | 2007 |
Pregnancy considerations in women with polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Anovulation; Aromatase Inhibitors; Clomiphene; Female; Fertility Agents, Fema | 2007 |
Polycystic ovary syndrome: androgens and hypertension.
Topics: Androgens; Blood Pressure; Endothelins; Estrogens; Female; Humans; Hypertension; Hypoglycemic Agents | 2007 |
Insulin levels, insulin resistance and the use of metformin in polycystic ovary syndrome.
Topics: Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Polycystic Ovary Syndro | 2007 |
[Effect of 6-month treatment with oral antiandrogen alone and in combination with insulin sensitizers on body composition, hormonal and metabolic parameters in women with polycystic ovary syndrome (PCOS) in order to determine therapeutic strategy].
Topics: Androgen Antagonists; Blood Glucose; Body Composition; Cyproterone Acetate; Drug Administration Sche | 2006 |
C-reactive protein in obese PCOS women and the effect of metformin therapy.
Topics: Adult; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Drug Administration Schedule; Female | 2007 |
Treatment of infertility in the polycystic ovary syndrome.
Topics: Clomiphene; Diarrhea; Drug Therapy, Combination; Female; Fertility Agents, Female; Humans; Hypoglyce | 2007 |
Treatment of infertility in the polycystic ovary syndrome.
Topics: Delayed-Action Preparations; Female; Humans; Hypoglycemic Agents; Infertility, Female; Live Birth; M | 2007 |
Controlled natural cycle IVF: a novel approach for a dominant follicle during an in-vitro maturation cycle.
Topics: Adult; Female; Humans; Hypoglycemic Agents; Infertility, Female; Metformin; Ovarian Follicle; Polycy | 2007 |
What is the best first-step therapeutic approach in treating anovulatory infertility in patients with polycystic ovary syndrome? Questions that are still unanswered.
Topics: Anovulation; Clomiphene; Female; Fertility Agents, Female; Humans; Hypoglycemic Agents; Infertility, | 2007 |
Ovulation disorders: Part II. Anovulation associated with normal estrogen.
Topics: Adrenal Hyperplasia, Congenital; Anovulation; Cervix Mucus; Clomiphene; Drug Therapy, Combination; E | 2007 |
The effects of metformin on metabolic and cardiovascular risk factors in nonobese women with polycystic ovary syndrome.
Topics: Adolescent; Cardiovascular Diseases; Female; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Lu | 2007 |
[Polycystic ovary syndrome (PCOS)].
Topics: Drug Therapy, Combination; Family Practice; Female; Humans; Hyperinsulinism; Hypoglycemic Agents; In | 2007 |
Clomiphene versus metformin for ovulation induction in polycystic ovary syndrome: the winner is ....
Topics: Body Mass Index; Clomiphene; Female; Fertility Agents, Female; Humans; Infertility, Female; Metformi | 2007 |
Risk of multiple gestation after ovulation induction in polycystic ovary syndrome.
Topics: Adult; Clomiphene; Female; Fertility Agents, Female; Gonadotropins; Humans; Infertility, Female; Met | 2007 |
Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance.
Topics: Body Weight; Female; Humans; Insulin Resistance; Metformin; Obesity; Overweight; Polycystic Ovary Sy | 2007 |
Asymmetrical dimethylarginine, inflammatory and metabolic parameters in women with polycystic ovary syndrome before and after metformin treatment.
Topics: Adult; Androgens; Arginine; Blood Glucose; Body Mass Index; C-Reactive Protein; Cholesterol, LDL; Cr | 2008 |
[Clinical study on effect of Bushen Huayu Qutan Recipe in treating polycystic ovarian syndrome].
Topics: Adolescent; Adult; Capsules; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Humans; Insul | 2007 |
Metformin decreases circulating acylation-stimulating protein levels in polycystic ovary syndrome.
Topics: Acylation; Adult; Body Mass Index; Case-Control Studies; Complement C3a; Female; Humans; Hypoglycemi | 2007 |
Pioglitazone and metformin for increased small low-density lipoprotein in polycystic ovary syndrome: counterpoint.
Topics: Adult; Atherosclerosis; Cholesterol, LDL; Female; Follow-Up Studies; Humans; Hyperlipidemias; Metfor | 2008 |
Polycystic ovarian syndrome, biomarkers, and metformin: research, risk, and reality.
Topics: Arginine; Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Risk Factors | 2008 |
The investigation and management of severe hyperandrogenism pre- and postmenopause: non-tumor disease is strongly associated with metabolic syndrome and typically responds to insulin-sensitization with metformin.
Topics: Adult; Cohort Studies; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; Metabolic Syndrome; Me | 2008 |
Therapeutic response to metformin in an underweight patient with polycystic ovarian syndrome.
Topics: Adult; Female; Fetal Proteins; Humans; Hypoglycemic Agents; Insulin; Menstrual Cycle; Metformin; Pol | 2008 |
Metformin and oral contraceptive treatments reduced circulating asymmetric dimethylarginine (ADMA) levels in patients with polycystic ovary syndrome (PCOS).
Topics: Adult; Androgens; Arginine; Body Mass Index; Case-Control Studies; Contraceptives, Oral; Cyproterone | 2008 |
Does metformin improve polycystic ovary syndrome symptoms through reduction in body iron stores?
Topics: Female; Humans; Hypoglycemic Agents; Iron; Metformin; Polycystic Ovary Syndrome | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Consensus on infertility treatment related to polycystic ovary syndrome.
Topics: Clomiphene; Diet, Reducing; Exercise; Female; Fertilization in Vitro; Gonadotropin-Releasing Hormone | 2008 |
Metformin decreases the adipokine vaspin in overweight women with polycystic ovary syndrome concomitant with improvement in insulin sensitivity and a decrease in insulin resistance.
Topics: Adipose Tissue; Adult; Androgens; Biopsy; Blood Glucose; Cytokines; Estradiol; Female; GPI-Linked Pr | 2008 |
Dietary intervention versus metformin to improve the reproductive outcome in women with polycystic ovarian syndrome.
Topics: Female; Humans; Hypoglycemic Agents; Metformin; Polycystic Ovary Syndrome; Pregnancy; Pregnancy Comp | 2008 |
Metformin in polycystic ovary syndrome.
Topics: Contraceptives, Oral; Endometrial Neoplasms; Female; Humans; Hypoglycemic Agents; Metformin; Polycys | 2008 |
Metformin in polycystic ovary syndrome.
Topics: Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Polycystic Ovary Syndrome | 2008 |
Metformin in polycystic ovary syndrome.
Topics: Fatty Liver; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Polycystic Ovary Sy | 2008 |
Metformin in polycystic ovary syndrome.
Topics: Female; Ferritins; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Polycystic Ovary Synd | 2008 |
The use of metformin as first line treatment in polycystic ovary syndrome.
Topics: Adolescent; Adult; Amenorrhea; Body Mass Index; Clomiphene; Female; Follicle Stimulating Hormone; Hi | 2008 |
Acarbose for polycystic ovary syndrome.
Topics: Acarbose; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Hypoglycemic Agents; Metformi | 2008 |
Continuation of metformin in the first trimester of women with polycystic ovarian syndrome is not associated with increased perinatal morbidity.
Topics: Adult; Birth Weight; Female; Humans; Hypoglycemic Agents; Infant, Newborn; Insulin Resistance; Metfo | 2009 |
Extended-release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome.
Topics: Adult; Clomiphene; Delayed-Action Preparations; Female; Fertility Agents, Female; Humans; Metformin; | 2008 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy.
Topics: Adult; Androgens; Anthropometry; Blood Pressure; Endocrine Glands; Female; Gonadotropins; Hormones; | 1994 |
Can metformin reduce insulin resistance in polycystic ovary syndrome?
Topics: Adult; Androstenedione; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Fasting; Fem | 1996 |
Insulin and the polycystic ovary syndrome.
Topics: 17-alpha-Hydroxyprogesterone; Female; Humans; Hydroxyprogesterones; Hyperandrogenism; Insulin; Lutei | 1996 |
Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome.
Topics: Adolescent; Adult; Blood Glucose; Female; Humans; Hypoglycemic Agents; Insulin; Lipoprotein(a); Metf | 1997 |
[Use of metformin in the management of adolescents with polycystic ovary syndrome].
Topics: Adolescent; Adult; Blood Glucose; Data Interpretation, Statistical; Estradiol; Female; Humans; Hypog | 1997 |
Insulin-sensitising agents in polycystic-ovary syndrome.
Topics: Chromans; Controlled Clinical Trials as Topic; Female; Humans; Hyperinsulinism; Hypoglycemic Agents; | 1998 |
The treatment of insulin resistance does not improve adrenal cytochrome P450c17alpha enzyme dysregulation in polycystic ovary syndrome.
Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adrenal Glands; Adrenocorticotropic Hormone; Adult; Andros | 1999 |
Administration of metformin to a diabetic woman with extreme hyperandrogenemia of nontumoral origin: management of infertility and prevention of inadvertent masculinization of a female fetus.
Topics: Adult; Diabetes Mellitus, Type 1; Disorders of Sex Development; Female; Humans; Hyperandrogenism; Hy | 1999 |
Ovarian responses to hCG stimulation: insulin resistance/hyperinsulinaemia vs. insulin deficiency.
Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adrenocorticotropic Hormone; Blood Glucose; Chorionic Gona | 1999 |
The effects of metformin on insulin resistance and ovarian steroidogenesis in women with polycystic ovary syndrome.
Topics: 17-alpha-Hydroxyprogesterone; Adult; Androstenedione; Buserelin; Case-Control Studies; Female; Folli | 1999 |
Metformin and polycystic ovary syndrome.
Topics: Dexamethasone; Female; Glucocorticoids; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; | 2000 |
Metformin and ovarian steroidogenesis in PCOS women.
Topics: Dexamethasone; Female; Glucocorticoids; Gonadotropin-Releasing Hormone; Humans; Hypoglycemic Agents; | 2000 |
Effect of metformin on insulin-like growth factor (IGF) I and IGF-binding protein I in polycystic ovary syndrome.
Topics: Adult; Body Mass Index; Female; Humans; Insulin; Insulin-Like Growth Factor Binding Protein 1; Insul | 2000 |
Insulin sensitizers and antiandrogens in the treatment of polycystic ovary syndrome.
Topics: Androgen Antagonists; Chromans; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; | 2000 |
Insulin sensitizers and polycystic ovary syndrome: can a diabetes medication treat infertility?
Topics: Female; Humans; Hypoglycemic Agents; Infertility, Female; Insulin; Metformin; Polycystic Ovary Syndr | 2000 |
Association of metformin and pregnancy in the polycystic ovary syndrome. A report of three cases.
Topics: Adult; Female; Humans; Hypoglycemic Agents; Infertility, Female; Insulin Resistance; Metformin; Poly | 2000 |
Polycystic ovary syndrome, infertility, familial thrombophilia, familial hypofibrinolysis, recurrent loss of in vitro fertilized embryos, and miscarriage.
Topics: Abortion, Habitual; Adult; Amenorrhea; Androstenedione; Embryo Transfer; Female; Fertilization in Vi | 2000 |
Insulin-sensitizing agents and their effect on adrenal androgens.
Topics: Adrenal Glands; Androgens; Female; Humans; Insulin Resistance; Metformin; Polycystic Ovary Syndrome | 2000 |
Metformin and the polycystic ovary syndrome.
Topics: Female; Humans; Metformin; Polycystic Ovary Syndrome | 2001 |
Metformin treatment of patients with polycystic ovary syndrome undergoing in vitro fertilization improves outcomes and is associated with modulation of the insulin-like growth factors.
Topics: Adult; Chorionic Gonadotropin; Clomiphene; Drug Resistance; Embryo Transfer; Embryo, Mammalian; Estr | 2001 |
The effects of long-term metformin treatment on adrenal and ovarian steroidogenesis in women with polycystic ovary syndrome.
Topics: Adrenal Glands; Adrenocorticotropic Hormone; Adult; Female; Glucose Tolerance Test; Gonadotropin-Rel | 2001 |
[Effects of metformin on insulin resistance and on ovarian steroidogenesis in women with polycystic ovary syndrome].
Topics: Adult; Female; Gonadal Steroid Hormones; Humans; Insulin Resistance; Metformin; Polycystic Ovary Syn | 2001 |
Metformin and intervention in polycystic ovary syndrome. Endocrine Society of Australia, the Australian Diabetes Society and the Australian Paediatric Endocrine Group.
Topics: Diabetes Mellitus, Type 2; Endocrinology; Evidence-Based Medicine; Female; Glucose Intolerance; Huma | 2001 |
Metformin improves ovulation and pregnancy rates in patients with polycystic ovary syndrome.
Topics: Adult; Clomiphene; Female; Fertility Agents, Female; Humans; Infertility, Female; Metformin; Ovulati | 2001 |
Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy.
Topics: Adolescent; Adult; Androgens; Blood Glucose; Endothelin-1; Endothelium, Vascular; Female; Humans; Hy | 2001 |
Ovarian steroidogenic response to human chorionic gonadotrophin in obese women with polycystic ovary syndrome: effect of metformin.
Topics: 17-alpha-Hydroxyprogesterone; Adult; Androstenedione; Blood Glucose; Chorionic Gonadotropin; Estradi | 2001 |
[Our experience in the treatment of polycystic ovary syndrome with Metformin].
Topics: Body Mass Index; Female; Follicle Stimulating Hormone; Humans; Hypertension; Luteinizing Hormone; Me | 2001 |
[Effect of long-term treatment with metformin on steroid levels and parameters of insulin resistance in women with polycystic ovary syndrome].
Topics: 17-alpha-Hydroxypregnenolone; 17-alpha-Hydroxyprogesterone; Adult; Androgens; Female; Glucose Tolera | 2001 |
[Study on treatment of hyperandrogenism and hyperinsulinism in polycystic ovary syndrome with Chinese herbal formula "tiangui fang"].
Topics: Adolescent; Adult; Drugs, Chinese Herbal; Female; Humans; Hyperandrogenism; Hyperinsulinism; Hypogly | 2000 |
Effects of metformin on early pregnancy loss in the polycystic ovary syndrome.
Topics: Abortion, Spontaneous; Adult; Androgens; Blood Glucose; Female; Humans; Hypoglycemic Agents; Insulin | 2002 |
Biochemical and body weight changes with metformin in polycystic ovary syndrome.
Topics: Adult; Body Weight; Female; Humans; Hypoglycemic Agents; Insulin; Menstruation; Metformin; Obesity; | 2001 |
Fowler's syndrome: cause or consequence of insulin resistance?
Topics: Adult; Electromyography; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Polycys | 2002 |
Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome.
Topics: Adult; Blood Glucose; Body Weight; Cohort Studies; Diabetes Complications; Diabetes Mellitus; Diabet | 2002 |
Homocysteine and steroids levels in metformin treated women with polycystic ovary syndrome.
Topics: 17-alpha-Hydroxypregnenolone; Adolescent; Adult; Blood Glucose; Body Constitution; Body Mass Index; | 2002 |
Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance.
Topics: Adolescent; Adrenal Glands; Adrenocorticotropic Hormone; Androgens; Body Composition; Female; Glucos | 2002 |
Pregnancies following use of metformin for ovulation induction in patients with polycystic ovary syndrome.
Topics: Adult; Anovulation; Clomiphene; Female; Fertility Agents, Female; Humans; Infertility, Female; Metfo | 2002 |
[Effects of metformin on the plasminogen activator system, endocrine, metabolic profiles in patients with polycystic ovary syndrome and clomiphene resistant cases].
Topics: Adult; Androstenedione; Blood Glucose; Cholesterol; Cholesterol, LDL; Clomiphene; Drug Resistance; E | 2002 |
Prediction of the effect of metformin treatment in patients with polycystic ovary syndrome.
Topics: Female; Forecasting; Humans; Insulin Resistance; Menstrual Cycle; Metformin; Polycystic Ovary Syndro | 2002 |